Document

0000899866-19-000087.txt : 20190724 0000899866-19-000087.hdr.sgml : 20190724 20190724080001 ACCESSION NUMBER: 0000899866-19-000087 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 122 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190724 DATE AS OF CHANGE: 20190724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 19969263 BUSINESS ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 4752302596 MAIL ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960111 10-Q 1 alxn630201910q.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q



☒	Quarterly report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2019



☐	Transition report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the transition period from to

Commission file number: 0-27756

ALEXION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)



Delaware	13-3648318
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

121 Seaport Boulevard, Boston Massachusetts 02210

(Address of Principal Executive Offices) (Zip Code)

475-230-2596

(Registrant’s telephone number, including area code)

N/A

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:



Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock $0.0001 par value	ALXN	NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐

Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒



Common Stock	$0.0001 par value	224,226,878
Class		Outstanding as of July 22, 2019

Alexion Pharmaceuticals, Inc.

Table of Contents



			Page
PART I.		FINANCIAL INFORMATION
	Item 1.	Condensed Consolidated Financial Statements (Unaudited)
		Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018	2
		Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2019 and 2018	3
		Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2019 and 2018	4
		Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and six months ended June 30, 2019 and 2018	5
		Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018	7
		Notes to Condensed Consolidated Financial Statements	9
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	34
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	54
	Item 4.	Controls and Procedures	56
PART II.		OTHER INFORMATION	57
	Item 1.	Legal Proceedings	57
	Item 1A.	Risk Factors	58
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	86
	Item 5.	Other Information	86
	Item 6.	Exhibits	86
SIGNATURES

Alexion Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(amounts in millions, except per share amounts)



	June 30,			December 31,
	2019			2018
Assets
Current Assets:
Cash and cash equivalents	$	1,984.2		$	1,365.5
Marketable securities	105.4			198.3
Trade accounts receivable, net	1,123.6			922.3
Inventories	494.6			472.5
Prepaid expenses and other current assets	460.7			426.4
Total current assets	4,168.5			3,385.0
Property, plant and equipment, net	1,123.5			1,471.5
Intangible assets, net	3,487.6			3,641.3
Goodwill	5,037.4			5,037.4
Right of use operating assets	209.5			—
Other assets	541.2			396.7
Total assets	$	14,567.7		$	13,931.9
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable and accrued expenses	$	728.7		$	698.2
Revolving credit facility	—			250.0
Current portion of long-term debt	126.6			93.8
Current portion of contingent consideration	100.0			97.6
Other current liabilities	76.2			34.4
Total current liabilities	1,031.5			1,174.0
Long-term debt, less current portion	2,438.3			2,501.7
Contingent consideration	158.2			183.2
Facility lease obligation	—			361.0
Deferred tax liabilities	341.2			391.1
Noncurrent operating lease liabilities	165.5			—
Other liabilities	269.5			155.6
Total liabilities	4,404.2			4,766.6
Commitments and contingencies (Note 18)
Stockholders' Equity:
Common stock, $0.0001 par value; 290 shares authorized; 237.3 and 236.2 shares issued at June 30, 2019 and December 31, 2018, respectively	—			—
Additional paid-in capital	8,677.0			8,539.1
Treasury stock, at cost, 13.1 and 12.7 shares at June 30, 2019 and December 31, 2018, respectively	(1,738.8		)	(1,689.9		)
Accumulated other comprehensive loss	(57.9		)	(9.7		)
Retained earnings	3,283.2			2,325.8
Total stockholders' equity	10,163.5			9,165.3
Total liabilities and stockholders' equity	$	14,567.7		$	13,931.9

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alexion Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(amounts in millions, except per share amounts)



	Three months ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Net product sales	$	1,202.5		$	1,044.7		$	2,342.7		$	1,975.1
Other revenue	0.8			0.3			1.0			0.8
Total revenues	1,203.3			1,045.0			2,343.7			1,975.9
Cost of sales	99.2			95.3			185.0			186.9
Operating expenses:
Research and development	187.6			173.4			383.5			350.0
Selling, general and administrative	299.3			277.3			580.8			534.4
Acquired in-process research and development	(4.1		)	803.7			(4.1		)	803.7
Amortization of purchased intangible assets	80.1			80.1			160.1			160.1
Change in fair value of contingent consideration	6.1			4.7			(22.6		)	57.4
Restructuring expenses	2.5			10.6			11.6			16.1
Total operating expenses	571.5			1,349.8			1,109.3			1,921.7
Operating income (loss)	532.6			(400.1		)	1,049.4			(132.7		)
Other income and expense:
Investment (expense) income	(14.9		)	7.7			27.6			113.5
Interest expense	(18.3		)	(25.0		)	(38.2		)	(49.1		)
Other income and (expense)	0.1			(1.2		)	2.5			1.3
Income (loss) before income taxes	499.5			(418.6		)	1,041.3			(67.0		)
Income tax (benefit) expense	39.7			38.8			(6.4		)	141.3
Net income (loss)	$	459.8		$	(457.4	)	$	1,047.7		$	(208.3	)
Earnings (loss) per common share
Basic	$	2.05		$	(2.05	)	$	4.68		$	(0.94	)
Diluted	$	2.04		$	(2.05	)	$	4.64		$	(0.94	)
Shares used in computing earnings (loss) per common share
Basic	224.2			222.6			224.0			222.3
Diluted	225.6			222.6			225.7			222.3

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alexion Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(unaudited)

(amounts in millions)



	Three months ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Net income (loss)	$	459.8		$	(457.4	)	$	1,047.7		$	(208.3	)
Other comprehensive income (loss), net of tax:
Foreign currency translation	1.5			(8.1		)	(0.5		)	(4.3		)
Unrealized gains (losses) on debt securities	—			—			0.2			(0.4		)
Unrealized gains on pension obligation	—			—			—			0.7
Unrealized gains (losses) on hedging activities, net of tax of $(12.1), $15.4, $(14.3) and $10.5, respectively	(38.9		)	50.9			(47.9		)	35.5
Other comprehensive income (loss), net of tax	(37.4		)	42.8			(48.2		)	31.5
Comprehensive income (loss)	$	422.4		$	(414.6	)	$	999.5		$	(176.8	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alexion Pharmaceuticals, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(unaudited)

(amounts in millions)



Three months ended June 30, 2019	Common Stock			Additional Paid-In Capital		Treasury Stock at Cost				Accumulated Other Comprehensive Income (Loss)			Retained Earnings		Total Stockholders’ Equity
	Shares Issued	Amount		Additional Paid-In Capital		Shares	Amount			Accumulated Other Comprehensive Income (Loss)			Retained Earnings		Total Stockholders’ Equity
Balances, March 31, 2019	237.0	$	—	$	8,604.9	12.8	$	(1,701.2	)	$	(20.5	)	$	2,823.4	$	9,706.6
Repurchase of common stock	—	—		—		0.3	(37.6		)	—			—		(37.6		)
Issuance of common stock under stock option and stock purchase plans	0.1	—		11.2		—	—			—			—		11.2
Issuance of restricted common stock	0.2	—		—		—	—			—			—		—
Share-based compensation expense	—	—		60.9		—	—			—			—		60.9
Net income	—	—		—		—	—			—			459.8		459.8
Other comprehensive loss	—	—		—		—	—			(37.4		)	—		(37.4		)
Balances, June 30, 2019	237.3	$	—	$	8,677.0	13.1	$	(1,738.8	)	$	(57.9	)	$	3,283.2	$	10,163.5



Three months ended June 30, 2018	Common Stock			Additional Paid-In Capital		Treasury Stock at Cost				Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total Stockholders’ Equity
	Shares Issued	Amount		Additional Paid-In Capital		Shares	Amount			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total Stockholders’ Equity
Balances, March 31, 2018	235.2	$	—	$	8,350.9	12.7	$	(1,689.9	)	$	(45.7	)	$	2,497.4		$	9,112.7
Repurchase of common stock	—	—		—		—	—			—			—			—
Issuance of common stock under stock option and stock purchase plans	0.2	—		15.1		—	—			—			—			15.1
Issuance of restricted common stock	0.1	—		0.3		—	—			—			—			0.3
Share-based compensation expense	—	—		53.9		—	—			—			—			53.9
Net income (loss)	—	—		—		—	—			—			(457.4		)	(457.4		)
Other comprehensive income	—	—		—		—	—			42.8			—			42.8
Balances, June 30, 2018	235.5	$	—	$	8,420.2	12.7	$	(1,689.9	)	$	(2.9	)	$	2,040.0		$	8,767.4



Six Months Ended June 30, 2019	Common Stock			Additional Paid-In Capital		Treasury Stock at Cost				Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total Stockholders’ Equity
	Shares Issued	Amount		Additional Paid-In Capital		Shares	Amount			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total Stockholders’ Equity
Balances, December 31, 2018	236.2	$	—	$	8,539.1	12.7	$	(1,689.9	)	$	(9.7	)	$	2,325.8		$	9,165.3
Repurchase of common stock	—	—		—		0.4	(48.9		)	—			—			(48.9		)
Issuance of common stock under stock option and stock purchase plans	0.2	—		21.3		—	—			—			—			21.3
Issuance of restricted common stock	0.9	—		—		—	—			—			—			—
Share-based compensation expense	—	—		116.6		—	—			—			—			116.6
Net income	—	—		—		—	—			—			1,047.7			1,047.7
Other comprehensive loss	—	—		—		—	—			(48.2		)	—			(48.2		)
Adoption of new accounting standards (see Note 2)	—	—		—		—	—			—			(90.3		)	(90.3		)
Balances, June 30, 2019	237.3	$	—	$	8,677.0	13.1	$	(1,738.8	)	$	(57.9	)	$	3,283.2		$	10,163.5



Six Months Ended June 30, 2018	Common Stock			Additional Paid-In Capital		Treasury Stock at Cost				Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total Stockholders’ Equity
	Shares Issued	Amount		Additional Paid-In Capital		Shares	Amount			Accumulated Other Comprehensive Income (Loss)			Retained Earnings			Total Stockholders’ Equity
Balances, December 31, 2017	234.3	$	—	$	8,290.3	12.0	$	(1,604.9	)	$	(34.4	)	$	2,242.1		$	8,893.1
Repurchase of common stock	—	—		—		0.7	(85.0		)	—			—			(85.0		)
Issuance of common stock under stock option and stock purchase plans	0.3	—		24.6		—	—			—			—			24.6
Issuance of restricted common stock	0.9	—		—		—	—			—			—			—
Share-based compensation expense	—	—		105.3		—	—			—			—			105.3
Net income (loss)	—	—		—		—	—			—			(208.3		)	(208.3		)
Other comprehensive income	—	—		—		—	—			31.5			—			31.5
Adoption of new accounting standards	—	—		—		—	—			—			6.2			6.2
Balances, June 30, 2018	235.5	$	—	$	8,420.2	12.7	$	(1,689.9	)	$	(2.9	)	$	2,040.0		$	8,767.4

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alexion Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(amounts in millions)



	Six months ended June 30,
	2019			2018
Cash flows from operating activities:
Net income (loss)	$	1,047.7		$	(208.3	)
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	193.7			202.0
Change in fair value of contingent consideration	(22.6		)	57.4
Share-based compensation expense	117.6			105.2
Non-cash expense for acquired IPR&D	—			86.6
Deferred taxes (benefit)	(40.8		)	111.5
Unrealized foreign currency loss (gain)	(4.1		)	12.7
Unrealized loss (gain) on forward contracts	11.3			3.1
Unrealized gain on strategic equity investments	(8.6		)	(100.5		)
Other	(2.3		)	13.2
Changes in operating assets and liabilities:
Accounts receivable	(196.4		)	(137.0		)
Inventories	(24.0		)	(4.1		)
Prepaid expenses, right of use operating assets and other assets	(126.8		)	(55.7		)
Accounts payable, accrued expenses, lease liabilities and other liabilities	23.6			(130.6		)
Net cash provided by operating activities	968.3			(44.5		)
Cash flows from investing activities:
Purchases of available-for-sale debt securities	(41.1		)	(612.8		)
Proceeds from maturity or sale of available-for-sale debt securities	139.3			1,054.8
Purchases of mutual funds related to nonqualified deferred compensation plan	(10.9		)	(7.5		)
Proceeds from sale of mutual funds related to nonqualified deferred compensation plan	9.0			5.9
Purchases of property, plant and equipment	(82.8		)	(129.4		)
Purchases of strategic investments	(43.8		)	—
Purchase of intangible assets	(8.0		)	—
Other	0.2			2.6
Net cash provided by (used in) investing activities	(38.1		)	313.6
Cash flows from financing activities:
Debt issuance costs	—			(7.6		)
Proceeds from revolving credit facility	—			250.0
Payments on term loan facility	(32.7		)	(293.8		)
Payments on revolving credit facility	(250.0		)	—
Repurchases of common stock	(48.9		)	(85.0		)
Net proceeds from issuance of common stock under share-based compensation arrangements	20.5			24.6
Other	(2.4		)	(4.7		)
Net cash used in financing activities	(313.5		)	(116.5		)
Effect of exchange rate changes on cash and cash equivalents and restricted cash	0.7			(6.1		)
Net change in cash and cash equivalents and restricted cash	617.4			146.5
Cash and cash equivalents and restricted cash at beginning of period	1,367.3			586.3
Cash and cash equivalents and restricted cash at end of period	$	1,984.7		$	732.8



	Six months ended June 30,
	2019		2018

Supplemental cash flow disclosures from investing and financing activities:
Fair value of contingent liability related to strategic investment and purchase option	$	27.4	$	—
Operating ROU lease assets obtained in exchange for operating lease liabilities	$	20.7	$	—
Capitalization of construction costs related to facility lease obligations	$	—	$	33.2
Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets	$	14.3	$	15.8

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)


1.	Business

Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies.

We are the global leader in complement inhibition and have developed and commercialize two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In addition, Alexion has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development with strategic focus in hematology and nephrology, neurology, metabolics and neonatal Fc receptor (FcRn). We were incorporated in 1992 under the laws of the State of Delaware.


2.	Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2018. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of December 31, 2018 was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full year or any other future periods.

The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.

The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2 and within Note 17, Leases.

Reclassifications

Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation.

New Accounting Pronouncements

Accounting Standards Update (ASU) 2016-13, "Measurement of Credit Losses on Financial Instruments": In June 2016, the Financial Accounting Standards Board (FASB) issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

be reported based on expected losses compared to the current incurred loss model. The new standard also requires enhanced disclosure of credit risk associated with respective assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. We are currently assessing the impact of this standard on our consolidated financial statements.

ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract": In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA). Under the new guidance, customers will assess if a CCA includes a software license and if a CCA does include a software license, implementation and set-up costs will be accounted for consistent with existing internal-use software implementation guidance. Implementation costs associated with a CCA that do not include a software license would be expensed to operating expenses. The standard also provides classification guidance on these implementation costs as well as additional quantitative and qualitative disclosures. The standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Entities can choose to adopt the new guidance prospectively or retrospectively. We are currently assessing the impact this standard will have on our consolidated financial statements.

Recently Adopted Accounting Pronouncements

ASU 2016-02, "Leases": In February 2016, the FASB issued a new standard that requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right of use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as financing or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

We adopted the new standard on January 1, 2019 using the modified retrospective approach. We have elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the consolidated financial statements and recognize a cumulative-effect adjustment to the opening balance of retained earnings on the date of adoption. We also elected the “package of practical expedients”, which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs.

Results for reporting periods beginning after January 1, 2019 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2019, we derecognized $472.8 of property, plant and equipment and other assets and $372.2 of facility lease obligations associated with previously existing build-to-suit arrangements. We capitalized ROU assets of $326.1, inclusive of opening adjustments of $70.8 primarily related to prepaid rent existing at transition, and $255.3 of lease liabilities, within our condensed consolidated balance sheets upon adoption. At transition we recorded a decrease of $90.3 to retained earnings, net of tax, primarily related to our derecognition of previously recorded build-to-suit arrangements.

ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income": In February 2018, the FASB issued a new standard that permits entities to make a one-time reclassification from accumulated other comprehensive income (AOCI) to retained earnings for the stranded tax effects resulting from the newly enacted corporate tax rates under the Tax Cuts and Jobs Act (the Tax Act), that was effective for the year ended December 31, 2017. We adopted the new standard on January 1, 2019 and elected not to reclassify the income tax effects of the Tax Act from AOCI to retained earnings. We continue to release disproportionate income tax effects from AOCI based on the aggregate portfolio approach. The adoption of this standard did not have an impact on our condensed consolidated financial statements.


3.	Acquisitions

Wilson Therapeutics AB

On May 25, 2018, we completed the acquisition of Wilson Therapeutics AB (publ), a biopharmaceutical company based in Stockholm, Sweden (Wilson Therapeutics) that developed a novel therapy for patients with rare copper-mediated disorders, pursuant to a recommended public cash offer of SEK 232 for each share of stock of Wilson Therapeutics. As a result of the acquisition, we added WTX101 (ALXN1840), a highly innovative drug candidate that is currently in Phase III clinical trials for the treatment of patients with Wilson disease, to our clinical pipeline.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

The acquisition of Wilson Therapeutics was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in a single asset, WTX101.

The following table summarizes the total consideration for the acquisition and the value of assets acquired and liabilities assumed:



Consideration
Cash paid for acquisition of Wilson Therapeutics outstanding shares	$	749.3
Transaction costs	15.1
Total consideration	$	764.4

Assets Acquired and Liabilities Assumed
Cash	$	45.1
In-process research & development	803.7
Employee related liabilities	(71.4		)
Other assets and liabilities	(13.0		)
Total net assets acquired	$	764.4

The acquired in-process research and development asset relates to WTX101. Due to the stage of development of this asset at the date of acquisition, significant risk remained and it was not yet probable that there was future economic benefit from this asset. Absent successful clinical results and regulatory approval for the asset, there was no alternative future use associated with WTX101. Accordingly, the value of this asset was expensed during the second quarter of 2018.

Employee related liabilities include the value of outstanding employee equity incentive awards that were accelerated in connection with the Wilson Therapeutics acquisition that have been settled in cash. Also included in this amount were employer tax obligations associated with the employee equity incentive awards.

In connection with rights to WTX101 that were previously acquired by Wilson Therapeutics from third parties, we could be required to pay up to approximately $19.0 if certain development, regulatory and commercial milestones are met over time, as well as royalties on commercial sales.

Syntimmune, Inc.

In September 2018, we entered into a definitive agreement to acquire Syntimmune, Inc. (Syntimmune), a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn. Syntimmune’s lead candidate, SYNT001 (ALXN1830), is a monoclonal antibody that is designed to inhibit the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes, that is being studied for the treatment of IgG-mediated autoimmune diseases. The acquisition of Syntimmune closed in November 2018. Under the terms of the acquisition agreement, Alexion acquired Syntimmune for an upfront cash payment of $400.0, with the potential for additional milestone-dependent payments of up to $800.0, for a total potential value of up to $1,200.0.

The acquisition of Syntimmune was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in a single in-process research and development asset, SYNT001.

In connection with the agreement of the final working capital adjustment for the Syntimmune acquisition, we recognized a benefit of $4.1 associated with previously acquired in-process research and development in the second quarter 2019.

The following table summarizes the total consideration for the acquisition and the value of the assets acquired and liabilities assumed:

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)



Consideration
Upfront payment for acquisition of Syntimmune outstanding shares	$	400.0
Cash acquired	4.2
Working capital adjustment	2.3
Transaction costs	0.9
Total consideration	$	407.4

Assets Acquired and Liabilities Assumed
Cash	$	4.2
In-process research & development	375.2
Deferred tax assets	25.1
Other assets and liabilities	2.9
Total net assets acquired	$	407.4

The acquired in-process research and development asset relates to SYNT001. Due to the stage of development of this asset at the date of acquisition, significant risk remained and it was not yet probable that there was future economic benefit from this asset. Absent successful clinical results and regulatory approval for the asset, there was no alternative future use associated with SYNT001. Accordingly, the value of this asset was expensed during the fourth quarter of 2018.


4.	Inventories

The components of inventory are as follows:



	June 30,		December 31,
	2019		2018
Raw materials	$	38.2	$	31.4
Work-in-process	116.6		90.4
Finished goods	339.8		350.7
	$	494.6	$	472.5

5.Intangible Assets and Goodwill

The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:



		June 30, 2019							December 31, 2018
	Estimated Life (years)	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net
Licensing rights	5-8	$	47.0	$	(30.9	)	$	16.1	$	39.0	$	(29.3	)	$	9.7
Patents	7	10.5		(10.5		)	—		10.5		(10.5		)	—
Purchased technology	6-16	4,710.5		(1,239.2		)	3,471.3		4,710.5		(1,079.1		)	3,631.4
Other intangibles	5	0.4		(0.2		)	0.2		0.4		(0.2		)	0.2
Total		$	4,768.4	$	(1,280.8	)	$	3,487.6	$	4,760.4	$	(1,119.1	)	$	3,641.3
Goodwill	Indefinite	$	5,040.3	$	(2.9	)	$	5,037.4	$	5,040.3	$	(2.9	)	$	5,037.4

Amortization expense for the three months ended June 30, 2019 and 2018 was $81.2 and $80.3, respectively. Amortization expense for the six months ended June 30, 2019 and 2018 was $161.7 and $160.6, respectively. As of June 30, 2019, assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is $161.7 for the six months ending December 31, 2019, and approximately $323.0 for each of the years ending December 31, 2020 through December 31, 2024.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

As of June 30, 2019, the net book value of our purchased technology includes $3,122.5 associated with the KANUMA intangible asset, which we acquired in the acquisition of Synageva BioPharma Corp. As part of our standard quarterly procedures, we reviewed the KANUMA asset as of June 30, 2019 and determined that there were no indicators of impairment. Cash flow models used in our assessments are based on our commercial experience to date with KANUMA and require the use of significant estimates, which include, but are not limited to, long-range pricing expectations and patient-related assumptions, including patient identification, conversion and retention rates. We will continue to review the related valuation and accounting of this asset as new information becomes available to us.


6.	Debt

On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).

The Credit Agreement provides for a $1,000.0 revolving credit facility and a $2,612.5 term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments.

In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of $53.1 in financing costs. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended June 30, 2019 and 2018 was $1.3 and $3.2, respectively, and amortization expense associated with deferred financing costs for the six months ended June 30, 2019 and 2018 was $2.5 and $5.5, respectively. Remaining unamortized deferred financing costs as of June 30, 2019 and December 31, 2018 were $18.3 and $20.8, respectively.

We made principal payments of $32.7 on the term loan during the three and six months ended June 30, 2019 and as of June 30, 2019, we had $2,579.8 outstanding on the term loan. In January 2019, we paid the outstanding balance on the revolving credit facility of $250.0 in full and we had no outstanding borrowings under the revolving credit facility as of June 30, 2019. As of June 30, 2019, we had open letters of credit of $1.0 that offset our availability in the revolving facility.

The fair value of our long term debt, which is measured using Level 2 inputs of the fair value hierarchy, approximates book value.


7.	Earnings Per Common Share

Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the applicable period. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

The following table summarizes the calculation of basic and diluted EPS for the three and six months ended June 30, 2019 and 2018:



	Three months ended					Six months ended
	June 30,					June 30,
	2019		2018			2019		2018
Net income (loss) used for basic and diluted calculation	$	459.8	$	(457.4	)	$	1,047.7	$	(208.3	)
Shares used in computing earnings (loss) per common share—basic	224.2		222.6			224.0		222.3
Weighted-average effect of dilutive securities:
Stock awards	1.4		—			1.7		—
Shares used in computing earnings (loss) per common share—diluted	225.6		222.6			225.7		222.3
Earnings (loss) per common share:
Basic	$	2.05	$	(2.05	)	$	4.68	$	(0.94	)
Diluted	$	2.04	$	(2.05	)	$	4.64	$	(0.94	)

We exclude from diluted EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of diluted EPS for the three and six months ended June 30, 2019 were 1.9 and 2.9 shares of common stock, respectively, because their effect was anti-dilutive. For the three and six months ended June 30, 2018, we reported a net loss; therefore, no outstanding stock awards were included in the computation of diluted net loss per share since such inclusion would have been anti-dilutive.


8.	Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of June 30, 2019 and December 31, 2018 were as follows:



	June 30, 2019
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses		Fair Value
Commercial paper	$	274.0	$	—	$	—	$	274.0
Corporate bonds	28.0		—		—		28.0
Other government-related obligations:
U.S.	117.8		—		—		117.8
Bank certificates of deposit	24.3		—		—		24.3
Total available-for-sale debt securities	$	444.1	$	—	$	—	$	444.1



	December 31, 2018
	Amortized Cost		Gross Unrealized Holding Gains		Gross Unrealized Holding Losses			Fair Value
Commercial paper	$	52.1	$	—	$	—		$	52.1
Corporate bonds	122.9		—		(0.1		)	122.8
Other government-related obligations:
U.S.	17.5		—		—			17.5
Bank certificates of deposit	33.2		—		—			33.2
Total available-for-sale debt securities	$	225.7	$	—	$	(0.1	)	$	225.6

The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of June 30, 2019 and December 31, 2018 was $25.5 and $128.7, respectively. We did not have any investments in a continuous unrealized

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

loss position for more than twelve months as of June 30, 2019 and December 31, 2018. As of June 30, 2019, we believe that the cost basis of our available-for-sale debt securities is recoverable.

The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:



	June 30, 2019		December 31, 2018
Cash and cash equivalents	$	359.4	$	43.8
Marketable securities	84.7		181.8
	$	444.1	$	225.6

The fair values of available-for-sale debt securities at June 30, 2019, by contractual maturity, are summarized as follows:



	June 30, 2019
Due in one year or less	$	438.3
Due after one year through three years	5.8
	$	444.1

We sponsor a nonqualified deferred compensation plan which allows certain highly-compensated employees to elect to defer income to future periods. Participants in the plan earn a return on their deferrals based on several investment options, which mirror returns on underlying mutual fund investments. We choose to invest in the underlying mutual fund investments to offset the liability associated with our nonqualified deferred compensation plan. These mutual fund investments are valued at net asset value per share and are carried at fair value with gains and losses included in investment income. The changes in the underlying liability to the employee are recorded in operating expenses. As of June 30, 2019 and December 31, 2018, the fair value of these investments was $20.7 and $16.5, respectively.

We utilize the specific identification method in computing realized gains and losses. Realized gains and losses on our marketable securities were not material for the three and six months ended June 30, 2019 and 2018.


9.	Derivative Instruments and Hedging Activities

We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on outstanding borrowings under our revolving credit facility, if any, and term loan facility. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.

We enter into foreign exchange forward contracts, with durations of up to 60 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, and certain forecasted expenses that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results. These hedges are designated as cash flow hedges upon contract inception. As of June 30, 2019, we had open revenue related foreign exchange forward contracts with notional amounts totaling $1,136.1 that qualified for hedge accounting with current contract maturities through December 2020. As of June 30, 2019, we had open expense related foreign exchange forward contracts with notional amounts totaling $17.1 that qualified for hedge accounting with contract maturities through September 2022.

To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate on a portion of our debt to a fixed rate, plus a borrowing spread.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

The following table summarizes the total interest rate swap contracts executed as of June 30, 2019:



Type of Interest Rate Swap	Notional Amount	Effective Date	Termination Date	Fixed Interest Rate or Rate Range
Floating to Fixed	1,531.3	December 2016 - January 2018	December 2019	0.98% - 1.62%
Floating to Fixed	450.0	December 2018	December 2022	2.60% - 2.79%
Floating to Fixed	300.0	January 2019	December 2019	2.08%
Floating to Fixed	1,300.0	December 2019	December 2022	2.37% - 2.83%

The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2019 and 2018 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:



	Three months ended					Three months ended
	June 30, 2019					June 30, 2018
Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded	Net Product Sales		Interest Expense			Net Product Sales			Interest Expense
Total amount presented in the Condensed Consolidated Statements of Operations	$	1,202.5	$	(18.3	)	$	1,044.7		$	(25.0	)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts	$	9.1	$	—		$	(1.7	)	$	—
Interest rate swap contracts	$	—	$	4.5		$	—		$	3.1



	Six months ended					Six months ended
	June 30, 2019					June 30, 2018
Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded	Net Product Sales		Interest Expense			Net Product Sales			Interest Expense
Total amount presented in the Condensed Consolidated Statements of Operations	$	2,342.7	$	(38.2	)	$	1,975.1		$	(49.1	)
Impact of cash flow hedging relationships:
Foreign exchange forward contracts	$	16.1	$	—		$	(14.8	)	$	—
Interest rate swap contracts	$	—	$	9.1		$	—		$	4.5

The impact on AOCI from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and six months ended June 30, 2019 and 2018 were as follows:



	Three months ended						Six months ended
	June 30,						June 30,
	2019			2018			2019			2018
Foreign Exchange Forward Contracts:
Gain (loss) recognized in AOCI, net of tax	$	(3.9	)	$	49.0		$	10.3		$	16.5
Gain (loss) reclassified from AOCI to net product sales, net of tax	$	7.0		$	(1.3	)	$	12.4		$	(11.4	)
Interest Rate Contracts:
Gain (loss) recognized in AOCI, net of tax	$	(24.6	)	$	3.1		$	(38.8	)	$	11.2
Gain (loss) reclassified from AOCI to interest expense, net of tax	$	3.4		$	2.5		$	7.0		$	3.6

Assuming no change in foreign exchange rates from market rates at June 30, 2019, $4.8 of gains recognized in AOCI will be reclassified to revenue over the next 12 months. Assuming no change in LIBOR-based interest rates from market rates at June 30, 2019, $5.2 of losses recognized in AOCI will be reclassified to interest expense over the next 12 months. Amounts recognized in AOCI for expense related foreign exchange forward contracts was immaterial at June 30, 2019.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

We enter into foreign exchange forward contracts, with durations of up to 8 months, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of June 30, 2019, the notional amount of foreign exchange contracts where hedge accounting is not applied was $1,963.0.

We recognized a gain (loss) of $(5.8) and $18.4, in other income and (expense) for the three months ended June 30, 2019 and 2018, respectively, associated with the foreign exchange contracts not designated as hedging instruments. We recognized a gain (loss) of $(2.6) and $10.3, in other income and (expense) for the six months ended June 30, 2019 and 2018, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.

The following tables summarize the fair value of outstanding derivatives as of June 30, 2019 and December 31, 2018:



	June 30, 2019
	Derivative Assets			Derivative Liabilities
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	12.4	Other current liabilities	$	7.6
Foreign exchange forward contracts	Other assets	1.1		Other liabilities	1.8
Interest rate contracts	Prepaid expenses and other current assets	5.6		Other current liabilities	10.8
Interest rate contracts	Other assets	—		Other liabilities	52.2
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	16.1		Other current liabilities	15.4
Total fair value of derivative instruments		$	35.2		$	87.8

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)



	December 31, 2018
	Derivative Assets			Derivative Liabilities
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	$	16.9	Other current liabilities	$	7.3
Foreign exchange forward contracts	Other assets	0.3		Other liabilities	3.1
Interest rate contracts	Prepaid expenses and other current assets	20.1		Other current liabilities	0.8
Interest rate contracts	Other assets	—		Other liabilities	17.3
Derivatives not designated as hedging instruments:
Foreign exchange forward contracts	Prepaid expenses and other current assets	23.6		Other current liabilities	11.5
Total fair value of derivative instruments		$	60.9		$	40.0

Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:



	June 30, 2019
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	35.2		$	—	$	35.2		$	(24.4	)	$	—	$	10.8
Derivative liabilities	(87.8		)	—		(87.8		)	24.4			—		(63.4		)



	December 31, 2018
									Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet
Description	Gross Amounts of Recognized Assets/Liabilities			Gross Amounts Offset in the Condensed Consolidated Balance Sheet		Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet			Derivative Financial Instruments			Cash Collateral Received (Pledged)		Net Amount
Derivative assets	$	60.9		$	—	$	60.9		$	(30.2	)	$	—	$	30.7
Derivative liabilities	(40.0		)	—		(40.0		)	30.2			—		(9.8		)

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)


10.	Other Investments

Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with license agreements. These investments are included in other assets in our condensed consolidated balance sheets.

Moderna

During 2014, we purchased $37.5 of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was recorded at cost. During the first quarter 2018, Moderna announced the completion of a new round of financing. As a result, we recognized an unrealized gain of $100.8 in investment income during the first quarter 2018 to adjust our investment in Moderna to fair value as of the date of the observable price change, based on the per share price in Moderna's new round of financing. There were no observable price changes during the second quarter 2018.

On December 6, 2018, Moderna completed its initial public offering (IPO) and shares of Moderna began trading on the Nasdaq Global Select Market under the symbol “MRNA.” As part of the IPO, our preferred stock was converted into Moderna common stock and subject to a one year lock-up period. As our equity investment in Moderna common stock now has a readily determinable fair value, we are recording the investment at fair value, with the effects of the holding period restriction estimated using an option pricing valuation model. During the three and six months ended June 30, 2019, we recognized an unrealized (loss) gain of $(29.0) and $0.8, respectively, in investment income to adjust our investment in Moderna to fair value as of June 30, 2019.

The fair value of this investment was $82.7 and $81.9 as of June 30, 2019 and December 31, 2018, respectively.

Dicerna

In October 2018, we purchased $10.3 of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and six months ended June 30, 2019, we recognized an unrealized gain of $0.9 and $4.2, respectively, in investment income to adjust our equity investment in Dicerna to fair value as of June 30, 2019.

The fair value of this investment was $13.1 and $8.9 as of June 30, 2019 and December 31, 2018, respectively.

Caelum

In January 2019, we purchased $41.0 of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a $16.1 option to acquire the remaining equity in Caelum in connection with an agreement that we entered into with Caelum, see Note 18, “Commitments and Contingencies” for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we are recording the assets at cost, less impairment, and adjusted for any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer.

There were no observable price changes associated with these assets during the six months ended June 30, 2019. The carrying value of the investment and option of $41.0 and $16.1, respectively, were not impaired as of June 30, 2019.

Zealand

In March 2019, we purchased $13.8 of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark, see Note 18, “Commitments and Contingencies” for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. We have considered the effects of a six month holding period restriction and determined that the impact on the fair value of the investment is immaterial. During the three and six months ended June 30, 2019, we recognized an unrealized gain of $2.9 and $3.6, respectively, in investment income to adjust our equity investment in Zealand to fair value as of June 30, 2019.

The fair value of this investment was $17.4 as of June 30, 2019.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)


11.	Stockholders' Equity

In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under the repurchase program, which superseded all prior repurchase programs. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.3 shares of our common stock at a cost of $37.6 during the three months ended June 30, 2019. During the six months ended June 30, 2019 and 2018, we repurchased 0.4 and 0.7 shares of our common stock at a cost of $48.9 and $85.0, respectively. The Company did not repurchase any shares during the three months ended June 30, 2018.

Subsequent to June 30, 2019, we repurchased 0.1 shares of common stock under our repurchase program at a cost of $9.0. As of July 22, 2019, there is a total of $393.6 remaining for repurchases under the repurchase program.


12.	Other Comprehensive Income and Accumulated Other Comprehensive Income

The following tables summarize the changes in AOCI, by component, for the six months ended June 30, 2019 and 2018:



	Defined Benefit Pension Plans			Unrealized Gains (Losses) from Debt Securities			Unrealized Gains (Losses) from Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2018	$	(2.6	)	$	(0.3	)	$	9.6		$	(16.4	)	$	(9.7	)
Other comprehensive income (loss) before reclassifications	—			0.2			(28.5		)	(0.5		)	(28.8		)
Amounts reclassified from other comprehensive income	—			—			(19.4		)	—			(19.4		)
Net other comprehensive income (loss)	—			0.2			(47.9		)	(0.5		)	(48.2		)
Balances, June 30, 2019	$	(2.6	)	$	(0.1	)	$	(38.3	)	$	(16.9	)	$	(57.9	)



	Defined Benefit Pension Plans			Unrealized Gains (Losses) from Debt Securities			Unrealized Gains (Losses) from Hedging Activities			Foreign Currency Translation Adjustment			Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2017	$	(4.8	)	$	0.2		$	(13.9	)	$	(15.9	)	$	(34.4	)
Other comprehensive income (loss) before reclassifications	1.3			0.1			27.7			(4.3		)	24.8
Amounts reclassified from other comprehensive income	(0.6		)	(0.5		)	7.8			—			6.7
Net other comprehensive income (loss)	0.7			(0.4		)	35.5			(4.3		)	31.5
Balances, June 30, 2018	$	(4.1	)	$	(0.2	)	$	21.6		$	(20.2	)	$	(2.9	)

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

The table below provides details regarding significant reclassifications from AOCI during the three and six months ended June 30, 2019 and 2018:



Details about Accumulated Other Comprehensive Income Components	Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,						Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,						Affected Line Item in the Condensed Consolidated Statements of Operations
	2019			2018			2019			2018
Unrealized Gains (Losses) on Hedging Activity
Foreign exchange forward contracts	$	9.1		$	(1.7	)	$	16.1		$	(14.8	)	Net product sales
Interest rate swap contracts	4.5			3.1			9.1			4.5			Interest expense
	13.6			1.4			25.2			(10.3		)
	(3.2		)	(0.2		)	(5.8		)	2.5			Income tax (benefit) expense
	$	10.4		$	1.2		$	19.4		$	(7.8	)


13.	Fair Value Measurement

Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.

The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)



		Fair Value Measurement at June 30, 2019
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Money market funds	$	498.5	$	—	$	498.5	$	—
Cash equivalents	Commercial paper	$	240.2	$	—	$	240.2	$	—
Cash equivalents	Bank certificates of deposit	$	12.2	$	—	$	12.2	$	—
Cash equivalents	Other government-related obligations	$	107.0	$	—	$	107.0	$	—
Marketable securities	Mutual funds	$	20.7	$	20.7	$	—	$	—
Marketable securities	Commercial paper	$	33.8	$	—	$	33.8	$	—
Marketable securities	Corporate bonds	$	28.0	$	—	$	28.0	$	—
Marketable securities	Other government-related obligations	$	10.8	$	—	$	10.8	$	—
Marketable securities	Bank certificates of deposit	$	12.1	$	—	$	12.1	$	—
Other assets	Equity securities	$	113.3	$	30.6	$	82.7	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	28.5	$	—	$	28.5	$	—
Other assets	Foreign exchange forward contracts	$	1.1	$	—	$	1.1	$	—
Other current liabilities	Foreign exchange forward contracts	$	23.0	$	—	$	23.0	$	—
Other liabilities	Foreign exchange forward contracts	$	1.8	$	—	$	1.8	$	—
Prepaid expenses and other current assets	Interest rate contracts	$	5.6	$	—	$	5.6	$	—
Other current liabilities	Interest rate contracts	$	10.8	$	—	$	10.8	$	—
Other liabilities	Interest rate contracts	$	52.2	$	—	$	52.2	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	100.0	$	—	$	—	$	100.0
Contingent consideration	Acquisition-related contingent consideration	$	158.2	$	—	$	—	$	158.2
Other current liabilities	Other contingent payments	$	13.9	$	—	$	—	$	13.9
Other liabilities	Other contingent payments	$	13.5	$	—	$	—	$	13.5

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)



		Fair Value Measurement at December 31, 2018
Balance Sheet Classification	Type of Instrument	Total		Level 1		Level 2		Level 3
Cash equivalents	Money market funds	$	569.4	$	—	$	569.4	$	—
Cash equivalents	Commercial paper	$	35.4	$	—	$	35.4	$	—
Cash equivalents	Corporate bonds	$	0.2	$	—	$	0.2	$	—
Cash equivalents	Other government-related obligations	$	8.2	$	—	$	8.2	$	—
Marketable securities	Mutual funds	$	16.5	$	16.5	$	—	$	—
Marketable securities	Commercial paper	$	16.7	$	—	$	16.7	$	—
Marketable securities	Corporate bonds	$	122.6	$	—	$	122.6	$	—
Marketable securities	Other government-related obligations	$	9.3	$	—	$	9.3	$	—
Marketable securities	Bank certificates of deposit	$	33.2	$	—	$	33.2	$	—
Other assets	Equity securities	$	90.8	$	8.9	$	81.9	$	—
Prepaid expenses and other current assets	Foreign exchange forward contracts	$	40.5	$	—	$	40.5	$	—
Other assets	Foreign exchange forward contracts	$	0.3	$	—	$	0.3	$	—
Other current liabilities	Foreign exchange forward contracts	$	18.8	$	—	$	18.8	$	—
Other liabilities	Foreign exchange forward contracts	$	3.1	$	—	$	3.1	$	—
Prepaid expenses and other current assets	Interest rate contracts	$	20.1	$	—	$	20.1	$	—
Other current liabilities	Interest rate contracts	$	0.8	$	—	$	0.8	$	—
Other liabilities	Interest rate contracts	$	17.3	$	—	$	17.3	$	—
Current portion of contingent consideration	Acquisition-related contingent consideration	$	97.6	$	—	$	—	$	97.6
Contingent consideration	Acquisition-related contingent consideration	$	183.2	$	—	$	—	$	183.2

There were no securities transferred between Level 1, 2 and 3 during the six months ended June 30, 2019.

Valuation Techniques

We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.

Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy include money market funds, commercial paper, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.

Other investments in equity securities of publicly traded companies which are subject to holding period restrictions are carried at fair value using an option pricing valuation model and classified as Level 2 equity securities within the fair value hierarchy. The most significant assumptions within the option pricing valuation model are the term of the restrictions and the stock price volatility, which is based upon the historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on such investments.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.

Contingent consideration liabilities related to business acquisitions and derivative liabilities associated with other contingent payments are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.

As of June 30, 2019, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.

Acquisition-Related Contingent Consideration

In connection with prior business combinations, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt of 5.1% for developmental and regulatory milestones and a weighted average cost of capital of 10.0% for sales-based milestones.

Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time.

As of June 30, 2019, estimated future contingent milestone payments related to prior business combinations range from zero if no milestone events are achieved, to a maximum of $702.0 if all development, regulatory and sales-based milestones are reached. In the second quarter 2019, a sales-based milestone associated with our acquisition of Enobia Pharma Corp. was achieved. In connection with such achievement, we will make a $100.0 milestone payment in the third quarter 2019.

As of June 30, 2019, the fair value of acquisition-related contingent consideration was $258.2. The following table represents a roll-forward of our acquisition-related contingent consideration:



	Six months ended
	June 30, 2019
Balance at beginning of period	$	280.8
Changes in fair value	(22.6		)
Balance at end of period	$	258.2

Other Contingent Payments

Each reporting period, we adjust the derivative liability associated with the contingent fees to fair value with changes in fair value recognized in other income and expense. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, change in fair value will only reflect the interest component of the liability related to the passage of time. As of June 30, 2019, the fair value of our contingent fees was $27.4. We recorded $0.3 in other income and (expense) during the three and six months ended June 30, 2019 related to the change in the fair value of the liability.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)


14.	Revenue Recognition

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below.



	Three months ended June 30,				Six months ended June 30,
	2019		2018		2019		2018
SOLIRIS
United States	$	496.3	$	395.8	$	960.0	$	731.8
Europe	280.2		253.4		544.7		504.2
Asia Pacific	110.3		93.6		211.2		179.1
Rest of World	94.0		155.4		226.9		283.2
Total	$	980.8	$	898.2	$	1,942.8	$	1,698.3

ULTOMIRIS
United States	$	54.2	$	—	$	78.8	$	—
Europe	—		—		—		—
Asia Pacific	—		—		—		—
Rest of World	—		—		—		—
Total	$	54.2	$	—	$	78.8	$	—

STRENSIQ
United States	$	106.2	$	99.9	$	205.7	$	189.1
Europe	19.5		16.4		37.0		30.4
Asia Pacific	12.1		6.3		22.0		12.0
Rest of World	3.5		2.5		6.7		4.3
Total	$	141.3	$	125.1	$	271.4	$	235.8

KANUMA
United States	$	15.3	$	13.0	$	29.1	$	24.9
Europe	6.8		5.8		13.1		11.7
Asia Pacific	1.3		1.1		2.1		2.1
Rest of World	2.8		1.5		5.4		2.3
Total	$	26.2	$	21.4	$	49.7	$	41.0

Total Net Product Sales	$	1,202.5	$	1,044.7	$	2,342.7	$	1,975.1

Contract Balances and Receivables

Contract liabilities relate to consideration received and/or billed for goods that have not been delivered to the customer and for which the performance obligation has not yet been completed. These amounts are included within other current liabilities in the condensed consolidated balance sheets.

The following table provides information about receivables and contract liabilities from our contracts with customers.



	June 30, 2019		December 31, 2018
Receivables, which are included in "Trade accounts receivable, net"	$	1,123.6	$	922.3
Contract liabilities, which are included in "Other current liabilities"	$	3.1	$	3.4

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)


15.	Income Taxes

The following table provides a comparative summary of our income tax (benefit) expense and effective income tax rate for the three and six months ended June 30, 2019 and 2018:



	Three months ended						Six months ended
	June 30,						June 30,
	2019			2018			2019			2018
Income tax (benefit) expense	$	39.7		$	38.8		$	(6.4	)	$	141.3
Effective income tax rate	7.9		%	(9.3		)%	(0.6		)%	(210.9		)%

Income tax (benefit) expense is attributable to the U.S. federal, state and foreign income taxes on our profitable operations. During the first quarter 2019, in connection with the future integration of intellectual property of Wilson Therapeutics, with and into the Alexion corporate structure, we recognized certain one-time tax benefits. The deferred tax benefits include $95.7 and $30.3 associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the six months ended June 30, 2019 by approximately 12.1%. Future changes to our intellectual property integration planning could materially impact our effective tax rate in subsequent periods.

On July 1, 2019, the Wilson Therapeutics intellectual property was integrated with and into the Alexion corporate structure. The Company is currently evaluating the impact of the integration on the Company's consolidated financial statements and will record the associated tax effects in the third quarter of 2019.

The income tax expense for the three and six months ended June 30, 2018 includes a decrease in the effective tax rate of approximately 19.4% and 230.1%, respectively, attributable to the acquisition of Wilson Therapeutics. Absent successful clinical results and regulatory approval, there is no alternative future use of the WTX101 asset acquired. Accordingly, the value of the asset of $803.7 was expensed as in-process research and development costs during such three and six month periods, for which no tax benefit has been recognized. Also included in the six months ended June 30, 2018 is a U.S. tax reform measurement period adjustment to deferred taxes of $38.4. This deferred tax cost increased the effective tax rate by approximately 5.2%.

In 2017, the IRS commenced an examination of our U.S. income tax returns for 2015. We anticipate this audit will conclude within the next twelve months. We have not been notified of any significant adjustments proposed by the IRS. It is reasonably possible that previously unrecognized tax benefits could be recognized upon the conclusion of the IRS examination. At this time, an estimate of the change in unrecognized tax benefits cannot be made.

We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign, local, and U.S. state income taxes.

We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.


16.	Defined Benefit Plans

We maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments. The total net periodic benefit cost for the three and six months ended June 30, 2019 and 2018 was not material.


17.	Leases

At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the unique facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

financing lease; and (iv) recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.

Most leases include options to renew and, or, terminate the lease, which can impact the lease term. The exercise of these options is at our discretion and we do not include any of these options within the expected lease term as we are not reasonably certain we will exercise these options. We have elected to combine lease components (for example fixed payments including rent) with non-lease components (for example, non-dedicated parking and common-area maintenance costs) on our real estate and commercial fleet asset classes. We separate lease and non-lease components on our embedded contract manufacturing organization (CMO) arrangements. Lease and non-lease components on these CMO arrangements are determined based on an allocation of the consideration in the contract to the embedded lease and non-lease components of the arrangement based on the relative standalone selling prices of these components.

Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis, while fixed, or in substance fixed, payments on financing leases are recognized using the effective interest method. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our condensed consolidated statements of operations. Financing lease ROU asset amortization and interest costs are recorded within operating expenses and interest expense, respectively, within our condensed consolidated statements of operations. We have operating and financing leases for corporate offices, research and development facilities, regional executive and sales offices, commercial fleet, and CMO embedded lease arrangements. We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.

Operating leases are included in right of use operating assets, other current liabilities, and noncurrent operating lease liabilities in our condensed consolidated balance sheet as of June 30, 2019. Financing leases are included in property, plant and equipment, other current liabilities, and other liabilities in our condensed consolidated balance sheet as of June 30, 2019.

The following table summarizes our lease assets and liabilities as of June 30, 2019:



ROU Assets and Liabilities
	Balance Sheet Location	Financing		Operating
ROU - Asset	Right of use operating assets	$	—	$	209.5
ROU - Asset	Property, plant, and equipment	121.8		—
Lease liabilities (current)	Other current liabilities	5.0		20.3
Lease liabilities (noncurrent)	Noncurrent operating lease liabilities	—		165.5
Lease liabilities (noncurrent)	Other liabilities	75.5		—

The following table summarizes our lease related costs for the three and six months ended June 30, 2019:



Lease Cost
	Statement of Operations Location	Three months ended		Six months ended
		June 30, 2019		June 30, 2019
Financing Lease Cost		$	3.5	$	7.5
Amortization of ROU Assets	Operating Expenses	2.5		5.5
Interest on Lease Liabilities	Interest Expense	1.0		2.0
Operating Lease Cost	Operating Expenses	8.6		17.6
Variable Lease Cost	Operating Expenses	2.3		4.3
Total Lease Cost		14.4		29.4

Amounts above include $3.0 and $6.3 of lease costs associated with our CMO embedded lease arrangement for the three and six months ended June 30, 2019, respectively, which have been capitalized within other assets as a prepayment of inventory.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

The following table summarizes supplemental cash flow information for the three and six months ended June 30, 2019:



Other Information	Three months ended		Six months ended
	June 30, 2019		June 30, 2019
Cash Paid For Amounts Included In Measurement of Liabilities	$	8.8	$	16.4
Operating Cash Flows From Financing Leases	1.0		2.0
Operating Cash Flows From Operating Leases	6.5		11.9
Financing Cash Flows From Financing Leases	1.3		2.5
ROU Assets Obtained In Exchange For New Financing Liabilities ⁽¹⁾	—		—
ROU Assets Obtained In Exchange For New Operating Liabilities ⁽²⁾	20.7		20.7

(1) We capitalized $83.1 of ROU financing assets upon adoption of the new lease standard in the first quarter of 2019 that are excluded from the figures for the six months ended June 30, 2019. This figure excludes $44.2 of opening adjustments to ROU finance assets related, primarily, to prepayments of rent.
(2) We capitalized $172.2 of ROU operating assets upon adoption of the new lease standard in the first quarter of 2019. This figure excludes $26.6 of opening adjustments to ROU operating assets related, primarily, to prepayments of rent.

The following tables summarize maturities of lease liabilities and the reconciliation of lease liabilities as of June 30, 2019:



Lease Liability Maturity Summary
Year	Financing		Operating		Total
2019 (remaining)	$	4.4	$	13.6	$	18.0
2020	8.8		24.8		33.6
2021	9.0		22.1		31.1
2022	9.2		20.8		30.0
2023	9.2		20.5		29.7
2024	9.4		20.2		29.6
Thereafter	54.6		109.3		163.9



Reconciliation of Lease Liabilities	Financing			Operating			Total
Weighted-average Remaining Lease Term (years)	11.17			10.46			10.67
Weighted-average Discount Rate	4.85		%	4.35		%	4.51		%

Total Undiscounted Lease Liability	$	104.6		$	231.3		$	335.9
Imputed Interest	24.0			45.4			69.4
Total Discounted Lease Liability	80.5			185.8			266.3

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

For comparable purposes, our aggregate future minimum non-cancellable commitments under operating leases as of December 31, 2018 were as follows:



Year
2019	$	27.8
2020	24.7
2021	21.3
2022	19.9
2023	19.7
Thereafter	132.2

Excluded from the table above are commitments with Lonza Group AG and its affiliates (Lonza), a third party manufacturer that produces a portion of commercial and clinical quantities of our commercial products and product candidates. During the third quarter 2015, we entered into an agreement with Lonza whereby Lonza constructed a facility to be used to manufacture product under a supply agreement for Alexion at one of its existing facilities, resulting in the determination that the CMO arrangement contained a lease. This agreement requires us to make certain payments during the construction of the manufacturing facility and annual payments for ten years thereafter. As the arrangement contains both a lease and non-lease component, related to the supply of product, the consideration paid to Lonza is allocated between these components. As of December 31, 2018, we had various manufacturing and licensing agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,084.6. This amount includes $88.7 of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza.


18.	Commitments and Contingencies

Asset Acquisition and In-License Agreements

We have entered into asset purchase agreements and license arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any.

In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and could be required to pay up to an additional $30.0 in contingent milestone-dependent fees. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of contingent milestone-dependent fees, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments.

In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase 1 studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was $13.8 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of $5.0 within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $21.2 as research and development expense during the first quarter 2019. As of June 30, 2019, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

milestones, as well as royalties on commercial sales. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.

In March 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the FcRn and is currently in Phase 1 development. The agreement with Affibody was subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and, following receipt of such approval, the transaction closed in April 2019. Pursuant to the agreement, Alexion will lead the clinical development and commercial activities for ABY-039 in rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development of ABY-039 in an undisclosed indication. Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039. Due to the early stage of the asset we are licensing, we recorded the upfront license payment as research and development expense during the second quarter 2019. As of June 30, 2019, we could also be required to pay up to $625.0 for amounts due upon achievement of specific development, regulatory, and commercial milestones, as well as royalties on commercial sales.

In connection with our prior acquisition of Syntimmune (see Note 3), we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones.

In addition, as of June 30, 2019, we have other license agreements under which we may be required to pay up to an additional $838.2 for currently licensed targets, if certain development, regulatory and commercial milestones are met. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.

Asset Sale and Out-License Arrangements

In connection with prior asset sale and out-license arrangements, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of June 30, 2019.

Manufacturing Agreements

We have various manufacturing development and license agreements to support our clinical and commercial product needs.

We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,044.1. This amount includes $102.3 of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to its sale and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.

In addition to our commitments with Lonza, as of June 30, 2019 we have non-cancellable commitments of approximately $65.1 through 2020 with other third party manufacturers.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

Contingent Liabilities

We are currently involved in various claims, disputes, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted.

We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results.

In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures. Alexion is cooperating with these investigations.

The investigations have focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws.

At this time, Alexion is unable to predict the duration, scope or outcome of these investigations. While it is possible that a loss related to these matters may be incurred, given the ongoing nature of these investigations, management cannot reasonably estimate the potential magnitude of any such loss or range of loss, or the cost of the ongoing investigation. Any determination that our operations or activities are not or were not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations.

Alexion is committed to strengthening its compliance program and is currently implementing a comprehensive company-wide transformation plan that is designed to enhance and remediate its business processes, structures, controls, training, talent and systems across Alexion’s global operations.

As previously reported, on December 29, 2016, a shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants’ filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference. During that conference, the court informed counsel that it was preparing a ruling granting the Defendants’ pending motion to dismiss. The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so. On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss. On May 31, 2019, Plaintiffs filed a second amended complaint against the same defendants. The complaint alleges that defendants engaged in securities fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud. The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs. Defendants’ motion to dismiss the

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

amended complaint is due August 2, 2019; plaintiffs’ opposition to that motion is due October 2, 2019; and defendants’ reply in further support of their motion is due November 16, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case, nor can we estimate the possible loss or range of loss at this time.

In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered in to a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid $13.1 to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce.

In May 2017, Brazilian authorities seized records and data from our Sao Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry.

In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time.

On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling. Pursuant to an order made by the Federal Court of Canada, we will place approximately $31.6 in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for the period from September 2017 to June 2019. Pursuant to US GAAP, our revenues for the quarter ended June 30, 2019 were reduced by this amount. In addition, on a quarterly basis until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive.

In October 2018, the Japanese Ministry of Health, Labour and Welfare (MHLW) conducted an administrative inspection of Alexion’s Japanese operations. The MHLW inquiry primarily focused on our communication efforts regarding the proper use of SOLIRIS in Japan for aHUS, among other matters. We have cooperated with the inquiries and the investigation, and in March 2019, the MHLW indicated that it has completed its investigation.

Chugai Pharmaceutical Co., Ltd. has filed two lawsuits against Alexion. The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd. The second lawsuit was filed in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd. Chugai’s complaints seek unspecified damages and certain injunctive relief. In both cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case has been set for May 2021. The case is still at the briefing stage in Japan. Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time.

Alexion Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(amounts in millions, except per share amounts)

On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS: U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleges the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. We expect the PTO to review Amgen’s petitions and Alexion's submissions, and to issue a decision in September 2019 as to whether the PTO will institute IPR. At this time we cannot determine what decision the PTO will make.


19.	Restructuring and Related Expenses

In the first quarter 2019, we initiated corporate restructuring activities to re-align our commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources.

In the first quarter 2017, we initiated a company-wide restructuring designed to help position the Company for sustainable, long-term growth that we believe will further allow us to fulfill our mission of serving patients and families with rare diseases. In September 2017, we committed to an operational plan to re-align the global organization with its refocused corporate strategy. The re-alignment included the relocation of the Company's headquarters to Boston, Massachusetts and a reduction of the Company's global workforce. The restructuring was designed to result in cost savings by focusing the development portfolio, simplifying business structures and process across the Company's global operations, and closing multiple Alexion sites.

The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:



	Three months ended June 30,								Three months ended June 30,
	2019								2018
	Employee Separation Costs		Asset-Related Charges		Other		Total		Employee Separation Costs		Asset-Related Charges		Other		Total
Cost of sales	$	—	$	—	$	—	$	—	$	—	$	0.5	$	—	$	0.5
Research and development	—		—		—		—		—		—		—		—
Selling, general and administrative	—		—		—		—		—		6.5		—		6.5
Restructuring expense	2.4		—		0.1		2.5		3.1		—		7.5		10.6
Other (income) expense	—		—		—		—		—		—		—		—
	$	2.4	$	—	$	0.1	$	2.5	$	3.1	$	7.0	$	7.5	$	17.6



	Six months ended June 30,								Six months ended June 30,
	2019								2018
	Employee Separation Costs		Asset-Related Charges		Other		Total		Employee Separation Costs		Asset-Related Charges		Other			Total
Cost of sales	$	—	$	—	$	—	$	—	$	—	$	5.8	$	—		$	5.8
Research and development	—		—		—		—		—		0.1		—			0.1
Selling, general and administrative	—		—		—		—		—		10.1		—			10.1
Restructuring expense	11.5		—		0.1		11.6		4.1		—		12.0			16.1
Other (income) expense	—		—		—		—		—		—		(0.1		)	(0.1		)
	$	11.5	$	—	$	0.1	$	11.6	$	4.1	$	16.0	$	11.9		$	32.0

The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of June 30, 2019:



	Three months ended June 30,										Six months ended June 30,
	2019										2019
	Employee Separation Costs			Asset Charges		Other Costs		Total			Employee Separation Costs			Asset Charges		Other Costs		Total
Liability, beginning of period	$	10.8		$	—	$	—	$	10.8		$	4.2		$	—	$	—	$	4.2
Restructuring and related expenses	5.3			—		—		5.3			14.2			—		—		14.2
Cash settlements	(3.8		)	—		—		(3.8		)	(6.3		)	—		—		(6.3		)
Adjustments to previous estimates	(2.8		)	—		—		(2.8		)	(2.6		)	—		—		(2.6		)
Asset impairments	—			—		—		—			—			—		—		—
Liability, end of period	$	9.5		$	—	$	—	$	9.5		$	9.5		$	—	$	—	$	9.5

The restructuring reserve of $9.5 and $4.2 is recorded in accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of June 30, 2019 and December 31, 2018, respectively. The accrued amounts are expected to be paid in the next twelve months. We currently estimate incurring up to an additional $10.0 in restructuring expenses related to the first quarter 2019 action.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)


Item 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Note Regarding Forward-Looking Statements

This quarterly report on Form 10-Q contains forward-looking statements. Words such as “anticipates,” "may," "forecasts," “expects,” “intends,” “plans,” "potentially," “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on current expectations, estimates and projections about our industry, management's beliefs, and certain assumptions made by our management, and may include, but are not limited to, statements regarding:


•	the potential benefits and commercial potential of ULTOMIRIS®, SOLIRIS®, STRENSIQ® and KANUMA® for approved indications and any expanded uses;


•	sales of our products in various markets worldwide, pricing for our products, level of insurance coverage and reimbursement for our products, timing regarding development and regulatory approvals for products or for additional indications or in additional territories;


•	plans for clinical trials (and proof of concept trials and exploratory clinical studies), status of our ongoing clinical trials for our product candidates, commencement dates for new clinical trials, clinical trial results and evaluation of our clinical trial results by regulatory agencies;


•	potential benefits offered by product candidates, including improved dosing intervals and potential to improve treatment in a number of IgG-mediated diseases;


•	the medical and commercial potential of additional indications for our products;


•	the expected timing for the completion and/or regulatory approval of our facilities and facilities of our third-party manufacturers;


•	future expansion of our commercial organization and transition to third-parties in certain jurisdictions to perform sales, marketing and distribution functions;


•	future governmental and regulatory decisions regarding pricing (and discounts) and the adoption, implementation and interpretation of healthcare laws and regulations (and the impact on our business);


•	plans and prospects for future regulatory approval of products and product candidates;


•	competitors, potential competitors and future competitive products (including biosimilars);


•	plans to grow our product pipeline (and diversify our business, including through acquisitions) and anticipated benefits to the Company;


•	future objective to expand business and sales;


•	future plans to retain earnings and not pay dividends;


•	expected decisions to appeal certain litigation and intellectual property decisions;


•	expectations to realize the carrying value of product inventory;


•	impact of accounting standards;

•

future costs, operating expenses (including research and development, sales, general and administrative and restructuring expenses) and capital requirements, capital investment, sufficiency of cash to fund operations for at least the next 12 months, ability to fund operations and make payment on credit facility and make contingent payment obligations, the sufficiency of our existing capital resources and projected cash needs, price approval and funding processes in various countries;


•	the sources of expected increases in cash flow from operations, if any;


•	anticipated impact of interest rate changes on financial statements;


•	anticipated future milestone, contingent and royalty payments and lease payments (and, in each case, expected impact on liquidity);


•	timing and anticipated amounts of future tax payments and benefits (including the potential recognition of unrecognized tax benefits), as well as timing of conclusion of tax audits;

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)


•	collection of accounts receivable and impact of any delay in the future in collecting accounts receivable on financial condition and operations, as well as the ability of counterparties to our derivative to perform their obligations;


•	the safety and efficacy of our products and our product candidates;


•	the adequacy of our pharmacovigilance and drug safety reporting processes;


•	the uncertainties involved in the drug development process and manufacturing;


•	performance and reliance on third party service providers;


•	our future research and development activities, plans for acquired programs, our ability to develop and commercialize products with our collaborators;


•	periods of patent, regulatory and market exclusivity for our products;


•	the scope of our intellectual property and the outcome of any challenges or opposition to our intellectual property;


•	estimates of the capacity of manufacturing and other service facilities to support our business operations, products and product candidates.

Such risks and uncertainties include, but are not limited to, increased competition, actions by regulatory agencies, product candidates not receiving regulatory approvals, the possibility that expected tax benefits will not be realized, assessment of impact of recent accounting pronouncements, potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products, delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement, uncertainties surrounding legal proceedings, company investigations and government investigations, including our Securities and Exchange Commission (SEC) and U.S. Department of Justice (DOJ) investigations, the securities class action litigation filed in December 2016, the investigation of our Brazilian operations by Brazilian authorities, risks related to the short and long-term effects of other government healthcare measures, and the effect of shifting foreign exchange rates, as well as those risks and uncertainties discussed later in this report under the section entitled “Risk Factors.” Unless required by law, we undertake no obligation to update publicly any forward-looking statements, whether because of new information, future events or otherwise. However, readers should carefully review the risk factors set forth in this and other reports or documents we file from time to time with the SEC.

Overview

Recent Developments

In March 2019, we entered into an agreement with Affibody AB (Affibody). The agreement became effective in April 2019 following receipt of clearance under the Hart-Scott Rodino Antitrust Improvements Act. Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039, a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn) and is currently in Phase 1 development. We could also be required to pay up to $625.0 for amounts due upon achievement of specific development, regulatory, and commercial milestones, as well as royalties on commercial sales.

In June 2019, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved ULTOMIRIS as a treatment for adult patients with PNH.

In June 2019, the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for the use of ULTOMIRIS as a potential treatment for patients with aHUS in order to inhibit complement-mediated thrombotic microangiopathy (TMA) and set a Prescription Drug User Fee Act (PDUFA) action date of October 19, 2019.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

In June 2019, SOLIRIS was approved by the FDA as a new treatment option for adult patients with NMOSD who have anti-aquaporin-4 auto antibodies.

In July 2019, the European Commission (EC) approved ULTOMIRIS as a treatment for adult patients with PNH with hemolysis with clinical symptoms indicative of high disease activity, and also for adult patients who are clinically stable after having been treated with SOLIRIS for at least the past six months.

Products and Development Programs

We focus our product development programs on life-transforming therapeutics for rare diseases for which current treatments are either non-existent or inadequate. We have developed or are developing innovative products for, among others, the following indications:



Paroxysmal Nocturnal Hemoglobinuria (PNH)	PNH is a chronic, progressive, debilitating and life-threatening ultra-rare blood disorder characterized by intravascular hemolysis (destruction of red blood cells) that is mediated by an uncontrolled activation of the complement system, a part of the immune system. Chronic hemolysis in patients with PNH may be associated with life-threatening thromboses, recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria).



Atypical Hemolytic Uremic Syndrome (aHUS)	aHUS is a severe and life-threatening, ultra-rare genetic disease characterized by chronic uncontrolled complement activation and thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count (thrombocytopenia) and life-threatening damage to the kidney, brain, heart and other vital organs.



Generalized Myasthenia Gravis (gMG)	Myasthenia Gravis (MG) is a debilitating, complement-mediated neuromuscular disease in which patients suffer profound muscle weakness throughout the body, resulting in slurred speech, impaired swallowing and choking, double vision, upper and lower extremity weakness, disabling fatigue, shortness of breath due to respiratory muscle weakness and episodes of respiratory failure.



Hypophosphatasia (HPP)	HPP is an ultra-rare genetic and progressive metabolic disease in which patients experience devastating effects on multiple systems of the body, leading to debilitating or life-threatening complications. HPP is characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, as well as systemic complications such as profound muscle weakness, seizures, pain, and respiratory failure leading to premature death in infants.



Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D)	LAL-D is a serious, life-threatening ultra-rare disease associated with premature mortality and significant morbidity. LAL-D is a chronic disease in which genetic mutations result in decreased activity of the LAL enzyme that leads to marked accumulation of lipids in vital organs, blood vessels, and other tissues, resulting in progressive and systemic organ damage including hepatic fibrosis, cirrhosis, liver failure, accelerated atherosclerosis, cardiovascular disease, and other devastating consequences.



Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Relapsing NMOSD is a severe and ultra-rare autoimmune disease of the central nervous system that primarily affects the optic nerves and the spinal cord. Each relapse of the disorder results in a stepwise accumulation of disability, including blindness and paralysis, and sometimes premature death. Complement activation due to anti-AQP4 antibodies is one of the primary underlying causes of the destruction in these patients.



Wilson Disease	Wilson disease is a rare disorder that can lead to severe liver disease, including cirrhosis and acute liver failure, as well as debilitating neurological morbidities such as impaired movement, gait, speech, swallowing, and psychiatric disorders.



Warm Autoimmune Hemolytic Anemia (WAIHA)	WAIHA is a rare autoimmune disorder caused by pathogenic Immunoglobulin G (IgG) antibodies that react with and cause the premature destruction of red blood cells at normal body temperature. The disease is often characterized by profound, and potentially life-threatening anemia and other acute complications, including severe and life-threatening hemolysis, severe weakness, enlarged spleen and/or liver, rapid heart rate (tachycardia), chest pain, heart failure and fainting (syncope).

Marketed Products

Our marketed products consist of the following:

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)



Product	Therapeutic Area	Approved Indication
	Hematology	Paroxysmal Nocturnal Hemoglobinuria (PNH)


	Hematology	Paroxysmal Nocturnal Hemoglobinuria (PNH)
	Hematology/Nephrology	Atypical Hemolytic Uremic Syndrome (aHUS)
	Neurology	Generalized Myasthenia Gravis (gMG)
	Neurology	Neuromyelitis Optica Spectrum Disorder (NMOSD)
	Metabolic Disorders	Hypophosphatasia (HPP)
	Metabolic Disorders	Lysosomal Acid Lipase Deficiency (LAL-D)

ULTOMIRIS (ALXN1210/ravulizumab-cwvz)

ULTOMIRIS is an innovative, long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. In clinical studies, ULTOMIRIS demonstrated rapid, complete, and sustained reduction of free C5 levels.

In December 2018, ULTOMIRIS was approved by the FDA as a new treatment option for adult patients with PNH in the U.S.

ULTOMIRIS was approved as a new treatment option for adult patients with PNH by the Ministry of Health, Labour and Welfare (MHLW) in Japan in June 2019. ULTOMIRIS was also approved by the European Commission (EC) in July 2019 as a treatment for adult patients with PNH with hemolysis with clinical symptoms indicative of high disease activity, and also for adult patients who are clinically stable after having been treated with SOLIRIS for at least the past six months.

In June 2019, the U.S. FDA accepted for priority review a supplemental Biologics License Application (sBLA) for the use of ULTOMIRIS as a potential treatment for patients with aHUS in order to inhibit complement-mediated thrombotic microangiopathy (TMA) and set a PDUFA action date of October 19, 2019.

SOLIRIS (eculizumab)

SOLIRIS is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in several therapeutic areas, including hematology, nephrology and neurology. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses currently prescribed.

SOLIRIS is approved for the treatment of PNH and for the treatment of pediatric and adult patients with aHUS in the U.S., Europe, Japan and in several other countries. We are sponsoring a multinational registry to gather information regarding the natural history of patients with PNH and aHUS and the longer term outcomes during SOLIRIS treatment.

In 2017, the U.S. FDA and EC approved SOLIRIS for the treatment of refractory gMG in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Additionally, in 2017 the Ministry of Health, Labour and Welfare (MHLW) in Japan approved SOLIRIS as a treatment for patients with gMG who are AChR antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy or plasmapheresis (PLEX).

In June 2019, SOLIRIS became the first U.S. FDA-approved treatment option for adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who have anti-aquaporin-4 auto antibodies. Alexion has submitted applications for SOLIRIS as a treatment for patients with NMOSD to the EMA (January 2019) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) (March 2019).

STRENSIQ (asfotase alfa)

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

STRENSIQ, a targeted enzyme replacement therapy, is the first and only approved therapy for patients with HPP and is designed to directly address underlying causes of HPP by aiming to restore the genetically defective metabolic process, thereby preventing or reversing the severe and potentially life-threatening complications in patients with HPP. STRENSIQ is approved in the U.S. for patients with perinatal-, infantile- and juvenile-onset HPP, Europe for the treatment of patients with pediatric-onset HPP, and Japan for the treatment of patients with HPP. We are sponsoring a multinational registry to gather information regarding the natural history of patients with HPP and the longer-term outcomes during STRENSIQ treatment.

KANUMA (sebelipase alfa)

KANUMA, a recombinant form of the human LAL enzyme, is the only enzyme-replacement therapy that is approved for the treatment for patients with LAL-D. KANUMA is approved in the U.S. for the treatment of patients with LAL-D, Europe for long-term enzyme replacement therapy in patients with LAL-D, and Japan for the treatment of patients with LAL-D. We are sponsoring a multinational registry to gather information regarding the natural history of patients with LAL-D and the longer-term outcomes during KANUMA treatment.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Clinical Development Programs

Our ongoing clinical development programs include the following:



Product	Development Area	Indication	Phase I	Phase II	Phase III	Filed
ULTOMIRIS (ALXN1210/ravulizumab-cwvz) (Intravenous)	Hematology/Nephrology	aHUS				l

	Neurology	gMG			l

ULTOMIRIS (ALXN1210/ravulizumab-cwvz) (Subcutaneous)	Hematology/Nephrology	PNH/aHUS			l

ALXN1810 (Subcutaneous)	Next Generation Subcutaneous Complement Inhibitor		l

ALXN1840 (WTX101)	Metabolic Disorders	Wilson disease			l

ALXN1830 (SYNT001) Intravenous	Hematology	WAIHA		l

ABY-039	FcRn		l

In addition to our ongoing development programs, we hold a minority interest and option to acquire Caelum Biosciences (Caelum), a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class monoclonal antibody (mAb) designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. A Phase 1a/1b study for CAEL-101 has been completed.

ULTOMIRIS (ALXN1210/ravulizumab-cwvz)

ULTOMIRIS is an innovative, long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. In clinical studies, ALXN1210 demonstrated rapid, complete, and sustained reduction of free C5 levels.

Intravenous (IV)

In January 2019, we announced that the Phase III, global, single arm, multicenter study evaluating the safety and efficacy of ALXN1210 administered by IV infusion every 8 weeks to adult patients with aHUS who had never been treated with a complement inhibitor (inhibitor-naïve patients) met its primary objective. In the study's initial 26 week treatment period, 53.6 percent of patients demonstrated complete thrombotic microangiopathy (TMA) response. A second Phase III, single arm, multicenter study to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmaco-dynamics (PD) of ALXN1210 administered by IV infusion every 8 weeks in inhibitor-naïve pediatric patients (including adolescents) with aHUS is ongoing.

In June 2019, the U.S. FDA accepted for priority review our sBLA application for ULTOMIRIS for the treatment of people with aHUS in order to inhibit complement-mediated thrombotic microangiopathy (TMA) and set a target action date of October 19, 2019.

In March 2019, Alexion initiated a Phase III double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ALXN1210 in adult patients for the treatment of gMG.

In addition to aHUS and gMG, Alexion plans to initiate: (i) a clinical study of ALXN1210 in NMOSD; (ii) a proof-of-concept study for ALXN1210 in Amyotrophic Lateral Sclerosis (ALS); and (iii) an exploratory clinical study for ALXN1210 in Primary Progressive Multiple Sclerosis (PPMS).

Subcutaneous (SC) Delivery

In March 2019, Alexion initiated a single, PK-based Phase III study of ALXN1210 delivered subcutaneously once per week to PNH patients to support regulatory approval submissions in both PNH and aHUS.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

ALXN1810 Subcutaneous (SC) Delivery

ALXN1810 combines ALXN1210 with recombinant human hyaluronidase enzyme (rHuPH20) from Halozyme Therapeutics, Inc. to potentially further extend the dosing interval for ALXN1210 SC from once per week to once every two weeks or more. Alexion completed a SC healthy volunteer study with ALXN1810 in December 2018. Strategic planning for the best development path for ALXN1810 is ongoing.

ALXN1840 (WTX101)

ALXN1840 (WTX101), an innovative product candidate that addresses the underlying cause of Wilson disease, is a first-in-class oral copper-binding agent with a unique mechanism of action and ability to access and bind copper from serum and promote its removal from the liver.

ALXN1840 is in Phase III development as a treatment for Wilson disease. In addition, ALXN1840 has received Fast Track designation in the U.S.

ALXN1830 (SYNT001)

ALXN1830 (SYNT001) is a humanized monoclonal antibody that is designed to inhibit the interaction of the neonatal Fc receptor (FcRn) with IgG and IgG immune complexes and has the potential to improve treatment in a number of rare IgG-mediated diseases. Alexion plans to initiate Phase II/III trials in WAIHA and gMG in 2020.

ABY-039

In March 2019, we entered into an agreement with Affibody, through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the FcRn. Following receipt of applicable antitrust approval, the transaction closed in April 2019. Pursuant to the agreement, Alexion is leading the clinical development and commercial activities for ABY-039 in rare IgG-mediated autoimmune diseases. A Phase I study of single ascending doses and multiple ascending doses is ongoing.

Manufacturing

We utilize both internal manufacturing facilities and third party contract manufacturers to supply clinical and commercial quantities of our products and product candidates. Our internal manufacturing capability includes our Ireland facilities, a fill/finish facility in Athlone and a packaging facility in Dublin, as well as facilities in Massachusetts and Georgia. Third party contract manufacturers, including Lonza Group AG and its affiliates (Lonza), provide bulk drug substance as well as other manufacturing services like purification, product filling, finishing, packaging, and labeling.

We have various agreements with Lonza through 2030, with remaining total non-cancellable commitments of approximately $1,044.1. If we

terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangements. Under an existing arrangement, we pay Lonza a royalty on sales of SOLIRIS that was previously manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF). The ARIMF site was sold in 2018. We also pay Lonza a royalty on the sales of ULTOMIRIS and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. Lonza is in the process of qualifying a new manufacturing facility dedicated to Alexion products and commitments entered into under this arrangement are included in the non-cancellable commitments amount noted above.

In addition, we have non-cancellable commitments of approximately $65.1 through 2020 with other third party manufacturers.

In April 2014, we purchased a fill/finish facility in Athlone, Ireland, which has been refurbished to become our first company-owned fill/finish facility. In July 2016, we announced plans to construct a new biologics manufacturing facility at this site, the construction of this facility is on-going and based on current expectations, we anticipate this facility will receive regulatory approval in 2020.

In May 2015, we announced plans to construct a new biologics manufacturing facility on our existing property in Dublin, Ireland, the construction of this facility has commenced and, based on current expectations, we anticipate this facility will receive regulatory approval in 2020.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Critical Accounting Policies and the Use of Estimates

The significant accounting policies and basis of preparation of our consolidated financial statements are described in Note 1, Business Overview and Summary of Significant Accounting Policies of the Consolidated Financial Statements included in our Form 10-K for the year ended December 31, 2018. Under accounting principles generally accepted in the U.S., we are required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosure of contingent assets and liabilities in our financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results could differ materially from those estimates.

We believe the judgments, estimates and assumptions associated with the following critical accounting policies have the greatest potential impact on our consolidated financial statements:


•	Revenue recognition;


•	Contingent liabilities;


•	Inventories;


•	Share-based compensation;


•	Valuation of goodwill, acquired intangible assets and in-process research and development;


•	Valuation of contingent consideration; and


•	Income taxes.

For a complete discussion of these critical accounting policies, refer to “Critical Accounting Policies and Use of Estimates” within “Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations” included within our Form 10-K for the year ended December 31, 2018.

New Accounting Pronouncements

For information on new accounting pronouncements adopted in the current period and recently issued standards, see Note 2, “Basis of Presentation and Principles” to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Results of Operations

Net Product Sales

Net product sales by significant geographic region for the three and six months ended June 30, 2019 and 2018 are as follows:



	Three months ended						Six months ended
	June 30,				%		June 30,				%
	2019		2018		Change		2019		2018		Change
SOLIRIS
United States	$	496.3	$	395.8	25.4	%	$	960.0	$	731.8	31.2	%
Europe	280.2		253.4		10.6	%	544.7		504.2		8.0	%
Asia Pacific	110.3		93.6		17.8	%	211.2		179.1		17.9	%
Rest of World	94.0		155.4		(39.5	)%	226.9		283.2		(19.9	)%
Total	$	980.8	$	898.2	9.2	%	$	1,942.8	$	1,698.3	14.4	%

ULTOMIRIS
United States	$	54.2	$	—	**		$	78.8	$	—	**
Europe	—		—		**		—		—		**
Asia Pacific	—		—		**		—		—		**
Rest of World	—		—		**		—		—		**
Total	$	54.2	$	—	**		$	78.8	$	—	**

STRENSIQ
United States	$	106.2	$	99.9	6.3	%	$	205.7	$	189.1	8.8	%
Europe	19.5		16.4		18.9	%	37.0		30.4		21.7	%
Asia Pacific	12.1		6.3		92.1	%	22.0		12.0		83.3	%
Rest of World	3.5		2.5		40.0	%	6.7		4.3		55.8	%
Total	$	141.3	$	125.1	12.9	%	$	271.4	$	235.8	15.1	%

KANUMA
United States	$	15.3	$	13.0	17.7	%	$	29.1	$	24.9	16.9	%
Europe	6.8		5.8		17.2	%	13.1		11.7		12.0	%
Asia Pacific	1.3		1.1		18.2	%	2.1		2.1		—	%
Rest of World	2.8		1.5		86.7%		5.4		2.3		134.8%
Total	$	26.2	$	21.4	22.4	%	$	49.7	$	41.0	21.2	%

Total Net Product Sales	$	1,202.5	$	1,044.7	15.1	%	$	2,342.7	$	1,975.1	18.6	%

** Percentages not meaningful

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Net Product Sales



	United States		Asia Pacific
	Europe		Rest of World

SOLIRIS net product sales



	United States		Asia Pacific
	Europe		Rest of World

ULTOMIRIS net product sales



	United States		Asia Pacific
	Europe		Rest of World

STRENSIQ net product sales



	United States		Asia Pacific
	Europe		Rest of World

KANUMA net product sales



	United States		Asia Pacific
	Europe		Rest of World

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

The components of the increase in net product sales are as follows:

The increase in net product sales for the three and six months ended June 30, 2019, as compared to the same periods in 2018, was primarily due to an increase in unit volumes of 23.1% and 24.1%, respectively. This increase in unit volumes is primarily due to increased global demand for SOLIRIS therapy including sales to patients with gMG as well as ULTOMIRIS volumes due to the loading doses required in a patient's first year on therapy. Partially offsetting this increase is the conversion of PNH patients in the US from SOLIRIS to ULTOMIRIS. While ULTOMIRIS contributed to the first six months of 2019, the ULTOMIRIS volumes were primarily attributable to PNH patient conversion from SOLIRIS in the U.S. Additional unit volume increases were due to increased demand of STRENSIQ and KANUMA during 2019 as a result of our continuing efforts to identify and reach more patients with HPP and LAL-D globally.

The increase in net product sales for the three and six months ended June 30, 2019, as compared to the same periods in 2018 was partially offset by $31.6 or 3.1% and 1.6%, respectively, as a result of a recent judicial order related to SOLIRIS pricing in Canada. The decision led to a reduction of revenue in the second quarter of 2019, which includes the impact for the period from September 2017 to June 2019 (see Note 18).

As a result of strategic pricing decisions implemented for STRENSIQ in the U.S. that limits annual

treatment costs given weight based dosing, we expect price to be unfavorably impacted for STRENSIQ in the U.S. in future periods as compared to prior periods.

Cost of Sales

Cost of sales includes manufacturing costs, actual and estimated royalty expenses associated with sales of our products, and amortization of licensing rights.

The following table summarizes cost of sales for the three and six months ended June 30, 2019 and 2018:



	2019 Cost of Sales
	2018 Cost of Sales
●	Cost of sales as a percentage of net product sales

The decrease in cost of sales as a percentage of net product sales for the three and six months ended June 30, 2019 as compared to the same periods in 2018, was primarily due to decreases in royalty expenses due to a contract expiration that occurred during the fourth quarter 2018. Additionally, the six months ended 2018 included asset related charges associated with the closure of the ARIMF facility as part of our 2017 restructuring activities (see Note 19).

Research and Development Expense

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)



	2019 Research and Development Expense (R&D)
	2018 Research and Development Expense (R&D)
●	R&D as a % of net product sales

Our research and development expense includes personnel, facility and direct costs associated with the research and development (R&D) of our product candidates, as well as product development costs.

R&D expenses are comprised of costs paid for clinical development, product development and discovery research, as well as costs associated with certain strategic licensing agreements we have entered into with third parties. Clinical development costs are comprised of costs to conduct and manage clinical trials related to eculizumab, ALXN1210 and other product candidates. Product development costs are those incurred in performing duties related to manufacturing development and regulatory functions, including manufacturing of material for clinical and research activities, milestone expenses related to our licensing agreements and other administrative costs incurred during product development. Discovery research costs are incurred in conducting laboratory studies and performing preclinical research for other uses of our products and other product candidates. Upfront payments include upfront payments related to license agreements. Clinical development costs have been accumulated and allocated to each of our programs, while product development and discovery research costs have not been allocated.

Other R&D expenses consist of costs to compensate personnel, to maintain our facilities and equipment, and other occupancy costs associated with our research and development efforts. These costs relate to efforts on our clinical and preclinical products, our product development and our discovery research efforts. These costs have not been allocated directly to each program.

The following graph provides information regarding research and development expenses for the three and six months ended June 30, 2019 and 2018:



	Clinical Development		Discovery
	Product Development		Payroll and Benefits
	Upfront Payments		Facilities and Other

For the three months ended June 30, 2019, the increase in research and development expense, as compared to the same period in the prior year, was primarily related to the following:


•	Increase of $25.0 in upfront payments relating to the license payment made during the second quarter 2019 in connection with the arrangement we entered into with Affibody. No upfront payments related to licensing arrangements were made for the three months ended June 30, 2018.


•	Increase of $6.4 in payroll and benefits primarily related to headcount increases.

Partially offset by the following:


•	Decrease of $15.6 in product development expenses primarily related to a decrease in costs associated with milestone expenses related to our licensing agreements.

For the six months ended June 30, 2019, the increase in research and development expense, as compared to the same period in the prior year, was primarily related to the following:

•Increase of $46.2 in upfront payments relating to the license payments made in connection with the arrangements we entered into with Zealand and

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Affibody. No upfront payments related to licensing arrangements were made for the six months ended 2018.

•Increase of $13.0 in payroll and benefits primarily related to headcount increases.

Partially offset by the following:


•	Decrease of $19.4 in product development expenses primarily related to a decrease in costs associated with the manufacturing of material for ALXN1210 further driven by a decrease in costs associated with milestone expenses.


•	Decrease of $5.2 in external clinical development expenses primarily related to decreases in various eculizumab and ALXN1210 clinical studies (see graph below).

The following graph summarizes R&D expenses related to our clinical development programs. Please refer to "Clinical Development Programs" above for a description of certain of these programs:



	2019		2018



	2019		2018

The successful development of our drug candidates is uncertain and subject to a number of risks. We cannot guarantee that results of clinical trials will be favorable or sufficient to support regulatory approvals for any of our product development programs. We could decide to abandon development or be required to spend considerable resources not otherwise contemplated. For additional discussion regarding the risks and uncertainties regarding our development programs, please refer to Item 1A "Risk Factors" in this Form 10-Q.

Selling, General and Administrative Expense



	2019 Selling General and Administrative Expense (SG&A)
	2018 Selling General and Administrative Expense (SG&A)
●	SG&A as a % of net product sales

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Our selling, general and administrative expense includes commercial and administrative personnel, corporate facility and external costs required to support the marketing and sales of our commercialized products. These selling, general and administrative costs include: corporate facility operating expenses and depreciation; marketing and sales operations in support of our products; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit, government affairs and our global corporate compliance program.

The graph below provides information regarding selling, general and administrative expense:



	Salary, benefits and other labor expense
	External selling, general and administrative expense

For the three months ended June 30, 2019, the increase of $22.0 in selling, general and administrative expense, as compared to the same period in the prior year, was primarily related to the following:


•	Increase in salary, benefits and other labor expenses of $27.4. The increase was primarily related to headcount increases driven by an increase in commercial activities related to SOLIRIS for gMG and increased staff costs associated with commercial support activities including NMOSD pre-launch efforts.

For the six months ended June 30, 2019, the Increase of $46.4 in selling, general and administrative expense, as compared to the same period in the prior year, was primarily related to the following:


•	Increase in salary, benefits and other labor expenses of $51.6. The increase was primarily related to headcount increases driven by an increase in commercial activities related to SOLIRIS for gMG and increased staff costs

associated with commercial support activities including NMOSD pre-launch efforts.

Acquired In-Process Research and Development

The three and six months ended June 30, 2019 includes a benefit of $4.1 to acquired in-process research and development (IPR&D) associated with previously acquired IPR&D related to the Syntimmune acquisition as a result of the agreement of the final working capital adjustment in the second quarter 2019.

For both the three and six months ended June 30, 2018 we recorded IPR&D expense of $803.7 related to the Wilson Therapeutics acquisition completed in the second quarter of 2018. The IPR&D asset associated with the Wilson Therapeutics acquisition has not reached technological feasibility and had no alternative future use as of the acquisition date and was therefore expensed during the second quarter 2018.

Amortization of Purchase Intangible Assets

For both the three and six months ended June 30, 2019 and 2018 we recorded amortization expense of $80.1 and $160.1, respectively, related to purchased intangible assets. Amortization expense is primarily associated with intangible assets related to STRENSIQ and KANUMA, for which we received regulatory approval in the third quarter 2015.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Change in Fair Value of Contingent Consideration

For the three and six months ended June 30, 2019, the expense (income) resulting from the change in fair value of contingent consideration associated with our prior business combinations was $6.1 and $(22.6), respectively, as compared to $4.7 and $57.4 for the three and six months ended June 30, 2018. The change in the fair value of contingent consideration will fluctuate based on the timing of recognition of changes in the probability of achieving and the expected timing of milestone payments in connection with previous acquisitions.

For the three months ended June 30, 2019 and 2018, changes in the fair value of contingent consideration expense reflect the interest component of contingent consideration related to the passage of time. Changes in the fair value of contingent consideration expense for the six months ended June 30, 2019 and 2018 include the impact of changes in the expected timing and probability of achieving contingent milestones, in addition to the interest component related to the passage of time.

Restructuring Expenses

For the three months ended June 30, 2019 and 2018, we recorded $2.5 and $10.6, respectively, compared to $11.6 and $16.1 for the six months ended June 30, 2019 and 2018, respectively, in restructuring expenses. The charges recorded during the three and six months ended June 30, 2019 relate to restructuring

activities initiated in the first quarter 2019 to re-align our commercial organization. The charges recorded during the three and six months ended June 30, 2018 relate to a company-wide restructuring initiated in 2017. (see Note 19)

Other Income and (Expense)

The following table provides information regarding other income and expense:



	Investment (expense) Income
	Interest Expense
	Other Income (expense)

For the three and six months ended June 30, 2019, we recognized investment (expense) income of $(14.9) and $27.6, respectively, primarily related to the recognition of unrealized (losses) gains of $(25.2) and $8.6, respectively, on our strategic equity investments recorded at fair value, with the largest component related to our Moderna Therapeutics Inc. equity investment. For the three and six months ended June 30, 2018, we recognized investment expense of $7.7 and $113.5, respectively. The six months ended June 30, 2018 included the recognition of an unrealized gain of $100.8 on our investment in Moderna Therapeutics, Inc. following the completion of a new round of equity financing in the first quarter 2018.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Income Taxes



	2019 Income Tax (Benefit) Expense
	2018 Income Tax (Benefit) Expense
●	Effective tax rate

During the three and six months ended June 30, 2019, we recorded income tax (benefit) expense of $39.7 and $(6.4) and an effective tax rate of 7.9% and (0.6)%, respectively, compared to income tax expense of $38.8 and $141.3 and an effective tax rate of (9.3)% and (210.9)%, respectively, for three and six months ended June 30, 2018.

record the associated tax effects in the third quarter of 2019.

We continue to benefit from a reduced tax rate as a result of our centralized global supply chain and technical operations in Ireland.

We continue to maintain a valuation allowance against certain other deferred tax assets where realization is not certain. We periodically evaluate the likelihood of realizing deferred tax assets and reduce the carrying amount of these deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized.

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

Financial Condition, Liquidity and Capital Resources

The following table summarizes the components of our financial condition as of June 30, 2019 and December 31, 2018:



	June 30, 2019		December 31, 2018		$ Change
Cash and cash equivalents	$	1,984.2	$	1,365.5	$	618.7
Marketable securities	$	105.4	198.3		(92.9		)
Long-term debt (includes current portion & revolving credit facility)	$	2,579.8	2,862.5		(282.7		)

Current assets	$	4,168.5	3,385.0		783.5
Current liabilities	$	1,031.5	1,174.0		(142.5		)
Working capital	$	3,137.0	2,211.0		926.0

The aggregate increase in cash and cash equivalents and marketable securities of $525.8 at June 30, 2019 as compared to December 31, 2018 was primarily attributable to cash generated from operations and net proceeds from the issuance of common stock under share-based compensation arrangements. Partially offsetting these increases was cash utilized to repurchase shares of common stock, payments on our revolving credit facility and term loan facility, upfront payments related to agreements with Caelum, Zealand and Affibody, and purchases of property, plant, and equipment.

Excluding the impact of any future acquisitions, we expect our annual operating expenses to decrease as a percentage of sales in 2019 as compared to 2018. We also expect reduced capital investment in 2019 as compared to 2018. We anticipate that cash generated from operations and our existing available cash, cash equivalents and marketable securities should provide us adequate resources to fund our operations as currently planned for at least the next twelve months.

We have financed our operations and capital expenditures primarily through positive cash flows from operations. We expect to continue to be able to fund our operations, including principal and interest payments on our Amended and Restated Credit Agreement and contingent payments associated with our in-licenses and acquisitions principally through our cash flows from operations. We may, from time to time, also seek additional funding through a combination of equity or debt financings or from other sources, if necessary for future acquisitions or other strategic purposes. New sources of financing through equity and/or debt financing(s) may not always be available on acceptable terms, or at all, and we may be required to

obtain certain consents in connection with completing such financings.

Financial Instruments

Until required for use in the business, we may invest our cash reserves in money market funds, bank deposits, and high quality marketable debt securities in accordance with our investment policy. The stated objectives of our investment policy are to preserve capital, provide liquidity consistent with forecasted cash flow requirements, maintain appropriate diversification and generate returns relative to these investment objectives and prevailing market conditions.

Financial instruments that potentially expose us to concentrations of credit risk are cash equivalents, marketable securities, accounts receivable and our derivative contracts. As of June 30, 2019, three customers accounted for 52.6% of the accounts receivable balance, with these individual customers accounting for 16.9% to 17.9% of the accounts receivable balance. At December 31, 2018, three customers accounted for 48.7% of the accounts receivable balance, with these individual customers accounting for 14.0% to 19.1% of the accounts receivable balance.

For the three months ended June 30, 2019, three customers accounted for 46.9% of our net product sales with these individual customers accounting for 14.7% to 16.7%. For the six months ended June 30, 2019 four customers accounted for 55.2% of our net product sales with these individual customers accounting for 10.0% to 17.1% of our net product sales. For the three and six months ended June 30, 2018, four customers accounted for 50.3% and 49.7% of our net product sales, respectively, with these individual customers accounting for 10.4% to 16.3% and 10.4% to 16.1% of our net product sales, respectively.

We continue to monitor economic conditions, including volatility associated with international economies and the associated impacts on the financial markets and our business. Substantially all of our accounts receivable are due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance of our customers so that we can appropriately respond to changes in their credit worthiness. We operate in certain jurisdictions where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to collection of our accounts receivable.

We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

of June 30, 2019, we had foreign exchange forward contracts with notional amounts totaling $3,116.2. These outstanding foreign exchange forward contracts had a net fair value of $4.8, of which $29.6 is included in other current assets and noncurrent assets and $24.8 is included in other current liabilities and noncurrent liabilities. As of June 30, 2019, we had interest rate swap contracts with notional amounts totaling $3,581.3. These outstanding interest rate swap contracts had a net fair value liability of $57.4 of which $5.6 is included in other current assets and $63.0 is included in other current liabilities and noncurrent liabilities. The counterparties to these contracts are large domestic and multinational commercial banks, and we believe the risk of nonperformance is not material.

As of June 30, 2019, our financial assets and liabilities were recorded at fair value. We have classified our financial assets and liabilities as Level 1, 2 or 3 within the fair value hierarchy. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Our Level 1 assets consist of mutual fund investments and equity securities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, but substantially the full term of the financial instrument. Our Level 2 assets consist primarily of money market funds, commercial paper, municipal bonds, U.S. and foreign government-related debt, corporate debt securities, certificates of deposit, equity securities subject to holding period restrictions and derivative contracts. Our Level 2 liabilities consist also of derivative contracts. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. Our Level 3 liabilities consist of contingent consideration related to business acquisitions and derivative liabilities associated with other contingent payments.

Business Combinations and Contingent Consideration Obligations

At June 30, 2019, the purchase agreements for our business combinations include contingent payments totaling up to $702.0 that will become payable if and when certain development and commercial milestones are achieved. Of these milestone amounts, $367.0 and $335.0 of the contingent payments relate to development and commercial milestones, respectively. We do not expect these amounts to have a significant impact on our liquidity in the near-term, and, during the next 12 months, we expect to make milestone payments of up to $100.0, associated with our prior business combinations.

As additional future payments become probable, we will evaluate methods of funding payments, which could be made from available cash and marketable

securities, cash generated from operations or proceeds from the sale of equity securities or debt.

Asset Acquisitions and In-License Agreements

In March 2019, we entered into an agreement with Zealand that provides us with exclusive worldwide licenses, as well as development and commercial rights for preclinical peptide therapies subcutaneously delivered for up to four complement pathway targets. Zealand will lead the joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with investigational new drug filing and Phase 1 studies. In addition to the agreement, we made an equity investment in Zealand. Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. We could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial milestones, as well as royalties on commercial sales. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.

In March 2019, we entered into an agreement with Affibody that provides us with an exclusive worldwide license, as well as development and commercial rights to ABY-039, a bivalent antibody-mimetic that targets the neonatal Fc receptor (FcRn) and is currently in Phase 1 development. The agreement with Affibody was subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and, following receipt of such approval, closed in April 2019. Pursuant to the agreement, Alexion will lead the clinical development and commercial activities for ABY-039 in rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development of ABY-039 in an undisclosed indication. Under the terms of the agreement, we made an upfront payment

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

of $25.0 for the exclusive license to ABY-039. As of June 30, 2019, we could also be required to pay up to $625.0 for amounts due upon achievement of specific development, regulatory, and commercial milestones, as well as royalties on commercial sales.

In connection with our prior acquisition of Syntimmune, a clinical-stage biotechnology company developing an antibody therapy targeting the neonatal Fc receptor (FcRn), we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones. In addition, as of June 30, 2019, we have other license and collaboration agreements under which we may be required to pay up to an additional $838.2 for currently licensed targets, if certain development, regulatory and commercial milestones are met. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.

We do not expect the payments associated with milestones under our asset acquisitions and licensing agreements to have a significant impact on our liquidity in the near-term. During the next 12 months, we may make milestone payments related to these arrangements of approximately $73.1.

As additional future payments become probable, we will evaluate methods of funding payments, which could be made from available cash and marketable securities, cash generated from operations or proceeds from the sale of equity securities or debt.

Operating and Financing Lease Liabilities

Operating and financing lease liabilities are recorded at lease commencement based on the present value of fixed, or in substance fixed, lease payments over the expected lease term. Lease liabilities are amortized over the lease term.

At June 30, 2019, we have $266.3 of total financing and operating lease liabilities recorded on our condensed consolidated balance sheets. The total undiscounted lease commitments as of June 30, 2019 were $335.9, of which, $35.3 is payable during the next 12 months. Refer to Note 17 Leases for a summary of the maturity of our lease liabilities by year. We do not expect the payments associated with the maturity of lease liabilities to have a significant impact on our liquidity in the near-term.

Long-term Debt

On June 7, 2018, Alexion entered into an Amended and Restated Credit Agreement (the Credit Agreement) with Bank of America, N.A. as administrative agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).

The Credit Agreement provides for a $2,612.5 term loan facility and a $1,000.0 revolving credit facility. Borrowings can be used for working capital requirements, acquisitions and other general corporate purposes. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments.

As of June 30, 2019, we had $2,579.8 outstanding on the term loan. As of June 30, 2019, we had open letters of credit of $1.0 that offset our availability in the revolving facility. In January 2019 we paid the outstanding balance on the revolving credit facility of $250.0 in full and we had no outstanding borrowings under the revolving credit facility as of June 30, 2019.

Manufacturing Obligations

We have supply agreements with Lonza relating to the manufacture of SOLIRIS and STRENSIQ and ULTOMIRIS which requires payments to Lonza at the inception of contract and upon the initiation and completion of product manufactured. On an ongoing basis, we evaluate our plans for future levels of manufacturing by Lonza, which depends upon our commercial requirements and the progress of our clinical development programs.

We have various agreements with Lonza, with remaining total non-cancellable commitments of approximately $1,044.1 through 2030. Certain commitments may be canceled only in limited circumstances. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at Alexion Rhode Island Manufacturing Facility (ARIMF) prior to its sale and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.

In addition to Lonza, we have non-cancellable commitments of approximately $65.1 through 2020 with other third party manufacturers.

Taxes

Common Stock Repurchase Program

In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that

Alexion Pharmaceuticals, Inc.

(amounts in millions, except per share amounts)

we are authorized to expend on future repurchases to $1,000.0 under the repurchase program, which superseded all prior repurchase programs. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.3 shares of our common stock at a cost of $37.6, during the three months ended June 30, 2019. The Company did not repurchase any shares during the

three months ended June 30, 2018. During the six months ended June 30, 2019 and June 30, 2018, we repurchased 0.4 and 0.7 shares of our common stock at a cost of $48.9 and $85.0, respectively. Subsequent to June 30, 2019, we repurchased 0.1 shares of our common stock under our repurchase program at a cost of $9.0. As of July 22, 2019, there is a total of $393.6 remaining for repurchases under the repurchase program.

Cash Flows

The following summarizes our net change in cash and cash equivalents:



	Six months ended June 30, 2019						$
	2019			2018			Change
Net cash provided by (used in) operating activities	$	968.3		$	(44.5	)	$	1,012.8
Net cash provided by (used in) investing activities	(38.1		)	313.6			(351.7		)
Net cash used in financing activities	(313.5		)	(116.5		)	(197.0		)
Effect of exchange rate changes on cash	0.7			(6.1		)	6.8
Net change in cash and cash equivalents	$	617.4		$	146.5		$	470.9

Operating Activities

Cash flows provided by (used in) operations for the six months ended June 30, 2019 was $968.3 compared to $(44.5) for the six months ended June 30, 2018. The increase in cash was primarily due to the acquisition of Wilson Therapeutics in the second quarter 2018. This increase was offset by upfront payments made in connection with agreements entered into with Zealand and Affibody, and decreases due to the timing of cash receipts and other payments during the six months ended June 30, 2019 as compared to the same period in the prior year.

We expect increases in cash flows from operations, if any, which will be highly dependent on sales levels and the related cash collections from sales of our products.

Investing Activities

Cash flows provided by (used in) investing activities for the six months ended June 30, 2019 was $(38.1) compared to $313.6 for the six months ended June 30, 2018. The increase in cash used in investing activities as compared to the prior year was primarily attributable to purchases and sales of available-for-sale debt securities, which resulted in a net cash inflow of $98.2 for the six months ended June 30, 2019, compared to net cash inflow of $442.0 for the six months ended June 30, 2018. Purchases of strategic equity investments for Zealand and Caelum resulted in $43.8 in cash outflows during the six months ended June 30, 2019 with no comparable activity in the prior year. Offsetting these impacts were decreases in purchases of property, plant and equipment during the six months ended June 30, 2019 as compared to the same period in the prior year.

Financing Activities

Cash flows used in financing activities for the six months ended June 30, 2019 was $(313.5) compared to $(116.5) for the six months ended June 30, 2018. The increase in cash used for financing activities was primarily due to an increase in payments on our revolving credit facility and term loan facility of $282.7 and reduced common stock repurchases, as compared to the six months ended June 30, 2018.

Contractual Obligations

Other than potential payments related to agreements with Caelum, Zealand and Affibody, there have been no significant changes to the disclosure of payments we have committed to make under our contractual obligations as summarized in our Annual Report on Form 10-K for the twelve months ended December 31, 2018, in the section titled “Management's Discussion and Analysis of Financial Condition and Results of Operations” under the caption “Contractual Obligations.”


Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

(amounts in millions, except

percentages)

Interest Rate Risk

As of June 30, 2019, we invested our cash in a variety of financial instruments, principally money market funds, corporate bonds, municipal bonds, commercial paper and government-related obligations. Most of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Our investment portfolio is comprised of marketable debt securities of highly rated financial institutions and investment-grade debt instruments, and we have guidelines to limit the term-to-maturity of our investments. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1%, the fair value of our investment portfolio would increase (decrease) by approximately $(0.5) and $0.5, respectively.

On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America N.A. as administrative agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Agreement). Loans under the Credit Agreement bear interest at our option, at either the base rate or a Eurodollar rate, in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.25% to 1.00% and the applicable margins on Eurodollar loans range from 1.25% to 2.00%, in each case based on our consolidated net leverage ratio (as calculated in accordance with the Credit Agreement).

Changes in interest rates related to the Credit Agreement could have a material effect on our financial statements.

To achieve a desired mix of floating and fixed interest rates on our term loan, we entered into a number of interest rate swap agreements that qualified for and are designated as cash flow hedges. As of June 30, 2019 we had cash flow hedges with aggregate amounts of approximately 78.1% of our current outstanding term loan covering periods over the next twelve months. If interest rates were to increase or decrease by 1%, interest expense over the next year would increase or decrease by $5.0, based on the unhedged portion of our outstanding term loan as of June 30, 2019.

Foreign Exchange Market Risk

Our operations include activities in many countries outside the U.S. As a result, our financial results are impacted by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets where we operate. We have exposure to movements in foreign currency exchange rates, the

most significant of which are the Euro, and Japanese Yen, against the U.S. dollar. We are a net receiver of many foreign currencies, and our consolidated financial results benefit from a weaker U.S. dollar and are adversely impacted by a stronger U.S. dollar relative to foreign currencies in which we sell our products.

Our monetary exposures on our balance sheet arise primarily from cash, accounts receivable, and payables denominated in foreign currencies. Approximately 42.2% and 43.5% of our net product sales were denominated in foreign currencies for the three and six months ended June 30, 2019, respectively, and our revenues are also exposed to fluctuations in the foreign currency exchange rates over time. In certain foreign countries, we may sell in U.S. dollar, but our customers may be impacted adversely by fluctuations in foreign currency exchange rates which may also impact the timing and amount of our revenue.

Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates are only partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. Additionally, we have operations based in Europe and accordingly, our expenses are impacted by fluctuations in the value of the Euro against the U.S. dollar.

We currently have a derivative program in place to achieve the following: (1) limit the foreign currency exposure of our monetary assets and liabilities on our balance sheet, using contracts with durations of up to 8 months and (2) hedge a portion of our forecasted product sales (in some currencies), including intercompany sales, and certain forecasted expenses using contracts with durations of up to 60 months. The objective of this program is to reduce the volatility of our operating results due to fluctuation of foreign exchange. This program utilizes foreign exchange forward contracts intended to reduce, not eliminate, the volatility of operating results due to fluctuations in foreign exchange rates.

As of June 30, 2019 and December 31, 2018, we held foreign exchange forward contracts with notional amounts totaling $3,116.2 and $2,523.0, respectively. As of June 30, 2019 and December 31, 2018, our outstanding foreign exchange forward contracts had a net fair value of $4.8 and $18.9, respectively.

We do not use derivative financial instruments for speculative trading purposes. The counterparties to these foreign exchange forward contracts are large domestic and multinational commercial banks. We believe the risk of counterparty nonperformance is not material.

Based on our foreign currency exchange rate exposures as of June 30, 2019, a hypothetical 10% adverse fluctuation in exchange rates would decrease

the fair value of our foreign exchange forward contracts that are designated as cash flow hedges by approximately $117.3 as of June 30, 2019. The resulting loss on these forward contracts would be offset by the gain on the underlying transactions and therefore would have minimal impact on future anticipated earnings and cash flows. Similarly, adverse fluctuations in exchange rates that would decrease the fair value of our foreign exchange forward contracts that are not designated as hedge instruments would be offset by a positive impact of the underlying monetary assets and liabilities.

Credit Risk

As a result of our foreign operations, we are exposed to changes in the general economic conditions in the countries in which we conduct business. The majority of our receivables are due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. Although collection of our accounts receivables from certain countries may extend beyond our standard credit terms, we do not expect any such delays to have a material impact on our financial condition or results of operations.


Item 4.	CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act), as of June 30, 2019. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2019, our disclosure controls and procedures were effective to provide reasonable assurance that information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure, and ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION


Item 1.	LEGAL PROCEEDINGS.

For a discussion of legal matters as of June 30, 2019, see Note 18, “Commitments and Contingencies,” Contingent Liabilities, within our notes to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.

Item 1A.Risk Factors.

(amounts in millions, except percentages)

You should carefully consider the following risk factors before you decide to invest in Alexion securities and our business, because the risks described below may have a material impact on our business, operating results, financial condition, and cash flows. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. If any of the following risks actually occurs, our business, financial condition and results of operations could be materially and adversely affected.

Risks Related to Revenue Concentration

We depend on the success of, and revenue from, SOLIRIS and if patients do not switch from SOLIRIS to ULTOMIRIS or ULTOMIRIS does not gain market acceptance, our future operating results may be adversely impacted.

Since 2007, our revenue has depended primarily on the sales of SOLIRIS. Unless we are able to develop or acquire new products and technologies, successfully commercialize ULTOMIRIS (and facilitate conversion from SOLIRIS to ULTOMIRIS for approved indications) as described below, and/or materially increase sales of STRENSIQ and KANUMA (two of our other currently approved products), we will remain dependent on sales of SOLIRIS as a source of our revenue.

The commercial success of SOLIRIS and our ability to generate revenue depends on several factors, including: the safety and efficacy of SOLIRIS; coverage or reimbursement by government or third-party payers for SOLIRIS; pricing for SOLIRIS; the analysis by doctors and patients of the cost of SOLIRIS relative to the perceived benefits; manufacturing and uninterrupted supply; the introduction of and success of competing products by competitors (including novel products and biosimilars to SOLIRIS); the size of patient populations and the number of patients diagnosed who may be treated with SOLIRIS; the impact of legal, administrative, regulatory or legislative developments; and our ability to develop, obtain regulatory approval for and commercialize SOLIRIS for new indications. Any of these or other factors may cause revenues from sales of SOLIRIS to decrease which would harm our business results as SOLIRIS accounts for a significant portion of our revenues.

While SOLIRIS has been studied for indications beyond PNH, aHUS, gMG and NMOSD (which are the current approved indications of SOLIRIS in the U.S.), there is no guarantee that we can obtain regulatory approval or achieve any commercial sales of SOLIRIS for other indications. Despite positive topline results from the Phase 3 PREVENT study of SOLIRIS in patients

with anti-aquaporin-4 (AQP4) auto antibody-positive NMOSD and regulatory approval from the FDA in June 2019, we may not be able to obtain regulatory approval to sell SOLIRIS as a treatment for NMOSD in the EU, Japan or any other jurisdiction outside the U.S. (or for SOLIRIS for any other proposed indications not yet approved) due to the failure to meet applicable regulatory requirements. Additionally, even if we obtain regulatory approval, physicians and patients may not accept SOLIRIS as a treatment for NMOSD or payers may not be willing to pay for or reimburse the costs of SOLIRIS as a therapy for NMOSD.

If we are not able to maintain revenues from sales of SOLIRIS, or our SOLIRIS revenues decrease, our operating results would be negatively impacted and our ability to fund research and development programs for the discovery and commercialization or acquisition of new products would be harmed, which would limit our ability to diversify our revenue base and our stock price could be adversely affected.

ULTOMIRIS has very recently been approved for adult patients with PNH by the FDA, the Ministry of Health, Labour and Welfare (MHLW) and the European Medicines Agency (EMA) (and we may submit applications for approval of ULTOMIRIS for patients with PNH in additional jurisdictions). In addition, we have submitted application for approval of ULTOMIRIS for patients with aHUS in the U.S.

One of our principal business objectives is to facilitate the conversion of PNH patients from SOLIRIS to ULTOMIRIS. While clinical trials demonstrated that ULTOMIRIS is non-inferior to SOLIRIS at an 8 week dosing interval (compared to a 2 week dosing interval for SOLIRIS), existing PNH patients taking SOLIRIS and their physicians may decline to switch to ULTOMIRIS for many reasons including: reluctance to try a new therapy, lack of clinical evidence that ULTOMIRIS is superior to SOLIRIS, no (or limited) reimbursement by government or third-party payers (including as a result of SOLIRIS being available as an alternative therapy), or our inability to manufacture quantities necessary to meet demands.

If we achieve our goal of promptly facilitating the conversion of current PNH patients from SOLIRIS to ULTOMIRIS, we anticipate that revenue from SOLIRIS, which accounted for approximately $3,563.0, or 86.3%, of our revenues in 2018, will decline as we move patients to ULTOMIRIS. We have established a price for ULTOMIRIS in the U.S. that, on an annual basis, represents an approximate 10% discount to the cost of current labeled maintenance therapy for SOLIRIS for adult PNH patients of average weight (and we have implemented a similar pricing strategy in Germany for ULTOMIRIS for adult PNH patients (Germany is the first country where ULTOMIRIS was launched in Europe following EMA approval in July 2019)). However, this represents an approximate 10% premium to the cost of SOLIRIS in a patient’s first year of switching due to the

loading doses required. We also expect to price ULTOMIRIS for patients with aHUS in the U.S. at a discount to the cost of SOLIRIS for patients with aHUS in the U.S. (if and when we receive regulatory approval of ULTOMIRIS for the treatment of aHUS in the U.S.) and such discount is anticipated to be approximately 30% on an annual basis for an average adult patient maintenance therapy.

In addition to the potential decrease in revenue due to the above described discounts of ULTOMIRIS (compared to SOLIRIS) as we attempt to facilitate conversion from SOLIRIS, if we are unable to facilitate such conversion to ULTOMIRIS (and subsequently maintain those patients on ULTOMIRIS) prior to the loss of intellectual property or regulatory exclusivities for SOLIRIS, our future revenues would be adversely impacted as we would expect that we would face biosimilar competition for SOLIRIS and these biosimilars would have comparable safety and efficacy to SOLIRIS and would be sold at a discount to SOLIRIS.

Risks Related to Pricing and Reimbursement

Sales of our products depend on reimbursement by government authorities, private health insurers and other organizations, each of which are subject to pressures to contain costs. If we are unable to obtain, or maintain at anticipated levels, reimbursement for and access to our products, or coverage is reduced, our pricing may be adversely affected or our product sales, results of operations or financial condition could be harmed.

Our products are significantly more expensive than traditional drug treatments and almost all patients require governmental payers, such as Medicare and Medicaid in the U.S. or country specific governmental organizations in foreign countries, and/or private third-party payers to pay all or a portion of the cost of our products. There is also a significant trend in the health care industry by public and private payers to contain or reduce their costs. As a result, payers have in the past (i) decreased the portion of costs they will cover, (ii) ceased providing adequate payment for our products or (iii) not covered our products at all, each of which payers may continue to do in the future (or other payers who have not taken such actions in the past may do so in the future). Any of the foregoing may have an adverse impact on our revenue and results of operations.

Our ability to set the price for our products varies significantly from country to country, including in those countries where pricing, coverage, reimbursement or funding of prescription drugs are subject to governmental control. We may be unable to timely or successfully negotiate coverage, pricing and reimbursement on terms that are favorable to us (or at all), or such coverage, pricing and reimbursement may differ in separate regions in the same country. In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed, which

could delay market entry (or, if pricing is not approved, we may be unable to sell at all in a country where we have received regulatory approval for a product). In addition, authorities in some countries impose additional obligations, such as HTAs, which assess how well a pharmaceutical works in relation to its cost. Additionally, U.S. payers are increasingly considering new metrics as the basis for reimbursement rates. If our products do not meet or surpass these metrics, including any HTAs and other metrics imposed on our products, these payers may not reimburse for use of our products or may reduce the rate of reimbursement for our products and as a result we expect revenue from such product may decrease. We may also, in some cases, elect to reduce prices or reimbursement with third parties which we believe provides value in the long term (but may impact revenue in the near term).

In the United States, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement governmental controls on pharmaceutical pricing. The U.S. presidential administration recently unveiled a number of proposals to implement such controls, among these was a recommendation to move from the current U.S. pricing and reimbursement regime to one that would establish pharmaceutical pricing by reference to a target price derived from the international price index (such a change may be expected to result in significant savings for the government for purchases of certain pharmaceuticals). Certain states have also proposed measures that are designed to control the costs of pharmaceuticals that they reimburse. If the U.S. (through the federal or state governments), which accounted for a significant portion of our revenue in 2018, were to move to a pricing system based on the international price index (or similar model) that were to apply to our products, we expect that our revenues for sales in the U.S. (or any other country adopting such a price index) may decrease, and such decrease may be material in amount.

Further, other countries have already established pricing and reimbursement amounts by reference to the price of the same or similar products in other countries. Therefore, if coverage or the level of reimbursement is reduced, limited or eliminated in one or more countries, we may be unable to obtain or maintain anticipated pricing or reimbursement in other countries or in new markets. In Canada, for example, the Federal Court of Canada recently confirmed the decision of the Patented Medicine Prices Review Board (PMPRB) that we had excessively priced SOLIRIS and ordered that the price be decreased to no higher than the lowest price in seven comparator countries (See Note 18 to the condensed consolidated financial statements for more information on this matter). If upheld, we expect that this lower price may have an adverse impact in Canada and in the jurisdictions that set prices by reference to prices in Canada.

Due to the cost of our therapies, any potential increase in the number of patients receiving our products (for example, we expect there may be increases in sales of SOLIRIS for patients with NMOSD as we launch for that indication in the U.S. and if that indication is approved by regulatory authorities in the EU and Japan), may cause third-party payers to modify, limit or eliminate coverage or reimbursement for our products because they may require an allocation of a greater percentage of the potential financial resources of any public or private payer for our products.

Further, health insurance programs may utilize coverage incentives and obstacles to discourage beneficiaries from using higher priced products such as ours, including:


•	establishing formularies under which only selected drugs are covered (which may exclude one or more of our products);


•	utilizing variable co-payments that make drugs that are not preferred by the payer more expensive for patients; and


•	utilizing management controls, such as requirements for prior authorization or failure first on another type of treatment.

Any of these actions may subject our products to payer-driven restrictions.

In countries where patients have access to insurance, their insurance co-payment amounts or other benefit limits may represent a barrier to obtaining or continuing use of our products or adoption of new treatment options, such as ULTOMIRIS. The imposition or continuation of the use of these types of limits or barriers by insurers or the imposition of similar limitations or barriers in the future may have an adverse impact on our revenue and results of operations. In some cases, we have financially supported non-profit organizations that assist patients in accessing treatment for PNH and aHUS, including SOLIRIS, among other therapies. Such organizations assist patients whose insurance coverage imposes prohibitive co-payment amounts or other expensive financial obligations. Such organizations’ ability to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be provided at adequate levels, if at all. We have also provided our products without charge to patients who have no insurance (or limited insurance) coverage for drugs through related charitable purposes. We are not able to predict the financial impact of the support we may provide for these and other charitable purposes; however, substantial support could have a material adverse effect on our profitability in the future. As third-party payers attempt to contain health care costs they are demanding price discounts or rebates and limiting both the types and variety of drugs that they may cover and the amounts that they will pay for drugs.

As a result, they may not cover or provide adequate payment to patients for our products or they may demand discounts or rebates from us, which may be material.

Our commercial success depends on obtaining and maintaining pricing for our products, which is directly tied to reimbursement for our products at anticipated levels for our products. It is difficult to project the impact of evolving reimbursement mechanics on the willingness of payers to cover our products, but we expect pharmaceutical pricing to continue to be subject to intense payer, political and societal pressures on a global basis. If we are unable to obtain or maintain coverage for our products, or coverage is reduced or eliminated in one or more countries or if the U.S. (or other countries) were to move to an international price index (or comparable price control mechanism(s) for our products, our pricing, product sales, results of operations or financial condition could be harmed.

Risks Related to Our Products and Product Candidates

Our future commercial success depends on gaining regulatory approval for new products and obtaining approvals for existing products for new indications.

We have invested, and continue to invest, significant amounts in acquiring new products and technologies and advancing our existing product candidates and technologies. Our long-term success and revenue growth and diversification will depend upon the successful identification, acquisition (including licenses from third parties), development and commercialization of new products and technologies, and approval of additional indications for our existing products and products under development. Product development (including products acquired in connection with acquisitions) is very expensive, takes significant time to obtain regulatory approval and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. The process for obtaining regulatory approval to market a biologic is expensive, often takes many years, and can vary substantially based on the type, complexity, the novelty of the product candidates involved and the indications to be treated. Further, success in early clinical trials, which may lead to further investment in a product candidate by us, may not result in success in later stage trials. In addition, our recent acquisitions have focused on new technologies with which we have very limited experience, including antibody therapeutics targeting the neonatal Fc receptor, which may make the development, approval and commercialization of such potential products challenging for us.

Our ability to maintain or grow revenues may be adversely affected if we are delayed or unable to successfully develop the products in our pipeline, if we are unable to gain approval for SOLIRIS and ULTOMIRIS for additional indications and in new jurisdictions, obtain

marketing approval for STRENSIQ and KANUMA in additional territories, obtain approval for additional delivery systems for our therapies (such as subcutaneous administration) or acquire or license products and technologies from third parties.

If we do not obtain regulatory approval of new products or additional indications for existing products or additional delivery systems, or are significantly delayed or limited in doing so, our revenue may be adversely affected, we may experience surplus inventory, we may be required to write down certain assets, our business may be materially harmed and we may need to significantly curtail operations.

We develop therapies for rare diseases with limited patient populations that have not been definitively determined, and our success will depend on our ability to identify patients in the disease areas we target.

The therapies that we have developed and that are in our product pipeline and in preclinical development target diseases that have a limited number of patients and for which, in many cases, there are either no or limited diagnostics tools. For example, KANUMA and STRENSIQ are currently approved to treat ultra-rare diseases with small patient populations that have not been definitively determined. Our development pipeline programs that may be the basis for future revenue growth also focus on rare (and ultra-rare) diseases for which there are a very limited number of patients. The lack of diagnostic tools, coupled with the fact that there is frequently limited awareness among certain health care providers concerning the rare diseases we treat, often means that a proper diagnosis can, and frequently does, take years to identify (or an appropriate diagnosis may never be made for certain patients). As a result, we may not be able to grow our revenues (even as we introduce new products or as existing products are approved for additional indications). There can be no guarantee that any of our programs will be effective at identifying patients, and even if we can identify patients that our therapies can help, the number of patients that our therapies treat may turn out to be lower than we expect, may not be otherwise amenable to treatment with our products (such as KANUMA and STRENSIQ), or new patients may become increasingly difficult to identify, all of which may adversely affect our results of operations and our business. In addition, even in instances where we do add patients, the number may be less than the number of patients that discontinue use of the applicable product in a given period resulting in a net loss of patients and potentially decreased revenue.

We may not be able to gain or maintain market acceptance of our products among the medical community, patients or payers, which could prevent us from maintaining profitability or growth.

Our products may not gain or maintain market acceptance among physicians, patients, healthcare payers and others. Although we have received regulatory approval for certain of our products in certain territories, such approvals do not guarantee future revenue. We cannot predict whether physicians, other healthcare providers, government agencies or private insurers will determine or continue to accept that our products are safe and therapeutically effective and that the benefits are meaningful relative to the cost. Nor can we predict whether patients, physicians or payers will continue use of SOLIRIS or elect to convert to ULTOMIRIS in the U.S., the EU or Japan (or other jurisdictions if and when approved for use by the appropriate regulatory authorities) or elect to utilize alternative treatments that may become available (which may be sold at a significant discount to SOLIRIS or ULTOMIRIS). Physicians’ willingness to prescribe, and patients’ willingness to accept, our products, depends on many factors, including:


•	prevalence and severity of adverse side effects in both clinical trials and commercial use;


•	the timing of the market introduction of competitive drugs and biosimilars;


•	demonstrated clinical safety and efficacy compared to other drugs;


•	perceived cost-effectiveness and/or evaluations in health technology assessments (HTAs);


•	pricing and availability of reimbursement from third-party payers, including governmental entities;


•	convenience and ease of administration;


•	effectiveness of our marketing strategy;


•	publicity concerning our products and our other product candidates (and those of competitive products); and


•	availability of alternative treatments.

The likelihood of physicians to prescribe SOLIRIS for patients with aHUS (and ULTOMIRIS, if approved for use by aHUS patients) may also depend on how quickly SOLIRIS can be delivered to the hospital or clinic and our distribution methods may not be sufficient to satisfy this need. In addition, we are aware that some healthcare providers have determined not to continue SOLIRIS treatment for some patients with aHUS. While SOLIRIS as a treatment for aHUS is recommended by some regulatory authorities to be used for the duration of a patient’s lifetime, we are aware that some healthcare providers prescribe SOLIRIS for aHUS for a shorter time period and, in some cases, may prescribe SOLIRIS for aHUS in emergency or acute situations only. Decisions such as this by aHUS patients and healthcare providers to use our products for a period that is less than the remaining lifetime of the patient or in only acute circumstances can cause our SOLIRIS revenues, and

revenues for our other products, to fluctuate and past sales of our products may not be indicative of future sales for such products.

If our products fail to achieve or maintain market acceptance among the medical community or patients in a particular country, we may not be able to market and sell our products successfully in such country, which may limit our ability to generate revenue and could harm our overall business.

If our products harm patients, or are perceived to harm patients even when such harm is unrelated to our products, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.

The testing, manufacturing, marketing and sale of biologics for use in humans may cause harm to patients, which exposes us to product liability risks and regulatory penalties.

Our products and our product candidates treat patients with rare diseases and, as a result, we generally are able to test our products in only a small number of patients. As more patients use our products, including more children and adolescents, new risks and side effects may be discovered, the rate of known risks or side effects may increase, and risks previously viewed as less significant could be determined to be significant. Previously unknown risks and adverse effects may also be discovered in connection with unapproved uses of our products, which may include administration of our products under acute emergency conditions, such as the Enterohemorrhagic E. coli health crisis in Europe, primarily Germany, which began in May 2011. Under pharmacovigilance guidelines, we are required to timely report any adverse events any patient using our products experiences and any clinical evaluations of outcomes in the post-marketing setting are required to be reported to appropriate regulatory agencies in accordance with relevant regulations, as a result any potential adverse events will be promptly brought to the attention of regulators that may likely require prompt remedial action (and any failure to report these adverse events or report such events in a timely manner may result in penalties being imposed on Alexion by regulators). In the event any new risks or adverse effects discovered as new patients are treated for approved indications, or as our products are studied in or used by patients for other indications, regulatory authorities may delay or revoke their approvals, we may be required to conduct additional clinical trials and safety studies, make changes in labeling, reformulate our products or make changes and obtain new approvals for our and our suppliers’ manufacturing facilities. If we experience any of the foregoing actions, it may harm our reputation and, particularly given that we rely on a very limited number of products for our revenue, our business and results of operations could be materially and adversely

impacted. Further, any investigation into the circumstances surrounding an adverse event may be costly and time consuming (even if it is ultimately determined that the adverse event is not the result of the use of our product) or the investigation may not be sufficiently conclusive to prevent a regulatory authority from taking one of the foregoing actions against us.

In addition, many patients who use our products are already very ill and may suffer adverse events, including death, during treatment for reasons that may or may not be related to our products. Also, there are risks associated with our products; for example, use of C5 Inhibitors, such as SOLIRIS and ULTOMIRIS, is associated with an increased risk for certain types of infection, including meningococcal infection. In certain cases, a physician may not have the opportunity to timely vaccinate a patient in the event of an acute emergency episode, such as in a patient presenting with aHUS, which could result in the patient using SOLIRIS or ULTOMIRIS experiencing a life-threatening meningococcal infection (and even in certain cases in which a vaccination can be delivered to the patient, it may not, eliminate all risk of meningococcal infection). Patients using our products and product candidates have died or suffered potentially life-threatening conditions either during or after ending their treatments, and these include patients who have died while participating in a clinical trial (for example, four patients died during the ULTOMIRIS Phase III clinical trial for aHUS, although none of these were considered related to the treatment with ULTOMIRIS). We may be sued by patients who are harmed during the course of using our products, whether as a prescribed therapy, during a clinical trial, during an investigator initiated study, or otherwise. Any such product liability lawsuit or injury claim, which could include class actions, could harm our reputation among patients, physicians, payers and others and require us to pay substantial amounts of money to injured patients, and even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations due to the expense of defending any such claim. While we do have product liability insurance, it may not cover all potential types of liabilities or may not cover certain liabilities completely. Moreover, we may not be able to maintain our insurance on acceptable terms, or at all.

We anticipate that we may face increased competition from companies that will enter into the markets we currently serve and as our product pipeline expands into markets that are currently served by other companies.

We expect that the business environment in which we operate will become increasingly competitive. Currently, certain of our products are the only approved therapy for the indication they treat. For example, SOLIRIS and ULTOMIRIS (in the U.S., EU and Japan) are the only approved treatments of PNH. In the future, we expect that SOLIRIS and ULTOMIRIS may compete with

new, novel drugs and pharmaceuticals currently in development. For example, several companies are developing and engaged in clinical trials for therapies to treat PNH, aHUS, gMG and NMOSD. Additionally, other pharmaceutical companies have publicly stated that they are developing and intend to commercialize a SOLIRIS biosimilar. For example, in 2019, a SOLIRIS biosimilar was approved in Russia for the treatment of PNH and aHUS and other SOLIRIS biosimilars may be approved in Russia and other jurisdictions in the future. If a second SOLIRIS biosimilar is approved in Russia, we could effectively be prevented from selling SOLIRIS in Russia (even in the absence of a second biosimilar in Russia, we have experienced a decrease in revenue from sales of SOLIRIS in Russia and expect that Russia will account for a very minor portion, if any, of future SOLIRIS revenue). Other biosimilars may be commercially available in other jurisdictions in the future, including the U.S., Europe and Japan and we could experience loss of revenue. STRENSIQ and KANUMA may also experience competition in the future. We are also aware of companies that have initiated or are planning to initiate studies for diseases that we are also targeting with our product pipeline. Our revenues could be negatively affected if patients or potential patients enroll in our clinical trials or clinical trials of other companies with respect to diseases that we also target with approved therapies.

Other pharmaceutical companies have publicly announced intentions to establish or develop rare disease programs and may introduce products that compete with ours (or products that are in our pipeline). These and other companies, many of which have significantly greater financial, technical and marketing resources than us, may commercialize products that are cheaper, more effective, safer, have less frequent dosing schedules, or easier to administer than our products. Our current and future competitors may develop products that are more broadly accepted or may receive patent protection that dominates, blocks or adversely affects our product development or business. These competitive products, including any biosimilars approved under alternative regulatory pathways, may significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may negatively impact our revenues and profitability. Given that a significant portion of our 2018 revenue was attributable to SOLIRIS, one or more competitive novel products or biosimilars could have a significant impact on our entire business. In addition, we experience competition in drug development from universities and other research institutions, and pharmaceutical companies compete with us to attract universities and academic research institutions as drug development partners, including for licensing their proprietary technology. If our competitors successfully enter into such arrangements with academic institutions, we may be precluded from pursuing those

unique opportunities and may not be able to find equivalent opportunities elsewhere.

If a company announces successful clinical trial results for a product that may be competitive with one of our products or product candidates, receives marketing approval of a competitive product, or gets to the market before we do with a competitive product, our business may be harmed or our stock price may decline.

We may not obtain marketing approval for ULTOMIRIS as a treatment for PNH in any jurisdictions beyond the U.S., Europe or Japan or for any indications beyond PNH.

There is no guarantee that any regulatory authorities (beyond the FDA, MHLW or EMA) will promptly approve the use of ULTOMIRIS in PNH patients or that they will approve the use of ULTOMIRIS in PNH patients at all. We believe that there may be additional important potential markets for ULTOMIRIS and if we are not able to sell ULTOMIRIS in these geographies, our business may be adversely impacted.

Subject to successful completion of clinical trials, we intend to pursue marketing approval for ULTOMIRIS in the U.S., the EU, Japan and other jurisdictions for indications in addition to PNH and, potentially, other delivery mechanisms. The FDA, the EMA or the MHLW could reject our applications for indications beyond PNH (and the other regulatory authorities could reject our application for ULTOMIRIS for PNH) or for a subcutaneous delivery mechanism for many reasons, including due to a finding of inadequate safety, tolerability, potency or efficacy profiles. Additionally, these and other regulatory agencies may request that we provide additional safety or efficacy data, which may require significant additional time and expense to generate prior to a decision on approval (and any additional data that is generated may not be indicative of safety and efficacy required by these agencies).

If ULTOMIRIS is not approved for use in PNH patients in jurisdictions beyond the U.S., EU and Japan, is not approved for indications in addition to PNH, or not approved for subcutaneous administration in the U.S., the EU, Japan or elsewhere or if any such approvals are delayed, our future business and results of operations may be harmed. In the event of any of the foregoing, while we would continue to sell SOLIRIS in the jurisdictions and for the indications authorized by the appropriate authorities, certain of the patents and regulatory exclusivities related to SOLIRIS expire earlier than patents and regulatory exclusivities we hold on ULTOMIRIS, which may allow competitors to enter those markets at an earlier date utilizing SOLIRIS or biosimilar technology.

Risks Related to Business Operations

We rely on a limited number of facilities to produce our products and manufacturing issues at our facilities or the facilities of our third party service providers could cause product shortages, stop or delay commercialization of our products, disrupt or delay our clinical trials or regulatory approvals, and adversely affect our business.

The majority of our products and product candidates are biologics, which cannot be manufactured synthetically and must be produced from biologic sources. As a result, the production of biologic therapeutics that meet all product specification and regulatory requirements is particularly complex. Even slight deviations at any point in the production process may lead to production failures or recalls. For example, in 2013 and 2014 we undertook a voluntary recall of SOLIRIS due to the presence of visible particles in a limited number of vials. In addition, because the production process involves the use of materials that are derived from biological sources, the process can be affected by contaminants that could impact those biological micro-organisms. Therefore, the manufacture of our products and our product candidates is highly regulated, complex and difficult, and, as noted above, even minor technical problems or deviations could result in significant defects or failures and regulatory action against us. These manufacturing challenges are coupled with the fact that we have limited experience manufacturing commercial quantities of certain of our products, including ULTOMIRIS, STRENSIQ and KANUMA (so we may have limited previous experience resolving any issues in connection with the manufacture of these products and it may take significant time to remediate or we may be unable to solve any manufacturing problems) and we rely on a limited number of facilities to manufacture our products for our development, clinical and commercialization needs, some of which we own and some of which are owned by third parties.

If we and/or our third party suppliers fail to meet the highly technical requirements/specifications of manufacturing our biologic products and our strict quality and control specifications, we (or they) may be unable to manufacture or supply our products. We depend on our third party manufacturers to perform effectively on a timely basis and to comply with regulatory requirements and meet our product specifications. If they are unable to do so, our contractual rights to address any failures and right to recover damages are limited. Our failure or the failure of our third-party manufacturers to produce sufficient quantities of our products and product candidates could result in lost revenue, diminish our profitability, delay the development of our product candidates, delay regulatory approval, result in the rejection of our product candidates or result in supply shortages for our patients, which may lead to lawsuits, loss of revenue or could

accelerate introduction of competing products to the market. For example, we recently experienced unexpected chemistry, manufacturing and control (or CMC) issues with our recently acquired ALXN 1830 program that has resulted in a delay in the clinical trial timeline for that program. We may experience similar CMC issues in the future that may impact marketed products or other clinical trials.

As noted above, the manufacture of our products and product candidates is at high risk of product loss due to contamination, equipment malfunctions, human error or raw material shortages, which may result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, or the facilities of our third party manufacturers, we or our third party manufacturers may need to close our or their manufacturing facilities for an extended period of time to investigate and remediate the contaminant.

If we underestimate demand for ULTOMIRIS, SOLIRIS or any of our products, or experience product interruptions at Alexion’s internal manufacturing facilities or a facility of a third party provider, including as a result of risks and uncertainties described in this Quarterly Report on Form 10-Q, we may not be able to increase our revenues and alternative therapies may gain greater market acceptance.

We also face external factors, many of which are beyond our control, that could cause production interruptions at our facilities or at the facilities of our third party providers, including natural disasters, labor disputes, acts of terrorism or war.

The risks to our business of any manufacturing stops or interruptions (whether the result of internal or external factors) are amplified because we rely on a limited number of facilities to produce our products and product candidates. For example, each of our products is manufactured at only one to two facilities. Sales of SOLIRIS, which accounted for 86.3% of our revenue for the fiscal year ended December 31, 2018, in the U.S., the EU, Japan and certain other territories were manufactured exclusively by Lonza at its facilities in Singapore and Spain. Manufacturing SOLIRIS for commercial sale in certain other territories may only be performed at a single facility in some cases until such time as we have received the required regulatory approval for an additional facility, if ever. We expect that we will continue to rely on a very limited number of manufacturing facilities in the future for all of our products, including ULTOMIRIS.

We and our third party providers are required to maintain compliance with cGMP and other stringent operation and manufacturing requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such

compliance. Governmental authorities will generally not permit products manufactured at a facility that is not registered by the applicable government agency to enter into the country and such products may be returned for failure to comply with such regulation, which may decrease or delay sales and result in the loss of inventory. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection or comply with on-going operating regulations could significantly impair our ability to supply our products and product candidates. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.

Our efforts to bring more of our manufacturing operations under our control present additional challenges. We have completed the build-out of a fill-finish facility in Ireland to support global drug product manufacture or vial fill finish of SOLIRIS and certain of our other clinical and commercial products. We also completed construction of a facility in Dublin, Ireland in the fourth quarter of 2015, which is comprised of laboratories, packaging and warehousing operations and we intend to make significant further investment in this facility for the manufacture of our products. We are also constructing new biologics manufacturing facilities at both sites. Despite the significant investment we have made in these facilities and operations, we cannot guarantee that we will be able to successfully and timely complete the construction of the biologics facilities or the appropriate validation processes or obtain the necessary regulatory approvals for these and other facilities, or that we will be able to perform the intended manufacturing and supply chain services at these facilities for commercial or clinical use. Prior to such time, we may continue to rely on third parties for these services.

If we experience any manufacturing issues, we may be unable to timely identify alternative manufacturers, and if we are able to timely identify alternative manufacturers, such alternative manufactures may not be able to satisfy our requirements. No guarantee can be made that regulators will approve additional third party providers in a timely manner or at all, or that any third party providers will be able to perform services for sufficient product volumes for any country or territory. Further, due to the nature of the current market for third-party commercial manufacturing, many arrangements require substantial penalty payments by the customer for failure to use the manufacturing capacity for which it contracted. The payment of a substantial penalty could harm our financial condition and may restrict our ability to transition to internal manufacturing or manufacturing by other third parties. In addition, the terms and conditions to engage an additional third party manufacturer may not be as favorable to us as our

current arrangements and may likely reduce the profit on the sales of any products to which they relate.

In addition, KANUMA is a transgenic product and the facilities on which we rely to produce raw material for KANUMA are the only animal facilities in the world that produce the necessary egg whites from transgenic chickens. Natural disasters, disease, such as exotic Newcastle disease or avian influenza, or other catastrophic events could have a significant impact on the supply of unpurified KANUMA, or destroy our animal operations altogether. If our animal operations are disrupted, it may be extremely difficult to set up another animal facility to supply the unpurified KANUMA.

Any adverse developments affecting our manufacturing operations or the operations of our third-party providers could result in a product shortage of clinical or commercial requirements, withdrawal of our product candidates or any approved products, shipment delays, lot failures or recalls. We may also have to write-off inventory and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Each of these could have an adverse material impact on our business individually or in the aggregate. Such manufacturing issues could increase our cost of goods, cause us to lose revenue, reduce our profitability or damage our reputation.

We rely on a limited number of providers for our raw materials and supply chain services, which could result in our being unable to continue to successfully commercialize our products and our product candidates (if approved) and to advance our clinical pipeline.

Certain of the raw materials required in the manufacture and the formulation of our products are derived from biological sources. Such raw materials are difficult to procure and may be subject to contamination or recall. Access to and supply of sufficient quantities of raw materials which meet the technical specifications for the production process is challenging, and often limited to single-source suppliers. Finding an alternative supplier could take a significant amount of time and involve significant expense due to the nature of the products and the need to obtain regulatory approvals. The failure of these single-source suppliers to supply adequate quantities of raw materials for the production process in a timely manner may impact our ability to produce sufficient quantities of our products for clinical or commercial requirements. A material shortage, contamination, recall, or restriction on the use of certain biologically derived substances or any raw material used in the manufacture of our products could adversely impact or disrupt manufacturing and materially limit our ability to generate revenues.

We also depend on a very limited number of third party providers for supply chain services with respect to our clinical and commercial product requirements,

including product filling, finishing, packaging and labeling.

These third party raw material providers and supply chain service providers operate as independent entities and we do not exercise control over any such third party provider’s operations or their compliance with our internal or external specifications or the rules and regulations of regulatory agencies, including the FDA, competent authorities of the EU Member States, or any other applicable regulations or standards. Any contractual remedies we may have under agreements with these parties may not protect us from the harm suffered by our business or our patients if they fail to provide material or perform services that meet our specifications. Due to the highly specialized nature of the services performed by these third parties, particularly the supply of our raw materials, we do not believe that we could quickly find replacement suppliers or service providers and, even if we were able to identify additional third parties, the terms of any such arrangement may not be favorable to us. In either of these cases, our revenue, results of operations, business and reputation may be harmed and we may not be able to provide the therapies that our patients require.

The success of our business may also depend on the security of our products while in the supply chain for delivery to patients, which, as noted above, is dependent on third-party providers. For example, if our products are not fully and adequately secured from unauthorized access by third parties, any of our products may be tampered with or contaminated. If our products were exposed to any tampering or contamination, or if they are not transported in accordance with the required specifications, our patients may be harmed through use of our products, and such harm may be severe. In addition, if the supply chain is not secure (or our distributors do not exercise control over our products while in their possession), we are also at risk for our products to be diverted to patients other than those who are the intended recipient or to patients who do not have a prescription to receive our therapies (or it may be used for treatment by physicians who have not completed the necessary REMs protocols in order to treat patients) or it may be sold by distributors, channels or other entities that are not authorized by Alexion to sell our products. In addition, an unauthorized distributor may not properly store or ship our products, thereby exposing patients to potential harm from use of the product that was not handled in accordance with our standards. If any of the foregoing were to happen, we could be subject to costly litigation, significant monetary penalties, harm to our reputation and investigation by regulatory authorities (and potentially subject to regulatory action, including recall, product withdrawals, suspensions and monetary penalties).

The sale and use of counterfeit versions of our products could result in significant harm to patients, reduced sales of our products and harm to our reputation.

We are aware that counterfeit versions of our products have been sold by entities that are not affiliated with Alexion using product packaging suggesting that the product was manufactured by Alexion. If unauthorized third parties illegally distribute and sell counterfeit versions of our products, those products may not meet our very stringent product specifications (or the manufacturing, handling and distribution requirements for our products) and any patient that takes any counterfeit product may suffer serious adverse health consequences, including death. Our reputation and business could suffer harm as a result of counterfeit drugs sold under our brand name and could result in lost sales for us and decreased revenues.

If we are unable to establish and maintain effective sales, marketing and distribution capabilities or to enter into agreements with third parties to do so, we may be unable to successfully commercialize our products.

We currently market and sell our products in the U.S., the EU, Japan and several other territories through a direct sales force. Most of our products are relatively new to the market (ULTOMIRIS for the treatment of PNH was approved by the FDA in December 2018, the MHLW in June 2019 and the EMA in July 2019, for example), and we have recently hired several senior members of our sales and commercial team. In addition, in order to gain greater efficiencies in our operations, we have begun to implement a plan pursuant to which certain portions of our international commercial operations will transition to a new operating model in which sales and marketing efforts in designated countries will be conducted to a greater extent by third-parties to promote and sell our products, and our direct sales and marketing presence will decrease (or be eliminated) in these regions.

Due to the fact that many of our products are new to the market, we do not have significant experience in marketing and selling these products to patients, healthcare providers and payers (for example, we are new to certain therapy areas, such as neurology (gMG and NMOSD), and our sales force has had very limited exposure in educating and targeting sales to patients and physicians in neurology practices). This challenge is coupled with the fact that many of our sales and marketing team are new to Alexion and we are transitioning to third parties to market and sell our product in certain countries. If we are unable to successfully market and sell our new products and to successfully sell our products in new therapy areas, as well as successfully implement the transition to third parties to distribute and market our products in certain countries, our business and sales may be harmed. One of our objectives is to expand our business and sales in the future. If we are unable to establish and/or expand

our capabilities to sell, market and distribute our products in those jurisdictions where we will continue to rely on our direct sales force and, at the same time, effectively transition from a direct sales force model (or maintain such distributor capabilities in countries where we have already commenced commercial sales), we may not be able to successfully sell our products. In that event, we may not be able to maintain or increase revenues and achieve our goal of expanding our business. We cannot guarantee that we will be able to establish and maintain our own capabilities or enter into and maintain any marketing or distribution agreements with third-party providers on acceptable terms, if at all, or that we will be able to manage the transition to third-party marketers and distributors in the relevant jurisdictions that will not cause any interruption or disruption in our business and sales of our products.

Even if we hire the qualified sales and marketing personnel necessary to support our objectives, or enter into marketing and distribution agreements with third parties on acceptable terms, we may not hire such employees or enter into such agreements in an efficient manner or on a timely basis. We may not be able to forecast accurately the size and experience of the sales and marketing force and the scale of distribution capabilities necessary to successfully market and sell our products. Establishing and maintaining sales, marketing and distribution capabilities are competitive, expensive and time-consuming. In addition, as we launch new products, such as ULTOMIRIS for the treatment of PNH, and we move into new therapeutic areas (such as neurology), and, if and when, the products we acquire in connection with acquisitions and development agreements with third parties move closer to regulatory approval, we may have a larger product portfolio and address more therapeutic areas and the foregoing risks may continue to apply and may even increase. Our expenses associated with building up and maintaining the sales force and distribution capabilities around the world, and in transitioning from direct sales to third party marketers and distributors, may be disproportionate compared to the revenues we may be able to generate on sales or any savings or efficiencies we gain through use of such third-parties. We cannot guarantee that we will be successful in commercializing any of our products for the above referenced or other reasons.

Completion of proof of concept trials, preclinical studies or clinical trials does not guarantee advancement to the next phase of development or regulatory approval or successful commercialization.

Completion of preclinical studies or clinical trials does not guarantee that we will initiate additional studies or trials for our product candidates, if further studies or trials are initiated, what the scope and phase of the trial will be or that they will be completed, or if these further studies or trials are completed, that the

design or results may provide a sufficient basis to apply for or receive regulatory approvals or to commercialize products. Results of clinical trials could be inconclusive, requiring additional or repeat trials. Data obtained from preclinical studies and clinical trials are subject to varying interpretations that could delay, limit or prevent regulatory approval. If the design or results achieved in our clinical trials are insufficient to proceed to further trials or to sustain regulatory approval of our product candidates, we could be materially adversely affected. Failure of a clinical trial to achieve its pre-specified primary endpoint generally increases the likelihood that additional studies or trials may be required if we even determine to continue development of the product candidate, reduces the likelihood of timely development of and regulatory approval to market the product candidate, and may decrease the chances for successfully achieving the primary endpoint(s) in scientifically similar indications.

We are currently planning and conducting several clinical trials of products and product candidates that we anticipate may be important to our goal of expanding our business and diversifying our product portfolio. These trials may not yield the anticipated results for a number of reasons. For example, the fact that we have obtained marketing authorization in the U.S., EU and Japan for ULTOMIRIS as a treatment for PNH does not mean that ULTOMIRIS will be approved as a treatment for aHUS, gMG and NMOSD or that any clinical trials may achieve its designated endpoints and prove to be safe and effective for use in patients with these indications. In addition, we are also conducting clinical trials in therapeutic areas with which we have limited experience (for example, in 2018 we acquired ALXN1840 (WTX101), a therapy for Wilson’s disease acquired from Wilson Therapeutics currently in Phase III clinical trials) and with technology platforms with which we also have limited experience (for example, in 2018 we acquired Syntimmune that develops humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes). Each of these clinical trials, and any other trial we commence, is subject to the risks highlighted in the preceding paragraph and the investments we have made in these technologies may not generate the expected returns if the clinical trials do not produce results that will meet the requirements of regulators and the needs of patients and their healthcare providers.

In addition, we intend to further increase the number of products in our preclinical and early-stage clinical pipeline and the number of indications that our products address. For example, in 2019 we plan to initiate a proof of concept clinical trial for ULTOMIRIS as a treatment for Amyotrophic Lateral Sclerosis (ALS) and an exploratory clinical study in Primary Progressive Multiple Sclerosis (PPMS). There is no guarantee that any proof of concept trial or exploratory clinical trial will provide sufficient evidence to advance our research

beyond the proof of concept stage or exploratory clinical trial stage, and we may expend significant resources in an effort to establish proof of concept that ULTOMIRIS is a potential therapy for ALS or PPMS or that any other product in development will meet the standard for proof of concept for other indications. In the event that a product does satisfactorily establish proof of concept, and it does advance into preclinical or clinical trials, such product may face the risks and challenges identified in the preceding paragraph.

Our clinical studies may be costly and lengthy, and there are many reasons why drug testing could be delayed or terminated.

For human trials, patients must be recruited and each product candidate must be tested at various doses and formulations for each clinical indication. In addition, to ensure safety and effectiveness, the effects of drugs often must be studied over a long period of time, especially for the chronic diseases that we are studying. Many of our programs focus on diseases with small patient populations making patient enrollment difficult. Insufficient patient enrollment in our clinical trials could delay or cause us to abandon a product development program. We may decide to abandon development of a product candidate or a study at any time due to unfavorable results or other reasons, including if there are concerns about patient safety. We may have to spend considerable resources repeating clinical trials or conducting additional trials, either of which may increase costs and delay revenue from those product candidates, if any. We may open clinical sites and enroll patients in countries where or for indications in which we have little experience.

We rely on a small number of clinical research organizations to carry out our clinical trial related activities, and one contract research organization (CRO) is responsible for many of our studies. We rely on such parties to accurately report their results. Our reliance on CROs may impact our ability to control the timing, conduct, expense and quality of our clinical trials. In addition, we may be responsible for any errors in clinical trials by a CRO as a result of the performance of services in connection with a clinical trial on our behalf. And regulatory agencies, in connection with a potential product approval or as part of on-going monitoring, will review a CROs compliance with regulatory requirements relating to clinical trials and we may be subject to findings and regulatory action (including denial or delay of product approval) if a CRO fails to comply with regulations.

Additional factors that can cause delay, impairment or termination of our clinical trials or our product development efforts include:


•	delay or failure in obtaining institutional review board (IRB) approval or the approval of other

reviewing entities to conduct a clinical trial at each site;


•	delay or failure in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;


•	withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to participate in our clinical trials;


•	clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial;


•	delay or failure in having patients complete a trial or return for post-treatment follow-up;


•	long treatment time required to demonstrate effectiveness;


•	lack of sufficient supplies of the product candidate;


•	disruption of operations at the clinical trial sites;


•	adverse medical events or side effects in treated patients;


•	failure of patients taking the placebo to continue to participate in our clinical trials;


•	insufficient clinical trial data to support safety and effectiveness of the product candidates;


•	lack of effectiveness or safety of the product candidate being tested;


•	inability to manufacture product candidates that meet required specifications or to manufacture sufficient quantities of the product candidate for development or commercialization activities in a timely and cost-efficient manner;


•	decisions by regulatory authorities, the IRB, ethics committee, or us, or recommendation by a data safety monitoring board, to suspend or terminate clinical trials at any time for safety issues or for any other reason;


•	failure to obtain the necessary regulatory approvals for the product candidate or the approvals for the facilities in which such product candidate is manufactured; and


•	decisions by competent authorities, IRBs or ethics committees to demand variations in protocols or conduct of clinical trials.

We may not accurately forecast demand for our products, including our new products, or the conversion of PNH

patients to ULTOMIRIS, which may cause our operating results to fluctuate.

Our quarterly revenues, expenses and net income (loss) may fluctuate, even significantly, due to certain risks, including those described in these “Risk Factors” as well as the timing of charges and expenses that we may take and acquisitions (such as the Wilson Therapeutics and Syntimmune acquisitions). In the future, we may not generate sufficient revenues or control expenses to achieve our financial goals, including continued profitability. We may not be able to sustain or increase profitability on a quarterly or annual basis. You should not consider our financial performance, including our revenue growth, in recent periods as indicative of our future performance. Since we have a limited sales and operating history with certain of our products (such as ULTOMIRIS as a treatment for PNH in the US, EU and Japan) and for new indications of existing products (such as SOLIRIS as a treatment for gMG and NMOSD), we may not be able to accurately forecast demand for our products. STRENSIQ and KANUMA, also relatively new products, each received marketing approval in 2015, and both products treat rare diseases for which there was no existing therapy in a new therapeutic area. Since approval of ULTOMIRIS as a treatment for PNH in the U.S. in December 2018, we have undertaken efforts to facilitate the conversion of PNH patients in the U.S. from SOLIRIS to ULTOMIRIS (and are commencing similar efforts in Japan and the EU). Product demand and, in the case of conversion to ULTOMIRIS, product preference and conversion, is dependent on a number of factors, many of which are beyond our control. For these reasons, we may not be able to accurately forecast demand for our products.

We cannot guarantee that we will achieve our financial goals, including our ability to maintain profitability on a quarterly or annual basis in the future.

Our investors and investment analysts may have widely varying expectations that may be materially higher or lower than actual revenues and profits and if our revenues and profits are different from these expectations, our stock price may experience significant volatility. Our revenues and profits are also subject to foreign exchange rate fluctuations due to the global nature of our operations and our results of operations could be adversely affected due to unfavorable foreign exchange rates. Although we use derivative instruments to manage foreign currency risk, our efforts to reduce currency exchange losses may not be successful.

In addition, we have in the past provided, and expect to continue to provide, financial guidance for future periods and if our actual operating results fail to meet or exceed the guidance that we have previously provided to our investors, our stock price could drop suddenly and significantly.

As we attempt to expand our pipeline, obtain regulatory approval for new products, facilitate the conversion of PNH patients from SOLIRIS to ULTOMIRIS in the U.S., EU and Japan, seek regulatory approval for existing products in new jurisdictions and approval of new indications for existing products (such as SOLIRIS as a treatment for NMOSD (in jurisdictions beyond the U.S.) and ULTOMIRIS as a treatment for aHUS), we may have substantial expenses as we continue our research and development efforts, continue to conduct clinical trials and continue to develop and expand manufacturing, sales, marketing and distribution capabilities worldwide, some of which could be delayed, scaled-back or eliminated to control expenses and/or achieve our financial objectives. In addition, these expenses may increase and such increases may exceed analyst and investor expectations.

If we fail to achieve the expected financial and operating benefits of our corporate restructurings, our business and financial results may be harmed.

We have undertaken corporate restructuring activities to re-align our global organization with our re-focused strategy, reduce costs, and realize operational efficiencies. We estimate that our most recent restructuring, which includes our transition in certain jurisdictions from a direct sales model to increased use of third parties for sales and marketing functions, will result in a charge of up to $25.0 in 2019. These recent restructuring activities, including work force reductions, closing certain operational sites and our increased use of third parties in certain countries to market and distribute products (and rely less on a direct sales force), subject us to many risks, including loss of business continuity, unanticipated costs, and higher than usual employee turnover. In addition, we will not exercise the same degree of control over any third parties that we do over our direct sales force or the ability to direct the third party and provide incentives for such third party to sell our products may not be as strong as in the case of a direct sales force. This transition and greater reliance on third party marketers and distributors may also increase the risk of litigation with third parties that we had previously engaged to perform services for us in jurisdictions where we are implementing changes in operational methods pursuant to this restructuring. The expected cost savings and operational efficiencies from the restructuring activities are based on assumptions and expectations that we believe were reasonable in our judgment at the time made but may not be achieved due to unforeseen difficulties and challenges that are beyond our control. If these assumptions and expectations are incorrect or if we experience delays or unforeseen events in realizing the benefits of the restructuring activities, our business operations and financial results may be harmed.

As we implement any restructurings, we must execute on our re-focused strategy, including growing

and maximizing our rare disease business and pursuing disciplined business development to expand our pipeline. If we are unable to effectively execute with fewer human resources and/or attract, retain or motivate key employees, our business may be adversely affected.

If we fail to attract and retain highly qualified personnel, we may not be able to successfully develop, manufacture or commercialize our products or products candidates.

The success of our business is dependent in large part on our continued ability to attract and retain our senior management, and other highly qualified personnel in our scientific, clinical, manufacturing and commercial organizations. There is intense competition in the biopharmaceutical industry for these types of personnel. In March 2017, our Board appointed a new Chief Executive Officer (CEO) and we have experienced other recent significant management changes. In addition, since 2017, we have moved our global headquarters and undertaken company-wide restructurings with the goal of re-aligning our global organization with our re-focused strategy and to make our international operations more efficient and effective. The relocation of our headquarters and restructurings have the potential to adversely impact our ability to recruit and/or retain key employees as well as to disrupt our business operations, financial conditions, programs, plans and strategies.

Our business is specialized and global and we must attract and retain highly qualified individuals across many geographies. We may not be able to continue to attract and retain the highly qualified personnel necessary to develop, manufacture and commercialize our products and product candidates. If we are unsuccessful in our recruitment and retention efforts, or if our recruitment efforts take longer than anticipated, our business may be harmed.

If we fail to satisfy our debt service obligations or obtain the capital necessary to fund our operations, we may be unable to commercialize our products or continue or complete our product development.

In June 2018, we amended and restated our credit facility to, among other things, increase the amount available under the revolving credit facility from $500.0 to $1,000.0 and extend the maturity date of the revolving credit facility and the term loan facility to June 7, 2023. As a result, we have significant debt service obligations. In addition to the obligations to make interest and principal payments under the facility throughout the term of the loans, any changes in interest rates related to this debt could significantly increase our annual interest expense and any hedging of this interest may not be effective to control expenses.

In addition, we have substantial contingent liabilities, including milestone and royalty obligations under acquisitions and strategic transactions, and we

have been, and in the future may again be, engaged in disputes with certain counterparties regarding potential milestone and royalty obligations. Our increased indebtedness, including increased interest expense, together with our significant contingent liabilities, could, among other things:

•make us more vulnerable to economic or industry downturns and competitive pressures;

•make it difficult for us to make payments on our credit facilities and require us to use cash flow from operations to satisfy our debt obligations, which may reduce the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;

•limit our ability to incur additional debt or access the capital markets; and

•limit our flexibility in planning for, or reacting to changes in, our business.

The Amended and Restated Credit Agreement requires us to comply with certain financial covenants and negative covenants, restricting or limiting our ability and the ability of our subsidiaries to, among other things, incur additional indebtedness, grant liens, and engage in certain investment, acquisition and disposition transactions, subject to limited exceptions. If an event of default occurs, the interest rate may increase and the administrative agent may be entitled to take various actions, including the acceleration of amounts due under the Amended and Restated Credit Agreement. If the interest rate imposed under our Amended and Restated Credit Agreement were to increase as a result of a default, our expenses may increase and we may need to allocate additional funds to this interest expense (which may limit the use of these funds for other purposes, including growing our business or responding to changes in our business and industry). If some or all of the amounts outstanding under the Amended and Restated Credit Agreement were to be accelerated by the lenders, we may not have sufficient cash on hand to pay the amounts due, we may not be able to refinance such debt on terms acceptable to us (or at all) and we may be required to sell certain assets on terms that are unfavorable to us.

Our ability to satisfy our obligations under the Amended and Restated Credit Agreement and meet our debt service obligations and our royalty and milestone obligations will depend upon our future performance, which will be subject to financial, business and other factors affecting our operations, many of which are beyond our control.

We may not be able to access the capital and credit markets on terms that are favorable to us or at all.

We may need to raise additional capital to supplement our existing funds and cash generated from

operations for working capital, capital expenditure and debt service requirements, and other business activities (including business and technology acquisitions). Funding needs may shift and the amount of capital we may need depends on many factors, including, the cost of any acquisition or any new collaborative, licensing or other commercial relationships that we may establish, the time and cost necessary to build new manufacturing facilities or enhance our manufacturing operations, amounts we may need to pay in connection with the resolution of any government investigation or litigation matter (including any securities class action matter or any product liability claim), the cost of obtaining and maintaining the necessary regulatory approvals for our manufacturing facilities, and the progress, timing and scope of our preclinical studies, clinical trials and product development and commercialization efforts. The capital and credit markets have experienced and may continue to experience extreme volatility and disruption. We may not receive additional funding when we need it or funding may only be available on unfavorable terms. If we cannot raise adequate funds to satisfy our working capital, capital requirements and debt repayment obligations (or royalty and milestone obligations), we may have to delay, scale-back or eliminate certain research, development, manufacturing, acquisition or commercial activities or sell certain assets and technologies.

Our business involves environmental risks and potential exposure to environmental liabilities.

As a biopharmaceutical company, our business involves the use of certain hazardous materials in our research, development, manufacturing and other activities. We and our third party providers are subject to various federal, state and local and foreign environmental laws and regulations concerning the handling and disposal of non-hazardous and hazardous wastes, such as medical and biological wastes, and emissions and discharges into the environment, such as air, soils and water sources. We also are subject to laws and regulations that impose liability and clean-up responsibility for releases of hazardous substances into the environment and a current or previous owner or operator of property may be liable for the costs of remediating its property or locations, without regard to whether the owner or operator knew of or caused the contamination. Although our safety procedures for handling and disposing of hazardous materials are designed to comply with the laws and regulations established by state, federal and foreign regulations, the risk of loss of, or accidental contamination or injury from, these materials cannot be eliminated. If an accident or environmental discharge occurs, or if we discover contamination caused by prior owners and operators of properties we acquire, we could be liable for remediation obligations, damages and fines that could exceed our insurance coverage and financial resources. Such obligations and liabilities, which to date

have not been material, could have a material impact on our business and financial condition. Additionally, the cost of compliance with environmental and safety laws and regulations may increase in the future, and we may be required to dedicate more resources, including substantial financial resources, to comply with such laws and regulations or purchase supplemental insurance coverage, which may not be available on acceptable terms or at all.

In order to meet one of our key business objectives of advancing and rebuilding our product pipeline, we plan to expand our business and product offerings through acquisitions of businesses and technologies. Our efforts to identify opportunities or complete transactions that satisfy our strategic criteria may not be successful, and we may not realize the anticipated benefits of any completed acquisition or other strategic transaction.

As noted above, in 2018 a substantial portion of our total revenue was derived from SOLIRIS. We expect that there may be increased competition to SOLIRIS from, among other products and therapies, biosimilars, and we are still in the very early stages of the launch of ULTOMIRIS in the U.S. for PNH (and very recently received regulatory approval for ULTOMIRIS for PNH in Japan and the EU) and cannot guarantee that our efforts to facilitate the conversion of patients in these regions from SOLIRIS to ULTOMIRIS or to have new PNH patients prescribed ULTOMIRIS will be successful (or that we will obtain clearance for ULTOMIRIS for PNH in any additional jurisdictions). As a result, we have identified rebuilding our product pipeline as a key strategic objective and, in order to achieve this objective, we expect to purchase businesses and acquire, co-develop or license technologies and products from third parties in the future. For example, in 2018, among other transactions, we completed acquisitions of Wilson Therapeutics and Syntimmune, Inc. We anticipate that we will regularly evaluate potential merger, acquisition, partnering and in-license opportunities in an effort to expand our pipeline or product offerings, and enhance our research platforms. Acquisitions of new businesses or products and in-licensing of new technologies and products may involve numerous risks, including:


•	substantial cash expenditures;


•	potentially dilutive issuance of equity securities and incurrence of debt;


•	assumption of material liabilities in connection with the target or purchased technology, some of which may be difficult or impossible to identify at the time of acquisition;


•	difficulties in assimilating the operations of the acquired companies;


•	failure of any acquired businesses or products or in-licensed products or technologies to achieve the

scientific, medical, commercial or other results we anticipate;


•	diverting our management’s attention away from other business opportunities and concerns;


•	the potential loss of our key employees or key employees of the acquired companies; and


•	risks of entering disease areas and indications in which we have limited or no direct experience.

A substantial portion of our strategic efforts are focused on opportunities for rare disorders, but the availability of such opportunities is limited. We may not be able to identify opportunities that satisfy our strategic criteria or are acceptable to us or our stockholders. Several companies have publicly announced intentions to establish or develop rare disease programs and we may compete with these companies for the same opportunities. For these and other reasons, we may not be able to acquire the rights to additional product candidates or approved products on terms that we or our stockholders find acceptable, or at all. In such event, we may not be able to rebuild our pipeline and any future revenue may remain largely dependent on our existing products which, as noted above, may be subject to increasing competition from biosimilars and other competitive or novel therapies.

Even if we are able to successfully identify and complete acquisitions and other strategic transactions, we may not be able to integrate or take full advantage of them. An acquisition or other strategic transaction may not result in short-term or long-term benefits to us. We may also incorrectly judge the value or worth of an acquired company or business or an acquired or in-licensed product, particularly if the acquired technology is in preclinical trials or early-stage clinical trials.

To effectively manage our current and future potential growth, we must continue to effectively enhance and develop our global employee base and our operational and financial processes. Supporting our growth strategy may require significant capital expenditures and management resources, including investments in research, development, sales and marketing, manufacturing and other areas of our operations. The development or expansion of our business, any acquired business or any acquired or in-licensed products may require a substantial capital investment by us and we may likely incur substantial expenses in advancing acquired products to commercialization. We may not have the necessary funds for these capital expenditures and expenses or they might not be available to us on acceptable terms. We may also seek to raise funds by incurring additional indebtedness and selling shares of our capital stock, which could dilute current stockholders’ ownership interest in our company, or securities convertible into our capital stock, which could dilute current stockholders’ ownership interest in us upon conversion.

We may incur impairment charges in the future for certain of our assets, including goodwill in connection with acquisitions, and such amounts may be material.

If the purchase price of a business acquisition exceeds the value of the assets (and liabilities) acquired, the acquirer must recognize goodwill in such amount. We may be required to recognize impairment charges for our goodwill and other intangible assets, and such charges may be material and have an adverse impact on our financial results in the period such charges are incurred.

As of June 30, 2019, the net carrying value of our goodwill and other intangible assets, net totaled $8,525.0. As required by GAAP, we periodically assess these assets to determine if there are indicators of impairment. We have recorded charges that include inventory write-downs for failed quality specifications or recalls, impairments with respect to investments and acquisitions, fixed assets and long-lived assets, outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters, and payments in connection with acquisitions and other business development activities, such as milestone payments. The impairment of tangible and intangible assets may be triggered by developments both within and outside our control. Deteriorating economic conditions, technological changes, disruptions to our business, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in the use of the assets, intensified competition, divestitures, market capitalization declines and other factors may impair our goodwill and other intangible assets. Any charges relating to such impairments could adversely affect our results of operations in the periods in which an impairment is recognized. As part of our standard quarterly procedures, we reviewed the KANUMA asset as of June 30, 2019 and determined that there were no indicators of impairment. We will continue to review the related valuation and accounting of this asset in future quarters as new information becomes available to us. Cash flow models used in our assessments are based on our commercial experience with KANUMA to date and require the use of significant estimates, which include, but are not limited to, long-range pricing expectations and patient-related assumptions, including patient identification, conversion and retention rates. As we continue to sell this product, new data may cause us to adjust the assumptions in our cash flow models. Changes to assumptions used in our net cash flow projections may result in material impairment charges in subsequent periods. The net book value of the KANUMA intangible asset as of June 30, 2019 was $3,122.5.

Our business could be adversely affected by litigation, government investigations and enforcement actions.

We operate in many jurisdictions in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety of matters in the U.S. or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, tax and custom/import duties, environmental, whistleblower, Qui Tam, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings which may arise from conducting our business. See Note 18, “Commitments and Contingencies” to the footnotes to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information on our material legal proceedings. For example, in May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the SEC requesting information related to our grant-making activities and compliance with the FCPA in various countries. In addition, in October 2015, we received a request from the DOJ for the voluntary production of documents and other information pertaining to Alexion’s compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures. Alexion is cooperating with these investigations. The investigations have focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws. Any determination that our operations or activities are not in compliance with existing laws or regulations, by the SEC or DOJ in the above referenced matter for example, could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, exclusion from the federal healthcare programs, healthcare debarment, product recalls, reputational damage and modifications of our business practices and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. In addition, we may be required to expend significant resources to defend the securities class action filed in December 2016 and, if we were found to have violated the securities laws, we could be required to pay significant damages to the plaintiffs. Legal proceedings, government investigations, including the SEC and DOJ investigations, and enforcement actions have been and we expect may continue to be expensive and time consuming. Any future litigation or investigation may also likely be expensive and time consuming.

The efficiency of our corporate structure depends on the application of the tax laws and regulations in the countries where we operate and we may have exposure to additional tax liabilities or our effective tax rate could increase, which could have a material impact on our results of operations and financial position.

As a company with international operations, we are subject to income taxes, as well as non-income based

taxes, in both the U.S. and various foreign jurisdictions. Significant judgment is required in determining our worldwide tax liabilities. Although we believe our estimates are reasonable at the time made, the final taxes we owe may differ from the amounts recorded in our financial statements (and such differences may be material). If the IRS, or other taxing authority, disagrees with the positions we take, we could have additional tax liability, and this could have a material impact on our results of operations and financial position. Our effective tax rate could be adversely affected by changes in the mix of earnings in countries with different statutory tax rates, changes in the valuation of deferred tax assets and liabilities, changes in tax laws and regulations, changes in interpretations of tax laws, including pending tax law changes, changes in our manufacturing activities and changes in our future levels of research and development spending.

We have designed, and from time to time we modify, our corporate structure, the manner in which we develop and use our intellectual property, and our intercompany transactions between our affiliates in a way that is intended to enhance our operational and financial efficiency and increase our overall profitability. The application of the tax laws and regulations of various countries in which we operate and to our global operations is subject to interpretation. We also must operate our business in a manner consistent with our corporate structure to realize such efficiencies. The tax authorities of the countries in which we operate may challenge our methodologies for valuing developed technology or for transfer pricing or other operations. If tax authorities determine that the manner in which we operate results in our business not achieving the intended tax consequences, our effective tax rate could increase (and such increase may be material) and harm our financial position and results of operations. In addition, certain governments are considering and may adopt tax reform measures that significantly increase our worldwide tax liabilities. The Organization for Economic Co-operation and Development and other government bodies have focused on issues related to the taxation of multinational corporations, including, in the area of “base erosion and profit shifting,” where payments are made from affiliates in jurisdictions with high tax rates to affiliates in jurisdictions with lower tax rates. It is possible that these reform measures could increase our effective tax rate (and such increase may be material) and harm our financial position and results of operations over the next several years.

Our sales and operations are subject to a variety of risks relating to the conduct of our international business.

We have increased our international presence, including in emerging markets. Our operations in foreign countries subject us to a variety of risks, including:


•	difficulties or the inability to obtain necessary foreign regulatory or reimbursement approvals of our products in a timely manner or at all;


•	political or economic determinations that adversely impact pricing or reimbursement policies;


•	economic problems or political instability;


•	fluctuations in currency exchange rates;


•	difficulties or inability to obtain financing in markets;


•	unexpected changes in tariffs, trade barriers and regulatory requirements;

•

customs and tax officials in foreign jurisdictions may disagree with the value we set when we or others import our products (including products that are donated for charitable purposes or used for clinical trials) and we may be required to pay additional duties or fines and such amounts may be substantial (for example, our offices in Brazil were visited by the Brazilian federal tax authorities and we received a written notice from such authorities requesting information with respect to the importation of SOLIRIS free of charge to patients in Brazil from 2014 to 2019 and they may be reviewing whether additional amounts are due to the government (we are cooperating with the authorities in this matter));


•	difficulties in establishing and enforcing contractual and intellectual property rights;


•	compliance with complex import and export control laws;


•	trade restrictions and restrictions on direct investments by foreign entities;


•	compliance with tax, employment and labor laws;


•	costs and difficulties in recruiting and retaining qualified managers and employees to manage and operate the business in local jurisdictions;


•	costs and difficulties in managing and monitoring international operations; and


•	longer payment cycles.

Additionally, our business and marketing methods are subject to the laws and regulations of the countries in which we operate, which may differ significantly from country to country and may conflict with U.S. laws and regulations. The FCPA and anti-bribery laws and regulations in the locations in which we operate our business are extensive and far-reaching, and we must maintain accurate records and control over the activities of our distributors and third party service providers in countries where we operate. We have policies and procedures, and we are currently implementing an enhanced company-wide compliance program and effort, designed to help us and our representatives,

including our employees and our vendors and distributors, comply with such laws, however we cannot guarantee that these policies and procedures will protect us against liability under the FCPA or other anti-bribery laws for actions taken by us, our employees or our representatives. Any determination that our operations or activities are not in compliance with existing laws or regulations, including the FCPA and the UK Anti-Bribery Act, could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of such findings could have a material and adverse effect on our business operations. In addition, as our international operations expand, we are likely to become subject to new anti-corruption/anti-bribery laws or existing laws may govern our activities in new jurisdictions in which we operate. In addition, as we move from a direct sales force to third-party distributors and marketers in certain countries and regions, we may also have liability under the FCPA and anti-bribery laws and regulations for the actions of these third parties. Although we can impose contractual restrictions on what these third parties are authorized to do on our behalf, we will exercise only limited control over the actions of these third parties but may still face the same liabilities for their actions. Our failure, and the failure of others who we engage to act on our behalf, to comply, with the laws and regulations of the countries in which we operate, or will operate in the future, could materially harm our business.

Currency fluctuations and changes in exchange rates could adversely affect our revenue, increase our costs and negatively affect our profitability.

We conduct a substantial portion of our business in currencies other than the U.S. dollar. We are exposed to fluctuations in foreign currency exchange rates and such fluctuations affect our operating results. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, including the Euro, Japanese Yen, British Pound, Canadian dollar and Turkish Lira. As the U.S. dollar strengthens against these foreign currencies, the relative value of sales made in the respective foreign currencies decrease. When the U.S. dollar weakens against these currencies, the relative value of such sales increase. We manage a portion of our foreign currency transaction risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. We enter into foreign exchange forward contracts to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues that are denominated in currencies other than the U.S. dollar. The purpose of the revenue hedges is to reduce the volatility of exchange rate fluctuations on

our operating results and to increase the visibility of the foreign exchange impact on forecasted revenues. Further, we enter into foreign exchange forward contracts, with durations of approximately eight months, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. While we attempt to hedge certain currency risks, currency fluctuations between the U.S. dollar and the currencies in which we do business have, in the past, caused foreign currency transaction gains and losses and have also impacted the amounts of revenues and expenses calculated in U.S. dollars and will do so in the future. Likewise, past currency fluctuations have at times resulted in foreign currency transaction gains, and there can be no assurance that these gains can be reproduced. Any significant foreign currency exchange rate fluctuations could adversely affect our financial condition and results of operations.

Risks Related to the Regulatory Environment

We operate in a highly regulated industry and if we or our third party providers fail to comply with U.S. and foreign regulations, we or our third party providers could lose our approvals to market our products or our product candidates, and our business may be seriously harmed.

We and our current and future third party vendors, contract manufacturers, CROs, distributors and suppliers and logistic providers are subject to rigorous and extensive regulation by governmental authorities around the world, including the FDA, EMA, the competent authorities of the EU Member States and the MHLW. These regulations, many of which are complex, relate to almost all aspects of our business, including GCP, GLP, cGMP and pharmacovigilance rules (for additional information on the regulations relating to our business, see “Business - Government Regulation” in Item 1 in our Annual Report on Form 10-K for the year ended December 31, 2018). If we or a regulatory agency discover previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured (such as product contamination), or in the case of KANUMA, problems with animal operations, a regulatory agency may impose restrictions on that applicable product, the manufacturing facility or us. We have received a Warning Letter from the FDA relating to compliance with FDA’s cGMP requirements at one of our facilities, which was remediated. If we had failed to address the FDA’s concerns or if we (or one of our third party contract manufacturers) were to receive another Warning Letter in the future relating to cGMP or other applicable regulations, the FDA or other regulatory authorities could take regulatory action, including fines, civil penalties, recalls, seizure of product, suspension

of manufacturing operations, operating restrictions, injunctions, suspension of clinical trials, withdrawal of FDA (or other regulatory authority) approval and/or criminal prosecution.

If we or our third-party providers, including our product or raw material manufacturers, product fill-finish providers, packagers and labelers, fail to comply fully with applicable regulations, then we may be required to initiate a recall or withdrawal of our products. In addition to our manufacturing operations and those of contract manufacturers’ manufacturing operations being subject to inspection and potential regulatory action for failure to comply with (among other regulations) cGMP, our animal operations may also be subject to FDA and U.S. Department of Agriculture, Animal and Plant Health Inspection Service (USDA APHIS) inspection to evaluate whether our animal husbandry, containment, personnel, and record keeping practices are sufficient to ensure safety and security of our transgenic chickens and animal products (e.g., eggs, waste, etc.). Any failure to ensure safety and security of our transgenic chickens and/or animal products could result in regulatory action by the FDA or another regulatory body, including USDA APHIS.

Failure to comply with the laws and requirements, including statutes and regulations, administered by the FDA, the EC, the competent authorities of the EU Member States, the MHLW or other comparable agencies, could result in:


•	a product recall;


•	a product withdrawal;


•	modification or revision to a product label;


•	significant administrative and judicial sanctions, including, warning letters or untitled letters;


•	significant fines and other civil penalties;


•	suspension, variation or withdrawal of a previously granted approval for our products;


•	interruption of production;


•	operating restrictions, such as a shutdown of production facilities or production lines, or new manufacturing requirements;


•	suspension or termination of ongoing clinical trials;


•	delays in approving or refusal to approve our products including pending BLAs or BLA supplements for our products or a facility that manufactures our products;


•	seizing or detaining product;


•	requiring us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs,

required due dates for specific actions and penalties for noncompliance;


•	injunctions; and/or


•	criminal prosecution.

In addition, we are subject to antitrust regulations with respect to our acquisitions, as well as our interactions with other participants in the markets we currently serve or may serve in the future. In addition, these antitrust laws are vigorously enforced in the U.S. and in other jurisdictions in which we operate. In connection with any business development transaction, acquisition, development agreement or collaboration that is reviewed by regulatory authorities, there can be no assurance that these antitrust approvals will be obtained. In addition, the governmental entities from which these approvals are required may impose conditions on the completion of such business development transaction or require changes to the terms of the applicable transaction. In addition, the regulatory review process may cause a delay in the closing of a transaction beyond the time that we anticipate and communicate. Any conditions or unexpected delays in approval could have the effect of jeopardizing or delaying completion of the applicable transaction or reducing the anticipated benefits of the transaction (or, as noted above, may prohibit closing of the transaction).

Our product candidates require extensive clinical testing and regulatory approval and failure to satisfy regulatory requirements that meet the appropriate safety and efficacy thresholds may prevent us from being able to market our products and limit our ability to grow our business and diversify our revenue.

We believe our future success may depend on our ability to develop and commercialize our product candidates and, to this end, we have recently acquired companies and technologies in an effort to expand our product pipeline. Our product candidates are in various stages of development and must satisfy the rigid safety and efficacy requirements of the FDA and other foreign regulatory agencies before they can be approved for sale to patients. To satisfy these standards, we must ensure, among other things, that we have appropriately established our protocol designs, obtained the necessary IRB approval, provide adequate patient enrollment rates, timely and appropriately report any adverse events and serious adverse events to the appropriate authorities and ensure compliance with cGCP. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.

If we discover safety or safety reporting issues with any of our approved products, or if we fail to comply with continuing U.S. and applicable foreign regulations, our

revenue may decrease, an approved product could lose its marketing approval or sales could be suspended and our business could be materially harmed.

Following marketing approval of a pharmaceutical product, the safety profile of such product continues to be closely monitored by the FDA and other foreign regulatory authorities. Regulations continue to apply after product approval, and cover, among other things, testing, manufacturing, quality control, finishing, filling, labeling, advertising, promotion, risk mitigation, adverse event reporting requirements and export of biologics. For example, the REMS program for SOLIRIS, most recently updated by the FDA in 2015, requires prescribing information regarding the level of fever needed to seek medical attention and reporting adverse events. Future changes to the SOLIRIS REMS (or similar requirements for other products) could be costly and burdensome to implement.

We are required to report any serious and unexpected adverse experiences and certain quality problems with our products to the FDA, the EMA, the MHLW and other health agencies. Adverse safety events involving our products may have a negative impact on our business. Discovery of safety issues with our products could result in product liability claims and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. In addition, governmental authorities are making greater amounts of safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any adverse events in connection with the use of our products could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations.

Regulatory agencies periodically inspect our pharmacovigilance processes. If these regulatory agencies determine that we or other parties whom we do not control that perform services on our behalf, including clinical trial investigators, have not complied with the applicable reporting or other pharmacovigilance requirements, we may become subject to additional inspections, warning letters or other enforcement actions, including monetary fines, marketing authorization withdrawal and other penalties.

As a condition of approval for marketing our products, governmental authorities may require us to conduct additional studies. In connection with the approval of SOLIRIS in the U.S., EU and Japan, for the treatment of PNH, we agreed to establish a PNH Registry, monitor immunogenicity, monitor compliance with

vaccination requirements, and determine the effects of anticoagulant withdrawal among PNH patients receiving eculizumab, and, specifically in Japan, we agreed to conduct a trial in a limited number of Japanese PNH patients to evaluate the safety of a meningococcal vaccine. In connection with the approval of SOLIRIS in the U.S. for the treatment of aHUS, we agreed to establish an aHUS Registry and complete additional human clinical studies in adult and pediatric patients. Furthermore, in connection with the approval of STRENSIQ in the U.S., we agreed to conduct a prospective observational study in treated patients to assess the long-term safety of STRENSIQ therapy and to develop complementary assays. Similarly, in connection with the approval of KANUMA in the U.S., we agreed to conduct a long-term observational study of treated patients, either as a standalone study or as a component of the existing LAL Registry. In the EU, in connection with the grant of authorization for STRENSIQ, we agreed to conduct a multicenter, randomized, open-label, Phase 2a study of STRENSIQ in patients with HPP and to extend the studies ENB-008-10 and ENB-009-10 to provide efficacy data in patients 13 to 18 years of age, which we have commenced.

In the U.S., the FDA can also propose to withdraw approval for a product if it determines that such additional studies are inadequate or if new clinical data or information shows that a product is not safe for use in an approved indication.

In addition, similar or more stringent post-approval requirements and obligations may be imposed by the FDA and/or other regulatory agencies with respect to our future products (such as ULTOMIRIS or SOLIRIS for the treatment of additional indications (or utilizing subcutaneous delivery devices), if approved for use by the FDA and such agencies). Compliance with these post-approval requirements could result in increased cost and expense and decrease our operating margins and, if we are unable to comply with these requirements, we may be subject to regulatory action by the applicable regulatory agency and the penalties may include fines and product withdrawals or restrictions in the use of a product.

If we fail to comply with applicable healthcare laws and regulations, including those related to healthcare fraud and abuse, we may be subject to investigations and civil or criminal penalties and our business could be adversely affected.

We are subject to healthcare “fraud and abuse” laws, such as the False Claims Act, the anti-kickback provisions of the federal Social Security Act, laws prohibiting off-label product promotion and other related federal and state laws and regulations.

The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or

indirectly, in cash or in kind to induce, or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs. Liability may be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. A conviction for violation of the Anti-kickback Statute requires mandatory exclusion from participation in federal healthcare programs. The majority of states also have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.

The FCA prohibits any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim. Pharmaceutical companies have been investigated and have reached substantial financial settlements with the Federal government under the FCA for a variety of alleged promotional and marketing activities, such as allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion of pharmaceuticals for uses that the FDA has not approved, or “off-label” uses; and submitting inflated best price information to the Medicaid Rebate Program.

We seek to comply with the Anti-Kickback Statute and FCA laws, including operating within any available safe harbors, but we cannot assure that our compliance program, policies and procedures will always protect us from acts committed by employees or third-party distributors or service providers.

Other related federal and state laws and regulations that may affect our ability to operate include, among others, the federal False Statements Statute, the federal Civil Monetary Penalties Law, HIPAA, the federal Open Payments program, state anti-kickback and false claims acts, and state and local disclosure requirements and marketing restrictions. Additional information about the scope of these requirements and potential penalties is provided under “Government Regulation - Fraud and Abuse” included in Item 1 in our Annual Report on Form 10-K for the year ended December 31, 2018.

In recent years, legislation has been adopted at the federal, state and local level requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports or make periodic public disclosures on sales, marketing, pricing, clinical trials, health care provider payments and other

activities. For example, as part of the PPACA, the federal government enacted the Open Payments (commonly known as the Sunshine Act) provisions. Open Payments requires pharmaceutical manufacturers to report annually to CMS payments or other transfers of value made by that entity to physicians and teaching hospitals. We also now have similar reporting obligations throughout the EU. Failure to comply with the reporting requirements may result in significant civil monetary penalties.

Violations of U.S. federal and state fraud and abuse laws (and comparable laws in foreign jurisdictions) may result in criminal, civil and administrative sanctions, including fines, damages, civil monetary penalties (which may be material in amount) and exclusion from federal healthcare programs (including Medicare and Medicaid). Any action initiated against us for violation of these laws, even if we successfully defend against it, could require the expenditure of significant resources and generate negative publicity, which could materially adversely affect our ability to operate our business and our financial results.

Finally, the FDA, the EU and EU Member States and the MHLW impose restrictions on the promotion and marketing of drug products and prohibit pharmaceutical manufacturers from promoting products for indications other than those cleared or approved by regulatory authorities or for use in manner that is not consistent with the product label approved by regulatory agencies, or off-label promotion. In certain instances, physicians are, however, in their medical judgment permitted to use products for unapproved purposes and we are aware of such uses of SOLIRIS. For information regarding a recent MHLW inquiry focused on our communication efforts regarding the proper use of SOLIRIS in Japan for aHUS, see Note 18, “Commitments and Contingencies” to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Although we believe that our marketing materials and training programs for physicians do not constitute improper promotion, the FDA, the U.S. Department of Justice (DOJ), other federal or state government agencies, the EU, EU Member States or the MHLW (or other foreign regulatory agencies) may disagree. If any governmental authority determines that our promotional materials, training or other activities constitute improper promotion of any of our products, it could request that we modify our training or promotional materials or other activities or subject us to regulatory enforcement actions, including the issuance of a warning letter, product withdrawal or recall, injunction, seizure, civil fine and criminal penalties. It is also possible that other enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws

prohibiting false or fraudulent claims for payment of government funds.

The sales and marketing practices of the pharmaceutical industry have been the subject of increased scrutiny from authorities such as the DOJ, and we expect that this trend may continue and may increase. If the government or the courts determine that we breached any of these sales and marketing laws, we may be subject to penalties identified above. Any action against us for violation of these laws, even if we successfully defend against them, also could cause us to incur significant legal expenses, harm our reputation and divert our management’s attention from the operation of our business.

Our business and operations may be materially adversely affected by government investigations.

We are subject to the FCPA, the U.K. Bribery Act and other anti-corruption laws and regulations that generally prohibit companies and their intermediaries from making improper payments to government officials and/or other persons for the purpose of obtaining or retaining business and we operate in countries that are recognized as having a greater potential for governmental and commercial corruption. While we have, and continue to, take steps that are intended to enhance our compliance and training programs, we cannot assure that our compliance program, policies and procedures will always protect us from acts committed by employees or third-parties acting on our behalf.

In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the SEC requesting information related to our grant-making activities and compliance with the FCPA in various countries. In addition, in October 2015, we received a request from the DOJ for the voluntary production of documents and other information pertaining to our compliance with the FCPA. The SEC and DOJ also seek information related to our recalls of specific lots of SOLIRIS and related securities disclosures. In December 2016, we received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts requesting documents relating generally to our support of certain 501(c)(3) organizations (as described in Note 18, Commitments and Contingencies to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q). We settled this investigation with the DOJ and the Office of Inspector General of the U.S. Department of Health and Human Services in April 2019 which resulted in a payment to the government of $13.1 million. In May 2017, Brazilian authorities seized records and data from our Sao Paulo, Brazil offices as part of an investigation being conducted into our Brazilian operations. In October 2018, the MHLW conducted an inspection of our Japanese operations and in March 2019, the MHLW indicated that

its investigation is complete. We are cooperating with the open investigations. At this time, we are unable to predict the duration, scope or outcome of the open investigations. In addition, even though we have settled the investigation relating generally to our support of certain 501(c)(3) organizations that was initiated by the U.S. Attorney’s Office for the District of Massachusetts in December 2016 and the October 2018 investigation by the MHLW has been closed by the MHLW, we may be subject to similar investigations in the future by the same or other regulatory agencies and government authorities and the penalties imposed on us may be materially greater in amount or we may be subject to material limitations on our operations, activities and our business. In addition, any remedial actions that have been or will be taken with the intent to address the matters that were the subject of these or other governmental investigations may not prevent future investigations and potential liability as a result of such further investigations.

Any determination that our operations or activities are not, or were not, in compliance with existing U.S. or foreign laws or regulations, could result in the imposition of a broad range of civil and criminal sanctions against us and certain of our directors, officers and/or employees, including injunctive relief, disgorgement, substantial fines or penalties, imprisonment, and other legal or equitable sanctions, including exclusion from Medicare, Medicaid, and other governmental healthcare programs. Any attempts to resolve some or all of these matters may not be successful. If we were to engage in settlement discussions with respect to any current or future investigation or litigation (and we may accrue amounts due to the nature of such discussions), but the matter is not settled, the ultimate resolution may result in monetary or other penalties materially stricter or greater than the terms or amounts that we proposed in discussions (or the amount that we accrued for such matter during negotiations). Additionally, remediation of any such findings resulting from these and any future investigations could have an adverse effect on our business operations, and we could experience interruptions of business, harm to our reputation, debarment from government contracts, loss of supplier, vendor or other third-party relationships, and necessary licenses and permits could be terminated. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence. Cooperating with and responding to requests for information in connection with these ongoing investigations, as well as responding to any future U.S., state or foreign governmental investigation or whistleblower lawsuit, has resulted and could continue to result in substantial expenses, and could divert management’s attention from other business concerns and could have a material adverse effect on our business and financial condition and growth prospects.

Changes in healthcare laws and implementing regulations, as well as changes in healthcare policy, may affect coverage and reimbursement of our products in ways that we cannot currently predict and these changes could adversely affect our business and financial condition.

In the U.S., there have been a number of legislative and regulatory initiatives focused on containing the cost of healthcare. The PPACA substantially changed the way healthcare is financed by both governmental and private insurers in the U.S., and significantly impacts the pharmaceutical industry. The PPACA contains a number of provisions that are expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under health insurance exchanges, expansion of the 340B program, expansion of state Medicaid programs, fraud and abuse enforcement and rules governing the approval of biosimilar products (and allowing biosimilars access to the market in accordance with the FDA’s Biosimilars Action Plan). These changes may impact existing government healthcare programs and may result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. In 2016, CMS implemented changes to the Medicaid Drug Rebate Program under the PPACA. Moreover, in the future, Congress could enact legislation that further increases Medicaid drug rebates or other costs and charges associated with participating in the Medicaid Drug Rebate Program. The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program has and may continue to increase our costs and the complexity of compliance, has been and may be time-consuming, and could have a material adverse effect on our results of operations.

Similar efforts to those in the United States, and in some cases even more aggressive efforts, are being taken by governments to control the costs of pharmaceutical drugs in countries outside the U.S. In these markets outside the U.S., the pricing and reimbursement of pharmaceutical products is subject to direct or indirect governmental control and such government authorities are increasingly attempting to limit or regulate the price of drug products and due to their control over pricing are able to move quickly to implement pricing changes.

We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot

predict how future federal or state legislative or administrative changes relating to healthcare reform may affect our business.

The current presidential administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs and negatively impact our stock price.

State governments have sought to put in place limits and caps on pharmaceutical prices and have also requested rebates for certain pharmaceuticals. Attempts to decrease prices of pharmaceutical products may lead to increased use of managed care organizations by Medicaid programs which could lead to managed care organizations influencing prescription decisions for beneficiaries and a corresponding limitation on prices and reimbursement for our products.

Governments in countries where we operate have adopted or have also shown significant interest in pursuing legislative initiatives to reduce costs of healthcare. We expect that the implementation of current laws and policies, the amendment of those laws and policies in the future, as well as the adoption of new laws and policies, could have a material adverse effect on our industry generally and on our ability to maintain or increase our product sales or revenues or successfully commercialize our product candidates, or could limit or eliminate our future spending on development projects. The announcement or adoption of regulatory or legislative proposals could delay or prevent our entry into new markets, affect our reimbursement or sales in the markets where we are already selling our products and materially harm our business, financial condition and results of operations.

If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program, Medicare, or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business, financial condition, results of operations and prospects.

We participate in and have certain price reporting obligations to the Medicaid Drug Rebate Program and we have obligations to report the average sales price under the Medicare program. Under the Medicaid Drug Rebate Program, we are required to pay a rebate to each state Medicaid program for quantities of our products that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our products under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by us on a

monthly and quarterly basis to CMS. Any failure to comply with these price reporting and rebate payment obligations could negatively impact our financial results.

Pricing and rebate calculations vary among products and programs. The calculations, including those in connection with the Medicaid Drug Rebate Program and 340B drug pricing program (as described further below) are complex and are often subject to interpretation by us, governmental or regulatory agencies and the courts. We cannot assure you that our submissions will not be found by CMS or other applicable government authorities to be incomplete or incorrect. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. For example, if we become aware that our reporting to CMS for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due, and CMS may request or require restatements for earlier periods as well. Such restatements and recalculations increase our costs for complying with the laws and regulations governing these programs, including the Medicaid Drug Rebate Program. Any corrections to our rebate calculations could result in an overage or underage in our rebate liability for past quarters, depending on the nature of the correction. Price recalculations also may affect the ceiling price at which we are required to offer our products to certain covered entities under the 340B pricing program.

We are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, civil monetary penalties can be applied if we are found to have knowingly submitted any false pricing information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, or if we fail to submit the required pricing data on a timely basis. Such conduct also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. If a governmental authority, such as CMS, were to take any of the foregoing actions, our business and results of operations may be negatively impacted.

The Public Health Service’s 340B drug pricing program, and other comparable government and payer regulations, may have a negative impact on the price we can charge for our products and result in a decrease in revenues.

Federal law requires that any company that participates in the Medicaid Drug Rebate Program also

participate in the Public Health Service’s 340B drug pricing program in order for federal funds to be available for the manufacturer’s drugs under Medicaid and Medicare Part B. The 340B pricing program requires participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B “ceiling price” for the manufacturer’s covered outpatient drugs. The 340B pricing program is described in Pharmaceutical Pricing and Reimbursement in Item 1 Business in our Annual Report on Form 10-K for the year ended December 31, 2018. The 340B ceiling price is calculated using a statutory formula, which is based on, among other prices, the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. We are a participant in the 340B drug pricing program and are, for the applicable covered entities, subject to the price ceiling. Any changes to the 340B drug pricing program, including:


•	the method of calculating the 340B ceiling price for our products;


•	any expansion of the entities that qualify as covered entities; and


•	any requirement that participating manufacturers agree to provide 340B discounted pricing on drugs used in an inpatient setting;

could have a material and negative impact our revenue and results of operations.

In addition, after multiple delays, the final rule implementing civil monetary penalties against manufacturers for instances of overcharging 340B covered entities became effective on January 1, 2019. Accordingly, we could be subject to such penalties if the government finds that we knowingly and intentionally overcharged a 340B covered entity.

In addition, the agreement that manufacturers must sign to participate in the 340B pricing program obligates a manufacturer to offer the 340B price to covered entities if the manufacturer makes the drug available to any other purchaser at any price and to report to the government the ceiling prices for its drugs.

Beyond the Public Health Service’s 340B drug pricing program, federal law requires that a company must participate in the Department of Veterans Affairs Federal Supply Schedule (FFS) pricing program to be eligible to have its products paid for with federal funds. If we overcharge the government in connection with our FSS contract or Section 703 Agreement, whether due to a misstated FCP or otherwise, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the FCA and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, may be

expensive, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.

We are subject to laws and regulations covering data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which have affected and may affect our business. In the U.S., numerous federal and state laws and regulations, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA.

Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. EU Member States and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the EC adopted the EU Data Protection Directive, as implemented into national laws by the EU Member States, which imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data from clinical trials and adverse event reporting. Data protection authorities from different EU Member States have interpreted the privacy laws differently, which adds to the complexity of processing personal data in the EU, and guidance on implementation and compliance practices are often updated or otherwise revised. Any failure to comply with the rules arising from the EU Data Protection Directive and related national laws of EU Member States could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.

In May 2016, the EU formally adopted the General Data Protection Regulation, which applies in all EU Member States and went into effect on May 25, 2018 and replaced the EU Data Protection Directive on that date. The regulation introduces new data protection requirements in the EU and substantial fines for breaches of the data protection rules. It increases our responsibility and liability in relation to personal data that we process and we may be required to put in place

additional mechanisms ensuring compliance with the new EU data protection rules.

Security breaches, cyber-attacks or other disruptions could expose us to liability and affect our business and reputation.

We are increasingly dependent on our information technology systems and infrastructure for our business. We collect, store and transmit sensitive information including intellectual property, proprietary business information and personal information in connection with business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, “hacktivists,” patient groups, disgruntled current or former employees and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance. We have implemented information security measures designed to protect patients’ personal information against the risk of inappropriate and unauthorized external use and disclosure. However, despite these measures, and due to the ever changing information cyber-threat landscape, we may be subject to data breaches through cyber-attacks. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. If our information technology systems become compromised, we may not promptly discover the intrusion. Like other companies in our industry, we have experienced attacks to our data and systems, including malware and computer viruses. If our systems failed or were breached or disrupted, we could lose product sales, and suffer reputational damage and loss of customer confidence. Such incidents may result in notification obligations to affected individuals and government agencies, legal claims or proceedings, and liability under foreign, federal and state laws that protect the privacy and security of personal information. Any one of these events could cause our business to be materially harmed and our results of operations may be adversely impacted.

Negative public opinion and increased regulatory scrutiny of recombinant and transgenic products, genetically modified products and genetically modified animals generally may damage public perception of our current and future products or adversely affect our ability to conduct our business and obtain regulatory approvals we may seek.

KANUMA is a transgenic product produced in the egg whites of genetically modified chickens who receive copies of the human lysosomal acid lipase gene to produce recombinant human lysosomal acid lipase. The success of KANUMA may depend in part on public

attitudes of the use of genetic engineering. Public attitudes may be influenced by claims and perceptions that these types of activities or products are unsafe, and our products may not gain sufficient acceptance by, or fall out of favor with, the public or the medical community. Negative public attitudes to genetic engineering activities in general could result in more restrictive legislation or regulations and could impede our ability to conduct our business, delay preclinical or clinical studies, or otherwise prevent us from commercializing our product.

Risks Related to Intellectual Property

If we cannot obtain new patents, maintain our existing patents and protect the confidentiality and proprietary nature of our trade secrets and other intellectual property, our business and competitive position may be harmed.

Our success depends in part on our ability to obtain and maintain patent and regulatory protections for our products and investigational compounds, to preserve our trade secrets and other proprietary rights, to operate without infringing the proprietary rights of third parties and to prevent third parties from circumventing our rights. Due to the time and expense of bringing new products through development and regulatory approval to the marketplace, there is particular importance in obtaining patent and trade secret protection for significant new technologies, products and processes.

We have and may in the future obtain patents or the right to practice patents through ownership or license. Our patent applications may not result in the issue of patents in the U.S. or other countries. In addition, a patent may be issued in one country, but a counterpart patent may not be issued in another country. For example, we have applied for a certain patent in the EU that would provide protection for the composition of matter for SOLIRIS through 2027, and while a similar patent was granted in the U.S., the European patent application remains under examination by the European Patent Office and a hearing on it scheduled for February 2019 has been delayed until later in the year.

Even if a patent is issued, that is not conclusive as to inventorship, scope, validity or enforceability and therefore that patent may not afford adequate (or any) protection for our products. Third parties may challenge our patents, and have challenged our patents in the past and, in some cases have been successful in such challenges. For example, on January 21, 2019, the Opposition Division of the European Patent Office determined, following multi-party opposition proceedings, to revoke our European patent No. 2359834, which relates to the formulation of SOLIRIS and on February 28, 2019, Amgen Inc. petitioned the U.S. Patent and Trademark Office to institute inter partes review of three of our patents that relate to SOLIRIS. In addition to the protections afforded by patents (which,

as noted above are subject to challenge and potentially invalidation), certain of our products do benefit from regulatory protections for applicable indications in certain geographies that allow such protections. For example, SOLIRIS is protected in Europe by orphan drug exclusivity through late 2023 for aHUS and until 2027 for gMG.

If any of our patents are narrowed, invalidated, revoked or become unenforceable, competitors may develop and market products similar to ours that do not conflict with or infringe our patents rights, which could have a material adverse effect on our financial condition.

We may also finance and collaborate in research conducted by government organizations, hospitals, universities or other educational or research institutions. Such research partners may be unwilling to grant us exclusive rights to technology or products developed through such collaborations. There is also a risk that disputes may arise as to the rights to technology or products developed in collaboration with other parties. Our products and product candidates are expensive and time-consuming to test and develop. Even if we obtain and maintain patents, our business may be significantly harmed if the patents are not broad enough to protect our products from copycat products.

Significant legal questions exist concerning the extent and scope of patent protection for biopharmaceutical products and processes in the U.S. and elsewhere. Accordingly, there is no certainty that patent applications owned or licensed by us will issue as patents, or that our issued patents will afford meaningful protection against competitors. Once issued, patents are subject to challenge through both administrative and judicial proceedings in the U.S. and other countries. Such proceedings include re-examinations, inter partes reviews, post-grant reviews and interference proceedings before the U.S. Patent and Trademark Office, as well as opposition proceedings before the European Patent Office and other non-U.S. patent offices. Certain countries have laws that provide stronger bases for challenging third party patent rights than are available to challenge patents in other countries. Therefore, we may be able to defend our patents against a third party claim in one country but counterpart patents may be invalidated in other countries and we may be able to invalidate a third-party patent in one country but not invalidate its counterpart patents in other countries. Litigation may be required to enforce, defend or obtain our patent and other intellectual property rights. Any administrative proceeding or litigation could require a significant commitment of our resources and, depending on outcome, could adversely affect the scope, validity or enforceability of certain of our patent or other proprietary rights.

In addition, our business requires using sensitive technology, techniques and proprietary compounds that

we protect as trade secrets. However, we may also rely heavily on collaboration with, or discuss the potential for collaboration with, suppliers, outside scientists and other biopharmaceutical companies, including in connection with development efforts such as those with Complement Pharma and Dicerna. Collaboration and discussion of potential collaboration present a strong risk of exposing our trade secrets. If our trade secrets were exposed, we may lose the protection and potential exclusive rights afforded by trade secret law, and such exposure may likely help our competitors and allow them to access technology without restriction and adversely affect our business prospects.

If we are found to be infringing third party patents, we may be forced to pay damages to the patent owner and/or obtain a license to continue the manufacture, sale or development of our products. If we cannot obtain a license, we may be prevented from the manufacture, sale or development of our products or product candidates, which may adversely affect our business.

Parts of our technology, techniques, proprietary compounds and potential product candidates, including those which are or may be in-licensed, may be found to infringe patents owned by or granted to others. We have and may in the future receive notices claiming our products infringe third party patents and third parties have and may in the future file civil lawsuits against us claiming infringement of their intellectual property rights. In late-2018, Chugai Pharmaceutical Co., Ltd. filed suits in the U.S. and Japan alleging that ULTOMIRIS infringes a U.S. and two Japanese patents, respectively, held by Chugai (See Note 18, Commitments and Contingencies to the footnotes to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information regarding these legal proceedings with Chugai).. Additional third parties may claim that the manufacture, use or sale of our products or product candidates infringes patents owned or granted to such third parties. We are aware of patents owned by third parties that might be claimed by such third parties to be infringed by the development and commercialization of our products or investigational compounds. In respect to some of these patents, we have obtained licenses, or expect to obtain licenses. However, with regard to other patents, we have determined in our judgment that:


•	our products and investigational compounds do not infringe the patents;


•	the patents are not valid or enforceable; and/or


•	we have identified and are testing various alternatives that should not infringe the patents and which should permit continued development and commercialization of our products and investigational compounds.

Any holder of these patents or other patents covering similar technology could sue us for damages

and seek to prevent us from manufacturing, selling or developing our products. Intellectual property disputes, such as those initiated by Chugai, can be costly and time consuming to defend. Prior to launch of a new product (or an existing product for a new indication), for various reasons, a patent owner may not be able to assert its patent rights so it is possible that any potential challenges to our products may be made after a product has been commercialized and not necessarily while the product is in development, in clinical trials or during the regulatory review process. If we cannot successfully defend against any future actions or conflicts, if they arise, we may incur substantial legal costs and may be liable for damages, be required to obtain costly licenses or be forced to stop manufacturing, using or selling our products (and we may be, in certain cases, prevented from initiating product launches in certain jurisdictions or required to withdraw the product from the market after it has been launched), which may adversely affect our business. We may seek to obtain a license prior to or during legal actions in order to reduce the risks in connection with product launches (or at a later time after product introduction) and to reduce further costs and the risk of a court determination that our technology, techniques, proprietary compounds or potential product candidates infringe the third party’s patents. A required license may be costly or may not be available on acceptable terms, if at all. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our business. In addition, even if we obtained a license, it would likely be non-exclusive and any competitive advantage resulting from the licensed technology may be of limited value and the same technology could be utilized by competitors.

In some instances, we believe we may prevail in a patent infringement action. There can, however, be no assurance that the court will agree with our position or that they will decide this or any other infringement case in our favor. Nor can we be certain that, if we do not prevail in litigation, that we may be able to obtain a license to any third-party patent on commercially reasonable terms or at all; successfully develop non-infringing alternatives on a timely basis (or at all); or license alternative non-infringing technology, if any exists, on commercially reasonable terms (or at all). Any impediment to our ability to manufacture, use or sell approved forms of our products or our product candidates could have a material adverse effect on our business and prospects.

It is possible that we could lose market exclusivity for a product earlier than expected, which may harm our competitive position.

In our industry, much of an innovative product’s commercial value is realized while it has market exclusivity. When market exclusivity expires and biosimilar or generic versions of the product are

approved and marketed, there can be substantial decline in the innovative product’s sales.

Market exclusivity for our products is based upon patent rights and certain regulatory forms of protection. The scope of our product patent rights vary from country to country and is dependent on the availability of meaningful legal remedies in each country. The failure to obtain patent and other intellectual property rights, or limitations on the use, or loss of such rights, could be material to our business. In some countries, patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents or we did not file patents in those markets. Also, the patent environment is unpredictable and the validity and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once regulatory exclusivity periods expire, biosimilar or generic versions of the product can be approved and marketed. For example, in 2019, a SOLIRIS biosimilar was approved in Russia for the treatment of patients with PNH and aHUS. Even prior to the expiration of regulatory exclusivity, a competitor could seek to obtain marketing approval by submitting its own clinical trial data.

The market exclusivity of our products may be impacted by competitive products that are either innovative or biosimilar or generic copies. In our industry, the potential for biosimilar challenges has been an increasing risk to product market exclusivity. U.S. law includes an approval pathway for biosimilar versions of innovative biological products. Under the pathway, the FDA may approve products that are similar to (but not generic copies of) innovative biologics on the basis of less extensive data than is required for a full biologic license application. After an innovator has marketed its product for four years, other manufacturers may apply for approval of a biosimilar version of the innovator product. However, qualified innovative biological products will receive 12 years of regulatory market exclusivity (i.e., the biosimilar product cannot be approved before 12 years after the innovative biological product). The law also provides a mechanism for innovators to enforce their patents that protect their products and for biosimilar applicants to challenge the patents. Such litigation may begin as early as four years after the innovative biological product is first approved by the FDA. Pathways for biosimilar products also exist in many other markets, including Europe, Japan and Russia. Other companies are developing and advancing SOLIRIS biosimilar programs, including conducting clinical trials. Competition, including from biosimilars approved for marketing, may likely result in a decrease in prices, increased promotion efforts and lower margins for our products. In addition, approval of a biosimilar that is substitutable for one of our products may increase the risk of accelerated market penetration by that biosimilar. Further, if patients or healthcare providers do not believe that ULTOMIRIS provides a

compelling profile for patient conversion from SOLIRIS, a SOLIRIS biosimilar may not only be expected to have a material and negative impact on our SOLIRIS revenues and margins (which accounted for a significant percentage of our revenue in 2018), it may also have a material impact on ULTOMIRIS revenue and margins and the ability of ULTOMIRIS to gain market acceptance.

Our other products are also at risk from biosimilars. Other than SOLIRIS for the treatment of gMG and SOLIRIS and ULTOMIRIS as a treatment for PNH, each of our products is currently the only approved drug for the disease(s) the product treats. If a competitive product is approved for sale, including a biosimilar or generic product or novel therapy, our market share and our revenues could decline, particularly if the competitive product is perceived to be more effective or is less expensive than our product.

Risks Related to Our Common Stock

Our stock price is volatile.

The trading price of our common stock has been volatile and may continue to be volatile in the future. Many factors could have an impact on our stock price, including fluctuations in our or our competitors’ operating results, clinical trial results or adverse events associated with our products or our competitors' products, product development by us or our competitors, changes in laws, including healthcare, tax or intellectual property laws, intellectual property developments, changes in reimbursement or drug pricing, the existence or outcome of litigation or government proceedings, including the SEC/DOJ investigation and the Chugai lawsuits alleging patent infringement, acquisitions or other strategic transactions, and the perceptions of our investors that we are not performing or meeting expectations. In addition, the sales of our common stock by our officers, directors, or by any entities that an officer or director may be affiliated with, may have caused our stock price to drop in the past and any future sales by such officer, director or affiliate (or the perception that such sales could occur) may have a negative impact on our stock price. The trading price of the common stock of many biopharmaceutical companies, including ours, has experienced price and volume fluctuations, which have at times been unrelated to the operating performance of the companies whose stocks were affected

Anti-takeover provisions in our charter and bylaws and under Delaware law could make a third-party acquisition of us difficult and may frustrate any attempt to remove or replace our current management.

Our corporate charter and by-law provisions may discourage certain types of transactions involving an actual or potential change of control that might be beneficial to us or our stockholders. Our bylaws provide that special meetings of our stockholders may be called only by the Chairman of the Board of Directors, the President, the Secretary, or a majority of the Board of Directors, or upon the written request of stockholders who together own of record 25.0% of the outstanding stock of all classes entitled to vote at such meeting. Our bylaws also specify that the authorized number of directors may be changed only by resolution of the Board of Directors. Our charter does not include a provision for cumulative voting for directors, which may have enabled a minority stockholder holding a sufficient percentage of a class of shares to elect one or more directors. Under our charter, our Board of Directors has the authority, without further action by stockholders, to designate up to five million shares of preferred stock in one or more series. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any class or series of preferred stock that may be issued in the future.

Because we are a Delaware corporation, the anti-takeover provisions of Delaware law could make it more difficult for a third party to acquire control of us, even if the change in control may be beneficial to stockholders. We are subject to the provisions of Section 203 of the Delaware General Laws, which prohibits a person who owns in excess of 15.0% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15.0% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.


Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

ISSUER PURCHASE OF EQUITY SECURITIES (amounts in millions, except per share amounts)

The following table summarizes our common stock repurchase activity during the second quarter 2019:



Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs	Maximum Dollar Value of Shares that May Yet Be Purchased Under the Program
April 1-30, 2019	0.1	$	134.8	0.1	$	427.7
May 1-31, 2019	0.1	$	130.5	0.1	$	414.1
June 1-30, 2019	0.1	$	121.0	0.1	$	402.6
Total	0.3	$	128.8	0.3


Item 5.	OTHER INFORMATION.

None.


Item 6.	EXHIBITS.

(a)Exhibits:




10.1		Form of 2017 Incentive Plan Restricted Stock Unit Agreement for Director Annual Grant**

10.2		Form of 2017 Incentive Plan Restricted Stock Unit Agreement for Director Fees**

31.1		Certificate of Chief Executive Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 Sarbanes Oxley Act of 2002.

31.2		Certificate of Chief Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of Sarbanes Oxley Act of 2002.

32.1		Certificate of Chief Executive Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act.

32.2		Certificate of Chief Financial Officer pursuant to Section 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act.

101		The following materials from the Alexion Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 formatted in eXtensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018, (ii) the Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2019 and 2018, (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2019 and 2018, (iv) the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018, (v) the Condensed Consolidated Statements of Changes in Stockholders' Equity the three and six months ended June 30, 2019 and 2018, and (vi) Notes to Condensed Consolidated Financial Statements.

** Indicates a management contract or compensatory plan or arrangement required to be filed pursuant to Item 6 of Form 10-Q.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	ALEXION PHARMACEUTICALS, INC.

	By:	/s/ Ludwig N. Hantson, Ph.D.
Date: July 24, 2019		Ludwig N. Hantson, Ph.D. Chief Executive Officer (principal executive officer)

	By:	/s/ Paul J. Clancy
Date: July 24, 2019		Paul J. Clancy Executive Vice President and Chief Financial Officer (principal financial officer)

EX-10.1 2 alxnex101incplana.htm EXHIBIT 10.1 Exhibit

ALEXION PHARMACEUTICALS, INC.

2017 INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-Employee DIRECTORS

Award: [ ] Restricted Stock Units

THIS AGREEMENT (the "Agreement") by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and you ("Participant") sets forth the terms and conditions of an award of restricted stock units granted to Participant on May 15, 2019 (the "Grant Date") under the Alexion Pharmaceuticals Inc. 2017 Incentive Plan (as amended and in effect from time to time, the "Plan"), which is incorporated herein by reference.

W I T N E S S E T H:

WHEREAS, pursuant to the Plan, the Company has granted to Participant, and Participant desires to accept, an award (the "Award") of restricted stock units ("RSUs"), upon the terms and conditions set forth in this Agreement and the Plan. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Plan.

NOW, THEREFORE, the parties hereto agree as follows:

1.Grant. The Company hereby grants to Participant on the Grant Date the number of RSUs set forth above, subject to the terms and conditions of the Plan and this Agreement. An RSU is an unfunded and unsecured promise to deliver (or cause to be delivered) to Participant, subject to the terms and conditions of the Plan and this Agreement, a share of Stock (each, a "Share") on the delivery date or as otherwise provided herein. Until such delivery, Participant has only the rights of a general unsecured creditor, and no rights as a shareholder, of the Company.

2.Vesting. The RSUs shall become fully vested on the earlier to occur of (a) the first anniversary of the Grant Date, and (b) the date of the 2020 annual meeting of shareholders (whichever date occurs earlier, the "Vesting Date"); provided that the Participant remains in continuous service as a Director from the Grant Date until the Vesting Date. While Participant’s continuous service is not required in order to receive delivery of Shares underlying RSUs that are vested in accordance with this Agreement at the time Participant’s service with the Company terminates, all other terms and conditions of this Agreement shall continue to apply to such vested RSUs. The Award will terminate, and no Shares underlying such vested RSUs will be delivered, if Participant fails to comply with such terms and conditions. Notwithstanding the foregoing, the RSUs, to the extent outstanding and unvested, shall immediately become fully vested prior to the Vesting Date in the event of (a) a Change in Control of the Company, (b) Participant’s cessation of service as a Director due to his or her death, or (c) Participant’s cessation of service as a Director at a time when he or she (i) is in good standing, as determined by the Board in its sole discretion, and (ii) has served a minimum of five (5) consecutive full years as a Director.

3.Delivery. As soon as administratively feasible after the date the RSUs vest under Section 2 above, but no later than thirty (30) days following such vesting date, the Company shall cause to be delivered to the Participant (or in the event of the Participant’s death, the Participant’s beneficiary or legal representative)

the Shares underlying the RSU in accordance with this Agreement. No Shares will be issued pursuant to the Award unless and until all legal requirements applicable to the issuance or transfer of such shares have been complied with to the satisfaction of the Company. In the event that any Shares are to be delivered to an individual other than the original Participant, the Company will be under no obligation to deliver shares of Stock hereunder unless and until it is satisfied as to the authority of the individual to receive the Shares.

4.Nontransferability. This Award may not be transferred except as expressly permitted by Section 6(a)(3) of the Plan.

5.Forfeiture and Recoupment of Gains. Except as otherwise provided in Section 2, upon the cessation of Participant’s service as a Director, Participant shall forfeit, without payment, any and all RSUs that were outstanding but that had not yet become vested immediately prior to such termination of service, and such RSUs shall cease to be outstanding and no Shares will be delivered in respect thereof. By accepting the Award the Participant expressly acknowledges and agrees that his or her rights (and those of any permitted transferee) under the Award or to any Shares acquired under the Award or any proceeds from the disposition thereof are subject to Section 6(a)(5) of the Plan (including any successor provision). Nothing in the preceding sentence shall be construed as limiting the general application of Section 8 of this Agreement.

6.Continuance as Director. Nothing in this Agreement shall be deemed to create any obligation on the part of the Board to nominate Participant for reelection as a Director by the Company’s stockholders or give Participant any right to continue to serve as a Director or interfere with the right of the Company or the Board to terminate the service of Participant.

7.Provisions of the Plan. The provisions of the Plan, the terms of which are incorporated in this Agreement, shall govern if and to the extent that there are inconsistencies between those provisions and the provisions hereof (except as expressly provided herein). Participant acknowledges that he or she received a copy of the Plan prior to the date of this Agreement. By acceptance of the Award, the Participant agrees to be subject to the terms of the Plan.

8.Tax Matters. Participant understands that he or she (and not the Company) shall be responsible for his or her own tax liability arising from or due in connection with the grant or vesting of the RSUs and/or the delivery of any Shares hereunder. The Company shall have no liability or obligation relating to the foregoing.

9.Miscellaneous. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written.

ALEXION PHARMACEUTICALS, INC.

By:

Name:

Title:

PARTICIPANT

__________________________________

Name:

EX-10.2 3 alxnex102incplanb.htm EXHIBIT 10.2 Exhibit

ALEXION PHARMACEUTICALS, INC.

2017 INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-Employee DIRECTORS

Award: [ ] Restricted Stock Units

THIS AGREEMENT (the "Agreement") by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and you ("Participant") sets forth the terms and conditions of an award of restricted stock units granted to Participant on May 15, 2019 (the "Grant Date") under the Alexion Pharmaceuticals, Inc. 2017 Incentive Plan (as amended and in effect from time to time, the "Plan"), which is incorporated herein by reference.

W I T N E S S E T H:

NOW, THEREFORE, the parties hereto agree as follows:

2.Vesting. The RSUs shall become fully vested as follows: twenty five percent (25%) of the Award on each of the following dates: August 15, 2019; November 15, 2019; February 15, 2020 and May 15, 2020 (each such date, a "Vesting Date"); provided that the Participant remains in continuous service as a Director from the Grant Date through the applicable Vesting Date. While Participant’s continuous service is not required in order to receive delivery of Shares underlying RSUs that are vested in accordance with this Agreement at the time Participant’s service with the Company terminates, all other terms and conditions of this Agreement shall continue to apply to such vested RSUs. The Award will terminate, and no Shares underlying such vested RSUs will be delivered, if Participant fails to comply with such terms and conditions.

3.Delivery. As soon as administratively feasible after each of the dates the RSUs vest under Section 2 above, but no later than thirty (30) days following each such vesting date, the Company shall cause to be delivered to the Participant (or in the event of the Participant’s death, the Participant’s beneficiary or legal representative) the Shares underlying the vested RSUs in accordance with this Agreement. No Shares will be issued pursuant to the Award unless and until all legal requirements applicable to the issuance or transfer of such shares have been complied with to the satisfaction of the Company. In the event that any Shares are to be delivered to an individual other than the original Participant, the Company will be under no obligation to deliver shares of Stock hereunder unless and until it is satisfied as to the authority of the individual to receive the Shares.

4.Nontransferability. This Award may not be transferred except as expressly permitted by Section 6(a)(3) of the Plan.

9.Miscellaneous. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.

IN WITNESS WHEREOF, this Agreement has been executed as of the date first above written.

ALEXION PHARMACEUTICALS, INC.

By:

Name:

Title:

PARTICIPANT

__________________________________

Name:

EX-31.1 4 alxnex311q219.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

I, Ludwig N. Hantson, Ph.D., certify that:


1	I have reviewed this quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc.;


2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Dated:	July 24, 2019	/s/ LUDWIG N. HANTSON, Ph.D.
		Chief Executive Officer

EX-31.2 5 alxnex312q219.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

I, Paul J. Clancy, certify that:


1	I have reviewed this quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc.;


2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4	The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.



Dated:	July 24, 2019	/s/ PAUL J. CLANCY
		Executive Vice President and Chief Financial Officer

EX-32.1 6 alxnex321q219.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended June 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Ludwig N. Hantson, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated:	July 24, 2019	/s/ LUDWIG N. HANTSON, Ph.D.
		Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 7 alxnex322q219.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Alexion Pharmaceuticals, Inc. (the “Company”) for the fiscal quarter ended June 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Paul J. Clancy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated:	July 24, 2019	/s/ PAUL J. CLANCY
		Executive Vice President and Chief Financial Officer

EX-101.SCH 8 alxn-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Acquisitions (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Acquisitions (Summary of Total Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Basis of Presentation and Principles Of Consolidation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2425401 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Statement link:presentationLink link:calculationLink link:definitionLink 1004501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Comprehensive Income Statement link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Defined Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Derivative Instruments and Hedging Activities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Earnings Per Common Share (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Fair Value Measurement (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Income Taxes (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Leases - Finance and Operating Lease Liability Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Leases - Lease Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Leases - Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Leases - Lease Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Leases - Lease Related Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Marketable Securities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Marketable Securities (Summary of Securities Held) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Other Investments link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2126100 - Disclosure - Restructuring and Related Expenses link:presentationLink link:calculationLink link:definitionLink 2426402 - Disclosure - Restructuring and Related Expenses (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2426403 - Schedule - Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) link:presentationLink link:calculationLink link:definitionLink 2326301 - Disclosure - Restructuring and Related Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2426404 - Disclosure - (Restructuring Reserve Roll Forward) (Details) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 2427401 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 alxn-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 alxn-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 alxn-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Investments, Debt and Equity Securities [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Trading securities. fair value Debt Securities, Trading, and Equity Securities, FV-NI Revenue from Contract with Customer [Abstract] Revenue Recognition Revenue from Contract with Customer [Text Block] Fair Value Disclosures [Abstract] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Caelum Biosciences [Member] Caelum Biosciences [Member] Caelum Biosciences [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement [Member] Collaborative Arrangement [Member] Asset Class [Axis] Asset Class [Axis] Fair Value by Asset Class [Domain] Asset Class [Domain] Interest Rate Contract [Member] Interest Rate Contract [Member] Money Market Funds [Member] Money Market Funds [Member] Mutual Funds [Member] Mutual Funds [Member] Mutual Funds [Member] Commercial Paper [Member] Commercial Paper [Member] Corporate Bond Securities [Member] Corporate Bond Securities [Member] Municipal Bonds [Member] Municipal Bonds [Member] Other Government Obligations [Member] Other Government Obligations [Member] Other Government Obligations [Member] Certificates of Deposit [Member] Certificates of Deposit [Member] Foreign Exchange Forward [Member] Foreign Exchange Forward [Member] Equity Securities [Member] Equity Securities [Member] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Acquisition Related Contingent Consideration [Member] Acquisition Related Contingent Consideration [Member] Acquisition-Related Contingent Consideration [Member] Other Contingent Payments [Member] Other Contingent Payments [Member] Other Contingent Payments [Member] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cash Equivalents [Member] Cash Equivalents [Member] Marketable Securities [Member] Marketable Securities [Member] Marketable Securities [Member] Other Assets [Member] Other Assets [Member] Other Assets Other Noncurrent Assets [Member] Current Liabilities [Member] Current Liabilities [Member] Current Liabilities [Member] Other Liabilities [Member] Other Liabilities [Member] Other Current Liabilities Other Current Liabilities [Member] Other Liabilities Other Noncurrent Liabilities [Member] ContingentConsiderationCurrent [Member] ContingentConsiderationCurrent [Member] ContingentConsiderationCurrent [Member] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Contingent Consideration [Member] Contingent Consideration [Member] Contingent Consideration [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative Liability Derivative Liability Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Marketable securities Investments, Fair Value Disclosure Foreign exchange forward contracts, asset Foreign Currency Contract, Asset, Fair Value Disclosure Foreign exchange forward contracts, liability Foreign Currency Contracts, Liability, Fair Value Disclosure Interest Rate Derivative Assets, at Fair Value Interest Rate Derivative Assets, at Fair Value Interest Rate Derivative Liabilities, at Fair Value Interest Rate Derivative Liabilities, at Fair Value Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Receivables, which are included in Trade accounts receivable, net Contract with Customer, Asset, Net, Current Contract liabilities, which are included in Other current liabilities Contract with Customer, Liability, Current Statement of Comprehensive Income [Abstract] Statement [Table] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Net income (loss) Net Income (Loss) Attributable to Parent Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gains (losses) on debt securities Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gains on pension obligation Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Separation Costs Employee Severance [Member] Asset-Related Charges Facility Closing [Member] Other Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Beginning Balance Restructuring Reserve Restructuring expenses Restructuring and Related Cost, Incurred Cost Cash settlements Payments for Restructuring Adjustments to previous estimates Restructuring Reserve, Accrual Adjustment Asset impairments Restructuring Reserve, Settled without Cash Ending Balance Accumulated Other Comprehensive Income [Abstract] Accumulated Other Comprehensive Income [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Asset Acquisition, Contingent Consideration, Milestone Payments Asset Acquisition, Contingent Consideration, Milestone Payments Asset Acquisition, Contingent Consideration, Milestone Payments Collaboration Agreement, Upfront Payment Collaboration Agreement, Upfront Payment Collaboration Agreement, Upfront Payment Derivative Fair Value, Discounted Cost Of Debt Derivative Fair Value, Discounted Cost Of Debt Derivative Fair Value, Discounted Cost Of Debt Increase in contingent consideration liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Collaboration Agreement, Potential Future Payments, Milestone Achievement Collaboration Agreement, Potential Future Payments, Milestone Achievement Collaboration Agreement, Potential Future Payments, Milestone Achievement Research and development Research and Development Expense Derivative Instruments and Hedging Activities [Abstract] Derivative Instruments and Hedging Activities [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Value, Inputs, Level 2 [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Derivatives, Fair Value [Line Items] Asset Derivatives, Fair Value Derivative Asset, Fair Value, Gross Asset Liability Derivatives, Fair Value Derivative Liability, Fair Value, Gross Liability Fair Value Measurement Fair Value Disclosures [Text Block] Leases [Abstract] Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Finance Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Lease, Liability, Payments, Due Year Five Lessee, Lease, Liability, Payments, Due Year Five Lessee, Lease, Liability, Payments, Due Year Five Lessee, Lease, Liability, Payments, Due Year Four Lessee, Lease, Liability, Payments, Due Year Four Lessee, Lease, Liability, Payments, Due Year Four Lessee, Lease, Liability, Payments, Due Year Three Lessee, Lease, Liability, Payments, Due Year Three Lessee, Lease, Liability, Payments, Due Year Three Lessee, Lease, Liability, Payments, Due Year Two Lessee, Lease, Liability, Payments, Due Year Two Lessee, Lease, Liability, Payments, Due Year Two Lessee, Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, Payments, Due Year Six Finance Lease, Liability, Payments, Due Year Six Finance Lease, Liability, Payments, Due Year Six Lessee, Operating Lease, Liability, Payments, Due Year Six Lessee, Operating Lease, Liability, Payments, Due Year Six Lessee, Operating Lease, Liability, Payments, Due Year Six Lessee, Lease, Liability, Payments, Due Year Six Lessee, Lease, Liability, Payments, Due Year Six Lessee, Lease, Liability, Payments, Due Year Six Finance Lease, Liability, Payments, Due After Year Six Finance Lease, Liability, Payments, Due After Year Six Finance Lease, Liability, Payments, Due After Year Six Lessee, Operating Lease, Liability, Payments, Due After Year Six Lessee, Operating Lease, Liability, Payments, Due After Year Six Lessee, Operating Lease, Liability, Payments, Due After Year Six Lessee, Lease, Liability, Payments, Due After Year Six Lessee, Lease, Liability, Payments, Due After Year Six Lessee, Lease, Liability, Payments, Due After Year Six Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Two Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Finance Lease, Liability, Payments, Due Year Five Finance Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Three Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Inventory, Net [Abstract] Inventory, Current [Table] Inventory, Current [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Inventory [Line Items] Inventory [Line Items] Raw materials Inventory, Raw Materials, Gross Work-in-process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventory, Net Inventory, Net Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Earnings Per Common Share [Abstract] Earnings Per Common Share [Abstract] Schedule Of Basic And Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Subsequent Event [Line Items] Subsequent Event [Line Items] Payments for exclusive licenses and equity investments Payments to Acquire Equity Method Investments Derivative [Table] Derivative [Table] Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Interest Rate Swap One [Member] Interest Rate Swap One [Member] Interest Rate Swap One [Member] Interest Rate Swap Three [Member] Interest Rate Swap Three [Member] Interest Rate Swap Three [Member] Interest Rate Swap Four [Member] Interest Rate Swap Four [Member] Interest Rate Swap Four [Member] Derivative [Line Items] Derivative [Line Items] Derivative, notional amount Derivative, Notional Amount Derivative, fixed interest rate Derivative, Fixed Interest Rate Asset Acquisitions [Abstract] Asset Acquisitions [Abstract] Acquisitions Asset Acquisition Disclosure [Text Block] Asset Acquisition Disclosure [Text Block] Schedule of Interest Rate Contracts Schedule of Interest Rate Derivatives [Table Text Block] Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Fair Value of Outstanding Derivatives Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Offsetting Assets and Liabilities Offsetting Assets and Liabilities [Table Text Block] Offsetting Assets and Liabilities [Table Text Block] Schedule Of Assets And Liabilites Measured At Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule Of Acquisition-Related Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Statement of Stockholders' Equity [Abstract] EX-101.PRE 12 alxn-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 alexionlogoa54.jpg begin 644 alexionlogoa54.jpg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end GRAPHIC 14 chart-1a4d05ee019a5c28a75.jpg begin 644 chart-1a4d05ee019a5c28a75.jpg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end GRAPHIC 15 chart-2a9e8b01181c5afc92f.jpg begin 644 chart-2a9e8b01181c5afc92f.jpg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end GRAPHIC 16 chart-2be5ae4d6bc35201b7a.jpg begin 644 chart-2be5ae4d6bc35201b7a.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" $* 3D# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@#P#]JGXT:[^SM^SG\9_CEX9^&?B3XQZ]\*_AYXC\;:5\,O":W[:[XQ MO-#LVN8](M3I.C>)-8B@8!KK4I]&\-^)-9MM*M;ZXTGP]KFHQ6VEW?X?^ _^ M"R?Q8\4_L)?%K]H#3M5_8@^('Q+\,?M$_"?X(>"_$?PI^*_Q2^(7PNT]_C1^ MT1&]2U_P"*V@7&@>(?#FF6 M&K:AK/@[2?WY^+?PYM_BY\-_&/PWN?&/Q$^'J>+M>F/QS\)O%^H^ OB/X2 MNFDBN++Q#X.\6::DLNE:YI5Y!!=VK7-KJ&E7HC?3MK?MD_M*3?M)?$[7?"UTO[3/@8?"'X;>+_"_AKX8_&SXO?&K MX<^#K+P1X0^$^D_"WQ=X7O?$/QF\<7/Q6\.?$[P9XXT;XBOXEU/0WM](\':1 MX(T#PJ!==_Z_IK[SX]U/_@LI\1/!'[+_ ($^*7CWQ)^R9%X@\6?MB:_^R_\ M$SXQ3^&OVN/A=\!_V1?L/PWF\:>'HOVG?AE\8/A[X8_:3\%_$+Q7K]I9^$-& MT/Q)X>\!>#W7QMX1\4:CXRTK0&:XU+UGX??\%/OVGOVE/"7[/WA#]EOX&_ / MQ%^T-\3?@A\:?VG?%#?$#XN^/=+^ ]]\"?A+\;9_@=X \2_"_P 5^'?AWJ'C M;5KK]JG6%MO%OPJ7Q;X:T+_A7_@@ZGJ?CRRU;5;"QT76/6;#_@DAHVCZAI/Q M;TS]JGX[W'[7EK\=/&W[0VN_M/\ B3PS\#O$.I>,?'7C_P"">A?LZZSI&O?! MV3X867P$XK*YN['Q?--K_B@:W2TO_@CG MX"^'F@^ ;G]G[]IK]H3]GGXP>&K3]HC0O&?QQ^'&E_ J3Q-\3/!_[5OQ3M/C M-\:?"FJ>"/$7P?U;X3>"M,7XC65OXF^%(^&7@;P@/A'?1R+X'?$OB[4/ _P "1K6IZMXX;P)X9U+4]*?A5X6^, M'P'\3ZSXE^"OQUT7PUH'A/5;KXA_#M?%-M:^+="L;#Q#XAUKX>ZYH6MMK$-O MXH\$ZS>:#XG\1:!>Z??GA?$O_!,/P5J7PE^'_P "?"/QI^*GPZ^$_P"S]_PR MCK/[*7A/P[H_PQU*#X ^/OV4/^$D.@^-HY_%7@?7?^%MW'Q%;6=+D^(NC?%Z M'Q5IG^"/#/P\TY]"^'WPR\-^%/ WA33K7PSX3TM;IK32 M[[Q%XBUB74O$'B[Q+XAU>]-U$!==U_7_ Z^\^R:***!A144\\-M#+<7$L<$ M$$;RS33.L<4,4:EY)99'*I'%&BL\DCLJ1HK.[*H)'!M\6/AA'X)T7XDR?$3P M/%\/?$EKIE]X?\<3^+- MO".MV>M0?:=(NM*\1W.H0Z/J$&J6_[[3Y+6\E6\ MBR]OYBAB #T&BN+M_B/\/[SPY8^,+3QOX0N?"FJ7B:?IOB:W\3Z%/X>O[^2] M?38[*RUR+4'TJ[O)-0BDL4M;>[EN'O(WM5C,Z-&.AU;6M(T&R_M'6]4T[1]/ M^TV5G]MU6]M=-M!=ZE>0:?I]J;F]E@@%Q?7]S;65G 9!+=7EQ!:VZ27$T4;@ M&G136945G9@JJ"S,3@*J@EB3T !))Z8JAI&L:5K^F66M:'J>GZSI&I6\=WI M^J:5>VNI:=?6LHS'.M,TG2M-LO%%_!9Z=IN MG66O06=C8VD*+#;6EK#%;P1*L<4:(H ^;?\ AJS]J+_HY+X^?^'A^(?_ ,T5 M=/\ MP?\GF?M6?\ 9P?Q6_\ 4MU&OERO]+N'LGRF>09'.65Y=*4LGRR4I2P. M&"H-RDW2;;;U;;NWJS_+KB'.'XA__ #15X'17L?V+D_\ T*^?\-6?M1?\ 1R7Q\_\ #P_$/_YHJBG_ &K?VHQ!.1^TE\?01#*0 M1\8OB&""(V((/_"1<$'D'L:\(J*?_43_ /7";_T4]']BY/\ ]"G+/_"#"_\ MRKR7W">=YU9_\*^:;/\ YC\7V_Z^^2^X_P!"O]FS4M1UG]G3X!:OJ]_>ZKJV MJ_!7X5ZEJFJ:E=3WVHZEJ-]X%T*ZO;^_O;J26YO+V\N99;BZNKB62>XGDDEE MD>1V8^U5X1^RU_R;'^SG_P!D(^$/_JOO#U>[$X_,#\R /U-?YDYLE'-DFT>&+X]>!-#^TZGJGPQF\02QVS06EQ+#_-S\ M)/!WA#XC_P#!-WX#:)\9O!/@OX(?LR?#W]LKP3X_7XV_"S_@GI\4_C/^SQ\6 M8M9_8AUG0+_XC>*_V4_C$WB_2_AA:>$OB5XRN/#&H?&>'X=_$[]FSQ;^T%X0 MT[QY;>%8)/$NK:S:_O'JG_!;G]BO2M2U/2;N/XS?:M*U/4=*NO*^&-_ MV6]>^#\GQ7M=&T/XH>(/V&_@_#X9T/X _M$_M3^##I_CKX>IK/@S1[R_:P\5 M^(O!^G?9_$]WX!U?R_\ ;8TW]O75?^"?/[!^CW'["_[1\_P0^ 7P-_X)I^)/ M#VEZO\?$&#]IU?CU\&-$U_3/CWX=\8>(_!WQ6UW6?!/@71[?X?>!GD^ M&^G>&M!\8?&?Q3\1OB5:>&[3X;Z9)X7_ ',/_!<;]B,@#R_C6,=Q\,I@Q^K# MQ"&/XDY//6G'_@N1^Q(1CR_C4!QT^&,@/!SU'B 'Z\\]#D$T_P#B&7B!_P!$ MAGW3_F7U^MO[O]Y?B+_B*GAS_P!%GP__ .'&AY?WO/\ JZO9_;:^,_QZ^._P MCN_@W^RO^S]\2_B]J=I\6_#_ ,*_VY_!'@_X@_#WX-?$KX6^ M1^%6B?%[Q; M\-? _C_XO>*/ 7P]\7:O\0K#Q;X/^%_B'X@?"OQ?XMTWPSX5\2^.KWPQJR^- M=+TY]*G_ ."#%YX^F_X).?L7Z9\1?A9XB^$NN>&/A)I7A:ST/Q+=Z!->:WH. MC3W,>C>+[33]#O[V?P[I7B&WF>73_#'B.#2O%6B0VWV;6M)M': RYX_X+D?L M2#)\OXU>M.3_ (+C_L2EDC6/XTY=TC4M\,9#R[!5 MR3X@)QEADG.!S2_XAGX@?]$AGO\ X;Z_E_=\U^(+Q4\.7_S6?#__ (<:'E_> M\_ZTO^QE%1PRI/%%-'G9+&DJ9&#MD177([':PR,G!XJ2OAMMS[].ZNMGJ@HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@#^!+]N#_D\S]JS_ +.#^*W_ *ENHU\N@$YP"<9^U9_ MV<'\5O\ U+=1JS^S?;^$;LRGQG\+?A[K/@72/%FCZM\9OBY\4KO7CH7@SX4/ M!#;77A7P?#I&K:"VF?$OQ%.NL3^$I]#E\0>//$NNC0M)T#1['1],\07MS_IE MEN-67\*9-BG1J5U3R;*;TZ4J,:DN;!X>,8P5:I252I.35.C2@Y5:U6<*5.$I M32/\M#C...F>V?2E((QD$9Z9&,_3UKZ8N='^&&O?LV:MJ7@CP1= MV?CK3/VBO _@U/&&O>)4U'Q'KVE>./"?Q:U/1O#%MIT,5CH'AO3;6#0/"@GB M\O5-2U/Q(FJZO?ZV-*.FZ7I_T)^TY\*OA%IO@OXBM\)]+\"76N?"KXO>!O ^ MOZ!X,\)^-_#OCCX46&KZ%X@TG4_"7Q,\2>)-7U71_CSK6J>/-'N-'MO&G@>W M-OIVI>&M6UB-K7PYXET[3;72IQ)AJ.,H8.KA,;3J5\95PCG*G3=.BZ<\OITZ MM>I2JU*="EB9YEAEAW6G3E4;E0Y5C94<)5SI\-XFM@\1C:6,P-6E0P5'&J,: ME6-2M&I#,*E2EAZ56C2JXBKA899B7BE0A5C2BHXCFE@8U\91_./!QG!QZXX_ M.H9_]1/_ -<)O_13U^D-K\)_A//\!K31TTSP!'\99?V5-7^-$W@BZ\-^+V^+ M>HZI'J5_XJT_XK:7\9DUP_#:S\&6_P ,(8_$E]3Q,Z#]O3=/VT(N488FA=_OL M+7<)NAB:7/AZZC+V56ZMT M'^\G_H:UX5^RU_R;'^SG_P!D(^$/_JOO#U>ZMT'^\G_H:U_F?FW_ ".,S_[& M6-_]2JI_J1DO_(FRG_L68#_U%I'^,O_ %*-7KEZZCQQ M_P CQXW_ .QV\9?^I1J]:7_I$3_*C$?[Q7_Z_5?\ TN04 M445L8A4D/_'Q;?\ 7U:_^E$=1U)#_P ?%M_U]6O_ *41U,_A?R_-#CNO5?F? MZ/VF?\@ZQ_Z\[3_TGBJ]5'3/^0=8_P#7G:?^D\57J_RKG\^'>D3^'_ %\3O'' M@[0;G5_[?N-%\/>(+W3M)FU[['%IW]M2:?&QM3JW]GP0V']H>4+K[%&MKYOD M90^K?MP?\GF?M6?]G!_%;_U+=1KYE" MM3IK\./$4TWAC5;.R?3+35=&EDOVDM-5M-,DETVTU,,]_:Z?+)96]Q%;2/$W ME-%>E_9F77D_J&"3G.I4DUA:"#49+,Z*MV++^SY-0 OY-,$8TV2^'VQ[1KG, MM>?3_P"HG_ZX3?\ HMZEJ*?_ %$__7";_P!%/712H4:/M/8T:5+VM25:K[*G M"G[2K.W/5JM6C!5JU6JJ-)4:2JU)U%2HP3Y*5/G MD_9TH7?+3C:$;NR5V?Z#W[+7_)L?[.?_ &0CX0_^J^\/5[JW0?[R?^AK7A7[ M+7_)L?[.?_9"/A#_ .J^\/5[JW0?[R?^AK7^7V;?\CC,_P#L98W_ -2JI_JS MDO\ R)LI_P"Q9@/_ %%I'^>\&(?'VC?"CX=^.+GXB6NB_"BW\0:;?V6M^.572O OB32?$?B;Q/\ MVIJ$GA+PAIFHZ/X:@UAX?%/Q#U'49(+3P\?]*\?B\5@LMPU7!TU6Q$_84J=- MX7$XJ,Y2HR<8S6%E%X>FYQBJF*JR]G0IN4U3Q-;V.%K_ .7N7X/"XW,\12QE M7V.'C[>K4JK%87"2A&%>"E*#Q49K$U%"4W3P=&/ML14Y8NKAJ"KXO#^#ZS\' M?BKX=\&Z;\0M=^'WBC2?!.KII$UAXDO;!$L)(/$44T_ARZN8DGDU#2[+Q)!; MSS^&[[5[+3[+Q%#$TNAW&H1[6;G]<\$^+_#.B^#_ !%XA\-ZMHNA_$'2;[7O M ^J:C;?9[3Q5HFF:G)HU]JVC,7,ES86^J0R61N6CB2:1?,MS-;O',_UA<:G\ M)/!7P\B@/Q4T'XSZC\2O^%1R_M#BWUSX@:3\2M9\#^#-9T+6++X)_#H>)_ MT>QAT Z1I,7BCXC^)?$\]]>MX>T_2O!&CZ1X=TL'Q&OQ_P#B-\'_ ([^$/AC M;:)XN\2>$/$^C0?M"ZGK-OX^L=/FT#PWINIWUGJOP^^'VBVGP^\.S-;G4;31 M-'$_#N*QW^'O#NBVUK#XOO--F5]03@PV=9G/$82-3+ZLL'5Q^+HU\;' 8RC M*EA:.75,11G]3J5)XJ,IXVG.A[>I24*U)X;V>&AB,9['"^AB,ERN&&Q(H+2YGT*?4887<<%#_Q\6W_ %]6O_I1'7V[\1_B MA\--6T_X^_$#1/%UCJ&K_M"_#7X.>!M/^%4&B>([;7/A[JG@V_\ A=J7B"X\ M4ZC>Z3;^$VT/P;_PK*[TKX=7'AW7M(M7:QT/Q9\-O"AU&VL/%?C_ ,-7^I^$_#NIO'::KJML+JPF MO #[@HKX*\"_\%0/V!?B/\,/B[\9/"?[47PQNOAQ\"+'P_JOQ9\1:K>ZOX7_ M .$-T;QA*;;P-KU]I'BK1]$\07OA[XB78^P_#7Q!HVDZGHWQ'OV2Q\#WVOWC MI UO_AY?^PP?@-)^TK_PT9X)_P"%0Q?$&+X1RZP;7Q2/$\?Q;GA%W#$G^&) M\/#XJK\4YM-9=8B^'!\$CQG)H9&NIHC:,?M] 'W517BO@3]HWX$_$SX)6_[2 M/@;XM> _$'P'G\,:]XRD^+%MXCT^W\#:=X:\*?VDOBW5M;UV_EL[7P_!X0ET M;6+7Q='KITVY\+7ND:K8^((-.O-.O((//OV9_P!MW]E;]L1?%O\ PS?\9_"W MQ/N? O\ 8DOBO3-,AUW1], M;+3[KPKXIBT^^DT#6-02TN#& ?5=%%% !1110 4444 %%%% !1110!_ E^W! M_P GF?M6?]G!_%;_ -2W4:^7*Y__ (*&?M-Z[X<_;S_;-T"'PCH=U#HO[3GQ MFTN*YFU/5(YKB.R\::G LTL<49C220+N=4)4$D*<5\=_\-:^(?\ H2O#_P#X M-M7_ /C5?ZG\-Y7CI<.Y!*-*+C+)'__ ;:O_\ &JBN/VM?$7V>YQX*\/Y%M<$?\3;5^HAO]/1/PJXV:?_"90U7_ $,LO\O^HGS_ ?8_P!0 M+]EK_DV/]G/_ +(1\(?_ %7WAZO=6Z#_ 'D_]#6OG+]CG4WUK]D7]EC6)84M MY=5_9Q^!^I201,SQPO?_ Q\+W;Q1NX#LD;3%$9QN95!;DFOHUN@_P!Y/_0U MK_*G.$XYSFD7O',\:GZK%54_Q/\ 1W*J4Z.5Y;1J*U2E@,'2FDTTIT\/3C)7 M5T[235TVGNC_ #F?''_(\>-_^QV\9?\ J4:O7,9/3)QZ9KI_''_(\>-_^QV\ M9?\ J4:O7+U_I_A_]WH?]>:7_I$3_*3$?[Q7_P"OU7_TN0N3TR<>F:2BBMC$ M*DA_X^+;_KZM?_2B.HZDA_X^+;_KZM?_ $HCJ9_"_E^:''=>J_,_T?M,_P"0 M=8_]>=I_Z3Q5>JCIG_(.L?\ KSM/_2>*KU?Y5S^.7^*7YL_UMA\$?\,?R044 M45)04444 %%%% !1110!1U.*6?3KZ&"VM+R:6SNHHK2_D>*QN99()$2WO9([ M>ZDCM)V817+QVUQ(D#R,D$S@1/\ RO?LC?LY?M>? KQE^TGH,'['/Q[U_P#9 M<\+?!KXA>%_''[$/[0/Q?_9N_:.^$7Q'U$_ #X+:)\(_@-^QO\4/%D>H?%+4 M/ 5YJ&F^)/".J7_QBU'P]\+K7X'VG@KPKXG^'M7^"2_ 3_A/QI?A?PGXD_P"$D_X66OACS_\ A)[:\N/L?]DGP5K?E_8O MLFS[1_:#_:/,W>3#LPWR=_Q$%N<@_LGY!Z@_&I"#^'_"M/\ //K7Z3EWA%XA M9M@,'F>7Y L1@SK9A3JPYH3B^2I3A..JE% M-6/S#,O&7PXRC,,;E68\1?5\?E^)K8/&4/[)SNK['$4)NG5I^UHY;4HU.2:: MYZ=2<)6O&333?GOAO]GW]H_]K7PM^UC\=?VF/V//VQ/AC^V'K7@S]E2[^$.C M^!;G]D7X9^!_A+HO[)OQ\?XW_!+X5_LNZWXG^-?Q:T7XI^/? OQ&O]:^)GCK MQI^T_P"&_ ?@[XMW+6W@[1_#?PL\+366FV&!H/["O[9XT3XR?MM>+M'_ &TY M?VH/$G[7'P2^-/P>M?#VJ_L)W/[4W@_3OAO^R=XD_98\:_%OQC\'M:UF']BN M]C^(WA/QIXA\+2_L^>'O'R:[H'PUTCP1KT/Q&NOBC9ZW:WOL _X."F7.W]DX M#/7'QIC&?KCX9TO_ !$%OC;_ ,,G_+C&/^%U)C'IC_A6>,5V_P#$$O$W_HFE MT_YG&1=;?]3/^\OQ.'_B.WA7_P!%0_\ PR\0?_.K^K/RO](_L*?"+]J7]E3] MG;XF^#/&/[/7C;XQ_%/]J#XD_MQ_M?7_ (:^*/Q3^#__ BO@GQ5XY\4^']9 M^'WP"^._Q#\*6NI>&K+QS\;[>_O->\3ZM$?A;XO^#W@WQC/X^TJU5?"MAX< MNM8D_P""=/P8_:1T?]LC]J_]H;XF?"/]H#X<_#7XN_"WX3>'-,D_;0^(?P&^ M)?Q_T;X@^$?B%\6?$>K_ P^"M]^SMXL\6^%?"O['_@31?',*^#=!\5WL7BG M5O&FH:GX@M&NM,GFE7YJ_P"(@M^#_P ,G\C@'_A=2< ]0/\ BVG&<#\J!_P< M%N.G[)^.<\?&I!R>IX^&G6C_ (@EXF_]$TNG_,XR+K;_ *F?]Y?B'_$=O"O_ M **A_P#AEX@_^=7]6?E?^DZBOEO]C7]I(_M:?L_^$OCD?!W_ @9\4:CXLL/ M^$9_MX>)/L7_ C'BC5?#?F_VN-*T7[1]M_LS[9L_LZ'[/YWD;IO+\U_J2OS M7,,!B\KQV,RW'TO88W+\57P>+H\].K[+$X:K*C6I^THSJ4JG)4A*//3J3IRM M>$I1:;_4,MS'!YOE^"S3+ZWUC YCA,/CL'7]G5I>VPN*I0KT*GLZT*=6GSTJ MD)J2V.G3QZ?IT!$U]>-#:QD/*I'Y*?LM_P#!6;Q- M^T;\#OC[\?=/_9 ^*/B3P?\ #FV@UOX36?[/OC_X.?M)ZQ\8+;6--\'77A_X M=+#\+_'6IQ^$?C.C^--'O/%6C:NI^'?AO0Y]2U63XB74?@_QBNE?KWXNTB^\ M0^%O$OA_2?$^K>"]5USP_K.CZ;XO\/QZ-/X@\*:AJ>FW-E9>)-#@\0Z9K>@R MZQH5S/%JNF1:YHVK:1)>VD":EIE_9-/:3?@Y\'/^"3_[4GP=U_\ :I^-?@/] MIC]G#X6_M6_%7P7XR^%WPQ^,OPD_8Z\.>!M!N[#QKXM^$/BS6/C-\?/A[9^/ M]4TGXI?%2P;X>:S;?#;0P^E>!?AAK'C3Q]KUII/B&P\<7'AS2.2S[/\ K_AU M]YVW7?\ K^FOO/IKP+_P4*_:4^)47[0_PM$?L)3?\-C?LR^)?@?'\1_V>_$ M?[4'PTTOP7<_#CX_:#XC\2>!OB#X6^/VD>$_$.@:I6>E_%#XP>%?$XU MO]N[X=>&_AI8_"WX0V<-MJ'QW\/?&._^$+:)XH\!ZEXNTWQQX?2:/0=+M(=) M\%77C>QUG6/#&L:3=3+^S%^P3^TW\$?V6_VM_@GX@^-OP!_X6W\?_!OBY/"_ M[1_PT^%7QJTSXK7?QG\:> _$WA'4_CG^T)XP^+?[0OQ>\5?&3QCI][=>$+[P MU!HNK^ M&\*:-X9_X1+PQI6C^&UT+3="]@^-'[ USX]_X)I:)_P3L^'WQ+M? MAWHMA$?@-\!-2\;IX?GO5U#X5_#C4?AWIOQ+T-="LM5TYTE^*/PZ\*>)O!L MTDNHRQ:>?%]Q>WL>IQ6\UK=%GV?]?\.OO%==U_7_ Z^\]0^#G[5/Q-^)G[$ M7A?]K'5/V7/'^G_$+Q=\/;OX@:%^S)X*\7>$_&?CS7+:_P!2NX_ .G:'XL\2 MCX9^%6F\>>''T#Q?;7'B9?"J>'='UT1>(H;._P!,O;6N1_82_;JN/VQKOXZ^ M%?$/PAD^%'C[]GSQ=X3\*^,H_#OQ5\ _'OX5:U-XV\+?$;I$?@GXS_#9XO# MFOZ_H=@ILOB#X0N-,TO7O ^K3Z;%?0W>G:UH^I7GM'QA^'7[1GC.X\3:-$? MV@O#/P)\*7_PANM"\(:KI/P?T3QUX\\&?&>V\9Z1JV@>-S-XNUR3P1K_ ,-X M_!]C>^$/$7PTN/"FGZUJB:G/J>A>/_"VH6]C=6?SE^P)^PIXC_9&\6?M%?$? MQAXX^#MYX@_:(U3X%UW7]?\ M.OO/TLHH!!Y!R/444AG^5K_P4O\ ^4B7[<__ &=A\<__ %/-6KXAK[>_X*7_ M /*1+]N?_L[#XY_^IYJU?$-?Z]<*_P#),<.?]B')_P#U7X<_#\7_ +WBO^PB MM_Z\]S_U[7'_ *(DJ6HI_P#CWN?^O:X_]$24X[KU7Y@? MZQ?[#_\ R9;^R'_V:_\ #_U4WA&OJ!N@_WD_P#0UKY?_8?_ .3+?V0_^S7_ M ( ?^JF\(U]/OT'^_'^LBBO\?,\_Y'N:7_I$3 M_.9\<$?$QXWY'_([>,NX_Z&C5ZY?(]1^8K\W/B1\5/B5%\1_B/''X[\5)'' M\1OB#'&BZO"V=2K59+.,J2E5G)7AC+I2E?6U% MZJ[^[S/U6R/4?F*,CU'YBORI_P"%L?$S_H??%?\ X.+G_&C_ (6Q\3/^A]\5 M_P#@XN?\:V_L3$?\_:7_ )-Y>7F_N\S/_B"F=_\ 0XRK_P !QGE_TX\W]WF? MJMD>H_,5)"1]HMN1_P ?5KW'_/Q'7Y2_\+8^)G_0^^*__!Q<_P"-3VOQ7^)A MNK4'Q[XK_P"/JU_YC%Q_S\Q9[^G%3+)*_*[U:7_DWEY=[_=YCCX*9W=?\+&5 M;K[.,\O^G'K]WF?ZZ6F?\@ZQ_P"O.T_])XJO5G:02=*TTDY)L+(DGJ2;6$DG MZUHU_DC/XY?XI?FS_06.D8K^ZOR"BBBI*"BBB@ HHHH **** /XS/^"TW_)^ M?BS_ +)=\*/_ $W:U7Y;Z%H6N>*-:TSPWX9T;5?$7B+6[I;'1M!T+3[O5M9U M:]9'E6TTW3+"*>\O;CRHI9FCMX9&2&*69PL44CK^I'_!:;_D_/Q9_P!DN^%' M_INUJODC]C?Q==^!OCWX'\2M\2_#7PN\,:;XA\+W/Q U?Q)XIA\)QZQX$L_% M.D:CKOAZQNS9W5]JDEZME#-?Z#ILEM+K&G6\MG>-=:?)M>)KW3M/N[VS\.:--J-KI$&K:[=6T4D&D M:=/JU]9Z9;WE_);P3ZA=06<+O<2+&=Z/X. M8_#6L/X1@NDNTL'BE\0+:'3$\O4)8]/EE:X$$6H21Z?+*EZZ6Y^J?A(MYH/@ M']H[X8ZK\>_@II7AGQ?X#U'1="T*3XNZ9;^'O$OQ%N_&'PEU^QUY98-*"ZK8 MV7A;0=:TVTUW46DL-&U.VU72-/@M;V]O9KWK/$7Q"^$OB'X36A.J?#?21I?[ M*6@_"*VL],\3_$:V^.R?%SPW-;6AT*VT6QN(/!%S\#O$^MV]SXT\3)>6-SX9 MUS2]7U'7-1NW^)$=A:V_KU\^QD<0Z5# NO2_M'#T%6HTZU?_ &.MAL-55246 ML/RU:E2I7A&4'6I4?82C-59M(\6AP_@YX55J^/CAZSRW$XAT:]2A0MC:.*Q% M)THR3Q/-2ITJ="(C*$J4$VOBKP]\./B%XNT77O$?A3P)XQ\3>'_" MR-)XEUSP_P"&M8UC2=!2.UDOY#JU_86D]M9F*PBEU"=)9!);Z?%)J%PD5DC3 MCC 00"""" 00<@@\@@C@@CD$<$._#FI>%_BCXTT5O$^G:M:^%+W6[S1_!T7PXN/^%SZ3XJF\,6^B^$1H_B M'X?:]9M)>Z-\0##X#O8YT_.BYECGN;F>&W6SAN+JYN(;-"I2SAN+B2:&S0HJ MH4M(Y%MD**J%8@4 7 'HY9F6+QN,S"C6P&C.,YX>=& ME@Y.34(*,*;Q%?$X6#57$1K/!SKQJ4Y3J87#?VB_\$;_ /DP'X2_]C#\5_\ MU:'BJOU$/ /T-?EW_P $;_\ DP'X2_\ 8P_%?_U:'BJOU$;H?H?Y5_GAX@?\ MEUQA_P!E+G7_ *L,0?Z1>''_ "0'!7_9*\/_ /JIPA_)_P#\%&OV]/VO_@[^ MV=\:?AQ\,_CKXF\(>!_#=UX,CT+P[8:/X*NK33DU+X>>$M7OEAGU7PMJ&H2" MXU*_O+M_M%Y,5DG=8RD2I&GQ)_P] _;[_P"CF?&7_A/_ Z_^8JNA_X*R?\ M*03]H7_K]^'W_JJO ]?'/PT^#OC_ .+;^*#X)TB"[L_!?AG6O%?B;5M2U*ST M?2-+TW1=#UKQ"UJU]?2(+S7M6T_P_J__ C_ (>T^.[U?69K"[:WM5LK+4+V MS_MCA+AO@Z/!/#&89EP_PRN;AO(J^*QF,RC*W*=6MEN#O6P[E.K6K3]Z M=24IU:L]7*<]?X7XNXGXTEQSQ5EV6\1\4VAQ/GU#"8+!9SFRC3I4,-.O_ \;ZIX:\7^-/#O@N_\ M&FF6?Q&\6>#_ #'J#[KQMX7T#QKI>M^-OA[:_$". M&3P=<^-O#UH@&EQ:R]U96+:PM_;R5-^#_K!XB^Q^L+ MB'C+V'L%B/:_VWG/)['V/UGGYOK=M,+%XMQ^-82+Q3BL.G47T7_P] _;[_Z. M9\9?^$_\.O\ YBJO_8E5\T^&_@CXM\6> M%V\2:-K?P[>]D\-^,O&6F> [GQ[H\/Q-U[PC\/8;VY\9^(M&\&(L\[V.B6>F M:O??9M5OM(UC5M/T?5=0T'2]5LK03R^0I@LA!!!92".A!(((]01R#Z5T4>%N M!\1.M3H\,\+5)X>?)6C'(\JTI5:=^>G42YZW%G'> M'A1J5N*>+*4,1!5*,YY]G"C4CRTYIQ?URS?)4I5.7XE3JT:EN2I3E+^\?_@G M[\1?&WQ9_8X^ ?Q%^(WB&[\5^-O%?@M]2\1>(;Z"PMKO5;X:]K5H+F>#3+2P ML(W^SVT$6VVLX(]L:G9N+,?L>O@3_@ES_P F!_LQ_P#9/I/_ %)O$-??=?YZ M<74J5#BOB:A0I4Z%"CG^<4J-&C"-*E2I4\PQ$*=*E3@HPITX02C"$(J,8I1B MDDD?Z/\ !U:KB.$>%J]>K4KUZ_#F1UJU:M.56M6JU,LPLZE6K5FY3J5*DY2G M.*_["*W_I MR04445[QSA44_P#Q[W/_ %[7'_HB2I:BG_X][G_KVN/_ $1)3CNO5?F!_K%_ ML/\ _)EO[(?_ &:_\ /_ %4WA&OI^3[H_P!^/_T8M?,'[#__ "9;^R'_ -FO M_ #_ -5-X1KZ?D^Z/]^/_P!&+7^/F>?\CW./^QMF'_J96/W+#_[O0_Z\TO\ MTB)_D(?$S_DI7Q)_[*1\0_\ U-M>KB:[;XF?\E*^)/\ V4CXA_\ J;:]7$U_ MKWA?]VP__7BC_P"FXGX?/XY?XI?FPHHHKK%I M_P ?5K_U]6O_ *4Q5,_A?R_-#CNO5?F?[!VC_P#()TS_ +!]C_Z20UI5FZ/_ M ,@G3/\ L'V/_I)#6E7^-<_CE_BE^;/W:.R]%^04445(PHHHH **** "BBB@ M#^,S_@M-_P GY^+/^R7?"C_TW:U7Y1@D="1]"1_*OK+_ (+_ 'QY\3> /^"D M?C7P[I>CZ!>6D/P?^"]VL^H+J1N2][I&O/(C?9KR&+8C(!'B,-@G<3Q7XK_\ M-7>-_P#H7?"7_?&M?_+&O],_#;+,75X X-J0A%QGPWD\HMSBM'@^YO[S<]>3_C29.,9./3/'Y5\$_\-7>-_P#H7?"7_?&M?_+&C_AJ[QO_ -"[ MX2_[XUK_ .6-?;_V3C?^?<>GVX^7GTO^#['R?_$)N,_^@/!_^'##?_)?U9^5 M_O;)YY//7D\_7UI*^"O^&KO&_P#T+OA+_OC6O_EC1_PU=XW_ .A=\)?]\:U_ M\L:%E.-_Y]Q7_;\?+S\_P?8/^(3<9_\ 0'@__#AAO_DOZL_*_P#H@?\ !&__ M ),!^$O_ &,/Q7_]6AXJK]1&Z'Z'^5?CO_P0<\87_CO_ ()F_!+Q-J=K9V=Y M?>)_C3'+;V G%J@LOC!XRLXS&+F6:;+QPJ[[I#\Y;:%7 '[$-T/T/\J_S'\1 M(2I<>\9TYVYJ?%&>0E9W7-#,L3&5GU5T]3^_N!\%7RW@WA7 8J,8XG!<.Y-A M:\8R4XQK8?+L-2J*,X^[)*<))26C5FMS^(7_ (*R?\I!/VA?^OWX??\ JJO M]?-'[._B[X:^ _&-]XJ^(NM^,].C@\+>/O#FE:?X0\%Z5XL:]E^('PT\:_#Z M?4;V?5?''@]-+.A-XGM]1BBAAU.75;>.\L5GTUG$LOTO_P %9/\ E()^T+_U M^_#[_P!55X'K\ZJ_O'A'"QQWA]PQ@ZE2I2IXGA/(Z%6='V:J>RJ9/A(581=6 MG5@O:4W*#ER.45)N#C-1DO\ .[B_%SP/B)Q5C:=.E5J87C#/:]*%;VCI^UI9 MQBITY25*K1F^2:C-1YU&3BE-3@Y0E]6>&/%OP#\ ?#/Q/I_@KQ5\3+;XN^)M M*\8^&M1\;ZM\*?#]Q;Q>#-0@N=*L/"O@G[/\6D/@6;QWHHCL?B3XRNM/\5>) MK'2M3U'PKX3-KI!U.Z\13:]XP_9[M/AQX?\ AO\ #WQ)\5-#T+5=7\!:K\8I MK[X6^%F\6^/+[2KM9-8N8O$B_%2XTRR\-> DO]:O_AA\.K'P_IVEZQK0M=;\ M<:]*6+G[1X22J5(6]A&HG@[2I85KGPE- M^[A:K5>AR5XQJ+Q5GE2-+V,,!E]."PGU.'LXXV+ITIZ5Y0:QMXUL7']WC*J] M[%4;X>OST)3I2^O?A9\8?A7\+_"'C32[&\^*.I1>,O"'Q!\)>+OAMJ'A;X<3 M>$OB-=:W8ZUHO@GQ-=?$)-0M_'?PZM=%L;GPWK?B#PKH%AKL]UKWAN2SL?$5 MYHVMS)8?(408>4&8NP\L,Y 4NP #.5'"ER"Q5> 3@< 44Y/OK_O+_,5W83+Z M&#K8O$4W4E6QLX3KSFX>][)35-6IPIQE*$9N"K5%/$2I1HT)UI4,-AJ='BQ> M8U\90P>&J*G&C@85(8>$%/W55<'4=ZDZDHQG*G&;HTW3P\:TJV(A1CB,5BJM M;^Y/_@ES_P F!_LQ_P#9/I/_ %)O$-??=? G_!+G_DP/]F/_ +)])_ZDWB&O MONO\VN,_^2PXJ_[*/.__ %98D_TZX)_Y(SA'_LF,@_\ 55A#_*U_X*7_ /*1 M+]N?_L[#XY_^IYJU?-W@#X*_&+XKVFOW_P +_A3\1OB-8^%8$N/$MYX'\&>( M/%%KH44MO=7D(U.?1K"[CM[B>SL;Z\M[$LU_<6=E>7<%K);6EQ+'](_\%+_^ M4B7[<_\ V=A\<_\ U/-6KL?V#_%G@?P!XU^'GQ"\=?%#X)PZ'\._C7X<\:WW MPT^-GC7XV^")/ KZ0?#MVG[1'P>MOAY%J/A/XB?%32M/L+_0=)\)ZUH?B._2 M_P!$\/VNK^$/$GA?7)5LO]/\#CL5EW N2XO!T'B<32X?RAT:"H5<0ZTUEV': MI*%*=*SJM>SC.=:G"$IQ?[VIR4*OYY.G"KF%>%27)!XFLI24?CBT^#GQ;O\ X<:A\8K'X7_$&\^$NE7,UIJ?Q-M?!^O3^ ]/ MGM[NVL+E;SQ3%8MH\$5IJ%Y::=?7;W0LK#4;NUT^]N;>^N8;>1WC3X,_%[X; MZ%X9\4?$+X6?$3P+X;\:0K/X1U[Q?X,\0^'-'\2Q/8V^J(='U#5M/M;:\EDT MN[M-5BMED%U-I5U:ZI% ^GW$-R_Z=>-_C-^SIXS^%<5WIOBCX;V.D^'_ -D# MQ/\ !#2I=5U_XI>'OVQKOXS:?XL\577A6.T\->'+BU^$UO\ !?XHZQJ>D_$? MXPZ?/8WOP^UJT\1_$"X\6,_Q$TSPQI]GY[\9M/\ #\?@N'X0:/\ M;? #XN: MK\=/CCX*^*_[1G[1'B'XUZMK-G?_ !(T;PKXVL/#UQIOA&/PI?>+O#WPN\%1 M>,/%5OXP^*GB'2[KQQX_\3:MH5K;>%/"?@?1]'TN]RPW$V9U:]*&(RV>$4\= MB:2NDN2RE:4K1WY::4Y3J-J-.?P OPB^*S_#E_C GPT\>M\)X] M2_L>3XEKX2UP^!(]3^VKIGV-_%(LO[(63^U'72C(;H6PU=ET@SC5&6S/F\__ M ![W/_7M]\ M1GXBW7Q:G\.:MX-A6+PN=#;PW+\,[WQIJ-I^TI-\0?\ A(18VNNVD^GS68^( M$=O;2_ESN*^@R;,,9CIXM8O"/#*AB%"FW2KTK7 ME-2PTO;JU>KAU",JF+P[^J5U7A["ZA-OFK4Z=/DY)J?-&[]Z,NB:E[OPJ5VE M"7[R/*^;='^L5^P__P F6_LA_P#9K_P _P#53>$:^GY/NC_?C_\ 1BU\P?L/ M_P#)EO[(?_9K_P /_53>$:^GY/NC_?C_P#1BU_DMGG_ "/KB:[;XF?\E*^)/_92 M/B'_ .IMKU>F_#O]F/XH_%+PO;^)O",OP]DFU=/',G@[P5K/Q1\#Z!\3_B0O MPST9_$'CX_#;XI"E#F5'VC]Z;2]VG3J59N]H4J=2I*T(2DOQ'DG4 MJ2C",IRYI/EBG)VYK;+75M)=VTEJTCY\HKW36OV:OC=X?\&_!3QUJW@'5+;1 M_P!HK6[W0/@Q8"2TE\5>.KVV3P@]C-8>$(YFU^RT[Q.OCOPO)X*U#5K*PA\8 MVNI1ZEH O-(:#4;B+XM_L]_$3X+V6CZMXJF\#:YH.M>(/%7@V+Q+\-?B'X5^ M)GAO3O'O@5M/'C7X>:[K7A*^OK31_''A=-6TNYU/0[IMEQI]_;:KH=]K.DL] M\CIYKEM6I1I4L?@ZE3$U,32H0IXBE.5:K@YU*6*I4U&;&WE_MF_\.VP\-ZUI5[XIBMQHMOXBL+KP\+F75+6]@M/*;3_ (^K7_KZM?\ MTIBK>&(P^(5=4*U*M]7K3PU?V52-3V.(I\KJ4*G*WR5:?-'GIRM*-TI),7)* M#AS1E'F49QYDUS1;TDK[Q=G9K1]#_8.T?_D$Z9_V#['_ -)(:TJS='_Y!.F? M]@^Q_P#22&M*O\<9_'+_ !2_-G[I'9>B_(****D84444 %%%% !1110!_G8_ M\''/_*4/QW_V17X%_P#IE\0U^$M?NU_P<<_\I0_'?_9%?@7_ .F7Q#7XI^ _ M /C?XH^+M#\ ?#?PCXB\=^-_$UVUCX>\)^$])N];U_6+J."6[FCL=.LHY)G2 MVM+>XO+RY<1VEC9P3WE[/;VT,DJ_ZK^&%2G1\-."ZM6I"E2I<*9/4JU:DHPI MTZ<,NH2G4J3DU&$(13E*4FHQBFVTDV?C.;)RS7'QBFY/&5DDDVVW4:226K;> MB2U;.1HKV+X?_L]?'/XK^']<\5_#3X3>.?'/AOPY=3:?K&L^'-%>]LK?4[;3 M9-:N='LV:6&;7-=MM&C?5[G0/#L.L:Y;Z7LU";3H[26&:2-_@!\;HOA=%\;9 M/A3XZ3X1S6\%[%\0FT*;_A&WTRYUAO#UKK?G!C>IX:NO$*-X?M/%EA94I8O#JJL3B%*5##.FZBFL16C&4J M5%KVE2,92A&239P*E5:YE3J.+C*:DH2LX1MS3O:W+&Z4I7Y4VDVFSR&BNU\# M?#?Q_P#$[4=9TGX>>#O$/C34_#OA+Q/X]U^R\.Z=)J$VB^"O!>G-JWBSQ5JF MPK'9:'X>TU?M>IWT[HD2-%%&);F>""7B00P# @JRAE(Y!5@&4@^A!!'L:ZHU M:4JE2E&I3E5I*$JM*,XNI3C4YO9RJ037_E%5\!/^QJ^.G_ *NOQO7[:MT/T/\ *OQ* M_P"#>7_E%5\!/^QJ^.G_ *NOQO7[:MT/T/\ *O\ *+Q-_P"3B\=_]E=Q#_ZM M<4?L^4_\BO+O^P'"?^F('^=O_P %M_CQX\\'?\%0/VI/#NC_ -@_V=INH_"] M;;[9I#75SBY^"WP[NY?-G%[%YA\Z>39^[7:FU.=N3^5'_#3_ ,3_ /J5_P#P M0-_\L:^\/^"\/_*5W]K+_L)?"?\ ]4;\-:_(>O\ 23P]P.$GP%P3*>&I2E+A M+AMMN"NV\FP3;?=MMMGX!G?!W"V)SG-L3B,@RNM7Q&9X^O6JSPE*4ZM:KBZM M2I4G)QO*^)YD0?\4ORZ_\P!O4?]1&OG2GQ_ZR/_?7_P!"%']G MX+_H%H_^ (/]1^$/^B=RG_PCH^7]WR_%]S_3P_X(W>(M1\6?\$ROV/\ Q%JW MV;^T=5^%TES=?9(#;6_F#Q?XHB_=0&27RUV1+\OF-SDYYP/TUK\K?^")'_** MW]BW_LD\O_J9^+:_5*O\G>.HJ/&_&,8I*,>*N(8Q2T2C'-\6DDNB22271']( MY/1I8?*,KP]"G&E0H9=@:-&E!*,*=*EAJ4*=.$5I&,(148I:))(_RM?^"E__ M "D2_;G_ .SL/CG_ .IYJU?$09AG!(SP<$C(]#CK7V[_ ,%+_P#E(E^W/_V= MA\<__4\U:OB&O]4.%O\ DF.'/^Q#D_\ ZK\.?D&+_P![Q7_816_].2%W-C&X MXSG&3C/KCIFG&20XS(YPUQ_Z(DJ6HI_^/>Y_P"O:X_]$24X[KU7Y@?ZQ?[#_P#R9;^R'_V: M_P# #_U4WA&OI^3[H_WX_P#T8M?,'[#_ /R9;^R'_P!FO_ #_P!5-X1KZ?D^ MZ/\ ?C_]&+7^/F>?\CW./^QMF'_J96/W+#_[O0_Z\TO_ $B)_D(?$S_DI7Q) M_P"RD?$/_P!3;7J^Q_V3?CQ\$/@)I=]XAUS6OB)-K6N^'_'_ (7^+7PC@^$7 MPR\4:/\ &/0-<\.>(O#WA72? _QZO-:T+XD?L\++I_B%M-\<:MH=MJ.N!;.7 M4_#]YK5OJ \+V/QQ\3/^2E?$G_LI'Q#_ /4VUZN)K_6K%990S?*J6!Q4JL%/%\^LZ7^SWI%W\/H?B%)/A7X8L?$>D^+F^%5SX$^"OPEM/"UK\2M4LM0L$GDN(OBG\5%URTM M=VHV6J>%_!&HVOA]K#4OB2BN:GPYA:=;ZPL7CI5?;5Z[E)X))U*M?%8JDG"G M@J=-PP>*QN+Q&%C*+M4KRC7=>E3H4Z5O%2<>7V=-1Y8QLO:;1C"$M74;O4A3 MIPFTU>,%R\LG*4OT+^(G[7OPD^(W[,?C7X1+\!9_ ?C.ZUG]F:R^'S>'OBIX MRU[P)X7\)? WP=\7-!OKBVT/6["W2PU"]U7XC:IKEYHA:_@\8^)_'GC/QMKN MM1:SIEA#J/Y^6G_'W;?]?5K_ .E,55ZL6G_'U:_]?5K_ .E,5=N7Y3@\II8F MG@HUXT\3B%B:D:^+Q6+:J_5\-A?&IMQ=1KGG/*>JIQC%N\GK;:RZ'^P=H_\ R"=,_P"P?8_^DD-:59NC_P#( M)TS_ +!]C_Z20UI5_C[/XY?XI?FS]QCLO1?D%%%%2,**** "BBB@ HHHH _S ML?\ @XY_Y2A^._\ LBOP+_\ 3+XAK\^?V O'MK\,_P!IGX;>-=>^-^@?!#P# MX?\ &/@36?BAJ&OZUXUTB'QK\/\ 0/'7A_Q#K/@F"V\#>%?%6I>)'N)M)LM8 MD\+ZA#I^BZLNEQK>WDIBBM)?T&_X..?^4H?CO_LBOP+_ /3+XAK\)@2.A(^A MQ_*O]3/#[ 4LT\*.$\NK2E"EC.#\HP]2<(TISA&IEU"+G35:G5I*I&_-3E.G M-0FHS2O%'XYF525'.,95BDY4\=5FDW))N-5NSY7&5GLTFKIM;,_9C]E[XQ?L M]_!/PM\-_!7C/XB?LQ^/&^&O[1?C?XJ^+?&'CC1OC=XF\2^ -*\3^&/!6C:7 MX\_8)\0^%OAI:16OQ2;1-*FN/$,?Q0T9[6/XP>!_A[>1>'U\):7-XCN_GM[[ MX9^!OV?O%OB3PE^TEX ^)?QI^+GP9'PCU_3/'WB'XD6WC/X.?L]Q^)-(NK#X M#>#O#DOPXN]"\7_$[5=)\.^'T\5>()O&VE_#'X?:*FL>&_AC8ZUK6HW/C"S_ M #KR>>3SUY//U]:-S8QN..F,G&/3%>]3X1P]/%5L6LQS&4\5BL+BL72F$Z& M(>%Q&)QD:+C]44J6'J8K%3K5J6'G25?V5&E7]I1=>%?F>-FX1I^SI6IPG"FT MI\T%.$*;DGSVMJ M.H?M!VWC;XY?"2#0)_AS\8/#,_P ^(_@/X,^&M%TSQ[X>T?XFZ)X=MO$OBW5 MM?TC3]6\/V%OK7Q,\0^%/$/C:'3=#\%6 T[\J2L"$I:BX%LF4MA>>3]L%LAV MVXN_LQ-M]K$(C%U]F)MOM'F?9R8=E)DYSDY.AE^,QV.IU M\56Q&8T$#%2Q%2$XSG@Y8J4*T5&G#DG-8N5-PB_8TJ%'#T,/2HT:,8&-2O* MK3I4W&$8T7/DY4TTIJ"<6W)W2]FG?XG*4Y3E*4FS_1R_X-Y?^457P$_[&KXZ M?^KK\;U^VK=#]#_*OQ*_X-Y?^457P$_[&KXZ?^KK\;U^VK=#]#_*O\MO$W_D MXO'?_97<0_\ JUQ1^Q93_P BO+O^P'"?^F('^:A_P7A_Y2N_M9?]A+X3_P#J MC?AK7QU^R'\//@M\3_&?C3PK\5X/'FI:P_PC^-6O_#C2O"E]IFA>'HO$_@/X M'_%#XD1>(_'.NSR3:[-INA7W@W1H],\'^'M.0^*[S4YAKOB'1M&TF?3]?^Q? M^"\/_*5W]K+_ +"7PG_]4;\-:_.WX.?'WXD_ 74=6U?X9W'@[3]6UJPO-*O- M3\2_"_X9?$._ATO4]%UCPYK.G:5=?$+PCXHFT.QU[P_X@UC1?$-MHS6$6NZ7 M?26>JK=PI"L?^CG"=#&XKPMX5P^75?88ZMP5P[#"UGB:F$5*L\EP')4>(HT, M35IQB]9>SHRG.*<(RIN2J1_*L9*G#.,9.K'FIQS#%.<>13O'ZQ4NE&4H1;?2 M\DD]7>UG]-_#?X3_ 5\?_L_>#-%\%+\%?%W[47C'X<_&[Q7-X3\4_$;]H31 MOB6FJ^!M0\;:WI&G>%-$$VD/P(L-3B^%OA-O%?A/1OB-JD,WQ#U&/4[+<@2 MP@NY_C;\*O@//$/$.N_L\S_ 2\62_"SPG\"_%'Q0U_P[\1_P!H74OBAHNE M>.M#\'>']?UW6=$\=VEA\#]0L3\7_$X\+>+-+^'LUYJWPZEOO#UJT1MY-8N[ M+P)?VL?CU#X5U;P58^,=+TGP[JMAXVT6&VT3X>_#+1M1\,>%_B3<7EU\0/ _ MP^\1Z;X,MO$_PU^'_C&;4M4&O> _ .M>'/"=U!JVLVD>D06FM:O!>V+_ /:\ M_:&U33= TK4?']O>VV@:S\.M>:>X\"_#9M4\6ZC$I;67X8#XH:XO@U=;^+^ MG>!38VOA9KWAK5] M0^)?[4'[/7QG^.6E?&>V\?:MI]A\+]8\&3_',> /"]I\/[:U?PKXE$QP_ 7 M44^+&I>(9)O$ D\9F7PQJ?AM/",46L?FW:2B>.TN IC%Q%;7 1N6C$\<%_!0U?2=.^* M-]_:7Q,\.^#?%;>&V\7> /"'Q!O"TGC+P;X&UWP[X6UZ.2YMKW27MK_4(;OP MB,YD0_[:_P#H0_SBO:RG!YEA:^85,?B56IXBJYX>G'%XG%*G?%XZLZB6)I4U MA%+"U\#A%@L/S8:D\!*O3DZF*K&%:=*<::IPY7&-IODC"_[NE&WNM\]IQJ3] MI*TY*JHM6A$_TT_^")'_ "BM_8M_[)/+_P"IGXMK]4J_*W_@B1_RBM_8M_[) M/+_ZF?BVOU2K_*WCS_DN.,_^RKXB_P#5OC#]DRW_ )%V _[ L+_Z8IG^5K_P M4O\ ^4B7[<__ &=A\<__ %/-6KXAK[>_X*7_ /*1+]N?_L[#XY_^IYJU?$-? MZG\*_P#),<.?]B')_P#U7X<_',7_ +WBO^PBM_Z\]S_U M[7'_ *(DJ6HI_P#CWN?^O:X_]$24X[KU7Y@?ZQ?[#_\ R9;^R'_V:_\ #_U M4WA&OI^3[H_WX_\ T8M?,'[#_P#R9;^R'_V:_P# #_U4WA&OI^3[H_WX_P#T M8M?X^9Y_R/*/_IN)^'S M^.7^*7YL****W)"K%I_Q]6O_ %]6O_I3%5>K%I_Q]6O_ %]6O_I3%4S^%_+\ MT..Z]5^9_L':/_R"=,_[!]C_ .DD-:59NC_\@G3/^P?8_P#I)#6E7^-<_CE_ MBE^;/W:.R]%^04445(PHHHH **** "DR!U('XTM?G-^U'^S'^WI\6_B?'XL_ M9Q_X*<>*/V2OAVOA;1=(?X4:1^R-^S=\;+23Q)8W6K3:MXM/C3XJ:==>*%FU MRVO=,M)-$67^RM.&C)/9(LM_>%@#^,K_ (..?^4H?CO_ +(K\"__ $R^(:_" M6O[:?VD?^#:[XY_M<_%._P#C5^T%_P %9?B5XY^)6IZ)H/AR^\0V_P"QW^SY MX4CFT;PS!<6^BVG]C^$]8T;1HS9PW5PIN(K!+BX,FZYEE94*^#_\0BL__23; MXH_^(O\ P@_^:VO[8X+^DCP/PYPEPYD..RGBNKC,HR;+LNQ-7"8')YX:=;"8 M:E0J3H3K9[0JRI2E"3A*I1I3<;_]"7C/_P -^1^7_51>;^[S.3_4W-/^ M?^ _\&XC_P"93^0ZBOZ\?^(16?\ Z2;?%'_Q%_X0?_-;1_Q"*S_])-OBC_XB M_P#"#_YK:/\ B:OP]_Z$O&?_ (;\C\O^JB\W]WF'^IN:?\_\!_X-Q'_S*?L! M_P &\I _X)5? 3)'_(U?'3O_ -5K\;U^VK$8/(Z'N/2OYZ_V=O\ @D-_P4*_ M90^%&@?!#X"?\%J/B%X(^&/A>[UZ^T/P[/\ L%?LD>*);.Z\3:W?>(];D;6? M%46L:UV6*VCCB3W#_AA3_@K>?^EA,YSW-E&M M&%2*J1IUJL%--1J3C:3_ $' T)X;!83#5'%SH8:A1FX-N#E3IQA)QA_'K_ ,%X?^4KO[67_82^%'_JC?AK7Y#U_:A\>O\ @V.^+O[3GQ9\ M7?'+XW?\%6_B9XP^*'CJ72)O%/B.']D+X!^&X]2DT+0M,\,Z6RZ+X:US2=$L MA;:+H^G6A6QT^W$[0&YG$ES--*_D'_$(K/\ ])-OBC_XB_\ "#_YK:_KSA3Z M2W N1<,<.Y+B\HXMJXK*,BRC+,34PV!R:>'GB,!E^&PE:="57/J-25&52E.5 M*52E2G*'*Y4X2;BOA\9PGF.(Q>*Q$*^"4*^)KUH*=2NI*-6K*<5)+#22DE)) MI2:3O9M:G\AU%?UX_P#$(K/_ -)-OBC_ .(O_"#_ .:VC_B$5G_Z2;?%'_Q% M_P"$'_S6U[__ !-7X>_]"7C/_P -^1^7_51>;^[S.;_4W-/^?^ _\&XC_P"9 M3^0ZGQ_ZR/\ WU_]"%?UW?\ $(K/_P!)-OBC_P"(O_"#_P":VE'_ :*W (( M_P""FWQ1R""/^,7OA >1['Q;BC_B:OP]_P"A+QG_ .&_(_+_ *J+S?W>8?ZF MYI_S_P !_P"#<1_\RG[Q_P#!$@@?\$K?V+MFU?JS^0Z MBOZ\?^(16?\ Z2;?%'_Q%_X0?_-;1_Q"*S_])-OBC_XB_P#"#_YK:]+_ (FK M\/?^A+QG_P"&_(_+_JHO-_=YF7^IN:?\_P# ?^#<1_\ ,I_(=44__'O<_P#7 MM&O"VDV>A:%I[ZAJ.FW6H7S66EV%K;->7US<7ER8C/=3S3O)(W4 M']A/_@K<>O\ P74\>'D'_E'3^Q-U!!'31AW K^#LQQ-/&9EC\924XTL5CL5B M:<:BBJBIU\14JP4U&4HJ:C)*2C*45*Z4FM7^CTH.G2IP=FX4X0;6UXQ2=KI. MUUI=+T/\[3XF?\E*^)/_ &4CXA_^IMKU<37]?^I_\&DVIZQJ>IZQJ/\ P4[^ M*$^HZQJ>HZQJ-P/V6O@Y"+C4=6OKC4=0N!##XJ2&(3WEU/,(H42&+?Y<*)$J M(M'_ (A%9_\ I)M\4?\ Q%_X0?\ S6U_=E'Z5'A]3HTJ/_$(K/_TD MV^*/_B+_ ,(/_FMH_P"(16?_ *2;?%'_ ,1?^$'_ ,UM:?\ $U?A[_T)>,__ M WY'Y?]5%YO[O,7^IN:?\_\!_X-Q'_S*?R'58M/^/JU_P"OJU_]*8J_KI_X MA%9_^DFWQ1_\1?\ A!_\UM.7_@T7N$='7_@IM\40R.DBD_LO?!\X>-@Z'!\6 M$'#*#@@@]"""12?TJ_#UIK^Q>,U>W_,OR/R_ZJ+U^[S!<&YHFG[? :._\7$? M_,I_9%HY']DZ9R/^0?8]Q_SZ0UIU^*]M^PA_P5IME@B3_@NAX\-O;B%%A/\ MP3L_8HYAAV*(C)_8Q<;HD\LOG>,[P=PS7[20I(D422RF>5(T628HL9ED5%5Y M3&GR(9&!?8ORKNVKP!7\!R=Y-KJV_O9^E+1)=DB2BBBD,**** "BBB@ HHHH M *X;XA?$[X;_ D\/GQ9\4_'_@OX;>%A>VVFGQ'X\\4:)X1T+^T;T2M9V']K M:_>V%B;V[$$QMK19VN)UAF>*)DBE9.YK\^_VKY]1^%?QW^ 7[5_B3PAXI\=_ M!7X%?"_]I?2/'EIX*\/+XO\ $OPW\1>/[/X5:EX=^,MGX1M-WB'6[+1_"/P_ M^)'P[UJ[\+6VIZ]H.F_$>2X;33X8O_%>HZ< ?5WB3X[?!/P:O@AO%WQ?^&'A M=?B8MJWPY;Q#X^\)Z*OCU;T6#6;>#6U'5[9?$Z78U33#;2Z(;Z*:9HZ0ZC-\&OA9$=;^^OV_?A#\,;K]C M[X^:5IWP \9?%3Q3\6/#GB&;0O"O@KX?>*/B3XDUKXT/\ ]2^&'PM\7>,M"M MWO9)SX8TO0/">C)XC\7)<:5X=U32/#FL7:GX M4T7Q[\4/AYX)UCQY="R\$:5XM\:>&_#FI>,+PRVL M?#%CK.I65SKUP;B_L+ M<1:9'(O$_Q,\"^-OA3XG\+V/A;Q)X9L=5\>^'AH'B']HO!VDZEH/A/PSHFL MZG+K6KZ/X>T32M4UB>266;5M1TW2[2ROM3EDG9IY)-0NH);QWF8S.TQ:4^86 MH Z2BBB@ KSOXC?%WX5?!_3+#6OBQ\2O /PRT?5-072=,U7X@>,/#W@W3M0U M1XGN%TVQO?$6HZ;;75\;>*6X-K!)),MM#+<.J0122+Z)7YF?M1W\OP*_:5T7 M]K'XF>#?%'Q'^ &A_LP>._A%?1^%?#^E^+KOX6^,/$'Q.$^)-5U35=!U*^T M^2R\*_&#PU::7X1\1>,1)_PBWA4>!--E^(^H>'/!][<:]:@'W/X@^-/P?$^ M)_"/@GQ3\5/ASX;\9>/UMG\"^%->\;^&=(\2>,UO)Q:VK>%=#O\ 5+?4_$"W M-R1;6S:5;7:W-R1;VYEG(CK1OOBE\,],T7Q%XDU'XA^![#P[X0UYO"WBS7KW MQ7H5KHWACQ,E]IVF/X>\0ZI/?QV.C:XNI:OI6GG2=1GMK_[=J>GV@MS<7MM' M+^#NB^#=6T'X(_!?]D7Q9^SQ\5WTCQA\'OV?%_7-1A\+_#3PD/[:^&,?B7Q; MX@M=7\%_9/\ P4>^$'P^M_V;_&&C^$OV>?&WQ,\=^,_']W\0/"VE_"_X9>)/ MB+-:_%W4-3\/7^L?$?6]-TI;K2M&UK^Q=(N8])\7:W%!)IM\B0Z#?66JW,?V M@ _0KQ1\9OA%X(\6^&? 7C+XH_#OPGXX\:/%'X/\'>)/&OAK0_%/BIY[QM.@ M3P[H&J:G:ZKK+3Z@IL(!I]I<>??#[%#YEU^YKTJOP%_:=\ _'+XP_$WXM_$; MX8^ _P!H7P[IGQR^'G[/^C^&/A5_PIW0S\//VDK?X7Z]XB\1?$E^UEKOQ C MT?XF?LR_V%K'B'Q#X3EO/!7B'X2WT'@34[7QK%JOQ3\0RVG@_0/WW0$*-RA6 M))8*2P#,2S88A21N)P2JDCDJI.T #Z*** &22)$CR2,$CC5G=V.%5$4LS$]@ MJ@DGL 37CGBC]HOX ^"/!7A_XD>,?C9\*/"_P^\6:-%XC\+^.-?^(/A72O"7 MB+P].FF20Z]H?B*\U2+2=5T:6/6]&=-4L;J>Q9-6TUO/Q?6OF^RD9&/UXX(. M01D$9!P1D$9K\R?@A^R]?_##QQ^W#+9Z'XE7PL=3\0>$/V7]%U*#35\/^#_A MA\4OASX:^,_Q0\*_"V&RM[>2#PSX@_:7\8^.7N8+PRR:?%X9\*^"=+:V$^! MO#>GV8!]'0_MS_L6SZ7XGC6](-T\7]I6?G?0T7C#PG-?ZKI,/B;0) M=5T+0='\4ZWID6L:=)J&C^&?$$FM0Z#XAU2S2Y,]AH>M2^&_$,>E:O=)%I^H M/H.LK:7$O]F7OD_D#X+T_P )].6]\7:EI/A,RZ??0:KK M-I:QRR'W+X6?L]^%O@Q^Q!X5T/\ :#^$&I?$3Q19_!CX3?#[XG> O ?AO6OB MQXAU#PMX$\8:[XC^&_P=31O"S7$_C_PC$KCQYJ'AO[!;P7?AS4O#UIK#7UI M>^%;B2T(!]M>)/CI\%/!W@?P[\3?%OQ>^&/ACX;^+X]'F\*>/_$'CWPKHW@K MQ-!X@L#JV@S^'_%&HZK;Z)K,.M:4K:II4NFWUS'?Z:CZA;-)9H\Z^F6=Y::A M:6M_875O>V-[;P7=G>6D\5S:W=K*_!OC;]E34/B#:V MR^(/A/\ "^R\7JOPUO/B3$_&-N]]J_@?2_"W@3XP>!M:U3P5I7F>+O#OCR* MU\%^(+S6-,_23]B/X4^,_@C^RA\"?A9\09YG\7^#? &F:9K-I<7>EWLNB2RW M%YJ-MX8:YT**#P^X\)V%]:>%U7P[$GAV)-'6'0 =&CL20#ZHHHHH SM8UC2O M#VDZIKVNZE8:-HFB:=?:OK&KZK=P6&F:5I6FVLM[J.I:C?73Q6UG8V-G!-=7 MEU<21P6UO#+-*Z1HS#R;X@?M(_L^?"C0-)\5_$[XX_"3X>^%]>TFVU[1/$GC M7XB>$_#.@ZMH5XUFEIK>G:OJ^K6EA>:/(+KX%?"/X=!&2 M2?P3I'C/XB^-=*\+OJ7C>$DM?VJ M/V=YW\>VUY>>"53XR_#W=XMM+#7+KPS>7?AS=X@4:Q:V_B2RO/#\EQ8F:$:W M:W.E!S?020+[;>?$'P'IR^-'O_&OA.Q3X;V*:I\0VN_$6D6R^ ],DT5_$::C MXS,]W&/"]BWA^*775N]<-C;G1XWU/S?L2M,/S"^)S>(_ 7QN\=PZ_P#LU?%[ MXY>'/BY_P3\^#OP9TWPWX/\ AY_PD_@WQ/XU\.>,?V@&\4?#3QWXHU*:V\$^ M"+?4-,^(/A^*^O\ QYJ.E^'1I>I7=Q->O%9W,1T_BG^SAX6^''_!/F[\!_$G MX1:U\<_BSJG[/WPQ^'GQ"A^'W@OQ1\6-6^)_QC^'_P #8_AKX2\1Z_H=G!-< M>*-%TK7[*":'5/%.G2:18*NG:YKD4%Q;1WEJ ?H1XU^./P7^&VC^'?$7Q#^+ M?PS\"Z!XO>&/PIKGC'QWX6\,Z1XE>YM8;Z!= U'6M5LK36#-8W$-\AT^6X7[ M%+'=L5MW64^G12Q3Q1S0R)+#-&DL4L;K)')'(H>.2-T)5T=&#(RDJRD,I((- M?@C\2?#'QF^)7AG]F'QMX/\ #W[67P&F\%_LF>/?@'JWC3P!^S]H'C/XR2>, M_$MO\,])U_X6>.?A!\:M%OM.TOX6:Q?>!M(\7:1\2=%TRRN]8U?0'L$^+/PX M\.M>*O#GPA^&^@>(O 7AS5[S7M M\%ZSHO@[1M,U#PKHVLZA?ZO>ZGIN@7%J^EVE[=:SK<\\-JK2:YK+9U2[ /:: M*** "BBB@ HHHH **** "BBB@ IK*KJ5=596!#*P!!!!!!!X(()!'<$BG44 M9VFZ/I.C6%II6DZ9IVEZ980);6.G:=8VMC8V=NF2D%I9VL4-M;0H6)6*&*.- M23M49-:!56&&56'H0"/R/%+10 W8@QA%&TY7Y1\I]1QP?<4ZBB@ HHHH *@N MK6VO;>>SO+>"ZM;J&6WN;:YBCGM[BWGC:&>">&57BFAFB=XI8I$:.2-VC=61 MF!GHH IV>GV&GVEI86-E:6=C86MO96-G:6T%M:V=G:1)!:VMK;01QP6UM;PQ MI%!!#''%#$BQQHJ*JBTRJWWE5L=-P!Q^8-.HH ;L3Y?D7Y?N_*/E_P!WCC\* M=110 4444 %)@<\#GKQUXQSZ\_(/'7FEHH 9Y<>-NQ-NC $?D:6B@!GEQX"[$ MV@Y VK@'U Q@'WI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 3 4444 %%%% !1110 4444 ?_V0$! end GRAPHIC 17 chart-7eb2fe509c415bcabe8.jpg begin 644 chart-7eb2fe509c415bcabe8.jpg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end GRAPHIC 18 chart-9cc04c86c1fe5bbfb22.jpg begin 644 chart-9cc04c86c1fe5bbfb22.jpg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end

GRAPHIC 19 chart-87af8901609352cd863.jpg begin 644 chart-87af8901609352cd863.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" "@ 1T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKD[/QWX* MU#QEK7P[L?%GAR\\>^&]$T;Q)X@\&6NM:=/XHT3P_P"(KC4K30=:U70HKAM3 ML-+UBZT?5(--OKJVBM[R6PN4AD8H-VO:ZYHU[J.J:/9ZKIMUJVB"P;6-,MK^ MTGU'2EU2&6XTQM1L89GN[%=1@AEGL#=PPB]ABDEM3+&C, #5HKFO#/C+PCXT MMK^\\'^*/#OBJTTK5K[0=3NO#>N:5KMMIVN:8RIJ.C7\^DW=Y%9ZK8.Z+>Z= MVK.JSP1D@5H_VWHW]L_$[_:NF_V^=-.LC13?V@U?\% ?VO\ Q?\ MN_$ M/X&_M2ZEH?PR\6ZWI_BJR\$?LC^./V;/B1\*UB\2^$-.^)WB30M-_9Z_:Z'B M?QM$?CTNM^"/"%GXL\87OB/^P-1\2Z!/JOC3X?^&/#.D?#WQ7X=N.G?_@I3 M^U+\+/V??^"I?Q4^-G@?X,W/Q8_9,_:.^$7P/^$7PU\$ZKXBO?AKH.M_'KX0 M?LIWOP]T+QS\0M5L?#OB3QQI/A3XF?M&VS_$GQQ9>'_!ZZOHVD:W)X3T30=. M_LGR@#]\**_-#]D'XT_M)6?[37[3/[&7[3WCCX=?&7Q?\&/AK^SS\=_!'QJ^ M&WPRO?@];>)? ?[0.J?&/PK=^$/%_P .9_''Q"LM&\2>!?&?P3\12:3J^E^) MIH?$?@WQ!H0U&PM=A?#B[O_ALWQ,O?"_PY^&?[78\;75AXS_:!TGPI\-;[ MQ/\ &#P_XV^'/A_X=:Y/9?$+P[$O$":[\-YM/\ $ !_1+10#D9'0\BB@ J, M31-*T(D0RHD MP;[I/8'/:OY$_P!BOXQVGP^_X*@Z_;Z]\>-'_:-USXR>*?B;X.O?C?\ #[]J M[XR6?Q)\,Z;H@_;,\>QVG[8O[ WQEMF\-^ /!7P*TWP3IOP[;5_"+>!?#?P: MUS3/@[J.C:8NC?';7K2Y /Z[00#@T AADH/8C(/8U_-S^PA^TG$A\7_ /@K;\-Y?^"HG@OQMKJ>-_A'XC\ _M)>,/C? M^SQXPUG3-$_X8N^#^K?$CXM^!?"#W47P6TOP%X"^(FK>)C_8>@^#8_A1X-U# M39-#U[3[R73=66Z]B_X) ?M9?L]P?!CX]>#=>_;/^'7Q-US1?^"B'[6?@;PS MX@^(7[1G@7QS\0O%7ASQK^U=XC\ _L_W-YJ)\1&XU.7XK+-H&E_#5M*TZPT3 MQ?>ZOI>G^ ]/^R7NEV- '[R!@20,Y'?:VW\&QM)'< DCG(X-+7\C?["GQS^- M;?M;?L\_$#XY-X3\2_'+XV?M@_M=_L\?&;P#X1_:N^.-S^U+\.=3\(:C^TYJ M>E:I\8_V7+N^N?@99?L>_#WP3\/_ AH'@+PU:>$/#>K>$+*_P#@G\:[#Q_K MWB'X@ZYH^N_UQJ254D$$@$@]02.A]QT- "TUAD=^HZ>Q'49&1_>'4C(%.I,C MU'YB@#^1?]F;PA_PIS_@K;K'_"O?A/K/Q-N=2^*?Q%\7?%2;XX_L7_$'X5?M M8?LW>$?B;XI_;:\2>-/BS=_MC^#K^[^$WQP^$-QJ?$7Q?_ &J_ M@CX!O?V4?$7C3P-^U1;?$;X[^+_A_P#L@ZM8_&;43\;?C'X(T&^M/B7K&LV_ MB+PYI&O^*_%?AJYMO$M[I$/@V"UL[/1[2+^S1;2S2[GODM[=+VYM[:TN+M8H MEN9[6RDNYK.VFG"B62"TFO[Z6VA=VCMY;R[DA5'N9VDF"H#G:#\ OC1\6]=_X1CPKJ'[.GBGX4?LI>"3\8 M_AC^P-\2/V3M2\!?M!>,_B]XE^&GA/\ 8[O/AQHGAYM2^)&@_#.#Q7IVM77Q M&\3>'+WQ9\%K#Q'>6/QG^(UQI%[;3Z)D?!;]H']DOP)_P73^*=UX2\7?&;6[ MSXN_LZVWP!\0>-?'/PU_:F\5VVJ?M0C]K_QWJMW\*-.\<>+OAW/X7\+^"O!7 MABXTG2?!-GH6I:)\'/#OA6WLAHNI2*]]J5S_ $RX3IN/7/,C$]<]2V0..5!P M1P1BDVIG.YLYS_K7Q_WSOVX]L8]J NNZ_K_AU]Y(#D9]>:*3(]1^=+0,**** M "BBB@ HHHH **** "BBOP__ ."L'[=/[4O[(WCCX+Z;\,8?#WPG^#'B&/2M M8\6?M'^./V<_C3^TGX N_&,7Q%T31F^"OC&V^">HV>J?!70;[P1/JGC'5OB/ MK=CK-]K^GPS>'_ %O:^(M*OIY #]P**_"']M3]NS]MCX'?#GP_\ M0?"K4?V M+M<^"6H>'/V;5^!GPFTZ[^(/QE^*?_!0SXH?&R;2Y/%'PZ_9W\7^&O$7@(^ MH++2M:L9?@]K:_#'XN7GC2/B!X[TGP/X"TS4EM?I/_@IC^T%^U=\&]/\ MV>?#_P"RKH7B5];^)OQ'\<:?X\\7>&OV4/&W[8%]X:\*^#/A'XO\8Z9H]I\. M?"OQ,^#&B:;K7C;QE9>'O#VG>)O&WQ5$^&].@&IOYU_<&.W !^I=%?(7["' MQTC_ &C?V6/A?\5I?B?I_P 7=:UB+Q3HOB[Q?9?!GQ'^SM^"O%?A36/%FNW%MX@T*_O(-0FL;ZT(^O M: "D(!&#['@XY!R/U'^/%!./S _,@?UK\ ?'O_!>'PQX&\=>-_!$G[,WBG4I M/!?C+Q7X0DU*+XG^'[:+49/"WB#4M!>_BMI/"\LEO'>MIYNH[>261X$E$3R2 M,A=OI>&^#^(^+JF*I<.Y;+,:F"A2J8F,<3@\-[*%:4XTG?&8C#J?-*G-6IN; M5O>235_EN)^-.&>#:>$J\29G'+*>/G5IX24L+C<3[6="-.56*6"PV(E#DC5@ M[U%%.]HMM-+[1^''_!*G]F;X5?%+Q'\3_!^J_&VS,NE:I9_"GP3=_'3XI:MX M!_9QUCQ%X4\>^"O$?BSX ^%-;\4ZIHWP^\3W/ASXD^+M(\-:G:V-P?AOI&OZ M_H/PZC\-Z!KVJ:7/PO@#_@C=^S/X1D^.5IXM^)W[7'QU$?M+Z!K>B_'OX>_ M'S]IWX@_$OP-\4[W6O"7A;P)'XR\4Z+>G3YIOB)X>\(^"?".A>#_ ![9W]GX MG\(VOAK0GT'4+*YTC3YK;X]_XB"O"O\ T:SXL_\ #J^'?_F3H_XB"O"O_1K/ MBS_PZOAW_P"9.OK/^(+^)G_1+U?_ YY)_\ /+S7WGR'_$\5_ MM'_%;QC\7_BMGW>KZWK6IZAH_#S_@G9^S5\,/BUH'Q6\*Z5X[CB\"^,?B#\2?A1\* M=2^)WC75_@9\&OB7\6H_%D7Q-^('PG^$5]JDOA/P9XF\8Q^/O'D<\]G;3:?X M>@\<>,+?P7IOAF#Q+K$=W^7O_$05X5_Z-9\6?^'5\.__ #)T?\1!7A7_ *-9 M\6?^'5\._P#S)T?\07\3/^B7J_\ ASR3_P">7FOO#_B.'A;_ -%52_\ #5GG M_P [/ZL_*_\ 15TZ45^-'[(W_!8#P_\ M7?'WP9\";'X"^(?!%UXPL_%5W'X MEO\ Q_HNN6M@/"_AC5/$KI)IEIX?L+BX-ZFF-9HR748@>99G$B(R']EF.!QZ MJ/S8 _H:^,XAX9SSA3&T\NS_ ,LOQM7"PQE.A*OA<0Y8:I5K485>?"5\122 ME5P]:/*YJ:Y+N*C*+?W'#?%60\7X"KF?#N/68X&CBJF"J5XX?%X91Q5*C0KU M*7)C*&'JOEI8FC+GC!TWS\JFY1DDM<+!\,?AW;>+O%?CZ#P3X6B\:>._#^B^ M%/&GBA-#TX:YXK\-^'3JW]B:)XAU VYGU?3=,77-4CM;6^::)8;MH7#Q16Z0 M_P 'W[5'_!>+_@IG\,/VGOVCOAIX-^,W@G3O"'P\^//Q?\#>%-/N?@G\-M2N M+'PWX2^(/B'0-#LY]1O-*>[OYK72]/M8);VZ=[FZ=&GG=I9&)\&_XB&_^"J_ M_1<_ ?\ X8;X6_\ RHK]MPGT8O$+&87#8REF'"JI8K#T<334\QS-35.O3A5@ MIJ.2RBI*,US)2DD[VDTKG-/B_+(3G!TL;>$I0;5*C:\79V_VA.U[]%MML?W] M:9^RQ^S-HOVS^Q_V>?@9I7]H:3J&@W_]F_"'X=V'VW1-6C\K5-'N_LGAJ'[3 MI>HQ?N[_ $Z?S+.\3Y+F"5>*U/#G[.7[/W@^9[CPG\#O@]X9GDNM$O9)_#WP MP\"Z),]YX:U.#6O#MV\NEZ!:.USH.KVUMJFBW#,9M*U*WAOK![>[BCF7_/Q_ MXB&_^"J__1<_ ?\ X8;X6_\ RHH_XB&_^"J__1<_ ?\ X8;X6_\ RHKH_P") M6?$;_H8<)?\ ARS3_P"D63K)9Z5J.OQ6BZO>Z;:2* MLEK875[+:6[JK0PH5!'2U_G%_P#$0W_P57_Z+GX#_P###?"W_P"5%?H?_P $ MH_\ @LW_ ,%!OVI/V_?V??@1\:/BOX1\1_#/Q]??$"#Q/HVF_"/P#X:O;V/0 M?A7XV\3Z8(-;T;38-2L3!K.BZ?<.;:5#/%$]M*3#-(I\W./HV\>Y)E&:9UC, M?PQ/"91EV-S/%1H8_,IUY8? 8:IBZT:,)Y/3A*K*G2DJ<9U*<93:C*<%>2UH M<5Y;B*]&A"EC%.O5IT8.5*BHJ56<81%O#'[2GQG\/^&_#GQP^)>B:!H6D^-]1L]+T;1]-\4ZA:Z?I MFG6D8V6UE96T<<%M GRQ1(J+P*_M9'('T%?P&?MK_P#)XW[57_9PGQ9_]3#4 MZZ/HZY?@,PSWB&GC\#@\="GE.'G3AC,+0Q483^N13E"->G449-:-Q2;6C=C\ M3^DIF.89=D/#=3+\?C'[:O_ $=7\=__ X&I_X4?\-X?MJ_]'5_'?\ \.!J?^%?)U%?UI_JSPW_ M -$]D?\ X:,Q_\ FD^L?^&\/VU?^CJ_ MCO\ ^' U/_"C_AO#]M7_ *.K^.__ (<#4_\ "ODZBC_5GAO_ *)[(_\ PTY? MY?\ 4/Y(/]9^)?\ HHL^_P##QF/_ ,TGZ_\ _!/#]K_]JGXA?MJ?L^^"_'7[ M0_Q>\7^$?$'BO6K77/#7B'QE?ZEHVK6T'@;Q9?0P7]E*!'<11WEI;72(QP)[ M>*3DH*_L/4Y52>I4']*_AD_X)@?\G]?LS?\ 8YZ__P"J[\:5_&HX:G*?\ :691YY0H0A&4^6,8N;3D MXQBF[))?V;]&_'X_,>$,ZK9ACL9CZL.)<13A5QN*KXJI"FLJRB2IQG7J5)1@ MI3G)134>:4G:[;;J***_ C^APHHHH **** "BBJTUY:V[;)KB")R%.V6>&-L M,< [9'4XZX..<8&3Q0!9KX5_:O\ V#/ _P"U3XH\%^.YOBW^T+\$/'/A.3PU MIE_XG^ ?QB\8?#B?QEX&\.^,(_&L7@KQ3I>EZC_85TL.M&\OO#?C&UTRU\=> M"K_4+RY\-^(+6"[O+&Y_!/6?^#JSP/I&LZSI#?L3>.YVT?6=7T=KA?CAX0C6 MX;2=3NM.-PB'P,Y1+@VIF1"[E%<(78J2 _BQ)*2X2J-22:?\ ;'#^J:NGKFU]NYX?^LF2_P#0:NW\#%>7_3CS1^MG MBO\ X(T? [4/BWX1^+WPR_:*_;*_9WU'XE^"?A=I?Q!^%_Q%U?P)IFMV&B6MWXTET#7[34/&FJS75[XCO= M0,JQQ_2/Q4_8,\*?%=-0O]2_:$_:\\+>,T^+WC/XM^"/B'X!_:!U_P )^+OA M4OCWPOX=\)^(_A=X#6STV;PLWP8FT_PW;7]A\.?&GA?QEIND^(;R_P#$>EW% MIK+6EY:?@%_Q%>>!O^C(?'G_ (?/P?\ _,)1_P 17G@;_HR'QY_X?/P?_P#, M)3_X@-XL?]$E4_\ #QP__P#/8/\ 63)?^@U?^",5Y?\ 3CS1_3I^S=^SI\+O MV4O@[X5^!_P>TO5=-\%^%I=?U'[3XB\1:UXQ\6>)/$_C'Q'JWC+QQXU\9^,/ M$=W?Z_XK\9>-O&.O:WXI\4>(-6O)KK4M8U6ZE @MQ;VT'NE?R+_\17G@;_HR M'QY_X?/P?_\ ,)7W)_P3O_X+S^%/V_OVD[#]G;3_ -FKQ+\*+B^\">,_&X\7 MZW\4_#?B:PB3P>=%#Z8VE6/AC1[AIM0_ME?*N1>A+<6[EXI X*<.:>#/B7DV M78W-LRX9GA5&,5=M:MI:ZL_H";H/]Y/_ $-:_P \ MSX__ /)>OCG_ -EI^+7_ *L3Q+7^A,VHV&/^/VT^\O\ R]6_]X?]-?\ ]?:O M\];X_P B'X]?'(AXR#\:/BT05EB8$'XA^)<$$.001R""01@@D$5^G?1HDEF/ M%=VE_L66+7SKXO\ R9_-OTHDWEO"%E?_ &[-_P#TQ@3R>BF>8G]Y/^_D?_Q= M'F)_>3_OY'_\77]<<\/YH_?_ %W_ #[,_CJS[/[F/HIGF)_>3_OY'_\ %T>8 MG]Y/^_D?_P 71SP_FC]_]=_S[,+/L_N9^G'_ 1Z_P"4A'P4_P"P-\6?_56^ M*J_M9;H/]Y/_ $-:_BA_X(^SPQ_\%!?@K))+#&BZ-\6,L\T*@9^%WBD#DN.I M( _+K7]J+:C88_X_;3[R_P#+U;_WA_TU_P#U]J_B;Z1K4N.+B&5E8JRD$$,I((Y!(KY9\MO0 M?]]+_C7^@>0RC_8>2^\O^13EW7_J#H?YH]?$)_6*^C_C5>G]]_YK[QE%/\MO M0?\ ?2_XT>6WH/\ OI?\:];GC_,OO]/\T86?9_U_PZ^\97Z[_P#!![_E*]^R M7_V$_BQ_ZHOXEU^1?EMZ#_OI?\:_7/\ X(1E8?\ @JU^R;)*\<<:ZG\6"SR2 M1HBY^!GQ+ RS,%&20!D_,Q"C+$ _'>(K?_P".U_ K^VM+&W[8G[5#+)$RM^T'\6&5EEB96!\8:G@A M@Y!!Z@@D$<@U_%OT:VEG_$EVE_PCX??_ +#8'Q7TGTWP]PQ97_X6<5_ZA,^9 MZ*9YB?WD_P"_D?\ \71YB?WD_P"_D?\ \77]A\\/YH_?_7?\^S/XOL^S^YCZ M*9YB?WD_[^1__%T>8G]Y/^_D?_Q='/#^:/W_ -=_S[,+/L_N9][?\$P/^3^O MV9O^QSU__P!5WXTK^YM/N+_NK_(5_#!_P3"FB3]OC]F=WEB1%\9:^69YH54# M_A7?C0YM[A<03PS;%3=Y4L737_&48G_U49,6****_G@_I M(**** "BBB@ K\_?VF/^"5W_ 3W_;&^(T7Q<_:;_93^%?QE^)$'AO2O",7B M_P 96&L7.KQ^&]$N-1N]*T=9;'6K"'['97&K:C+"OD%P]W*6=AM"_H%10!^/ MG_#@7_@CE_TCZ_9\_P#!)X@_^:2C_AP-_P $6FC7OCJY\)>&_AMXF^(/B./QUX4M/$OAFZ MU?X/^)-*T#XKK;>(=.>R$WTL&MPZ.K+LOZ_X9?M?M^^%/"&F^-1\0/@ M3^T/X$\;>$/ 7@WXIV7POUCPOX&UCQQXT^'/C+XAZ7\-%\3>$QX+^(GBOPQ+ M<>$?$>M:6GQ $ZWXDT7QGX0M;VSN;W0)HK_ $][KV>[_:E^&L'[1_A_]EZV MM/&.J?$+6O#?C7Q%>:O8>&;H> ?#,K.+1]!U^[75_#EWK?VB"" 0<@@$'U M!Y!HLNR_K_AE]P'X\_\ #@'_ ((X?](^_@!_X*?$O_S3T[_AP'_P1Q_Z1]?L M_?\ @F\1?_-+7["USGC'Q?X9^'_A+Q1X[\::U8>&_!_@OP[K?BSQ7XBU6;[/ MI>@>&O#>F76LZ[K6I7!#"WT_2M*LKN_O9R"(K:WD?!Q@L#\G?^' ?_!''_I' MU^S]_P"";Q%_\TM'_#@/_@CC_P!(^OV?O_!-XB_^:6OJ3PQ^WE\-]1N])B\? M?#KXT_!:R\8_"CQE\;?AAJ/Q+\&Z6TGQ1^'7P]T+2O$_C.Y\,^'? /B;QUXQ MTKQIH?AK6=.\2O\ ";QMX=\+?%34-!N9+O2?"%_=:/XFL-!Q=<_;^\,>#M"\ M<7_Q ^ 7[2'@3Q/X4^#+_'_0OAOKG@_P9?\ CKXC?#"S\1:%X6U[4?!UEX5^ M(7B32+7Q+X0UCQ3X6@\9?#_QGK/A3QOX<3Q+HLMYHCI=L8E9=E_7_#+[AW?= M_P!?\,ON/G7_ (,M.\7ZA/JFE>&+N3P)X0F\)> M%M/\9KH7BKQC>266F1>*O$?AN_\ [9T#PSH1U[5QI5K+JNO6V@Z==Z/^'K;P-\39_ 6G?M!I^RM>_&I+/P0/A_!\>Y-7L_#"^!O[$?QT MOQ9DA7QC?0>#I?%<7PU;PM'K;&Z.J'PNK>)5++LOZ_X9?<%WW?\ 7_#+[CY5 M/_! /_@C@1C_ (=]?L_?AH_B,'\QXF!IO_#@'_@CA_TC[^ '_@I\2_\ S3U^ MPP(8 CH0"/H>12TQ'X^#_@@+_P $<@,?\.^OV?...=$\0$_B3XDR?J>:/^' MW_!'+_I'U^SY_P""/7__ )I*_1/XN?'OPE\$_$?P9T;QOIOB&WT?XU_$NS^$ M&B^-K*VTZ;PCX6^(/B'2=2OO .B^.+R?4[;4-$@^).LZ6_@/P9JEOINH:??? M$35?"WA&]FL-0\5:&;OY/\>_\%&-)\+VWPIUWP?^S=\=_BSX&^.7Q@N_@=\) M/'G@O5_@%I.@>-O',5YXYMM-N=,MOB#\:?!FO1^"_$]O\.O%&L^%/'%SI$7A M[7] CTG6+*[:RUS3'G5EV7]?\,ON \<_X<#?\$^/_ !GX:\ :YH6C6^E>)M8M9M1\.:+<:R?7/%?[8'PV\%6/Q^U'Q#X>^)4- MO\ _&/AKP'+%I?@N[\2:C\6O$OB[X3^"_BWH%A\%=)\.SZGJ/C4WVF>-[/PV M99[?1H+/Q/H_B)=1FLO#^DR^(&++LOZ_X9? MO_\ S24A_P"" O\ P1Q((/\ P3Z_9]P?31?$*G\"OB4$?@:^S+[]L#PE-X3_ M &>]:\%?#WXF_$CQ;^TUX$C^)?PR^&/A6S\&V?BW_A!K;PCX7\8^(_$OBK6/ M%WC3PQ\._"ND^$[7QOX.T;6;O4O&VRZ\4>*=!T#P\NMWFI0D>S?!KXO>$OCE MX TSXA^#1JUMIUWJ7B?P[JNB^(=..C^)O"?C+P+XHUGP/X]\$>*=),URNF^* M/!/C7P[KWA;Q!9PW=[9QZII5P^GW^H:=):7UR679?U_PR^X#\RO^' /_ 1P M_P"D??P _P#!3XE_^:>G?\. _P#@CC_TCZ_9^_\ !/XB/\_$U?L+7B7QB^/' MA/X':C\)(O'&F^(H_#_Q;^*OASX-6GC33;*TN_#'@SQMXZ@O[7X"?$?A7]G7XY_%SP)\2?CHG[.G@'QYX&U7X$:7H/BOXEW/B[5/ FF#2;;X MA_&7P5KLO@_6?%.@Z_8:1XW;2E\/:A::3)K5M=/HM_I-_?Z/B#_@H-HWA'5/ MCA)XG_9W^/NG> /V9)/!MK^T-\4+$?!WQ)X=^%5YXF^$OPW^-6NOJ/AGPY\6 M]1^)?BC1OAOX$^)VD:CX]\0^ O!'BG2[-=(\27.@R>(=.THWDZLNR_K_ (9? M<.[[O^O^&7W'@G_#@/\ X(X_](^OV?O_ 3>(O\ YI:/^' ?_!''_I'U^S]_ MX)O$7_S2U]M:I^U_\,]$E^.!U/1?B"MA\$]9^&N@#4])$W7BF#XM:O\6/!' MA[QKX+T_X*67A2;6M8\?76HCQ+I_AKR8-.L2GB1+J$L-(@;6*QM0_;0\"+\, MOV8/'_AOP+\2O&6O?M@:/H.K? [X5:-:>"]/\>ZV=;^$.J?'"YLM;O?%/C;P M]\//#D_AKP!HVIZEXBEOO'36RW%E+8Z%)KUS) DI9=E_7_#+[@N^[_K_ (9? M5Y.TZE< M[_,W+L]M^"WQB\-?'+P0?&WAG3]>T6.S\5>._ FO^'O%%I86GB'PQXV^&?C/ M7/A_XY\,:N-(U/7-"N;WP_XL\.ZMI']=US0-1%NM[H^KZA8SQ7#>LTQ! M1110 4444 %%%% !1110!X7^TY\$[;]I#]G?XW? .[UV;PO%\8OA9XX^'*^) MK>S349O#ESXL\/7VD66O)IDDUO#J@T>^N;;4GTN>>&WU..V>PGECBN'=?SS5 M_P!I3XJ?M2:#XG^(WPC\%^&/C/\ L:_ SXRZK$O!6E^,?B$GPS_ &E_B;\8 M?!7P]\/OXRTOXR7?PCCT'X:_"'1[FSU;P0V@:E!XM^,%GXEU;5M:U3PA!X<\ M%Z%J7Q"_8"DQSG^IQ^73/OC/;I0!^='[&'PV_:"TKQY\2OBK^U/\+]#M/C;\ M0?#WAW3]<^*&E_%K1O'&@VFAZ!J-_>Z+\%_A1X#T[P;H$GPX^$OA"_UO7==T MZ34=6\0>+?&>NZG=>(_B!KNMZ]+9'1X?C5H7[5.J_MC_ 4^)7@CX ^#O$WP MM^#>A?%;PJWB?4OV@=,\+:_K]M\9-.^%,=YK%EX-F^&NLO81^$KCP;K,-QI] MSXB$^LDV5W93PBXD@@_1ZB@#\B-4_84\9^+/CKX;:X\$>%_ 'P?\&?M6Z?\ MM4Q:EHO[07Q8\:>&]5UWP[XZ\3?$S1YO G[-7B'P_8^ OA+\2O''C;4-+O/B MYXKL]?UCPV+>X\>ZGX&TF/Q)\2-0O="_791M55SG:H&<8S@8S@<#/I2T4 %> M/_M"?"*Q_: ^ WQJ^!.J:Q=>'M-^,_PG^(GPJO\ 7[&VCO+W0[3X@^$=7\*3 MZS9V<\D5O>76E)JQOX+2YD6VNY+=;:X(AE\1^.3\./VJ_BMX_\ A#8_"FWUS0?B5-\* ME\._!WX9:*-;\6:+KOA?Q'+XN^*NE^)?$6E:E'X;N_"/A.SUKQ_[-^QM\-_V MC+7XF^/?B_\ M9_"GP[9?&GQMX0T[1K[XDZ%\8M*\=>$_#'A_3=;_M2P^"'P M=\ VG@GP[?>"?AEINH:AJ/B.^\1Z]JVN>.?B)XAMK;6_'FI74EMX7T3P?^D6 M!G/^>W4=,\#GKCBEH _-_P#:'\/?M4:W^U=\!/B!\./@%X,\8_#?X'7'Q#,W MB+6/C_IO@S6O$L/Q5^'NE^%[\V'A&;X:Z^^GGPQJ*WC3)=Z^#JT%LES:-$]T MMO!\S3_\$\OBG)^T5%\9H?"GP^L_CPO[3T?QFE_;BL_BUXMM_%MW\'5^($<< MGP;OOV;HO Z^!KV]E_9H0?LO;+KQ!+H\6D!?C!'XJ7QL@T,_MS10 @! /\ M^KT&>^!QD\G&32T44 ?+W[;'P,N/VE_V2/VC/@1I^FZ%JFO?%#X/^./"WA&+ MQ+>7>F:/9>.KO1;B?P'KD^KZ?#<:EH5QX;\9VVA>(=-\0Z7"^K>']3TNSUK2 MMNH6-LZ\'^T;^S;K_CV+]BO2/A=I_A+0/#7[.'[4GPD^*.LZ++<2:'I^F?#3 MX>_#3XG^"FTCPE8V.FWD$U[8R>*M M=(T5AIMD--@N,7MO\ 98H)_MVB@#\A MO&/[.W[6VJWO_!0;X(^%_!7PKT[X8_MM_%'6=>L?CSK?Q0O+K4?A[X ^(/[, MWP*_9_\ '?QLTOX@>'O@=J/@[X*_#O3OB/KEQX>7P)8>'==^(=K\/+:VT*Z\/7>@ M_P!K77BB_P##?BE)Y=,A2Q\RS.DO/?\ F22)(GDF*3Z&HH _(31_V=/VA-8_ M9G_94\/^+O@/X/TSXR?LR:%HOPXM;SP7^UIXW^'7C6W\/:7\*O"?@75?%/PY M^,?P^^'UHD>E>--1T?['XQ^%_CCPW+I&I^']/T[Q$E\OB[P]X9MX_M/]C7]G MR[_9G^!FG?#K5IM!E\1ZIXY^+'Q2\6Q>%;C7KWPMIOBWXS?$_P 6?%/Q#HGA MS4O%+OXGUS1] U#Q7)HEKXH\3>7XE\8-I\OB[Q%!;:WKE_;0_5%% !7SA^V# M\&)?VB/V5?VB_@=9Z;H6J:Q\5/@K\2O!/AJW\23SV6C6_C#7?"6JVG@S5;K4 M[2"YO]%DT/Q:VBZW9:_ID#ZOX?O].M=;T@IJ>GVDB_1]% 'P-\>?V7?$_C+X M;?L:> ?AI8^$-"T[]G?]I#]EGXCZSI,M]/I.DZ?\/O@HT\6MZ9X72VTR]^U7 MUM9&W@T'3)H[&"[2/;-?6A&YO#?'WP"_:VNO&G_!0#P!\/\ P3\++?P)^VIX MFT2]T+XX^)OBE=>=\,] U']D[X*_LZ>+KS4/@Y9?#R^U/Q3XI\/W7@+Q7X@\ M*Z-'XST[P]XHFN/#=EK>N>&K.75;JW_6NB@#P3Q9H_B_X4_!'2/!WP4^'T'Q M.U'PMX=\->!=#\+Z]\0;'X?M<>'=*TBW\.K?WOBZ]\->)+47MCIEG;S2QG1) M3?S[P@B&$/Y>2_L??M%?%']E?]CSX0?'/X'?"_Q3X:_97\/>%?"?CO\ 9SNO MCS>6WAOXW:S\//A/X-\)?#7XMZ)\7/#?PVM-9\,7W@'Q9IOB>]TSX>:GIFF: M?KUKX@76];\217GAW2-#U#]OJ* /CW]AOX"^-?V;?@19?"GQ;J6E)I6C^,?' M-]\,_ .B:SJGB[2?@M\)=8\07%_\/O@O8?$#Q!I>B^)?B':_#_1I/L,7BSQ' MI=MJDJW/]C"34-/T6PU2^^PJ** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** -** "BBB@ HHHH __V0$! end GRAPHIC 20 chart-270bd56111f51ba4323.jpg begin 644 chart-270bd56111f51ba4323.jpg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end GRAPHIC 21 chart-470b1c81f0072df98af.jpg begin 644 chart-470b1c81f0072df98af.jpg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end GRAPHIC 22 chart-996c588aaa81582da31.jpg begin 644 chart-996c588aaa81582da31.jpg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
_YG_&@##_ .$G\/?]!G3O_ J+_P"*H_X2?P]_T&=._P# J+_XJMS ]_S/ M^-&![_F?\: ,/_A)_#W_ $&=._\ J+_ .*H_P"$G\/?]!G3O_ J+_XJMS ] M_P S_C1@>_YG_&@##_X2?P]_T&=._P# J+_XJC_A)_#W_09T[_P*B_\ BJW, M#W_,_P"-&![_ )G_ !H P_\ A)_#W_09T[_P*B_^*H_X2?P]_P!!G3O_ *B M_P#BJW,#W_,_XT8'O^9_QH P_P#A)_#W_09T[_P*B_\ BJO66J:=J7F?8+VV MN_)V>;]GE63R_,W;-VTG&[8V,]=I]*O8'O\ F?\ &EQCU_$D_P Z "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B__@H?X%?"^E7>N^)/$G@*70]!T6P6-[[5=7U36='L].TZT662&)KF\NIHH(5DEC0 MR.H9U7+#^1!_^"=7[=.]\?LL?%@_,W(L- (/)Z$>(>17]DO[8OQ/\&_!3]G' MXF?%_P"(=_&O"WC#PYK.LW=OI6F0W&HZC- M;V%I-)'96-O/=W+*(H(I)653] Z!K.E^)M#T?Q%I$AN-*U[2]/UK3+B2"6WD MGT_5K.'4;*9X+B..>%Y;6YB=H9HTEB9BDB*ZLH_6> _$WB#P^R?%4LOR; XS M 9CF=2?UW'TL;R?7*.%PL:V%I5:&(H4I3I4)8>K.G[U2"K0E*T:D#\D\0?"3 M(_$3-,%C\RS;,\#B,!@%A(4:DYRG!-.,6H62NFS^ M%E/^"=7[=.Y<_LL?%D#<,DV&@8'(Y/\ Q4%?V&_L+>"_%?P\_8__ &=O _CG M0=1\+>+_ O\+/#&C^(?#VJI#'J6D:I9P.MS87J037$*SPL0LBQ3RKS\KGJ/ MK#:G]U/R%*,8&W&.V,8Q[8XK+CSQ8SCC_+L'EN8Y;EF"I8/&?785,"L6JDZG ML*E#DG]8Q-:/)RU9/W8J5TM;70_#[PAR;P[S+&YGEN:9KCJN.P/U"I3Q[P;I MPI^WHXCGA]6PM"7/ST5'WI./*W[M[6_%*P_X)._$'2OVB_CI^U!H7[5IT+XY M>*OA]XQ\#_ SXVI^S]$KGXK>!KGQQX,T_P?+KOQHUC1].$:;^T-:^ K72] M.N/ /@WQ#8Z#X0NM:TW3?&?CW3/%GC+3[?5!ZS^SK_P3W^,GP-^$/C/X17?[ M56DZBOQ/\=:MXH^+'Q7\!? S4OA]\>_B;;^+?AEXP\#>./$?B_XPZ_\ '/XG M^*[_ ..>K^(-6\$>,/#GQI\]6\!6OP[TCP)X8\#V_@]]-L- _54$$9!!'J.1 M17Y6?K1^5W["W_!,C1OV,_B=X@^+!^(_AWQ)XCU7X,^$_@8=/^&/P+\#?L[> M&/%?A[PAK::WI_Q%^-&A>!]5UN'XP_'MVA32S\5-5FT1=.T2]U[3=#\,Z9%X MAU,R?JC110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !117R)^VO\ %S7_ (.?!J#7O#FO:CX/U#7OB!X!\%OX\@MO"]OH M/@2Q\2:XL-]XG\;>,/&^@>,?!WPU\'V]M;2:?J7Q"\1^ _'UAH%YJ.F11>#- M./&]GIMQ#JOQCT M3Q'X!\&>$-&O?B5\<=2^&/[5GB7X5:#/X0T?XC_"GX?:/\:(O&'PHT#2]7E^ M'?P;U7]G7XPR:IKR_$;P_P"&9_!&KZ#X=LC3];^(?[.M[\3M6O?CYXG^'?C/Q+^T1XL^#'PY\9^+M?^(7P.^(&G^!_V9/V(_ M!D_BK6?#&A7FG7/CSQAIW@K_ (5I\%_$'A"ZOHT8 _H"_P _Y]?PHK\ ='_: M'^/W@&Y_:,U#XG_&CXA_#WXH_%;XP_LB:K;_ X\8Q_"K1?!7[+_ (/^)O[) M_P ,=;\8:S9>,O%WPL\50?#CX0_\+FT/X@?!G_A/O%?@WXSZ;#\1/#VF^&!X M5U'XI>-]=\6WUKPI^V]^T[)IG[+WBCXD>+;71;CQ!';Z'XI^%7@CPCIB_$CX MG^(-%_:R\^.OBSP]\8AX,L-.M=%^ M+]WX]^&-IXFT74_$OP1\4>%OBS:>&/AKX=L]#\/_ C\-ZWX=L=<\&G5+C6D M^+GQ'\8:Q\09X])^(GPIN(? TNIZ?:^2?&G]J;XYZQ^T)\1?A3X>UR_N_AUJ MVL_M+_!?Q=\.=;TS0M*\7>!]+\*_LB?%3XE>#/B9I/@_0/A?J'C/2_#'C3QQ MX*M--\%_%/QU\>8M$^).GZW!?$/Q#N[O2[&7Q-X,^+QUWXE7VD^&=.\*GQ[X MRO\ QE9_KI^Q'\5_B)\;OV5_@Q\3?BUI-OHGQ)\2^%93XST^VT[4=)A77M&U MW6?#MYH63:@='349+>YT+07CENW"Z'HT7EZ9:@'S9_P6A_Y16_M MV?\ 9NWC?_T&RKZU\/ZQJ/A[]E71]>TC7?"OA?5=$_9_TW5]-\2^.I)HO!7A MZ_TWX96][9:YXODMY8+B/POI%U!%J/B%X)H9DT>VO6BECD"N/'?^"F7@GPM\ M2?V#_P!IWP!XX\6W7@+P;XS^&5]X:\5>-K+1W\07?A/P_K.JZ19:OXBMM#C9 M9-7GTBQEFOHM-0[[QX1 OS. ?G_PC_P5<_80$>$O#?@Z/XVVNI6_AGP[HWA MJ.^G\%_%*WEOX=$TJUTA+N6V3X<2QP27<=H)Y($DD2)I6C5W50Q^\P.69MGG M!N$P.39/G&:U\'Q-F^*Q/]G95F&-HT:6+RO(:-#GQ&'PU3#JI.>$K7H^U]M& M"C4G",*E.4_F$;2Z\ M5K;>!? WQQ^&^@>$_#5YK?@7QEX0T_Q3X:3QWI47ZS?!3XW_ !4U3]GS]O7P M%XE_:^\'^$M>_9G_ &@?C9\$?AC^V1\9_#_P[O7TWX=^!?A]\(O&VN?$7XBZ M/;2?#/X9^*?$GP,UOXD^*OAAXD\1+INA^$6\1>!M-O/'.E7VI1^)=-U/VW]E M3PQ^P]\6/A1\6K_]E[X'? ^_^$?Q;\:^(=-^,^EV'P]M_#OAWXB>+);*RO-? MLO&?A?Q+X T^+Q'9-8ZY;%;.^TVYT&&._N8-/MXO,O$;VG5?V2OV;]=\#Z'\ M,=;_ &2_V;M8^&_AGPIXL\"^&OA_J?PZ\ WO@OP_X(\=ZEH6L^-_"&B>%Y_ MCZ+I?AGQAK'ACPUJWBC1+*RAT[7]3T#1=0U:WN[O3;.:'XO%83%8'$5L'C<- M7P>+P\W3KX;%4:E#$4*BWIUJ-6,*E.:NKQG%275'O83&83'X:CC<#BL/C<'B M8*KA\5A*U/$8:O3E\-2C7HRG2JP=G:4)2B[:,^=/^":GC[XW?$70/CUKWC'Q MQ\4/BI^SJ_Q9TQ?V.OBQ\??"_A'P;\=?B7\(6^'/A)_%?C'Q-H'@SP7\-[;_ M (5[JWQ9_P"$RG^">N^)?A_X2\8^)OAXUEK5[I]WX;N?"FL:E^FE?/?P:_9] M^$'[.FG:_I'P!_9X^#'P3TOQ5JL6O>)].^%7AWPUX"LO$6MP6<>G0:QKEMX8 M$:9%JFIQ6$,=E'?WJ3W2VL:0"41*%'LWVOQ%_T!M/\ _!Z__P I:YSH-ZBL M'[5XB_Z VG_^#Q__ )2T?:O$7_0&T_\ \'C_ /REH WJ*P?M7B+_ * VG_\ M@\?_ .4M'VKQ%_T!M/\ _!X__P I: -ZBL'[5XB_Z VG_P#@\?\ ^4M'VKQ% M_P! ;3__ >/_P#*6@#>HK!^U>(O^@-I_P#X/'_^4M'VKQ%_T!M/_P#!X_\ M\I: -ZBL'[5XB_Z VG_^#Q__ )2T?:O$7_0&T_\ \'C_ /REH WJ*P?M7B+_ M * VG_\ @\?_ .4M'VKQ%_T!M/\ _!X__P I: -ZBL'[5XB_Z VG_P#@\?\ M^4M'VKQ%_P! ;3__ >/_P#*6@#>HK!^U>(O^@-I_P#X/'_^4M7[&749?-^W MV5O:;=GE>1?->^9G=OW;K*S\O;A,CH2*"H/7=U)X9@>?<$ M''MT]J=10 TJ#GJ,XZ,PZ<#&",>^,9XSG HVCCEN.GSOZYY^;GGUSQQTXIU% M "!0"2,\^K,1^ )('X 8Z=*-HR3\V3_M-CTZ9P/P'OUI:* $*@C!W=<\,P/3 M'4$''MTSSUYI0,']'_ +2& MGMM?TMX(^(/"/"&19O@^(/RS" MK:?X4OO"NK_&&XG_ $[_ &$OV0$_8H^#>K_"1/'\GQ(&J_$'7?'9UZ3PS'X5 M: ZWI'AW2CIG]FQZWKRR"V&@"?[9]M0RFZ,?V>,0AY/4->_91_9K\4?''PW^ MTMXB^!OPPUKX]^$-+N-(\.?%?4O!NB7?C32[2=](:.6+6)K1IY=4TR/1+.T\ M/ZW<^?K7AK3IM5TWP_?Z98:WK%M>_B_'N:8'.^,N(LVRRO\ 6S]VI3A+NC]Q\/,JQ^1\$\-91FE#ZMF&7Y70PV+P_M M:-?V5:#ES0]KAZE6C4M=>]3J3B^C/D;]CWXS?M,^*_VQ/^"@OP?_ &A_&7@/ M6]'^#=U^S#J?PM\-_#OPK)H'AKP'X=^*_@7Q]KEYHDNOZU6S\->$_#6D6ZPWOPU\%/VW_VI-:_;V\&:%X_\9^/T_9N M^+W[9/[8/[/'PZ\5'P'\&+_]D?XA>&O@YX;^)@^&_P .?A'XB\->'K3]JCP? M^U!H'BSX=>([/XG:S\<9X_@5XR;XZ-XD\/>-M5M_AKH0O?%NA^+W\SQ+I/B.9H6;6=/UA MR3>6M_YT3 E46-217M7AW]DK]E_PC\8]9_:%\+?L]?!GP[\<_$$^K7FM?%O1 M?AOX3TWX@ZC?Z_%);^(=3N/%-II46K'5O$5O*UOXBU9+E-3\06P6WUF[OH46 M,?(GV1]" Y /7(!R.G/I2T44 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%?-6O_M;? _PUX\^-_P -=5\2W\/B M[]GKX-V/QW^)5@GAW6Y;>R^'MY9^(-1GN]%U);/^S_$NLZ/I^A0WWB'PYHMS M=:SH-IXF\%7&J6MM%XPT%KP ^E:*\$\:_M+_ @^','PVU'QUXDF\+:!\5=% M\4:UX4\4ZQI&IVWA8IX2\ W/Q2U/3=9U\6SZ?H.M3_#_ $KQ)XITG2=4D@N] M8TWPEXI_L]9[C1;B!O,U_;M_9ZCB^,W]IZWXI\/W_P !?A'X%^-_Q&T3Q)X# M\5:!KMA\/?B!X33QAI6IZ3I6J:?;7/B.]TC3Y;>Q\8Z/HHN]3\%:]>Z9H?B: MVTW4-5TN*\ /L>BO!=$_:9^"?B/XK_$OX,:)XYTW4?&_P>$:=XU^)<=O'=- MX?\ "&D:CJ>N:7]FU;Q<81X9CU[3)_#^H3^(O#<.J3:WX7L7TV]\1V.EP:QI M37G/_!G]K;X0?'.[:T\(S>,=)%WX,M_B;X6NO'W@#Q;\/;/QY\++J:RM[?XF M>![GQ;I>F)X@\&&;4]+^TZA&+>\TV#5]$O=5TZQL=ZO@#Z:HKXOTS]O;] MGSQ%X%T7QWX.OO'?CJ'Q3\1/B3\-/!_A3P5\-/&GB/X@>,-;^$FJZEIWCS5? M#?@>QTIM>U#PAHUIICZ]'XO>VMM!U/0M1\.WFEW=Y<>*?#5EJWU!\/\ Q_X/ M^*?@GPK\1OA_KUGXF\%^-="T[Q)X:UVQ6XC@U'2-4MTN;217%AJ-I:7UM<6T0!\I_\ !1WXNZ]\ OV)/VB?C;X7TS2-9\1_ M"?P(OQ"T/2M?%Z=$U'5?"?B'0M9L;+5AIMS9WYT^XN+1(KL6=U;W)A9O)FC? M##^29_\ @Z=_;45W4?L^?LM8#L!F'XN9^\?3QZ!^0'TK^H/_ (+)?\HOOVV_ M^R#^*/\ TJTRO\PR3_62?[[?^A&OZ_\ HY\ <'<7<-9[C.),@P>;8G#9Y]6H M5L3+$*5*A]0P=7V4?8UZ4>7VE23UV/AN*H_$1XDUJT-A':.9XOLT,-Q]I +RM%E*_=/XL?' MGX+_ )M?"U[\9?BEX"^%]IXW\5Z3X&\(7'COQ5HWAB+Q)XNUVYBM-*\/:,^ MKWEJ+_4[N>:)1!;[Q CB:Z>"#,H_B^_X-6?^3K?VH/\ LWCPI_ZM&WK]HO\ M@M/^S;\4?B[X@_9W\>?![X7?&CQ1XW\.7_\ P@%IXI^&OA+]GCXX^!I=-\;? M$SX<:Y?_ \^-?P _:%?3+"\\$^(;KP;I6L#XB^%?%'A73]-MM&UGPK\4=?T MOP=KEM,_\+^.F09/PSXBYGE&0X"CEF6T<#E-2EA*#J.G"I7R^A5K23JSJ3O4 MJ2E.5Y-7;LDM#]%X=Q-?%Y72K8FK*M5E4K)U)VYFHU)**?*DM%IL?MOJ_P 6 M_A7X?\?>&OA3KWQ*\ :+\3_&>GW>K>#_ (<:OXS\-:9X\\5:5IYG&H:GX;\' M7VIP>(]=T^P-M<"]O-+TR[M[4P3":1##+LC\2_&'X3>#/&7@_P"'?B_XG_#S MPKX_^(3SQ^ ? _B/QMX8T/QAXXDM6"74?@_PQJFJ6FN>)GMF8+<+HEA?-"Q" MN%8XK^=JQ_9@_;N\+_M8WWCO6O@[IVM^+?B[\;?^">WQ?L8O#'PO_9F\<_LB M^ _"?PE^$'P8^'7[0_@WQCX^^)L=[^T3\,;W]G_6/#OQ@\6?LI)\&+K09U\0 M>+O#OB"TC\=:GXG^(-MX;D_X* ?LK_'K]JKQEXN\1? KX._'OP3XD_;2^$7P M!\">)+WXJ?!SX"ZC#\#->_9X^-WBW7/!?B=?C--\=V\=?LXW7@ZWU*Y^*/B? M2?#OPU^+J?$*VE\*R_!G5_"'Q=N?$,^F_D![A_3/12+TZ8Y8XSGJQ.>0.3G) M'8DCG&:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH 1@2I R,C&0<$ \$@^H&2/>OQK^)7_ 3^_:#\5:QXR^*.F?&>>^\=?%VR M_;0\%>/OAGKUUX,M_A;X>^'7[2WPLO\ P?X0MO"OB30_A-I_Q/U?5_!^M?"G M]F$ZC#XQ\5Z]HPTW1/'$NB6-HZZ%9I^RM% 'Y+>.?V;OVE?VM_@AX)_9Z^.' M@CX??L^^$_!%OX*\4GQ;X1^)-M\;_$6I?$[X/Z7H6K_!?4=%T^_^&_@6QT?1 M/#7Q=TK2_'_BF"^FNG\6Z#X/M_A]=0'P_P".O%$5KS7[0O[$O[2/QY^"/QHU MQ+SX3^#?VI?B1::'':K8Z]XBG^&M[H7CG]GWX/\ P;_:+^%VLZX?#LGB!?!/ MB/5/ UYXL\!WCZ/?7NF>)_!WPM\57]E!=6&KZ;)^QU% 'YIZQX _:YO?VNOB M1XX\,_#/X9^!_ASXL^!U_P# GPM\51\5[;Q-XF\+:E!XM^(7CO1OB[>?!FZ^ M&-AI7B!#K?BW34O? MUXZA:^FM+Z34-7GM[@E_F+X6?\$T/BIH?AWQUX%T+5 MM-_9E\+^,_@?H?PA\>R^&OBWXR_:C7XHZOHWC_POXKFU?1O#OQ;\)>#;#X)_ M#;6O#:_%/P-XC^&/PZU'0O#OB/0_BU=Q0>%O"EUX"\*:K-^Y-% 'X\_!?]CK M]K3]G_Q!!\7#XO\ A;\>?B#H'QR_;!U?3?!FK(?@OX?U/X/?M0^)O 7BB-[7 MQ/H'A;QY_8/C;0_$_P +_"FNRZ?/X:U'3(/#^L>)O"&GZHPL='O+[] OV5_@ MSJ/P ^!'@3X7ZWK%CKWB+1X_$6M^*=4TFWN+30Y_%WCOQAXB^(7BV+P[:7?^ MEVGABR\2^*]5L/#-I%/H2B@#Y\_:D\+^&?&_P0\7>#?& M?A_2O%7A+Q9>^"_#?B7PWKEG;ZCH^N:'K?Q \)Z;J>F:G8746-Y:7,L5 MQ:W$,L,\;&.5&1F!\!/_ 2N_P""=;LS']C/]G(%G=L#X1> @!EB< ?\(\< M= ,G [U]-?'[_DFM[_V-/PT_]6AX,J3XXS_'RV\#-)^S?I7PAUCXC_VUIBK9 M_&SQ!XW\->"O[ :6?^VI6U+X?^&O%?B :Q''Y!TNW&E&QGVFBU=_F#_AU9_P3K_Z,S_9S M_P##1> O_F>H_P"'5G_!.O\ Z,S_ &<__#1> O\ YGJYDZM_P5UP<> /^"<^ M>V?B]^U/C/O_ ,60K](K8W!MX#=B%;HPQ?:%MVD> 3^6OG"%I525HA+O$32( MKM&%+JK$@;_ZU<4?]%+Q!_X>LR_^:1_4\'_T"87_ ,)Z/_R'E^?=GP'_ ,.K M/^"=?_1F?[.?_AHO 7_S/4?\.K/^"=?_ $9G^SG_ .&B\!?_ #/5^@5%'^M7 M%'_12\0?^'K,O_FD/J>#_P"@3"_^$]'_ .0\OS[L^6_@[^Q;^S!^SSK.K^(O M@+\%/AS\&M?\0:7#HFNZU\-O!GA;PGJ>L:-;7@U&WTO4;S2]$@FNK&"_5;R* MWD8HEP!(!NKZ%_L2?_H/:[_X%6?_ ,KJWZ*\K%XS&8^O+$X[%XG&XF:C&>(Q M>(JXFO*,(J,(RJUYSJ-0BE&*7MW9\OR;:WV[]WS[MV=JXQ@YT** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(_CA&DGP]O%D7>G_" M2?#UB.>J?$;PDZGCG*LH8>X[]*]9##GANK?PL>Y]!7YS_P#!7+Q#K_A/_@FU M^V+XF\+:YJ_AKQ)H'P8UW5]"\0^']2O-&US1=6L-0TFYL-4TG5M.FM[_ $[4 M;*XCCN+2]LYX;FVF1)89$=0P_P Z"3]NW]M_S)/^,R/VJ3\[Y/\ PT)\6\DE MCDG_ (J[J3R:_:_#'P7S+Q-RK,,SP>>X/*Z>79@\!*ABL+B,1*I-X:AB'5BZ M52$8IQJP@TTY-QO>UCY_-\^HY17ITIX:=:5:BJG/"4(VBISBHNZ;=FI-:V7, M[;MG^KQN'HW_ 'P__P 31N'HW_?#_P#Q-?Y0G_#=O[;_ /T>1^U3_P")"?%O M_P":ZO8OV=?VW/VS]8_:%^ &D:M^UU^T[JFE:K\=?@SI>J:9J/Q[^*E[I^I: M9J/Q-\*V6H:=?V5SXKEMKRQO[.>>TO+2XCD@NK::6":-XI'0_HN)^BGGF&P] M?$2XNRJ2H4:M9Q678Q.2IPE/E3=:RBOJ>7#C/#RE&/U&LG*48W]K#3F M:5_AZ7?W>>G^HW17BW[0?QX\!_LR_!7XB?'CXG3ZE#X'^&F@W'B#7O[(M(;W M5)X1?6VFV=C817=WIVG1W6H:E?V.GPW>L:II&A:>UR+[7M9T?1K:^U.T^1?A MG_P4+U7XD_LZ^%OCCI_[('[2;^)/%WCN\\#:1\*="_X5%K[W$5KI6J:Y_P + M 7XTS?$[1OV>[+X5-INE7%F_CK7_ (G:':#QGY?P\M[*[\8WND:9JG\GGVA^ MD=%?'WA+]KA/B_\ LM> ?VH_V=?@A\6OCCIWQ(T_2-5\._"_2[GX7_#?XCI9 M7NL7>B:T^I2_^!O %NWA:\T^_P#[0DM/'-_8ZW;VRW_@N^\3:;?:;>WG M3_LD?M))^U?\'++XQVOPO\;_ ITS4_%'C3PYI.B^.M7^'.OWFN6?@OQ'?>% MIO%_A_7?A9XU\?>#]=\&>(-3TO4I/"FO:9XAN+?7]*MH];L!+I&H:9>W@!]- M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y MZ?&O]J;XQ:1X]^/GA[X'>#?AUXATG]D[X6^%/BA\6;;Q_J_B72]<^(>H>+=# M\7^-+3X9_#FZT*"33/"&I6O@3P;+J\OCSQ9;>)](FU[Q%H'AM/"L5I#K?B/3 M_*]'_P""FMYXLUBQ/A[]G?XHVWABX_:S\)_L\:'>7]KH.IZY\5= \<_L<^(/ MVI?#'B3X=Z1I'BD+I&N7;1^$].O[+Q[-HOAO1?"^OVWB'5O$-G)O%GB2^\7_$WP,GQ/\ Z7\*_C7H'PZ\1Z1H.A_&KX$[7X?:/\3?#GP%US]FUM+)O#MK?^$_#NJ>'M,T*XD\0KKP!Y0O\ P4R_ M9;DU#X(]9C7QYX>^'GB75KO4K#2?#X^&-C\5?'>L?"[P+;_$C3/$FOZ- MXAT[4]7^(OASQ%X4O--\+Z+XON?#^-O MA+\4/C?9:)X^TGXB MZQX1U[1H;Y[:RL]7O[(_V-/?V;K>'QOP_P#\$X_@7X4\6>"_%_AW5_&NGZAX M3'AV+4TGM?A=K$GC>T$?$SQM\5/"=IXAUS7_AAJWBS05T#7_B%XHTM;SX9> M(OA]JFO>$[NU\,>*[_7M.TW3UM_9-7_9OT>P_9@^)7[./@75+V"R\9> OC/X M7TO5O%%V]U-::G\71XVU"[NM0N=%M-.G-C8ZYXTO'A6PMXKNWTR&&&%Y;J(7 M$@!YI9_M]?"B\UO1_!R>!_C7!\1/$?COP?X'\.?#B\^'1L_%^M1_$/X>>//B MEX"\:6UMD?%5;/6],TW6O@Y<2_#V\CB_:+TC6?B=X6^#>DZA\$&: M_P >(8-0^(_CKP-HEN/$Y\&3'2/&7AGQ[)#'\.-6M_%QZ?X9_L5^!? ?C#PG M\3=9\;_$WX@?$WPKK'AG5+;Q=XS\0:)?W"-+C\3?%#P9\?KS3?#?@[P]X+DTJ\$6WV"( ]G^'_P#P4!\ M^.KZ32!\+OC5IFOP^'?BYXUU#P['X*CU_6O#7@_X-?$3QU\)/%-YXMMO#^J7 MT&E>)'^)/P\U_P )Z=X(TFZ\1^(;Z]DTZXLXKG3SK%YHF/I?_!2_X#Z]HZ77 MASP]\3?%?BA?&GCWX?WOP^\&:3X)\<>*M,\5?#KX5Z7\;-=TZ\O?!WQ"UWP, MXE^&.LV'B33I['QI>PW%Q,?"]P]GXP1O#]'(_$?A[X5?"+3_ !CXPTSQ/KOB M;5K[QE/\+?"NFZ]I^J67A_Q+X2\1M8ZQKWBGUGP=^P7\*?"?BUO'MQXN^)?B MCQG=>(?$'BG5]>&] M(%CI'A70/#^D6NN02ZH+*07=U;3 &#+_ ,%'?@ OA^_\006'Q)EBG?X&W'@& MUO?!\'AD_%?P[^TE#XKD^"OC'P3J_C+7?#?A;3_"OCB3P%XXM+;4OB1XA^'T MVD7OABZM?$-GI,VJ^&5UW[2\#>+K+Q[X/\-^,].TWQ#H]EXET>RUBWTKQ9H. MH^&/$>G)>PB3[%K.A:I%%>:=?V[;HIX7$D+E1/:7%U9S6]U-\HO^PK\,K;PK M8^%_#OC;XI>%SIOP5_9[^ MKK&G:GX(U6YE\"?LVO\13X)BUS0/%_@'Q/X$\ M83:Y%\3O$D:KHEEJ">__ -^#/@W]GSX5^$? MA!X!745\*>#;6_M]-.JW-M<7LDFJZSJ?B'4YW33['2](T^&XU?5]0GL]$\/Z M1HGACP_9R6^A^&-"T3P_IVFZ59@'R5_P5A\'>*OB%_P3I_:Y\#>!_#^I^*_& M/B[X0:OX=\,>&M%@6YU;7==U?4](LM,TG38'DB2:]OKJ6.WMXWEC5I'4,ZKE MA_GUR?\ !*/_ (*4^9)_QA%^T'P[C_D5=-[,1_T':_T2_P#@HSK6K^'/V)/V MCO$'A_4[[1==T3X>7.JZ/K&EW,EGJ6EZG8:OI%S9:A87<)66VO+2XCCGMYXV M#Q2HCJ00*_G"_P"";?[37[1GQ#_;A^!/@_Q[\=/BMXS\)ZYK7C"/6?#7B;QI MJ^L:'JL=M\.O&6HVR:AIMY-);7207]I:WD*RH1'-37]4^!_$/%?#G M O&&9Y%2X=K8++<7C9RQ=6>"R>CB)T\-+!8BC0C"=&C&,?:IR55M MM\EK?BWB!Q=DV5<8<+\-X_!YI6Q>?_4<+AL3@ZF$CAL/]>S1X"$J\:Z=67)4 MFYS]FG>&B7,?SW?\.H_^"E/_ $9%^T'_ .$KIO\ \O:];^ '_!+[_@HEX:^/ M?P*\2>(/V,_CSH^@>'?C9\(=?UW5[_PSIL-CI.B:)\2/#&J:OJE]-_;C&*RT MW3;2ZO;N4*QCMX)7"L5P?] W]LC]J;X8?L8?!Z3XJ^-O"FL>+KW5-:7P?X!\ M!>#]/T0>(_'WCNY\-^)O%=CX8T[4?$%[HWAG0P^@>#_$FL7^N>)-9TW2]/TW M1[QU>^U)].TG4?,_$W_!07]GWP%X7_9=U?XB>"OBKX&\8?M8?$3P%\,? 'PH MU[X3:I!\1O#GB/QU\2/#WPI34_B-8HKZ#X+\#Z'XQ\4:+:W/C[4O$)\+>)[3 M5-%N/ASJ'C:;Q'X=M=4PQ'TJ>+L3AZ^'GPWPU&%>E4HRE'^U>91J0<&XWQ[5 MTG=735]TUH?EVB7DJ&XMM=\">-H+_PSXO\-:S9 MK/HOB;PYJ4=M_;'A_4M2LK/5-%U&:SUBP_'S]GG_ ()3^)OV?OV;_&?P@\*_ M%W]E'3[GXJ?$+3?%7Q9^!]]^R]I/CG]A/QYX6TSP?K7A*7P=JW[//B'XF:?X MBM]5\27UUX=^('BSQWX9^(?A2[UWQ=X.\+Z9JWAW4_"VF75AJOZ6?M@_MA_ M']B#X:0?$[XUG7'T_4=7LM"T+PWX&\'7?C#QAX@U"ZOM/LKA[#2;&.*TL-'T M2/4H-1\2>*/$FI:%X5\.:8#=:QK5HTUI#=?6*V-@PR+*TZLO-M#U5BI_@]0< M>U?RZ?8'YF?#S]D/XM?"G]C;Q/\ L=^#OVLM DTI_P!E?QS\'/AO\3]5\"W: M>._AU\8?'=_\49/^%@Z0;7XIR:?;_"/X;Z-XS\&^&?@S\%+*.WU+P#X;^'NF MZ--\3M?MI;,Z7]O_ 7\&^$/@K\'_A7\'?#^K:.=!^%/PW\"_#;1/LTUK9VX MTGP+X6TKPMI_D6C7UTUK"UKI43QV[7-PT(?RVGF93*_JOV"Q_P"?*T_\!H?_ M (BC[!8_\^5I_P" T/\ \10!6_MO1_\ H*Z;_P"!]G_\>H_MO1_^@KIO_@?9 M_P#QZK/V"Q_Y\K3_ ,!H?_B*/L%C_P ^5I_X#0__ !% %;^V]'_Z"NF_^!]G M_P#'J/[;T?\ Z"NF_P#@?9__ !ZK/V"Q_P"?*T_\!H?_ (BC[!8_\^5I_P" MT/\ \10!6_MO1_\ H*Z;_P"!]G_\>H_MO1_^@KIO_@?9_P#QZK/V"Q_Y\K3_ M ,!H?_B*/L%C_P ^5I_X#0__ !% %;^V]'_Z"NF_^!]G_P#'J/[;T?\ Z"NF M_P#@?9__ !ZK/V"Q_P"?*T_\!H?_ (BC[!8_\^5I_P" T/\ \10!6_MO1_\ MH*Z;_P"!]G_\>H_MO1_^@KIO_@?9_P#QZK/V"Q_Y\K3_ ,!H?_B*/L%C_P ^ M5I_X#0__ !% %;^V]'_Z"NF_^!]G_P#'J/[;T?\ Z"NF_P#@?9__ !ZK/V"Q M_P"?*T_\!H?_ (BC[!8_\^5I_P" T/\ \10!6_MO1_\ H*Z;_P"!]G_\>JU; M7UG>;_LEW;7/E[?,^SW$,^S=G;O\IWV[MK;=V,X.,X.$^P6/_/E:?^ T/_Q% M316\$&[R8(8=V-WE1I'NQG&[8HSC)QGIDXZT 2T444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110!\2_P#!1W2=5U[]B#]I'1-#TS4-:UK5_AU= M:;I.D:59W&H:GJ>HWNK:3;V=AI]A:1S75Y>W=Q)'!;6MO%)-/,Z1Q(SL ?YM M_P#@FA^SK^T%X*_;H^ GB?QE\"_C%X2\-Z3K7C*35?$/B7X:>,M"T33$N/AQ MXTLH'U#5=3T:UL;-9KRYM[2)KB>,27,\,"$R2(I_J:_:L\>^$/A;\!_''Q(^ M(&NV?A?P/X$/A;Q9XM\1:@MR]EH?AW0O&_AC4=6U6[6S@NKHV]C902SRBWMY MIBB'RXG;"UP_[-/[>W[(/[8.M^+/#G[-?QT\)?%O6O ^FZ;K/BK3_#D'B&&; M1=+UJ^O=.TN\NO[9T72X6BO;RPN[>(6\D[AX'+JB[6;]8X/XQXAX?X)XKRS M<,U\RR;-8XS#YEGBHXYX7*YYAE]/+N6KB*-">%ISBJM*=.->M3(]2T3Q9X9^(_A"Z'BGP)XK\,Z)KMG8:_8 M0ZGXL>$OV?O#%SIO_"$V^B>*/%'BGQ- M;:$BW&A:GHD36ND:7^[^0.IZ\#W/I17Y.?J:T278_*/]MC]F']N;]K?]F'QM M^SS%\3_V3_"DGQ)U/PS:>)?$,GPO^,UXFE>$=$T'X7^)KJWT2UB^)_F7?B.Z M^,_AKQO\\!Z MA\3Q8R'QC>?#'3/$>C> Y]5>\NG#>&M,\6ZKK?B*TT];-K5/+U75+RY-RMQ( M)%A>*-/0** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH *3<,XSS_+/0$] 3G@'D]J6OQ(^/GQ&E^'/[96L>,-1^)EM\1]. MA^.7[+?@G2?AGX1_::^)?PA^/OP8_P"$RG^&OA>\\)>&/V8]0TN_^$_[37PH M^(NH:Z?'OB_5XWT;Q9J6B^(/'6BZ%J.N:]\,O#*^'P#]MZ*_ 3X*?MC?'CX* M_L\?#JX^)?CSP5XBTOQ5^R?XO^*7@[Q/J/A3Q)XM\2>%O%'A']H_X8?!;2HO M&WB'Q)\7?"NF?$.Q\9P_&[P]?7^O:[K_ ,(O"_@&ZT"XOO$?BZ+P2VHZYI'0 M>!?^"A/[4OB_3]>AT;PU\//$6H_"%/VTM:\66MAI6G:[XC^,ND_LQ> ?V9/B M1X'\->!1\,OB7X_\!^'_ !3\1S\=;KP/J^J:)XK^(.DZ5<6<6K:?I+:RLOAN MU /W;HK\*_A3_P %"?VA/&VB^$[/Q;KWP'^'VF^-/BG\(?#<_P >]=N?A+XA M\#> K#QU\*/B[\4M:\/Z]X1^#W[6GQ7TVQ?5M7^&_A3P'\*/$OCGXG>![_Q" M?B=:2:OX1?7_ _86?C#T'X=_M.?%CX3_P#!*SPE\?;#R_BC\2)_$$>CMX@\ M0:BEQH-O9>/_ -JG4_A[=?$34[[QYX[\'6:^"O GA?7V\6VUOXL^)7A/1(O# MVB:?INN>._#>AK=>(K$ _9.BOQ+T#_@H!\=XK;X%/XPC^&6EZ/\ $'XO>,?A M'XW\5PR^#?$Y\%^"M$^(/P\T+PY^T7XJ7X-_%OXQ_#GPEX?U'7O$%W^S;XF\ M*#XH^(++1?C-XS\#>.WUW3/!>A^.?#&E<;XW_P""EOQX\%Z+XJ\1^'W^"_Q: MU*;0OVDDN_ACX7T>;1?$G[.EY\%/VK/"_P !/#WCCXQ:QX@^*FE:?=^#=6\, M^*]0\0^)X_%"?"328=6\&S2:1XYM?"%SKGB72 #]YJ*_#S0?VV/VO/&FE6.E M:%=?!7PU?:1X#_;/\ _ M!^L:OJOQB\8^"?'&EVOQ@\236<.@V'BC3K;1;W4$\/:?I:S_ ,%'/BWHWCO4 M=1&C>!M?T34?A"OB_P"'OP0\$V_AOQMX\\1^+KS]C3_AIS1?!?B?7-(^,D7Q M9^'WB[5O$5CK>DV]YJ/[,VM?".?X?/X2OU^(]IXU\3+IMH ?MC17X/\ A'_@ MH)^T[XG^$&M>()[WX#:9J)\>?!#2-,\9S^+/V:Q=7UC\4_!'Q'\5^)?"O@WP M=I?[:OB;X67_ (GT"\\*>%KWP5_PM3]H+X5:IXO^'OB77[Y?#=WXP\(Z=IOC M+]=/V;_BK%\;_@3\*?BO%>P:B_CCP3HNN7M]:>&]5\(V5UJDL!M]7FT_PYK. MK^(KW2M.?5;:].GV_P#PDOBBS:R\B?3/%/B72YK+7=0 /CG_ (+(DC_@E_\ MMMD'!'P'\3D$=0?M6FZ?X\^'4WA.^\=>)(FF\/^#[37-;T6QN/$ MFM1+=V!?2]'AE>^OE^W6>;>&3-S" 9%_$;_@DA^SO^S9_P $R_B'\;?&GB;_ M (*%?LO?&&W^*WA#P?X5L]/\,Z]H'@Z;1)O"OB+7M9EO;NYUSX@:Q%?0WT6L M+!##;1Q2020,[O(DBA/Z!X)S?!1\%/$7AN*QM?.LVS7!5,OP6$RK-<8J\*57 M)*E2^*PF"K8.A*,,-6DX8C$4IM0NHOGAS?&9SB<)A.(\HKXS'9?@Z5/#U)3> M,S#!82?*UB8*4:6)KTJM2+G-1YJ<)1O=-W3M]H_\%;?VIOVN/V=/'W[/EU\& MM1\4>%_@=%JUEKGQ>\:_"/X1^$?VC_'^B:G'K&H2V5C\3O@A?_$?P5\3-3^! ME_X+T'Q?JMY>?!K2M5\7Z]KOA[4M&;Q1X&ETW2Y->Q9_V^/CYXE^*>J_&CP+ M\1/A]$/^"@O[*G[!UA\%#X$MVU'XL^#?VD/ ?[/VO3_ +0NE_$2YU63 MQ;I?B8:A^T9H7C;X?^%[&W7PE)\*/!.IV_B33]7U[Q*/$GAGWO\ :&\6_P#! M)S]JO4_ VL_'WQ3^RW\2-7^'>JPZEX:U37/B5\.O[1CLTEDN+OPKJE];>((+ MO7O >LW31W7B'P%K,U[X1U^YMK2?5M'NY+:-A[#\._!'[ /QT^.8_:(^$W@? MX$_%#XX?#RQ\-QS^./ .L^"M=U3PTUIH6J>#_!>N:GIVCZ[_ &''XDTKPH-; M\'>#_%^H:3+XHT3PHVJ>%M UFQT&2XTYOQ'$9)G.$HSQ&*RC-<+AZ?+[2OB, MNQE"C3YI*$>>K5HPIPYIRC"/-)7E*,5=M)^]A\]R/&5H8;"9SE.*Q%7F]G0P MV8X.O6J?H:\P]4W:*PO[5U+_H7-1_\ W0__EI1_:NI M?]"YJ/\ X&Z'_P#+2@#=HK"_M74O^A:'I% MUK^DP7-MI6MW.F64^L:;;7@ N[?3]4E@>^L8+H "XAM;B**<<3(];5% &(?# M?AYK863:'HYLQI=[H@M#I=A]F_L?46B;4-*\C[/Y7]FWQAB-YI^S['=&*/[1 M!)L7#]/\/:#I(METO1=)TU;.W-K9C3]-LK(6ELUMI]F;>V^S01?9X#::5IEL M88=D?V?3K&#;Y5G;)%L44 J7MQJ.IZ,NAZ6NDZCJ M%W=+?75]?Z:+065Y>7-ZB7EQ=7,$L\]TB7,LCS(KC8_LS3_L,NF?8;/^SYX[ MF*>Q^RP?8YHKQI6NXY;7R_(ECNFFF-RDD;+<&64S!_,?=>HH YZV\(^%K.PC MTNT\.:#:Z;#IEOHL6GVVCZ;!8Q:/:2O-:Z3':0VJ6Z:9;RR220:>L8LX7D=H MX59V)P/!'PM\ _#G2;O1?"'ANQTNQU"?6)]1+^;?WNHMKGB+Q!XJU"+4=2U& M2ZU&_M6UOQ1KUW:65Y=3VFG1ZE<6FGPVUFP@'H%% ^%O#6EV5CINF^']$ MT_3M,TZ[TC3;"RTC3K2RT_2K\P->Z;8VEO;1V]II]VUM;M=65O'%:W#00M/# M(T4958?"_ANVU6WUVWT#18-:M=)30K;5X=*T^+5+?1(Y%ECT>#4([=;R'2DE M19$TZ*=+))%5U@#*"-VB@#EF\#^#6T34?#3>$_#3>'=8N;J]U;06T'23HNIW ME[_9;^,/PMT2ZAL-7^(7ARS\'Z?J%S: M7E]:Z?<^(/$6AZ;'J%W:6 -Y/9V)N#=7:6^)!;0RL&0*77\!6_X("_'4LQ'[ M0/PDP6;&?"'C;.,G'2\(_(D>AK^GO OCCA3A?(TA*-I24KQO:UF_P"5/'S@/B[BOB')L9P[DF(S3#8; M)WAJ]6C7P=*-.N\;B*GLVL3B:$F^2<97C%QL][II?@ED^I_,U_1;_P &^I)\ M1?M49)/_ !)O@WU_["'Q*KSW_AP)\=O^C@?A'_X2'C?_ .3*_4/_ ()H_P#! M/;Q[^P[J?QAOO&OQ#\'^.D^)-CX%M-.3PMH^NZ4VFMX4N?%<]T]Z=9FE6=;L M>((%MQ;[3&;>;S5D?&^$OAEQYD'B#P[F^<<.8K Y;@YYC+$X MNIBE37+3E9RN[13:\E_X*B?MR_M0_LC?&7]G MRS\$V&F?#W]G#79&UGXA?'?7/V?OB7^T3X0N=G_$W]KO]I#X7 M_ML_LY?#K4[SX/ZK^SU^TM\3(/!?@U[#X9?%.UT"P^'VI_"OQCXH\-^,=0_; M*U/Q+9?!B]^/WB[Q]X1&F>$/V6=%^'NHZIXK\":U8ZSH/C*]NX;G4U^IOVCO MV#?V:/VK/%W@_P (O"-N='FN_#GC?QGX'3QQX+-AXOL7^&WQ-@ M\'Z[HL7Q!^'#GQUXGN6\(>)5O=.#ZWKMC'Y>B^*/%NE:^T_L!_LIGXNP_&Q? MAK>0^,;7QP?BG8Z1;_$+XFV_PMTWXN?\(>W@&/XPZ5\$(/&,?P:TOXO6WA$C M1[+XG6'@2W\:6"JE_9:S;ZLBZ@/XR/[=/F;]K7]I_P#:R^ _[0_P;T;PI=?L M\:[X'^+?QN^!7PC^%O[-UKH'CSQA^TQ\=?"GB[6-(A_:4^,EOXETSQ/H.@_! MWPQ^S5X7U*_\<75QJ'@#X@>"KCPUX2OI?'7CKPKJGCKPKI.D?K "2.??\<'& M1['J.O7J:_/?1O\ @F'^RMX=^,6D_'OP^W[0NB?%;3/"/PD\ 7/BO3OVO_VJ MH+GQ-X(^"%EIUE\/_"?CFU/Q@:R\=>';==-CO?$^C>++?5].\?:S=ZMK_CNW M\1:YK.J:A=_H3_G_ #_GCM0 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9 end GRAPHIC 23 chart-2233dba6a706559f890.jpg begin 644 chart-2233dba6a706559f890.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #I 3T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^0?VQOVT_A3^Q7X!T M_P 7_$+2_B!XT\0^)YO$=E\/_A=\)O!&N_$'XC^/=0$^%=4\<>*5T;0M#M9 MXM.T;POX0T75/$7BCQ9XCN]'\+>'M,M5?4]5BN;S3[6\ /KZBOA[XR?\%#/V M:_@1^Q_J/[;?Q%UKQGHGP+] ^+&HZW;ZGJ.BW?@>S^$?B[ M3?#?CF'QWI^J:-KD&K^&M5TO3;C0[30->US6IK#P[HNHZQ;\'\:O^"IG[+'P M(\=7?@GQ>WQ=U>U\(>#? ?Q"^-WQ!\ _!;X@>/\ X6?LU>"?BA'@>%[.X\:>*;70O!JKK[@'Z.T5\P?M+_M M.1?LW>&_"GB2+X#_ +2OQ_B\5ZY-HL6E?LR?"6?XO:YHB1:5/JJ:UXDL+77- M%&E>'[I8186FJF>>.XU*XMK58P)1*-C]E;]I/P=^UQ\#O"'Q\\ ^&?B'X2$ M^-9_$L&DZ-\4O"G_ AGC&-?"WBG6?"-[=7FA+J6KQ)I]]J6AWMSHFHVNHW= MCK6D/::M83RV=W!(P!]#T444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!. 3Z#- !7Y- M_P#!7[]E'X@_M7_LX6_AGX?_ ,^#/[0.H>%+KQ;X@7P7X_\:_$+X0?%#3-6 MO?!&LZ!X=\6_L_\ QL^'@O[KP5XZT?4M1-MK_AO7=$?P_P#$OP7J6L>%;_Q' MX7_=W%][+\4OVLO'G@;XA>*_".E^'O"-W8:#J:65K31M865V6N#;Z MK!"7#W+K^[B1=JKQG)/ _P##;OQ*/7PMX&_[\:__ /+NOGZO$^4T:M2C.I54 MZ52=*:5&32E"7)*SZI-/7JDV?F^+\5N#\%B\5@L1BL9&OA,17PM>,A?LS MVW[1OB'P?-X^N?!'_"8Z];Z7IMWXUU^RU"7]K_\ X)-_M1?&O3+7P#X7OO#. MM:S^T!^RO\/_ -G?]K7]I.S_ &F?BK^SSH?C#6O"FC^(/"$WC_XJ_L5?#+X? M>(?AS\<[KP%X)UZ0?!BPTCXJ_#X7WB"-?"WQ8FUGX<:?I<,/O?[1_P#P4!_: MVTC4?AUH_P (/"^E64&M0^/;WQ3K'A?]G_Q-\>M3BET&T\*KX9T6'1IOC+\) MM T ZJ^LZ_J1O=8\6O?ZU_PCHT'PQHVI:M,-*\$V?@FX@M-9\&2_$OQAXW6STWPKHVE:=KWB%O^$8OO$VN3.U[IVK M33OX)TZWUR[UQY;?PSJ$M(N/AW\1-)\.:S\38M)\.61\1W$6J>%_#NN6O MB1;OQ MKI/Z">!_!GAGX<>"_"/P]\%:/9^'?!O@3PQH/@SPEX?T^-8=/T/PQ MX6TJTT+0-'L($ 2"STW2;"TL[:% %BAA1 ,"OQJ_9<_X*1?'+XJ?!#PIXR\; MZ1\%]6\8W&K?$70?$MYX#M?$D'A274?!7Q3\<>"(I-&M;GQ=K%[:V=SIGAS3 M[R%;_4)KNY2Y74'2VBO8K6'Z!_X;=^)?_0K>!O\ OQK_ /\ +NHJ<4933J3I MRJU>:G.4)6HSM>,N5V>EU?9]4FSGQ'BQP;A<17PU7%XQ5CPKKNA^&;"Q.A:KJGVC28]52 M[\^PEL$BCS>:E=P^4XNI#(/*WY5-K* 0?M:O5P./P^8T/K&&E*5/GE3O*+@^ M:*BVK/RDCZ_(.(,MXEP#S'*JE6IA57J8?FK49T9^UI1A*:Y)ZV2J1M+9ZVV" MBBOR^_X*P_MR>//V#/V<+/XG?#_PAX8U#5?$_B36?!\WQ*^):>.S\'/@L+;X M;>.O&FD^,OB;_P *X$^,O$LUGXC\1>%-'^&OA"QN;;PUX7U#QWXS\/6OBGQ MUX6TMVN+GL/;/U!HK\8/CM_P5/UCX4_\$Y;#]JGPGX7^"WQB^/7B[X4_&OQY M\/?!/P4^,B_%_P" WB32_@%X>\4^+OB=\6X?BUH6CZ!J7NK-JVD:)X*\-^']5T*Z?Q%XFUW4)?#U@ ?JK17PQ^V5^T[\0O@Q>?L^?! M[X$>$?!/C3]H_P#:N^)NM_#/X2V/Q.US7_#OPO\ #%OX)^&/B_XQ?$?XA?$+ M4?"VE:QXFN=!$^!_!5_%I_A[P];1:MXG\5:UX>*_!^F?%;X&>-]0\%^ M);_P+XIU+2= U/7_ /XIMK?2O&'A6\U71-+UBVT?Q!;Z7K-G'JVG7A8 ^RJ M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH *1CA6/HI/Z4M-?[C?[K?R--*[2[NP'\Y?[6O[26@>$/VDOC#X9NK#3I;C M1O%,%K+)-XJTRQD=F\/:'<9>TFMWE@(6=1L=B2 &SAA7SM_PUKX8_P"@9I7_ M (6NC_\ R-7PA_P4O1#^WI^U 2BD_P#"Q+/DJ"?^1(\(=\5\->5&?^6:?]\K M_A7]8Y)]&GPUS?)'&'%<:7$$J=*'$V?1I4O[+RV?LZ4=% MSGR02ASR;E+XI-L_9'QU\:_A_P"/I='O+R\\6^%=5T)=3M[#7/AO\=;OP#K) MT[6ELEUG2+VYT/;;:CIFHC3K"1EO;*:_TRYM(;_P]J.B:COO'P;+QU\ +734 M\.77P\\,>(? UIH/@'P[HGPS\:>+_#_CGX8>&++X;VVLVGAV\\+^ _%^FZUH MFBZ]<6^NW:>)/$<,4NM^)V@T^;6+VXGLEED_.S4O@5XUT?P!\._B+J8\+66C M?%#Q:_A'PO87'B;1H]:AG;2-(UNPUOQ/;-,++P=X=UG3]9M[K2;[Q)J.GW4^ MGPW6LW.GVFABUU*ZC^('P#K71]0\0>';K^W_#GAF[N#!INOZ3J.G:YI5KJ7AO6K*Z$VG:O*\;P MKTT_HY>$DJD,V=.-2G.CB+1E.+64G3H8J5*K0K1I.E&I[.4J].HIPB MU2^LQE)P5:\_TO\ A1\6/@E\$/"$7@3X6^ ?"7@[PM%K/B/Q!_9>C>)?"^GQ M3:OXJUV_\0ZQ>W(T[2;&.YF>]U%[6T>6)I++1K/2M%@<:?I5E%%Z3_PUKX8_ MZ!FE?^%KH_\ \C5^/_B3X,>+O"?PQ\%?%?78] M?#WC[7M0T+P_ID.M6%]XH M06/A_2_$UOK&M:)8FX;P_I.N:3JL%SX?75KFVU?4[>*6_&DP:7+87U[Y7Y<*L*D)ZN MTDT]5IPXS,N-Z>(E+'\0XF.)KPI8J;Q.49T45:ZBFW?\ N?Z.6(Q^)\/)U,QQCQV(_M_,H^W>'H89^SC0P'+#V>'C"G[K M)/ >J^%_BA\/\ Q5HWB3P3\2/ &IZ;XCFGN]'UG0_[&-#U!A9P#4(1&C/=L\@\MTIRLGJD>K?M M5?\ !*?_ ()K1?LWQ_#7]J'5?$VM?$#QM;?M(^'?"OQZU*\\0W/QSU?XJ?M/ MZKKGQ5^,'C3PE\,?@=I?AKP?XCU-?$\+_$:7P)H/PDN/A[H&E>$;674?#=OX M!= M0U#X2Z%?6*/K'BC1]%\;^._!P\4:MJ1MK+2]-\+6OB32=$U&^CM[SQM<7/A[ M2SI&J\UX$_; \>_#7X2>&_A?\.O 7[0%AX<\-^#-#N;6U\4_%KP#IGB>75M9 M\8ZN_C>WDU'2=:\0Z,/BY8I<7GQ4L_$9EM/ NL>*-:LM+L-?\.7%M*-*3R'C M1-Q?!6?(/BK\#?CII_C[X'?';PWX ^#_@[XB_LX_%'PS\#;'X( M?%#P'JWPS\2?":WTBZTCXEZ9KOC3Q1\2/AG\7?!$EY"_Q0>/PZ/#^B:5X%ET MO[6_95_9D\'?LG_"D?#/PIK_ (L\;ZCK/C7X@?%+XC?$OQ_>/OBG\6/B MOXMU/QQ\1OB)XQN/#NC>'?#R:SXD\1ZMT#1/#V@Z1;Z7X>T'2K#2- M*L[=/YN?V9?VFOB9\+],^*<>K^(_CW:V?CCXJW'CO0YO&_C_ $3Q?\6]2M+W MP'X$\.7]_P#%OQ?X9U'^P_$'B(:IX8GTSPPEIE^$O#=YJ,\FF1V M]G],?\-U^,/^AO\ C'_X/W_^6M6^'>-G9PX*SN<)*,HR;P=-M246N:%3$1G" M2YDI1E%.,DUTUY<7]*'PZPN)JX=5Y8A4I**K8?$T*U&=U%^Y4I>TI3Y7/EDZ M=2I3YHRY*DXI2E_1_17XV?L8?M2^(?BK\=])\':CXA^(VHVMSX8\5Z@UKXDU M9KO2V?3K6TDC>2 W\^9XS*3 WEG:Q;!7K7[)URUL'F>"DJ.;99B3^(F25,^R3G^IT\?7RZ7/)2 M?M\/1PU:>L4E;DQ5/2W<****R/M@HHHH **** "BBB@ K\;O^"NG[>_QK_8A MT'X+S?#'3/ ?@WPU\0]^'5UH/CKX3:/I'P[\3VGP M:T#5KKPGJGQ0T+QKXRUJR\=^.M7\,^%M#\/_ W\46FBMXA\=:GX;TE/V0R/ M?\C_ (5\0_MC_L8-^U;;^"-0\/\ [0?QY_9S\;^!-6T>?3_%?P;\3Z;'8:QH M5K\0O 'Q U'1O%/@#QKH/C#X=^(;^'5/A]H^I>"_%M_X7?Q3X%U^!;G2=5D\ M.ZGXK\+^)0+KO_7]-?>?#W[7O[?W[8?PB_9N@_; ^$?AC]B.[_9Y\!_LN>#? MC]XR\<>)_C;XH^(_AO\ :.^)GBFZO4B_9L_9.\4_#V/PO>#Q->Z9Y_X\_P""Q>LV'[3'C7X9Z=/\'OA' MX'^"_P 3_P!FKX0_$S1_CCX$_:/U?5[_ ,9?''PI\,_&_B>+QA\>?A+X7\0_ M!7]D.S\(0?%;1_AO\/;WX]Z/K>D_&SXQ^'/%?AFTU?P/X;L1XJBH?M*?\$[O MV5?@WXP_9EUV7]O/]I_]F.T_9W^$U_X;^ OPY\-6/P=^-?A?P-%X7O[_ %;X MF?M-#PA\7OV=/CJWAOXASWOC2.3XG?M,ZC9:,WA2UU/3]*C\6^$-(U$:?<_1 MW[17[$W[)[VWC/XK?%7]H'XK:)\*/VF=8_9\F_:*^&_AG4/!&K>#/VT?'OPK MTSPS8?"W4=5TGP_\*_$WQ0G\7>,_#_@GPWIOBC0_V:M<\#_\+,\*>&K*UO\ M1Y]-T^[N7 [>>WGZ=SZ/_;:^+'[67PRT72-5_9SL/V9/!W@;P_X/^)_Q&^./ M[17[6?BK7[3X2_"S0?A]INEW6B>&9?"/@;Q#X8\87^H^.GOM:O-0\>W.N6'@ M_P"&6@>$-4O]5LO%.M:KH/AZZ]3_ &*_C]XA_:H_9+_9U_:.\5_#;5OA#XB^ M-GP@\#_$K5_AOK,MS<7?A.]\5Z+;ZG+IT5W>V.EWU]IC^:+[1+^^TS3;V^T2 M[TZ[O-/LKF:6VC^$?C-_P3[\'?\ !0#PO$_&L/[>7[5=[X-\!?%KXP?%?PU MI6E0? /Q'X%U'Q9XH^(EQK.A^&_B'\(OB[^S]XK\&:])^S-J.GW?@7X2Z%\0 M_ ]WXG^&;6%Q)K@NO'MFVNP_J=\+?"&N_#_X?>$_!GB?XD>,OB]K_AS1K?3- M5^)?Q M?"5IXS\9WD+2-)KGB.V\!>&/!O@Z'4[D.JS1^'O"^B::%B3R;&-B[ M.!==_P"OZ:^\[^BDSGU_(C^8I: "BBOR*_X*^_M0?M4?LO\ P7\(^)/V==%U M;1/#VNZOXFLOBO\ 'C0/@)XL_:BUGX*6&F:';:CX+EA^"G@CQ/X:UNYL/'OB M(S^'=5^(MVOB+P]X M+;;J?ANYO?$FD:GI0!^NM%?@M\>_VWOVKE_8V\(?M@ M_"[]I#]A7X<_!_PO\#?&WCGQ;\8=<^&/QE\?6'Q[_:/\-^+]4\'>#?V9_AO\ M$/%'C;X4_$CX5GQIK&@ZAX>\0Z-JVL_$7XYZ)\3K^W^$/A_P3J.O^'[[6]9] M?\5?MH?MF:7\7/\ @EGHOB?X&> ?@I\//VNO%/@WPK\<-+\5^)=5\3?%S1OB M/XF_8W^-W[0'BKX5>'O"T&D:7I/@K3?A+XR^&NG^&_$7C/Q'KFL^(/%U[>'2 MM&$Z!8Z?J.MZB ?L517P'_P4'_;$7]E#X.Q0^#=1\!M^T)\6K7QEX<^ 6A? M$37]/T'P@OB#PKX(UCQOXN^(GC:6[U#3KF7X<_";PEI%YXN\66^G3Q:CXCO1 MX:^'FAW$/BCQWX?W=]_P3_\ CSJ_[4'[#W[(_P"T)XEU;P]K/B_XQ_LY_!SX MA^.+SPO'9V^BQ^.O%7@#0=8\:6%KI]C?ZG!H[Z;XEN]2L+G0C?7,^AW,$NE7 M,AGM)* /KZFO]QO]UOY&G4V0X1SZ(Q_0TUHUZH#^%7_@I=_R?G^U!_V42S_] M0CPA7PW7I_\ P5>_:1TOPA_P49_:X\-3^$M3OY='^)UE:R7D.K6,$5P6\ >" MK@.D,MJ\D8"SA-K,QRI.<$5^>W_#6NC?]"/K'_@\TW_Y"K_4'@[+\;/A#A24 MUG;_.7BKP]XQQ7%/$N)P^25:E#$\0 MYU7H5%C,MBJE*MF6)J4IJ,\9&<5.$XRM*,9*]I)--+]3[3QO\"X?@EX;^'6I M6'Q$_"_@WQ#X/M_$=IXBU3Q+I&G2:9H M5W<:7XM'AK4-5CO+NU6Z\/-!!('Z/XB?&OX;>/O"GP[^'FL7'QR\5^'/ >K^ M-=4TSQ;XRG^&I^(/AG0=7\)6^E>%/A9X2CTI)M%E\#V'B?2]*\1>*=1UR].H M:@YO'\-Z)H$X\N]_(W_AK71O^A'UC_P>:;_\A4?\-:Z-_P!"/K'_ (/--_\ MD*NK_5";K0KRI8R=6EB,3BJ,Y8FDG0KXNG.E5G1Y91]F^6M57NI';7PSJ&E2?\ "A/BQJ/VNZU.SNH]MGJO@!&B\F"VB?=) M]I!#[]JA#E3D8_N0;H?H?Y5_#GTBZ-6AX@PIUH.G/^PWL?[?W[1\<5]>Q1IXA\'A8XKRYCC4'X8^!R0L:2JB@G).U M1DDDY))K\_O[0U$_\Q'4?_ ^[_\ CU??'_!5'_E(!^TC_P!C#X._]5AX'K\_ M/K7];<%4Z;X-X2;A%M\,9 VW%:O^RL)_7W]V?P_QS"#XVXQ;BFWQ5Q"]5U_M M?%_U_P .SV?5?A/X[T;X4>$OBW>>(=)DTGQIXSC\&:-X:L/%C:GXQ@FNO#TO MB+2M8UW2[">>U\.Z?KMM;W$6BV.L7UKX@NQ"=1GTBSTBXL+Z\@^+/PQ\9?!S M4O">D>)?$^BZM?>+/ ^F^.(CX/\ %DGB;3=+@U#7/$GAV?0KS7+"5]'O];T? M5?"VIV>KOH%YJNBQ72&WLM5OC#-(.D@\=?!]/@.OPLETGXM_\)/+\0K3XH7> MLP77PZ7PNWB1/!S^";S2H+&6V_MQO#\FFS3:A!=7$S:P=16&"X#67F$:GCWQ M]\!?%L7P>T^U\._'%-'^&?@2+X;ZE!?:Y\,+*_UKP_I^I?$#Q-I.IZ;=Z;I% M];:9K@\2>,;"#4+6YL;O27\.Z7=Q69@U6]@GMZIULTCB::JX2=3#QQF8QJJ& M#HPE/"QH^TP,H2EBGR>_RT$FG*M.7M*DJ-.,HO*I@,CEA:GLJV'IXB6"RR5) MU,74J*GBY5HT\?&<(X.+E>GS8B5FHT()TH1KSE%QYFU^&UO??"GQ)\3['XS: M/,WA.#PO#K'A&XT+XH:?J?\ PDGBZ^GM=*\&Z9XBO-%C$ZOXB-G8:SKDR6. MJ26,>@:#J^J/=)#!$)_&/[0U'_H):C_X'WG_ ,>KO-3\=V]W\(? WPPM-,FL MI_#WCCQ]X\\3ZK]HB:T\2ZOXITGP?X?\/-#:J@N+<>%M"\-ZC81&[EFW'7KQ M[;RQ+<>9YQ7K8&C72Q,L6Y3YL9B%AX58892I86G)4J2YL-1I0J0K.G/%4I3B MZT*.(IT:\I5:VJOEQ56M.$Z*J0P ME50DJ,ZV'JUJ,8TJL8K]9?\ @B]>7DO[>'A**:\O)HV^&'Q68I-=W,R$KINC M[24DE9"1DX)4D9X(K^RNOXR_^"+7_)^GA'_LE_Q7_P#39HU?V:5_&/TB(QCQ MWAE%)+_5[ :)6_YB\Q/[D^C8E'P^Q2227^LF8;?]@&5!1117X.?T"%%%% !1 M110 444AZ?BO\Q0!_.[\9OVN_"GASXP?%3P_?'FN$Y.,GGUKYT\N/_GFG_?*_P"% M?U-E_P!%;@/,,!@L?5S7B2-7&X3#8NI&&-H*$:F)HTZTU!/#.T5*;44V]$DV M[MG^86><6\5T\[SBG3S6A&G#-,PA"+PE=N,(XNJHQ;6/2=E%*Z23ULE>R_8; M]H?]MGQ+/+IWAOX8Q?$O6;/QMX3\2^&?B/\ %KP;XW^&5K\0/"7@::1/MG@; MP58?$7XI^$3/K/BL7=]>V_B/4KS4_!G@$P2>))/#/B+Q4VDV]IQ/Q8_:"L/& M7@CX7_#[PC#\4O!G@3X->,?A#J_AI/!7QK$>%?BS:^&_"WPKUK3-&M/@?XL ME\=W-GX \7?#_7;O2/AQXLEU?6;2;Q]\/KKQQI/A/7;O2O$,DNH><_L@ZC%I MWPY\5CP/IWC/4_BM)\9_A\VNV?PY^(G@CX5>+(?@['X>U%AKEQXI\8Z3K2W7 M@C0/&PN+OQ7X?M[$>'-1OY?#5S\2;A?"EC!;75CX'>%E\&_&?XQ>([&[G\9: M)XE\&_':P^$6K_#35/ 7@/XF?%&.W^*%AX/N/%'P*OI;HZ#\-O$^F&.X\03H M=!G>Y^'J>*M'\!^%]8L-3M+JR\6M]'?@/!8C-*7U_B2+RM0^J0J9O@J=3%8B MK1IS?-%X%O"*,9.M1JXFI*G/#T:V+IQC1P^.G0^MR[B#C!X7ANI0S3+_ -_/ M$5:]>&39S5^KOZQRK$5:D.(X+'UH1I1P<:>"HT5@Z]>E0A".88O"5L5]*?LS M_M+V_P -OAA)X8\6_$KQN+W_ (3WXC:[IDNM>/M/\4>/;WP]XE\4W>MZ5J7Q M<\8>'/$,.A>-/B]J+W=[>>//%FFB=-6NY;-;V^U#5;74+Z?Z _X;5\'?]%-\ M7_\ A2W?_P TU?CY^V*FF2_'&^O+&661K_P+\,[K4M/UF\T/6/'/A_6(_!FF MZ?J6@?%7Q!X>)-*G@AUC4K^&YN=+T741>Z18_+GEQ_ M\\T_[Y7_ KW,%]%G@',\)AP\E"=:$:DXJ:PD8U$I2 M:52*4*B7/#W9(^2SOBSC&EG&9TIYQA)SIX_%1E.EE^(HTYM5Y7E&E/-*TZ2E M:_LZE6I5A=PJSE44F?V1_P#!/7X_:%\6_B7X[T;2O%VN>(9M+\"VFJ2VVJ:M M-J$,$4GB*ULQ/'%)J^H".0NXB,@BC)0E2Y'RG]<*_E(_X($JJ_M&_&_:JK_Q M9+2^@ _YJ!I?H*_JV8X5B.RD_D*_#./^"$JL82 MIIQIXZK&"Y9U:TDXQ23?.[O5)+1&1[_D?\*^-OVR_P!BCX:_MH>#-+T#Q?XF M^)WPY\7>%8]=C\#?%'X0_$'Q?\/?&WA6#Q7%I=IXMTO[1X:UC3-/\3>&O%-A MH^G6NN>%?%EGK.@74^GZ5J\5E;ZWHVE:C:?@M^U_^WSK7P[_ &H?COX$M]*U M.:'PG\1M5T:.6*[ODBD2WM-.D#(B>([5%7]\%?1!U/SC_P /+/$'_0&U M?_P-U#_YJJ[,-X0^*>-P^'QF$X6PM7"XNA2Q6%JO/<'!U<-B*<:M"HX2IMP< MZ4XS<&VXM\K=[GPV:?29R?*\TS++)\+YI5GEN88W 3JPQ-HU98/$SPTJD4L% M*T:CIRG%[_='XG?\ !&O]FOQ_K7P0U_PY\5?VN/@SJ/[/?AWQGH_P MTG^$?[17BC3)],\0_$OQAXI\=?$[XK7VH>-=-\>:OJ?QM^)7B3QEKM[X\^,$ M^HKX\\3K=?9]0UAX T;:WQS_ ."3?P]_: \5_"OQIXP_:V_X* :1KWP6T;PC M;?#:X\&_M0:CX=C\,>,/"OPWUKX4W/Q:L(U\'WFSXL^,?!_B;Q/9^.?&:ND_ MB*X\1ZU<26=L+Z2(?DG\'/VL_''Q?T;Q;KNGV7CB"T\)ZMX6T6XM/"OP[^)' MQ6UR\O/%-EXGU&"6/1/!'BYN].L;5);FY"CGOA?^ MVIXM^*?C77/"6DG4=/A\/>&_&?B_4-3N=+\::IJEQH'@B W.HIH?@70=?U#Q M;KWB6[MS'):>$["W.HP(M_/J-Q9V6CZG>0\L,XU92IR4HPHNI-MJ/*IOE5P^DCA:D,NG#@O-''-9U*>7_P#" MCAE+$2I5?856X/#J="$*JG%U,3&C3M'G4W#WC^A#Q;_P3_\ V9OBKX2\5>#_ M -H/P3%^U)8>(/%7C+Q9H-]^U!9Z!\=]8^%=UXZ\+>&?"NNZ5\&M1^(/A[5V M^%_AWR/"FFZO8Z+X6BL[2R\0R7NKQAIIT2'V#]F7]F_X1?LB? ?X7_LX_ OP MK9>$/AC\)O"6D^$O#>FVEEIUM>7RZ=:QQW_B3Q'*/$VHZGKVJ/-J%_<2O\ R]_%/]N;Q;\+?%@\+WL5]K!N/#_AKQ19 M7L,/BK0+O^RO%>DPZQIMOK?AGQ)K]CXA\*^(;:VF$>K^'-:M4OM/E\J427-G M=V=U/YS_ ,/+/$'_ $!M7_\ W4/_FJKKH>#_BKB:-+$4.%<).C6IPJTY_V] MA(\T)Q4HMQG1C.+L]8SC&47I))W2X\1]*#*L+7JX;$<(9M3K4*DJ56'UN,^6 MI"2C-*=/!3A-)J5I0E*$DDXRDFF_[0,Y]?R(_F*;)_JY/]QO_037\]'_ 2P M_;"U3X\?M(Z[X+O=.O[6*U^$WB?Q LMSSY MI\WLJ/NR]IHN3INS_,0_X+,_\I1_VUO^RM:?_P"JV\ U^9-?IM_P69_Y2C_M MK?\ 96M/_P#5;> :_,GKTK_5C@;_ )(G@W_LE.'/_5/@SXK,?^1ACO\ L,Q7 M_I^845[3=_LX_'RQ^'NC?%B[^#_Q A^'/B%O#_\ 8OBP:#-/8ZA%XMU.31?" M-[%86TD^NPZ5XOUF)]($:W>:1;:)XLU4+IOAO4=4O988)<[XI_ GXR?!&XT MBU^+OPU\5_#V;7UU/^QO^$CLK>.'4)M#N(;37M/AN["[O[*/6O#UWC"C3Q>'G5G6PT8S MQ-*%.-1SE5P\91E7IQBYT8R3J**:9S.E52_#WQWIO@70/B?J/@_Q'I_PZ\5>(]<\(^&/&U]I5U:>&O$? MB;PQ96.H>(]%T+5)TCAU:]T*SU*PEU;[!Y]O8O=1VT\Z7BRV\7'5U4ZM.JI2 MI5(5%&=2E)TYQFHU*4W3JTY.+:4ZPZFUTZ MS_!_X=7C&5H-0AB)$ERZKLC4; H(+9)_,/\ X:K\=_\ 0#$?^ ^L?\ RUK[ M"_X+D_\ *5C]L'_L:_A[_P"J4^&5?D]7]J\ Y?@Y\"\%SE0BY2X2X#JU\3F>/Q%>K+VO-4K5L55J5:DK54 MKSG)R=DE=NR2T/I__AJOQW_T _"7_@/K'_RUH_X:K\=_] /PE_X#ZQ_\M:^8 M**^M_L[!?\^(??+_ #_J[\K>9_Q#_@W_ *)_ _\ E;_Y;Y?GW9]/_P##5?CO M_H!^$O\ P'UC_P"6M'_#5?CO_H!^$O\ P'UC_P"6M?,%%']G8+_GQ#[Y?Y_U M=^5C_B'_ ;_ -$_@?\ RM_\M\OS[L_I'_X( ?'?Q3X^_P""DG@GP[JVE^'[ M6SF^#_QINVFT^+44N1)9Z1H3QJIN;^>+8Q<[\QEB -K*GXK_,4M(>GXK_,4 ?Y?W[>/Q_^)NC?MP?MBZ38:II<=EIG M[4/QWT^S230--FD2UL_B7XDMX$>61-\KK&BAI'RSD%F.2:^4/^&D?BQ_T&-( M_P#";TO_ .(KT?\ X*#?\GY?MJ?]G7?M _\ JTO$U?(!S@[<;L';N!*[L';N M"D,5W8W!2&(R 0<$?Z[<.X/"/A_(I/#4&WD^6-MTH7;>"P[;>G=(_FO&$<+ M5<;BZE3AW)9U*F*KSG.66X24ISE5E*4I-T6W*4KN3;NVVWN>ZR?M%?%28*LN MHZ),-V467PMI$H#],H'B8!^0,J-PSC/-+)^T3\5#O$VH:(1*5:19?"ND,)3& M,(9 $$AC 0L&V8&W&*^OO#/A7]F_78?^";_B#3?A!=Z9X9\7?%;XW^%_C- M:%/%'QL\;?%K3_A9XA^%,^HZMX@\+^$["TU#7H0->\106/P]^'?AVQ&E>#6C MT<2ZSK2:GXBU#P_]I;PCH>J>#?@Y\9/ANO@F3P!\0K/XH>&[$>"OV=X?V>M5 MMO$/PGU/PS'XSU;Q!X,TKQO\2]%\1>']OC/0;CPYX[T_Q5):Q6_]J^$_$5AH MNN^';Z&?FPN:Y;B,7AL)+*ZF$>(J8ZA">(P\7!8C XS-L+.C[7#+$X95)?V' MB\3&$\13DZ'LW%2JN=."GP'PI"$I_P"KV03Y8TYM1RW!7<*E/#S4K3HPFX_[ M13@VH/WG.]HV;\R7]HWXKQ(JIJ>CQ1@814\,:5'&!G.$58PH&23A1C)-+_PT MC\6/^@QI'_A-Z7_\17UG\2/ WPWU_P#9,^*GB.P^$/PW^&_Q>^!_Q&^!F@^) M_ GAKP5\8_!/Q5^#'ACQ4OB[P=K8^-_C7XJ7[:3\#"^DI^:M=N55\OS6GB:D,N^KSPN+>$K4\12H\_M/J^%QD M)Q=.4XSIU*&*H3A5BW3K)^VPU3$82IA\57FMP/PI1<$^'@FFI4Y)QM>+O&:C-2A'^LC_@V/\ BMXT\??M7?M%Z=XFOK&ZM;']GC1K MVW2UTJSL'2X?XH:/;EFDME5I%\IF&QB5#88*>9PIPC""R_)+1A%1 M2OEN'OHK+7J?M' V P66\/8?"9?A@_M[?M;:-JOB>.UU+3?C5X@M;VV.FZQ*8+A M--T5FC,D.GR0O@.IW1R.IS@'(-?$_P#PO_X2?]#=%_X*M<_^5E(Q=:M.,%++IR4(RFU%2E*7*E>3=V_V3^&O[7/[./AG3-:T3 MQM=^.M;T[4->\+>)[.7X??$'Q5\.+M-2\*-J)M;'6+.7P?XH\/ZO8W!U%YK3 M6AH]KXQ\)WL)N_#.M0)>W]G-ZGHO_!1+X'6'Q(\:_%6XBUS3/&WQ2'Q4_P"$ MX\1>!O$^L>%==\-7'C_Q;IGB/1M7^">KS>!M6OOA]KV@Z;97_A3Q!J>IR^(K MKQKH6O:W&;KP[/J%Q,WYF^*_@'\*O"GPP_9E^)$WQRFUC2_C%XX^(OA3XK:M MX=^'FLZAHOPF7P#9_"/6-3M?#-EJ5SH.O_$_7M%T;XGF#7S#%X=\/W?BK2IM M"\,ZGJ&DVTGBF_M?M7?LWZ/^S_X?^#GBW2X_BYH=O\7/#7CSQ)%X!^-OA_P5 MI/Q$T?1O!?B"TT;2?%B7?PZUS7?"&H^%_B%;W4]UX?M6N+'Q'HE]HFM6&LVM MYI[Z)KVJ\<\HX4S'%T(5*F9SKYS4S'!48UI9CAX5JN7>VH8^A&E4A2ITH+^S M)U*L8TX49RP^$KU+U*^"G6ZZ'A3EV"H0C0S3-J=/!.A5@U_8$ZD'4G[6A4=7 M^QI5:LXO%5(0G.U_<^._\+_\ A)_T-T7_ (*M<_\ E97FWQ9_9.\$^ O#_P BZWX:\.:?\.-4L_B)JWA#PIXB@^%>LZ=K%UXIDNOA9XW M\?\ A#P[J[^,=.@A\;V5WJ_B/P^FAPZ5%I6H?"=>MDF6Y'B,!3CE-7%K!X54 M:%.,U*#C3GA<-C,.X_6*/M)TZV#Q6&Q%*=Y7IUXQDXU(3IP\['^#F18C%5L3 MC;BY-R6(O\,8JW;0_H7PNX=P7#'"T< MKP%7%5L.LPQF(4\7.E.MSUO9SNM;MG^8A_P69_Y2C_ +:W M_96M/_\ 5;> :_,@XPG W_)$\&_]DIPY_ZI\&?,9C_R,,=_V&8K_P!/S/U( M\$_$;P7^SYX$\-_$[X;_ +3WPM^(?[0?C*R^ 4_Q3\0>+H_B_P"(/$GPZ\ _ M"[XB_#CQSX8^ OP^^'NJ?#S3M.\"+SXA^)]8^)&C:?+X;\#Q_#7 MX+V.DV+W'BS7J7QX\7_LR^(/ACX8_9[^%/BGX/>";36?VA/B[^TIXJ\?>'-1 M_:*\>>!]#GN_A._AOP]X9N->^)'PZ\/_ !$;7_B-J>FQV&F^$]'\$7^E?#]5 M\*1>/OB'XMU6\U[Q!H/YBY/3)QZ9I,GU-3#A/#1Q4,:\QS*6)AB*V)]HIX6E M"I4>'^K8.-:A2PL,/6I972LLOHSI.E1:?-":K8E5T\9-P]G[.ER!_BQJ' MC_1/A=?ZY\6-3\5^&/AA??!?P!X!\/?#?0!J'PSA\#:9K/AS7]*UV6^\*Z9X MKM_#=I;"[UBUUW4[R_87/P2>">_N.E+D],G'IFDKV\NRZ&6TZ]*G6J585\7B M,6HSA0@J4L34=6I3IJA1HQ]FIN3CSJ=35\TY;F%6JZKBW&*<80A[KD[J"44W MSRD[V2O:R[)'] /_ ;3_P#*2V/_ +-P^,W_ *>/AK7^A*_W&_W6_D:_SVO^ M#:?_ )26Q_\ 9N'QF_\ 3Q\-:_T)7^XW^ZW\C7\ ?2>_Y.7#_LG,J_\ 3^// MTOA#_D4R_P"PNM_Z12/\SK_@N3_RE8_;!_[&OX>_^J4^&5?D\.O/([CIFOUA M_P""Y/\ RE8_;!_[&OX>_P#JE/AE7Y/5_'M6M_''QW^%7Q M6^+/BS3_ !;I&A_%/QEX(F^&EUHOB+P_IWB)+?2O#7@V\OM=^(&A?"]+"SLK MWQEX)\)P>,M7:]U._N4L?E3Q+^U)\>?&/P]T7X5^*O'D.O\ @/PYX*TOX<>' M=%U/P'\+KB[\/^!=&N1>:9X7T+Q1_P (*OC/1]+MKP/>$:=XCMKJZO)[N[O; MFZN;Z]EN..\+_&?XH^"_^$'_ .$7\::II"_#74_'.L^!(X[?1[R#PQJGQ+TJ MST3QY>Z?:ZGIE_;23>)]*T^QLM0^WPWL<<=I!)IZ65Q&)ZRHY1Q'3QM#&?VC M0A0H9GF&,EEM4JXNA1J M5*&%H1:G\^/&CWO@*+X MI_"KQO\ ;_A*;FV\*^"K/5?%/B'P9HYN_AIX6AL;?3OA_XPT;XF>,K[QJ-) MU3\M6&UF4'(5B ?7!QG\:]?U+]H'XTZO\,=.^#.I?$CQ#=_#'2]-T#1+7PFZ M:1%%)H'A.\FU'PGX;U/7+;2H/%>O>%O"FHSR:CX7\*^(/$&J^'/#M^8[S1M* MLKFWM98/'J]?),!F6 CCEF&,^MJOC9U<*GB,3BI4L-[*E3BZE7%1BZ=>K*$J MM?#X:$,#2J2D\+3A";BL:]2E4]G[.'(XTTI^[&"<[MNRC>\8WM&+]?T2'RHT^Q:;:>%9[)M2N-8UW5[BWT^ZL[""?4=2N[F[ MEALK2UM(WE9+>WAB"QKRG_#@G_@EW_T;M9?^%'XD_P#EG7]U95]*+@? 97EN M!JY'Q9*K@\!@\)4E3PF3.$IX?#TJ,Y0V':O9ZV;5^K/\^S6/VI_VG/$'A[1?"6M?'WXP MZEX8\-WVBZGX;T*?QUKR:=X=U+PWN>-?$ M.I:CJ/PY\2*R^(O 5U<75[(7\'>(/,D;7/#:JFDZO++-<:A:W-Q-+*_^AI_P MX)_X)=_]&[67_A1^)/\ Y9T?\."?^"7?_1NUE_X4?B3_ .6=.G])GPQI6=+A M'B"DU[1_N\HX=AK6<'6?NYTM:KA%U'O4<(<]^56'PEF[WQN%>V]?%/X?AWH? M9UMVN[6NS_/"\7?&[XU_$#PMH7@;QW\6?B9XT\&>&'M)?#OA7Q5XU\2:_P"' M]'ET^P;2M.FLM+U/4+FU$^FZ6[Z7I=Q-'-/I>F.^G:=):V+O;MY;L?\ NM_W MR?\ "O\ 2/\ ^'!/_!+O_HW:R_\ "C\2?_+.C_AP3_P2[_Z-VLO_ H_$G_R MSKIH?2E\/,-#V>'X;XJP]-RE-TZ&7Y%2@YS:6*P4G9*\JN(;LM$KO#O1+1+H?SX_\&KJL/VN_VEL@C_C&W1.H(_YJ MOHOK7]T4G^KD_P!QO_037Y]_LS_\$Q?V2_V.?%?B+QO^S/X*N_A-XJ\6>'H? M"GB+6=&OH]7GU3P];ZI#K4.F30^*K77[.**/5+>&[$MM;07)= C3F(M&?M(^ M%M>8%3\1O%Q!!!']G> >01@C_D2O2OY6\6.-,MX]XTQG$F58;'87!8G"Y=0A M1S&&'IXJ,\)A*6'JN4,-B<51493IN5-JM)N+7,HNZ/L\DP%7+\=]FS_,=_P""M2L?^"F/[<)"L1_PT'XGY /_ $!_ M#OM7YWE'(( =200&"Y*DC 8 @J2IY 8%21A@1D'_ $S?BC_P18_X)\?&KXB^ M,_BU\4?@RGC#XB_$+7KGQ/XS\47VM:G9WFO:[>1007.HW-KI$^G:9!++%:P( M8[&QM;<",%(5)8MP7_#@G_@EW_T;M9?^%'XD_P#EG7],9!])W@C*LBR3*Z^2 M<5U*^691EF7UJE'"9.Z4ZN"P6'PU6=)SSNG-TY3I3E3R\/)/?W?@UM U,V5]9\WXK_:*LO$OA3PW\-K M/X"_"#PS\)?!]A\8KCPS\,M*G^*NHZ-I?Q!^->A:%H'B+XLOXA\2_$?6O&=_ MXQT&U\*^%I?!^EW>O-X&TR3P_9KJOA773=ZO-J']^_\ PX)_X)=_]&[67_A1 M^)/_ )9T?\."?^"7?_1NUE_X4?B3_P"6=%/Z2/AC3E"<>'.->>%:OB(2E/"5 M'"OBO;^WK0]IQ//EJR>+QCA.-I498O$RHNG+$XAU!\*9NTT\5E]G&,6ESJ\8 M*"C%\N#5X_NZ=UM+D@I74(I?P*_$']J[QO\ $7P;XI\.ZAX,\ :+XJ^)>G_# MC2?C1\6-!L?$\7Q ^,FF?"=--/@FT\7)J/B;4?!^D,M]H?AW7?&%WX(\+>&; MKX@^)?#6@:[XJEN[JRF6[^6MC_W6_P"^3_A7^D?_ ,."?^"7?_1NUE_X4?B3 M_P"6='_#@G_@EW_T;M9?^%'XD_\ EG77@_I/^'&7TI4<'PWQ;0I2FIRA#"9. MU>-*C0@ESY_)QA2P]"EAZ%*+5.AAJ-##T84Z-*G3C%3A'-:K4IXK!2:5DW4K M]6Y/;#*[E*4IRD]93E*?%#]G'X?W'PL\?:AX9U'P;>>) M-'U$ZK=3^&=6O])U/4=):V\40:[IRPW5_H>DW+S)9)=H]E&L5PD;S)+]R'PO MKQ!!^(WBX@@@C^SO /0]?^9*K^8?%[CC+/$'C"?$.4X;'X3!RRW X/V.94\- M3Q*JX5554ERX7%8NE[.7M%R/VW,[/FC'2_U^1Y?6RS K"UYTIU/;5*G-2-OB5X_U2/6_&'BO4-9U&RO-*ZF(RK)2^7_4^]?P\S#_4S,O^@C _^#,1_P#,Q_FX;'_NM_WR?\*-C_W6_P"^ M3_A7^D?_ ,."?^"7?_1NUE_X4?B3_P"6='_#@G_@EW_T;M9?^%'XD_\ EG1_ MQ-;P'_T(N+__ CR7R_ZGWK^'F'^IF9?]!&!_P#!F(_^9C^7#_@VH5A_P4MC M)4@?\,X?&;D@C_F,?#6O]"1_N-_NM_(U^;W[/'_!*#]B[]D_XB#XL_L\?#F; MX8?$0>'M7\*CQ1I.I2:I=CP_KTVG3ZOIGV7Q-%KFF>5>RZ3ISR2_8?M*&U00 MSQ*\HD^[SX7UX@@_$;Q=@C!_XEW@'H?^Y*K^6O&'CK*_$/BZ/$&487,,)A%E M."P#I9E3PU+$^UPU3$SG-1PN*QE+V;5>*@_;$5:_P!CD675LKP3PU>= M*:BYN'+.,$E><(._NN_NVVU9_FV_\ !\@$ MC_DBGPRK\G]C_P!UO^^3_A7^F]\9_P#@CA^P5^T-\3O%GQE^,_PD_P"$\^)W MCFZL+WQ9XMU'6+ZPO=9NM,T?3?#]A-/::$^E:3 UMH^D:=8HMGI]LC1VJ22* M\[RRR>8?\."?^"7?_1NUE_X4?B3_ .6=?T3PQ])G@K).&N'LFQ62\55<3E&1 MY3E>(J8?"Y1*A4KX# 8;"5IT95,ZI5)4IU*4Y4W4I4YN#BYTX2O%?+8OA+,, M1B\57A7P:A6Q%:M!2G74E&I4E.*DEAY)22DKI-J][-K4_P W#8_]UO\ OD_X M4;'_ +K?]\G_ K_ $C_ /AP3_P2[_Z-VLO_ H_$G_RSH_X<$_\$N_^C=K+ M_P */Q)_\LZ]S_B:W@/_ *$7%_\ X1Y+Y?\ 4^]?P\SG_P!3,R_Z",#_ .#, M1_\ ,Q_FX;'_ +K?]\G_ HV/_=;_OD_X5_I'_\ #@G_ ()=_P#1NUE_X4?B M3_Y9T?\ #@G_ ()=_P#1NUE_X4?B3_Y9T?\ $UO ?_0BXO\ _"/)?+_J?>OX M>8?ZF9E_T$8'_P &8C_YF/Y2/^#I53HN#O[MK-:FU1117Y0>T%%% M% !1110 4444 %> _%S]ISX-?!'6+#PYX[\0ZR?$M_X:UCQL?#/@OP'\0/B? MXETSP)X>NK6QUWQ]XA\/?#/PMXNUGPSX#TF^O;:QO?&7B"RTWP\E_)]@BU": M^22V3WZOS'^.7BSQ!^R#^T=\9?VM?$GPV\4?$SX/?$[X!?L__#*XUSP1?>#A MKWPO\:?"/XG_ !>:PTOQ;!XV\4>#]/T/X8>/S\>M+OI?B"NJOX;^'^I^'/$N MM?$J?0/##6>N1 'TCXZ_;4_9J^'L&B7FM?$F+5M/USX8V'QN35? 7A?QK\4= M'T;X*:J+AM*^,GB[5_AKX;\6:;X)^$^J)9ZA-IGQ%\6W6C>$]1M])UNZL=4N M+70=;GT[M]/_ &DO@;J6H_%73H/B3X"[=+=OQRL?#/QZ^#/ M[*7P _8[\-_"/XO>*O#_ (L_9STF+X^_M3?LX>'? WQ02W\'^*];\8:E>? # MX ZGJ'C7P]=7'B.QTGQCXCTWPK\6O%&E'P)\/O!E]IWB+P;X;\3^+_$BZ5X6 M_6G5]"^&OPK^#-IJ_A_]GW7?$FD:7H_PBC@^&/A/P/H7B7XA2VG@6?PU9_#Z MSN-*UO5H(M3U;X7Q66F7EG<:AX@NKWPXV@O?Z5>3WUE;M* */VN/@%+\&_AG M\>;#QK=ZS\./C.=!B^$EUH/@SQWKOBKXDWWB?3=1UG0]'\%_#C2?#-Y\1=?U MV]T;1]8UM]#LO"KZK8:)H^KZUJEK8Z5I.HWEKZG\,_BCX%^,'A6+QE\/M<&N M:&^IZUH=T9M.U;0]7T;Q!X;U2ZT/Q'X:\2^&_$-AI/B3POXG\/:Q97>EZ]X; M\1:3I>MZ/?P26NH6$$@ /XY?"CP5\6+[]BO]EW3]1^ _[5WPO^.?[)GBS2I; M*_T30/@O+XVT2]U[P'\2/"?BSQ-H?@_QYXNU[P5\8_ =[X;\:7'A+QAX8CU' M3_%3+K9\0>#9D\1>&[24?.M$TKQ)I'@SPAHL/C2;P03X"T[Q/K6F> K;Q;J_AGP+N\)^#9_ M$0\(Z3<7RZ'-J%T ?=-%%% !7A/Q9_:2^$7P5U?1?#OCC6]=E\4>(-&USQ/I MOA'P/X"^(/Q3\8MX2\,3Z=;>)?&5WX1^&/A?Q?XCTSP9X?NM7TNSU?Q9J6F6 MF@6>H:EI^F-?OJ5[:VJ?#YO"UYXR^%?B3X5?&'XD^*+&[UG2?%WB?P;8Q_#KXA6GQLC M&M>,+75I=.\ ZAX ;7?'[Z-X,FD\1:0 ?0GB[]MC]F?P;IOA;6+OXE1>)-,\ M7_#)?C9I-[\-?"WC;XM06_P7=(GC^,'B!OA?X;\7GPI\*Y1*1!\0?$ZZ1X7N M6MM02UU*=]+U067=Z+^TC\#?$&J?$+2M*^)?AJ;_ (57X+^'OQ%\=ZU<73Z? MX/T/P)\5-)U[7? 7BX>.=1BM?!NI>'_$&C^&M:U&+5-)UR^M+.ULUEU&6T%U M9^?^.V@:7^T%\$?V6?@=^S;X$^$?Q/UT?%'X5^+_ !3\:?VH_P!FO0/A]\7K M?P!X0^)OQ0^(GCV/X#? _4+KQMX =!M[; MQMHVA^-=:UFS\&P_JROA/X6_"KX :/=>'?V??$&N^'?#WP_^#VB67PGTKP9H MOBKXFS>&_A\-#M/AYX7U#2]?UL_#.-HKN%=4\27LVB7FFZEJ6GWUQJ"" M6Y +5K^U[^SUJ'P5\"_M!:9X^.K_ N^)]_H^D_#;5-(\*^-=5\0_$#6O$&I M7^E:)H/@OP!I_ANY^(/B7Q!JMWI6IO9:%I/A:ZU:2PTZ_P!5:TCTJRN[V'TO MX6_%SP%\9= OO$?@'5[K4+72->U+PKX@TW6- \1>$?%/A7Q3HZ6LNI^&?%_@ MWQAI6A>+/"?B"SMK_3[Z32/$.C:=>OINI:9JL$4VF:GI]Y<_B1X>^%WQP^)_ M[%'P'^#_ (B_9]_:2^'5Q\'_ (_KXV^+EYHT7@?P7^T=I/AX:W\9_'GA/QG^ MROXME^(.M/\=P^'=?^.'B+QG\+]<^-][X7U;]I;Q;X.\1^$O! M$NHZ]^T1K_@[4M6T77_&D/C>V\4^'?!NH3WJ^)+;X-:!\-=$\566GZUH\]I& M ?H!1110 $XZ^H'KU.!T]S^'4\5\U6W[7/P'U#P;H'C;2?%>JZW8>)_B%X[^ M$VA:%HG@;QYJWCW4/B;\,9O&\/Q"\"1_#>Q\-S^/(_$_@\_#CQK-KNE7'AZ& M>QM-"GOG!L[FPGN_I4@$$$9!X(/0CT-?GU\.OV5=,$_M^_M$?M 0^$]3M/# M/C'X/_"34O"$\NJP3>"[?XV^+-0^('A;]HCQ9X9\*B9DT/QYXP^'7PK_ &8] M'\=>)4M+9]=TO0-*C@N)+N_\5R7P!?T7_@I/^RUKWA/QMXWLKSXW0^'?A_X^ MT/X2^(;G5/V5_P!IG1KR3XM^(OB-HWPETWX4^']'U7X3V>K^+/B0/B%X@TGP MY?\ @WPO8ZOKFE3W?VS4K2UTV"YO(O5+']LO]GB\\*^*/%MSXTU30+?P-XY^ M%GPV\<^'/%O@#XB>#_B'X)\9?&SQ+X2\(_"O2_%_PP\4>%-)^(7ARW\<:[XX M\-0Z#KNJ^&K?P[>6%]-K2:N=%TS5K^Q_-W6O@1\=?!_[.?QF8?"#QIXF\00? M\%BM%_:LTGP7X4_X1S4_%GBGX(Z%^W1\-?B[<^*O#=C=>(M.T^\DN/ &@ZIK MUEH]YJNG:K<1VQM#:1WLD=N_V)\&/ GBCXN_M&?&C]I/XB_!K5OACX%\6?"? M]G_X0^"? GQ2MO"UQX\\77GP:\??%;XM2_$OQ;X7T/5O%.E>&;31?$_Q+TK1 M/AKIVJZO)XML[WPUXA\2WECHUMJ'AX3 'T_8?'_X.ZK\:]8_9VTOQ[HNI_&? MP[X(3XB^(? NG?:[[4= $2ZSIN@P:AKMY:VTND:/>76HZQIGV30M1U&VU^Z ML+ZWU>#2WTB1+YN/\!?M;_ +XF>,['P+X-\;7.I:MKEQXNM/!^JW7A#QOHO@ M?XC7?@&ZN+3QM;?"KXD:YX;TWX??%6X\*S6=ZVN0_#SQ-XDDLK;3]3OR)-/T MS4+NU^0YM=\1Z/\ \%$?#_B+P]^RK\=].^'D7PP^)GPB\2_$S1OA]X,L/ .I M?$7XA_&3X->*%^(%W>6OC:WUG4_#=UH'@K4KS7O&4WA^34&33K6"YM[BX:UM MJ\8^$'[,?QC'QE_9=\#V^A?M">"_@;^Q[\8_'OQ&\-Z3\6M;^"EQX#\*>&5^ M%GQD^$W@CP'\,O%'PVDG^('QIAU>T^+$%QX9U7XD0Z>OPZ^&>CZCI'C-M1^) M\VF2@ _;2BD P .N !GZ4M 2!R>G^?T]3T'4\5\XV_[67P)O?"=IXPT[QA= MZK97_P 6O%WP(L]%TKPCXRU+QO@3>-O^$FT/_A" M/%&K75DVA*K^%]*?Q?;2S^%KFRU>Y^CNO6OSW\+_ ++5IH?_ 4.^+?[04/A M75H/!_B/X#_#O4]$GEUB.?P./VA]:UGQO\/_ (N>/-(\)RW$@TOXH:[\#?A_ M\ _!'B3QC#9VTFI>#-%TS1X+EI+GQ"+L T=(_P""E/[+.M>%_B5XRM[WXW67 MA[X1^*M%^'_CN\UO]E?]IK0)M,^)7B+QOX)^'6C?"^PT_6OA/8ZCXA^)=]XO M^(O@S2D\">';75/$R)KD&HRZ='IEM?7EMZ9#^VM^SD?"'CKQGJ?C/6?#%G\, M-<^&_AWXC>'?&GPY^)?@OXB^!]3^+^NZ+X:^&?\ PD_PN\4^$-(^(FE:7XUU MG7K&U\/^(9O#)\.ZA'%JMY#JS66@Z[/IWYS^,/@!\=M"_9T_;6AM_A-XN\1^ M(/$W_!57X:_M,^"O"'AM_#M]XF\;_!_P;^TK^R5\1=7\1>&;2Z\06%A/,WA7 MX;^,KZQTG4]3TK4KN31WM5MDN+BTCG^MOA1X \2_&W]IOXG?M)?$/X,:[\-/ MAUJ'P+^%?P/$>"?BWIWA2;QSX_O?!_Q.\<_%W4_&OB?PKHVO>*[#P[X?\(: MOXBT/1OAS9ZW?#Q-/KC>.=>DTC1-,?P]>:T ?5UO\>_A!>?&RY_9SLO'>C7W MQJL/ 5_\3M3\ 6/VN]U;1_!.G:SX:T";6-33M)U:_L] M;U:SU$:KI>FW>E6]U>P\7X7_ &N/@+XR\<6/@#P]XNU2\U36/%7BOP)X;U^; MP%\1-.^&_C#QSX%_X2+_ (3'P7X(^+.I^$[/X8>-?%GAS_A$?%8U3P_X7\7: MMJ43^%_$\<4$\GAS7$T_Y3\0>)]?T'_@H)X%\1>&OV4OCPG@?3OAM\;?A7XW M^*'AOX=^"[;P/K/C_P"+WQ(_95UC1?'MWJ$/CBRUS6M"M_#'PHUN'Q'XPN- MGU+3X/#]A8O;70&GP5\?? 7]EC]I'P?\=_@;XGG$_&O3?&?AK]H;XG?$KXX M>#?&'BKP3J?_ 3O\'>'?BC%\1%\;>,_V4? EKXKU+QIX2\?74NL07'PGU#3 M-+M_$5E<_$3XGO\ %30] B\>^*3:@'] %%(N=J[L;L#=CIG'./;/3VI: "BB MB@ HHHH **** "BBB@ J"ZM;:^MKBSO+>&[M+N&6VNK6YBCGM[BWGC:*>">" M57BFAFB=XIHI4:.6-VCD5D9E,]% %2TL+*PM+2PL;.UL[&QMH+*RL[6WAM[6 MSL[6)8;:UM;>%$AM[:WA1(H((42**-5CC144 6B 1@@$>A (XZ<=.*6B@!H1 M " J@'J H /U&.:=110 4444 %13P0W4,MM2" M 03G.2._//UH & .@ P!^ I:* &[$SNV+G.<[1G/KG&<^]+@ D@ $]3CD MXX&?7 I:* "BBB@ H_S_ )_,T44 )M7!&!@\D8&"?4CO0 , = !@#\!2T M4 -V)G=M7=G.=HSD=#G&"<#)'H3UI:* "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D! end GRAPHIC 24 chart-2558ff03f0675fad9fd.jpg begin 644 chart-2558ff03f0675fad9fd.jpg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end GRAPHIC 25 chart-7726c3b84e715ea7a5c.jpg begin 644 chart-7726c3b84e715ea7a5c.jpg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end GRAPHIC 26 chart-95052c11230d5ce8b52.jpg begin 644 chart-95052c11230d5ce8b52.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" #( 1T# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "@G')HI&&1C&>1WQT(.1UY'4>X'(ZT ?'7@G]O_ /8^^(O[2'B; M]DSP9\>? NN_'?PM!>_;?!EGJ$FW4M7T6Z\0VGBWPEX9UZ6&/P]XL\;^ V\+ MZS-X^\&^'-4U/Q%X.MK.YGURPM%T_5QIGF7PR_X*N?L(?&2W^(5[\,_C'KWB M[3?AA\-/%7Q@\6ZSI_P,_:'BT(?#KP5>Z=8>(?$7AG7;_P"$UGH_CU;>YU6P M6PTKP'?>)=/A9\:/V(O$/@CQMXB_;0\1W_B;]GF[UW0KW]HKX6_%/ MXB?$WQKX/\?6'A/P9H/@O3?A%K'C?XYV?C72_$'@G7O 9\:=U_P3K_9G_:V^ M#_[1'P$T[1OA3^U[^S5^SG$?V9_&'PD_:/$?M/_MH^'OVJ_AS\5_&VEP?# MC0_V?K;]E_0?#OQ UW3/">F?##2M"\4/??$C3/A)^SC!X@\'7>F^&]6^&K>( M9KR'20#]5?V8O^"@7[)O[8OB/QGX0_9Z^)FI>,_$_P /M$T#Q)XOT+6?A=\8 M/AKJ6CZ#XIU'6=(\/:LUK\5/A_X(>]L=7U/P]KME9SZ:+Q)+C2-10[3:3;/8 MM9_:+^"7A_X[^#/V9-7^(WA^T^/7Q!\ ^*?BCX2^%^^\N/$VJ?#[P7J-CI'B M'Q9)%:VD]IIFCVNJ:A%86D^KW=@VLW5OJ<.B1ZB^C:N+'X5_8TTO]H/X6?!C MXH?M!?&[X$_$;Q'^TS^T[^UWXV\0>./ASINN^ K[Q?\ #[X,WGQRO/@U\ K% M=6U7Q=:^&K?X=_!C]F?1_"'Q"U7P[H^O76I,^H^/-9T[1=1^(/BK6++4/@?P M9^P__P %*_!7_!6'X#?M,^-[K]F'XE_#[5]3_;1UGXK?%[PQX<^*FE>*_#_P M_P#B--\!=#^&GPIURU\0^.Y+.+4_"OPZ\"Z7X/\ @9;>$-"E\#:+)X?^+7BW MXB07_C/XD-K>K@'])E%(,X&<9P,XZ9[XSSCTI: "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KM>6B M,5>ZMU92596GB5E8=006!!'<$9%6*_@3_;5NKI?VP?VHU6ZN55?V@/BRJJMQ M,%51XUU? 50^% [ #@ 5^N>$?A9_Q%/,\WR[^W/[#_LO 4<;[;^S?[2] MO[7$*A[/D^O8'V7+?GY^>I?X>5;G\\_2&\>?^(#9'P_G/^J_^M/]NYKB,M^K M_P!M?V+]55#"_676]K_9.:^WY_X?L_9TN7XE.7PG]\7VVRZ_;+7G_IXB_P#B M_P!?IZ"D%[8C.+NT&>3B>'D^I^?FO\X+[7=_\_=U_P"!,W_Q='VN[_Y^[K_P M)F_^+K]X_P")0/\ JX'_ )J__P",)_)W_%1A?]&B?3_FNU_=O_S1W^+^K'^C M[]LL,8^U6F,YQY\.,YSG&[&<\_7FE^VV.0?M=ID9P?M$.1GK@[^^!GZ5_G _ M:[O_ )^[K_P)F_\ BZ/M=W_S]W7_ ($S?_%T?\2@?]7 _P#-7_\ QA#_ (J, M+_HT3Z?\UVO[M_\ FCO\7]6/](!+NUD8)'+]=#*\\S*0/ /B\X*ERK<@?>!]J_N03[B M_P"ZO\A7\_\ BUX:?\0NSW+\D_MG^V_KV44\T^L_V?\ V=[+VF,QF$]A['Z[ MCN>WU3VGM/:0O[3EY%R\TOZ]^CYXW?\ $=N$\UXG_P!6O]6/[+X@KY%]2_M? M^V?;NCEV6X]XKZQ_9F5>SYGF'LO8^PG;V7/[5\_+!U%%%?E9^]!1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M5_ 9^VO_ ,GA?M2_]G _%K_U-=7K^_.OX#/VU_\ D\+]J7_LX'XM?^IKJ]?U MO]$?_DIN+?\ L183_P!6$3_//]H=_P D/X?_ /949C_ZJSYBHHHK^\3_ ";" MBBB@#[W_ ."7O_)_'[-?_8WZ]_Z@'C"O[ET^XO\ NK_(5_#1_P $O?\ D_C] MFO\ [&_7O_4 \85_/K6 M#QK#\2/$OA.ZMOV&_P""KGQ(_:*\'_\ !/#]I+XU_LL?%K1?A)JWPX_9Q^-G MQ@U/QK-X$G\7>/UTOP9\'_$GC3PYI?P[MM2U33_#W@OQ)JVO6>D0ZQXK\6Z+ MXIF\,^&FU631?##>*&TS5M) /U%HKD? %Y?:AX&\'7VI33W&H7GA7PY=7L]R M"+B>\N-%L)KJ:;,W Z#KJ "BBB@ HK\FW6J^#;GXG^%_&OCWQ$OQ%\8:EI'A_2?#_ ,-/$6A^&EU7XB:_X6M[?A_V MTO\ @JWXJ^"'[.'P6\;_ (TOX&_%WXM>.O"O[./Q=^)6J^&/&^J_$?]G_X? M? WXN_&KX:?!>Z\;>'/&FFQ^!M:\='XD>-/'5UX5_9^2YL/"USXGMO#_ (Z^ M(&MZ7;Z1\,?$V@78!^XU%?*/[7FO?'SPU\'M1\<_ +XN_LZ?!>?P(^K^-?B9 MX\_:5^&7CSXJ?#W2OA3X7\,Z_J_B:\72_A[\6_A!J>C:AIHM+'6Y_$-]X@U' M2[;1-/U6WDT:6>\M;VRY[_@G_P#$O]HGXS_LK_#/XN?M-P?#VU^('Q,M+_QS MH=O\./!'BKX<:7_PJSQ+>R:G\);[7? _C+QW\2-=\)^--=\ 3Z)XC\6^&+OQ M;J%^U+_P!G _%K_P!375Z_K?Z(_P#R4W%O M_8BPG_JPB?YY_M#O^2'\/_\ LJ,Q_P#56?,5%%%?WB?Y-A1110!][_\ !+W_ M )/X_9K_ .QOU[_U /&%?W+I]Q?]U?Y"OX:/^"7O_)_'[-?_ &-^O?\ J >, M*_N73[B_[J_R%?Y_?2T_Y+OA_P#[)+#_ /JXS@_U\_9\?\FHXK_[.!CO_6>X M;'4445_+!_>@4444 %%%% !112$D=!GD#\"0"?P'- "U\I?M+_L/_LH?MA-X M*F_:1^!7P[^+5[\/=;L=:\)ZGXL\.:;?ZMI:VNI6FJ7N@?VI);F_NO!WB*XL M;5/%?@VZN)?#?B:&"!-7TZY:""2+^1?Q#_P=%_MD:1X@\0:1!^SI^S3+!I'B M#7M(@EEG^+0EE@TK6+W3H99=GBM4\V2*V2278JIYC-L4+@#(_P"(IS]LW_HW M#]F7_O\ _%W_ .:ROW>/T;_%.<8RCEF6-22:_P"%K+UH^6W_ "]_O+\3YO\ MUKR;;VU;>W^[U?+^[Y_@^Q_83\3?V)_V2OC+KW@+Q+\4/V=_A+XUUKX9Z3I/ MA[P;=ZWX,TF6/2_#&@7B:EX?\(SV,$-OINL>#?#^J(NK:!X/UVSU3POH>K9U M/2M(L[YFN#YS\7?^":'["OQYTCQ#H/Q;_9L^'_C?1O%GQ8\6_''Q-IFJCQ#% M9:_\5_'?A[P]X4\7^-=7@TW7K!+_ %;7_#OA3P]I&H)?\13G[9O\ T;A^S+_W_P#B[_\ -91_Q%.?MF_]&X?LR_\ ?_XN_P#S657_ M !+=XJ?]"O*^G_,[R_K;_I[_ 'E^(?ZUY-_S^K?^$]7R_N^?X/L?V?\ [/O[ M./P4_97^'%C\(_@!\/\ 1_AE\.=-U+5=7L/"FA3:K/IUKJ.MW"W>J7,3ZQJ. MJ7H:[N%61T-V8D("PQQH-M>VU_"G_P 13G[9O_1N'[,O_?\ ^+O_ ,UE?I-_ MP2B_X+E?M'_M\?M>:7^SU\2_@Y\%?!?A:^^&GQ"\:R:YX%E^(#^($U'PA_PC MWV"SC7Q%KVHZ:;.Z.L3B[+6QGS'#Y$B?/N\S.? 7Q'R'*K>BL^Q_4-12$X[9Y _,@9_#J?:OQ*\;?\%R/@%X'\9^+_ M 5J/P>^-5U?^#O%7B+PI>W5G'X"-G=7GAO6;W1;JYM//\613_99Y[&26W\^ M**;RF3S8T?K@:=*KBX8>>'@Z%.O*<*4I>WK44 MU.5.:7*Y/W7=+0\3C?Q*X&\-Z&7XGCCB/!<.T,TK5Z&7U<;#$SCB:V&A3G7A M#ZM0KM.G"K3E)S45:2LV]#[;_:__ &*M/_:L;P+K.F_'7X]_L^^.? 6JZ(]A MXP^"7CH:,FK>&K/XA^ _B%JOA[Q'X,\1:;XF^'^NWCZK\/\ 1K[PAXMU+PM< M>)_ 6NP)J&BZB^C7OB7PWXC^8?C7_P $,O\ @FS\=O@SX-^#OC#]GSPRDW@# MPE\,O ?A3XMQ:?I.M_&_3?!_PQ\;V?CJUT!_B1XPTSQ'J6H6?BV_'B#3/&\F MH07%SKFC^-_&<,,UA=:U]KM_&_\ A_A^SM_T1?XY_P#?OX>__-?1_P /\/V= MO^B+_'/_ +]_#W_YKZ^N_P"('^*W_1%YE_X.R_\ ^;#\[_XFC\ ?^CFY%_X* MS3R_ZE_G^#['WS\4_P!@_P "?%G]GG]IC]ES6_BC\9-(^#'[2/A+3?AS#X2\ M-:SX-TNQ^!/PPLOAUX4^&EW\-?@+ ? \]OX7\&ZSHOABXO\ 4]/\40^,[C^V M/%'B62RO+/3;G3],TW[8T[3[/2;"STS3X$M;#3[2VL;*VB&([>TLX([:V@C' M9(H(HXU'95%?A=_P_P /V=O^B+_'/_OW\/?_ )KZ/^'^'[.W_1%_CG_W[^'O M_P U]'_$#_%;_HB\R_\ !V7_ /S8'_$T?@#_ -'-R+_P5FGE_P!2_P _P?8_ M=VBORA_9@_X*V?!O]J;XU^%/@AX1^&7Q5\.Z]XMMO$=U9ZQXF3P<-%M4\->' M=3\1W2W9TGQ'J%_NN+;3);>W\FTE'VF6+S3'%OD7]7J^)XDX6X@X1QU/+.), MLKY5CJV%IXVGAL1*C.<\+5JUJ%.LG0JU8<(^ M(>55L[X+SS"Y_E6'QU7+*V-PD<1"E3Q]"AAL55PS6)HT)N<*&,PU1M0<+58V MDVFD44F1[_D?\*,CW_(_X5\^?7"T4F1[_D?\*,CW_(_X4 +129'O^1_PHS]? MR/\ A0 M?P&?MK_\GA?M2_\ 9P/Q:_\ 4UU>O[\Z_@._;71_^&POVI?D;_DX M'XM?PG_H==7]J_K?Z(__ "4W%O\ V(L)_P"K")_GG^T-_P"2'\/_ /LJ,P_] M59\P44[8_P#=;_OD_P"%&Q_[K?\ ?)_PK^\;KNOZ_P"'7WG^3=GV?]?\.OO& MT4[8_P#=;_OD_P"%&Q_[K?\ ?)_PHNNZ_K_AU]X6?9_U_P .OO/O7_@E[_R? MQ^S7_P!C?KW_ *@'C"O[ET^XO^ZO\A7\-7_!+U'_ .&^/V;#M; \7Z]D[3Q_ MQ0'C \\>@-?W*KPJY_NC^5?Y_?2T_P"2[X?_ .R2P_\ ZN,X/]?/V?/_ ":C MBO\ [.!COQX>X;L.HHHK^6#^] HHHH **** "N7U?P?H>N78OM034VN!#'!F MT\0^(M,A\N)G=/\ 1M+U6RM=X:1MTOD^:XVAW940+U%% 'YS3_\ !(S_ ()H MW4]Q=7/[$_[/<]S=7$]U [226>YNIGN+F>61IRTDL\\DDTLC$L\CL[$L MQ-1?\.A?^"9?_1D/[.__ (0%E_\ 'J_1ZBOH5Q;Q6E9<3<0I+1)9UF5DNW^\ MG+]1P7_0'A?_ GI?_('YP_\.A?^"9?_ $9#^SO_ .$!9?\ QZC_ (="_P#! M,O\ Z,A_9W_$"R_^/5^CU%'^MW%?_13\0_^'K,O_FD/J."_Z \+_P"$]+_Y M _.'_AT+_P $R_\ HR']G?\ \("R_P#CU>C_ K_ ."/?@Y^S M+\*OA=XV@TW4-&A\6> M#G\+>(8M)U;[/_:>FQZOH]]:WJV5_P#9+;[7;"41 M7'V>$R*QC3'VO165?B?B3%4:N'Q/$.>8C#UH2IUJ%?-L?5HU:$A)3AA S;-,JE4GE M>98_+I5E&-:6 QF(PDJL8-RA&H\/4IN:@VW%2NHMNUKN_#FN0Y'GL*-/.\FR MK.(8>4YX>&:Y=A,PA0G4454E1CBZ-:-*4U&*G*"BY**4FTK'Q1_P[D_8;_Z- M@^$G_A.?_=5'_#N3]AO_ *-@^$G_ (3G_P!U5]KT5Z7^M_%G_13\0_\ AZS+ MR_ZB?)'B_P#$/> ?^B(X0_\ $;R;_P"8O+\^[/BC_AW)^PW_ -&P?"3_ ,)S M_P"ZJ/\ AW)^PW_T;!$/_"<_P#NJOM>BC_6_BS_ **?B'_P]9EY?]1/D@_X MA[P#_P!$1PA_XC>3?_,7E^?=GRCX+_8;_9,^'/B.P\8> ?@3X#\&>*]+2\CT MWQ'X7LK[0];L$U"SGT^^2TU/3M0@N[=;RQN;BSN5BE436T\L,@:.1E/N3?#C MPL #Y>N_>7_FA!'%=Y36Z#_>3_ -#6O*QV8YAF=:.(S+'X MS,*\*<:,*^.Q5?%UHT8RE.-*-2O.I-4XRG.2@I**E.>$ MR7*\NRC"U*TL1/#99@L-@,/.O.%.G.O.CA:5*G*M*G2I0E4<7.4*<(N34(I? MYE/[8?[=/[;/@[]KC]J;PCX4_; _:?\ #OA?PK^T;\;_ WX;\/Z1\=_B9:: M5H6@:'\3/$^F:/H^F6B>)"EKI^F:=:VUE96Z$K#;011*<**^Q^U?_X?_P")W_S25A_MT?\ )[7[8O\ V=/^T'_ZMKQ=7RQ7^KF1<.Q^U?\ ^'_^)W_S24?\/#/V^/\ H]C] MJ_\ \/\ _$[_ .:2OCRBO5_U:X=_Z$.2_P#AKP7_ ,H\OS[LQ^M8K_H)Q'_@ M^KY?W_)'V'_P\,_;X_Z/8_:O_P##_P#Q._\ FDK]._\ @C7^UY^UG\9_^"DW M[-'PT^+'[4?[1GQ$^'_B?4/B5'XA\'>+?C9\2-8\/:RFF_!WQ_K.G+J.G7'B M3R;D6.K:?8ZC;"3*QWEI!+@E,'\ :_7?_@@]_P I7OV2_P#L)_%C_P!47\2Z M^1X_X?R&CP)QK6HY)E%*K2X3XBJ4JM/+<'"I3J0RC%RA.$XT5*$X2BI1E%J4 M9*Z:>IVY9B<1+,N]!_P SCXS_ /F@KYXUS_@G_P#L9^)M:U;Q'XB_9T^&>N:_KVI7NL:WK6JZ M//?ZIJVJZC<27=_J6HWUS>R7%Y?7MS+)<75U/(\T\TCR2.SL2?L)>@^@_E2U M_E]@,US/*IU*F69CCLNJ58J%6>!Q>(PDZD(RYHPJ2P]2FYQ4O>49-I/5*Y^G MYKD629[3I4<[R?*\XI4)NI0I9IE^$S"G1J2CRRJ4H8NC6C3G*/NRE!*3C[K; M6A\4?\.Y/V&_^C8/A)_X3G_W51_P[D_8;_Z-@^$G_A.?_=5?:]%>G_K?Q9_T M4_$/_AZS+R_ZB?)'B?\ $/> ?^B(X0_\1O)O_F+R_/NSXH_X=R?L-_\ 1L'P MD_\ "<_^ZJ/^'3?\ S%Y?GW9\D^%/V$/V0O OB'2_%O@SX _# MWPIXHT2:2YT?Q#X>TZ[TC6M+N);>:TEFL-2L;^&[M)9+6XGMW>"5&:":6)B4 MD8'Z8T3PUI7A[[3_ &8M\OVOR1-]MUG6=6X@\SRQ%_:^H7WV?'FON^S^5YGR M^9OV)MWJ*\K'9EF.:585\SQ^-S&M3IJC"MCL57Q=6%*,I35*%3$5*DXTU.IA\KP.%P%&I6<(4W6G2PM*E" M=5PITX.I*+FXPA%NT4D4445Q'IA1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !36Z#_ 'D_]#6G44 ?Y//[=-Q;C]MO]L4&YME(_:H_:$!# M7$*L"/BWXN!!!<$$'@@@$'@BOE?[3;?\_5K_ .!,'_QRO]?^Y\ ^!;F>:ZNO M!OA.>YN9I)[BXG\.:)-/<7$SM)+++++8M)--+(S.\CLTDCL69F8DF$?#GX?' M&/!'@XYZ8\+Z">GTT^O[(R_Z5N&P. P6"? ]:I]3PF&PKJ?ZQ0A[3ZO1ITG/ MD_L.7+SHY(_P"0?R0!DCJ*NZ?X)\':5=PZAI?A M3PUIU];ES;WMAH.D6=W"9(WB88*KA%7='^QJ7M51=9U'3]K3]HH*?AOJ'QYO?V8_&'[1/A/2/V??B_K%S\+_ (:?&S3O"_BJ^T+Q;H.MVVA? M%N[\'V<&A3_%'PK\.O$'P_?Q9X?L=+/CE\0/AG\5?$=Y\9/@3\:_"7[.NFZ7XR^+OPW.C_#K MX^_"KX'Q^.?%?B.R\4MJ4D'Q %M\-=?^)6JR>.O#?B&X;]KOC%\&/A3^T#\. M_$OPF^-7@#PK\3?ASXNL)M.\0>$/&.C6.N:/?P3121),MO?0S?8]1LS(;C2] M7L3;:KI%ZD5_I=Y:7L,4Z>?:]^RA\#=9G^%8L_ N@>&-$^$7AKQ_\/\ PYX+ M\+:#X>T?P!J'PG^*7AV#P[\0?@[X@\#PZ0WAF_\ ACXH73/#&MWWABWTZQA7 MQ!X-\,WT,R06U_9ZB ?@5^S]XC\7:GXH_:%\2_!K_@IQ\<6_8TTW]BKQ=H'Q M@_;Z_:0^+'A#QOX)U[]K"#QYX02Y_:1_9*\ _$N\CTCP)\.?A_X+'Q$TCQ5K M_A8:!^S'=^(_%7P\T;X9:3XTO?!&I:P_V-_P2_\ %_B*'QM^T]XOL?CA\:/% MG["_BS6/V?M"_9&U#]L3XTW/Q!^,WBWQUJEKXMT?XI_$/PU=?$>\'Q;\*_"# MXR:W<>!;3X.>"OB?<6_B/Q)X@T+Q9XG\#^#_ UX.\2>'[#4/N3PW_P34_X) MW>#H?%UOX2_82_8^\,P>/O"F\'^*%L/"4 M U[PQ+K?AGPYK#Z#J?VG3&U/0-%OS:_:=+LI(>F^'W[!'[#OPFM]3M?A=^QW M^R]\.K;6_%GP^\>ZS!X'^ WPP\+0ZMXX^$VNW7B?X6^,M2CT7PS9K?>*?AQX MDOKW7_ NOW(EU7PGK5WH31! M+>?6/&>E?#RP\1Z_+:Q0VKZ_J.J&VBCAV(OL/_#._P %++X@>*?C)X:^%?PT M$_'3Q;HEWH>J_'/P]\./ EO\6I[:XLDLHFN_&UQX=N=8U9;1(+%H[/6KC4- M/N5TZPM=0M+RQMH[8;WP<^$O@SX%?#'P7$/A_9W-GX3\"Z';Z+I9O[DW^K7 M[K)+=ZEKFO:FZ1RZOXD\1ZO=:AXA\2ZU<(+K6=?U34M4N?W]W)0!Z91110 4 M444 %%%% !1110 4444 %%%% !1110 4444 M%_ OP^\+:_XU\9^)=2,JZ=X?\*^%M*N]<\0:W?&&.:86FEZ58W=[<>3#+,T< M++#%+*R1M\HZ'^W-X%^UW%C\3/A?\7GP9\8_'_P1IWQ)\%:7>:W\2?A MA\/+31KWQU<^$O#?PV\3?$'Q''XZ\*6GB7PS=:O\'_$FE:!\5UMO$.G/9>$; MZ6#6X=']G_:<^"=M^TA^SO\ &[X!W>NS>%XOC%\+/''PY7Q-;V::C-X:O^TI\5/VI-!\3 M_$;X1^"_#'QG_8U^!GQEU7X3>"M+\8_$)/AG^TO\3?C#X*^'OA]_&6E_&2[^ M$<>@_#7X0Z/K>"&T#4H/%OQ@L_$NK:MK6J>$(/#G@O0M2^(0!]$:U^W[X M4\(:;XU'Q ^!/[0_@3QMX0\!>#?BG9?"_6/"_@;6/''C3X<^,OB'I?PT7Q-X M3'@OXB>*_#$MQX1\1ZUI:?$#PGK?B31?&?A"UO;.YO= FBO]/>Z]GN_VI?AK M!^T?X?\ V7K:T\8ZI\0M:\-^-?$5YJ]AX9NAX!\-R>"=,\#:Y<^%];\87LEE M83>--8T'X@Z#X@TKPWX>37;NTT(OJ7B9O#T5_H"ZS\\?L8?#;]H+2O'GQ*^* MO[4_POT.T^-OQ!\/>'=/USXH:7\6M&\<:#::'H&HW][HOP7^%'@/3O!N@2?# MCX2^$+_6]=UW3I-1U;Q!XM\9Z[J=UXC^(&NZWKTMD='A^-6A?M4ZK^V/\%/B M5X(^ /@[Q-\+?@WH7Q6\*MXGU+]H'3/"VOZ_;?&33OA3'>:Q9>#9OAKK+V$? MA*X\&ZS#<:?<^(A/K)-E=V4$N)(( #TS1OVX?AUK'BO1M//@GXFZ9\-/%/Q MBU?X >#OCWJ>F>$H/A3XJ^+^B>(?$?@VY\*:?'#XSN/B/86.I>._"NM> O"_ MC37OA]I'@GQ9XRLXM'T'7[M=7\.7>M_:(((!!R" 0?4'D&OR)U3]A3QGXL^. MOAMKCP1X7\ ?!_P9^U;I_P"U3%J6B_M!?%CQIX;U77?#OCKQ-\3-'F\"?LU> M(?#]CX"^$OQ*\<>-M0TN\^+GBNSU_6/#8M[CQ[J?@;28_$GQ(U"]T+]=E&U5 M7.=J@9QC.!C.!P,^E "USGC'Q?X9^'_A+Q1X[\::U8>&_!_@OP[K?BSQ7XBU M6;[/I>@>&O#>F76LZ[K6I7!#"WT_2M*LKN_O9R"(K:WD?!Q@]'7C_P"T)\(K M']H#X#?&KX$ZIK%UX>TWXS_"?XB?"J_U^QMH[R]T.T^(/A'5_"D^LV=G/)%; MWEUI2:L;^"TN9%MKN2W6VN"(97( /G[PQ^WE\-]1N])B\??#KXT_!:R\8_"C MQE\;?AAJ/Q+\&Z6TGQ1^'7P]T+2O$_C.Y\,^'? /B;QUXQTKQIH?AK6=.\2O M$O&WAWPM\5-0T&YDN])$7]UH_B:PT'%US]O[PQX.T+QQ?_ ! ^ 7[2'@3Q M/X4^#+_'_0OAOKG@_P &7_CKXC?#"S\1:%X6U[4?!UEX5^(7B32+7Q+X0UCQ M3X6@\9?#_P 9ZSX4\;^'$\2Z++>:(Z7;&+YQT^U_:3^(_P"TO$[;XM_"_PE MX;^)G[%/P@^)_P 0/AI:>'O$?CD_#C]JOXK>/_A#8_"FWUS0?B5-\*E\._!W MX9:*-;\6:+KOA?Q'+XN^*NE^)?$6E:E'X;N_"/A.SUKQ_P"S?L;?#?\ :,M? MB;X]^+_[6?PI\.V7QI\;>$-.T:^^).A?&+2O'7A/PQX?TW6_[4L/@A\'? -I MX)\.WW@GX9:;J&H:CXCOO$>O:MKGCGXB>(;:VUOQYJ5U);>%]$\'@'T?KW[5 M7PST/]HCP3^S+]D\8ZK\0/&6G>+]0GU32O#%W)X$$3>$O"VG^,UT+Q5XQO) M++3(O%7B/PW?_P!LZ!X9T(Z]JXTJUEU77K;0=.N]'N=4\X@_;I^'-SXYO?#U MMX&^)L_@+3OV@T_96O?C4EGX('P_@^/,?AO\ ZX^ M(9F\1:Q\?]-\&:UXEA^*OP]TOPO?FP\(S?#77WT\^&-16\:9+O7P=6@MDN;1 MHGNEMX/F:?\ X)Y?%.3]HJ+XS0^%/A]9_'A?VGH_C-+^W%9_%KQ;;^+;OX.K M\0(XY/@W??LW1>!U\#7M[+^S0@_9>V77B"71XM("_&"/Q4OC9!H9 /VX!# $ M=" 1]#R*6D ( !__ %>@SWP.,GDXR:6@#P_XN?'OPE\$_$?P9T;QOIOB&WT? MXU_$NS^$&B^-K*VTZ;PCX6^(/B'2=2OO .B^.+R?4[;4-$@^).LZ6_@/P9JE MOINH:???$35?"WA&]FL-0\5:&;OY/\>_\%&-)\+VWPIUWP?^S=\=_BSX&^.7 MQ@N_@=$/'G@O5_@%I.@>-O',5YXYMM-N=,MOB#\:?!FO1^"_$]O\.O%&L^% M/'%SI$7A[7] CTG6+*[:RUS3'G]__;8^!EQ^TO\ LD?M&? C3]-T+5->^*'P M?\<>%O",7B6\N],T>R\=7>BW$_@/7)]7T^&XU+0KCPWXSMM"\0Z;XATN%]6\ M/ZGI=GK6E;=0L;9UX/\ :-_9MU_Q[%^Q7I'PNT_PEH'AK]G#]J3X2?%'6=%E MN)-#T_3/AI\/?AI\3_!3:1X2L;'3;R":]L9/%6@6ND:*PTVR&FP7&+VW^RQ0 M3@')ZQ_P4(\/>&;_ ...H>*/@!\>='^%7[-/BO0O!7QY^-,,?PDU_P '?#36 M[[X;?"WXK>)[[5_#7AWXK:E\5-3$?#;PE\6-"O?'_C/PUX US0M&M]*\3:Q M:S:CX*_VP/AMX*L?C]J/B'P]\2H;?X!^,?#7@.6+2_!=WXDU'XM M>)?%WPG\%_%O0+#X*Z3X=GU/4?&IOM,\;V?ALRSV^C06?B?1_$2ZC-9>'])E M\0-\9^,?V=OVMM5O?^"@WP1\+^"OA7IWPQ_;;^*.LZ]8_'G6_BA>76H_#WP! M\0?V9O@5^S_X[D/P;L_ ,E_X@\?:':_#[QCJ7@W3)_&=CX4U74KOPU-K^L6. MFG5+1?O/XV:7\0/#WP.U'P=\%?AWIWQ'URX\/+X$L/#NN_$.U^'EM;:%=>'K MO0?[6NO%%_X;\4I/+ID*6/F69TEY[_S))$D3R3%( <;??M@>$IO"?[/>M>"O MA[\3?B1XM_::\"1_$OX9?#'PK9^#;/Q;_P (-;>$?"_C'Q'XE\5:QXN\:>&/ MAWX5TGPG:^-_!VC:S=ZEXVV77BCQ3H.@>'EUN\U*$CV;X-?%[PE\!?%&L^!_'O@CQ3I)FN5TWQ1X)\:^' M=>\+>(+.&[O;./5-*N'T^_U#3I+2^N?S6T?]G3]H36/V9_V5/#_B[X#^#],^ M,G[,FA:+\.+6\\%_M:>-_AUXUM_#VE_"KPGX%U7Q3\.?C'\/OA]:)'I7C34= M'^Q^,?A?XX\-RZ1J?A_3].\1)?+XN\/>&;>/[3_8U_9\N_V9_@9IWPZU:;09 M?$>J>.?BQ\4O%L7A6XUZ]\+:;XM^,WQ/\6?%/Q#HGAS4O%+OXGUS1] U#Q7) MHEKXH\3>7XE\8-I\OB[Q%!;:WKE_;0@'U17B7QB^/'A/X':C$(O'&F^(H_# M_P 6_BKX<^#5IXTTVRM+OPQX,\;>.H+^U^',?CRX>_@O]%T?X@^,[?2?AAX: MUBTL-2MF^(WC#P7H&I"PA\00ZA#[;7SA^V#\&)?VB/V5?VB_@=9Z;H6J:Q\5 M/@K\2O!/AJW\23SV6C6_C#7?"6JVG@S5;K4[2"YO]%DT/Q:VBZW9:_ID#ZOX M?O\ 3K76](*:GI]I(H!\Y_$O_@HMHO@>P\$^(_"O[.OQS^+G@3XD_'1/V=/ M/CSP-JOP(TO0?%?Q+N?%VJ>!-,&DVWQ#^,O@K79?!^L^*=!U^PTCQNVE+X>U M"TTF36K:Z?1;_2;^_P!'Q!_P4&T;PCJGQPD\3_L[_'W3O '[,DG@VU_:&^*% MB/@[XD\._"J\\3?"7X;_ !JUU]1\,^'/BWJ/Q+\4:-\-_ GQ.TC4?'OB'P%X M(\4Z79KI'B2YT&3Q#IVE&\GT?CS^R[XG\9?#;]C3P#\-+'PAH6G?L[_M(?LL M_$?6=)EOI])TG3_A]\%&GBUO3/"Z6VF7OVJ^MK(V\&@Z9-'8P7:1[9KZT(W- MX;X^^ 7[6UUXT_X* > /A_X)^%EOX$_;4\3:)>Z%\@:C^R=\ M%?V=/%UYJ'P%=&C\9Z=X>\437'ANRUO7/#5G+ MJMU;@'V!JG[7_P ,]$E^.!U/1?B"MA\$]9^&N@#4])\(W7BF#XM:O\6/!'A[ MQKX+T_X*67A2;6M8\?76HCQ+I_AKR8-.L2GB1+J$L-(@;6*QM0_;0\"+\,OV M8/'_ (;\"_$KQEKW[8&CZ#JWP.^%6C6G@O3_ ![K9UOX0ZI\<+FRUN]\4^-O M#WP\\.3^&O &C:GJ7B*6^\=-;+<64MCH4FO7,D"2^D^+-'\7_"GX(Z1X.^"G MP^@^)VH^%O#OAKP+H?A?7OB#8_#]KCP[I6D6_AU;^]\77OAKQ):B]L=,L[>: M6,Z)*;^?>$$0PA_+R7]C[]HKXH_LK_L>?"#XY_ [X7^*?#7[*_A[PKX3\=_L MYW7QYO+;PW\;M9^'GPG\&^$OAK\6]$^+GAOX;6FL^&+[P#XLTWQ/>Z9\/-3T MS3-/UZU\0+K>M^)(KSP[I&AZ@ ?K+\%OC%X:^.7@@^-O#.GZ]HL=GXJ\=^!- M?\/>*+2PM/$/ACQM\,_&>N?#_P <^&-7&D:GKFA7-[X?\6>'=6TN34/#^NZY MH&HBW6]T?5]0L9XKAO6:^/?V&_@+XU_9M^!%E\*?%NI:4FE:/XQ\+M)^"WPEUCQ!<7_ ,/O@O8?$#Q!I>B^)?B':_#_ $:3[#%XL\1Z7;:I M*MS_ &,)-0T_1;#5+[["H **** "BBB@ HHHH **** "DQSG^IQ^73/OC/;I M2T4 %%%% !1110 4444 )@9S_GMU'3/ YZXXI:** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ..**** "BBB@ HHHH _]D! end GRAPHIC 27 chart-54231418cc365d0a16b.jpg begin 644 chart-54231418cc365d0a16b.jpg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end GRAPHIC 28 chart-065336660b54572793d.jpg begin 644 chart-065336660b54572793d.jpg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end GRAPHIC 29 chart-a7367b5baf6e53a3ad3.jpg begin 644 chart-a7367b5baf6e53a3ad3.jpg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end GRAPHIC 30 chart-c52813e437f858f69d3.jpg begin 644 chart-c52813e437f858f69d3.jpg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end GRAPHIC 31 chart-d70f8b3d9fa957a6bcb.jpg begin 644 chart-d70f8b3d9fa957a6bcb.jpg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end GRAPHIC 32 chart-ec1239fbf0ab58a8a54.jpg begin 644 chart-ec1239fbf0ab58a8a54.jpg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end GRAPHIC 33 chart-ffce7e2bcdc6598da5f.jpg begin 644 chart-ffce7e2bcdc6598da5f.jpg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end GRAPHIC 34 kanumaimagea08.jpg begin 644 kanumaimagea08.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ 4%!0@%" P'!PP,"0D)# T,# P,#0T-#0T-#0T-#0T- M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T!!0@("@<*# <'# T, M"@P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T- M#0T-#0T-#?_$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( +$!3 ,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H HMJEFEP+-IX10 <#. M<'L.E;SPTX3]E'WFU?0Z*F%G"HJ4?>;5U8ZNPU6UU*W6[MI%>%^C9P/0CGN# MQ7+*$H/DDK-=#DE"4)^((_$*W30A7C>2,C MJ4P %;<-H(4 C!YR>+Y*+P_+?1I/U\C53LN6QY_K_B_P 7>$=3EDG3 MS[%G.S*DQE.VPC[O'<@UWTZ&&KTTHOEG;776_H;1C"2MLSO/#7QATG6ML5WF MQG/&'.4)]GP.I[;?QK@JX&I2UA[R\M_N(E1E'5:H]8AF2=0\3!U/0JAS[$E( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * *=_80:G"UM=(LL3]589'U^H['M5QDX/FB[- M%QDZ;4H.S78Y76/ >G:IIPTJ-?LT2.)%,8'#8(R1QG(/.:Z(8B<)^U>KM;4Z MJ>)G3G[5^\VK._8Y3Q#\.[A-&@TK1I2!!(7<,Q4R;LDY[<$Y )P,<5U4L2O: M.I56ZLO(ZZ6*C[656LMU96Z%?Q!/XA$:+9061,\J;A<2!?-(Q@J,$$XY(SC MMZ8ITU2KU)N6B^RMBJ2HXBK-S]U/X5>WJ8.D_&>X@/EZK;[L<%D^5O?*G:!6 ML\$GK3E]YM/ 1>M*5O)[?>=1KNNV?C>P$&EW*Q3JVXQ2'RRW3C+84D=L$C-8 M4H2PT[U(W7=:V.%49X>5YQNNZU(-5U;4_"MA9VDR"Z60-YI8;Q@;=L><$'() M^O;-7"%.O.%]1G6(AM,NWCCD9D7$2M(BN M%*#I]X D+751JUX*_P <4VK-ZZ.VC*ASQ5UJK_,YV"+Q-\/")K&3[;I^>#&W MFQ$=_DY*''4E1]:Z&Z&+]V:Y9^>C^_K]YK^[JZ2TE]S/7O"/Q7T[Q#B"Z(L[ MKIM<_(Q_V6Z#_@6*\FM@YTM8>]'RW7R.:IAY0UCJCU4$,,CD'H17F;'&+0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 A (P1D>E&P;'(>)/#FBW%M)I3=H2?IN> V'A?3?$R2W7AVY9/LQR\=QA"/1@_R M@+[D=U.- ME_VE.0![]_6M54IUO=DK2\]'\F8+M<^'#4IRI/EFK,\B<)4WRR5F:]9&84 % !0 4 % !0 4 % !0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!6O+2* M_A>VG&Z.52C#U!'-5&3@U*.C6J'L>4:C$[6VTBYT[17:&:Y=7WR,3G8*/ +&&97-N>"K R0./I]/7 M%>JW0Q.L;7^Z2.I_'ST9VQK5*>C]]?T;NI\R%Q_,<>H%8/V=71Z2^YHW? ML<3Y2^YHW8Y-'\7CC&G7Y[?\LW;Z\8)]2.*E2J4/[T/Q1QSI5*&WO0_%%>%/%=IXKM1<6YVR*,21G[R-W^H]#W&.AXKPZU&5"7++;H^YY%:C*A+EEM MT?<+GRR?=>=H_W0*[X8J<=)ZK\3IC5<='JCR62SU_X>RE M'#/;'J"/,@=?<'@) ]!6?/*GI+5=^IU1JSI:3]Z/?JO7N;-IK]SI/_$JUV(SVP./G M&64'^*-^I'H0<>E/E3_>4G9^6WS0Y48U5[2B[2\MOFNAH/8OH_\ Q,=*<7-C M)PZ]< _PR)_B./KBM%-5?W=1DZG#K%K'>6YW1RJ&'MZ@^A'I7@S@ZC;W<0 MN62Y9K[U_P V98X( -1L1YMA=N[AT;TSD[6QQD<5M&3FO9RTFM4_R M?^9Q6E%\DM)+6+_)G0?#>)]/>^TU3NMH6AFMV]4G\W/Y&(#%88I\W)4VD[J7 MK&W^88IJ:IU=I--2]8V_S/4:\X\P* "@ H * "@#A_B+K%QH.B3WMFWES1E MK8S]Y@#_ #KMPM.-6K&$U=.Y<%=V9\]^%/B5XAU?5;:RDN,I-*%8;>W)/\J] M^MA:%.G*:CJEIJ=#A%)NQ]=.ZQJ78A54$DG@ #DD^U?)[Z(Y#Y2\:?%[4?[3 MDAT67R[6+Y <9WL"V>]?4X? P4$ZRO)Z^GD=48*VNYZ[\,YM=U*V. MHZW*=DHQ#$5P<<'>?3(Z#T)SBO*Q:HPE[.@M5N[_ (&4[+2)ZE7EF04 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '+^)/" M=IXCBVS ),!\DH'S#V/J/:G>QM3J.F]-NQXLJWG@V=M/OT\ZRFX93RC#LRYZ M,.HZ&HYG!W1ZJM52G!VDMNZ\F:,6WP[,)$/GZ7>C!]E/4$=G3G'J0#FO1C/V MJ4HZ21;_ '\>5Z5(_P!?WWA3Q.G*NNK?S MM_D>?B$X')%'\ MK@%>LO)/\C6G\1\^_"*U^T>([<_\\MTGY8']:][&OEH2\[(Z)Z19ZS\8?B#] MBC;0].?]](,3NI^XO]P$=ST;T&1UKR\#A>9^WJ+1?"N[[F5./VG\CE?A9\,G MU5UU?54(M5.8HVX\TCN>^S^?/I75C,6J:=&D_>ZOM_P2ISMHMSZL51& J@*! MP . !["OECE%H Y+5_'6BZ&Q2ZNHPZ]45@SCZJI)'Y5UT\-5J:PB[=]D6HM[ M(X/4_CEHEHO^B++=-GH%,8'OEA@UW0RZK+X[17W_ )%JF^NAU?@;QN/&<$MT ML!MXX6VC)!).,GIZ#'YURXC#_5FH\UVU?T)E'ET.?U#XT:)82O!B5WC8J0$* M\@X/45T1R^K)*6B35]RE39V6K>---T.QCU"]D\M)T5XTZNP90V HY.,\G'%< M5/#SJS=."O9V;Z(A1;=D>8M\>],$FP6TQ3/W]R_GC&:]/^S9V^*-^QI[)]SU MOPYXELO%%L+NP?>F<,IX9&]&'4>WJ.1Q7E5:,Z$N2HK/IV9DTXZ,Q?%7Q!TW MPA*L%]O\R1=P"J3QTZ@$5M1PL\0G*%K+35V'&+EL2^$/&]IXR65[)'58" 2W M726,+W$O"1*6;'/ &3Q7+%.345N]"/(\G3X MTZ--.EO DTCR.J#Y2.6('<>]>J\OJQ3E)I)*^YM[-H[?Q1XOL?",,=QJ&]5F M8JNU2W(&2#@''XUQ4:$\0W&G;3N[&<8N6B,?PM\1M/\ %D\EO:*Z^4F\L_ P M.O88K:MA)X>*E.VKM9%2@X[F#KWQGT;1IFMX ]XZ'#&,@+GV8@AOP-;T\!5J M+FE:*\]_N*5-OR+/A?XN:5XDN%LRKVLTAP@D((8^@8 #)[#O45L#4HQY[J26 M]N@G3<=3I_%'C?3/"2 WTF)&&5B7ES[X&2![D8KFHX>I7_AK3JWLB8QM%>IHJ;]" M[X*^)L?C&::-+=K>.VC$C.S \'/I]*C$81X=1?-=MV22%*'*-;XASMTB.&E08]6%RDOO-_85-^5_<5V M\06"=9D_!A6BG%[-#]A4_E?W&7=>-M+M!S(6/HJD_P JM:[&JPM5]+>IYQXL M\=V6K6[6J6_F'^%V/*GU&,'\^*W5+GT;.^CA)0?,Y6\D>=6<,U\8H#*88RV1 MO)V<\'C/X9%8TY_5ING46C_I,[':GS.UWY;GOGP\@$6GM@ 8D*<#&=G?\=U= M%5W:]#Q,5\?RO]YWM&_'>X\K2(8O^>LW_H(!KV\M7[R3 M[1_,WI[GS/X>\0W7AJ=[JRVB5XFB#$9VAR,D2.1\[L\&0G@R9ZKGK65=35)K#V32_#R\Q2NE[I]UVXC M6-1#@1A1MV]-N.,>V*^(=[N^_4X27I2 ^8/BI\3IGG?1](RCH3ZY'O7TN#PB25:JKM_"NWF=,(6U9F>#?@]<^(85U#596@BD&43!:1P>Y M)(VCTZYK6OCHT7[.DKM;OHBI5.71'*?$_P )67@^]AM+ R,'BWN9&!.[/; & M!BNG"5IXB#G.VCLK%0;DKL]\^"MF+;P\7Q@S32-^&Q /Y&O#S!WK6[)+\S"I M\1\L^+%$>LWBCHMS*/R$;SXERB_U=VCL;=$AC M"\$A% VIG@#N6YR2>*\RO7C@E[.DESMMOROW,I25/1;E'XI_#FU$1PW>GL_ MDR,499#N(;&1@@#@@'M5X/%2Q#<*B5TKJPX2YM&:_P KR1+^YM<_NVB#8[! M@W7\ABLJS'' MX@"OG\M_B2_PG/2W/G'PQ>7ZROIVF_ZV_ A)&=VTGG!'3W^E?0U8PLJE3:&I MT.V[Z'T''\"["+3V\^61[[RRV]2 @?;G&W!)&>,Y&>N!TKP7F,W/W4E"^W6Q MS^T=]-CYB5Y-*N]T9P]O(0#TY1L?TKZ/2<;=&OS.G<]W$> [CXBRR:]KTCK M#,QV(G!;G^$G.U!VX.:\6OB5@TL/02NMV^G_ 3&4N3W8G&?%'P1;^#;R)+) MF:">/< _+*=Q!&1C/3.<#KBNO!XAXB+A5F22G"2W:?X6,:NZ)?BQ\27T/.D:6VVY8?O9!UC!&=J_P"T M0>O:E@L(JG[VJO=Z+O\ \ (0OJ]CR_P7\-+_ ,;YU"^E:&V9N'8%GD/?:"1Q M[Y_"O3Q&+AAOW<%>79:)&LIJ&B)/B?X"T[P9!;FS:1Y9F.XN01@ ] !QSCN: M6$Q$\2Y^ NW/U[GWKS)WJ>$Y)"6#@ ^IQ M_2O!6#=.[XL;';E=S"E\';OO3HOYG^@K>')'[<2_K7:$BL/!=DO,U MUO\ 553^I;^E=D:U..TK^A'UF;^&%O5_\ ECTS1M.YA@:X<=#*1P?4*!_6MO MK#>D3)SJSTE+E79&7XCLKG4H/MA58U@P%P-HQGH![=:QJIRCS=452:A+D6K9 MZCX4M_(TZ,X"F3YR!ZG _I74I>>/O"+^#]2>U&3 _P \+'NAYQGU7.T^XKT, M-66(@I_:6C7G_P $TC+F5SZ$^#7C,ZU9'2KILW-H/D)/+Q'I[DJ'M*L(=&_ MRU,HJ[2/BOP?IPU_6[:WG^=9IU,F?XE+ OGZC-?95Y>RI2E'2T=/T.V3LG8^ M^8T$2A%X50 !["OA=]3@/BKXO:JFI^()A$"8F<_B6_P *^A]V>%=,CT?2K6TB&T)"I/^\PW-_P"/ M,:^(K3=2I*;ZM_Y'"W=MGD7Q[G"Z=;0]VFW?]\J1_P"S5ZV6KWY/M']36ENS ME/@!;YOKN;^["JCZEQ73F3M""\V74V1Q_P 89_/\1S#_ )YJJ?ED_P!:[,"K M4(^;;_(NG\)]%?"&U%KX5D<\_B9-\5[Y;'P[ M<[CCSE\H#UWY%+!1YJ\?+7[A07O(^:?A';^?XCMC_P \RS?^.D?UKZ+&NU"7 MG9'3/2+/8?C[_)]HF-+=G$? G2$N]3FOG&?LL8"Y[- M(3@CW&P_G7;F,^6G&"^T]?1?\.74=E8^JKV00P22'HD;M^2DU\O%7:7FCF/S MTEB-YJ#HG)DG;'_ G/\ C7WR]R"?:*_([]D?H'I&GQZ39PV<(PD$:HN/0#%? M!SDYRXA+?F[C^E?19:O99Y/$&J;Y2=]Y<#.>QDDZ?09P*]]) M4H66T8_DCHV7H??VDV4>FV<-K$ J11JH Z=.?S.37PDY.GR.FFK*YZ-\"[46^B228YEN&; M\D1?Z5Y^8N]5+M%?J9U-SVJO&,0H K7<#3IM0[3G-<.*HRQ%/V<'9W3_ . : MTY*$KM7.??1Y!R\B@>Y:O(C@)4]92BOZ]#M]NGI%,H2Z;:1;^&/WE*2\LK+_41>:_JW*G\.1^E=L5&/PK[Q\DY?$[+R,C4$N=5V MI<$J92$CB'&,G&[:.@'(C&6C3:^=FB9^AL2>6BI_=4#\ABO@7J[GGGS%\?[LMB/(OBFK+ MXDO-W&9 1]-HKU<'_ A;L:P^%'T)\+O%FFC08H9IXX9+8%9%=@I !X//8CFO M!QE&?MG*,6U+56,)Q=]#R3XK>-O^$KF^RZ=E[&SY=QT=V_B)Z;> %]P3GFO6 MP>'^KKFJ:3ELNR_S-81Y=7N4_@FH/B 9[0N1]Q^*[K[%I%Y+TQ;R@?5D('ZFO(HQYJD(_P!Y?F8QW1\.^$8_M6MV MB'GS+A ?Q:OM*SY:4WVBSMEHF?H$.!7P9P'QO\;;O[1KYB_YX1(GYC?_ .S5 M]=E\>6C?NV_T.RGI$].^'&GL?!=PJ#YYC,1] JG_ !KSL5*V*C?9P7#_=AFCD(]D<,?Y5])-CI>NA]M7_ ,1=&T_31?BXCD)C M!2-&!=FQ]W'7@]?2OC8X6K*?L^5K75M:(XU!WM8^,/$&H76KWLFH7@*O'8<=2SY^NXU\KC_ .._ M1?DSG5A&2W3DDT;QHU)+FC%M= MTAG]K68_Y;1_]]"CZYA^E6'_ ($A^PJ_R2^XS+_4[*<;1<1CCL0?ZUQUL3AY MV_?05O.YT4Z56/\ R[E]UCF;B_TV+B21G/\ LC'ZG(_2N3ZWAX;2>G9: M(Z_P_H,MH_VR];?.PX!_A!_K^@]*]3#8>5-^UK.\W^!YM>NIKV5)6@OQ.NKU M3S@H * "@ H * "@#P;QW\*K_P 6ZK)J$<\21,(U16W;@%C16SA2.6#'KT-> M[AL9##TU3<6WK?YM_H;QFHJUCM_AUX.F\&64EK.Z2/))NRF<8Q[@5Q8JNL1) M2BFDE;4BH(P1^5<"TU70S/F/4?@3>7%S++;SPK&[L MR@[L@$YQPIZ5])',8**4HNZ6ITJHET/9/"7A>?2-&.C:DZ7"X9 5SCRVX Y M^[VKR*]95*OMJ2<=G\S*3N[K0\&USX&ZG#*6W8DIN8JZ@GH1M(XZ9!. M>M>Y3S"FXKVB:EUML;JHNNAU/@_X)M9SI=ZW(LGE$,L,>64DGH <^O M%QRP102OE02VX#Z!,?K54L?3I4 MXP:DVEKM;\QJHHI(];B\-W5MX;_L2.1&N!;M$LAR%R22"< D#GTKR75BZ_MF MGR\U[=3&_O7/'=!^">HZ;?0WD\T!6&17(4N2=ISQE!7L5WA<7##4W" M2;=[Z?\ #F\)J*L=9\-_!D_@NSEMKATD>67?E,X VA<<@>GI7+BZZQ$E**:2 M5M2)RYG='-_$KX6MXJE&HZ>ZQW07:Z/D*X'(.0#AN3VYXYXKHPF,5!>SJ)N. MZMNBH3Y='L>36/P3UZ60)*8H(\_,Q=NGL O/XXKU99A1BKQNWVM_P3;VB6QZ MS>_"A+/P_)I.F%6NYWC:2:3*[MIZO*CC7*LJM32"322Z?D8\_ MO7>QF^ /A3?^%-134+F:%@JE2J%CD'ZJO?%:8G&PK4W3C%[WNQRFFK(N_$?X M;:CXSOX[JWEACBBB$8#LP/4L> A'4^M1A<7##0<9)MMWTM_F$)J*L==\.?!\ MW@VP>TN'21WD+Y3.,8 Y ]^UPM65 M)9@H4N2%'S G. 3T![5A0FJ52-26R[$Q=G=GBGA7X,ZAHFIV^H7$T#);RK(5 M0L20#G R@KV:V/A4IRIQC)-JW3_,VE435D?2%?.G.?.GC#X0ZGXDU>XU%)H$ MCF92H9GW *BKR A';UKZ"AC:=&G&FXRNM]N_J=$9J*L>O>#/#K^&]*CTR=ED M9-VXKG:=P /4#^5>5B*JK5'4CHGL92=W='A_C#X)WU0Q\5%1K732M==;&T:BM9C?#/P-NFF636I46%3GRXR69O M8DA0H]QGZ4ZN8Q2M13OW>EANI;X3>\;_ DN_$&H++I[06]I'#'$JL6!4(H7 M "H1CCUKGP^-C1@U44G)MO[_ )DQFHK7<],\!>&)O"6G?8)Y%E(=B:RKU/:15M+&4GS.Z.UKB(.+N_"KSR-()/O$GG(ZG/O7P=;(9U*DZL M:J]Z3EJM5=WL>_#'QC%1<-DEH^Q2/@Z4_P#+0#\3_A2CD51;U(_0N1N(]AUIV= MKVT'9VO;3N24A!0 4 % $:S1NQC5E++U4$9'U'44[-:]!V:5[:$E(04 % !0 M 4 % !0 4 % !0 4 % !0 A(49/ % #(IDG7?$RNIZ%2"/S'%-IK1Z#:<=&K M,P=8\5Z9H+!+Z=8W/.W[S8/R*46]DR2.5)1E&##V(/\J5K>0FFM]!LL M\< S(RH/<@4)-[ DWHD$4\;ZM)Y?BNSW-M7R) M"A#_ '>?^)?J>M37^R5+?SQ_4]#2^MY&V)(A/H&%<'*UT9Y?)):M M/[BU4D$$MW#;\2.J'W(%4DWLBE%O9,E1U<;D((]0W)KT*G\&G\SU*W^[T?5_H=!H&B3:5/56OW\S?DO((?OR(OU8#^M8*+Z)G,HM[)_3P*1)3.H6RMM,J9]-P_P :KE>]F7R2 MWL_N+2.KC*$$>QS_ "J=B;6W(9+R&$[9'13Z%@#5*+>R8U%O9,F219!E"&'L M0?Y4K6%:V^A'+<16XS(ZI]2!0DWLAJ+>R'1RI*-T;!AZ@@_RH:MHQ--:/0DI M"$)"C)X ]: *G]H6V=OFQY]-P_QJ^5]F7R2[/[AFH.&M)2A!'EMR#['THCI) M>HX:27JCB/A?*%\/P-(V,M)RQ_VCZUUXI?O96\COQJ_?RMY?D97@RWM=0O\ M4;V\"2S?:#&I?! 157 /'?M6M=N$*<(72Y;Z=[LWQ+E"G2IT[IPF:#H.EZ"LMSI9S&ZY(63>@VY/RC)"DYYQ[ M5YU2I.I:-3=>5F>15JU*MH5=T^UGJ>(B[J+<9-6:: MZ7+7BK2;?7/$EG;78+1/ Y(!*Y^YU([5-*3IT)RCNI+]2:$Y4L-4G#=27ZG0 MW/PST9X\6\9MI5Y26-B&5NQXQG![5@L543]YW79['+'&UD_>?,NJ>QE:3XJN M;'1+R2\/F7.FL\>XGEP -A)/?KGZ5I.BI5(*&D9I.W;N;5,/&5:"AI&HD[=N MYDZ)I6AZE;I?Z[E:SG5@^2A%QBM%9;^?S- MJE2M3DZ>&@X0B[*RWMU;ZW+^B7-OH.M1Z=IEP)]/NT8B+?O\F09^[UP#QZ>E M143J4G4J1M.+WM:Z9G5C*M1=6K'EJ0:UM;F3[^9J>'O^1CU+Z+_,UG5_@T_F M95O]VH_,B\!R,UWJ@8D[;MP,]N!3Q&D:5OY?U'BE:%&W\GZLYOP'X2TWQ!:3 M7NHQF><74R;F8GY5(P,'ZFMJ]:=*2C3=ERIZ'1B<14H2C"D^5FAI>(M B M\#HNM:,6MTBD07$0)*21LP0_+TS\WIQUZU%.H\1^YK:W3Y7U32N11K/%MT*^ MK:?++JFE?QB:=E.&\HX^4$?CD=ZBE%4XSK25^5V2? MSBU.WM][; M6W?4\B<8U-'=+:SU?4\]T2'2?$D?]J>(+F.::9F,<+R86),X"[#P#QGI M[]Z[YNI1?LZ$6DMVEJWZGJ575H/V.%@XQ6\DM9/U)Q/8^%M3M3HDZO:7DABF MME?< 6!*NHZ+R ,\=<=ZFTJT)>VC:45=2M;Y$VGB*4_K$6IP7-&35F]5=/[S MVFO)/!/,/$\\^N:Q#X=BD:& Q&>Y*$AG3*@*".V6Y'3OVKT:25*FZ[5Y7M&_ M1]SUJ"C1I2Q+2,6_6[(/!'ART\ M1^&K6&]#E8Y)'78Y0YRPY(]B:JO4E2K2<+;+H5B:TJ&(FZ=KM):JYA>#O FF M:K)>K<"7%OA=Z+> M[.BU2T-UJ-OX2LY'@LH(/-GPQWO&-H5=W4\MSD^_:L(-1A+$R2G M)0IRQDTG-RM'31/6[L=!_P *TT'8$^SCCOD[OSZYK'ZU5_F.;Z[7_G^70H_" MO(TN9,DB.[F1*+QW\1/O"+_,]+K@/+"@ H * "@ H * " M@ H * "@ H 9+)Y2,Y!(4$X'4X&< >M-:Z#2N['FTOB_PSJN4OU1)!PRW$>Q MQ[98!ORKO5&M#^'>W]UW7X'J+#XFEK2NUWB[K\#)\'PPW&JW3:.)%TAH0F&W M>693NSY>XG@ C.#WY[5K6;C3BJMO:7^=M-S;$-QI05>WME*_2_+IO;YF+H\6 MF>#9)-*U^V4()&-OBGJGZ&]3VF)2JX M63O9*4$[-/T.NL-6\*7EW':V<44D[L NR+(!SP2PX ]S7+*%>$7*;:2[LXYT M\5"+E4Z"7[1*>$CC&YF8]!@9QD]^U8+"U&]5RKJWHDB1BZ5X5N;[0[R.['EW6I,\@4C!0'&P$'OUS]:UG54:L.76,++ MU[FU2O&%:#AK&FDK]^YAZ#JFA:= FGZ]:QVE[;J$;S(^) OR[PQX.[KQUSD5 MM4A5D^>A)R@]59[>1T5:=:.E;5Z,ZDE*"NN5'3BL-4JRC.FKKE2W-C7=>7QY&NC MZ,CS0R2(;B@J*,E4C.C)VT^80$4X"XSN/88SFML1'^'!-?"E M?INSIQ<=:---?"E>^F[-&?Q5X5U96^VB)7'WEFCV2#VR<-^M2J->'P7MY.Z, MXX?%4OX=[?W7=?Y&=X.LEU!]1CL?,32+B,Q0!]V-S+M9DW<[1EL8X_&KKRY5 M3<[>T3N[>NE[=33$R<%2=2WMHN\K6V3NKVZF/H4^D^&U.D^(;5(9HF81S/'E M94SD'=TS[YQV[&M:BJ5?WF'DVGND]4_0Z*L:M?\ ?86;<6M8IZQ?H=AI&J>& M+^]2VT^*-Y^2&2+A< G)8<#IQ7+.%>$6YMI=F_T.&I#$TX.55M1[-_H>D5P' MEGE_BB*;0-9A\1)&TMOY1@N=H)*)E2&P.V5Y/3MWKT:-JE-T&[2O>-^OD>M0 M<:U*6%;2E?FC?1-ZZ?B:C_$C1=@,$K3R/]R*-2TC$]!M&2#^'%9_5:BW5EW> MB,OJ59/WH\J[O1?><]\/"SZ+?.59"]S<-M88(RB<$5KB-*D$OY8_FS?%Z5J: M3O:,=O5FU\+%*>'X 1@AI.O^^:SQ7\67R,<=_'E;R_(K_#U2LNHY!&;Q\?\ M?*56)VI_X/U9IC/AI?X%^;(?$J2^'M:B\1+&TMLT1@N=H),:Y!#8';*\GIV[ MTZ5JM-T+VE>\;]?(=#EK4989M*=^:-]+[W7XFJ_Q'T;8#!(UQ(_W(HU+2,3T M&T9(_+BL_JM1?$N5=WHC'ZE67Q1Y5U;T7WF=\*26TN9F4H6O)CM88(R$ZBJQ M6DTE_*OU+QVE2*72$=OF>FUP'EA0 4 % !0 4 % !0 4 % !0 4 % %2;3[> MC;+7*@S*T]E!<_P"MC1\?WE!JE)QV M;1:E*/PMH?#;Q6XQ$BH/]D ?RI-M[B;;W9*%"G( !/4XYI"\ANQ4!V@#/7 Q MFF!YI\,K,?V9*)XQG[9.0'7G'R^HZ5W8E^^N5_96QZ>,E^\7*_L1V?J>E1PI M",1JJ#V '\JX;OJ>8VWN/(!&#R*0MBHFGVT;>8L2!O4*,U?,]KNQ?/)JS;MZ MEI45,X &>N!C-03[!R;W;+%22(R MAA@@$'L:-M@VV*L>GVT+;XXD5O4* :IR;T;9;G)Z-NWJ6514&% /8#%22*J MA!A0%'H!B@0BHJ?= &>N!B@8K*&&& (/8T;"VV*L6GVT#;XXD5O4*,U3DWHV MRW.3T;=O4LJBIPH"CV&*D@=0 4 % !0 4 % !0 4 % !0 4 % !0!E17MP]] M):M"5MXT5DGR,.QQE0,Y&,D<@=* -6@"GJ-X-.MI+I@6$*,Y ZD*,X% "Z?= MB_MX[E05$R*X!Z@,,X- %N@ H * "@ H * "@! O3B@!: "@ H * "@#,U: M[GLH?,M83A]/PH =0!PU_?ZCJ6JOI> MG2K:);0K++(45V8NS *H92 !CD]: .VC#*H#GT^/4+B\NQ/-O/RR* M%4AV P-G3@=U?-$>Y1O!5N"!SC'/I3 Z'PO MH[:;IL=VMQ<2E[92$D9"B_+GY0$4C';)- &9X7L'>PCUZYNKF:81O*8V=/*) M )QM" X_X%0!+HVAR^)K9=4U"YN%>XRZ1Q.$2-"3L &TDG;C))/- %6PCOIM M.U"VMKB5IK*Z80,Q4L0BJVQCM (.3GC- &M?^+?/T..\M<"ZO=L,2C^&9\*X M^L?S-_P&@#G]7U4VUU!HM[=200PVZR3R)CS99&+ KNQ@*".RYP>M $VB:Q': M:I#::=/-=VERK!UEY,3@95@P X(!!!SR1S0 WP]HK>)EN+J\N[H,MU/&JQNJ MJJI*RJ -AZ #J30!8L]?NM%M-2MY'-R^FNJPN^-S"3A0V !\I'7% &A!X.GN MH%N9[ZZ%\ZA]ZLHC5R,X";""H/&"22.](#+'B*[N]-MG9RL\>H):S,O ?:W) MQS@,I&??-,#L/&5U+9:/<30,8Y$$>UAU&98P>OJ"1^-(#E?$5Q/YEH;Q[B/3 M6ME:1[^<]* M0$?CJ]FL--\VW@'I3 /LL_AO5K;3X;B::UU%98V$K!FC=49@Z,%'.%(Y!'- &18> M&/,\07=O]LNUV6\+;P\>]LLWRL?*Q@8XP ?>@#LM*N9AK=U9M(SQ000;0V.I MWY/ ')P,T@'7EY,GB*UME78GE,G*R*%4J[*,#9Z =64D=VWFRVMQ)!OZ%P@4ACCC/S,8X[$_2@"YX=TI]%T^*Q=@[1 M!LE&VM[:]M97!%]+.X*Y^42EB,Y Y&?I[T 0:+INLV4 M0L;QK5[6.,QI)&TGFD8(3F1Z;,0^R,HQ7."""#C M(!Z'TH YZRT77-"0V>FR6LMF"3$9VD62)6).T!(I%<+G"Y8< #B@#8\,Z'<: M.MQ]KD2:2YF:4L@('S*HQ@@8Z=LT 95EX+-KJIO6DW6B.\T$'/R329WMC&T# MYFQ@]QQ0!>UO0+J:[35-+DCCNT3RV67/E2IDD!BJL5(+'!"GK0!:TJ+61,6U M+[(D6T@+;M([;N,$EX8\#&>!F@!?#.B2:%#+%(RN9;B68;<\"1V< Y Y&>?Y MT 4$\)B234?M+!H=2*D!<[DVYZ\#G)!&">E %.+3?$MG$+*&>T>% $6=S()@ M@& 3&(60N!W\SD\YH GG\&J-+73[:39/%*+A9B/O3 EMS 9.">#UX% %+4M* M\1ZS:M87)L(XI-H=XY9F?"LK<*;91DE?[U &[=VNL6XC33FM7CCC5&2?3 H AT#0KJTNY]2OVB$]PJ)Y=N6,2A-W.62,LQW2%P..M $$>@R)K U7>OEBU6WV<[MRECNZ8Q\W MKGVH ?JFAR7^I65^CJJ632%E.'?-&L)$@:1_O;N27BBZ$^] !=67B*=7MS_9\L3Y'F.TJN%/\ MTS$#*2!_M_C0 RV\'/9MINR4,FF;MQ;(9]T3Q_*,$#ELX)&!0 XZ#J>C7$LN MB/;F&Y GRAPHIC 35 solirisimagea08.jpg begin 644 solirisimagea08.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ 4%!0@%" P'!PP,"0D)# T,# P,#0T-#0T-#0T-#0T- M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T!!0@("@<*# <'# T, M"@P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T- M#0T-#0T-#?_$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( *P!90,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M"@ H * "@ H * "@ H * "@ H * $)"]3BE=+<=NQ6DOK>+[\L:_5E']:QE6 MIP^*<5\T:JE4E\,)/T3,V;Q+IMOP]Q&/HV?Y9KEECL-#>K'Y._Y'3'!XB7PT MY?=;\S-F\RJY_\ 9:XYYMA*?_+S[E+_ ".J.68J7V+>K7^9F2?$ MC3$^Z)&^BD?SQ7)+.\-';F?W'4LGQ#W<5\RG)\3;-?N0RM]=H_K7++/Z*^&$ MOP_S-EDM7[4XK[_\BFWQ04?=MV_$C_&L7Q!#I#[S99*^M1?=_P A/Q0?M;# M\6_^O63XA[4U][+_ +%76J_N(S\3YNULG_?1K)\12Z4H_>RO[%A_S\?W(3_A M9]Q_S[Q_]]-4KB*IM[&/_@3#^Q8+_EY+[D64^)$[?\NZ?]]-71'/JC_Y=1^] MF;R>"_Y>2^Y%I/B%*>L"_@QK=9W/_GTOO,WE,5M4?W%N/QVS=8,?1O\ Z];K M.&]Z7X_\$R>5I;5/P+D?C16ZPL/Q'^-=$C\6 MP-U1Q^7^-=*S*GUC)?=_F8/+YK:2_$MIXEMF[,/P_P *V6/I/HU\C%X*HNWW MEQ-:M7_BQ]0?\*Z(XND_M6^3_P C!X:I'I^*+"ZC;MT<5LJ]-[21FZ-1?998 M6>,]&7\Q6JG%[-?>9.$ET?W$@8'H15W70FS0M,04 % !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 (2%Y/%+;<=NQBWOB33M/_ -=/&I] P)_*O/J8 MW#T?CJ1TZ)W?W'=3P=>K\%.7K:R.6N_B3I\!(A5Y<=P,#^1KQJF>8>&D$Y?@ M>K3R>O+XW&/XG,W/Q0G?(MX43T+$D_H17DU,^J.ZITTNSU9ZD,EA'6I-OTT, M27QAK=]Q&S*#_P \X_\ '-><\RQU9>Y=?X5_P&=TO7W M)%T^?8J/T KFMF%;1JIZV?Z6-[X.CHO9+[F*OA36;CDPR?\ F;^M-9=CI]) M?._ZB>.PL-%./R2+"> M7?\ Y9*OU:JCDV+>\;?,R>9X9?;?R1;C^'6J'KY: M_C_]>NA9%B'NTOF9/-L.MN9EI?AKJ!ZR1K_GZUHN'ZW\T3)YQ06T9?U\B4?# M*]_Y[1C\/_KU:X?J_P \?Z^9']LT?Y)??_P!P^&-W_SW3_OG_P"O5_ZOU/YX M_P!?,7]LTOY)??\ \ =_PK&Z_P">Z_\ ?/\ ]>J_U?G_ #K^OF+^V:?_ #[? MWA_PK&Z'_+=/^^?_ *]+_5^?\Z_KYA_;-/\ D?WC?^%97@Z3I_WS_P#7I?ZO MU%M./]?,?]LTOY)??_P"9?AQ>ITF3\O_ *]4LBKQVJ1^[_@D?VO1?V)??_P" M=? 5\G22,_I_6M%DV(CM*/\ 7S(_M2B_LR7]>A(/!NH1_P#/,_C_ /7J_P"R M\3'^7^OF+^T:#_F1*OAC4$_A4_0U:R_$1^ROO)^NT'U?W$HT*^3K'^1J_J=> M/V"?K5%[2)%TVZ3K$U5]7JQW@R/;4GM-$PMI4^\C#\#5^SG'>+7R)YXO:2^\ MF52O4$?A6B5MU^!#?9_B6%('M6JL9,N1L1T)'XUTQ;6S?WF#7=%Q)77HQK=2 MDNK,7&/9%M+B0=ZZ%4DNIBX1[%E;ANX%;*HS%P2V)A/[5JI^1')8D$@JN9$< MK0X$55Q6%IB"@ H * "@ H * "@ H * "@"">ZBM5W2NJ ?WB!64ZD*:O.2B MO-V-(PE-VA%M^2.6N_&EE"3';+)=2#M$A(_,X%>54S*E'W:2E4>WNK3]#UJ> M759+FJN-./>3L_N5S%DU;Q)J?_'G:I:H>C2-EOK@#C\ZX)8C'U_X%-4UW>NG MX6.U4,!0_C574DND59%5O!NL:FG!ZJF2![8.*YWEN+Q'^\UM/)MV_(V6 M886AIAZ.O=V7^9!](MSD0!L?WN?Z5Z$FAM0Z+8V_\ JX8U MQZ**[XX6A3^"G%?(XI8FM+XIR?S+ZP1I]U0/P%=*A&.R2^1SN4GNW]X\ #H* MJUB1:8@H * "@ H * "@ H * "@ H * "@ H * # I -V+Z"BR[#NT,,$9ZJ M/RJ.2/9%<\ELV1FSB/\ "*GV4/Y45[22ZL;]AB'08J?8PZ(KVLA/L:CH2*7L M4MFP]J^POV8CH:?L[;,.?R%\EEHY&A!5$CA5"'"F2+3 * "@ M H * "@ H * ,ZY2ZF^6)A"O][ +?AG(KCFJL_=IM07?=_JCJ@Z4-9IR?;9& M6OA>U=O,NR]R_P#TT9BO_?&=OZ5QQR^DWS5G*I+^\VU]U[?@=3QU2*Y:*C37 M]U)/[]_Q-Z"TAM1MA1(P.RJ%_D!7IQIPIZ0BH^B2_(\^52<]9R;]6W^9/6IF M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % &5K&MV6@0&ZU"58(QT+'ECZ*OWF/LH)]JTA"51\L% M=D2DH*\G9&#I'C_1M:N!:6\S),PRJ3Q20%Q_L"94W_\ R/'Q&+]D^2GNCPZX^*7B:=BQOI$SV0*!^H M->JL-2CIRH\J6*JRU3:]"O\ \+*\2?\ 00F_\=_^)JOJ]+^6/]?,GZQ6_FE^ M'^0?\+*\2?\ 00F_\=_^)H^KTOY8_P!?,/K%;^:7X?Y!_P +*\2?]!";_P = M_P#B:/J]+^6/]?,/K%;^:7X?Y'J?P>\::SK6O"UO[N2XA,3G8VW&1C!X KS\ M72IPIMPBD[K8]'"5:DYVFVU;J?71./PKYT]X^:?'GQT;3;A]/T*-7>(E7GDR M5W#LJC&<>N[\*]NA@N9*=7[D>/7QGLVX4]^__ /$[OXK>)KIRYO6CSVC4 #\ M\UZJPM*.G*OF>7+%59;-KT*G_"RO$G_00F_\=_\ B:KZO2_EC_7S(^L5OYI? MA_D'_"RO$G_00F_\=_\ B:/J]+^6/]?,/K%;^:7X?Y%NT^*WB:T8,MZTF.SJ M"/TQ4/"TI:MA\6JKY)Z2/HZO%/6/A'Q-\0?$-KJ]U!#?2I&DY55&W & M1P/EKZRG0IN";BKV/F*M>I&HXJ32OMI_D?:OAR>2ZTRUFF)>22WB9F/4L4!) M_$U\Q42C.26R;_,^D@[Q3?9&S6184 % 'F'Q=U6[T;P_+=6$K03*Z .N,@'= MD<@UW86*G42DKJQR8B3A3$Q.2C;<9 .#P!7J8 MNC"G3;A%)GF8.M.I-JC>(9;6QNY((5CC(1=N M2#D\@]:^DPE&G.DI2BF[L^=Q=:I3JN,)-*RT1YE_PLKQ*/\ F(3?^.__ !-= MWU>E_)'\?\SA^L5NDI?A_D'_ LKQ)_T$)O_ !W_ .)H^KTOY8_U\Q_6*W\T MOP_R#_A97B3_ *"$W_CO_P 31]7I?RQ_KYA]8K?S2_#_ "'+\3?$J'(U"7\0 MO_Q-+ZO2_E7]?,/K-9?:E^'^1W7AGXZZQILR)JFR\MB0'."L@'J#D@X]-MA@X1G-J:3TZG#BYRIPO%M. M_0XKX&^*]6U_4KJ'4KF2Y2. ,JOC ;>!D8 [5UXVE"G"+A%)WZ>AQX*K.I.2 MG)M*-]?4^G:\$]P^=?B9\99O#UV^DZ.B-/%Q+*^2JM_=501DCN<_A7LX;"*H ME4J;=$>3B<7[%\D/B[G@MS\4_$URYE_+'^OF'UBM_-+\/\@_X65XD_Z"$W_CO_Q-'U>E_+'^OF'UBM_-+\/\ MCTOX2>-M:UGQ##:7UY)/"R2$HVW!PC$= .A&:X,51IPIMPBD]-O4]#"5:DYV MFVUYG:>/KN:YU#5)I,A])LXC9CJ TADW2A3D,W )! V]*YJ"48TTOMR?-\K M:'56;ZTVTGE.9);:!W/JS M1*S'\R:\:HK3DELI-?B>C!N48R>[2?WHUJS- H * $/0T ?G+XW4KKM^"""+ MJ7@_[QK[6C_#C;^5'QE?2K*_\S/7?#'B;P#96$4=[99NE4"5GB5RS]SNYX)Z M>U>;4IXER?)+W>EFT>K2GAE%RQ7\_XL/:87LON-6P\0?#>](7R;>$GM)!C]0A%9 MRABH]6_1EQGA9.R4;^G_ #U?PYH7AV)A?Z)#;!B,"2$+G![<#(^AKSZDZOP M56_1G;"%->]32]4=3?<6\F/[C?RKGCNO4W>S/S5:,3WIC;I)/M/T9\&OMUI' M3HCXIZSU[_J?<^C?"GPW8VT:_8XI6V*2\BAF)(!)R0>]?*SQ55MVDUKTT/JH MX:DDO=3MW1L?\*Z\._\ /A;?]^U_PK+ZQ5_G?WE^PI?R+[@_X5SX=_Y\+;_O MVO\ A1]8J_SO[P]A2_D7W'.>)?A5X=N+&9H[2."1(V97B4(P(!(/ %;T\554 MDG)M7ZF4\-2Y7:*7IH?%WA\;-5M0/X;E!^38KZ:IK!^C_(^:I>[45NY^E-?$ M'V9^A\?6_C/U/O_P *_P#((LO^O:'_ -%K7R%7 M^)+_ !/\SZRG\$?1?D;]8F@4 % 'D'QP_P"19E_ZZ)_)J]'!_P 5>C.+%?PI M'S]\"_\ D94_ZY2?^@FO8QO\)_+\SQL!\;]#[@KY8^F/A?XW_P#(SS?]/Q(4KXDU$'@_:9#^;'%?98;^%"W\J_(^1Q6E65^[/2O"?B/P'8Z?%' MJ%GNNU7]ZTD2N6;)Y#<\8QBN&K3Q#DW"5H]+-H[Z4\,H+FBKKNM3I?\ A,_A MU_SXI_X#I6/LL5_/^+-_:87LON#_ (3/X=?\^*?^ Z4>RQ7\_P"+#VF%[+[C M3L?$7PWO#M,%O"3T\R#'ZA2*S=/%1ZM^C*4\*]+1^[_@'JOAO0_#8==0T2*U MWJ"!)"J[@",'H 1GWK@J3JVY*KE;LSNA"FO>II7[HC\7>"E\0NMY;2"WO8D, M89E#QRQDD^5,AX>,DG@@XR>**5;V7NR5X[]FGW7F%2GSZQ=FON:[,YF+X?ZG MJ]SYVO7%MY>%5TM(]AG1""J2N50E 0#LY&0*W=>$%:BI?]O/9]UN91I3;O5: M^2W]3UZ.-846- %5 %4#H !@ >P%><]=6=NP^D 4 % !0!XIX\^#5GXLN&U" MUD-I=O\ ?(&4<^K#!Y]QBO3H8N5%:!K5M';NWD7,@CDB))0ANA Z @X.1BGB:49P M;:U2NF&$JRA-0Z/H?>=]_P >\G^XW\J^4CNO4^I>S/S8B_Y""_\ 7R/_ $8* M^U^S\OT/BOMKU_4_2JT_U,?^XO\ Z"*^)EN_5GVJ)ZD84 9FM?\ 'C/_ -OZGZ4U\2?9 MGYP^+O\ D-W?_7P?YBOM:7\->A\?6_C/U/O_ ,*_\@BR_P"O:'_T6M?(5?XD MO\3_ #/K*?P1]%^1OUB:!0 4 >0?'#_D69?^NB?R:O1P?\5>C.+%?PI'S]\" M_P#D94_ZY2?^@FO8QO\ "?R_,\; ?&_0^X*^6/ICX8^-_P#R-$W_ %RB_D:^ MLP7\%>K/E,;_ !GZ(M>%/C->^$].CTR"VAE6'=\[%\G@51^./6O4A!48\D=D>3.(DI59..Q]=1BXPBGV//?V@_^ M0)#_ -?"_P#H+5V8#XWZ''C?X?S//_V=?^0K>?\ 7LO_ *,%=N8?!'_%^AY^ M7_'+_#^I]>U\V?1GCOC[X067C&;[?!(;2\(PS 95\#C*W/[/VNQ'$,L$H['.W^9KU%CZ?5-'EO 2Z-%3_ (4+XB_Z M8?\ ?8_^*JOKU/S%]0GW0?\ "A?$7_3#_OL?_%4?7J?F'U"?=&+K'P<\1:/" MUR\*S1Q@LWEL"0!WV@DG\*UABZ4WRWL_,RG@ZD%=:F-\._$MYXH;U /YU\?L? M6#J "@ H * "@ H A-Q$IP74$=MP_P :=GV%=!]IA_OI_P!]#_&BS[,+H/M, M/]]/^^A_C19]F%T'VF'^^G_?0_QHL^S"Z.2\;ZO96>CW?G31KNA< ;@221T M!ZUTT(2=2-D]T8U91C!W:V/A'P;QK5C_ -?"5]56_AR]#Y;#_P 5>I^BU]_Q M[R?[C?RKXZ/Q+U/KGL?FNKB._#MPJW )/H X)-?;?9T[?H?%[3^?ZGZ-Z5JU MG>VL4MO-&Z%%P0P]![U\7.$HR:::U/LXR32::-+[3#_?3_OH?XUG9]F5=!]I MA_OI_P!]#_&BS[,+HP?$FKV5CI\[SS1QKY3CEAUVGC -;4H21_'#_ )%F7_KHG\FKT,'_ !5Z,XL5_"D?/WP+_P"1E3_KE)_Z":]C M&_PG\OS/&P'QOT/N"OECZ8^%_C?_ ,C1-_URC_D:^LP7\%>K/E<;_&?HCMO MGP>TOQ7H<6H32S17$H<94@J"&90=N!GH,C/- M>>+_ (4:SX49I=GVJT!XFB!R!_M+V/T)KLI8J%72]GV9Q5<'.GK'5' Z8]I% M<*=0222W!PZQML?Z@D'D>F*[)7:]QJ_0XH*,9)54[=>A[WX7^'W@WQ8H-E>S MI)WAD*JX_H?K^E>14Q%>C\45;NCV:>&H5=82?H>V^'?A+X?\-R">&$SS+T>8 MARI]5& !^M>74Q56IHW9=EH>E3PU.EJE=]V>E@8X'&*X3L/ OV@_^0)#_P!? M"_\ H+5Z^ ^-^AYF-_A_,\__ &=?^0K>?]>R_P#HP5VYA\$?\7Z'GY?\U\V?1D1N(E."Z@CJ"PS_.G9]A70GVF'^^G_ 'T/\:+/LPN@^TP_WT_[ MZ'^-%GV870?:8?[Z?]]#_&BS[,+HP?$>LV5A83O<31QKY;CEAU(/&,UM3A*4 ME9/_$/MNJ_\ /2[_ M #EHM#R#FJ_WOQ#[;JG_ #TN_P Y:+0\OP#FJ_WOQ'1Z;JNJL%6&ZN6/3Y)& M_F,4^?##X.WT5Y%J^M+]G2 [XH,@NS8X+;20 ,YP3 MG..*\C$XN+BZ=+6^[/6PN$<&JE32VR/JQD#@JW((P1]:^?VV/=/CCQY\%M3T MZYDO-'3[7:R,7\M2!)'GDC!(W#TVY-?2T,9!I0J:-?JZ42ACN[8CJ-LJ?T KTKPEK=/YIGFI58:)25O)H3[;JG_/2[_.6BT/+\!\ MU7^]^(?;=5_YZ7?YRT6AY!S5?[WXBK8ZKJK!!%=7)/0;)7_H:+PAK=+YI"M5 MEHU)_)L]O^&WP5\Z>^?G+XNMICK-X1'(1Y[TDTGN9:W>IH JO= #@ &4 #T J[0\C-.JM%S?B.^VZK_ ,]+O\Y:+0\A M\U7^]^(?;=5_YZ7?YRT6AY!S5?[WXGU)^S[-E5>C-L2OW4DCP#X'021 M^)$+HZCRI.2I ^Z?45Z^-:]D[>7YGDX&+C-W5M#[)B_XK M/=PRM32/5&4."K $'@@]*X-MCK/'?&/P8TGQ)NN+0"QNCD[HQA&/^T@XY/4X MS7I4<9.EI+5?B<%7"PJZK1^1\M^)? .N>"9]\L;[%/[NY@R5/OE?F0_[P'M7 MO4Z].NK)J_9GA3H5<.[J]NZ/0O!_QJUC1MMOJ\,M];CC?L;SE'KD@;_^!$FN M.M@Z<]:;47^!VTL54C[M2+:[]3Z?\->+M.\5PF;3Y"Q7&]&5D="1G!5@#^(R M/0UX52E*B[37HSVH5(U%>#VW\CRO]H&-GT6((I8_:%^Z"?X6]*[\#I-^AQ8Q M-T].YP'[/$,D6JWA=&0?9E^\I'\8]0*[<>UR1M_-^AP8"+C.5U;W?U/KFOG# MZ$^!/B#=ZBGB+4%B>Y""YDP%,FT#<<8QQCTQ7UV'4?90O;X5^1\OB'4527+> MUWM_$/MNJ#_ M ):7?YRT6AV7X!S5?[WXBI8:IJC!%BNKACT&R5OY@BCFA#6Z7S2%:K+1J3^3 M/5TZ>K?7HCU<- MA)1DJE32W0^N@,# [5\Z>\% !0 4 % !0 4 <_JDNG:<4-Q#$TEPX1!Y:%F8 MY.>F3P"2:OFDM$W][)LNR^XTAI=G_P \(?\ OVG_ ,31SR[O[V'*NR^X/[+L M_P#GA#_W[3_XFCGEW?WL.5=E]P?V79_\\(?^_:?_ !-'-+N_O8*UA M@_U4:)_NJJ_R I-M[MCLEL3U(PH * *\MG!,R>5=E]Q')I]E$C2-!"%0%C^[3H!D_P -'-+N_O8< MJ[+[BEI@TS5H!H10N?K@"I;;W;&DEMH.EACG79*JNOHP! M'Y'(H3:U6@6Z,ABL;>W;?%%'&WJJ*I_, &FY-Z-O[PLELD6JD95EL;>=M\L4 M;MZLBD_F035*36B;7S%9=4B:*%(%V1*J*.@4!0/P&!2;;W#;1$E(84 1RPI. MNR55=3V8 C\CD4TVM5H*Q5_LNS'_ "PA_P"_:?\ Q-5S2[O[V+E79?<2P65O M:DM#''$3U*(JY^NT#/XTG)O=O[QI);)(DFMXK@;9D61>N&4,,_0@TDW'9V"R MZC(;."V),,:1D]2B*I/UP!3;;W;!)+96+%2,IOIUK(Q=X8F8\DF-"2?]/FEW?WL.5=E]QH_V79_\ M\(?^_:?_ !-'/+N_O8$/\ W[3_ .)HYI=W][#E79?<31VD M,',4:(1_=55_D!2;;W;'9+9%6PU6'4'EBCR)+=RCJ>"#V/T/4&I&:5 !0 4 M% !0 4 % '"67_$WUV:9^8]/7RXQVWM]YOK@$?C0!W= $4\RV\;2R'"H"2?0 M"@#A(=?U?6 USIEO&+8$[#,Y5I #U4!6P#VR:!'0>']=768V#H8;B!MDL1ZJ MWMZ@]C0,Z"@#GO$&NC18T6-#-<3MLBB'&YCZGL!W- &#)K^KZ28YM3MXS;2, M%)A8LT9;IN!151DHI('TH RO#>JR:S81W MDJA'D!RJG('XX'\J *V@:W+JLUU%(BH+:8QJ0U 'H% &'XCU231K&2[B4.T?12< _C@_RH N"\8V?VK W>5OQV MSMSB@"AX:U:36K);N50C,6&%.1\K%?0>GI0!OT <7K'B2YL-073[>$3-+'E. M<'?_ +7'"@.#]!0!TM ' M >.Y_LOV.;!?R[@,%'5B-IP/7MM']C)&X(Y,D:GH6!4 ^^& MH&=Y!.ES<9RCJ&4^Q&10!+0!P6KO\ V-K5M=I\L=YF"7T)P2I^N5% MCO: M!A0 4 % !0 4 !H X7PB=EWJ,3??%QD_0EL4 =U0!B^(HWETZX2/EC&< =Z M.%\-:5+J%A%+;WTD2!<&-=N(R."I!&1CWH$:WA*UM8KNZDM[B2ZERJRLRX7< M,]&P%)P><$T =]0,X#Q*PMM8T^XE^6$$IN/ #$\9/0=10(Z;6M7MM(M_/N1O M4LJJH )8GIA><_@*!FM$_F(K@;0P!P>",C.".U %74@3;2@==C?RH Y?P'/& M-&B^8?NPV[D?+CKGTH I>!Y%FFOY$.5:Y)!'<;5']*!'H5 S@?%_%[IW_7P* M .^% %6^_P"/>7_KF_\ Z": .8\"?\@I/]^3_P!#:@#L: .+\2:Y*KC2M,PU M[.,%NT*'J['H"!D@'VH UM TB#0[<01D-(QW2.3EG<]23U/M0!O4 UL MW\J!">(?^0UIWU?_ -EH 3QK_K;#_KZ7_P!!:@#OJ!E+4KH6-M)<$;A&A;'K MB@#@M+@U+7K9;Z2[%K!("PCA5!M7W;'7'7F@0> =HFO0CF11* ')R6P.I/>@ M#TJ@9POC29+>2QEEP$2Y!;/0#*\F@#4\4WD,&E3,[+MD3:O(.XMC 'K^% %G MPS ]MIEO'+PPB7.>V1G^5 &[0!Y[XY^>2PC7[YND(]< $G]*!'H*\ ?2@8M M!0 4 % !0 4 <)= Z%K2W>,6U^/+<]EE'*D_4!A]30!W= 1D8/2@#D[CP98 M32-(GFP>8OMB@#=TW2[?28A!:H(T'/N3ZD]S0!?H HZCIMOJ MD)M[I Z'MW!]0>QH P[7P=8VLJS'S9FC^X)7W*OT&!^N: .JH " 1@]#0!R3 M^"M/:4RKYD:NVYHT?$;'.>5QG'T(H V--T:VT@R&U4IYS!F&>,@!>/08 H U M: ,R_P!(M]1DBFG!+6S;X\'&#[\FZ;#I,(M MK8%8U)(!.3EB2?3N: +] '+77@^PNYWNG$@EE^\5?'08].G% !;^#[&UE69# M-NC.1F0D9]QCF@#J: (IX([F-H95#(XPRGH0: .6@\$Z= W'F,@SB-GS&,\< M+@?AS0!OZ;IL.DPBWMP1&I) )SU))].YH OT 9K:3;M>#42#YZH4!SQM/MC^ MM "76D6]Y<17/>@#3 MH 9)&LJE'&588(/<&@#E%\$Z?&QV&98RV: -;3M"M=*EDFM M5,9FQN7/R_+TP.W7GF@#8H S-2T>VU;8+I=XB;1P,?F10!L+)LC#RD#"@L?X>G)^G]* '1R+*H>,AE/0@Y'YT ,-Q$&"%E#'@ M#(R<=<"@":@#&N]4:VOK>R"@K<*[%NXV;>GUS0!J2SQP#,C*@ SR0.* %:55 M0R9&T#.>V* *6F:G#JL(G@/RY(QW&#CF@"V+B(MY892YY"Y&[K&,L0HZ<\@!D4R3 F-@P!P<$'!].* $>>.(A795+'"@D D^WK0!(S!!E MC@#N: $WKG;D9(R!WQZT 1RW$];3;.6Z0!C"C M.%/0X&<4 9MSK;P?9,(#]K8!O]G*D\<^U &]-/';KOE8(OJQ 'ZT 2*P89'( M/0B@"..>.1BB,K,GW@""1]1VH EH * "@ H * "@ H Y;PX?GO?^OJ3^9H X MTVD26DM\,_:%OAM?)RH\T# ]!CJ*!'7>(B.VOL&W$#,BL<*S\Y/U R1]* )/#4C-ITHR6C1Y%C)_N #' MX YQ0!R>F6L=M!IUS'Q-).0SY.2"CDJ?;VH$>NT#.0\76L4Z6QD4,?M*+SZ% M7)'XD#\J &>)PN^SM7^2U>4*XZ @?=4GT) % "^'@MO?7EM;?\>L9C*@@A<[<\$_-U'>@"7PV@DTMXF^9%:50#SA1T% "^#8(8=/!B"J2S[ ML>S$#- %?PC80;9;O;F8SR#>>2!QP/04 9GBB2*YGG18D,EO"&>65RNS."OE M@ Y/'M0(VY[=]4T)5!+2>0KH>Y=5ROZ@4#*WAJ4:M=2:ESM2-(4],C/F?KMH M$)2PXSZD?6@8[ M2;:.PU:>"W&R,P(VT=-V5Y^O)H P;F*WO9M1DU XD@&(LG!C01@AD]]Q)SZT M"-F\EDET!9)L^88T+'O]X.75[=8V#%;/D YQGI0!E^(;3R;N2^D$= MW"J*'B9]KQ $G=&,'.<^W2@1WMC*D]O')%D(Z*5W=<$<9]Z!F9XG4MI=R%&3 MY+\#_=- ',7<\7-Y2L3;2ML5P M0?F!P?F';CM0,EM[U9-$>>Q5HML;!5ZE6'7'J/2@#G/#VFO'-:W2S0J&3)"9 M+S97)W\]<\GW% CU&@84 % !0 4 % !0!7@M(K4N8E"^8Q=L=V/4F@"N=*M3 M&8?+78S^85QP7SNW?7/- &3K5G<7EQ;1PQ_NHI!(\A90% & NW.XDY[#'% & MU?:?!J4?DW*!TSGGJ".A!Z@^XH +*P@TZ/R;9!&F64-_&8 M;A0Z'L?YCT([&@!MCI\&FQ^3;((TSG [GU)ZD_6@"2"TBMB[1*%,K;FQW;U- M %B@"M)9Q2RI<.H,D0(1NX#8SCZX% "M:1-,+@J/-4%0W< ]1^M !;6D5HAB MA4(A).!TR>OYT 066F6^G;_LZ"/S6+,!T)/4X[?A0!/;6D5FI2%0BEBQ ]3U M/XT 4KW1+._D$UQ&KN 5R>X/8^H],]* +EI:16,0@@7;&N<#TR<_UH +2SAL M4\JW41IDM@# R>I_&@"C>:%97THGGB5I!CGUQTW>N/>@"]/9PW,8BE4,BD$+ MC@%>GY4 *MI$DIN%4"1E"EN^!V_2@"E>Z'9ZA(LUQ$KNOQH T)( M$EC,+J"A&"I'&/3% &=8:'9Z:WF6\81\$;N^#VSUQZ#M0 V[T&ROIA<31AI! MCGUQTW#H<>] &N %&!P!T% RAAM(R#U!H R++0;+3Y3/;Q*CG//H#U"_P!T M?3% $NHZ-:ZIM-R@ GRAPHIC 36 strensiqimagea08.jpg begin 644 strensiqimagea08.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ 4%!0@%" P'!PP,"0D)# T,# P,#0T-#0T-#0T-#0T- M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T!!0@("@<*# <'# T, M"@P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T- M#0T-#0T-#?_$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$! M 0$! 0$! 0 $" P0%!@<("0H+$ " 0,# @0#!04$! 7T! @, M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( *@!70,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M"@ H * "@ H * "@ H * "@ H * "@ H * "@ ) Z\4 8FH>)-,TG/VRYA@Q MV=P#^IJDF]D8RJPI_')+U9Q5W\7_ [;$JDYF(_YYKN'YBGR-'&\;16BE?T, M.7XUV)XM[:1_=F"_IMJ'[I/UR/V8O\C/;XPW#_ZJV11_M,3_ "(K!S:V0OK3 MZ)$)^*&I2_=2%/HK?_%5RRK26UA?6)/L ^(6JO\ Q1CZ*?\ &N26(J+:WW"= M>?D3+X[U7^^G_?/_ ->N.6+K+9K[B/;S[EE/'>ICJR'_ ("?\:YWCZ\>J^X7 MUBHNQ=C^(%^OWDB;\&_^*J5F=:.ZC]S_ ,Q_6IKHOZ^9IP_$&;_EI"I_W21_ M,FNF.:2^U!?)FJQ3ZI&O!X[@?[\3+]#G^E=<K%#_M#%=<<=1?6WJC958OR-B#4+>X_U4BM]"*[(UJ<_@DG\S523V9<^E;E! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M-=UC&YB% ZDG _.@-CA-=^)6AZ 3'+/YTP_Y90#S')_#"_K5J+9Q5,52I:-W M?9:O_(\YN?B;XCUP^7X>TN15/ EF !^NTX'_ (]6G(E\3.!XJM4TH4W;N]_N M=OS,J3P=X]\2_P#(0O%M8SU02.!S_LJI'ZT[QCLC)T,55^.5EVNU^")K3]GU M7.^_OW=NX5,Y_$N/Y4>T[(<5)_!-_-?\ !,'A%]F7X&3-X$OX/]68Y![$@_R_K7%++:T/ MA<7^'Z&+PTX[69E3:'?V?^MA8 =Q@C]*Y98:M3^*#^6I/LYQW3*X!3A@5/N" M*PLUNK#6A;C;'(XHVV-DS7MM4N;;_5R,!Z9XK6->K2^";7ST.B,FCHK;Q3,G M$JAQZC@UW0S2I#2I%27EHSH4CHK77K:XX),9]&_^MFO6I9E0J:2?(^TO\U: M?DMU/_75MJN!_L,35\MM]#CE7;]VA%R??:/W]?D8LW@C5?$9WZ_?NL1_Y=K0 M^5&!_=9U =O^^C3YE'X48NA4JZUINW\L=%\^YT^C^!-$T(#[):1!A_&Z^8_U MW/N;/XU+DV=,,/2I?#%?/7\SK54(,* .@' %2=6VPM !0 4 % !0 4 % !0 M 4 % !0 4 4Y]/M[D8EC1O\ @(S^>,UC*E">DHI_)$.*>Z1S]UX0M9FAS]UX7NK7F/$JCTX/Y?X5Y%7+ZL-86DO+?[ MC/V;CMJ8S1O"=LBE#Z$$?SKQ9PE!VFFGYJPUH2J:XIQ.B++]M=RVQS$Q7VSQ M^72L8UZN&?-1FX^5]/NV-T=+:>(B/EN%_P"!+_4?X5[M#/G"T<9#3^:/ZK_) M%\E_A.DM[J*Y&Z)@W\_RZU]EA\71Q<>;#S4O)/5>JW1DXN.Y8KM)"@ H * " M@ H * "@ H * "@ H * "@ H 3PDU)S-@Y6(?+$OX=6/N6Q[55[;&/L^;6H[^6R-V*%+=0D2A%'0* M!^E2;I*.BT)*!A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 5Y[2&Y& MV50P]Q6,Z4*JM.*:%8YF\\+K]ZU;:?[K)4B=,66;>=[9P\9P01^/M M7GPJU,)5C7H-QE&2]&KZIKS1T:25F>EQMO0-Z@'\Z_>:4O:0C-]8I_>KGGO1 MV'UL(* "@ H * "@ H * "@ H * "@#G?%'B:T\)V+W]Z<*O"H/O.W95'J?P M [FJ2N[(YZM6-"+G/Y+N?)/B'XT:[J\A%H_V&#)VK']_'NXP^22 M#QBE"/,;8O$O#)**NV-/HHW^]O_(\H\#^'4\5:O#ILK^5')DLPQNPHSA1].L!17 M1_>SFM9^ 6F7*EM-FEMI.RL0R?CD%O\ QZJ51K)$\):K'J3 MAZWU>:FU>W38]\C_ &A[3< ]C*%[D2+Q^E8^R\SVUF<>L']Z/== URW\1646 MHVA)BF&1GJ#W!]Q6#5G8]NG456*J1V9ROBWXEZ1X0;R+ES+<_P#/&/EA_O8S MM_&JC%O8Y:V*IT-).\NR_K0\P;]H>W#?+8R;/^NBY_E6OLO,\W^TUT@_O1Z/ MX.^*.E>,)/LL.ZWNL9$4G4@==IP V/05G*#B>C0Q=.N^5:2[,[;5]:L]!MS= M7\J01+W8@9/H,]2>P'-0E?1'7.I&DN:;LCQ;4?C_ *7;N4M+>:X /WLA ?H& M&:V5-]3R)YE".D(M_@&F_'_2KAPEW;RVP)^]G>!]0HS0Z;6P0S&#TG%Q_$]K MTK5[36[=;NQD6:%^C*0?P..A'<=JQ:MHSV(3C47-!W1+J.I6VDP-=7DBPPQ_ M>=R !^)[T)7T0Y2C37--V2[GBVJ?'O1[-REG%+=X.-P^13]-PY%:JFSR)YC3 MCI!.7X%"T_:#T^1MMQ:31+_>#!L?@!FFZ;6S,XYE!_%!KYH]A\.>+=-\51>= MILRR[?O)T=?]Y>H_$5DXN.YZU*M"LKTW\NJ^1TE2=!Y1XE^,.B>'96ME8W?E_F<&W[0\&?EL7V^\@S_*M/9>9P_P!I MK^1_>;>F?'W2+E@EW#-:@_Q?? _[Y%2Z;6QM#,:,XSCSQ=T>'ZQ\?+&PNWMK:VDG2)V0R;@H)4D' M:".F1P>];*GYGCU,QC"3C&+=NM['K?A+Q-#XMT]-2MT:))"1M;J",9]/6LFN M5V/4HU56@II6\BQK_B73_#,'VG495A3^$$_,Q]%7JQ^E"3>PZE6%%*2ERVZ7^2Z MGHM9GH!0 4 % !0 4 % !0 4 % !0 4 ?-_QX\)SWBPZU:J7$">5,%&2%!+* MWN,LV:Z*;MH?/YA1XDM9!+"QCD0Y5E."#[5T'S:;B[K M1H](TWXO>)-- 7[0)U7C$R[N/J"*S<$>A#&UH:/"_C;2_%T>_3Y)3IRJRY(;G=_\ "G/$W_/NG_??_P!C4\1VXO+:)(X7Y1I6*[A MZJ K<5#FEH=M/!U:L>>*5O-V_0[CP+\-M8\.ZY'?ZG&(+:Q5IFD#95L#[H.! MUY/([5$I)JR.W#X6I1JJ=16C#6_3T/.O'OC.X\8:A),[$6T;%8(\_*$!P&QZ ML.3[FKC'E1P8FO*O-O[/1>1N^"OA-J/B^#[876TM2<([ LSXZE5XX[9SUSQ2 ME-1T-J&"G77/\,>C[_(SO'GPYN_ IC:619X)B0KJ-I##G!7)QD9[GI3C+F,\ M1A98:S;NGU-_X+>))]*UI-/W$VUYE63/ ?'RL!V.<9]JFHM+F^ JN%10^S+I M^0GQC\6SZSJ\FG(Y%I9'8$!X9_XF/KQ@#TYHA&RN&.KNI4=-/W8Z6\^YYSH' MAK4/$LQMM-B,SJ,L>BJ/5CVK1M1W//I4IUGRTU?]#6\0^ -:\+Q"XU"#;"3C M>AW*#Z'@8I*2>QK5PU2@N::T[F7X9\07/AJ_BOK5BA1AO&>&0GY@1].?J*;5 MU8SHU949J<7:WY'V!\2?%,ECX6-_9DH]Y'$%8=56;;N_':Q_&N6*]ZSZ'U6* MK.-#GA]I+[GO^!\2QJ9Y I."[ %F]2>I-=>Q\?N]3Z4L/@+97,"N=2#.R@_N MT4KDCM^\R1^5<_M+=#Z&.71:_B*_DO\ @G/:[\!M3L$:73IDO O.P@QN?]T9 M<$_B*I5%UT,*F73@KP:E^#^[4]L^'/AFZ\*^'FM;XXF<22%,YV;E^[]?6L9. M[T/8PU*5"BXSW=W;MH?$M]_Q\S?]=9/_ $,UV+8^/G\3]3[!^%FIQ:-X.%]. M<1P&5V_ "N22O*R/K,+-4\/SRV5V?+7BOQ3=^+;Y[Z[8X)/EQY^6-.RCZ#O7 M3%)X1AE^)O ^J^$6 U&+:C<+(A+(3Z9P.?J*:DGL9UN7F:T/J/80;YK?Y'55)U!0 4 % !0 4 % !0 4 M % !0 4 -DC652C@,K#!!&00>Q!H$UT9Y'K_ ,%M"UEVFA5K*1N28CA<_P"Y MG:/P%:J;1Y=3 TJFJ]U^7^6QYM?_ +/5RF397B-Z"52#_P".KBM%4[H\^66M M?!)?/_@'D?BOP'JO@XJ;^,>4YPLJ$%"?3@Y!^H&>U:QDI;'E5L-/#_&M._0R MO#&LSZ!J4%[;,49)%#8.-R,0&4^H()Z]^:;5U8SHU'2G&47:S/9OCY-]IFT^ M8<>9;[_^^B3_ %K&GU/7S%W<'WBF<=\&?^1F@_ZYR?\ LM74V.7 ?QD?<=<9 M]B>=?%?CPU>?]<_\:TA\2.#&?P9^A\(QC+*#T) _,BNP^)6Y^CGA^-8M-M40 M8 MX< ?][/T"DK0BE_*OR,7X@S/!X?OGC^\(#C'N0*J.Z,<2^6C-KL? MGR!QBNX^%ZGKNF?&?6=(LXK"U2!(X%V+\HSCD^G7)K%P5[GJPQU2G%0BDDMM M#C?$GC+5/%\BMJ,OF[#\B*H503Z*H )]\9JU%1V..K7J5W^\?HMOP/4?@UX% MO;C4DUB[B>"VM@2F\%2[D8&T'!P#@YQBLYR5K(]/ X>7.JLDU%=^K/*?&)_X MG5Y_UW;^E:1V/+Q'\67J?2'[/D"+IEU, -[3@$]\ 'CZ5A4W1]#EJ2A)];K\ MCT[XAVZ7/AZ_20 @6TC#/8A3@_45G'='H8I7HSO_ "L_/RNX^&/M:Z\,MXM\ M%06$9Q-]FA>(G^^BJP7VW8Q^-<=^65SZ]TO;X:,%ORIKY'QQJ6EW6D3-;7L3 MPR(2"'4C..X)X(]QQ76G?8^3G"5-\LDTQ;35KRQQ]FN)H<=/+D=1_P".D460 M*91_#-^\!'IELD?A4."9V0QE6GM)M>>OYGU5X M)\=1>-]*FGVB*X@1EFC]"5;#+_LG!_*N:4>5GTU#$+$4V]I):KY'PY??\?,W M_763_P!#-=BV/C9_$_4][69X?AH=G&^?:23[K\S]#9KVQ\-:N4*,$VTHI(\C\1>.M!\=Z/?V$#YD@B\U/,4KDJ<;DW 75KTL33G!/5*ZO^A\@*Q7##@C!'U'-=1\IL]#]&_#8SCI4BGZ:,[B/]H'22N6MYU/IG/Z[:S]FSM6 M8T_Y7]__ #RKXD_%-?&D"6-K 8($?>67BL7]82A M%62=SR_0]/EU6_M[. %GEE0 #TW L?H%!)^E:/1'G4HN(/!D^H6QS'-#G'H><@^X-3%HJN&E]9PM/X(Z^G^9Z7X"\<6OC6V MDEMH_L[0.4,1() ZJ> ."".W7BLY1Y3TIN?19=_#EZH]/\ '?\ R +_ /Z] M9?\ T$U$=UZGHXG^#4_PO\C\]:[CX0^\-*UV#PWX3M]1N#A(;2,@=-S;!M4> M[-@?C7$U>5EW/M85%1P\9RZ17WVT1P=I\6O"_B- FM6XAD[^8@=?^^\*1^=7 MR2CL<4<90JZ58V?I?\1MY:?#:^0OOMHB1G*2D-^ +$9_"CWT*2P3UO%/R>OY MGS)KT5E!?S1Z6[26:O\ NF;J5P,],=#D#VQ70MM3YRHHQFU3=XWT/UEZ=IOI;_ #/ K[_CYF_ZZR?^AFMUL>)/XGZG MU1X+T'_A)/ 3Z>OWY/,*>S@#;7*WRRN?34:?M<*X+?6WJ?*LT$MA,T4H,4T+ M8(/!5E/\P174?,-.#L]&F>LZW\1X_%'AQ=(O]\5Y;E-CKRDH0C 8?PG QG/7 MG%9*'*[K8].IBE6H^RGI)6L^C]3R!79/NDKD8.#CCT^E;'D[;'0^%/#\_B74 MX+"!2V]U+D=%C4Y+IFO0[V MUXXY=?F5L# RN1^>:TC-QT/,KX.%=N5^67?_ (!X1JOP,UZQ8_9?*NT[;6*M M^(90!^=;JHCQ)Y?5C\-FO+$KK3V;_#_, MVM,^#/B._8"6%;53U:5QQ^";JES2-X8&M+=/)+Y/L?)6L?!GQ#ILK+;PB[C!^5XF R/<-MP?I MFNI37H?+5,#6@_=7,O+_ (-B#3O@[XDOW"O;BV4GEI7 _[XW']*'-(4,#6E MO'E]?^!<]Q;X=7F@^$KO1[>1KVXG!81CA58C!"9(]!R<5CS)R3V/:>&E2P\J M47S-]/\ (^?X_A;XF5E)L9,!@?O1^H_VZWYX]SP5A*]_@?X?YGW)I,3V]E;Q M2#:\<,2L/0JB@C\"*XWN?9P7+&*>Z2_(T*1H>4?$#X66GC+_ $J%A;7RC DQ M\KXZ!\<_CR1Z5I&?+IT/,Q.$CB/>6D^_?U/F_4/@_P");!RJ6PN%!X:)Q@_] M];3^E="FO0^>G@JT-HW]+?K8;9_"'Q-=L ;7R1ZR.H'_ (Z6/Z4W-+J$<%6E M]FWK;]#Z!^&7PQNO!4SWEU;6 MUNI>66WD5%'4L5( &>.:B.C1W5XN5*<8K5Q:2/B?_A6?B7_GQE_-/_BZ[.9= MSX[ZK6_Y]R_#_,^I[KP'_P )/X:M-)O7DM)8(HR0O.'51PZ@@$ CU]ZY>;E; M:/IGA_;4(4IMQ:2^^W4\'U;X%Z[8L?LABNT[;6*M^(*@ _\ C6ZJ(\6>7U8 M_#9KRW.6;X6>)D.W[#)^#1X_]#JN>/WI7,W=W9])3HQH0]G#M][/CB\^&OB-YY66QE*M(Y!RG(+$@_?[BNM M27<^2EA:W,[0?X?YGU7\*-)N]$T&*TOHS!,KN2C8R <8Z$BN:;N]#ZC"0E3I M*,U9WV,?Q_\ "6T\6.;VT86M]CEL?))_OXY!_P!K!/M3C/ETZ&.)P<:_OQ]V M7X,^=;_X1>);!RBVOGJ#PT3*0?\ OHJ?TKH4UW/GYX*M#11OZ6_X!F:A\-]? MTJS?4+NU:.&/&[D%@#WPI/ [T^97LC.6%JPBYRBTEZ#_ ()BZ*S#:2 2OH2.1^' M2N(^V6P^@84 % !0 4 % !0 4 % !0 4 % !0 4 <]J/BG3=*N([*XF47$[* MB1CYFRY 7(&2H)/4X%,#H:0!0 4 % #)94@0R2$(B EF)P !R22>@ H \\E^ M*OAZ"7R3<9(."P1RN?\ > QCWS3L!WMG=PWT*W%NPDBD 964Y!!Y!XI; 6: M"@!%8-T(./2@!: "@ H * "@ H * "@ H * ,[5=5MM%MGO+QO+AB&6;!/Y ME0A0OR+5]>IUE2=(4 % !0 4 % !0 4 % M !0 4 % !0 4 8'BC5_["TRXON\49*_[Q^4?J #Z X.?TJ;#+'A MSXK:5X@G6T(>VF*O&EAX1C5[PDR29V1IRS8[^P]Z M$@//8_CA8%@)+6=$/\77CUQM'\Z=A&G\1=>2_P#"KWM@Y\JY,8#=#M9U# ^G M<&DMQGAGA;4/#5G:M'K5O+/<.Y^=>BI@8Q[YSG\*KT$?2K>(M&\'Z1;R!C': MF-?(3J[KMR,#CG'6I&<;;_'#2Y)0DL$T<9.-_!P/7;@?SIV$=[K>KQ7^@W%] M82;D:%BCJ>G3\C2V&?.OPZ^($7A;SSJ!FG\[:5P=V",9Z^M4T(^A!X[T_P#L M;^WOG^S=,8^;=_=QFIMT&<&GQRT\MAK694S][.?TVC^=.PCU30_$=CX@M?MM ME(&B&=V>"A'4,.V*G89YWJGQFTNRG:"VBENMA(+)PN1UQPV1^5581K^%_B?I MWB:Y%BB26]PX)57'#8!)P>.< GI2M89J>*O'NF^$L)P*P/D"],GJ3WSUJO0#Z%TWQ5H/A'0H[ZPCD6UN)&V1XRYDX# ^@QBHL,S;?X MX::[A9K>:)"?O=<>^,#^=.PCK/%&DP?$310+&8;6Q)$PY!93PK<\;H"L[%O^^0?Y4V(XO4 M/&DFKZK-!H>F6\\Q8@NZ(TC[>"QR, ?4T6L!Y_K:7MMK$3WULEA<&2)O+B"J MOWU^8!.,GO\ 6J ]8^*OA/4=8-MJ5DAN ENJ.BD;@>6W $C(.[MD\5*T XH^ M-M4TZ);?5=.AD@ VXE@"9'IG9C/XT[=@.Y\5:Q::UX*6>QC%O$KQIY0 0K* MH(&.,9'![TMF!'\+O!>DZ]I!NK^W6:43NNX]=H5"!^9-#T X_P")JA_$,5A) M^ZM85AC0=%2-MH8CTXIH#TSQEX*T*R\/R301Q0O#%OBF4 ,[!QY!=WNLZWIKS)I5LED5R M)$CC4JHYW([D>* MT\W.1N,8F1ER2"I&['Y TP.V\%^.[:[U>*+4;&&"[:XNH3>%+C @/\ &% VKCT]N^:?0#=:'@^/&\G[OVB3IZ8&?Z4^@'U94#"@ H * "@ H * "@ H * "@ MH * "@ H R-?TI=:L)[%^DR%1['J/U H ^9O!.JWW@/63HMY$2EW*L3*V1RQ M"K(A[@C![\5;$=+=_#'7-#U%]0\/3J-Y8KDJ&4,QWNIM$[HR98NGW58'&%P.@]*=T@/1/&7A+7=3D@N-(N_(-O$J>4#M!8=6SG M!STYSTJ1G!7_ (#\9>( MMJF?E 8\$]Z>B$=SJ7PZEC\,C0= M/96FWJ[._ 9MX=CVP.N/;%*XSH?AUX;N?"VF&RO"ID,SO\AR,%4 [G^Z:&!F M_$#X>1^+U6XMV$-Y$,!C]UU_NM^F"",4)V \I'PM\47@6TNIP+9#@;I=R@>R M;L_0'-5="/;]!\$VFAZ2^DH2_GJ1+(>K,1U^@["IN,\0;X3>(M(N&&ES 1-D M"19/+)3MN&>N/_K55Q'>WOPXO]7T"+3K^Y#WML[/%(>1AL91CG)Y'7/>E>P' M*1>#_&]E:'2X98S:;=FW=%C;Z D%@/QHT ZGX>> ]4\-0WB7+I#)=1[8F0AM MC8P&.">AYH; P/\ A#O&^E,R65X)HR3C+)W]I QHT N>$OA=?PZFNKZY(ID1 MC($3!+.<\L5X !.< #FB_8"]XZ^%TVKWG]JZ/((;AL%T)V@L.C*W&TXQW[4) M@8%AX'\9R31FZO#''$ZMS(&X!Z84@G(]![_P>UP;XH1,%"[#GICKR?2A@6OB/\/I/%WEW M-HXCN8 5PWW64\@=L$'/.>]).PSS^[\'^-[VT_LR>6.2UP%VEXNBXQR &XP. M]/01KV7V[X3^'9FN51[B:?\ =A6RJ[E503@\X/.*-PV*?PB\+W,UW)X@OE*A M@1%N&"Y1]' MLUGMH7:/S)93&9&0E7V*(WR P(!)&<4]@.YM9))HE>5/*=AEDSG:?3/&:0$] M !0 4 9$.I227\EB8'6.*-7$YQL@""ZF-O$\JJ9"BE@J]6 M(&<#W- %72;U]1M8[F2)K=I!DQO]Y>2,''YT :- !0 $X_"@"M:7D-]&)K=Q M)&>C+TXH S]/U26\N;BV>"2%;=@%D;&V3(!RN/3./PHV V: "@ H * "@ H M* *EY86]^H2YC655(8!AD CH: +*(L8"J H'0#@"@!U !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0!!=?ZE_]QOY&@#R/P1INK2Z>);6]6"#[ M1<'RC$C8 N)-PW%"?FY[\9JF(W+.]U3Q7)*UG.+*Q@J> M*;V[2UN/L-I92^2-J(SR.$5BQ+ X'S8P#VHV [S3H+BV@6.[D\^5>LFT+G\% M _*D!S\6M3#6;NSD(^S6ULLP SDA2QSU/!/%,#$TMM8\4Q'4$NOL-N[,(( MDC1CM5BNYRRD\D'C/2C8"YI6O7JK?6-\5:[T]"ZRJ %D4JQ1MN >!D8'6@" MD/%MV-)LI(PLNH:BWEQY " EL%V Q\J+S[XHL FLKJOA^T;4GU!7DB 9H72) M8WY&47"AL^F.: +-UX@O]5N(--TO;;S2VZW,\KKGR48#"A2""Y+ ,\C M<5)Y]@%#3(M;\1VZZB;S[$DV6AACC1@J D+O+*22<9/)ZXHV V_"NL7-_\ M:+._"_:K&01NR<*X.=K@<8SM.1@4; =;2 * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * "@ H AN1F)P/[C?R- '&_#Z!X-(6.52C>?< M\,,'!GD(/X@Y%-@8>C:C_P (.9M-U-'6W,SRP7"J2C*^"58]F4@]^010!*TC M^,M5M;BV1TL-/9I3*ZE?-D*LBJF>P#DD\]*-@-'P/!)!)J7F*R;KYF7(QD>7 M'R/44,#OJ0'G;02?VYJ3[6V/8!5;'!.U> >YI@;/@>)X=&MDD4HP#Y4C!'[U MSTH Y]X9$U75Y"I"-9*%8C@D1MG!]J .8ET26_T+2[V%'G^Q$M)%&2':,DAM MA'.X#)'KTIB-"TN/#)="([B>?(Q%)YCLK>Z%L<>X- &UJQF\.:R-:$3RV=Q M()O+7+0E2I5MH_A^4 ],9I>0S?L/%MAK$GV6T+N[*3G8=J\?Q'L:+6 Y#P?K M]OH%HNDWRRQW<4K)LV$ELGAE]5/K0(4:')K$^MVA!C^T[!&Q& 6\A,'W ;K^ M-&P&AI?C.#2[9+/5DEMKN!0C)L)#[> T9XR"*+=AE*VM;K4_[3UN6)X%N;1X M+>)@0YC"?>8=06*@@>]'D!V/A&-HM(M4<%66( @\$')ZBD!D^&H9(]6U5V4J MKRP[21@-@2YQZ]:8' GRAPHIC 37 ultomirisr2.jpg begin 644 ultomirisr2.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! %$2 0 ! #_VP!# (! 0(! M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L, M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P 1" "A M 3@# 2( A$! Q$!_\0 'P 04! 0$! 0$ $" P0%!@<("0H+ M_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#]_**** "BBB@ HHHH ***I^(O$>G^$-"N]4U:^L]+TS3XFGNK MN[F6&"VC499W=B%50.220!0-)MV1&&9X]*KBG[&'FKR^4=+?]O-/R/VZ^.G_!:3 M]GSX(27%K'XSC\::M;EE-CX7C&HY<=4,X(ME;_9:4$>E?)/Q?_X.//$&HO-# MX ^&^F:7%AA%>>(;UKN4GH";>#8J^O$S5\G_ +-__!)#X^?M)+;7NF^![KPS MH\P#IJ7BECI,)Y_YXNINB#C(982I!'/-?;?P8_X-PM'M%AN/B'\2-4OY,AWL M?#MG':1+ZH9YQ*T@]Q'&>3[$='L\/3^)W?\ 78^R62<"Y+ICJOMJBZ7W+ M"R7I,^.OB3_P5\_:*^)EPS2_$B^T.W;'^BZ+96UC&OKAUC,W/O(2/6O&?%'[ M5/Q"\37$@UGXI>/KZ1B"RW?BN]D^G#3?E7[F?##_ () ?LZ_"R"-8?AIH^O3 M)DF;Q!))J[,2 "=MPSH.G15 ]J]R\)?!OP?X A2/0?"OAO18X\[%L-,AME7/ M7 11CI2^MTX_!'\D#\4>'\'[N6Y?IZ0I_DI?B?S2S>)-8\3/YTE_J6H,?F\Q MIWE)SWSD]_N_C_ , S_P"(V1V6!5O^OG_W,_F/TW]I+QAHMQYUC\1_%]A)@#-KXENH M, =,;)1TQ7HGA/\ X*'_ !X\#HHT[XO>/_E.1]MU9]2_#%SY@Q[8K][O&>M> M =5\1R>'[S3M&\2:ZJJTNDP6$=_J^N0?Q1_4Z)>*V5U8KZ]EU MD^_+*Z])1CH?D[\.?^"X/[1/A.-/MWB;0_%"QG&W5M#@7,/AMI-U$"%EN=&U.2W8' R5AE20'O@&4?6OHOQQ_P0[_ &>? M%HD:R\-ZUX:FDZRZ7K=S\OT2=I8Q_P!\UXC\0_\ @WMMM,L9F\!_$:Z\S.Z. MT\0V22*Y]YX NWC'_+%JY,14A)7@M3/^W. ,R]VOA_9-_P!QP_&DVOOT/HWX M*_\ !77X)_&4)"_B"?PGJ3#/V3Q#"+->W_+QEK;DG !E!/I7NLWBW6=5LX[C M0]'T_4+>==\4UQJJPQ2+C@AHDER#ZC-?BW\9?^";GQD_9Z:YFUCP?>:II<)_ MY">AG^T+4@=6(0>;&H[M)&@'Y9PO@'^TYX\_9XGCN/!_BC5-(C\S?):)+YEG M.=W.^!\QL3R,E=P[$'FO*JXITW[Z,\1X7Y;C:;Q.18A27:3YH^G-!IQ]&I,_ M9W4?%/Q>3/V7P/\ #N3#<>9XTNP2/I_9?!_&N?U7XA?'BTCW0?#7P)<-G[L? MBZ5L?BUJGY\?2O ?V8?^"SND^+$M=/\ B9I*Z#=2G8-7TU7FLF.<9DAYDC[< MJ9!GD[17VUX;\3:=XQT*UU32;^SU33;Y!+;W5I,LT,ZG^)74D,/<&BG4C77[ MNH_E:_XH_.I?M&?'?P^I>Z^ D=U& M"/FL?%=O*??"A2Q_(5CW?_!0WQ-X89V\1?!/QKI,,?WI%\V11V)W- B8]]V* M^HJ*YZV!Q;_@XF2]8P?_ +:CGHYYE?\ S$9=!_X9U8_G.2_ ^9]"_P""IO@# M49UCO-+\3Z?V9S;PRHOUVR%O_':](\#_ +9OPQ^(!5;+Q=IMM,Q"B+4"UBY8 M]AYP4,?]TFNN\8_"'PK\0E;^W/#>AZLS#&^ZLHY)!]&(W ^X.:\/^*/_ 3& M\#^+DEF\.W6H>%KQLE41C=VF?>.0[A]%=0/2O'JQXBP_O4Y4ZR[-.$GZ:\OW ML]>A+@[&>[5C6PTNZDJD%ZZPS.E*A/S5U\FE?YVMYG;B/#' M%5:+Q625X8JG_=:C+YIMI/RYK^1]P45R?PF^./A;XWZ)]N\-:O;Z@J >=#S' M<6Q/:2-L,OL2,''!(YKK*^QHUZ=:"J4I*47LT[I_,_.,3A:V'JNCB(N,H[II MIKU3"BBBM3 **** "BBB@ HHHH **** "BBB@ HHK(\?^/='^%G@?6/$OB+4 M+?2=!T&SEU#4+VX;;':P1(7=V]@H)XYH*C%R?+%7;.4_:@_:B\&_L??![4O& M_CC4QI^CV V1QH ]SJ$Y!*6\$>1OE?!P,@ LQ559A_/_P#\% /^"HGQ#_X* M%^)I%U>>;P[X#MYQ+I?A2UN-UO#M/RRW+@#[3/G!RPV(0/+53N9\#_@I!_P4 M-\1?\%$OVA;GQ%=->:?X-T?S+7PMHDC;186I89FE4'!N9MJM(>=N%C!*H&;[ MC_X(P_\ !%:T\8Z'HOQ@^,VDK=:?=*E]X8\*WD68[B,_-'>WL;#YE;(:.!N, M8=P251.N$537-+<_:\FRG <,X+^T\SUK/9;M/^6/G_-+ILG;?Y[_ .">O_!% MOXF?MH6UMXDU8R?#SX>W2AX=7OK?S+W5(R0=UG;$@LI .)I2J?,K*)AD5^P7 M[(/_ 3%^#O[%%M%/X3\,17OB0)MF\1ZR5OM6F]<2L L*D@$I L:9&=N>:^@ M%4(H51A1P .U%93KREIT/@L_XWS/-+TY3Y*7\D796_O/>7ST[)!114=S=1V5 MN\TTD<,48W.[L%51ZDGI6)\>245\W_M!_P#!6?X#?LYVER-2\=:=K^IVV0=, M\.L-4NMP&=K&,^5$?^NKH/>OGG0?VG_VFO\ @J$WV?X6Z$WP-^%UUE9/%VI! MI=0O8CCFV.%W$C/^H&T$'%RI%;1H2:YGHN[/J,#PCF%:E]:Q"5&BMYU/=C\D M_>D^RBFV?57[2?[?GP]_9JUZU\-W5W>>*/'^J$)IO@_P]!_:&M7SD$J/)4XB M4@%M\I1<*Q!.,5A>%_AO\8OVERNH?$S5F^%OA6;YHO!OA342=5N$.?EO]53: MR'!YCLO+P!.I*3T/R) M_:D_X)H^.OV7K:34K5#XN\)P[G?4[&$B6R49)-Q!DE% S\ZED &6*Y KE_V9 MOVJ_&G[,?B%;CPWJ)^PW#!KS2[K=)97?&"63(VO@##J0W !)&5/[/5\B_M@_ M\$N='^*5S/XD\ +9^'?$3%I;G3\>78:DQ!R0!_J92>X^1CG(!8O7S.8Y15A^ M_P &W=:VZ_+_ "/VKAWQ-PV.I_V;Q)"+C+3GM[K_ ,4>G^):+LK7/7/V6?VS MO"G[4NB+_9\G]E^((4W7>C7,@,T7JT;8 EC_ -I0",C5_NO<_,,9PSFV%=L1AJD?6,K?)VL_DSMZ\9_:%_8?\'_ !XA MGO$@7P_XBD^9=2LXQ^];_IM'PL@/<\/P,,!Q7J5EXYT74U5K;6-+N%;D&.[C M?/Y&KPOX&.!-"2>@WBM<9A,+C:3HXB*G%]_T[/S6ISY?F&/RRNL1A)2IS75: M?)K9KNFFC\N/B/\ "SQM^R1\2+?[1)Y?% M;X5:+\9_!%YX?UZU%Q8W0RK#B2WD&=LL;?PNN>#]0002#^7WQF^$VK? 3XG7 MWA_4&876GR"6VNH\I]HB)S',G<9QV/RL",Y6ORW'X7&<+8E8G!RP5^K8'&4L7AX8FB[Q MDKK^NZV?F?@N:9;7R_%U,%B5:<'9_P":\FM5W3"BBBNH\\**** "BBB@ HKX MV\=?\%U/@7X$\27VER-XPU"ZTVYDM)S::2-@='9&P9)$R,KU'7(KJ_V;_P#@ MKG\(?VI/BOH_@KPW-XDA\0:YYWV6&^TSRD;RH))WRZLRC"1OWY(Q73+!UU'G M<';T/G:7%V2U:ZPU/%0M6_@>;6'N/#\<,M['?V)MRBRLZI@Y(;/EMT/'% M?,W[6'[07[$OAK]I+Q:WQ(^&NA^+/B%:W,4&KWEYX134Y)Y(XDC4>9,"IV1A M%[ ! !T%=%/#U/:-4SZ?8M)X_\EJ_4;X%?ME_L2:[X\T'P_X3^%OA71-9\1:A;Z39I'\/K.UW M332K'&&>-, %V')/'6ONW1/AQX=\,QJFFZ#HNGK&J!P2GV/P]I,V[! .-MF>YQ7>>'/VV/V]OB T<>EZA\;+Y7.X/;_#J M(+CGJXTX #KU/7WK]F?VI/VN/!/[&_@C3_$'CF]O+'3=2OETZW:VLWN6:8QO M(!M0$@;8VY/M7A7_ _3_9Y_Z#WB#_P17'_Q-:4_:3CS0I77I_P#R,=XR<-X M*HZ&(P>&ISWM-T[Z[:WEU*^\2W##@];AHTC;/ M<%^Q]J^H?^'Z?[//_0>\0?\ @BN/_B:/^'Z?[//_ $'O$'_@BN/_ (FJY<7] MFG;T1Y,_'[!05L#6PM#S@H7_ !;7X&E^S1_P1?\ @7^SA-9WTGA^;QQKED0T M5_XE9+M86!R"ELJK;J5/W6\LN,#YJ^KHXUBC555551@ # KR7]E']N#X>_M MHV>N3> ]0OKY?#KPI>BYLI+5HS*'*8#@9!\M^1Z5Z-XZ\?:'\,?"UWKGB/5] M-T/1[%=]Q>WUPMO!".@R[$#D\ =23@5P5?:&X\C_ $F_TJ.6(#/I;RROQU^[ M^=;_ %#$-,IW_Q*WW[?B?<%%*[F:TT M'1%C:YDAA::0>9*D2!47DDO(H_'TKEY)S2;YKKELM6 M[[6MU.PHKXBO/^"_OP(M9ML=OX\N%_OQZ1&%_P#'I@?TKV?]DS_@HU\+?VT= M?U'2/!>J7QUC2[9;R:QU"T-K,T);:70$D.%8J&VD[2ZYZBMJF#KPCS3@TO0\ MC!\5Y-BZRP^&Q,)3>R4E=^G<]VHHHKG/H HKY/\ CO\ \%G?@I\ /B7JWA/4 M+OQ%K&K:%1)UBBE(VY.1MF3D'')]*VEAZL8\\HM+N>/A>(, MLQ.)>#P]>$JBO>*DF]-]/+J='\7/@9X3^.N@C3_%6BVFJPQY\F1P5GMB>ICE M7#H3QG:1G'.:^6OB3_P2/A5Y9O!?BAH58EEL]8BW $XX$T8R />-C[]Z^@?V MH_VQ? ?[''AG3M6\>:G=:;::M.UK:>192W332*N\KB-3CY>]<]^RU_P4 M3^%O[8_BO4-#\"ZMJ%]JFF6GVZXAN=-FMML.]4W!G4*?F=1@'/->3F'#^&QU M/GQ%*Z_F5U^*_4^JR?Q&Q&38I8#"8Q1F_P#EVY)WOKI!WW6MTD_,^1O%G_!/ M_P"*GA5WV^'8]6ACZS:?>Q2*?HK,LA_[YKA=8^ 7CK0G9;SP7XLAQ_$=)G9# M]&"E3^!K[\_:L_;\^&O[&&IZ+9^/-3O[*YU^*6:T2UL);HLD10,6V [>7&,] M>?2O)?\ A^G^SS_T'O$'_@BN/_B:^/J>%-"JN?#RFD_)27Y+\S[G_B9*&"JO M#YC*ASQW7/R2VOJG)][[(^/=0\':AI__ !]Z3?6^#C]]:.F/S%9I\B!L?N4/ MIP*^U/\ A^G^SS_T'O$'_@BN/_B:N:'_ ,%O/V<];OEMYO%VI:>LA $EUH5Y MY>?%]5T7Q%H]YGRKW3YH[B M%R/O#J:JII_P#E,_-+]AOXYK\'/C[IGG7*+I/B%ETJ^7>-H\Q@(I#_ +DA M7GLK/ZU^F=?(LW_!:S]FF*XV?\)9>,HSF0>'+[:/_(.?TKZRTG5(=;TJUO;5 M_,MKR)9XFP5W(P#*<'D9!'6OO.'N'<3DV'>&K3._$VF^ M&]/=BD37+EI;EAR5BB4&25@#DJBL0.<8KY1\5_\ !P-\#= U%H+'3O'^O1C_ M )>+/2X8XCSV$\\;_FM?34<+6JZTXMGP>:<2Y5ETN3'8B$)=FU?[M[?(^Y** M^(?"'_!?[X$^)+T0WUKX[\.Q]Y[[28Y(Q^%O-*W_ ([7U!\!OVI/A[^T]HDU M_P" O%NC^)(;94:XBMI"MS:!\[?-@<++%NVMC>HSM..AHJX6M3UG%H,MXFRK M,)&P#M/!P:*P<6MSV*=:G47-3DFO)W/RA_X*(_\ !'=?V6?A#XK^ M*4?Q#_MJ-=31TTDZ#]G(%S=!0/.^TO\ <\SKL^;';/'DO_!&7_E)?\,?][5/ M_33>U^F7_!<3_E'1XL_Z_P#3?_2V*OS-_P"",O\ RDO^&/\ O:I_Z:;VOJ<+ MB*E; 5)5'=ZK\#^:.)LCP65\:X"A@(R^5D?$\,9'@LRX&I1QL. M90564=6K23G9Z-7]'IY'X4_L7_\ )Y'PC_[';1?_ $X05_1]7\X/[%__ ">1 M$_^QVT7_P!.$%?T?4\__B1]##P,_P!PQ/\ C7_I)\]?\%&OV#Q^W[\*M#\- MKXH7PG-HNK#4UNSIOV_S%\F6(Q[/-BQGS V[B_R/T;..!;Z/['-,OWO)+#/3.*_3#P[_P;E3>(/#UAJ"_&2.'[=;1W'EGPB6V;U#8S M]MYQGK@5^:.N?\?5Y_OO_,U_35\-_P#DG>@_]@ZW_P#12U]!G&,K45#V3M>] M]O(_"/"GA7*\XJ8I9C2Y^3DY?>DK7YK_ M7V6Y\V_\ !/S]@.R_X)C^#_B! MJ6K>/(?$-AK$4%]>77%Y8^#].G8:#HC,!'91?=$LBCAIW'+,2<;BJG:!7ZZ?\ !8CQM=>! M?^"='Q&GLYO)N-0AM=,SG[T=Q=PPRK^,3R#\:_&']BCX:V?QA_:Z^&_AO4(X M9M-U3Q#9I>0RKN2>!90\L9'^VBLOI\U8Y5[ZGC*VK7Z(]CQ,D$/"<)Y5^[I M2L[7;NYS:2;;;:3N[-]5V5OJ3]CK_@A)XN_: ^'VG^*_&GB1? >FZM$MQ9:> MM@;K4)H6Y5Y SHL.X88 [VP>54\5W'QX_P"#=G6- \*76H?#OQU'X@U*VC+I MI&K62VC79')5+A7**QZ*'0+D\NHY'ZN45YLLXQ+GS)_*VA^A4?";AR&%^KSI M.4K:SYI'DZ3JC^&K/Q]:6[O,T'VQ] M)N;>ZCDDB9-T?F;)8&3.5R,,."*_,K_@NA\-K'X??M^:G=6,:PKXJT>SUJ=% M7:OG'S+=R!_M?9PQ/=F8]37UQ_P;J>,KC4OVW6VNA\'_ /!1G]@/_AW_ .._#>B?\)9_PEO_ D%A)?>=_9?V#R-DFS; MM\Z7=GKG(^E>1_ 7XX>(/V;_ (NZ%XV\+W(MM8T&Y$\0?)BN$Z20R $$QR(6 M1@"#AC@@X(^Y_P#@XT_Y+O\ #G_L W'_ *45\\?##]AZ?XU_\$[?%'Q4\/0S MW'B+P'XGN(=3MU8L+K2A9VLC.J]-\#N\AQC,;29R405WX;$*>%C*OKS:/YL^ M(XAR">&XDQ&%R6+C["TXI-MI1C&3LVVVU=O?TZ(_;O\ 9C_:)T']JOX(:#XZ M\-R-_9^M0[G@D/[VQG4[98)/]I'!7/0@!AE2"?(/^"JW[<WA!_AA5E(X(,CQ C!)'YO?\$9L1Z1>@;8[HGHJ, (Y#QQL8D",@^9_MN?M*Z]_P4,_:_N-0TFW MOKVVO[R/0_">E*,2" R;(5"GI),[;VR>&DQG:HQY-/*7'%-2^!:W\NW^9^HY MAXJ1K<-1J89_[94_=\JW4NLTNS3]W^\TM;,\$N+B2\N))II))IIF+R22,69V M)R22>22>23UK]B_^#=G_ ),W\7?]CM<_^F^PK\^O^"D/[)-C^Q9\0O ?@R"1 M;G5&\&6NHZW=*Q*W=_+>7HE9?1%")&O RL2D_,23^@O_ ;L_P#)F_B[_L=K MG_TWV%=N;5(U,'SQV;1\=X8Y?6P/%KPF)^.,97\G9-KY7L<__P '&W_)#OAO M_P!A^?\ ])C7BO\ P;K?\G4^-O\ L5&_]++>O:O^#C;_ )(=\-_^P_/_ .DQ MKQ7_ (-UO^3J?&W_ &*C?^EEO7+1_P"17+^NI])FG_)R:/\ V[_Z;9]J?\%( M/^"7R_\ !03Q'X4U)?&Y\(R>&;:YMF0Z/_: NA*T; _Z^+9MV'^]G<.F.?Q/ M^-WPW_X4U\:?&'@_[9_:7_"*:W>Z-]K\GR?M7V>=X?,V;FV[MF=NXXSC)ZU_ M3!7\X_[;W_)Z?Q@_['?6O_2^>KR+$5)7I-Z):?>8^-61X*@J68TH6JU9-2E= MZI126C=ELMDCZ\_9W_X((S?'[X$^$?&R_%B/25\5:5!J?V(^%S=[2&-F"@+C)R6&,-,*^8>WM9VOVTMZV+Q62\!K)G5YX*M[ M._NU).7/R_R\S5[]+6]#Y(_X))_M=:U^S-^UGX;TN.\F;PKXZU&WT;5[ M^Z M9IG$4-P >%>.1U);J4WKW&/WEK^=G_@G_P#![5OCE^V3\.]$TF"21H=;M=2O M)%4E;6TMI5FFD8]!A$(&>"[(O5A7]$U<^?1@JR:W:U/>\$\1B:F4U856W",[ M1OTNKR2\KV=N[\S^7>ZZ2?C7]-7PL_Y)CX;_ .P7;?\ HI:_F5NNDGXU_35\ M+/\ DF/AO_L%VW_HI:Z>(-H?/]#YWP'^/&>E/_V\_ O_ (*3?'_5_P!HC]LS MQSJ6I74TMGHNJ7&B:3 SDQVEI;2M$@0?P[RID8?WI&K[._8/_P""''@7XM?L M]>&/''Q U[Q%>:AXLL(]4@L-*N([:UM+>50T09BC.\FPJQ(*@%BNT[=Q^3_^ M"J/[)?B#]F+]K'Q3=7>GW7_"+^,-4N-7T741&3;SK.[2O 'Z"2)F92A.[:JM MC# FQ^RE_P %;_C!^R3X1M?#>DWVD>(?#-EQ:Z;K=JTRV2EB66*2-TD4'/"L MS*O91SGMJ0JU,+!825MCY++\9EV!XDQ4N*J+J-RENKI/FNFU=736UKJUK*VJ M^W/BY_P;M?#_ %O2Y'\$^-/%'A_4>2B:HL.HVA]%PJQ2+GINWMCK@]#G_L-_ M\$T_B9^RA\'_ (_6FMVMK=:QXDTV#3='&CZ@N[5[>-9GG$,AV-$THE$2F3RV M5P3P-KU3^#G_ <8Z#J5S%;^/OAWJ>DHQ56O=#O4O5ROZ4SF*1HMR2VT@Y,U[ MH^%_ ,\VO^,=2T73-=;Q#/J][J#>$?#>GZC--<>";A-?,FG7%[ITMP_]G1VU MCY+IY<%JL<0GMID:5H56=67_;K2\O+-7=@H,L]AU?S\_M9_L=>//V'/BFVE>)+2[A MMX[C?H^O6R,EKJ2JW1PFY*_92O9/NO0_HJK\T?^#COQ?8Q> _AAX?\Y6U*XU"\ MU$1 Y*0QQ)&68=LM* /7:WH:^;? _P#P78^/O@SP='I,U]X5U^6&/RDU+5-* M9[T#H"6BDC1F QRR$G&6R22?G_Q+XH^)O[=?QT%Q>-KGC[QQK6V&.*" /((U M/"I&@"0PIN). J+EF.,DU6!RFI1K>UJM6B8\9>)^7YME,LMRVG.52M96:VU3 M:T;NW:R2TZWZ/[K_ .#;O3YF\6?%RZV'R([32HBV.-Q>[('Y*:^[?^"C/_)A MOQ=_[%6__P#1+5SW_!,G]B;_ (8>_9PAT/4)H;KQ5KEP=4UV:$[HTG9558(S MU*1HH7/\3%V& V!T/_!1G_DPWXN_]BK?_P#HEJ\W$UHU<9SQVNOPLC]#X=R> MOEG"2P>)5IJG-M=G+FE;U5[/S/PI_8O_ .3R/A'_ -CMHO\ Z<(*_H^K^8OP M-XSU#X<>-]%\1:3,MOJWA^_@U.RE9!(L4\,BRQL5;(8!E4X(P<9;D.%K4<&]N(\\U^Z5K*T]M'(R[6=0Q'I MD5\[C,#4PUO:6U[>1^\\*\:9?Q![7ZBI+V?+?F27Q7M:S?9G\O\ KG_'U>?[ M[_S-?TU?#?\ Y)WH/_8.M_\ T4M?S*ZW_P ?=Y_OO_,U_35\-_\ DG>@_P#8 M.M__ $4M>QG^U/Y_H?E/@;_%QW_;GYS/%_\ @JG\,+SXN_\ !/\ ^)6DZ>C2 M7EOIR:K&BCNV=] M=^6NYFMTE4S*!ZF+>![FOZ3'42*58!E88((ZU^*W_!3;_@DAXE_9R\::MXP^ M'^CW>N?#>^D>[,%E&9KCPWGYFBDC'S-;KSLE .U1B0@@.^638FFHRP]33F_X M9H]+QVVCVV_9_0=>LO%.AV6J:;=6 M]]IVI0)=6MS XDBN(G4,CHPX964@@C@@U;K^?O\ 99_X*B_&']DGPY'HGAGQ M!:ZCX;AW=8MOMEK;%CD^405DC&OE*]K>;U\BK_P %C?CMIOQZ_;M\1W&CW$=YIGAFV@\/0W,; M!DG:#>TI!'4":650>?O7Y\_L(?\ !-GQU^VWXLLY+2QN]#\"QRC[?XBN(2L' MEAL/';9&)IN" %RJG[Y' /[P?"_X:Z/\'/AUHOA7P_:+8Z+X?LX[&S@!W%(T M4*,GJS'J6/+$DG))K?-*U.G0CA(.[5K_ "_4\7PSR?'9AG-;BC&PY(SYN7S< MNW>,8Z7ZOT9^5?\ P<:?\EW^'/\ V ;C_P!**]S_ .#>"".Z_8Z\9QR(LD\ ME]HCJO[NQ;=F6RSV\HD%,]8V3EF5R/J#_@@O^P@T!D^-_BBS9699;+PI!,G\ M)^2:^QUY^:)#QP9C@@HU?H'^TG^S'X-_:T^&K>$_'&F-J6D_:8[R/RY6AFMY MDSM>.1<,K;6=21U5V'0UV'A;POI_@CPSI^C:19V^GZ5I-M'9V=K NV.WAC4* MB*.P"@ ?2N:MFTYX94>NS?E_6Y]'E?A?A<)Q%/-E;V2]Z$.TWOY6CO'S:_EU M_'7_ (.&?^3VO#O_ &)5I_Z6W]?3_P#P;L_\F;^+O^QVN?\ TWV%?,'_ <, M_P#)[7AW_L2K3_TMOZ^G_P#@W9_Y,W\7?]CM<_\ IOL*[,5_R+(?(^2X=_Y. M+B?^W_R1S_\ P<;?\D.^&_\ V'Y__28UXK_P;K?\G4^-O^Q4;_TLMZ]J_P"# MC;_DAWPW_P"P_/\ ^DQKQ7_@W6_Y.I\;?]BHW_I9;TJ/_(KE_74K-/\ DY-' M_MW_ --L_82OYQ_VWO\ D]/XP?\ 8[ZU_P"E\]?T<5_./^V\<_MI?%__ +'? M6O\ TOGJ.'_XD_0[O'/_ ''"_P"-_P#I)]1_##_@A5K_ ,8/V5]'^(FA^/;. MXU;7M!36;+09-',?FR/'O6W^TF? )^Z',>,XR ,D?"T^GOHFMO::I:WEO)9W M!AO+9AY-Q$5;;)&0P^1Q@C##@CD=J_H6_P""=!_XP0^$?_8JV'_HE:^&?^"Z M'_!/,V-W/\;O!UC^XF*IXMLX$_U;\*E^%'8\)+COL?',C#HP6:2=>5&L]&]' M^AX/&'AOAZ62T'G$&"S3*(?5(1ING[LH1T47W2 M[2W3]4VVF?R\W723\:_IJ^%G_),?#?\ V"[;_P!%+7\RMUTD_&OZ:OA9_P D MQ\-_]@NV_P#12UZO$&T/G^A^8> _QXSTI_\ MY)XM\'>'?BQX9NM(US2]'\2 M:/<,8KBSO;>.[MW93@AD8%#;F9M[2: M'J;*F?:*<2QJ/9%7VQ7Y??%3]H;XP?LE?MB?$34=)UWQ1X'UK5?$FH:A-;R* MR0WHDN9"DC6\RF*9"#\K,C C&.*]B\)_\'!?QNT'38[?4-(^'VN/&FTW-QIM MQ#-*V/O-Y4ZI[D*B_A6$,LQ5-*6'GH^SM_P#V<5XC<,X^<\-GF%:E!M>]%3V M=M'I)>EE;NS(_P""D7_!(6]_8C\#0^--"\4?\)-X3DO$LKB*[MQ;WVGM(#Y9 M)4E)D+*02 A4LHVL,L(_^"$GQ6U3P/\ MX:;X?M9IO[+\:Z;=V5] "?+>8 A9)#)))(Y 8X&_;DYVY (^Q/^"&O_!/?Q5X%\=3?%[QMI-YH,*V,EGX> ML;V(Q75P9?EDNFC8;HTV HFX N)&;&T*6]"O*=/!2CBFG)Z+]#X3)<-@\=QA M0K<,TY1HPE&4KWLDOCW;LI+1)O=V6ED?J!1117R)_5850\3>%M+\:Z'<:7K. MFV&K:;>+LGM+VW2X@G7T9'!5A[$5?HH%**DK/8\2U'_@FW\!-4O3<2?"3P*K MG/RPZ7'#'_WP@"_I7H_PS^"_@_X+Z9)9^#_"OAWPO:S,&EBTG3HK-96Z981J M-Q]SDUTU%:2JSDK2;9QT,MPE"?M*-*,9=U%)_>D%4O$7AS3_ !AH-YI>K6%E MJFEZA$T%U9W<"SV]S&PPR.C JRD<$$$&KM?.'[2?[3GC#1?VMOAW\*O <.F+ MJ&KXU;5[B_0O$UF/.W1#'*G9#*^1\VX1 '!8&%?H='+3Q9 MJ$FFGQ1.]O9S&(M"A0QAFE?I&H\U26;@#)[5D_#G]MKX=_$[X6^)?&UCK$MO MX5\*W36E[J%Y;/"K,%C8%$(\QMWF(%7:'9B%"YP*U]M5_F?WL\_^Q\!_SXA_ MX#'_ "+*_L2_!A&!'PC^& (Y!'A:QX_\A5Z?7@?P;_X*5?"OXW_$*V\,Z7J6 MI66IZ@YCL?[0LC!%?/SA4?) 8X. ^TD\#+$"N\\,_M,>%?%GQYUOX;6L]ZOB MOP_:_;+N"6U9(_*_*]5MK:.RMXX88TAAA4(B(NU44# X M [5P%C^T_X3U/X\ZK\-[>:^F\4:+9_;KR-;5C##%LC?)D^[TEC&/5L55^%? M[6G@WXR?!W7/'6AW-_-X>\/&X%Y)+9O'*OD0K-)M0\M\C#&.IXI2E*7Q.X\/ MA*%"_L(*-][)*_W'=>,/&6E_#[PS>:SK=_:Z7I5@GF7%U/XCZ#)X"7Q5_;&GKX;:T_M#^TWG5;46^W=YI<\!-O.3QBO!/VL?C%H?Q\_ MX)P^,/%?AR6XFT?4K,B!YH6AD)CO%B;*MR/F1JUOA)#X?G_X)GZ'_P )6MQ) MX9C\!I)JJV^[S3:K:;I=FWG=M!QCG-%CH-W5/V8O@3^U#9?\)-)X+^'/C"/4 M&ZFBLC+#-<7 M DDNI@V58E\>:),9Z#':K7PB_P""D/PM^.'Q%TOPMX?U#5IM7UAG2V273I(D M8I&\C98\#Y4:K]I42LF[>IY\LJP,I^UE1@Y=^57^^USW:"".U@2.-%CCC4*B M*-JJ!P !V IU<+\,/VBO#/Q>\?>+O#6BSWDFJ^"+E;354EMFC2-V:11M8\,, MQ/R/2F_![]H_PO\ '2V\12^'Y[R9/"]Z^GW_ )ULT6R9 2P7/WAQU'%9'H%K MXG_L[> /C9=VUQXR\#^$O%5Q9H8K>;5](M[R2!"<*!V%>#WO_!7' MX,6MA9W$>J:U=+=N5=(M+DW6J@X#R!L<'G 7.F;WBW_@JG\&/"?B2VT_ M_A(+S4XYDC>6]T^PDGM;4.H8!VP&+!3RJ*Q4@J0&! OFG;EUL<\<+053VR@N M?O97^_<^C**Y;QS\:O"_PX^%\GC36-9M;?PS';QW2WR$RQS1R;?+,80$OOW+ MM"@DY&*\S^!7_!1?X8_M!>/(O#6C:AJ5GK%V&:SAU"S, O@H+'RV!*YVJ3M8 M@D X!P:BS.@V?C7\-_@E\3/BOHND^/\ P[\/]=\::E:F/3(M8TZWN+^X@0R/ MLC+J6**?-;;G .\XY-=U\,_A%X5^"^@2:5X/\-:#X6TV:8W$EKI-A%9PRRE5 M4R,L:@,Y5%!8Y)"@9X%?)?[;/Q'T?X0_\%&OA'XF\07?V'1M'T6ZFNI]C2%0 M4NU "J"6)9E4 #DD5[W^S9^VSX"_:JO]0L?"][>)JFF1^=/8WUOY$_E;@OF* M,D,H8@'!)4LN0-RYTE*7+:^AS1PE"-5UHP2F^ME?[]SN/B3\'O"/QETR"R\7 M^%O#OBJSM9/.A@UC38;Z.%\8W*LJL%;!(R.<5G_#7]G+X>_!G5+B^\'^!?!W MA6^NHO(FN-(T:WLIIH\AMC/&BDKD X)QD UV=(O%FI+I M^G)(L$>V-I);F5LE8XT4$LQ )XX 4DD $B>>5N6^@Y82@ZGMG!RO]^YV% M>6^)/V'_ (->,/$5YJ^J?"OX>ZAJFH3OVC485$10%5 M0. !4NK:3:Z_I5U8WUK;WMC>Q-!<6\\8DBGC8%61U;(96!(((P0<5Y_P## M+]J_P9\7/@QK'C[1;VZF\.Z$MPUY++;-%)%Y$0ED^1N>$((]AV7AC1;/3=-L[73]-T^!+:UM;: M)88;:)%"I&B* JJJ@ * !7$_%[]I?PK\$?&7A/P_KD]Z-6\:W1L]*@MK5 MIS+)YD4?S;?N#=,@R>.I[&O-?&G_ 5+^$/@+QIJ^@:CJ>L+J6AWT^GW2)ID MKJLT,C1N 0.0&4\CK52E.6[;.>A@\-0;=&G&+>]DE^1V4W[!OP/GF\QO@]\, M-WMX7L@#^'EXKU2UM8K&UC@@CCAAA4)'&BA510, #@ #C KP7]H/]I'7M<_ M8PF^)GPFN+(K"!J#2:E:'>UE%*RS[8SP&^0YW?P;\8;:1Z5^SK\7X_CY\$/# M7C".W^QG7+-9I8,[A!*"4D0'NH=6 /< 'BE*4I?$[CP^#P]"_L(*-][)*_W' M1>*O!>C^.M-:SUO2=-UBS;.8+ZU2XC.>ORN"*\TN?V /@;=S&1_@_P##4,?[ MGART0?D$ KUVBB-24?A8L1@<-7=ZU.,GYI/\T<'\.?V6OAG\']2^V^%?A_X+ M\.WW3[5IVC6]O/CT\Q4#8]LUWE%%$I.3NS2CAZ5&/)1BHKLDDOP"BBBI-@HH MHH **** "OCOXA?\IF_ W_8IO_Z*U"OL2OCGXG3+IW_!9GX?M.RQ+=>%72(L MHC ]\@BJB!#_P %2/#]GXM^.?[.VDZC;I=:?JOB=K*Z@?[LT,EUIZ.A M]BK$?C7NW[6'PV^'OB']G[4+'QY=?V!X)TUH;JY>TD^S!/+($:@(I)^8J%10 M23M !.!7BO\ P4HE6/\ :6_9D#,JEO&* GK_INFUO?\%>O!FL>+_P!D.232 M8;BXCT75[?4=0CB!)-LJ2QLQ Y*J\D;D_P (4L>%)!V$>$?M8?M(>!?C//\ M!6W\#Z9K=G#X9\1VD-E>7.DO9PBV#1*$AD( /*1G:,8V@\8KU?XXV7_"GO\ M@JU\,?$R[8=/\>Z9+H]R,?J]F/PKR/]KO]L;P;^T>/@W8^#;>^CT[ M1O$5B]Y)-:-;V^GRML6.T#'Y6<*)#\N5P@P3SCV__@KEH=WI7P4\+^/-+98= M5^'_ (CMK^*X8?ZE'.T?G.+;KZ50C$_8'M&^)O[1'[0'Q*E"RPW6J2:)ITXY M+11LY89_ZY):'CK7+_\ !.W_ )1A?%;_ 'M9_P#37#7M'_!,;X;'P;^Q1H+. M%6\\5&XUB=^OF>^84A-?*?[-G[2NC?LU?LJ?%+X2>*-/URV\>7$VHQ M6VFQV32&5I;)(>2.%">6SLQX,>&4MTH ]$\#_P#*$"]_Z]KS_P!.[UZYHO\ MRB/D_P"R83_^FYZX']G;X?W_ ,7?^".+Z%HL7VS4K^RU(VL,;#-Q)'J,\@C! MZ98IM&>YH^"G[0&G_$K_ ()M?$3P>=/U32?$/PV\"76F:O;WL'D[#]CN4C89 M.>1"VX,%*D$8Q@E >K?\$SDB?]A+P/YRQM&L=ZS;P-HQ?7')S7F?[$%H/VH/ MVOOB%\:IH5;0](D/A[PQP-@0* TJCJK>3M/IF\D':N'?XXR_!?\ X(O^')+& M3R[SQ4]UX?MYU;B$37=XTK9['R8Y0".0Q4]J[[_@GI^V'\*-)$^!_A+X=N= M5F\07$#B1WL3'#<7?ER7%PV[<3C*R;<]@HH[L"U^P!_R>1^TQ_V';?\ ]*+^ MJW_!,3_D!?'#_L;;S_T%JXKX=_M#:+^Q#^W#\;+?Q];ZI8P^,[N+4M+F@M&G M%RHDG= H7EMXN-H8?*&C920173?\$G=8;7_ 'QAO)()+6:Z\27$LUO(,26SM M$6:-AU#*3@@\Y%,#C_V%?#]CN% Z4O M[!DRR?\ !)KXJLK*R_9==Y!X_P"0:E6_AQ(K?\$0=08,I7[!J!R#Q_R$Y:.O MS&=[_P (1\/?''_!-#X9GIDU4_:4_:T$_M0_M _L_P G@V/4I=*T7Q1;)<75Q9M;0I/+& MD18\MMR '7!()H0CTW]J'2[?6?\ @J;\#X+J".XA_L^>;9(NY=\8NI$;'JKJ MK#T*BDOK*'PU_P %F+#[#%';_P!N>$VEO=BA?/;9*-Q]3^XBY/\ =K#_ &[/ MB=9_!S_@HG$?$E_;W=U9:3I,\US':Q&6983]I220(.2(U8N59C-(0IP=L1.!THZ > MD?$__@HW_P *U^(&M:#_ ,*J^)&K?V/=/:_;+/3]\%UM.-\9[J>QKB_^"B]Q M'XT^._[-.E7EN?[-UKQ$)[JRN$R''GV V.IX^[(ZD?[1K[*KY'_X*DZ9?>$] M7^$GQ+AT^ZU#2_AWXA%UJBVZ[FCA:6WDW'LJG[.4W' #.N2,U,=RCW/Q9^S! MX9\8?M >'?B7<'4+?Q-X9@:VMFMY5CAFC995(E7:2WRS..HX-?&P\6+^S+XY M_;"T,R?95NM._M2P"\")KK>J;1[-J$(_X"!7M'PO_;]OOVEOVK=$\-_#6QAU M+P#;V+W/B'5+S3YHYK9]DI18VWA5RPB4;T)8E\<+NKQ'_@IO\-[FX_;6\*6% MJWDV?Q:L+#0;P9P;@IJ,6X?AMM#_ ,!IQ[,GS.?^'.IW?[-?[(W[0G@/4)MM MQ!IFC7L:]-YU6WABF"_[H9%/T]C76?M0_!ZX^$7_ 3R^"7B:QMU75_A_=6> MJ2<8,)N_W\@]<_:?)%4_^"G7PVN[K]L;PII%@WV:Q^*]A8:'=*O_ "V>*_0$ MX]4!MSGTXK[(_:]^%Z_%/]ECQMX8;5)%.Y\;IO[HHZ@?7G[1W@/3_A=^P-XR\-Z5'Y> MFZ'X-NK*W4_>*1VK*"3W8XR3W))JI_P36_Y,A\!_]>]S_P"E<]0?'OXSZ'\9 MO^">OC;Q=H\TBZ-K?AN_6U>Z40NQ(DA (SP6D& ,Y.1W.*L?\$V8VB_8C\ A ME92;:=@",9!NIB#^((/XU/0H]RHHHJ0"BBB@ HHHH **** "BBB@ KS?XX?L MJ>$?V@/%7A76]>@O(]4\'WJWEE5PI#>2[#DQ[U5N"&!7Y67"WCW%]D481=QZG [^]3D;ASS7SO MXE_:\\._%7X5?$[3[ZQ^)'@6[$Z+_:-XJQ)I^L_8Y$9DN+1MY"L0I'S%2I( M!QSBQXD_;7\-? [PWX;TE=)\?>,)H?"UMK][-:VJ7EUI^G; HNKV1I%&\[69 MMNXDJQ. 02[ ?0 &!4+:9;O?"Z:WA-RJE!*8QY@4]1NZX]J\:^+?[=?A7X7W M6FPVND^*/%SZAH/_ E,G]AV2S?8=*/2[E\QTVH>< 9/RG('&>/E_; U7Q%^ MV3X)TGP_I_BC5/ OB3PW'?1?9K*W\F]^T/ T>H!G(E6"%)=LG*L&! C8@9+ M?38&T<<4$9KYK^&/[3?A?X/_ 6:^M[CXF>-)M7\7WFAZ?9:D\=_J]W>"1@T M,/SA1;IY;%=S#:O7D@5T=_\ M\^$['X5Z/XI71O%MQ_:WB(^%&TB*Q0ZI9:D M/,S;RQ&0#?E,85F.77WP6 ]PV*5QM&/3%((U4\*H_"N%_9^_:#TO]H?PWJ5] MI^GZSHUYH>HR:5J6FZK;B&[L;B,*Q1U5F7[K*002.?4$5\_>!_C[/J'[:7Q4 MU_Q9'X^TWPY\.=/1;2W:0)I>DP"U>2>6Y@CD.^6?;OA(5B5(!VG:H+ ?6]UI MMO>S0R36\,TENVZ)W0,T1]5)Z'Z5,!BO#/!7[>_AOQ9H?B:ZNO#OC#P]=^&_ M#I\5C3]4LXH;K4M-VLPN+<"1E8$C;\S+AF ]<=K^S[^T!9_M%>%7UO3=!\3: M/I;")[2?5[,6PU!'3=OA 9MR#INX!/*Y4@DLP.]" #&!CTQ1L&W;@8],5\U> M#?VI?"WP0\#>*-2,WQ/\6QW7Q+N_#'DW[Q7]W%?L!^XM%\P8LP4Q&F=X+D;> M:Q?VE?V[;V\_9!\9>(?!>G^+/"_BKP_JT.BWBWVGV_GZ!-YL3-).CL\9C>,[ M%90^6E7@"WAC)*QQ1A%7/)P!Q7BWBO M]N+3_!_B'0="N/ GQ$F\2^(=-?4K71X-.AFNU59VB*2!9BJ'"M)N)V!!][<0 MI=9_MY^$[[XJQ^'%TOQ.-/GU]_"L/B(V:_V3-JJYS:+)OWEBP*AMFTD'G;\U M%F![=M!;..?6H;'3K?2X/+M;>&WCW%MD2!%R>IP.YKQW2/VX_"VM?#;PEXCB MTSQ H\8>)E\)VNGO#"+RVO3))&?.7S=JHOE%B0Q(#+QDXJ'P+^WCX4\??$ZQ M\/V^D^*;6QUC4+K2M)U^YLE32=6NK?=YD<,@()/"T6M7-A$--_M%795@ M\Q96;+[>"%(Y&<8;;=O?V]/"=E\6G\,G2?%4EA#KR>%I?$:6*G1X=4; ^RM) MOWA@Q"D[,!CR=OS468'L^FZ5:Z-;>39VMO:PYW;(8Q&N?7 XJP5#'ITZ5X_X MA_;4\,>&_"GC+6)M/UY[?P/XCB\,WJ)#$7FN)'A0/'F0 QYF7)8J>#\O3.?\ M0?V]O"/PY^(6I:+=Z3XJNM,T&_MM,UGQ#;6*OI&CW,^T)'-*7#<;T#%58*64 M=3BBS ]P*ACTZ=**X_XX_&G3?@)X'77]6M=0N[-KVVL-EFBO('GE6)&(9E&T M,PR(Z5^WOX2/@7QMK&MZ3XJ\*WGP_2 MWDU?1]4L5CU!5N>+8QJKLK>:WRK\PP?O;003U7P$_:3TWX\7>O:?'HOB+PSK MWAF2%=1TG6[5;>Z@69"\,F%9E*NH;'.?E.0.,E@+7[1?[.N@_M._#@^%_$4F MI0:?]KAO-UC&?#5AX-\.V.DZ7:PV.FZ9 MEK:V\0PD$2*%50/0 5>HH **** "BBB@ HHHH **** "BBB@ HHHH *^ _V MLYT&D_MD?.ORS^$\\]/W5M7WY5*Z\-Z=>BZ$VGV4POMIN=\"M]HV_=WY'S8Q MQG.*:=@/C3]II@?BO^T..X^$UOD?C/7'>.;[0_"/Q'GE\7>.M:\"Z-K'PCTM MT_LX6IDUZ)(WCELT^T1.&D.[A$*M\V6+7$O\ 9[(XD6(*R_O,E,;CM W]"01V&F?#71;'PSHNE3:?:ZA; MZ!;Q6]FUY"DSQ"-%56!(X;"CD8I\PCY%\&_$GPC^RQ\?-+U/Q!>:EI/A>3X- M:;%I/]MI'%>WBV\A)M67A#=;"N8E/5O0UVVL_%;1[7]M#X/^*KZ.Y\.Z+XT\ M%3V&E#4(1 WVF>>VDBM6 )592K*-N>I KZ4UOPQIOB9(5U+3['4%MW\R(7," MRB-O[R[@<'W%6+RP@U!8UN(89UC=94$B!MCKR&&>A'8]J+C/S]^'^N6?@G0O MACXFU:ZAT_0=(^+VO17M],VV"T,WGHAD;HJ[A@LV .Y INEW\>O:#X?URTD\ M[1_$G[3/]H:7&--N=*FL9-.L9+&X8M+;M;J M8I23DEEQ@DGGD=:5/#FGQV5K;+862V]@RO;1"!=ENR_=*#&%([$8Q1S"L>%_ ML8-GXP_'SV\;L#[?Z+#7E'Q6TBYU[6?VTK6SCDFN&TG1W"1CUO)[B*WACN+K;YTJ1A7 MFVC"[CU.!P,]*.89\&^,?B)HGQB\9>-]<\,:A;ZMI.D_L^W5A?7-JV^.UN)' M>1;>0C[LFU6)4\C:>X./KS]EC;_PS%\.=N-O_"+Z9C'3'V2*NJTWP=I&C65S M;6>EZ;:V]X2;B*&V2-)R1@[P!ALCCFK]M;1V=O'##&D4,2A$1%VJBC@ < M=J5P/@"W8#P_#S_S=.H_\CBK'Q\TBZU_X-?M@6]G!)=31^(M-G9(QN98XA:2 MR,?98U9CZ $U]V+X9T]2?]!L\?:?M@'D)@3_ //7I]__ &NOO5BVTVWLYII( M;>&*2Y;?,R1A6E.,98CJ<>M/F%8^;/#7Q!T3XH?\%"O!^N>'M2M=6TG4?AK> M26US VY)5&I1H??AE*D'D$$'D5X5XP^-=Y\6?B?X)_M[QIMUJQ^-%K8P^!XK M>VA32+6"Y:-;AQL\]I#D R,^PF4@+E?E_0&P\-Z=I^;2]-:^D=)'N#;)YK,GW&+8R2O8YX[4._>Z6WA6ZD01O,(QYC*.@+=2!Z57@\,Z;:ZW-J<>GV,>I7"[ M);M8%6>1>.&?&XC@<$]A1S ?"?AN9#\%? 'S+_R<.J]>_P!MN.*S=9\1Z?!H M?BKX>M=PP^-=0^/0O8-(8[;J6WDNXI4N GWO*,8W;\8QCGD9^_U\-Z&--;75U0Z?8G4U3RQ=F!?/"]-N_&['MF MCF"Q^?/QO^(6A^'?!OQU\*W^J6=GXDU3XIV5Y::9,^RZN(#+9N)50\E-L;'= MTZ?WESUG[0_Q8T?X-_&'QMKO@'7=2T7QW#KUA9ZUX#U:&*:U\;-*852>UBRS MJ6C<-YJ8/R8*J6!;[6O_ 9H^JZ@]W=:3IMS=21B)YI;5'D9 00I8C) (!QT MR*ENO#>G7NL0:A-I]E-J%JNV&Y>!6FB'/"N1D#D]#W-',!X?_P %++M=/_95 MO+R59!;66M:3<7$@7<((UOX"SMCL/;UKP[6_'WPY^(GCO]JC6M8:^\6> +R/ MPLEQ<^'G6:1-D3QBXB?< 1#,H8L"0!&V0PR#]U7EG#J-I+;W$4<\$R&.2.10 MR2*1@@@\$$=C573?"VF:-!)%9Z;8VL+;>%'NF@-U&\L$TJ I/) JA]^" M M1%)#_+A&--T#3&LK#3[&QLW)+06\"QQ,3P XML 38 alxn630201910q_htm.xml IDEA: XBRL DOCUMENT 0000899866 2019-01-01 2019-06-30 0000899866 2019-07-22 0000899866 2018-12-31 0000899866 2019-06-30 0000899866 2018-04-01 2018-06-30 0000899866 2018-01-01 2018-06-30 0000899866 2019-04-01 2019-06-30 0000899866 alxn:NetProductSalesMember 2018-04-01 2018-06-30 0000899866 alxn:NetProductSalesMember 2018-01-01 2018-06-30 0000899866 alxn:OtherRevenueMember 2019-01-01 2019-06-30 0000899866 alxn:OtherRevenueMember 2018-01-01 2018-06-30 0000899866 alxn:NetProductSalesMember 2019-01-01 2019-06-30 0000899866 alxn:OtherRevenueMember 2019-04-01 2019-06-30 0000899866 alxn:NetProductSalesMember 2019-04-01 2019-06-30 0000899866 alxn:OtherRevenueMember 2018-04-01 2018-06-30 0000899866 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000899866 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000899866 us-gaap:TreasuryStockMember 2018-12-31 0000899866 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000899866 us-gaap:TreasuryStockMember 2019-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000899866 us-gaap:CommonStockMember 2018-12-31 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000899866 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000899866 us-gaap:RetainedEarningsMember 2018-12-31 0000899866 us-gaap:RetainedEarningsMember 2019-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000899866 us-gaap:TreasuryStockMember 2019-01-01 2019-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000899866 us-gaap:CommonStockMember 2019-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000899866 us-gaap:RetainedEarningsMember 2018-06-30 0000899866 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000899866 us-gaap:CommonStockMember 2018-06-30 0000899866 us-gaap:CommonStockMember 2018-03-31 0000899866 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000899866 us-gaap:TreasuryStockMember 2018-06-30 0000899866 us-gaap:TreasuryStockMember 2018-03-31 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000899866 us-gaap:RetainedEarningsMember 2018-03-31 0000899866 2018-03-31 0000899866 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000899866 2018-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000899866 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000899866 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000899866 2019-03-31 0000899866 us-gaap:RetainedEarningsMember 2019-03-31 0000899866 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000899866 us-gaap:TreasuryStockMember 2019-03-31 0000899866 us-gaap:CommonStockMember 2019-03-31 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000899866 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000899866 2017-12-31 0000899866 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0000899866 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0000899866 us-gaap:CommonStockMember 2017-12-31 0000899866 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000899866 us-gaap:TreasuryStockMember 2017-12-31 0000899866 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0000899866 us-gaap:RetainedEarningsMember 2017-12-31 0000899866 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 0000899866 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000899866 alxn:SyntimmuneIncMember 2018-11-01 2018-11-30 0000899866 alxn:SyntimmuneIncMember 2018-11-30 0000899866 us-gaap:InProcessResearchAndDevelopmentMember 2018-04-30 0000899866 alxn:SyntimmuneIncMember 2018-01-01 2018-12-31 0000899866 alxn:SyntimmuneIncMember us-gaap:InProcessResearchAndDevelopmentMember 2018-04-01 2018-06-30 0000899866 us-gaap:InProcessResearchAndDevelopmentMember 2018-05-25 0000899866 us-gaap:InProcessResearchAndDevelopmentMember 2018-05-25 2018-05-25 0000899866 alxn:SynagevaBioPharmaCorp.Member alxn:PurchasedTechnologyMember 2019-06-30 0000899866 alxn:PurchasedTechnologyMember 2019-06-30 0000899866 us-gaap:LicensingAgreementsMember 2019-06-30 0000899866 us-gaap:LicensingAgreementsMember 2018-12-31 0000899866 us-gaap:PatentsMember 2018-12-31 0000899866 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0000899866 us-gaap:PatentsMember 2019-06-30 0000899866 alxn:PurchasedTechnologyMember 2018-12-31 0000899866 us-gaap:OtherIntangibleAssetsMember 2019-06-30 0000899866 srt:MaximumMember alxn:PurchasedTechnologyMember 2019-01-01 2019-06-30 0000899866 srt:MinimumMember alxn:PurchasedTechnologyMember 2019-01-01 2019-06-30 0000899866 srt:MinimumMember us-gaap:LicensingAgreementsMember 2019-01-01 2019-06-30 0000899866 srt:MaximumMember us-gaap:LicensingAgreementsMember 2019-01-01 2019-06-30 0000899866 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-06-30 0000899866 us-gaap:PatentsMember 2019-01-01 2019-06-30 0000899866 us-gaap:RevolvingCreditFacilityMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2019-01-01 2019-01-31 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2019-06-30 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2018-06-07 0000899866 alxn:SeniorSecuredTermLoanMember alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2019-04-01 2019-06-30 0000899866 alxn:CreditAgreementMember us-gaap:LineOfCreditMember 2019-06-30 0000899866 us-gaap:RevolvingCreditFacilityMember alxn:CreditAgreementMember 2018-06-07 0000899866 us-gaap:CashAndCashEquivalentsMember 2019-06-30 0000899866 us-gaap:CashAndCashEquivalentsMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember 2018-12-31 0000899866 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0000899866 us-gaap:CertificatesOfDepositMember 2018-12-31 0000899866 us-gaap:CorporateBondSecuritiesMember 2018-12-31 0000899866 us-gaap:DebtSecuritiesMember 2018-12-31 0000899866 us-gaap:CommercialPaperMember 2018-12-31 0000899866 us-gaap:CertificatesOfDepositMember 2019-06-30 0000899866 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0000899866 us-gaap:CorporateBondSecuritiesMember 2019-06-30 0000899866 us-gaap:DebtSecuritiesMember 2019-06-30 0000899866 us-gaap:CommercialPaperMember 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-04-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-04-01 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-04-01 2018-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-04-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-04-01 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2019-04-01 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2018-04-01 2018-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember 2018-01-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2018-04-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2019-04-01 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-04-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2018-01-01 2018-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:SalesMember 2019-01-01 2019-06-30 0000899866 alxn:InterestRateSwapThreeMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 alxn:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 alxn:InterestRateSwapOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 alxn:InterestRateSwapTwoMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 alxn:ForeignExchangeForwardOpenExpenseMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0000899866 us-gaap:NondesignatedMember 2018-01-01 2018-06-30 0000899866 us-gaap:NondesignatedMember 2019-01-01 2019-06-30 0000899866 us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SalesMember 2019-01-01 2019-06-30 0000899866 us-gaap:NondesignatedMember 2018-04-01 2018-06-30 0000899866 us-gaap:NondesignatedMember 2019-04-01 2019-06-30 0000899866 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0000899866 srt:MaximumMember alxn:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 srt:MinimumMember alxn:InterestRateSwapFourMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 srt:MinimumMember alxn:InterestRateSwapOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 srt:MaximumMember alxn:InterestRateSwapOneMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0000899866 alxn:ZealandMember 2019-03-01 2019-03-31 0000899866 alxn:DicernaMember 2019-01-01 2019-06-30 0000899866 alxn:CaelumBiosciencesMember 2019-01-01 2019-01-31 0000899866 alxn:ModernaLLCMember 2019-06-30 0000899866 alxn:ZealandMember 2019-06-30 0000899866 alxn:ModernaLLCMember 2019-01-01 2019-06-30 0000899866 alxn:ZealandMember 2019-04-01 2019-06-30 0000899866 alxn:ModernaLLCMember 2018-04-01 2018-06-30 0000899866 alxn:ModernaLLCMember 2014-01-01 2014-12-31 0000899866 alxn:ModernaLLCMember 2019-04-01 2019-06-30 0000899866 alxn:ZealandMember 2019-01-01 2019-06-30 0000899866 alxn:ModernaLLCMember 2018-12-31 0000899866 alxn:DicernaMember 2018-12-31 0000899866 alxn:DicernaMember 2018-10-01 2018-10-31 0000899866 alxn:DicernaMember 2019-04-01 2019-06-30 0000899866 alxn:DicernaMember 2019-06-30 0000899866 us-gaap:CommonStockMember 2017-02-28 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-06-30 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-06-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-12-31 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-06-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-04-01 2018-06-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-04-01 2019-06-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-06-30 0000899866 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-06-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-01-01 2018-06-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2017-12-31 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000899866 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0000899866 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000899866 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2018-06-30 0000899866 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0000899866 alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 alxn:CaelumBiosciencesMember srt:MinimumMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-03-31 0000899866 us-gaap:SubsequentEventMember 2019-07-01 2019-09-30 0000899866 alxn:CaelumBiosciencesMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-01-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-06-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0000899866 srt:MinimumMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-01-01 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember 2019-06-30 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel2Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:OtherLiabilitiesMember alxn:OtherContingentPaymentsMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member alxn:OtherContingentPaymentsMember 2019-06-30 0000899866 alxn:ContingentConsiderationCurrentMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember 2019-06-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:FairValueInputsLevel3Member alxn:OtherContingentPaymentsMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member alxn:OtherContingentPaymentsMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember alxn:OtherContingentPaymentsMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 alxn:CurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 alxn:ContingentConsiderationCurrentMember alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 alxn:CurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2019-06-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 alxn:CurrentLiabilitiesMember us-gaap:InterestRateContractMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 alxn:CurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:OtherAssetsMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 alxn:ContingentConsiderationMember alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 alxn:ContingentConsiderationCurrentMember us-gaap:FairValueInputsLevel2Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000899866 alxn:ContingentConsiderationCurrentMember us-gaap:FairValueInputsLevel1Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member alxn:OtherContingentPaymentsMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2019-06-30 0000899866 us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-06-30 0000899866 us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2019-01-01 2019-06-30 0000899866 us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2018-12-31 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateContractMember 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 alxn:ContingentConsiderationCurrentMember us-gaap:FairValueInputsLevel2Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 alxn:ContingentConsiderationMember alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel2Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 alxn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:OtherGovernmentObligationsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember 2018-12-31 0000899866 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2018-12-31 0000899866 alxn:ContingentConsiderationCurrentMember us-gaap:FairValueInputsLevel1Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 alxn:ContingentConsiderationCurrentMember alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0000899866 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 alxn:ContingentConsiderationCurrentMember us-gaap:FairValueInputsLevel3Member alxn:AcquisitionRelatedContingentConsiderationMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CorporateBondSecuritiesMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0000899866 us-gaap:OtherAssetsMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeForwardMember 2018-12-31 0000899866 alxn:MarketableSecuritiesMember alxn:MutualFundsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0000899866 us-gaap:CashEquivalentsMember us-gaap:MunicipalBondsMember 2018-12-31 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2019-01-01 2019-06-30 0000899866 alxn:KanumaProductLineMember 2019-04-01 2019-06-30 0000899866 country:US alxn:KanumaProductLineMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2019-04-01 2019-06-30 0000899866 alxn:StrensiqProductLineMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2018-04-01 2018-06-30 0000899866 alxn:StrensiqProductLineMember 2019-01-01 2019-06-30 0000899866 country:US alxn:KanumaProductLineMember 2019-01-01 2019-06-30 0000899866 us-gaap:ProductMember 2019-04-01 2019-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2019-04-01 2019-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2019-01-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2018-04-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2018-01-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2019-01-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2019-04-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2019-01-01 2019-06-30 0000899866 country:US alxn:UltomirisMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2018-01-01 2018-06-30 0000899866 alxn:UltomirisMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2018-04-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2018-04-01 2018-06-30 0000899866 country:US alxn:StrensiqProductLineMember 2018-01-01 2018-06-30 0000899866 alxn:SolirisMember 2018-04-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2019-01-01 2019-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2018-04-01 2018-06-30 0000899866 country:US alxn:SolirisMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2019-04-01 2019-06-30 0000899866 country:US alxn:SolirisMember 2019-01-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2019-01-01 2019-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:KanumaProductLineMember 2018-01-01 2018-06-30 0000899866 alxn:UltomirisMember 2019-01-01 2019-06-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2019-04-01 2019-06-30 0000899866 alxn:UltomirisMember 2018-04-01 2018-06-30 0000899866 country:US alxn:SolirisMember 2019-04-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:KanumaProductLineMember 2018-04-01 2018-06-30 0000899866 alxn:UltomirisMember 2019-04-01 2019-06-30 0000899866 country:US alxn:StrensiqProductLineMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:UltomirisMember 2018-04-01 2018-06-30 0000899866 srt:EuropeMember alxn:SolirisMember 2018-04-01 2018-06-30 0000899866 alxn:KanumaProductLineMember 2018-01-01 2018-06-30 0000899866 country:US alxn:UltomirisMember 2019-01-01 2019-06-30 0000899866 country:US alxn:SolirisMember 2018-04-01 2018-06-30 0000899866 alxn:SolirisMember 2019-01-01 2019-06-30 0000899866 country:US alxn:StrensiqProductLineMember 2019-01-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2018-01-01 2018-06-30 0000899866 country:US alxn:KanumaProductLineMember 2018-04-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:StrensiqProductLineMember 2019-01-01 2019-06-30 0000899866 alxn:StrensiqProductLineMember 2018-01-01 2018-06-30 0000899866 us-gaap:ProductMember 2018-04-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2019-04-01 2019-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2018-01-01 2018-06-30 0000899866 alxn:SolirisMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2018-04-01 2018-06-30 0000899866 country:US alxn:UltomirisMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2018-01-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2018-04-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2018-01-01 2018-06-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2019-01-01 2019-06-30 0000899866 country:US alxn:StrensiqProductLineMember 2018-04-01 2018-06-30 0000899866 srt:EuropeMember alxn:SolirisMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:SolirisMember 2019-01-01 2019-06-30 0000899866 alxn:SolirisMember 2019-04-01 2019-06-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2018-04-01 2018-06-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2018-04-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:StrensiqProductLineMember 2019-04-01 2019-06-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2019-01-01 2019-06-30 0000899866 alxn:KanumaProductLineMember 2019-01-01 2019-06-30 0000899866 srt:EuropeMember alxn:KanumaProductLineMember 2018-01-01 2018-06-30 0000899866 alxn:StrensiqProductLineMember 2018-04-01 2018-06-30 0000899866 us-gaap:ProductMember 2018-01-01 2018-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:UltomirisMember 2019-01-01 2019-06-30 0000899866 srt:EuropeMember alxn:SolirisMember 2018-01-01 2018-06-30 0000899866 srt:EuropeMember alxn:StrensiqProductLineMember 2018-01-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:UltomirisMember 2018-01-01 2018-06-30 0000899866 srt:AsiaPacificMember alxn:SolirisMember 2019-04-01 2019-06-30 0000899866 alxn:KanumaProductLineMember 2018-04-01 2018-06-30 0000899866 country:US alxn:UltomirisMember 2018-04-01 2018-06-30 0000899866 country:US alxn:KanumaProductLineMember 2019-04-01 2019-06-30 0000899866 us-gaap:ProductMember 2019-01-01 2019-06-30 0000899866 alxn:OtherNonUsExcludingEuropeAndAsiaPacificMember alxn:SolirisMember 2019-01-01 2019-06-30 0000899866 alxn:IntellectualPropertyElectionMember 2019-01-01 2019-06-30 0000899866 alxn:WilsonTherapeuticsMember 2018-04-01 2018-06-30 0000899866 alxn:ValuationAllowanceReleaseMember 2019-01-01 2019-06-30 0000899866 alxn:WilsonTherapeuticsMember 2018-01-01 2018-06-30 0000899866 alxn:LonzaGroupAGMember 2019-06-30 0000899866 alxn:InventoryMember 2019-01-01 2019-06-30 0000899866 alxn:LonzaGroupAGMember 2018-12-31 0000899866 alxn:InventoryMember 2019-04-01 2019-06-30 0000899866 us-gaap:OtherCurrentAssetsMember 2019-06-30 0000899866 us-gaap:OtherLiabilitiesMember 2019-06-30 0000899866 alxn:RightOfUseOperatingLiabilitiesMember 2019-06-30 0000899866 us-gaap:PropertyPlantAndEquipmentMember 2019-06-30 0000899866 alxn:RightOfUseOperatingAssetsMember 2019-06-30 0000899866 alxn:AffibodyMember alxn:AffibodyABDomain 2019-01-01 2019-06-30 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-06-30 0000899866 alxn:DOJAndOIGMember 2019-06-30 0000899866 alxn:CaelumBiosciencesMember us-gaap:CollaborativeArrangementMember 2019-01-31 0000899866 alxn:AffibodyMember alxn:AffibodyABDomain 2019-03-01 2019-03-31 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-01-01 2019-06-30 0000899866 alxn:CanadianPatentedMedicinePricesReviewBoardMember 2019-06-21 0000899866 alxn:OtherThirdPartyManufacturersMember 2019-06-30 0000899866 alxn:CollaborationandLicenseAgreementMember 2019-01-01 2019-06-30 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-03-01 2019-03-31 0000899866 alxn:ZealandMember alxn:ZealandPharmaMember 2019-04-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember 2019-01-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember 2018-01-01 2018-06-30 0000899866 us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000899866 us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-06-30 0000899866 us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2018-01-01 2018-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember 2019-01-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2018-01-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-06-30 0000899866 us-gaap:FacilityClosingMember 2018-01-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:FacilityClosingMember 2019-01-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember 2018-01-01 2018-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2019-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2019-03-31 0000899866 us-gaap:EmployeeSeveranceMember 2019-04-01 2019-06-30 0000899866 us-gaap:OtherRestructuringMember 2018-12-31 0000899866 us-gaap:FacilityClosingMember 2019-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2018-12-31 0000899866 us-gaap:OtherRestructuringMember 2019-06-30 0000899866 us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000899866 us-gaap:FacilityClosingMember 2018-12-31 0000899866 us-gaap:FacilityClosingMember 2019-04-01 2019-06-30 0000899866 us-gaap:FacilityClosingMember 2019-03-31 0000899866 us-gaap:OtherRestructuringMember 2019-03-31 0000899866 us-gaap:CostOfSalesMember us-gaap:FacilityClosingMember 2018-04-01 2018-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2018-04-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2019-04-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2019-04-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:EmployeeSeveranceMember 2018-04-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:FacilityClosingMember 2019-04-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:EmployeeSeveranceMember 2018-04-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember 2018-04-01 2018-06-30 0000899866 us-gaap:EmployeeSeveranceMember 2018-04-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeSeveranceMember 2018-04-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:FacilityClosingMember 2018-04-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:FacilityClosingMember 2018-04-01 2018-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:EmployeeSeveranceMember 2019-04-01 2019-06-30 0000899866 us-gaap:FacilityClosingMember 2018-04-01 2018-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:FacilityClosingMember 2019-04-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember 2018-04-01 2018-06-30 0000899866 alxn:RestructuringExpenseMember 2019-04-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:EmployeeSeveranceMember 2018-04-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember 2019-04-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:FacilityClosingMember 2018-04-01 2018-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000899866 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:FacilityClosingMember 2018-04-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:EmployeeSeveranceMember 2019-04-01 2019-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:FacilityClosingMember 2019-04-01 2019-06-30 0000899866 us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000899866 us-gaap:CostOfSalesMember us-gaap:FacilityClosingMember 2019-04-01 2019-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:EmployeeSeveranceMember 2019-04-01 2019-06-30 0000899866 alxn:RestructuringExpenseMember us-gaap:OtherRestructuringMember 2019-04-01 2019-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000899866 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2018-04-01 2018-06-30 0000899866 us-gaap:OtherIncomeMember us-gaap:FacilityClosingMember 2019-04-01 2019-06-30 iso4217:USD iso4217:SEK shares shares iso4217:USD shares pure 44200000 26600000 false --12-31 Q2 2019 0000899866 0.0001 0.0001 290000000 290000000 236200000 237300000 0.0283 0.0162 0.0279 0.0098 P16Y P8Y P6Y P6Y P5Y P7Y 323000000 323000000 323000000 323000000 15400000 10500000 -12100000 -14300000 300000 12700000 13100000 10-Q true 2019-06-30 false 0-27756 ALEXION PHARMACEUTICALS, INC. DE 13-3648318 121 Seaport Boulevard Boston MA 02210 475 230-2596 Common Stock $0.0001 par value ALXN NASDAQ Yes Yes Large Accelerated Filer false false false 224226878 1984200000 1365500000 105400000 198300000 1123600000 922300000 494600000 472500000 460700000 426400000 4168500000 3385000000.0 1123500000 1471500000 3487600000 3641300000 5037400000 5037400000 209500000 0 541200000 396700000 14567700000 13931900000 728700000 698200000 0 250000000.0 126600000 93800000 100000000.0 97600000 76200000 34400000 1031500000 1174000000.0 2438300000 2501700000 158200000 183200000 0 361000000.0 341200000 391100000 165500000 0 269500000 155600000 4404200000 4766600000 0 0 8677000000.0 8539100000 1738800000 1689900000 -57900000 -9700000 3283200000 2325800000 10163500000 9165300000 14567700000 13931900000 1202500000 1044700000 2342700000 1975100000 800000 300000 1000000.0 800000 1203300000 1045000000.0 2343700000 1975900000 99200000 95300000 185000000.0 186900000 187600000 173400000 383500000 350000000.0 299300000 277300000 580800000 534400000 -4100000 803700000 -4100000 803700000 80100000 80100000 160100000 160100000 6100000 4700000 -22600000 57400000 2500000 10600000 11600000 16100000 571500000 1349800000 1109300000 1921700000 532600000 -400100000 1049400000 -132700000 -14900000 7700000 27600000 113500000 18300000 25000000.0 38200000 49100000 100000 -1200000 2500000 1300000 499500000 -418600000 1041300000 -67000000.0 39700000 38800000 -6400000 141300000 459800000 -457400000 1047700000 -208300000 2.05 -2.05 4.68 -0.94 2.04 -2.05 4.64 -0.94 224200000 222600000 224000000.0 222300000 225600000 222600000 225700000 222300000 459800000 -457400000 1047700000 -208300000 1500000 -8100000 -500000 -4300000 0 0 200000 -400000 0 0 0 -700000 -38900000 50900000 -47900000 35500000 -37400000 42800000 -48200000 31500000 422400000 -414600000 999500000 -176800000 237000000.0 0 8604900000 12800000 -1701200000 -20500000 2823400000 9706600000 300000 37600000 37600000 100000 11200000 11200000 200000 0 0 60900000 60900000 459800000 459800000 -37400000 -37400000 237300000 0 8677000000.0 13100000 -1738800000 -57900000 3283200000 10163500000 235200000 0 8350900000 12700000 -1689900000 -45700000 2497400000 9112700000 0 0 0 200000 15100000 15100000 100000 300000 300000 53900000 53900000 -457400000 -457400000 42800000 42800000 235500000 0 8420200000 12700000 -1689900000 -2900000 2040000000.0 8767400000 236200000 0 8539100000 12700000 -1689900000 -9700000 2325800000 9165300000 400000 48900000 48900000 200000 21300000 21300000 900000 0 0 116600000 116600000 1047700000 1047700000 -48200000 -48200000 -90300000 -90300000 237300000 0 8677000000.0 13100000 -1738800000 -57900000 3283200000 10163500000 234300000 0 8290300000 12000000.0 -1604900000 -34400000 2242100000 8893100000 700000 85000000.0 85000000.0 300000 24600000 24600000 900000 105300000 105300000 -208300000 -208300000 31500000 31500000 6200000 6200000 235500000 0 8420200000 12700000 -1689900000 -2900000 2040000000.0 8767400000 1047700000 -208300000 193700000 202000000.0 -22600000 57400000 117600000 105200000 0 86600000 -40800000 111500000 4100000 -12700000 -11300000 -3100000 8600000 100500000 2300000 -13200000 196400000 137000000.0 24000000.0 4100000 126800000 55700000 23600000 -130600000 968300000 -44500000 41100000 612800000 139300000 1054800000 10900000 7500000 9000000.0 5900000 82800000 129400000 43800000 0 8000000.0 0 -200000 -2600000 -38100000 313600000 0 7600000 0 250000000.0 32700000 293800000 250000000.0 0 48900000 85000000.0 20500000 24600000 -2400000 -4700000 -313500000 -116500000 700000 -6100000 617400000 146500000 1367300000 586300000 1984700000 732800000 27400000 0 20700000 0 0 33200000 14300000 15800000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Business</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are the global leader in complement inhibition and have developed and commercialize two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In addition, Alexion has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development with strategic focus in hematology and nephrology, neurology, metabolics and neonatal Fc receptor (FcRn). We were incorporated in 1992 under the laws of the State of Delaware.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Basis of Presentation and Principles of Consolidation</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The results of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are not necessarily indicative of the results to be expected for the full year or any other future periods. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2 and within Note 17, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">Reclassifications</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">New Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Accounting Standards Update (ASU) 2016-13, "Measurement of Credit Losses on Financial Instruments":</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016, the Financial Accounting Standards Board (FASB) issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">be reported based on expected losses compared to the current incurred loss model. The new standard also requires enhanced disclosure of credit risk associated with respective assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. We are currently assessing the impact of this standard on our consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract":</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA). Under the new guidance, customers will assess if a CCA includes a software license and if a CCA does include a software license, implementation and set-up costs will be accounted for consistent with existing internal-use software implementation guidance. Implementation costs associated with a CCA that do not include a software license would be expensed to operating expenses. The standard also provides classification guidance on these implementation costs as well as additional quantitative and qualitative disclosures. The standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Entities can choose to adopt the new guidance prospectively or retrospectively. We are currently assessing the impact this standard will have on our consolidated financial statements.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">ASU 2016-02, "Leases":</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016, the FASB issued a new standard that requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right of use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as financing or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new standard on January 1, 2019 using the modified retrospective approach. We have elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the consolidated financial statements and recognize a cumulative-effect adjustment to the opening balance of retained earnings on the date of adoption. We also elected the “package of practical expedients”, which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Results for reporting periods beginning after January 1, 2019 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2019, we derecognized </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$472.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of property, plant and equipment and other assets and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$372.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of facility lease obligations associated with previously existing build-to-suit arrangements. We capitalized ROU assets of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$326.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, inclusive of opening adjustments of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$70.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> primarily related to prepaid rent existing at transition, and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$255.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of lease liabilities, within our condensed consolidated balance sheets upon adoption. At transition we recorded a decrease of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$90.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to retained earnings, net of tax, primarily related to our derecognition of previously recorded build-to-suit arrangements.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income":</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018, the FASB issued a new standard that permits entities to make a one-time reclassification from accumulated other comprehensive income (AOCI) to retained earnings for the stranded tax effects resulting from the newly enacted corporate tax rates under the Tax Cuts and Jobs Act (the Tax Act), that was effective for the year ended December 31, 2017. We adopted the new standard on January 1, 2019 and elected not to reclassify the income tax effects of the Tax Act from AOCI to retained earnings. We continue to release disproportionate income tax effects from AOCI based on the aggregate portfolio approach. The adoption of this standard did not have an impact on our condensed consolidated financial statements.</span></div> 472800000 372200000 326100000 70800000 255300000 -90300000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Acquisitions</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Wilson Therapeutics AB </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May 25, 2018, we completed the acquisition of Wilson Therapeutics AB (publ), a biopharmaceutical company based in Stockholm, Sweden (Wilson Therapeutics) that developed a novel therapy for patients with rare copper-mediated disorders, pursuant to a recommended public cash offer of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>SEK 232</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for each share of stock of Wilson Therapeutics. As a result of the acquisition, we added WTX101 (ALXN1840), a highly innovative drug candidate that is currently in Phase III clinical trials for the treatment of patients with Wilson disease, to our clinical pipeline.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The acquisition of Wilson Therapeutics was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in a single asset, WTX101. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the total consideration for the acquisition and the value of assets acquired and liabilities assumed:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0868ac;font-weight:bold;">Consideration</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for acquisition of Wilson Therapeutics outstanding shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>749.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Transaction costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>764.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0868ac;font-weight:bold;">Assets Acquired and Liabilities Assumed</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>45.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research & development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>803.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee related liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(71.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>764.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The acquired in-process research and development asset relates to WTX101. Due to the stage of development of this asset at the date of acquisition, significant risk remained and it was not yet probable that there was future economic benefit from this asset. Absent successful clinical results and regulatory approval for the asset, there was no alternative future use associated with WTX101. Accordingly, the value of this asset was expensed during the second quarter of 2018.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee related liabilities include the value of outstanding employee equity incentive awards that were accelerated in connection with the Wilson Therapeutics acquisition that have been settled in cash. Also included in this amount were employer tax obligations associated with the employee equity incentive awards.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with rights to WTX101 that were previously acquired by Wilson Therapeutics from third parties, we could be required to pay up to approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$19.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if certain development, regulatory and commercial milestones are met over time, as well as royalties on commercial sales.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Syntimmune, Inc.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018, we entered into a definitive agreement to acquire Syntimmune, Inc. (Syntimmune), a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn. Syntimmune’s lead candidate, SYNT001 (ALXN1830), is a monoclonal antibody that is designed to inhibit the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes, that is being studied for the treatment of IgG-mediated autoimmune diseases. The acquisition of Syntimmune closed in November 2018. Under the terms of the acquisition agreement, Alexion acquired Syntimmune for an upfront cash payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$400.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with the potential for additional milestone-dependent payments of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$800.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, for a total potential value of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,200.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The acquisition of Syntimmune was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in a single in-process research and development asset, SYNT001.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the agreement of the final working capital adjustment for the Syntimmune acquisition, we recognized a benefit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with previously acquired in-process research and development in the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">second</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> quarter </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the total consideration for the acquisition and the value of the assets acquired and liabilities assumed:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0868ac;font-weight:bold;">Consideration</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upfront payment for acquisition of Syntimmune outstanding shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>400.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Transaction costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>407.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0868ac;font-weight:bold;">Assets Acquired and Liabilities Assumed</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research & development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>375.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>407.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">    </span></div>The acquired in-process research and development asset relates to SYNT001. Due to the stage of development of this asset at the date of acquisition, significant risk remained and it was not yet probable that there was future economic benefit from this asset. Absent successful clinical results and regulatory approval for the asset, there was no alternative future use associated with SYNT001. Accordingly, the value of this asset was expensed during the fourth quarter of 2018. 232 <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the total consideration for the acquisition and the value of assets acquired and liabilities assumed:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0868ac;font-weight:bold;">Consideration</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid for acquisition of Wilson Therapeutics outstanding shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>749.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Transaction costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>15.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>764.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#0868ac;font-weight:bold;">Assets Acquired and Liabilities Assumed</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>45.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research & development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>803.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee related liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(71.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total net assets acquired</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>764.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 749300000 15100000 764400000 45100000 803700000 71400000 13000000.0 764400000 19000000.0 400000000.0 800000000.0 1200000000.0 4100000 400000000.0 4200000 2300000 900000 407400000 4200000 375200000 25100000 2900000 407400000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>38.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>116.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>90.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>339.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>350.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>472.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>38.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>116.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>90.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>339.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>350.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>494.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>472.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 38200000 31400000 116600000 90400000 339800000 350700000 494600000 472500000 <span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Intangible Assets and Goodwill</span><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:22%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Estimated<br/>Life (years)</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Net</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Licensing rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(30.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(29.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4,710.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(1,239.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3,471.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,710.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,079.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,631.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4,768.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(1,280.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3,487.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,760.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,119.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,641.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5,040.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5,037.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,040.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,037.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$81.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$80.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Amortization expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$161.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$160.6</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$161.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ending</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$323.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for each of the years ending December 31, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> through December 31, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net book value of our purchased technology includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3,122.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with the KANUMA intangible asset, which we acquired in the acquisition of Synageva BioPharma Corp. As part of our standard quarterly procedures, we reviewed the KANUMA asset as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and determined that there were no indicators of impairment. Cash flow models used in our assessments are based on our commercial experience to date with KANUMA and require the use of significant estimates, which include, but are not limited to, long-range pricing expectations and patient-related assumptions, including patient identification, conversion and retention rates. We will continue to review the related valuation and accounting of this asset as new information becomes available to us.</span></div> <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:22%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Estimated<br/>Life (years)</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Net</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Accumulated<br/>Amortization</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Net</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Licensing rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5-8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>47.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(30.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(29.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6-16</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4,710.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(1,239.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3,471.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,710.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,079.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,631.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other intangibles</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4,768.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(1,280.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3,487.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4,760.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1,119.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3,641.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5,040.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5,037.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,040.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5,037.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 47000000.0 30900000 16100000 39000000.0 29300000 9700000 10500000 10500000 0 10500000 10500000 0 4710500000 1239200000 3471300000 4710500000 1079100000 3631400000 400000 200000 200000 400000 200000 200000 4768400000 1280800000 3487600000 4760400000 1119100000 3641300000 5040300000 2900000 5037400000 5040300000 2900000 5037400000 81200000 80300000 161700000 160600000 161700000 323000000.0 3122500000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Debt</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement). </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Credit Agreement provides for a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,000.0</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revolving credit facility and a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2,612.5</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.00%</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of the original principal amount of the term loan facility annually, payable in equal quarterly installments. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$53.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in financing costs. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and amortization expense associated with deferred financing costs for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Remaining unamortized deferred financing costs as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We made principal payments of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$32.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the term loan during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2,579.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding on the term loan. In January 2019, we paid the outstanding balance on the revolving credit facility of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$250.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in full and we had no outstanding borrowings under the revolving credit facility as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had open letters of credit of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that offset our availability in the revolving facility. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our long term debt, which is measured using Level 2 inputs of the fair value hierarchy, approximates book value.</span></div> 1000000000.0 2612500000 0.0500 53100000 1300000 3200000 2500000 5500000 18300000 20800000 32700000 2579800000 250000000.0 1000000.0 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Earnings Per Common Share</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the applicable period. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the calculation of basic and diluted EPS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) used for basic and diluted calculation</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>459.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(457.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,047.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(208.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in computing earnings (loss) per common share—basic</span></div></td><td colspan="2" style="vertical-align:top;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>224.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>224.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in computing earnings (loss) per common share—diluted</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>225.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>225.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings (loss) per common share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.05</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.68</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.04</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.64</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude from diluted EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of diluted EPS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock, respectively, because their effect was anti-dilutive. For the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we reported a net loss; therefore, no outstanding stock awards were included in the computation of diluted net loss per share since such inclusion would have been anti-dilutive.</span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the calculation of basic and diluted EPS for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) used for basic and diluted calculation</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>459.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(457.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,047.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(208.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in computing earnings (loss) per common share—basic</span></div></td><td colspan="2" style="vertical-align:top;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>224.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>224.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock awards</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in computing earnings (loss) per common share—diluted</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>225.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>225.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>222.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings (loss) per common share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.05</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.68</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.04</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.05</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.64</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.94</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 459800000 -457400000 1047700000 -208300000 224200000 222600000 224000000.0 222300000 1400000 0 1700000 0 225600000 222600000 225700000 222300000 2.05 -2.05 4.68 -0.94 2.04 -2.05 4.64 -0.94 1900000 2900000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Gains</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Losses</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>274.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>274.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Gains</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Losses</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$128.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We did not have any investments in a continuous unrealized </span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">loss position for more than twelve months as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we believe that the cost basis of our available-for-sale debt securities is recoverable.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>359.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>84.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>181.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of available-for-sale debt securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, by contractual maturity, are summarized as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>438.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through three years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:96px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">        </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor a nonqualified deferred compensation plan which allows certain highly-compensated employees to elect to defer income to future periods. Participants in the plan earn a return on their deferrals based on several investment options, which mirror returns on underlying mutual fund investments. We choose to invest in the underlying mutual fund investments to offset the liability associated with our nonqualified deferred compensation plan. These mutual fund investments are valued at net asset value per share and are carried at fair value with gains and losses included in investment income. The changes in the underlying liability to the employee are recorded in operating expenses. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of these investments was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$20.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We utilize the specific identification method in computing realized gains and losses. Realized gains and losses on our marketable securities were not material for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div> <span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were as follows:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Gains</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Losses</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>274.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>274.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>117.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>24.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Gains</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Unrealized Holding Losses</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>52.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 274000000.0 0 0 274000000.0 28000000.0 0 0 28000000.0 117800000 0 0 117800000 24300000 0 0 24300000 444100000 0 0 444100000 52100000 0 0 52100000 122900000 0 100000 122800000 17500000 0 0 17500000 33200000 0 0 33200000 225700000 0 100000 225600000 25500000 128700000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>359.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>84.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>181.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>225.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 359400000 43800000 84700000 181800000 444100000 225600000 <div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of available-for-sale debt securities at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, by contractual maturity, are summarized as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>438.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through three years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>444.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 438300000 5800000 444100000 20700000 16500000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on outstanding borrowings under our revolving credit facility, if any, and term loan facility. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into foreign exchange forward contracts, with durations of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, and certain forecasted expenses that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results. These hedges are designated as cash flow hedges upon contract inception. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had open revenue related foreign exchange forward contracts with notional amounts totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,136.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that qualified for hedge accounting with current contract maturities through December 2020. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had open expense related foreign exchange forward contracts with notional amounts totaling </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$17.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that qualified for hedge accounting with contract maturities through September 2022.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;background-color:#ffffff;">on a portion of our debt to a fixed rate, plus a borrowing spread.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the total interest rate swap contracts executed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:15%;"/><td style="width:9%;"/><td style="width:31%;"/><td style="width:31%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Type of Interest Rate Swap</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Notional Amount</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Fixed Interest Rate or Rate Range</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,531.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2016 - January 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.98% - 1.62%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>450.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2018 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.60% - 2.79%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>300.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.08%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,300.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.37% - 2.83%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total amount presented in the Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,202.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(18.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,044.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Impact of cash flow hedging relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total amount presented in the Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2,342.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(38.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,975.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(49.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Impact of cash flow hedging relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The impact on AOCI from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Foreign Exchange Forward Contracts:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) recognized in AOCI, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) reclassified from AOCI to net product sales, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Interest Rate Contracts:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) recognized in AOCI, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(24.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) reclassified from AOCI to interest expense, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assuming no change in foreign exchange rates from market rates at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">gains</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recognized in AOCI will be reclassified to revenue over the next 12 months. Assuming no change in LIBOR-based interest rates from market rates at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">losses</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recognized in AOCI will be reclassified to interest expense over the next 12 months. Amounts recognized in AOCI for expense related foreign exchange forward contracts was immaterial at </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into foreign exchange forward contracts, with durations of up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8 months</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the notional amount of foreign exchange contracts where hedge accounting is not applied was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,963.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized a gain (loss) of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$(5.8)</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$18.4</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in other income and (expense) for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, associated with the foreign exchange contracts not designated as hedging instruments. We recognized a gain (loss) of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$(2.6)</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in other income and (expense) for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the fair value of outstanding derivatives as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="width:29%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total fair value of derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="width:29%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total fair value of derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts of Recognized Assets/Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Cash Collateral Received (Pledged)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(87.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(87.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(63.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts of Recognized Assets/Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Cash Collateral Received (Pledged)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(30.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(40.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(40.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P60M 1136100000 17100000 <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the total interest rate swap contracts executed as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:15%;"/><td style="width:9%;"/><td style="width:31%;"/><td style="width:31%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Type of Interest Rate Swap</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Notional Amount</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Termination Date</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Fixed Interest Rate or Rate Range</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,531.3</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2016 - January 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.98% - 1.62%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>450.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2018 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.60% - 2.79%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>300.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.08%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Floating to Fixed</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,300.0</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.37% - 2.83%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1531300000 450000000.0 300000000.0 0.0208 1300000000.0 <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total amount presented in the Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,202.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(18.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,044.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(25.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Impact of cash flow hedging relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Net Product Sales</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total amount presented in the Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2,342.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(38.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,975.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(49.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Impact of cash flow hedging relationships:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The impact on AOCI from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Foreign Exchange Forward Contracts:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) recognized in AOCI, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>49.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) reclassified from AOCI to net product sales, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(11.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Interest Rate Contracts:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) recognized in AOCI, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(24.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(38.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) reclassified from AOCI to interest expense, net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1202500000 18300000 1044700000 25000000.0 9100000 0 -1700000 0 0 -4500000 0 -3100000 2342700000 38200000 1975100000 49100000 16100000 0 -14800000 0 0 -9100000 0 -4500000 -3900000 49000000.0 10300000 16500000 7000000.0 -1300000 12400000 -11400000 -24600000 3100000 -38800000 11200000 3400000 2500000 7000000.0 3600000 4800000 -5200000 P8M 1963000000.0 -5800000 18400000 -2600000 10300000 <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the fair value of outstanding derivatives as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="width:29%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ffffff;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total fair value of derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;"><span>87.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" style="padding-top:4px;padding-bottom:4px;"><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="width:29%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Assets</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Derivative Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair<br/>Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>23.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Total fair value of derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"><span>40.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 12400000 7600000 1100000 1800000 5600000 10800000 0 52200000 16100000 15400000 35200000 87800000 16900000 7300000 300000 3100000 20100000 800000 0 17300000 23600000 11500000 60900000 40000000.0 The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts of Recognized Assets/Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Cash Collateral Received (Pledged)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>35.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(87.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(87.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(63.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts of Recognized Assets/Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Gross Amounts Offset in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Cash Collateral Received (Pledged)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;font-weight:bold;">Net Amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>60.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(30.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(40.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(40.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 35200000 0 35200000 24400000 0 10800000 87800000 0 87800000 24400000 0 63400000 60900000 0 60900000 30200000 0 30700000 40000000.0 0 40000000.0 30200000 0 9800000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Other Investments</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">    </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with license agreements. These investments are included in other assets in our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Moderna</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During 2014, we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$37.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was recorded at cost. During the first quarter 2018, Moderna announced the completion of a new round of financing. As a result, we recognized an unrealized gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in investment income during the first quarter 2018 to adjust our investment in Moderna to fair value as of the date of the observable price change, based on the per share price in Moderna's new round of financing. There were no observable price changes during the second quarter 2018.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 6, 2018, Moderna completed its initial public offering (IPO) and shares of Moderna began trading on the Nasdaq Global Select Market under the symbol “MRNA.” As part of the IPO, our preferred stock was converted into Moderna common stock and subject to a one year lock-up period. As our equity investment in Moderna common stock now has a readily determinable fair value, we are recording the investment at fair value, with the effects of the holding period restriction estimated using an option pricing valuation model. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized an unrealized (loss) gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$(29.0)</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in investment income to adjust our investment in Moderna to fair value as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of this investment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$82.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$81.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Dicerna</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018, we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized an unrealized gain of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in investment income to adjust our equity investment in Dicerna to fair value as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of this investment was</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$8.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Caelum</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019, we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> option to acquire the remaining equity in Caelum in connection with an agreement that we entered into with Caelum, see Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">“Commitments and Contingencies”</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we are recording the assets at cost, less impairment, and adjusted for any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no observable price changes associated with these assets during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The carrying value of the investment and option of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$41.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$16.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were not impaired as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Zealand </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, we purchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark, see Note 18, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">“Commitments and Contingencies”</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. We have considered the effects of a six month holding period restriction and determined that the impact on the fair value of the investment is immaterial. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized an unrealized gain of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$2.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.6</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in investment income to adjust our equity investment in Zealand to fair value as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of this investment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$17.4</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div> 37500000 100800000 -29000000.0 800000 82700000 81900000 10300000 900000 4200000 13100000 8900000 41000000.0 16100000 41000000.0 16100000 13800000 2900000 3600000 17400000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Stockholders' Equity</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,000.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the repurchase program, which superseded all prior repurchase programs. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$37.6</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three months ended June 30,</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.4</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$48.9</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$85.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The Company did not repurchase any shares during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsequent to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock under our repurchase program at a cost of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.0</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July 22, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there is a total of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$393.6</span> remaining for repurchases under the repurchase program. 1000000000.0 300000 37600000 400000 700000 48900000 85000000.0 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Other Comprehensive Income and Accumulated Other Comprehensive Income</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in AOCI, by component, for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Debt Securities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Hedging Activities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(28.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(19.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(19.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(47.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(48.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(38.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(16.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(57.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Debt Securities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Hedging Activities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(34.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below provides details regarding significant reclassifications from AOCI during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:26%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Details about Accumulated Other Comprehensive Income Components</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Affected Line Item in the Condensed Consolidated Statements of Operations</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c7fb8;">Unrealized Gains (Losses) on Hedging Activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net product sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>25.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>19.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the changes in AOCI, by component, for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.61013645224172%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Debt Securities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Hedging Activities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(28.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(19.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(19.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(47.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(48.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(38.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(16.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(57.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Defined Benefit Pension Plans</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Debt Securities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Unrealized Gains (Losses) from Hedging Activities</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total Accumulated Other Comprehensive Income (Loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(13.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(15.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(34.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>31.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances, June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -2600000 -300000 9600000 -16400000 -9700000 0 200000 -28500000 -500000 -28800000 0 0 19400000 0 19400000 0 200000 -47900000 -500000 -48200000 -2600000 -100000 -38300000 -16900000 -57900000 -4800000 200000 -13900000 -15900000 -34400000 1300000 100000 27700000 -4300000 24800000 600000 500000 -7800000 0 -6700000 700000 -400000 35500000 -4300000 31500000 -4100000 -200000 21600000 -20200000 -2900000 <div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below provides details regarding significant reclassifications from AOCI during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:26%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Details about Accumulated Other Comprehensive Income Components</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Affected Line Item in the Condensed Consolidated Statements of Operations</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2c7fb8;">Unrealized Gains (Losses) on Hedging Activity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net product sales</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>25.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(10.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>19.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(7.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9100000 -1700000 16100000 -14800000 4500000 3100000 9100000 4500000 13600000 1400000 25200000 -10300000 3200000 200000 5800000 -2500000 10400000 1200000 19400000 -7800000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Fair Value Measurement</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:25%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair Value Measurement at<br/>June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Classification</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Type of Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>498.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>498.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>240.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>240.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>107.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>107.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>113.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>82.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>158.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>158.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other contingent payments</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other contingent payments</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">—</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">—</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:25%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair Value Measurement at<br/>December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Classification</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Type of Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>569.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>569.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>81.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>97.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>97.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>183.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>183.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no securities transferred between Level 1, 2 and 3 during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">Valuation Techniques</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy include money market funds, commercial paper, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other investments in equity securities of publicly traded companies which are subject to holding period restrictions are carried at fair value using an option pricing valuation model and classified as Level 2 equity securities within the fair value hierarchy. The most significant assumptions within the option pricing valuation model are the term of the restrictions and the stock price volatility, which is based upon the historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on such investments.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration liabilities related to business acquisitions and derivative liabilities associated with other contingent payments are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">Acquisition-Related Contingent Consideration</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with prior business combinations, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for developmental and regulatory milestones and a weighted average cost of capital of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.0%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for sales-based milestones.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, estimated future contingent milestone payments related to prior business combinations range from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>zero</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if no milestone events are achieved, to a maximum of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$702.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if all development, regulatory and sales-based milestones are reached. In the second quarter 2019, a sales-based milestone associated with our acquisition of Enobia Pharma Corp. was achieved. In connection with such achievement, we will make a </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$100.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment in the third quarter 2019.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of acquisition-related contingent consideration was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$258.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table represents a roll-forward of our acquisition-related contingent consideration:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>280.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>258.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-weight:bold;">Other Contingent Payments</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the first quarter 2019 and could be required to pay up to an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestone-dependent fees. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, based on the probability-weighted cash flows, discounted using a cost of debt ranging from </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.3%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.5%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Each reporting period, we adjust the derivative liability associated with the contingent fees to fair value with changes in fair value recognized in other income and expense. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, change in fair value will only reflect the interest component of the liability related to the passage of time. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of our contingent fees was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.4</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We recorded </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$0.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in other income and (expense) during the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the change in the fair value of the liability.</span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:25%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair Value Measurement at<br/>June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Classification</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Type of Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>498.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>498.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>240.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>240.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>107.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>107.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>113.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span></span><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>82.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>52.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>158.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>158.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other contingent payments</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other contingent payments</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">—</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">—</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:top;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:25%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Fair Value Measurement at<br/>December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Classification</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Type of Instrument</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>569.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>569.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mutual funds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>122.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other government-related obligations</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bank certificates of deposit</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>33.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity securities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>81.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>40.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>18.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange forward contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>20.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>97.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>97.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition-related contingent consideration</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>183.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>183.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 498500000 0 498500000 0 240200000 0 240200000 0 12200000 0 12200000 0 107000000.0 0 107000000.0 0 20700000 20700000 0 0 33800000 0 33800000 0 28000000.0 0 28000000.0 0 10800000 0 10800000 0 12100000 0 12100000 0 113300000 30600000 82700000 0 28500000 0 28500000 0 1100000 0 1100000 0 23000000.0 0 23000000.0 0 1800000 0 1800000 0 5600000 0 5600000 0 10800000 0 10800000 0 52200000 0 52200000 0 100000000.0 0 0 100000000.0 158200000 0 0 158200000 13900000 0 0 13900000 13500000 13500000 569400000 0 569400000 0 35400000 0 35400000 0 200000 0 200000 0 8200000 0 8200000 0 16500000 16500000 0 0 16700000 0 16700000 0 122600000 0 122600000 0 9300000 0 9300000 0 33200000 0 33200000 0 90800000 8900000 81900000 0 40500000 0 40500000 0 300000 0 300000 0 18800000 0 18800000 0 3100000 0 3100000 0 20100000 0 20100000 0 800000 0 800000 0 17300000 0 17300000 0 97600000 0 0 97600000 183200000 0 0 183200000 0.051 0.100 0 702000000.0 100000000.0 258200000 he following table represents a roll-forward of our acquisition-related contingent consideration:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;background-color:#0092cb;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>280.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(22.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>258.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div> -280800000 22600000 -258200000 30000000.0 30000000.0 27100000 0.033 0.035 27400000 300000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">Disaggregation of Revenue</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below. </span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">SOLIRIS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>496.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>395.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>960.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>731.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>253.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>544.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>504.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>110.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>211.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>179.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>94.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>155.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>226.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>283.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>980.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>898.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,942.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,698.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">ULTOMIRIS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>54.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>78.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>54.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>78.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">STRENSIQ</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>99.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>205.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>189.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>141.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>271.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>235.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">KANUMA</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">Total Net Product Sales</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,202.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,044.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2,342.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,975.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">Contract Balances and Receivables</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract liabilities relate to consideration received and/or billed for goods that have not been delivered to the customer and for which the performance obligation has not yet been completed. These amounts are included within other current liabilities in the condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides information about receivables and contract liabilities from our contracts with customers.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Receivables, which are included in "Trade accounts receivable, net"</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,123.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>922.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract liabilities, which are included in "Other current liabilities"</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below. </span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">SOLIRIS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>496.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>395.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>960.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>731.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>280.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>253.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>544.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>504.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>110.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>93.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>211.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>179.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>94.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>155.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>226.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>283.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>980.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>898.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,942.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,698.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">ULTOMIRIS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>54.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>78.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>54.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>78.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">STRENSIQ</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>106.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>99.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>205.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>189.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>19.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>37.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>12.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>22.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>141.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>125.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>271.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>235.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">KANUMA</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>29.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>24.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asia Pacific</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of World</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>26.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>49.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;">Total Net Product Sales</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,202.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,044.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2,342.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>1,975.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 496300000 395800000 960000000.0 731800000 280200000 253400000 544700000 504200000 110300000 93600000 211200000 179100000 94000000.0 155400000 226900000 283200000 980800000 898200000 1942800000 1698300000 54200000 0 78800000 0 0 0 0 0 0 0 0 0 0 0 0 0 54200000 0 78800000 0 106200000 99900000 205700000 189100000 19500000 16400000 37000000.0 30400000 12100000 6300000 22000000.0 12000000.0 3500000 2500000 6700000 4300000 141300000 125100000 271400000 235800000 15300000 13000000.0 29100000 24900000 6800000 5800000 13100000 11700000 1300000 1100000 2100000 2100000 2800000 1500000 5400000 2300000 26200000 21400000 49700000 41000000.0 1202500000 1044700000 2342700000 1975100000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Receivables, which are included in "Trade accounts receivable, net"</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>1,123.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>922.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contract liabilities, which are included in "Other current liabilities"</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1123600000 922300000 3100000 3400000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a comparative summary of our income tax (benefit) expense and effective income tax rate for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>39.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective income tax rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(210.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense is attributable to the U.S. federal, state and foreign income taxes on our profitable operations. During the first quarter 2019, in connection with the future integration of intellectual property of Wilson Therapeutics, with and into the Alexion corporate structure, we recognized certain one-time tax benefits. The deferred tax benefits include </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$95.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the six months ended </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Future changes to our intellectual property integration planning could materially impact our effective tax rate in subsequent periods.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2019, the Wilson Therapeutics intellectual property was integrated with and into the Alexion corporate structure. The Company is currently evaluating the impact of the integration on the Company's consolidated financial statements and will record the associated tax effects in the third quarter of 2019.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The income tax expense for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> includes a decrease in the effective tax rate of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>19.4%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>230.1%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, attributable to the acquisition of Wilson Therapeutics. Absent successful clinical results and regulatory approval, there is no alternative future use of the WTX101 asset acquired. Accordingly, the value of the asset of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$803.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was expensed as in-process research and development costs during such three and six month periods, for which no tax benefit has been recognized. Also included in the six months ended June 30, 2018 is a U.S. tax reform measurement period adjustment to deferred taxes of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$38.4</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This deferred tax cost increased the effective tax rate by approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.2%</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2017, the IRS commenced an examination of our U.S. income tax returns for 2015. We anticipate this audit will conclude within the next twelve months. We have not been notified of any significant adjustments proposed by the IRS. It is reasonably possible that previously unrecognized tax benefits could be recognized upon the conclusion of the IRS examination. At this time, an estimate of the change in unrecognized tax benefits cannot be made.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign, local, and U.S. state income taxes. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a comparative summary of our income tax (benefit) expense and effective income tax rate for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax (benefit) expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>39.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>38.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>141.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective income tax rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(9.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(210.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 39700000 38800000 -6400000 141300000 0.079 -0.093 -0.006 -2.109 -95700000 -30300000 0.121 0.194 2.301 803700000 38400000 0.052 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Defined Benefit Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments. The total net periodic benefit cost for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was not material. </span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the unique facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">financing lease; and (iv) recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Most leases include options to renew and, or, terminate the lease, which can impact the lease term. The exercise of these options is at our discretion and we do not include any of these options within the expected lease term as we are not reasonably certain we will exercise these options. We have elected to combine lease components (for example fixed payments including rent) with non-lease components (for example, non-dedicated parking and common-area maintenance costs) on our real estate and commercial fleet asset classes. We separate lease and non-lease components on our embedded contract manufacturing organization (CMO) arrangements. Lease and non-lease components on these CMO arrangements are determined based on an allocation of the consideration in the contract to the embedded lease and non-lease components of the arrangement based on the relative standalone selling prices of these components.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis, while fixed, or in substance fixed, payments on financing leases are recognized using the effective interest method. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our condensed consolidated statements of operations. Financing lease ROU asset amortization and interest costs are recorded within operating expenses and interest expense, respectively, within our condensed consolidated statements of operations. We have operating and financing leases for corporate offices, research and development facilities, regional executive and sales offices, commercial fleet, and CMO embedded lease arrangements. We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months or less. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating leases are included in right of use operating assets, other current liabilities, and noncurrent operating lease liabilities in our condensed consolidated balance sheet as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Financing leases are included in property, plant and equipment, other current liabilities, and other liabilities in our condensed consolidated balance sheet as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our lease assets and liabilities as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:38%;"/><td style="width:31%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">ROU Assets and Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">ROU - Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Right of use operating assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>209.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">ROU - Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>121.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Lease liabilities (noncurrent)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Noncurrent operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>165.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Lease liabilities (noncurrent)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our lease related costs for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:40%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Statement of Operations Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Amortization of ROU Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Operating Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Interest on Lease Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Interest Expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Operating Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Operating Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">Total Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts above include </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$3.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$6.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of lease costs associated with our CMO embedded lease arrangement for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which have been capitalized within other assets as a prepayment of inventory.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes supplemental cash flow information for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Other Information</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash Paid For Amounts Included In Measurement of Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Operating Cash Flows From Financing Leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Operating Cash Flows From Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Financing Cash Flows From Financing Leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ROU Assets Obtained In Exchange For New Financing Liabilities </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ROU Assets Obtained In Exchange For New Operating Liabilities </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(1) We capitalized $83.1 of ROU financing assets upon adoption of the new lease standard in the first quarter of 2019 that are excluded from the figures for the six months ended June 30, 2019. This figure excludes $44.2 of opening adjustments to ROU finance assets related, primarily, to prepayments of rent.</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(2) We capitalized $172.2 of ROU operating assets upon adoption of the new lease standard in the first quarter of 2019. This figure excludes $26.6 of opening adjustments to ROU operating assets related, primarily, to prepayments of rent.<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize maturities of lease liabilities and the reconciliation of lease liabilities as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Lease Liability Maturity Summary</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>109.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Reconciliation of Lease Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average Remaining Lease Term </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">(years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>11.17</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>10.46</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>10.67</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average Discount Rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.85</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.35</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.51</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Undiscounted Lease Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>104.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>231.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>335.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>69.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Discounted Lease Liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>185.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>266.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For comparable purposes, our aggregate future minimum non-cancellable commitments under operating leases as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;text-decoration:none;background-color:#0092cb;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>132.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excluded from the table above are commitments with Lonza Group AG and its affiliates (Lonza), a third party manufacturer that produces a portion of commercial and clinical quantities of our commercial products and product candidates. During the third quarter 2015, we entered into an agreement with Lonza whereby Lonza constructed a facility to be used to manufacture product under a supply agreement for Alexion at one of its existing facilities, resulting in the determination that the CMO arrangement contained a lease. This agreement requires us to make certain payments during the construction of the manufacturing facility and annual payments for ten years thereafter. As the arrangement contains both a lease and non-lease component, related to the supply of product, the consideration paid to Lonza is allocated between these components. As of December 31, 2018, we had various manufacturing and licensing agreements with Lonza, with remaining total non-cancellable future commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,084.6</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$88.7</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza.</span></div> <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our lease assets and liabilities as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:38%;"/><td style="width:31%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">ROU Assets and Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Balance Sheet<br/>Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">ROU - Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Right of use operating assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>209.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">ROU - Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Property, plant, and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>121.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Lease liabilities (noncurrent)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Noncurrent operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>165.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Lease liabilities (noncurrent)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>75.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 209500000 121800000 0 5000000.0 20300000 0 165500000 75500000 0 <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our lease related costs for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:40%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Statement of Operations Location</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financing Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Amortization of ROU Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Operating Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Interest on Lease Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Interest Expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Operating Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Variable Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Operating Expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;font-weight:bold;">Total Lease Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3500000 7500000 2500000 5500000 1000000.0 2000000.0 8600000 17600000 2300000 4300000 14400000 29400000 3000000.0 6300000 <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes supplemental cash flow information for the </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and six months ended</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Other Information</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash Paid For Amounts Included In Measurement of Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>16.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Operating Cash Flows From Financing Leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Operating Cash Flows From Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">  Financing Cash Flows From Financing Leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ROU Assets Obtained In Exchange For New Financing Liabilities </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ROU Assets Obtained In Exchange For New Operating Liabilities </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(1) We capitalized $83.1 of ROU financing assets upon adoption of the new lease standard in the first quarter of 2019 that are excluded from the figures for the six months ended June 30, 2019. This figure excludes $44.2 of opening adjustments to ROU finance assets related, primarily, to prepayments of rent.</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">(2) We capitalized $172.2 of ROU operating assets upon adoption of the new lease standard in the first quarter of 2019. This figure excludes $26.6 of opening adjustments to ROU operating assets related, primarily, to prepayments of rent.<br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8800000 16400000 1000000.0 2000000.0 6500000 11900000 1300000 2500000 0 0 20700000 20700000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Lease Liability Maturity Summary</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>109.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Lease Liability Maturity Summary</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019 (remaining)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>18.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>30.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>9.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>29.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>54.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>109.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>163.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4400000 13600000 18000000.0 8800000 24800000 33600000 9000000.0 22100000 31100000 9200000 20800000 30000000.0 9200000 20500000 29700000 9400000 20200000 29600000 54600000 109300000 163900000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:9pt;color:#0868ac;font-style:italic;font-weight:bold;">Reconciliation of Lease Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Financing</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average Remaining Lease Term </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">(years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>11.17</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>10.46</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>10.67</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average Discount Rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.85</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.35</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>4.51</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Undiscounted Lease Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>104.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>231.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>335.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Imputed Interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.0</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>69.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Discounted Lease Liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>80.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>185.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>266.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P11Y2M1D P10Y5M15D P10Y8M1D 0.0485 0.0435 0.0451 104600000 231300000 335900000 24000000.0 45400000 69400000 80500000 185800000 266300000 <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For comparable purposes, our aggregate future minimum non-cancellable commitments under operating leases as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;text-decoration:none;background-color:#0092cb;">Year</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>19.7</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0868ac;"><span>132.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 27800000 24700000 21300000 19900000 19700000 132200000 1084600000 88700000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Commitments and Contingencies</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Asset Acquisition and In-License Agreements</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into asset purchase agreements and license arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the first quarter 2019 and could be required to pay up to an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$30.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestone-dependent fees. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$27.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We allocated the total consideration of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$57.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, inclusive of the fair value of contingent milestone-dependent fees, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$500.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase 1 studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10). Under the terms of the agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$40.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.8</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$5.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$21.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense during the first quarter 2019. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could be required to pay up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$610.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, for the lead target, upon the achievement of specified development, regulatory and commercial </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestones, as well as royalties on commercial sales. Each of the three subsequent targets can be selected for an option fee of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$15.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the FcRn and is currently in Phase 1 development. The agreement with Affibody was subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and, following receipt of such approval, the transaction closed in April 2019. Pursuant to the agreement, Alexion will lead the clinical development and commercial activities for ABY-039 in rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development of ABY-039 in an undisclosed indication. Under the terms of the agreement, we made an upfront payment of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$25.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the exclusive license to ABY-039. Due to the early stage of the asset we are licensing, we recorded the upfront license payment as research and development expense during the second quarter 2019. As of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could also be required to pay up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$625.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for amounts due upon achievement of specific development, regulatory, and commercial milestones, as well as royalties on commercial sales.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our prior acquisition of Syntimmune (see Note 3), we could be required to pay up to </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$800.0</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the achievement of specified development, regulatory and commercial milestones.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> In addition, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have other license agreements under which we may be required to pay up to an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$838.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for currently licensed targets, if certain development, regulatory and commercial milestones are met. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Asset Sale and Out-License Arrangements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with prior asset sale and out-license arrangements, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Manufacturing Agreements</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have various manufacturing development and license agreements to support our clinical and commercial product needs. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$1,044.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This amount includes </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$102.3</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to its sale and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our commitments with Lonza, as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we have non-cancellable commitments of approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$65.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> through 2020 with other third party manufacturers.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;font-style:italic;">Contingent Liabilities</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims, disputes, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products. Under the guidance of ASC 450, </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Contingencies</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures. Alexion is cooperating with these investigations. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The investigations have focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At this time, Alexion is unable to predict the duration, scope or outcome of these investigations. While it is possible that a loss related to these matters may be incurred, given the ongoing nature of these investigations, management cannot reasonably estimate the potential magnitude of any such loss or range of loss, or the cost of the ongoing investigation. Any determination that our operations or activities are not or were not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Alexion is committed to strengthening its compliance program and is currently implementing a comprehensive company-wide transformation plan that is designed to enhance and remediate its business processes, structures, controls, training, talent and systems across Alexion’s global operations.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As previously reported, on December 29, 2016, a shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants’ filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference. During that conference, the court informed counsel that it was preparing a ruling granting the Defendants’ pending motion to dismiss. The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so. On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss.  On May 31, 2019, Plaintiffs filed a second amended complaint against the same defendants.  The complaint alleges that defendants engaged in securities fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud.  The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs.  Defendants’ motion to dismiss the </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">amended complaint is due August 2, 2019; plaintiffs’ opposition to that motion is due October 2, 2019; and defendants’ reply in further support of their motion is due November 16, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case, nor can we estimate the possible loss or range of loss at this time.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered in to a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$13.1</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017, Brazilian authorities seized records and data from our Sao Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling. Pursuant to an order made by the Federal Court of Canada, we will place approximately </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$31.6</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for the period from September 2017 to June 2019. Pursuant to US GAAP, our revenues for the quarter ended June 30, 2019 were reduced by this amount. In addition, on a quarterly basis until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018, the Japanese Ministry of Health, Labour and Welfare (MHLW) conducted an administrative inspection of Alexion’s Japanese operations. The MHLW inquiry primarily focused on our communication efforts regarding the proper use of SOLIRIS in Japan for aHUS, among other matters. We have cooperated with the inquiries and the investigation, and in March 2019, the MHLW indicated that it has completed its investigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chugai Pharmaceutical Co., Ltd. has filed two lawsuits against Alexion. The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd. The second lawsuit was filed in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd.  Chugai’s complaints seek unspecified damages and certain injunctive relief.  In both cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case has been set for May 2021. The case is still at the briefing stage in Japan. Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS: U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleges the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. We expect the PTO to review Amgen’s petitions and Alexion's submissions, and to issue a decision in September 2019 as to whether the PTO will institute IPR. At this time we cannot determine what decision the PTO will make.</span></div> 30000000.0 30000000.0 27100000 57100000 500000000.0 40000000.0 13800000 5000000.0 21200000 610000000.0 15000000.0 25000000.0 625000000.0 800000000.0 838200000 1044100000 102300000 65100000 13100000 31600000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:10pt;color:#002f6c;font-weight:bold;">Restructuring and Related Expenses</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter 2019, we initiated corporate restructuring activities to re-align our commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> In the first quarter 2017, we initiated a company-wide restructuring designed to help position the Company for sustainable, long-term growth that we believe will further allow us to fulfill our mission of serving patients and families with rare diseases. In September 2017, we committed to an operational plan to re-align the global organization with its refocused corporate strategy. The re-alignment included the relocation of the Company's headquarters to Boston, Massachusetts and a reduction of the Company's global workforce. The restructuring was designed to result in cost savings by focusing the development portfolio, simplifying business structures and process across the Company's global operations, and closing multiple Alexion sites. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring and related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset impairments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The restructuring reserve of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$9.5</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$4.2</span></span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is recorded in accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The accrued amounts are expected to be paid in the next twelve months. We currently estimate incurring up to an additional </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>$10.0</span></span> in restructuring expenses related to the first quarter 2019 action. <div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:21%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset-Related Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>12.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other (income) expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>16.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of </span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Three months ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Six months ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Employee Separation Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Asset Charges</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Other Costs</span></div></td><td style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#0092cb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Franklin Gothic Medium,sans-serif;font-size:8pt;color:#ffffff;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability, beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>10.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring and related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settlements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(6.3</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to previous estimates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset impairments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#eaeaea;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#eaeaea;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0092cb;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#eaeaea;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br/></span></div> 0 0 0 0 0 500000 0 500000 0 0 0 0 0 0 0 0 0 0 0 0 0 6500000 0 6500000 2400000 0 100000 2500000 3100000 0 7500000 10600000 0 0 0 0 0 0 0 0 2400000 0 100000 2500000 3100000 7000000.0 7500000 17600000 0 0 0 0 0 5800000 0 5800000 0 0 0 0 0 100000 0 100000 0 0 0 0 0 10100000 0 10100000 11500000 0 100000 11600000 4100000 0 12000000.0 16100000 0 0 0 0 0 0 -100000 -100000 11500000 0 100000 11600000 4100000 16000000.0 11900000 32000000.0 10800000 0 0 10800000 4200000 0 0 4200000 5300000 0 0 5300000 14200000 0 0 14200000 3800000 0 0 3800000 6300000 0 0 6300000 -2800000 0 0 -2800000 -2600000 0 0 -2600000 0 0 0 0 0 0 0 0 9500000 0 0 9500000 9500000 0 0 9500000 9500000 4200000 10000000.0 XML 39 R1.htm IDEA: XBRL DOCUMENT v3.19.2

Document and Entity Information Document - shares
6 Months Ended

Jun. 30, 2019

Jul. 22, 2019

Document and Entity Information [Abstract]

Document Type 10-Q

Document Quarterly Report true

Document Period End Date Jun. 30, 2019

Document Transition Report false

Entity File Number 0-27756

Entity Registrant Name ALEXION PHARMACEUTICALS, INC.

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 13-3648318

Entity Address, Address Line One 121 Seaport Boulevard

Entity Address, City or Town Boston

Entity Address, State or Province MA

Entity Address, Postal Zip Code 02210

City Area Code 475

Local Phone Number 230-2596

Title of 12(b) Security Common Stock $0.0001 par value

Trading Symbol ALXN

Security Exchange Name NASDAQ

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Large Accelerated Filer

Entity Small Business false

Entity Emerging Growth Company false

Entity Shell Company false

Entity Central Index Key 0000899866

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 224,226,878

Amendment Flag false

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q2

X

- Definition
Document and Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: alxn_DocumentAndEntityInformationAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 13
-Subsection a-13
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1-
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:Security12bTitle@anonymousType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 40 R2.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Balance Sheets - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Assets

Cash and cash equivalents $ 1,984.2 $ 1,365.5

Marketable securities 105.4 198.3

Trade accounts receivable, net 1,123.6 922.3

Inventories 494.6 472.5

Prepaid expenses and other current assets 460.7 426.4

Total current assets 4,168.5 3,385.0

Property, plant and equipment, net 1,123.5 1,471.5

Intangible assets, net 3,487.6 3,641.3

Goodwill 5,037.4 5,037.4

Right of use operating assets 209.5 0.0

Other assets 541.2 396.7

Total assets 14,567.7 13,931.9

Liabilities and Stockholders' Equity

Accounts Payable and Accrued Liabilities, Current 728.7 698.2

Revolving credit facility 0.0 250.0

Current portion of long-term debt 126.6 93.8

Current portion of contingent consideration 100.0 97.6

Other current liabilities 76.2 34.4

Total current liabilities 1,031.5 1,174.0

Long-term debt, less current portion 2,438.3 2,501.7

Contingent consideration 158.2 183.2

Facility lease obligation 0.0 361.0

Deferred tax liabilities 341.2 391.1

Noncurrent operating lease liabilities 165.5 0.0

Other liabilities 269.5 155.6

Total liabilities 4,404.2 4,766.6

Commitments and contingencies (Note 18)

Stockholders' Equity:

Common stock, $0.0001 par value; 290 shares authorized; 237.3 and 236.2 shares issued at June 30, 2019 and December 31, 2018, respectively 0.0 0.0

Additional paid-in capital 8,677.0 8,539.1

Treasury stock, at cost, 13.1 and 12.7 shares at June 30, 2019 and December 31, 2018, respectively (1,738.8) (1,689.9)

Accumulated other comprehensive loss (57.9) (9.7)

Retained earnings 3,283.2 2,325.8

Total stockholders' equity 10,163.5 9,165.3

Total liabilities and stockholders' equity $ 14,567.7 $ 13,931.9

X

- Definition
Facility Lease Obligation, Noncurrent
+ References
No definition available.
+ Details

Name: alxn_FacilityLeaseObligationNoncurrent

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LinesOfCreditCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.2)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 41 R3.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
shares in Millions

Jun. 30, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 290.0 290.0

Common stock, shares issued 237.3 236.2

Treasury Stock, Shares 13.1 12.7

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 42 R4.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Revenue from Contract with Customer, Excluding Assessed Tax $ 1,203.3 $ 1,045.0 $ 2,343.7 $ 1,975.9

Cost of Goods and Services Sold 99.2 95.3 185.0 186.9

Operating expenses:

Research and development 187.6 173.4 383.5 350.0

Selling, general and administrative 299.3 277.3 580.8 534.4

Acquired in-process research and development (4.1) 803.7 (4.1) 803.7

Amortization of purchased intangible assets 80.1 80.1 160.1 160.1

Change in fair value of contingent consideration 6.1 4.7 (22.6) 57.4

Restructuring expenses 2.5 10.6 11.6 16.1

Total operating expenses 571.5 1,349.8 1,109.3 1,921.7

Operating income (loss) 532.6 (400.1) 1,049.4 (132.7)

Other income and expense:

Investment (expense) income (14.9) 7.7 27.6 113.5

Interest expense (18.3) (25.0) (38.2) (49.1)

Other income and (expense) 0.1 (1.2) 2.5 1.3

Income (loss) before income taxes 499.5 (418.6) 1,041.3 (67.0)

Income tax (benefit) expense 39.7 38.8 (6.4) 141.3

Net income (loss) $ 459.8 $ (457.4) $ 1,047.7 $ (208.3)

Earnings (loss) per common share

Basic $ 2.05 $ (2.05) $ 4.68 $ (0.94)

Diluted $ 2.04 $ (2.05) $ 4.64 $ (0.94)

Shares used in computing earnings (loss) per common share

Basic 224.2 222.6 224.0 222.3

Diluted 225.6 222.6 225.7 222.3

Net Product Sales [Member]

Revenue from Contract with Customer, Excluding Assessed Tax $ 1,202.5 $ 1,044.7 $ 2,342.7 $ 1,975.1

Other Revenue [Member]

Revenue from Contract with Customer, Excluding Assessed Tax $ 0.8 $ 0.3 $ 1.0 $ 0.8

X

- Definition
Amortization of Intangible Assets Acquired
+ References
No definition available.
+ Details

Name: alxn_AmortizationofIntangibleAssetsAcquired

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Restructuring Charges And Accrual Adjustment
+ References
No definition available.
+ Details

Name: alxn_RestructuringChargesAndAccrualAdjustment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares used in computing net income per share.
+ References
No definition available.
+ Details

Name: alxn_SharesUsedInComputingNetIncomePerShare

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(a),(b))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=alxn_NetProductSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=alxn_OtherRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R5.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Statements of Comprehensive Income Statement - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Net income (loss) $ 459.8 $ (457.4) $ 1,047.7 $ (208.3)

Other comprehensive income (loss), net of tax:

Foreign currency translation 1.5 (8.1) (0.5) (4.3)

Unrealized gains (losses) on debt securities 0.0 0.0 0.2 (0.4)

Unrealized gains on pension obligation 0.0 0.0 0.0 0.7

Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent (38.9) 50.9 (47.9) 35.5

Other comprehensive income (loss), net of tax (37.4) 42.8 (48.2) 31.5

Comprehensive income (loss) $ 422.4 $ (414.6) $ 999.5 $ (176.8)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss), attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R6.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Unrealized losses on hedging activities - tax effect $ (12.1) $ 15.4 $ (14.3) $ 10.5

X

- Definition
Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 45 R7.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Statements of Changes in Stockholder's Equity Statement - USD ($)
shares in Millions, $ in Millions

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Treasury Stock [Member]

AOCI Attributable to Parent [Member]

Retained Earnings [Member]

Common Stock, Shares, Outstanding at Dec. 31, 2017 234.3

Stockholders' Equity Attributable to Parent at Dec. 31, 2017 $ 8,893.1 $ 0.0 $ 8,290.3 $ (1,604.9) $ (34.4) $ 2,242.1

Treasury Stock, Shares at Dec. 31, 2017 12.0

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Treasury Stock, Shares, Acquired 0.7 0.7

Treasury Stock, Value, Acquired, Cost Method $ (85.0) $ (85.0)

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0.3

Stock Issued During Period, Value, Stock Options Exercised 24.6 24.6

Stock Issued During Period, Shares, Restricted Stock Award, Gross 0.9

Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition 105.3 105.3

Net income (loss) (208.3) (208.3)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 31.5 31.5

Treasury Stock, Shares at Jun. 30, 2018 12.7

Stockholders' Equity Attributable to Parent at Jun. 30, 2018 8,767.4 $ 0.0 8,420.2 $ (1,689.9) (2.9) 2,040.0

Common Stock, Shares, Outstanding at Jun. 30, 2018 235.5

Common Stock, Shares, Outstanding at Mar. 31, 2018 235.2

Stockholders' Equity Attributable to Parent at Mar. 31, 2018 9,112.7 $ 0.0 8,350.9 $ (1,689.9) (45.7) 2,497.4

Treasury Stock, Shares at Mar. 31, 2018 12.7

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Treasury Stock, Shares, Acquired 0.0

Treasury Stock, Value, Acquired, Cost Method 0.0 $ 0.0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0.2

Stock Issued During Period, Value, Stock Options Exercised 15.1 15.1

Stock Issued During Period, Shares, Restricted Stock Award, Gross 0.1

Stock Issued During Period, Value, Restricted Stock Award, Gross 0.3 0.3

Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition 53.9 53.9

Net income (loss) (457.4) (457.4)

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 42.8 (48.2)

Treasury Stock, Shares at Jun. 30, 2018 12.7

Stockholders' Equity Attributable to Parent at Jun. 30, 2018 8,767.4 $ 0.0 8,420.2 $ (1,689.9) (2.9) 2,040.0

Common Stock, Shares, Outstanding at Jun. 30, 2018 235.5

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Cumulative Effect of New Accounting Principle in Period of Adoption 6.2 6.2

Common Stock, Shares, Outstanding at Dec. 31, 2018 236.2

Stockholders' Equity Attributable to Parent at Dec. 31, 2018 $ 9,165.3 $ 0.0 8,539.1 $ (1,689.9) (9.7) 2,325.8

Treasury Stock, Shares at Dec. 31, 2018 12.7 12.7

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Treasury Stock, Shares, Acquired 0.4 0.4

Treasury Stock, Value, Acquired, Cost Method $ (48.9) $ (48.9)

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0.2

Stock Issued During Period, Value, Stock Options Exercised 21.3 21.3

Stock Issued During Period, Shares, Restricted Stock Award, Gross 0.9

Stock Issued During Period, Value, Restricted Stock Award, Gross 0.0 0.0

Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition 116.6 116.6

Net income (loss) 1,047.7 1,047.7

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent $ (48.2)

Treasury Stock, Shares at Jun. 30, 2019 13.1 13.1

Stockholders' Equity Attributable to Parent at Jun. 30, 2019 $ 10,163.5 $ 0.0 8,677.0 $ (1,738.8) (57.9) 3,283.2

Common Stock, Shares, Outstanding at Jun. 30, 2019 237.3

Common Stock, Shares, Outstanding at Mar. 31, 2019 237.0

Stockholders' Equity Attributable to Parent at Mar. 31, 2019 $ 9,706.6 $ 0.0 8,604.9 $ (1,701.2) (20.5) 2,823.4

Treasury Stock, Shares at Mar. 31, 2019 12.8

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Treasury Stock, Shares, Acquired 0.3 0.3

Treasury Stock, Value, Acquired, Cost Method $ (37.6) $ (37.6)

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 0.1

Stock Issued During Period, Value, Stock Options Exercised 11.2 11.2

Stock Issued During Period, Shares, Restricted Stock Award, Gross 0.2

Stock Issued During Period, Value, Restricted Stock Award, Gross 0.0 0.0

Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition 60.9 60.9

Net income (loss) 459.8 459.8

Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent $ (37.4) (37.4)

Treasury Stock, Shares at Jun. 30, 2019 13.1 13.1

Stockholders' Equity Attributable to Parent at Jun. 30, 2019 $ 10,163.5 $ 0.0 $ 8,677.0 $ (1,738.8) $ (57.9) 3,283.2

Common Stock, Shares, Outstanding at Jun. 30, 2019 237.3

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Cumulative Effect of New Accounting Principle in Period of Adoption $ (90.3) $ (90.3)

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 46 R8.htm IDEA: XBRL DOCUMENT v3.19.2

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Cash flows from operating activities:

Net income (loss) $ 1,047.7 $ (208.3)

Adjustments to reconcile net income to net cash flows from operating activities:

Depreciation and amortization 193.7 202.0

Change in fair value of contingent consideration (22.6) 57.4

Share-based compensation expense 117.6 105.2

Research and Development in Process 0.0 86.6

Deferred taxes (40.8) 111.5

Unrealized foreign currency loss (gain) (4.1) 12.7

Unrealized loss (gain) on forward contracts 11.3 3.1

Unrealized gain on strategic equity investments (8.6) (100.5)

Other (2.3) 13.2

Changes in operating assets and liabilities

Accounts receivable (196.4) (137.0)

Inventories (24.0) (4.1)

Prepaid expenses and other assets (126.8) (55.7)

Accounts payable, accrued expenses, lease liabilities and other liabilities 23.6 (130.6)

Net cash provided by operating activities 968.3 (44.5)

Cash flows from investing activities:

Payments to Acquire Debt Securities, Available-for-sale (41.1) (612.8)

Proceeds from maturity or sale of available-for-sale debt securities 139.3 1,054.8

Purchases of mutual funds related to nonqualified deferred compensation plan (10.9) (7.5)

Proceeds from sale of mutual funds related to nonqualified deferred compensation plan 9.0 5.9

Purchases of property, plant and equipment (82.8) (129.4)

Purchases of strategic investments (43.8) 0.0

Payments to Acquire Intangible Assets (8.0) 0.0

Payments for (Proceeds from) Other Investing Activities 0.2 2.6

Net cash provided by (used in) investing activities (38.1) 313.6

Cash flows from financing activities:

Debt issuance costs 0.0 (7.6)

Proceeds from Lines of Credit 0.0 250.0

Payments on term loan facility (32.7) (293.8)

Repayments of Lines of Credit (250.0) 0.0

Repurchases of common stock (48.9) (85.0)

Net proceeds from issuance of common stock under share-based compensation arrangements 20.5 24.6

Other (2.4) (4.7)

Net cash used in financing activities (313.5) (116.5)

Effect of exchange rate changes on cash and cash equivalents and restricted cash 0.7 (6.1)

Net change in cash and cash equivalents and restricted cash 617.4 146.5

Cash and cash equivalents and restricted cash at beginning of period 1,367.3 586.3

Cash and cash equivalents and restricted cash at end of period 1,984.7 732.8

Supplemental cash flow disclosures from investing and financing activities:

Fair value of contingent liability related to strategic investment and purchase option 27.4 0.0

Operating ROU lease assets obtained in exchange for operating lease liabilities 20.7 0.0

Capitalization of construction costs related to facility lease obligations 0.0 33.2

Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets $ 14.3 $ 15.8

X

- Definition
Operating Right-Of-Use Assets Exchanged For Operating Lease Liability
+ References
No definition available.
+ Details

Name: alxn_OperatingRightOfUseAssetsExchangedForOperatingLeaseLiability

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase during the period in capital lease obligations due to entering into new capital leases.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalLeaseObligationsIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) and income tax credits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DeferredIncomeTaxesAndTaxCredits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959
+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_OtherNoncashIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash (inflow) outflow from investing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investments classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireOtherInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ProceedsFromLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_RepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 47 R9.htm IDEA: XBRL DOCUMENT v3.19.2

Business
6 Months Ended

Jun. 30, 2019

Business [Abstract]

Business
Business
Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies.
We are the global leader in complement inhibition and have developed and commercialize two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In addition, Alexion has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development with strategic focus in hematology and nephrology, neurology, metabolics and neonatal Fc receptor (FcRn). We were incorporated in 1992 under the laws of the State of Delaware.

X

- Definition
Business [Abstract]
+ References
No definition available.
+ Details

Name: alxn_BusinessAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R10.htm IDEA: XBRL DOCUMENT v3.19.2

Basis of Presentation and Principles Of Consolidation
6 Months Ended

Jun. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2018. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of December 31, 2018 was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full year or any other future periods.
The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense.
The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2 and within Note 17, Leases.
Reclassifications
Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation.
New Accounting Pronouncements
Accounting Standards Update (ASU) 2016-13, "Measurement of Credit Losses on Financial Instruments": In June 2016, the Financial Accounting Standards Board (FASB) issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses
be reported based on expected losses compared to the current incurred loss model. The new standard also requires enhanced disclosure of credit risk associated with respective assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. We are currently assessing the impact of this standard on our consolidated financial statements.
ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract": In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA). Under the new guidance, customers will assess if a CCA includes a software license and if a CCA does include a software license, implementation and set-up costs will be accounted for consistent with existing internal-use software implementation guidance. Implementation costs associated with a CCA that do not include a software license would be expensed to operating expenses. The standard also provides classification guidance on these implementation costs as well as additional quantitative and qualitative disclosures. The standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Entities can choose to adopt the new guidance prospectively or retrospectively. We are currently assessing the impact this standard will have on our consolidated financial statements.
Recently Adopted Accounting Pronouncements
ASU 2016-02, "Leases": In February 2016, the FASB issued a new standard that requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right of use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as financing or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.
We adopted the new standard on January 1, 2019 using the modified retrospective approach. We have elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the consolidated financial statements and recognize a cumulative-effect adjustment to the opening balance of retained earnings on the date of adoption. We also elected the “package of practical expedients”, which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs.
Results for reporting periods beginning after January 1, 2019 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2019, we derecognized $472.8 of property, plant and equipment and other assets and $372.2 of facility lease obligations associated with previously existing build-to-suit arrangements. We capitalized ROU assets of $326.1, inclusive of opening adjustments of $70.8 primarily related to prepaid rent existing at transition, and $255.3 of lease liabilities, within our condensed consolidated balance sheets upon adoption. At transition we recorded a decrease of $90.3 to retained earnings, net of tax, primarily related to our derecognition of previously recorded build-to-suit arrangements.
ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income": In February 2018, the FASB issued a new standard that permits entities to make a one-time reclassification from accumulated other comprehensive income (AOCI) to retained earnings for the stranded tax effects resulting from the newly enacted corporate tax rates under the Tax Cuts and Jobs Act (the Tax Act), that was effective for the year ended December 31, 2017. We adopted the new standard on January 1, 2019 and elected not to reclassify the income tax effects of the Tax Act from AOCI to retained earnings. We continue to release disproportionate income tax effects from AOCI based on the aggregate portfolio approach. The adoption of this standard did not have an impact on our condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R11.htm IDEA: XBRL DOCUMENT v3.19.2

Acquisitions
6 Months Ended

Jun. 30, 2019

Asset Acquisitions [Abstract]

Acquisitions
Acquisitions
Wilson Therapeutics AB
On May 25, 2018, we completed the acquisition of Wilson Therapeutics AB (publ), a biopharmaceutical company based in Stockholm, Sweden (Wilson Therapeutics) that developed a novel therapy for patients with rare copper-mediated disorders, pursuant to a recommended public cash offer of SEK 232 for each share of stock of Wilson Therapeutics. As a result of the acquisition, we added WTX101 (ALXN1840), a highly innovative drug candidate that is currently in Phase III clinical trials for the treatment of patients with Wilson disease, to our clinical pipeline.
The acquisition of Wilson Therapeutics was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in a single asset, WTX101.
The following table summarizes the total consideration for the acquisition and the value of assets acquired and liabilities assumed:
Consideration

Cash paid for acquisition of Wilson Therapeutics outstanding shares
$
749.3

Transaction costs
15.1

Total consideration
$
764.4

Assets Acquired and Liabilities Assumed

Cash
$
45.1

In-process research & development
803.7

Employee related liabilities
(71.4
)
Other assets and liabilities
(13.0
)
Total net assets acquired
$
764.4

The acquired in-process research and development asset relates to WTX101. Due to the stage of development of this asset at the date of acquisition, significant risk remained and it was not yet probable that there was future economic benefit from this asset. Absent successful clinical results and regulatory approval for the asset, there was no alternative future use associated with WTX101. Accordingly, the value of this asset was expensed during the second quarter of 2018.
Employee related liabilities include the value of outstanding employee equity incentive awards that were accelerated in connection with the Wilson Therapeutics acquisition that have been settled in cash. Also included in this amount were employer tax obligations associated with the employee equity incentive awards.
In connection with rights to WTX101 that were previously acquired by Wilson Therapeutics from third parties, we could be required to pay up to approximately $19.0 if certain development, regulatory and commercial milestones are met over time, as well as royalties on commercial sales.
Syntimmune, Inc.
In September 2018, we entered into a definitive agreement to acquire Syntimmune, Inc. (Syntimmune), a clinical-stage biotechnology company developing an antibody therapy targeting the FcRn. Syntimmune’s lead candidate, SYNT001 (ALXN1830), is a monoclonal antibody that is designed to inhibit the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes, that is being studied for the treatment of IgG-mediated autoimmune diseases. The acquisition of Syntimmune closed in November 2018. Under the terms of the acquisition agreement, Alexion acquired Syntimmune for an upfront cash payment of $400.0, with the potential for additional milestone-dependent payments of up to $800.0, for a total potential value of up to $1,200.0.
The acquisition of Syntimmune was accounted for as an asset acquisition, as substantially all of the fair value of the gross assets acquired was concentrated in a single in-process research and development asset, SYNT001.
In connection with the agreement of the final working capital adjustment for the Syntimmune acquisition, we recognized a benefit of $4.1 associated with previously acquired in-process research and development in the second quarter 2019.
The following table summarizes the total consideration for the acquisition and the value of the assets acquired and liabilities assumed:
Consideration

Upfront payment for acquisition of Syntimmune outstanding shares
$
400.0

Cash acquired
4.2

Working capital adjustment
2.3

Transaction costs
0.9

Total consideration
$
407.4

Assets Acquired and Liabilities Assumed

Cash
$
4.2

In-process research & development
375.2

Deferred tax assets
25.1

Other assets and liabilities
2.9

Total net assets acquired
$
407.4


The acquired in-process research and development asset relates to SYNT001. Due to the stage of development of this asset at the date of acquisition, significant risk remained and it was not yet probable that there was future economic benefit from this asset. Absent successful clinical results and regulatory approval for the asset, there was no alternative future use associated with SYNT001. Accordingly, the value of this asset was expensed during the fourth quarter of 2018.

X

- Definition
Asset Acquisition Disclosure [Text Block]
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionDisclosureTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Asset Acquisitions [Abstract]
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionsAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R12.htm IDEA: XBRL DOCUMENT v3.19.2

Inventories
6 Months Ended

Jun. 30, 2019

Inventory, Net [Abstract]

Inventories
Inventories
The components of inventory are as follows:

June 30,

December 31,

2019

2018
Raw materials
$
38.2

$
31.4

Work-in-process
116.6

90.4

Finished goods
339.8

350.7

$
494.6

$
472.5

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R13.htm IDEA: XBRL DOCUMENT v3.19.2

Intangible Assets and Goodwill
6 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill Intangible Assets and Goodwill
The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:

June 30, 2019

December 31, 2018

Estimated
Life (years)

Cost

Accumulated
Amortization

Net

Cost

Accumulated
Amortization

Net
Licensing rights
5-8

$
47.0

$
(30.9
)

$
16.1

$
39.0

$
(29.3
)

$
9.7

Patents
7

10.5

(10.5
)

—

10.5

(10.5
)

—

Purchased technology
6-16

4,710.5

(1,239.2
)

3,471.3

4,710.5

(1,079.1
)

3,631.4

Other intangibles
5

0.4

(0.2
)

0.2

0.4

(0.2
)

0.2

Total

$
4,768.4

$
(1,280.8
)

$
3,487.6

$
4,760.4

$
(1,119.1
)

$
3,641.3

Goodwill
Indefinite

$
5,040.3

$
(2.9
)

$
5,037.4

$
5,040.3

$
(2.9
)

$
5,037.4

Amortization expense for the three months ended June 30, 2019 and 2018 was $81.2 and $80.3, respectively. Amortization expense for the six months ended June 30, 2019 and 2018 was $161.7 and $160.6, respectively. As of June 30, 2019, assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is $161.7 for the six months ending December 31, 2019, and approximately $323.0 for each of the years ending December 31, 2020 through December 31, 2024.
As of June 30, 2019, the net book value of our purchased technology includes $3,122.5 associated with the KANUMA intangible asset, which we acquired in the acquisition of Synageva BioPharma Corp. As part of our standard quarterly procedures, we reviewed the KANUMA asset as of June 30, 2019 and determined that there were no indicators of impairment. Cash flow models used in our assessments are based on our commercial experience to date with KANUMA and require the use of significant estimates, which include, but are not limited to, long-range pricing expectations and patient-related assumptions, including patient identification, conversion and retention rates. We will continue to review the related valuation and accounting of this asset as new information becomes available to us.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R14.htm IDEA: XBRL DOCUMENT v3.19.2

Debt
6 Months Ended

Jun. 30, 2019

Debt [Abstract]

Debt
Debt
On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement).
The Credit Agreement provides for a $1,000.0 revolving credit facility and a $2,612.5 term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments.
In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of $53.1 in financing costs. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended June 30, 2019 and 2018 was $1.3 and $3.2, respectively, and amortization expense associated with deferred financing costs for the six months ended June 30, 2019 and 2018 was $2.5 and $5.5, respectively. Remaining unamortized deferred financing costs as of June 30, 2019 and December 31, 2018 were $18.3 and $20.8, respectively.
We made principal payments of $32.7 on the term loan during the three and six months ended June 30, 2019 and as of June 30, 2019, we had $2,579.8 outstanding on the term loan. In January 2019, we paid the outstanding balance on the revolving credit facility of $250.0 in full and we had no outstanding borrowings under the revolving credit facility as of June 30, 2019. As of June 30, 2019, we had open letters of credit of $1.0 that offset our availability in the revolving facility.
The fair value of our long term debt, which is measured using Level 2 inputs of the fair value hierarchy, approximates book value.

X

- Definition
Debt [Abstract]
+ References
No definition available.
+ Details

Name: alxn_DebtAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R15.htm IDEA: XBRL DOCUMENT v3.19.2

Earnings Per Common Share
6 Months Ended

Jun. 30, 2019

Earnings Per Common Share [Abstract]

Earnings Per Common Share
Earnings Per Common Share
Basic earnings per common share (EPS) is computed by dividing net income by the weighted-average number of shares of common stock outstanding during the applicable period. For purposes of calculating diluted EPS, the denominator reflects the potential dilution that could occur if stock options, unvested restricted stock units or other contracts to issue common stock were exercised or converted into common stock, using the treasury stock method.
The following table summarizes the calculation of basic and diluted EPS for the three and six months ended June 30, 2019 and 2018:

Three months ended

Six months ended

June 30,

June 30,

2019

2018

2019

2018
Net income (loss) used for basic and diluted calculation
$
459.8

$
(457.4
)

$
1,047.7

$
(208.3
)
Shares used in computing earnings (loss) per common share—basic
224.2

222.6

224.0

222.3

Weighted-average effect of dilutive securities:

Stock awards
1.4

—

1.7

—

Shares used in computing earnings (loss) per common share—diluted
225.6

222.6

225.7

222.3

Earnings (loss) per common share:

Basic
$
2.05

$
(2.05
)

$
4.68

$
(0.94
)
Diluted
$
2.04

$
(2.05
)

$
4.64

$
(0.94
)

We exclude from diluted EPS the weighted-average number of securities whose effect is anti-dilutive. Excluded from the calculation of diluted EPS for the three and six months ended June 30, 2019 were 1.9 and 2.9 shares of common stock, respectively, because their effect was anti-dilutive. For the three and six months ended June 30, 2018, we reported a net loss; therefore, no outstanding stock awards were included in the computation of diluted net loss per share since such inclusion would have been anti-dilutive.

X

- Definition
Earnings Per Common Share [Abstract]
+ References
No definition available.
+ Details

Name: alxn_EarningsPerCommonShareAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R16.htm IDEA: XBRL DOCUMENT v3.19.2

Marketable Securities
6 Months Ended

Jun. 30, 2019

Investments, Debt and Equity Securities [Abstract]

Marketable securities
Marketable Securities

The amortized cost, gross unrealized holding gains, gross unrealized holding losses and fair value of available-for-sale debt securities by type of security as of June 30, 2019 and December 31, 2018 were as follows:

June 30, 2019

Amortized Cost

Gross Unrealized Holding Gains

Gross Unrealized Holding Losses

Fair Value
Commercial paper

$
274.0

$
—

$
—

$
274.0

Corporate bonds

28.0

—

—

28.0

Other government-related obligations:

U.S.

117.8

—

—

117.8

Bank certificates of deposit

24.3

—

—

24.3

Total available-for-sale debt securities

$
444.1

$
—

$
—

$
444.1

December 31, 2018

Amortized Cost

Gross Unrealized Holding Gains

Gross Unrealized Holding Losses

Fair Value
Commercial paper

$
52.1

$
—

$
—

$
52.1

Corporate bonds

122.9

—

(0.1
)

122.8

Other government-related obligations:

U.S.

17.5

—

—

17.5

Bank certificates of deposit

33.2

—

—

33.2

Total available-for-sale debt securities

$
225.7

$
—

$
(0.1
)

$
225.6

The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of June 30, 2019 and December 31, 2018 was $25.5 and $128.7, respectively. We did not have any investments in a continuous unrealized
loss position for more than twelve months as of June 30, 2019 and December 31, 2018. As of June 30, 2019, we believe that the cost basis of our available-for-sale debt securities is recoverable.
The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:

June 30, 2019

December 31, 2018
Cash and cash equivalents
$
359.4

$
43.8

Marketable securities
84.7

181.8

$
444.1

$
225.6

The fair values of available-for-sale debt securities at June 30, 2019, by contractual maturity, are summarized as follows:

June 30, 2019
Due in one year or less
$
438.3

Due after one year through three years
5.8

$
444.1


We sponsor a nonqualified deferred compensation plan which allows certain highly-compensated employees to elect to defer income to future periods. Participants in the plan earn a return on their deferrals based on several investment options, which mirror returns on underlying mutual fund investments. We choose to invest in the underlying mutual fund investments to offset the liability associated with our nonqualified deferred compensation plan. These mutual fund investments are valued at net asset value per share and are carried at fair value with gains and losses included in investment income. The changes in the underlying liability to the employee are recorded in operating expenses. As of June 30, 2019 and December 31, 2018, the fair value of these investments was $20.7 and $16.5, respectively.

We utilize the specific identification method in computing realized gains and losses. Realized gains and losses on our marketable securities were not material for the three and six months ended June 30, 2019 and 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI http://asc.fasb.org/subtopic&trid=2176304
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R17.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities
6 Months Ended

Jun. 30, 2019

Derivative Instruments and Hedging Activities [Abstract]

Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities
We operate internationally and, in the normal course of business, are exposed to fluctuations in foreign currency exchange rates. The exposures result from portions of our revenues, as well as the related receivables, and expenses that are denominated in currencies other than the U.S. dollar, primarily the Euro and Japanese Yen. We are also exposed to fluctuations in interest rates on outstanding borrowings under our revolving credit facility, if any, and term loan facility. We manage these exposures within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.
We enter into foreign exchange forward contracts, with durations of up to 60 months, to hedge exposures resulting from portions of our forecasted revenues, including intercompany revenues, and certain forecasted expenses that are denominated in currencies other than the U.S. dollar. The purpose of these hedges is to reduce the volatility of exchange rate fluctuations on our operating results. These hedges are designated as cash flow hedges upon contract inception. As of June 30, 2019, we had open revenue related foreign exchange forward contracts with notional amounts totaling $1,136.1 that qualified for hedge accounting with current contract maturities through December 2020. As of June 30, 2019, we had open expense related foreign exchange forward contracts with notional amounts totaling $17.1 that qualified for hedge accounting with contract maturities through September 2022.
To achieve a desired mix of floating and fixed interest rates on our term loan, we enter into interest rate swap agreements that qualify for and are designated as cash flow hedges. These contracts convert the floating interest rate on a portion of our debt to a fixed rate, plus a borrowing spread.
The following table summarizes the total interest rate swap contracts executed as of June 30, 2019:
Type of Interest Rate Swap
Notional Amount
Effective Date
Termination Date
Fixed Interest Rate or Rate Range
Floating to Fixed
1,531.3
December 2016 - January 2018
December 2019
0.98% - 1.62%
Floating to Fixed
450.0
December 2018
December 2022
2.60% - 2.79%
Floating to Fixed
300.0
January 2019
December 2019
2.08%
Floating to Fixed
1,300.0
December 2019
December 2022
2.37% - 2.83%

The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2019 and 2018 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:

Three months ended

Three months ended

June 30, 2019

June 30, 2018
Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded
Net Product Sales

Interest Expense

Net Product Sales

Interest Expense
Total amount presented in the Condensed Consolidated Statements of Operations
$
1,202.5

$
(18.3
)

$
1,044.7

$
(25.0
)
Impact of cash flow hedging relationships:

Foreign exchange forward contracts
$
9.1

$
—

$
(1.7
)

$
—

Interest rate swap contracts
$
—

$
4.5

$
—

$
3.1

Six months ended

Six months ended

June 30, 2019

June 30, 2018
Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded
Net Product Sales

Interest Expense

Net Product Sales

Interest Expense
Total amount presented in the Condensed Consolidated Statements of Operations
$
2,342.7

$
(38.2
)

$
1,975.1

$
(49.1
)
Impact of cash flow hedging relationships:

Foreign exchange forward contracts
$
16.1

$
—

$
(14.8
)

$
—

Interest rate swap contracts
$
—

$
9.1

$
—

$
4.5

The impact on AOCI from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and six months ended June 30, 2019 and 2018 were as follows:

Three months ended

Six months ended

June 30,

June 30,

2019

2018

2019

2018
Foreign Exchange Forward Contracts:

Gain (loss) recognized in AOCI, net of tax
$
(3.9
)

$
49.0

$
10.3

$
16.5

Gain (loss) reclassified from AOCI to net product sales, net of tax
$
7.0

$
(1.3
)

$
12.4

$
(11.4
)
Interest Rate Contracts:

Gain (loss) recognized in AOCI, net of tax
$
(24.6
)

$
3.1

$
(38.8
)

$
11.2

Gain (loss) reclassified from AOCI to interest expense, net of tax
$
3.4

$
2.5

$
7.0

$
3.6

Assuming no change in foreign exchange rates from market rates at June 30, 2019, $4.8 of gains recognized in AOCI will be reclassified to revenue over the next 12 months. Assuming no change in LIBOR-based interest rates from market rates at June 30, 2019, $5.2 of losses recognized in AOCI will be reclassified to interest expense over the next 12 months. Amounts recognized in AOCI for expense related foreign exchange forward contracts was immaterial at June 30, 2019.
We enter into foreign exchange forward contracts, with durations of up to 8 months, designed to limit the balance sheet exposure of monetary assets and liabilities. We enter into these hedges to reduce the impact of fluctuating exchange rates on our operating results. Hedge accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and losses on underlying balance sheet exposures. As of June 30, 2019, the notional amount of foreign exchange contracts where hedge accounting is not applied was $1,963.0.
We recognized a gain (loss) of $(5.8) and $18.4, in other income and (expense) for the three months ended June 30, 2019 and 2018, respectively, associated with the foreign exchange contracts not designated as hedging instruments. We recognized a gain (loss) of $(2.6) and $10.3, in other income and (expense) for the six months ended June 30, 2019 and 2018, respectively, associated with the foreign exchange contracts not designated as hedging instruments. These amounts were partially offset by gains or losses on monetary assets and liabilities.
The following tables summarize the fair value of outstanding derivatives as of June 30, 2019 and December 31, 2018:

June 30, 2019

Derivative Assets

Derivative Liabilities

Balance Sheet
Location

Fair
Value

Balance Sheet
Location

Fair
Value
Derivatives designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

$
12.4

Other current liabilities

$
7.6

Foreign exchange forward contracts
Other assets

1.1

Other liabilities

1.8

Interest rate contracts
Prepaid expenses and other current assets

5.6

Other current liabilities

10.8

Interest rate contracts
Other assets

—

Other liabilities

52.2

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

16.1

Other current liabilities

15.4

Total fair value of derivative instruments

$
35.2

$
87.8

December 31, 2018

Derivative Assets

Derivative Liabilities

Balance Sheet
Location

Fair
Value

Balance Sheet
Location

Fair
Value
Derivatives designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

$
16.9

Other current liabilities

$
7.3

Foreign exchange forward contracts
Other assets

0.3

Other liabilities

3.1

Interest rate contracts
Prepaid expenses and other current assets

20.1

Other current liabilities

0.8

Interest rate contracts
Other assets

—

Other liabilities

17.3

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

23.6

Other current liabilities

11.5

Total fair value of derivative instruments

$
60.9

$
40.0

Although we do not offset derivative assets and liabilities within our condensed consolidated balance sheets, our International Swap and Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:

June 30, 2019

Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet

Description

Gross Amounts of Recognized Assets/Liabilities

Gross Amounts Offset in the Condensed Consolidated Balance Sheet

Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet

Derivative Financial Instruments

Cash Collateral Received (Pledged)

Net Amount
Derivative assets

$
35.2

$
—

$
35.2

$
(24.4
)

$
—

$
10.8

Derivative liabilities

(87.8
)

—

(87.8
)

24.4

—

(63.4
)

December 31, 2018

Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet

Description

Gross Amounts of Recognized Assets/Liabilities

Gross Amounts Offset in the Condensed Consolidated Balance Sheet

Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet

Derivative Financial Instruments

Cash Collateral Received (Pledged)

Net Amount
Derivative assets

$
60.9

$
—

$
60.9

$
(30.2
)

$
—

$
30.7

Derivative liabilities

(40.0
)

—

(40.0
)

30.2

—

(9.8
)

X

- Definition
Derivative Instruments and Hedging Activities [Abstract]
+ References
No definition available.
+ Details

Name: alxn_DerivativeInstrumentsAndHedgingActivitiesAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R18.htm IDEA: XBRL DOCUMENT v3.19.2

Other Investments
6 Months Ended

Jun. 30, 2019

Investments, All Other Investments [Abstract]

Other Investments
Other Investments
Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with license agreements. These investments are included in other assets in our condensed consolidated balance sheets.
Moderna
During 2014, we purchased $37.5 of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was recorded at cost. During the first quarter 2018, Moderna announced the completion of a new round of financing. As a result, we recognized an unrealized gain of $100.8 in investment income during the first quarter 2018 to adjust our investment in Moderna to fair value as of the date of the observable price change, based on the per share price in Moderna's new round of financing. There were no observable price changes during the second quarter 2018.
On December 6, 2018, Moderna completed its initial public offering (IPO) and shares of Moderna began trading on the Nasdaq Global Select Market under the symbol “MRNA.” As part of the IPO, our preferred stock was converted into Moderna common stock and subject to a one year lock-up period. As our equity investment in Moderna common stock now has a readily determinable fair value, we are recording the investment at fair value, with the effects of the holding period restriction estimated using an option pricing valuation model. During the three and six months ended June 30, 2019, we recognized an unrealized (loss) gain of $(29.0) and $0.8, respectively, in investment income to adjust our investment in Moderna to fair value as of June 30, 2019.
The fair value of this investment was $82.7 and $81.9 as of June 30, 2019 and December 31, 2018, respectively.
Dicerna
In October 2018, we purchased $10.3 of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and six months ended June 30, 2019, we recognized an unrealized gain of $0.9 and $4.2, respectively, in investment income to adjust our equity investment in Dicerna to fair value as of June 30, 2019.
The fair value of this investment was $13.1 and $8.9 as of June 30, 2019 and December 31, 2018, respectively.
Caelum
In January 2019, we purchased $41.0 of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a $16.1 option to acquire the remaining equity in Caelum in connection with an agreement that we entered into with Caelum, see Note 18, “Commitments and Contingencies” for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we are recording the assets at cost, less impairment, and adjusted for any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer.
There were no observable price changes associated with these assets during the six months ended June 30, 2019. The carrying value of the investment and option of $41.0 and $16.1, respectively, were not impaired as of June 30, 2019.
Zealand
In March 2019, we purchased $13.8 of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark, see Note 18, “Commitments and Contingencies” for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. We have considered the effects of a six month holding period restriction and determined that the impact on the fair value of the investment is immaterial. During the three and six months ended June 30, 2019, we recognized an unrealized gain of $2.9 and $3.6, respectively, in investment income to adjust our equity investment in Zealand to fair value as of June 30, 2019.
The fair value of this investment was $17.4 as of June 30, 2019.

X

- Definition
A table of investments, shown as a text block.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 6
-Section 10
-Paragraph (c)
-Subparagraph (1)
+ Details

Name: invest_InvestmentTableTextBlock

Namespace Prefix: invest_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R19.htm IDEA: XBRL DOCUMENT v3.19.2

Stockholders' Equity
6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Stockholders' Equity
Stockholders' Equity
In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under the repurchase program, which superseded all prior repurchase programs. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.3 shares of our common stock at a cost of $37.6 during the three months ended June 30, 2019. During the six months ended June 30, 2019 and 2018, we repurchased 0.4 and 0.7 shares of our common stock at a cost of $48.9 and $85.0, respectively. The Company did not repurchase any shares during the three months ended June 30, 2018.
Subsequent to June 30, 2019, we repurchased 0.1 shares of common stock under our repurchase program at a cost of $9.0. As of July 22, 2019, there is a total of $393.6 remaining for repurchases under the repurchase program.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R20.htm IDEA: XBRL DOCUMENT v3.19.2

Other Comprehensive Income and Accumulated Other Comprehensive Income
6 Months Ended

Jun. 30, 2019

Accumulated Other Comprehensive Income [Abstract]

Other Comprehensive Income and Accumulated Other Comprehensive Income
Other Comprehensive Income and Accumulated Other Comprehensive Income

The following tables summarize the changes in AOCI, by component, for the six months ended June 30, 2019 and 2018:

Defined Benefit Pension Plans

Unrealized Gains (Losses) from Debt Securities

Unrealized Gains (Losses) from Hedging Activities

Foreign Currency Translation Adjustment

Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2018
$
(2.6
)

$
(0.3
)

$
9.6

$
(16.4
)

$
(9.7
)
Other comprehensive income (loss) before reclassifications
—

0.2

(28.5
)

(0.5
)

(28.8
)
Amounts reclassified from other comprehensive income
—

—

(19.4
)

—

(19.4
)
Net other comprehensive income (loss)
—

0.2

(47.9
)

(0.5
)

(48.2
)
Balances, June 30, 2019
$
(2.6
)

$
(0.1
)

$
(38.3
)

$
(16.9
)

$
(57.9
)

Defined Benefit Pension Plans

Unrealized Gains (Losses) from Debt Securities

Unrealized Gains (Losses) from Hedging Activities

Foreign Currency Translation Adjustment

Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2017
$
(4.8
)

$
0.2

$
(13.9
)

$
(15.9
)

$
(34.4
)
Other comprehensive income (loss) before reclassifications
1.3

0.1

27.7

(4.3
)

24.8

Amounts reclassified from other comprehensive income
(0.6
)

(0.5
)

7.8

—

6.7

Net other comprehensive income (loss)
0.7

(0.4
)

35.5

(4.3
)

31.5

Balances, June 30, 2018
$
(4.1
)

$
(0.2
)

$
21.6

$
(20.2
)

$
(2.9
)

The table below provides details regarding significant reclassifications from AOCI during the three and six months ended June 30, 2019 and 2018:
Details about Accumulated Other Comprehensive Income Components

Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,

Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,

Affected Line Item in the Condensed Consolidated Statements of Operations

2019
2018

2019
2018

Unrealized Gains (Losses) on Hedging Activity

Foreign exchange forward contracts

$
9.1

$
(1.7
)

$
16.1

$
(14.8
)

Net product sales
Interest rate swap contracts

4.5

3.1

9.1

4.5

Interest expense

13.6

1.4

25.2

(10.3
)

(3.2
)
(0.2
)

(5.8
)
2.5

Income tax (benefit) expense

$
10.4

$
1.2

$
19.4

$
(7.8
)

X

- Definition
Accumulated Other Comprehensive Income [Abstract]
+ References
No definition available.
+ Details

Name: alxn_AccumulatedOtherComprehensiveIncomeAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-URI http://asc.fasb.org/topic&trid=2134417
+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R21.htm IDEA: XBRL DOCUMENT v3.19.2

Fair Value Measurement
6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurement
Fair Value Measurement
Authoritative guidance establishes a valuation hierarchy for disclosure of the inputs to the valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value.
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.

Fair Value Measurement at
June 30, 2019
Balance Sheet
Classification
Type of Instrument
Total

Level 1

Level 2

Level 3
Cash equivalents
Money market funds
$
498.5

$
—

$
498.5

$
—

Cash equivalents
Commercial paper
$
240.2

$
—

$
240.2

$
—

Cash equivalents
Bank certificates of deposit
$
12.2

$
—

$
12.2

$
—

Cash equivalents
Other government-related obligations
$
107.0

$
—

$
107.0

$
—

Marketable securities
Mutual funds
$
20.7

$
20.7

$
—

$
—

Marketable securities
Commercial paper
$
33.8

$
—

$
33.8

$
—

Marketable securities
Corporate bonds
$
28.0

$
—

$
28.0

$
—

Marketable securities
Other government-related obligations
$
10.8

$
—

$
10.8

$
—

Marketable securities
Bank certificates of deposit
$
12.1

$
—

$
12.1

$
—

Other assets
Equity securities
$
113.3

$
30.6

$
82.7

$
—

Prepaid expenses and other current assets
Foreign exchange forward contracts
$
28.5

$
—

$
28.5

$
—

Other assets
Foreign exchange forward contracts
$
1.1

$
—

$
1.1

$
—

Other current liabilities
Foreign exchange forward contracts
$
23.0

$
—

$
23.0

$
—

Other liabilities
Foreign exchange forward contracts
$
1.8

$
—

$
1.8

$
—

Prepaid expenses and other current assets
Interest rate contracts
$
5.6

$
—

$
5.6

$
—

Other current liabilities
Interest rate contracts
$
10.8

$
—

$
10.8

$
—

Other liabilities
Interest rate contracts
$
52.2

$
—

$
52.2

$
—

Current portion of contingent consideration
Acquisition-related contingent consideration
$
100.0

$
—

$
—

$
100.0

Contingent consideration
Acquisition-related contingent consideration
$
158.2

$
—

$
—

$
158.2

Other current liabilities
Other contingent payments
$
13.9

$
—

$
—

$
13.9

Other liabilities
Other contingent payments
$
13.5

$
—

$
—

$
13.5

Fair Value Measurement at
December 31, 2018
Balance Sheet
Classification
Type of Instrument
Total

Level 1

Level 2

Level 3
Cash equivalents
Money market funds
$
569.4

$
—

$
569.4

$
—

Cash equivalents
Commercial paper
$
35.4

$
—

$
35.4

$
—

Cash equivalents
Corporate bonds
$
0.2

$
—

$
0.2

$
—

Cash equivalents
Other government-related obligations
$
8.2

$
—

$
8.2

$
—

Marketable securities
Mutual funds
$
16.5

$
16.5

$
—

$
—

Marketable securities
Commercial paper
$
16.7

$
—

$
16.7

$
—

Marketable securities
Corporate bonds
$
122.6

$
—

$
122.6

$
—

Marketable securities
Other government-related obligations
$
9.3

$
—

$
9.3

$
—

Marketable securities
Bank certificates of deposit
$
33.2

$
—

$
33.2

$
—

Other assets
Equity securities
$
90.8

$
8.9

$
81.9

$
—

Prepaid expenses and other current assets
Foreign exchange forward contracts
$
40.5

$
—

$
40.5

$
—

Other assets
Foreign exchange forward contracts
$
0.3

$
—

$
0.3

$
—

Other current liabilities
Foreign exchange forward contracts
$
18.8

$
—

$
18.8

$
—

Other liabilities
Foreign exchange forward contracts
$
3.1

$
—

$
3.1

$
—

Prepaid expenses and other current assets
Interest rate contracts
$
20.1

$
—

$
20.1

$
—

Other current liabilities
Interest rate contracts
$
0.8

$
—

$
0.8

$
—

Other liabilities
Interest rate contracts
$
17.3

$
—

$
17.3

$
—

Current portion of contingent consideration
Acquisition-related contingent consideration
$
97.6

$
—

$
—

$
97.6

Contingent consideration
Acquisition-related contingent consideration
$
183.2

$
—

$
—

$
183.2

There were no securities transferred between Level 1, 2 and 3 during the six months ended June 30, 2019.

Valuation Techniques
We classify mutual fund investments and equity securities, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.
Cash equivalents and marketable securities classified as Level 2 within the valuation hierarchy include money market funds, commercial paper, U.S. and foreign government-related debt, corporate debt securities and certificates of deposit. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for similar securities, issuer credit spreads, benchmark yields, and other observable inputs. We validate the prices provided by our third-party pricing sources by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances.
Other investments in equity securities of publicly traded companies which are subject to holding period restrictions are carried at fair value using an option pricing valuation model and classified as Level 2 equity securities within the fair value hierarchy. The most significant assumptions within the option pricing valuation model are the term of the restrictions and the stock price volatility, which is based upon the historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on such investments.
Our derivative assets and liabilities include foreign exchange and interest rate derivatives that are measured at fair value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the valuation hierarchy.
Contingent consideration liabilities related to business acquisitions and derivative liabilities associated with other contingent payments are classified as Level 3 within the valuation hierarchy and are valued based on various estimates, including probability of success, discount rates and amount of time until the conditions of the milestone payments are met.
As of June 30, 2019, there has not been any impact to the fair value of our derivative liabilities due to our own credit risk. Similarly, there has not been any significant adverse impact to our derivative assets based on our evaluation of our counterparties’ credit risks.

Acquisition-Related Contingent Consideration
In connection with prior business combinations, we may be required to pay future consideration that is contingent upon the achievement of specified development, regulatory approvals or sales-based milestone events. We determine the fair value of these obligations using various estimates that are not observable in the market and represent a Level 3 measurement within the fair value hierarchy. The resulting probability-weighted cash flows were discounted using a cost of debt of 5.1% for developmental and regulatory milestones and a weighted average cost of capital of 10.0% for sales-based milestones.
Each reporting period, we adjust the contingent consideration to fair value with changes in fair value recognized in operating earnings. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time.
As of June 30, 2019, estimated future contingent milestone payments related to prior business combinations range from zero if no milestone events are achieved, to a maximum of $702.0 if all development, regulatory and sales-based milestones are reached. In the second quarter 2019, a sales-based milestone associated with our acquisition of Enobia Pharma Corp. was achieved. In connection with such achievement, we will make a $100.0 milestone payment in the third quarter 2019.
As of June 30, 2019, the fair value of acquisition-related contingent consideration was $258.2. The following table represents a roll-forward of our acquisition-related contingent consideration:

Six months ended

June 30, 2019
Balance at beginning of period
$
280.8

Changes in fair value
(22.6
)
Balance at end of period
$
258.2

Other Contingent Payments
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 during the first quarter 2019 and could be required to pay up to an additional $30.0 in contingent milestone-dependent fees. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1, based on the probability-weighted cash flows, discounted using a cost of debt ranging from 3.3% to 3.5%.
Each reporting period, we adjust the derivative liability associated with the contingent fees to fair value with changes in fair value recognized in other income and expense. Changes in fair values reflect new information about the probability and timing of meeting the conditions of the milestone payments. In the absence of new information, change in fair value will only reflect the interest component of the liability related to the passage of time. As of June 30, 2019, the fair value of our contingent fees was $27.4. We recorded $0.3 in other income and (expense) during the three and six months ended June 30, 2019 related to the change in the fair value of the liability.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R22.htm IDEA: XBRL DOCUMENT v3.19.2

Revenue Recognition
6 Months Ended

Jun. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenue Recognition
Revenue Recognition
Disaggregation of Revenue
The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below.

Three months ended June 30,

Six months ended June 30,

2019

2018

2019

2018
SOLIRIS

United States
$
496.3

$
395.8

$
960.0

$
731.8

Europe
280.2

253.4

544.7

504.2

Asia Pacific
110.3

93.6

211.2

179.1

Rest of World
94.0

155.4

226.9

283.2

Total
$
980.8

$
898.2

$
1,942.8

$
1,698.3

ULTOMIRIS

United States
$
54.2

$
—

$
78.8

$
—

Europe
—

—

—

—

Asia Pacific
—

—

—

—

Rest of World
—

—

—

—

Total
$
54.2

$
—

$
78.8

$
—

STRENSIQ

United States
$
106.2

$
99.9

$
205.7

$
189.1

Europe
19.5

16.4

37.0

30.4

Asia Pacific
12.1

6.3

22.0

12.0

Rest of World
3.5

2.5

6.7

4.3

Total
$
141.3

$
125.1

$
271.4

$
235.8

KANUMA

United States
$
15.3

$
13.0

$
29.1

$
24.9

Europe
6.8

5.8

13.1

11.7

Asia Pacific
1.3

1.1

2.1

2.1

Rest of World
2.8

1.5

5.4

2.3

Total
$
26.2

$
21.4

$
49.7

$
41.0

Total Net Product Sales
$
1,202.5

$
1,044.7

$
2,342.7

$
1,975.1

Contract Balances and Receivables
Contract liabilities relate to consideration received and/or billed for goods that have not been delivered to the customer and for which the performance obligation has not yet been completed. These amounts are included within other current liabilities in the condensed consolidated balance sheets.
The following table provides information about receivables and contract liabilities from our contracts with customers.

June 30, 2019

December 31, 2018
Receivables, which are included in "Trade accounts receivable, net"
$
1,123.6

$
922.3

Contract liabilities, which are included in "Other current liabilities"
$
3.1

$
3.4

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 61 R23.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes
6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

The following table provides a comparative summary of our income tax (benefit) expense and effective income tax rate for the three and six months ended June 30, 2019 and 2018:

Three months ended

Six months ended

June 30,

June 30,

2019

2018

2019

2018
Income tax (benefit) expense
$
39.7

$
38.8

$
(6.4
)

$
141.3

Effective income tax rate
7.9
%

(9.3
)%

(0.6
)%

(210.9
)%

Income tax (benefit) expense is attributable to the U.S. federal, state and foreign income taxes on our profitable operations. During the first quarter 2019, in connection with the future integration of intellectual property of Wilson Therapeutics, with and into the Alexion corporate structure, we recognized certain one-time tax benefits. The deferred tax benefits include $95.7 and $30.3 associated with a tax election made with respect to intellectual property of Wilson Therapeutics and a valuation allowance release and corresponding recognition of net operating losses, respectively. These deferred tax benefits decreased the effective tax rate for the six months ended June 30, 2019 by approximately 12.1%. Future changes to our intellectual property integration planning could materially impact our effective tax rate in subsequent periods.
On July 1, 2019, the Wilson Therapeutics intellectual property was integrated with and into the Alexion corporate structure. The Company is currently evaluating the impact of the integration on the Company's consolidated financial statements and will record the associated tax effects in the third quarter of 2019.
The income tax expense for the three and six months ended June 30, 2018 includes a decrease in the effective tax rate of approximately 19.4% and 230.1%, respectively, attributable to the acquisition of Wilson Therapeutics. Absent successful clinical results and regulatory approval, there is no alternative future use of the WTX101 asset acquired. Accordingly, the value of the asset of $803.7 was expensed as in-process research and development costs during such three and six month periods, for which no tax benefit has been recognized. Also included in the six months ended June 30, 2018 is a U.S. tax reform measurement period adjustment to deferred taxes of $38.4. This deferred tax cost increased the effective tax rate by approximately 5.2%.
In 2017, the IRS commenced an examination of our U.S. income tax returns for 2015. We anticipate this audit will conclude within the next twelve months. We have not been notified of any significant adjustments proposed by the IRS. It is reasonably possible that previously unrecognized tax benefits could be recognized upon the conclusion of the IRS examination. At this time, an estimate of the change in unrecognized tax benefits cannot be made.
We have recorded tax on the undistributed earnings of our controlled foreign corporation (CFC) subsidiaries. To the extent CFC earnings may not be repatriated to the U.S. as a dividend distribution due to limitations imposed by law, we have not recorded the related potential withholding, foreign, local, and U.S. state income taxes.
We continue to maintain a valuation allowance against certain deferred tax assets where realization is not certain.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R24.htm IDEA: XBRL DOCUMENT v3.19.2

Defined Benefit Plans
6 Months Ended

Jun. 30, 2019

Retirement Benefits [Abstract]

Employee Benefit Plans
Defined Benefit Plans
We maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments. The total net periodic benefit cost for the three and six months ended June 30, 2019 and 2018 was not material.

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R25.htm IDEA: XBRL DOCUMENT v3.19.2

Leases
6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases
Leases
At the inception of an arrangement, we determine if an arrangement is, or contains, a lease based on the unique facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then determined at the lease commencement date. For arrangements that contain a lease we (i) identify lease and non-lease components, (ii) determine the consideration in the contract, (iii) determine whether the lease is an operating or
financing lease; and (iv) recognize lease ROU assets and liabilities. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and as such, we use our incremental borrowing rate based on the information available at the lease commencement date, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.
Most leases include options to renew and, or, terminate the lease, which can impact the lease term. The exercise of these options is at our discretion and we do not include any of these options within the expected lease term as we are not reasonably certain we will exercise these options. We have elected to combine lease components (for example fixed payments including rent) with non-lease components (for example, non-dedicated parking and common-area maintenance costs) on our real estate and commercial fleet asset classes. We separate lease and non-lease components on our embedded contract manufacturing organization (CMO) arrangements. Lease and non-lease components on these CMO arrangements are determined based on an allocation of the consideration in the contract to the embedded lease and non-lease components of the arrangement based on the relative standalone selling prices of these components.
Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease on a straight-line basis, while fixed, or in substance fixed, payments on financing leases are recognized using the effective interest method. Variable lease expenses that are not considered fixed, or in substance fixed, are recognized as incurred. Fixed and variable lease expense on operating leases is recognized within operating expenses within our condensed consolidated statements of operations. Financing lease ROU asset amortization and interest costs are recorded within operating expenses and interest expense, respectively, within our condensed consolidated statements of operations. We have operating and financing leases for corporate offices, research and development facilities, regional executive and sales offices, commercial fleet, and CMO embedded lease arrangements. We have elected the short-term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with an original term of 12 months or less.
Operating leases are included in right of use operating assets, other current liabilities, and noncurrent operating lease liabilities in our condensed consolidated balance sheet as of June 30, 2019. Financing leases are included in property, plant and equipment, other current liabilities, and other liabilities in our condensed consolidated balance sheet as of June 30, 2019.
The following table summarizes our lease assets and liabilities as of June 30, 2019:
ROU Assets and Liabilities

Balance Sheet
Location
Financing

Operating
ROU - Asset
Right of use operating assets
$
—

$
209.5

ROU - Asset
Property, plant, and equipment
121.8

—

Lease liabilities (current)
Other current liabilities
5.0

20.3

Lease liabilities (noncurrent)
Noncurrent operating lease liabilities
—

165.5

Lease liabilities (noncurrent)
Other liabilities
75.5

—

The following table summarizes our lease related costs for the three and six months ended June 30, 2019:
Lease Cost

Statement of Operations Location
Three months ended
Six months ended

June 30, 2019
June 30, 2019
Financing Lease Cost

$
3.5

$
7.5

Amortization of ROU Assets
Operating Expenses
2.5

5.5

Interest on Lease Liabilities
Interest Expense
1.0

2.0

Operating Lease Cost
Operating Expenses
8.6

17.6

Variable Lease Cost
Operating Expenses
2.3

4.3

Total Lease Cost

14.4

29.4

Amounts above include $3.0 and $6.3 of lease costs associated with our CMO embedded lease arrangement for the three and six months ended June 30, 2019, respectively, which have been capitalized within other assets as a prepayment of inventory.

The following table summarizes supplemental cash flow information for the three and six months ended June 30, 2019:
Other Information
Three months ended
Six months ended

June 30, 2019
June 30, 2019
Cash Paid For Amounts Included In Measurement of Liabilities
$
8.8

$
16.4

  Operating Cash Flows From Financing Leases
1.0

2.0

  Operating Cash Flows From Operating Leases
6.5

11.9

  Financing Cash Flows From Financing Leases
1.3

2.5

ROU Assets Obtained In Exchange For New Financing Liabilities ⁽¹⁾
—

—

ROU Assets Obtained In Exchange For New Operating Liabilities ⁽²⁾
20.7

20.7

(1) We capitalized $83.1 of ROU financing assets upon adoption of the new lease standard in the first quarter of 2019 that are excluded from the figures for the six months ended June 30, 2019. This figure excludes $44.2 of opening adjustments to ROU finance assets related, primarily, to prepayments of rent.
(2) We capitalized $172.2 of ROU operating assets upon adoption of the new lease standard in the first quarter of 2019. This figure excludes $26.6 of opening adjustments to ROU operating assets related, primarily, to prepayments of rent.

The following tables summarize maturities of lease liabilities and the reconciliation of lease liabilities as of June 30, 2019:
Lease Liability Maturity Summary

Year
Financing

Operating

Total
2019 (remaining)
$
4.4

$
13.6

$
18.0

2020
8.8

24.8

33.6

2021
9.0

22.1

31.1

2022
9.2

20.8

30.0

2023
9.2

20.5

29.7

2024
9.4

20.2

29.6

Thereafter
54.6

109.3

163.9

Reconciliation of Lease Liabilities
Financing

Operating

Total
Weighted-average Remaining Lease Term (years)
11.17

10.46

10.67

Weighted-average Discount Rate
4.85
%

4.35
%

4.51
%

Total Undiscounted Lease Liability
$
104.6

$
231.3

$
335.9

Imputed Interest
24.0

45.4

69.4

Total Discounted Lease Liability
80.5

185.8

266.3

For comparable purposes, our aggregate future minimum non-cancellable commitments under operating leases as of December 31, 2018 were as follows:
Year

2019
$
27.8

2020
24.7

2021
21.3

2022
19.9

2023
19.7

Thereafter
132.2

Excluded from the table above are commitments with Lonza Group AG and its affiliates (Lonza), a third party manufacturer that produces a portion of commercial and clinical quantities of our commercial products and product candidates. During the third quarter 2015, we entered into an agreement with Lonza whereby Lonza constructed a facility to be used to manufacture product under a supply agreement for Alexion at one of its existing facilities, resulting in the determination that the CMO arrangement contained a lease. This agreement requires us to make certain payments during the construction of the manufacturing facility and annual payments for ten years thereafter. As the arrangement contains both a lease and non-lease component, related to the supply of product, the consideration paid to Lonza is allocated between these components. As of December 31, 2018, we had various manufacturing and licensing agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,084.6. This amount includes $88.7 of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza.

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R26.htm IDEA: XBRL DOCUMENT v3.19.2

Commitments and Contingencies
6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
Asset Acquisition and In-License Agreements
We have entered into asset purchase agreements and license arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any.
In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and could be required to pay up to an additional $30.0 in contingent milestone-dependent fees. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of contingent milestone-dependent fees, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments.
In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase 1 studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was $13.8 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of $5.0 within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $21.2 as research and development expense during the first quarter 2019. As of June 30, 2019, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial
milestones, as well as royalties on commercial sales. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target.
In March 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the FcRn and is currently in Phase 1 development. The agreement with Affibody was subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and, following receipt of such approval, the transaction closed in April 2019. Pursuant to the agreement, Alexion will lead the clinical development and commercial activities for ABY-039 in rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development of ABY-039 in an undisclosed indication. Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039. Due to the early stage of the asset we are licensing, we recorded the upfront license payment as research and development expense during the second quarter 2019. As of June 30, 2019, we could also be required to pay up to $625.0 for amounts due upon achievement of specific development, regulatory, and commercial milestones, as well as royalties on commercial sales.
In connection with our prior acquisition of Syntimmune (see Note 3), we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones.
In addition, as of June 30, 2019, we have other license agreements under which we may be required to pay up to an additional $838.2 for currently licensed targets, if certain development, regulatory and commercial milestones are met. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements.
Asset Sale and Out-License Arrangements
In connection with prior asset sale and out-license arrangements, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of June 30, 2019.
Manufacturing Agreements
We have various manufacturing development and license agreements to support our clinical and commercial product needs.
We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,044.1. This amount includes $102.3 of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to its sale and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS.
In addition to our commitments with Lonza, as of June 30, 2019 we have non-cancellable commitments of approximately $65.1 through 2020 with other third party manufacturers.

Contingent Liabilities
We are currently involved in various claims, disputes, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted.
We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results.
In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures. Alexion is cooperating with these investigations.
The investigations have focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws.
At this time, Alexion is unable to predict the duration, scope or outcome of these investigations. While it is possible that a loss related to these matters may be incurred, given the ongoing nature of these investigations, management cannot reasonably estimate the potential magnitude of any such loss or range of loss, or the cost of the ongoing investigation. Any determination that our operations or activities are not or were not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations.
Alexion is committed to strengthening its compliance program and is currently implementing a comprehensive company-wide transformation plan that is designed to enhance and remediate its business processes, structures, controls, training, talent and systems across Alexion’s global operations.
As previously reported, on December 29, 2016, a shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants’ filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference. During that conference, the court informed counsel that it was preparing a ruling granting the Defendants’ pending motion to dismiss. The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so. On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss.  On May 31, 2019, Plaintiffs filed a second amended complaint against the same defendants.  The complaint alleges that defendants engaged in securities fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud.  The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs.  Defendants’ motion to dismiss the
amended complaint is due August 2, 2019; plaintiffs’ opposition to that motion is due October 2, 2019; and defendants’ reply in further support of their motion is due November 16, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case, nor can we estimate the possible loss or range of loss at this time.
In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered in to a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid $13.1 to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce.
In May 2017, Brazilian authorities seized records and data from our Sao Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry.
In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time.
On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling. Pursuant to an order made by the Federal Court of Canada, we will place approximately $31.6 in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for the period from September 2017 to June 2019. Pursuant to US GAAP, our revenues for the quarter ended June 30, 2019 were reduced by this amount. In addition, on a quarterly basis until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive.
In October 2018, the Japanese Ministry of Health, Labour and Welfare (MHLW) conducted an administrative inspection of Alexion’s Japanese operations. The MHLW inquiry primarily focused on our communication efforts regarding the proper use of SOLIRIS in Japan for aHUS, among other matters. We have cooperated with the inquiries and the investigation, and in March 2019, the MHLW indicated that it has completed its investigation.
Chugai Pharmaceutical Co., Ltd. has filed two lawsuits against Alexion. The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd. The second lawsuit was filed in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd.  Chugai’s complaints seek unspecified damages and certain injunctive relief.  In both cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case has been set for May 2021. The case is still at the briefing stage in Japan. Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time.
On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS: U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleges the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. We expect the PTO to review Amgen’s petitions and Alexion's submissions, and to issue a decision in September 2019 as to whether the PTO will institute IPR. At this time we cannot determine what decision the PTO will make.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R27.htm IDEA: XBRL DOCUMENT v3.19.2

Restructuring and Related Expenses
6 Months Ended

Jun. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring and Related Expenses
Restructuring and Related Expenses
In the first quarter 2019, we initiated corporate restructuring activities to re-align our commercial organization through re-prioritization of certain geographical markets and to implement operational excellence through strategic reallocation of resources.
In the first quarter 2017, we initiated a company-wide restructuring designed to help position the Company for sustainable, long-term growth that we believe will further allow us to fulfill our mission of serving patients and families with rare diseases. In September 2017, we committed to an operational plan to re-align the global organization with its refocused corporate strategy. The re-alignment included the relocation of the Company's headquarters to Boston, Massachusetts and a reduction of the Company's global workforce. The restructuring was designed to result in cost savings by focusing the development portfolio, simplifying business structures and process across the Company's global operations, and closing multiple Alexion sites.
The following table summarizes the total expenses recorded related to the restructuring activities by type of activity and the locations recognized within the consolidated statements of operations:

Three months ended June 30,

Three months ended June 30,

2019

2018

Employee Separation Costs

Asset-Related Charges

Other

Total

Employee Separation Costs

Asset-Related Charges

Other

Total
Cost of sales
$
—

$
—

$
—

$
—

$
—

$
0.5

$
—

$
0.5

Research and development
—

—

—

—

—

—

—

—

Selling, general and administrative
—

—

—

—

—

6.5

—

6.5

Restructuring expense
2.4

—

0.1

2.5

3.1

—

7.5

10.6

Other (income) expense
—

—

—

—

—

—

—

—

$
2.4

$
—

$
0.1

$
2.5

$
3.1

$
7.0

$
7.5

$
17.6

Six months ended June 30,

Six months ended June 30,

2019

2018

Employee Separation Costs

Asset-Related Charges

Other

Total

Employee Separation Costs

Asset-Related Charges

Other

Total
Cost of sales
$
—

$
—

$
—

$
—

$
—

$
5.8

$
—

$
5.8

Research and development
—

—

—

—

—

0.1

—

0.1

Selling, general and administrative
—

—

—

—

—

10.1

—

10.1

Restructuring expense
11.5

—

0.1

11.6

4.1

—

12.0

16.1

Other (income) expense
—

—

—

—

—

—

(0.1
)

(0.1
)

$
11.5

$
—

$
0.1

$
11.6

$
4.1

$
16.0

$
11.9

$
32.0

The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of June 30, 2019:

Three months ended June 30,

Six months ended June 30,

2019

2019

Employee Separation Costs

Asset Charges

Other Costs

Total

Employee Separation Costs

Asset Charges

Other Costs

Total
Liability, beginning of period
$
10.8

$
—

$
—

$
10.8

$
4.2

$
—

$
—

$
4.2

Restructuring and related expenses
5.3

—

—

5.3

14.2

—

—

14.2

Cash settlements
(3.8
)

—

—

(3.8
)

(6.3
)

—

—

(6.3
)
Adjustments to previous estimates
(2.8
)

—

—

(2.8
)

(2.6
)

—

—

(2.6
)
Asset impairments
—

—

—

—

—

—

—

—

Liability, end of period
$
9.5

$
—

$
—

$
9.5

$
9.5

$
—

$
—

$
9.5

The restructuring reserve of $9.5 and $4.2 is recorded in accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of June 30, 2019 and December 31, 2018, respectively. The accrued amounts are expected to be paid in the next twelve months. We currently estimate incurring up to an additional $10.0 in restructuring expenses related to the first quarter 2019 action.

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 R28.htm IDEA: XBRL DOCUMENT v3.19.2

Acquisitions (Tables)
6 Months Ended

Jun. 30, 2019

Asset Acquisitions [Abstract]

Summary of Total Consideration
The following table summarizes the total consideration for the acquisition and the value of assets acquired and liabilities assumed:
Consideration

Cash paid for acquisition of Wilson Therapeutics outstanding shares
$
749.3

Transaction costs
15.1

Total consideration
$
764.4

Assets Acquired and Liabilities Assumed

Cash
$
45.1

In-process research & development
803.7

Employee related liabilities
(71.4
)
Other assets and liabilities
(13.0
)
Total net assets acquired
$
764.4

X

- Definition
Asset Acquisitions [Abstract]
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionsAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule Of Asset Acquisition, By Acquisition [Table Text Block]
+ References
No definition available.
+ Details

Name: alxn_ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R29.htm IDEA: XBRL DOCUMENT v3.19.2

Inventories (Tables)
6 Months Ended

Jun. 30, 2019

Inventory, Net [Abstract]

Schedule of Inventory, Current
The components of inventory are as follows:

June 30,

December 31,

2019

2018
Raw materials
$
38.2

$
31.4

Work-in-process
116.6

90.4

Finished goods
339.8

350.7

$
494.6

$
472.5

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 68 R30.htm IDEA: XBRL DOCUMENT v3.19.2

Intangible Assets and Goodwill (Tables)
6 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill
The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization:

June 30, 2019

December 31, 2018

Estimated
Life (years)

Cost

Accumulated
Amortization

Net

Cost

Accumulated
Amortization

Net
Licensing rights
5-8

$
47.0

$
(30.9
)

$
16.1

$
39.0

$
(29.3
)

$
9.7

Patents
7

10.5

(10.5
)

—

10.5

(10.5
)

—

Purchased technology
6-16

4,710.5

(1,239.2
)

3,471.3

4,710.5

(1,079.1
)

3,631.4

Other intangibles
5

0.4

(0.2
)

0.2

0.4

(0.2
)

0.2

Total

$
4,768.4

$
(1,280.8
)

$
3,487.6

$
4,760.4

$
(1,119.1
)

$
3,641.3

Goodwill
Indefinite

$
5,040.3

$
(2.9
)

$
5,037.4

$
5,040.3

$
(2.9
)

$
5,037.4

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 69 R31.htm IDEA: XBRL DOCUMENT v3.19.2

Earnings Per Common Share (Tables)
6 Months Ended

Jun. 30, 2019

Earnings Per Common Share [Abstract]

Schedule Of Basic And Diluted Earnings Per Share
The following table summarizes the calculation of basic and diluted EPS for the three and six months ended June 30, 2019 and 2018:

Three months ended

Six months ended

June 30,

June 30,

2019

2018

2019

2018
Net income (loss) used for basic and diluted calculation
$
459.8

$
(457.4
)

$
1,047.7

$
(208.3
)
Shares used in computing earnings (loss) per common share—basic
224.2

222.6

224.0

222.3

Weighted-average effect of dilutive securities:

Stock awards
1.4

—

1.7

—

Shares used in computing earnings (loss) per common share—diluted
225.6

222.6

225.7

222.3

Earnings (loss) per common share:

Basic
$
2.05

$
(2.05
)

$
4.68

$
(0.94
)
Diluted
$
2.04

$
(2.05
)

$
4.64

$
(0.94
)

X

- Definition
Earnings Per Common Share [Abstract]
+ References
No definition available.
+ Details

Name: alxn_EarningsPerCommonShareAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 R32.htm IDEA: XBRL DOCUMENT v3.19.2

Marketable Securities (Tables)
6 Months Ended

Jun. 30, 2019

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block] June 30, 2019 and December 31, 2018 were as follows:

June 30, 2019

Amortized Cost

Gross Unrealized Holding Gains

Gross Unrealized Holding Losses

Fair Value
Commercial paper

$
274.0

$
—

$
—

$
274.0

Corporate bonds

28.0

—

—

28.0

Other government-related obligations:

U.S.

117.8

—

—

117.8

Bank certificates of deposit

24.3

—

—

24.3

Total available-for-sale debt securities

$
444.1

$
—

$
—

$
444.1

December 31, 2018

Amortized Cost

Gross Unrealized Holding Gains

Gross Unrealized Holding Losses

Fair Value
Commercial paper

$
52.1

$
—

$
—

$
52.1

Corporate bonds

122.9

—

(0.1
)

122.8

Other government-related obligations:

U.S.

17.5

—

—

17.5

Bank certificates of deposit

33.2

—

—

33.2

Total available-for-sale debt securities

$
225.7

$
—

$
(0.1
)

$
225.6

Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]
The fair values of available-for-sale debt securities by classification in the condensed consolidated balance sheets were as follows:

June 30, 2019

December 31, 2018
Cash and cash equivalents
$
359.4

$
43.8

Marketable securities
84.7

181.8

$
444.1

$
225.6

Investments Classified by Contractual Maturity Date [Table Text Block]
The fair values of available-for-sale debt securities at June 30, 2019, by contractual maturity, are summarized as follows:

June 30, 2019
Due in one year or less
$
438.3

Due after one year through three years
5.8

$
444.1

X

- Definition
Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]
+ References
No definition available.
+ Details

Name: alxn_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 71 R33.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities (Tables)
6 Months Ended

Jun. 30, 2019

Derivative Instruments and Hedging Activities [Abstract]

Schedule of Interest Rate Contracts
The following table summarizes the total interest rate swap contracts executed as of June 30, 2019:
Type of Interest Rate Swap
Notional Amount
Effective Date
Termination Date
Fixed Interest Rate or Rate Range
Floating to Fixed
1,531.3
December 2016 - January 2018
December 2019
0.98% - 1.62%
Floating to Fixed
450.0
December 2018
December 2022
2.60% - 2.79%
Floating to Fixed
300.0
January 2019
December 2019
2.08%
Floating to Fixed
1,300.0
December 2019
December 2022
2.37% - 2.83%

Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts
The amount of gains and (losses) recognized in the condensed consolidated statements of operations for the three and six months ended June 30, 2019 and 2018 from foreign exchange and interest rate swap contracts that qualified as cash flow hedges were as follows:

Three months ended

Three months ended

June 30, 2019

June 30, 2018
Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded
Net Product Sales

Interest Expense

Net Product Sales

Interest Expense
Total amount presented in the Condensed Consolidated Statements of Operations
$
1,202.5

$
(18.3
)

$
1,044.7

$
(25.0
)
Impact of cash flow hedging relationships:

Foreign exchange forward contracts
$
9.1

$
—

$
(1.7
)

$
—

Interest rate swap contracts
$
—

$
4.5

$
—

$
3.1

Six months ended

Six months ended

June 30, 2019

June 30, 2018
Financial Statement Line Item in which the Effects of Cash Flow Hedges are Recorded
Net Product Sales

Interest Expense

Net Product Sales

Interest Expense
Total amount presented in the Condensed Consolidated Statements of Operations
$
2,342.7

$
(38.2
)

$
1,975.1

$
(49.1
)
Impact of cash flow hedging relationships:

Foreign exchange forward contracts
$
16.1

$
—

$
(14.8
)

$
—

Interest rate swap contracts
$
—

$
9.1

$
—

$
4.5

The impact on AOCI from foreign exchange and interest rate swap contracts that qualified as cash flow hedges, for the three and six months ended June 30, 2019 and 2018 were as follows:

Three months ended

Six months ended

June 30,

June 30,

2019

2018

2019

2018
Foreign Exchange Forward Contracts:

Gain (loss) recognized in AOCI, net of tax
$
(3.9
)

$
49.0

$
10.3

$
16.5

Gain (loss) reclassified from AOCI to net product sales, net of tax
$
7.0

$
(1.3
)

$
12.4

$
(11.4
)
Interest Rate Contracts:

Gain (loss) recognized in AOCI, net of tax
$
(24.6
)

$
3.1

$
(38.8
)

$
11.2

Gain (loss) reclassified from AOCI to interest expense, net of tax
$
3.4

$
2.5

$
7.0

$
3.6

Schedule of Fair Value of Outstanding Derivatives
The following tables summarize the fair value of outstanding derivatives as of June 30, 2019 and December 31, 2018:

June 30, 2019

Derivative Assets

Derivative Liabilities

Balance Sheet
Location

Fair
Value

Balance Sheet
Location

Fair
Value
Derivatives designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

$
12.4

Other current liabilities

$
7.6

Foreign exchange forward contracts
Other assets

1.1

Other liabilities

1.8

Interest rate contracts
Prepaid expenses and other current assets

5.6

Other current liabilities

10.8

Interest rate contracts
Other assets

—

Other liabilities

52.2

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

16.1

Other current liabilities

15.4

Total fair value of derivative instruments

$
35.2

$
87.8

December 31, 2018

Derivative Assets

Derivative Liabilities

Balance Sheet
Location

Fair
Value

Balance Sheet
Location

Fair
Value
Derivatives designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

$
16.9

Other current liabilities

$
7.3

Foreign exchange forward contracts
Other assets

0.3

Other liabilities

3.1

Interest rate contracts
Prepaid expenses and other current assets

20.1

Other current liabilities

0.8

Interest rate contracts
Other assets

—

Other liabilities

17.3

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts
Prepaid expenses and other current assets

23.6

Other current liabilities

11.5

Total fair value of derivative instruments

$
60.9

$
40.0

Offsetting Assets and Liabilities The following tables summarize the potential effect on our condensed consolidated balance sheets of offsetting our foreign exchange forward contracts and interest rate contracts subject to such provisions:

June 30, 2019

Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet

Description

Gross Amounts of Recognized Assets/Liabilities

Gross Amounts Offset in the Condensed Consolidated Balance Sheet

Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet

Derivative Financial Instruments

Cash Collateral Received (Pledged)

Net Amount
Derivative assets

$
35.2

$
—

$
35.2

$
(24.4
)

$
—

$
10.8

Derivative liabilities

(87.8
)

—

(87.8
)

24.4

—

(63.4
)

December 31, 2018

Gross Amounts Not Offset in the Condensed Consolidated Balance Sheet

Description

Gross Amounts of Recognized Assets/Liabilities

Gross Amounts Offset in the Condensed Consolidated Balance Sheet

Net Amounts of Assets/Liabilities Presented in the Condensed Consolidated Balance Sheet

Derivative Financial Instruments

Cash Collateral Received (Pledged)

Net Amount
Derivative assets

$
60.9

$
—

$
60.9

$
(30.2
)

$
—

$
30.7

Derivative liabilities

(40.0
)

—

(40.0
)

30.2

—

(9.8
)

X

- Definition
Derivative Instruments and Hedging Activities [Abstract]
+ References
No definition available.
+ Details

Name: alxn_DerivativeInstrumentsAndHedgingActivitiesAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Offsetting Assets and Liabilities [Table Text Block]
+ References
No definition available.
+ Details

Name: alxn_OffsettingAssetsandLiabilitiesTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 72 R34.htm IDEA: XBRL DOCUMENT v3.19.2

Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)
6 Months Ended

Jun. 30, 2019

Accumulated Other Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following tables summarize the changes in AOCI, by component, for the six months ended June 30, 2019 and 2018:

Defined Benefit Pension Plans

Unrealized Gains (Losses) from Debt Securities

Unrealized Gains (Losses) from Hedging Activities

Foreign Currency Translation Adjustment

Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2018
$
(2.6
)

$
(0.3
)

$
9.6

$
(16.4
)

$
(9.7
)
Other comprehensive income (loss) before reclassifications
—

0.2

(28.5
)

(0.5
)

(28.8
)
Amounts reclassified from other comprehensive income
—

—

(19.4
)

—

(19.4
)
Net other comprehensive income (loss)
—

0.2

(47.9
)

(0.5
)

(48.2
)
Balances, June 30, 2019
$
(2.6
)

$
(0.1
)

$
(38.3
)

$
(16.9
)

$
(57.9
)

Defined Benefit Pension Plans

Unrealized Gains (Losses) from Debt Securities

Unrealized Gains (Losses) from Hedging Activities

Foreign Currency Translation Adjustment

Total Accumulated Other Comprehensive Income (Loss)
Balances, December 31, 2017
$
(4.8
)

$
0.2

$
(13.9
)

$
(15.9
)

$
(34.4
)
Other comprehensive income (loss) before reclassifications
1.3

0.1

27.7

(4.3
)

24.8

Amounts reclassified from other comprehensive income
(0.6
)

(0.5
)

7.8

—

6.7

Net other comprehensive income (loss)
0.7

(0.4
)

35.5

(4.3
)

31.5

Balances, June 30, 2018
$
(4.1
)

$
(0.2
)

$
21.6

$
(20.2
)

$
(2.9
)

Reclassification out of Accumulated Other Comprehensive Income

The table below provides details regarding significant reclassifications from AOCI during the three and six months ended June 30, 2019 and 2018:
Details about Accumulated Other Comprehensive Income Components

Amount Reclassified From Accumulated Other Comprehensive Income during the three months ended June 30,

Amount Reclassified From Accumulated Other Comprehensive Income during the six months ended June 30,

Affected Line Item in the Condensed Consolidated Statements of Operations

2019
2018

2019
2018

Unrealized Gains (Losses) on Hedging Activity

Foreign exchange forward contracts

$
9.1

$
(1.7
)

$
16.1

$
(14.8
)

Net product sales
Interest rate swap contracts

4.5

3.1

9.1

4.5

Interest expense

13.6

1.4

25.2

(10.3
)

(3.2
)
(0.2
)

(5.8
)
2.5

Income tax (benefit) expense

$
10.4

$
1.2

$
19.4

$
(7.8
)

X

- Definition
Accumulated Other Comprehensive Income [Abstract]
+ References
No definition available.
+ Details

Name: alxn_AccumulatedOtherComprehensiveIncomeAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).
+ References
No definition available.
+ Details

Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R35.htm IDEA: XBRL DOCUMENT v3.19.2

Fair Value Measurement (Tables)
6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Schedule Of Assets And Liabilites Measured At Fair Value
The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018, and indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair value.

Fair Value Measurement at
June 30, 2019
Balance Sheet
Classification
Type of Instrument
Total

Level 1

Level 2

Level 3
Cash equivalents
Money market funds
$
498.5

$
—

$
498.5

$
—

Cash equivalents
Commercial paper
$
240.2

$
—

$
240.2

$
—

Cash equivalents
Bank certificates of deposit
$
12.2

$
—

$
12.2

$
—

Cash equivalents
Other government-related obligations
$
107.0

$
—

$
107.0

$
—

Marketable securities
Mutual funds
$
20.7

$
20.7

$
—

$
—

Marketable securities
Commercial paper
$
33.8

$
—

$
33.8

$
—

Marketable securities
Corporate bonds
$
28.0

$
—

$
28.0

$
—

Marketable securities
Other government-related obligations
$
10.8

$
—

$
10.8

$
—

Marketable securities
Bank certificates of deposit
$
12.1

$
—

$
12.1

$
—

Other assets
Equity securities
$
113.3

$
30.6

$
82.7

$
—

Prepaid expenses and other current assets
Foreign exchange forward contracts
$
28.5

$
—

$
28.5

$
—

Other assets
Foreign exchange forward contracts
$
1.1

$
—

$
1.1

$
—

Other current liabilities
Foreign exchange forward contracts
$
23.0

$
—

$
23.0

$
—

Other liabilities
Foreign exchange forward contracts
$
1.8

$
—

$
1.8

$
—

Prepaid expenses and other current assets
Interest rate contracts
$
5.6

$
—

$
5.6

$
—

Other current liabilities
Interest rate contracts
$
10.8

$
—

$
10.8

$
—

Other liabilities
Interest rate contracts
$
52.2

$
—

$
52.2

$
—

Current portion of contingent consideration
Acquisition-related contingent consideration
$
100.0

$
—

$
—

$
100.0

Contingent consideration
Acquisition-related contingent consideration
$
158.2

$
—

$
—

$
158.2

Other current liabilities
Other contingent payments
$
13.9

$
—

$
—

$
13.9

Other liabilities
Other contingent payments
$
13.5

$
—

$
—

$
13.5

Fair Value Measurement at
December 31, 2018
Balance Sheet
Classification
Type of Instrument
Total

Level 1

Level 2

Level 3
Cash equivalents
Money market funds
$
569.4

$
—

$
569.4

$
—

Cash equivalents
Commercial paper
$
35.4

$
—

$
35.4

$
—

Cash equivalents
Corporate bonds
$
0.2

$
—

$
0.2

$
—

Cash equivalents
Other government-related obligations
$
8.2

$
—

$
8.2

$
—

Marketable securities
Mutual funds
$
16.5

$
16.5

$
—

$
—

Marketable securities
Commercial paper
$
16.7

$
—

$
16.7

$
—

Marketable securities
Corporate bonds
$
122.6

$
—

$
122.6

$
—

Marketable securities
Other government-related obligations
$
9.3

$
—

$
9.3

$
—

Marketable securities
Bank certificates of deposit
$
33.2

$
—

$
33.2

$
—

Other assets
Equity securities
$
90.8

$
8.9

$
81.9

$
—

Prepaid expenses and other current assets
Foreign exchange forward contracts
$
40.5

$
—

$
40.5

$
—

Other assets
Foreign exchange forward contracts
$
0.3

$
—

$
0.3

$
—

Other current liabilities
Foreign exchange forward contracts
$
18.8

$
—

$
18.8

$
—

Other liabilities
Foreign exchange forward contracts
$
3.1

$
—

$
3.1

$
—

Prepaid expenses and other current assets
Interest rate contracts
$
20.1

$
—

$
20.1

$
—

Other current liabilities
Interest rate contracts
$
0.8

$
—

$
0.8

$
—

Other liabilities
Interest rate contracts
$
17.3

$
—

$
17.3

$
—

Current portion of contingent consideration
Acquisition-related contingent consideration
$
97.6

$
—

$
—

$
97.6

Contingent consideration
Acquisition-related contingent consideration
$
183.2

$
—

$
—

$
183.2

Schedule Of Acquisition-Related Contingent Consideration he following table represents a roll-forward of our acquisition-related contingent consideration:

Six months ended

June 30, 2019
Balance at beginning of period
$
280.8

Changes in fair value
(22.6
)
Balance at end of period
$
258.2

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R36.htm IDEA: XBRL DOCUMENT v3.19.2

Revenue Recognition (Tables)
6 Months Ended

Jun. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue from contracts with customer
The Company disaggregates revenue from contracts with customers into product and geographical regions as summarized below.

Three months ended June 30,

Six months ended June 30,

2019

2018

2019

2018
SOLIRIS

United States
$
496.3

$
395.8

$
960.0

$
731.8

Europe
280.2

253.4

544.7

504.2

Asia Pacific
110.3

93.6

211.2

179.1

Rest of World
94.0

155.4

226.9

283.2

Total
$
980.8

$
898.2

$
1,942.8

$
1,698.3

ULTOMIRIS

United States
$
54.2

$
—

$
78.8

$
—

Europe
—

—

—

—

Asia Pacific
—

—

—

—

Rest of World
—

—

—

—

Total
$
54.2

$
—

$
78.8

$
—

STRENSIQ

United States
$
106.2

$
99.9

$
205.7

$
189.1

Europe
19.5

16.4

37.0

30.4

Asia Pacific
12.1

6.3

22.0

12.0

Rest of World
3.5

2.5

6.7

4.3

Total
$
141.3

$
125.1

$
271.4

$
235.8

KANUMA

United States
$
15.3

$
13.0

$
29.1

$
24.9

Europe
6.8

5.8

13.1

11.7

Asia Pacific
1.3

1.1

2.1

2.1

Rest of World
2.8

1.5

5.4

2.3

Total
$
26.2

$
21.4

$
49.7

$
41.0

Total Net Product Sales
$
1,202.5

$
1,044.7

$
2,342.7

$
1,975.1

Summary of receivables and contract liabilities from contracts

June 30, 2019

December 31, 2018
Receivables, which are included in "Trade accounts receivable, net"
$
1,123.6

$
922.3

Contract liabilities, which are included in "Other current liabilities"
$
3.1

$
3.4

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 75 R37.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes (Tables)
6 Months Ended

Jun. 30, 2019

Income Tax Disclosure [Abstract]

Schedule of Income Tax Provision and Effective Tax Rate

The following table provides a comparative summary of our income tax (benefit) expense and effective income tax rate for the three and six months ended June 30, 2019 and 2018:

Three months ended

Six months ended

June 30,

June 30,

2019

2018

2019

2018
Income tax (benefit) expense
$
39.7

$
38.8

$
(6.4
)

$
141.3

Effective income tax rate
7.9
%

(9.3
)%

(0.6
)%

(210.9
)%

X

- Definition
Schedule of Income Tax Provision and Effective Tax Rate
+ References
No definition available.
+ Details

Name: alxn_ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 76 R38.htm IDEA: XBRL DOCUMENT v3.19.2

Leases (Tables)
6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of Lease Assets and Liabilities
The following table summarizes our lease assets and liabilities as of June 30, 2019:
ROU Assets and Liabilities

Balance Sheet
Location
Financing

Operating
ROU - Asset
Right of use operating assets
$
—

$
209.5

ROU - Asset
Property, plant, and equipment
121.8

—

Lease liabilities (current)
Other current liabilities
5.0

20.3

Lease liabilities (noncurrent)
Noncurrent operating lease liabilities
—

165.5

Lease liabilities (noncurrent)
Other liabilities
75.5

—

Schedule of Lease Related Costs
The following table summarizes our lease related costs for the three and six months ended June 30, 2019:
Lease Cost

Statement of Operations Location
Three months ended
Six months ended

June 30, 2019
June 30, 2019
Financing Lease Cost

$
3.5

$
7.5

Amortization of ROU Assets
Operating Expenses
2.5

5.5

Interest on Lease Liabilities
Interest Expense
1.0

2.0

Operating Lease Cost
Operating Expenses
8.6

17.6

Variable Lease Cost
Operating Expenses
2.3

4.3

Total Lease Cost

14.4

29.4

Schedule of Lease Cash Flow Information

The following table summarizes supplemental cash flow information for the three and six months ended June 30, 2019:
Other Information
Three months ended
Six months ended

June 30, 2019
June 30, 2019
Cash Paid For Amounts Included In Measurement of Liabilities
$
8.8

$
16.4

  Operating Cash Flows From Financing Leases
1.0

2.0

  Operating Cash Flows From Operating Leases
6.5

11.9

  Financing Cash Flows From Financing Leases
1.3

2.5

ROU Assets Obtained In Exchange For New Financing Liabilities ⁽¹⁾
—

—

ROU Assets Obtained In Exchange For New Operating Liabilities ⁽²⁾
20.7

20.7

(1) We capitalized $83.1 of ROU financing assets upon adoption of the new lease standard in the first quarter of 2019 that are excluded from the figures for the six months ended June 30, 2019. This figure excludes $44.2 of opening adjustments to ROU finance assets related, primarily, to prepayments of rent.
(2) We capitalized $172.2 of ROU operating assets upon adoption of the new lease standard in the first quarter of 2019. This figure excludes $26.6 of opening adjustments to ROU operating assets related, primarily, to prepayments of rent.

Schedule of Operating Lease Liability Maturity
Lease Liability Maturity Summary

Year
Financing

Operating

Total
2019 (remaining)
$
4.4

$
13.6

$
18.0

2020
8.8

24.8

33.6

2021
9.0

22.1

31.1

2022
9.2

20.8

30.0

2023
9.2

20.5

29.7

2024
9.4

20.2

29.6

Thereafter
54.6

109.3

163.9

Schedule of Finance Lease Liability Maturity
Lease Liability Maturity Summary

Year
Financing

Operating

Total
2019 (remaining)
$
4.4

$
13.6

$
18.0

2020
8.8

24.8

33.6

2021
9.0

22.1

31.1

2022
9.2

20.8

30.0

2023
9.2

20.5

29.7

2024
9.4

20.2

29.6

Thereafter
54.6

109.3

163.9

Schedule of Operating and Finance Lease Additional Information
Reconciliation of Lease Liabilities
Financing

Operating

Total
Weighted-average Remaining Lease Term (years)
11.17

10.46

10.67

Weighted-average Discount Rate
4.85
%

4.35
%

4.51
%

Total Undiscounted Lease Liability
$
104.6

$
231.3

$
335.9

Imputed Interest
24.0

45.4

69.4

Total Discounted Lease Liability
80.5

185.8

266.3

Schedule of Future Minimum Non-cancellable Operating Lease Commitments
For comparable purposes, our aggregate future minimum non-cancellable commitments under operating leases as of December 31, 2018 were as follows:
Year

2019
$
27.8

2020
24.7

2021
21.3

2022
19.9

2023
19.7

Thereafter
132.2

X

- Definition
Lessee, Lease Assets And Liabilities [Table Text Block]
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Lessee, Lease Cash Flow [Table Text Block]
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseCashFlowTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Lessee, Operating And Finance Lease Additional Information [Table Text Block]
+ References
No definition available.
+ Details

Name: alxn_LesseeOperatingAndFinanceLeaseAdditionalInformationTableTextBlock

Namespace Prefix: alxn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 77 R39.htm IDEA: XBRL DOCUMENT v3.19.2

Restructuring and Related Expenses (Tables)
6 Months Ended

Jun. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

Three months ended June 30,

Three months ended June 30,

2019

2018

Employee Separation Costs

Asset-Related Charges

Other

Total

Employee Separation Costs

Asset-Related Charges

Other

Total
Cost of sales
$
—

$
—

$
—

$
—

$
—

$
0.5

$
—

$
0.5

Research and development
—

—

—

—

—

—

—

—

Selling, general and administrative
—

—

—

—

—

6.5

—

6.5

Restructuring expense
2.4

—

0.1

2.5

3.1

—

7.5

10.6

Other (income) expense
—

—

—

—

—

—

—

—

$
2.4

$
—

$
0.1

$
2.5

$
3.1

$
7.0

$
7.5

$
17.6

Six months ended June 30,

Six months ended June 30,

2019

2018

Employee Separation Costs

Asset-Related Charges

Other

Total

Employee Separation Costs

Asset-Related Charges

Other

Total
Cost of sales
$
—

$
—

$
—

$
—

$
—

$
5.8

$
—

$
5.8

Research and development
—

—

—

—

—

0.1

—

0.1

Selling, general and administrative
—

—

—

—

—

10.1

—

10.1

Restructuring expense
11.5

—

0.1

11.6

4.1

—

12.0

16.1

Other (income) expense
—

—

—

—

—

—

(0.1
)

(0.1
)

$
11.5

$
—

$
0.1

$
11.6

$
4.1

$
16.0

$
11.9

$
32.0

The following table presents a reconciliation of the restructuring reserve recorded within accounts payable and accrued expenses on the Company's condensed consolidated balance sheets as of June 30, 2019:

Three months ended June 30,

Six months ended June 30,

2019

2019

Employee Separation Costs

Asset Charges

Other Costs

Total

Employee Separation Costs

Asset Charges

Other Costs

Total
Liability, beginning of period
$
10.8

$
—

$
—

$
10.8

$
4.2

$
—

$
—

$
4.2

Restructuring and related expenses
5.3

—

—

5.3

14.2

—

—

14.2

Cash settlements
(3.8
)

—

—

(3.8
)

(6.3
)

—

—

(6.3
)
Adjustments to previous estimates
(2.8
)

—

—

(2.8
)

(2.6
)

—

—

(2.6
)
Asset impairments
—

—

—

—

—

—

—

—

Liability, end of period
$
9.5

$
—

$
—

$
9.5

$
9.5

$
—

$
—

$
9.5

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 78 R40.htm IDEA: XBRL DOCUMENT v3.19.2

Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Jan. 01, 2019

Dec. 31, 2018

Jun. 30, 2018

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Derecognition of Facility Lease Obligation $ 0.0 $ 361.0

Right of use operating assets 209.5 $ 0.0

Lease liability 185.8

Decrease to retained earnings 90.3 $ (6.2)

Accounting Standards Update 2016-02 [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Derecognition of Fixed and Other Assets $ 472.8

Derecognition of Facility Lease Obligation 372.2

Right of use operating assets 326.1

Prepaid rent 70.8

Lease liability 255.3

Retained Earnings [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Decrease to retained earnings $ 90.3 $ (6.2)

Retained Earnings [Member] | Accounting Standards Update 2016-02 [Member]

New Accounting Pronouncements or Change in Accounting Principle [Line Items]

Decrease to retained earnings $ 90.3

X

- Definition
Facility Lease Obligation, Noncurrent
+ References
No definition available.
+ Details

Name: alxn_FacilityLeaseObligationNoncurrent

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fixed And Other Assets
+ References
No definition available.
+ Details

Name: alxn_FixedAndOtherAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidRent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R41.htm IDEA: XBRL DOCUMENT v3.19.2

Acquisitions (Narrative) (Details)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended

May 25, 2018

USD ($)

Nov. 30, 2018

USD ($)

Jun. 30, 2018

USD ($)

Dec. 31, 2018

USD ($)

Apr. 30, 2018

kr / shares

Syntimmune, Inc [Member]

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Upfront payment for acquisition of Syntimmune outstanding shares $ 400.0

Additional payments to acquire businesses $ 800.0

Total acquisition value $ 1,200.0

Cash acquired 4.2

Transaction costs 0.9

Asset Acquisition, Consideration Transferred 407.4

Cash 4.2

Deferred tax assets 25.1

Other assets and liabilities 2.9

Total net assets acquired $ 407.4

In Process Research and Development

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Cash paid for acquisition of Wilson Therapeutics outstanding shares $ 749.3

Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles 803.7

Cash offer price per share (in sec per share) | kr / shares kr 232

Potential development, regulatory and commercial milestones and royalties payment 19.0

Transaction costs 15.1

Asset Acquisition, Consideration Transferred 764.4

Cash $ 45.1

In Process Research and Development | Syntimmune, Inc [Member]

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Business Combination, Recognized Benefit From Previously Acquired Research And Development $ 4.1

X

- Definition
Additional Payments To Acquire Businesses, Gross
+ References
No definition available.
+ Details

Name: alxn_AdditionalPaymentsToAcquireBusinessesGross

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Asset Acquisition, Cash Acquired
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionCashAcquired

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Asset Acquisition, Consideration Transferred
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionConsiderationTransferred

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Asset Acquisition, Potential Payments For Development, Regulatory, Commercial Milestones And Royalties On Sales
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionPotentialPaymentsForDevelopmentRegulatoryCommercialMilestonesAndRoyaltiesOnSales

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Benefit From Previously Acquired Research And Development
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedBenefitFromPreviouslyAcquiredResearchAndDevelopment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangibles

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDeferredTaxAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Assets
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedNetAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Share Price
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionSharePrice

Namespace Prefix: alxn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Asset Acquisition, Transaction Costs
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionTransactionCosts

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
[Line Items] for Schedule Of Asset Acquisition, By Acquisition [Table]
+ References
No definition available.
+ Details

Name: alxn_ScheduleOfAssetAcquisitionByAcquisitionLineItems

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=alxn_SyntimmuneIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R42.htm IDEA: XBRL DOCUMENT v3.19.2

Acquisitions (Summary of Total Consideration) (Details) - USD ($)
$ in Millions
1 Months Ended

May 25, 2018

Nov. 30, 2018

In Process Research and Development

Consideration

Cash paid for acquisition of Wilson Therapeutics outstanding shares $ 749.3

Transaction costs 15.1

Total consideration 764.4

Assets Acquired and Liabilities Assumed

Cash 45.1

In-process research & development 803.7

Employee related liabilities (71.4)

Other assets and liabilities (13.0)

Total net assets acquired $ 764.4

Syntimmune, Inc [Member]

Consideration

Transaction costs $ 0.9

Total consideration 407.4

Upfront payment for acquisition of Syntimmune outstanding shares 400.0

Cash acquired 4.2

Working capital adjustment 2.3

Assets Acquired and Liabilities Assumed

Cash 4.2

In-process research & development 375.2

Deferred tax assets 25.1

Other assets and liabilities 2.9

Total net assets acquired $ 407.4

X

- Definition
Asset Acquisition, Cash Acquired
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionCashAcquired

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Asset Acquisition, Consideration Transferred
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionConsiderationTransferred

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangibles

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, In-Process Research And Development
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Labor And Related Liabilities
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLaborAndRelatedLiabilities

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Net
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDeferredTaxAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Other
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLiabilitiesOther

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Assets
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedNetAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssets

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Asset Acquisition, Transaction Costs
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionTransactionCosts

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Asset Acquisition, Working Capital Adjustment
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionWorkingCapitalAdjustment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=alxn_SyntimmuneIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R43.htm IDEA: XBRL DOCUMENT v3.19.2

Inventories (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Inventory [Line Items]

Raw materials $ 38.2 $ 31.4

Work-in-process 116.6 90.4

Finished goods 339.8 350.7

Inventory, Net $ 494.6 $ 472.5

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InventoryLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 82 R44.htm IDEA: XBRL DOCUMENT v3.19.2

Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) - USD ($)
$ in Millions
6 Months Ended

Jun. 30, 2019

Dec. 31, 2018

Finite-Lived Intangible Assets [Line Items]

Intangible Assets, Cost $ 4,768.4 $ 4,760.4

Goodwill, Gross 5,040.3 5,040.3

Intangible Assets, Accumulated Amortization (1,280.8) (1,119.1)

Goodwill, Accumulated Amortization (2.9) (2.9)

Intangible assets 3,487.6 3,641.3

Goodwill 5,037.4 5,037.4

Licensing Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross 47.0 39.0

Finite-Lived Intangible Assets, Accumulated Amortization (30.9) (29.3)

Licenses, patents and purchased technology $ 16.1 9.7

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Asset, Useful Life 7 years

Finite-Lived Intangible Assets, Gross $ 10.5 10.5

Finite-Lived Intangible Assets, Accumulated Amortization (10.5) (10.5)

Licenses, patents and purchased technology 0.0 0.0

Purchased Technology [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Assets, Gross 4,710.5 4,710.5

Finite-Lived Intangible Assets, Accumulated Amortization (1,239.2) (1,079.1)

Licenses, patents and purchased technology $ 3,471.3 3,631.4

Other Intangible Assets [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Asset, Useful Life 5 years

Finite-Lived Intangible Assets, Gross $ 0.4 0.4

Finite-Lived Intangible Assets, Accumulated Amortization (0.2) (0.2)

Licenses, patents and purchased technology $ 0.2 $ 0.2

Minimum [Member] | Licensing Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Asset, Useful Life 6 years

Minimum [Member] | Purchased Technology [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Asset, Useful Life 6 years

Maximum [Member] | Licensing Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Asset, Useful Life 8 years

Maximum [Member] | Purchased Technology [Member]

Finite-Lived Intangible Assets [Line Items]

Finite-Lived Intangible Asset, Useful Life 16 years

Synageva BioPharma Corp. [Member] | Purchased Technology [Member]

Finite-Lived Intangible Assets [Line Items]

Licenses, patents and purchased technology $ 3,122.5

X

- Definition
Goodwill, Accumulated Amortization
+ References
No definition available.
+ Details

Name: alxn_GoodwillAccumulatedAmortization

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Intangible Assets, Accumulated Amortization
+ References
No definition available.
+ Details

Name: alxn_IntangibleAssetsAccumulatedAmortization

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Intangible Assets, Cost
+ References
No definition available.
+ Details

Name: alxn_IntangibleAssetsCost

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=alxn_PurchasedTechnologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=alxn_SynagevaBioPharmaCorp.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 83 R45.htm IDEA: XBRL DOCUMENT v3.19.2

Intangible Assets and Goodwill (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Amortization of Intangible Assets $ 81.2 $ 80.3 $ 161.7 $ 160.6

2019 (remainder) 161.7 161.7

2020 323.0 323.0

2021 323.0 323.0

2022 323.0 323.0

2023 323.0 323.0

2024 $ 323.0 $ 323.0

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 84 R46.htm IDEA: XBRL DOCUMENT v3.19.2

Debt (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended

Jan. 31, 2019

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Dec. 31, 2018

Jun. 07, 2018

Debt Instrument [Line Items]

Payments of financing costs $ 53.1

Amortization of deferred financing costs $ 1.3 $ 3.2 2.5 $ 5.5

Remaining unamortized deferred financing costs 18.3 18.3 $ 20.8

Credit Agreement [Member] | Line of Credit [Member]

Debt Instrument [Line Items]

Letters of credit, amount outstanding 1.0 1.0

Credit Agreement [Member] | Revolving Credit Facility [Member]

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity $ 1,000.0

Credit Agreement [Member] | Revolving Credit Facility [Member] | Line of Credit [Member]

Debt Instrument [Line Items]

Repayments of Debt $ 250.0

Credit Agreement [Member] | Senior Secured Term Loan [Member] | Line of Credit [Member]

Debt Instrument [Line Items]

Debt instrument, principal amount $ 2,612.5

Debt Instrument, quarterly payment as a percent of total borrowings 5.00%

Debt Instrument, Periodic Payment 32.7

Outstanding debt $ 2,579.8 $ 2,579.8

X

- Definition
Debt Instrument, Quarterly Payment, Percentage of Total Borrowings
+ References
No definition available.
+ Details

Name: alxn_DebtInstrumentQuarterlyPaymentPercentageofTotalBorrowings

Namespace Prefix: alxn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of amortization expense attributable to debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the required periodic payments including both interest and principal payments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_DeferredFinanceCostsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.
+ References
No definition available.
+ Details

Name: us-gaap_LettersOfCreditOutstandingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow for loan and debt issuance costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=alxn_CreditAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=alxn_SeniorSecuredTermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 85 R47.htm IDEA: XBRL DOCUMENT v3.19.2

Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Earnings Per Common Share [Abstract]

Net income (loss) used for basic and diluted calculation $ 459.8 $ (457.4) $ 1,047.7 $ (208.3)

Shares used in computing earnings per common share—basic 224.2 222.6 224.0 222.3

Stock awards 1.4 0.0 1.7 0.0

Shares used in computing earnings per common share-diluted 225.6 222.6 225.7 222.3

Earnings (loss) Per Share, Basic $ 2.05 $ (2.05) $ 4.68 $ (0.94)

Earnings (loss) Per Share, Diluted $ 2.04 $ (2.05) $ 4.64 $ (0.94)

X

- Definition
Earnings Per Common Share [Abstract]
+ References
No definition available.
+ Details

Name: alxn_EarningsPerCommonShareAbstract

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 86 R48.htm IDEA: XBRL DOCUMENT v3.19.2

Earnings Per Common Share (Narrative) (Details) - shares
shares in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2019

Earnings Per Share [Abstract]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1.9 2.9

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 87 R49.htm IDEA: XBRL DOCUMENT v3.19.2

Marketable Securities (Summary of Securities Held) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Debt Securities, Available-for-sale [Line Items]

Fair Value $ 444.1 $ 225.6

Commercial Paper [Member]

Debt Securities, Available-for-sale [Line Items]

Debt Securities, Available-for-sale, Amortized Cost 274.0 52.1

Gross Unrealized Holding Gains 0.0 0.0

Gross Unrealized Holding Losses 0.0 0.0

Fair Value 274.0 52.1

Corporate Bond Securities [Member]

Debt Securities, Available-for-sale [Line Items]

Debt Securities, Available-for-sale, Amortized Cost 28.0 122.9

Gross Unrealized Holding Gains 0.0 0.0

Gross Unrealized Holding Losses 0.0 (0.1)

Fair Value 28.0 122.8

US Government Agencies Debt Securities [Member]

Debt Securities, Available-for-sale [Line Items]

Debt Securities, Available-for-sale, Amortized Cost 117.8 17.5

Gross Unrealized Holding Gains 0.0 0.0

Gross Unrealized Holding Losses 0.0 0.0

Fair Value 117.8 17.5

Certificates of Deposit [Member]

Debt Securities, Available-for-sale [Line Items]

Debt Securities, Available-for-sale, Amortized Cost 24.3 33.2

Gross Unrealized Holding Gains 0.0 0.0

Gross Unrealized Holding Losses 0.0 0.0

Fair Value 24.3 33.2

Debt Securities [Member]

Debt Securities, Available-for-sale [Line Items]

Debt Securities, Available-for-sale, Amortized Cost 444.1 225.7

Gross Unrealized Holding Gains 0.0 0.0

Gross Unrealized Holding Losses 0.0 (0.1)

Fair Value $ 444.1 $ 225.6

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 88 R50.htm IDEA: XBRL DOCUMENT v3.19.2

Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Debt Securities, Available-for-sale [Line Items]

Fair Value $ 444.1 $ 225.6

Cash and Cash Equivalents [Member]

Debt Securities, Available-for-sale [Line Items]

Fair Value 359.4 43.8

Marketable Securities [Member]

Debt Securities, Available-for-sale [Line Items]

Fair Value $ 84.7 $ 181.8

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_MarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 89 R51.htm IDEA: XBRL DOCUMENT v3.19.2

Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Investments, Debt and Equity Securities [Abstract]

Due in one year or less $ 438.3

Due after one year through three years 5.8

Estimated Fair Value $ 444.1 $ 225.6

X

- Definition
Available-for-sale Securities, Debt Maturities, Year Two Through Three, Fair Value
+ References
No definition available.
+ Details

Name: alxn_AvailableForSaleSecuritiesDebtMaturitiesYearTwoThroughThreeFairValue

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 90 R52.htm IDEA: XBRL DOCUMENT v3.19.2

Marketable Securities (Narrative) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $ 25.5 $ 128.7

Trading securities. fair value $ 20.7 $ 16.5

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.4)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_TradingSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 91 R53.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Derivative [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax $ 1,203.3 $ 1,045.0 $ 2,343.7 $ 1,975.9

Interest expense (18.3) (25.0) $ (38.2) (49.1)

Designated as Hedging Instrument [Member]

Derivative [Line Items]

Foreign Exchange Forward Contracts Term 60 months

Not Designated as Hedging Instrument [Member]

Derivative [Line Items]

Foreign Exchange Forward Contracts Term 8 months

Gain (loss) reclassified from AOCI to net product sales, net of tax (5.8) 18.4 $ (2.6) 10.3

Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]

Derivative [Line Items]

Notional amount of derivative instruments 1,136.1 1,136.1

Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member] | Revenue

Derivative [Line Items]

Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months 4.8

Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]

Derivative [Line Items]

Notional amount of derivative instruments 1,963.0 1,963.0

Foreign Exchange Forward, Open Expense [Member] | Designated as Hedging Instrument [Member]

Derivative [Line Items]

Notional amount of derivative instruments 17.1 17.1

Interest Rate Swap One [Member] | Designated as Hedging Instrument [Member]

Derivative [Line Items]

Notional amount of derivative instruments $ 1,531.3 $ 1,531.3

Interest Rate Swap One [Member] | Designated as Hedging Instrument [Member] | Minimum [Member]

Derivative [Line Items]

Fixed interest borrowing spreads 0.98% 0.98%

Interest Rate Swap One [Member] | Designated as Hedging Instrument [Member] | Maximum [Member]

Derivative [Line Items]

Fixed interest borrowing spreads 1.62% 1.62%

Interest Rate Swap Two [Member] | Designated as Hedging Instrument [Member]

Derivative [Line Items]

Notional amount of derivative instruments $ 450.0 $ 450.0

Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]

Derivative [Line Items]

Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months (5.2)

Cash Flow Hedging [Member] | Interest Rate Contract [Member] | Interest Expense [Member]

Derivative [Line Items]

Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net 7.0 3.6

Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]

Derivative [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 9.1 (1.7) 16.1 (14.8)

Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] | Foreign Exchange Forward [Member]

Derivative [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 9.1 (1.7) 16.1 (14.8)

Interest expense 0.0 0.0 0.0 0.0

Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] | Interest Rate Contract [Member]

Derivative [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 0.0 0.0 0.0 0.0

Interest expense 4.5 3.1 9.1 4.5

Net Product Sales [Member]

Derivative [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax $ 1,202.5 $ 1,044.7 $ 2,342.7 $ 1,975.1

X

- Definition
Foreign Exchange Forward Contracts Term
+ References
No definition available.
+ Details

Name: alxn_ForeignExchangeForwardContractsTerm

Namespace Prefix: alxn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 12
-Section 13
-Sentence Column B
+ Details

Name: invest_DerivativeNotionalAmount

Namespace Prefix: invest_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Fixed interest rate related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=alxn_ForeignExchangeForwardOpenExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=alxn_InterestRateSwapOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=alxn_InterestRateSwapTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=alxn_NetProductSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 92 R54.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) - Designated as Hedging Instrument [Member]
$ in Millions

Jun. 30, 2019

USD ($)

Interest Rate Swap One [Member]

Derivative [Line Items]

Derivative, notional amount $ 1,531.3

Interest Rate Swap Three [Member]

Derivative [Line Items]

Derivative, notional amount $ 300.0

Derivative, fixed interest rate 2.08%

Interest Rate Swap Four [Member]

Derivative [Line Items]

Derivative, notional amount $ 1,300.0

Minimum [Member] | Interest Rate Swap One [Member]

Derivative [Line Items]

Derivative, fixed interest rate 0.98%

Minimum [Member] | Interest Rate Swap Four [Member]

Derivative [Line Items]

Derivative, fixed interest rate 2.79%

Maximum [Member] | Interest Rate Swap One [Member]

Derivative [Line Items]

Derivative, fixed interest rate 1.62%

Maximum [Member] | Interest Rate Swap Four [Member]

Derivative [Line Items]

Derivative, fixed interest rate 2.83%

X

- Definition
Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 12
-Section 13
-Sentence Column B
+ Details

Name: invest_DerivativeNotionalAmount

Namespace Prefix: invest_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Fixed interest rate related to the interest rate derivative.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeFixedInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=alxn_InterestRateSwapOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=alxn_InterestRateSwapThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=alxn_InterestRateSwapFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 93 R55.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Derivative Instruments, Gain (Loss) [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax $ 1,203.3 $ 1,045.0 $ 2,343.7 $ 1,975.9

Interest expense (18.3) (25.0) (38.2) (49.1)

Foreign Exchange Forward [Member] | Cash Flow Hedging [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Gain (loss) recognized in AOCI, net of tax (3.9) 49.0 10.3 16.5

Foreign Exchange Forward [Member] | Sales | Cash Flow Hedging [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 7.0 (1.3) 12.4 (11.4)

Interest Rate Contract [Member] | Cash Flow Hedging [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Gain (loss) recognized in AOCI, net of tax (24.6) 3.1 (38.8) 11.2

Interest Rate Contract [Member] | Interest Expense | Cash Flow Hedging [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 3.4 2.5

Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 9.1 (1.7) 16.1 (14.8)

Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] | Foreign Exchange Forward [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 9.1 (1.7) 16.1 (14.8)

Interest expense 0.0 0.0 0.0 0.0

Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] | Interest Rate Contract [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 0.0 0.0 0.0 0.0

Interest expense $ 4.5 $ 3.1 $ 9.1 $ 4.5

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 94 R56.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Interest Rate Contract [Member] | Other Current Liabilities | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Liability Derivatives, Fair Value $ 10.8 $ 0.8

Interest Rate Contract [Member] | Other Assets | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Asset Derivatives, Fair Value 0.0

Interest Rate Contract [Member] | Other Liabilities | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Liability Derivatives, Fair Value 52.2 17.3

Interest Rate Contract [Member] | Prepaid Expenses and Other Current Assets [Member] | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Asset Derivatives, Fair Value 20.1

Foreign Exchange Forward [Member]

Derivatives, Fair Value [Line Items]

Asset Derivatives, Fair Value 35.2 60.9

Liability Derivatives, Fair Value 87.8 40.0

Foreign Exchange Forward [Member] | Other Current Liabilities | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Liability Derivatives, Fair Value 7.6 7.3

Foreign Exchange Forward [Member] | Other Assets | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Asset Derivatives, Fair Value 1.1 0.3

Foreign Exchange Forward [Member] | Other Liabilities | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Liability Derivatives, Fair Value 1.8 3.1

Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member] | Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Asset Derivatives, Fair Value 12.4 16.9

Foreign Exchange Forward [Member] | Other Current Liabilities | Not Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Liability Derivatives, Fair Value 15.4 11.5

Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member] | Not Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

Asset Derivatives, Fair Value 16.1 23.6

Interest Rate Contract [Member] | Other Assets

Derivatives, Fair Value [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.8

Interest Rate Contract [Member] | Prepaid Expenses and Other Current Assets [Member]

Derivatives, Fair Value [Line Items]

Interest Rate Derivative Assets, at Fair Value 5.6 20.1

Interest Rate Contract [Member] | Fair Value, Inputs, Level 2 [Member] | Other Current Liabilities

Derivatives, Fair Value [Line Items]

Interest Rate Derivative Assets, at Fair Value 52.2 17.3

Interest Rate Contract [Member] | Fair Value, Inputs, Level 2 [Member] | Other Assets

Derivatives, Fair Value [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0 0.8

Interest Rate Contract [Member] | Fair Value, Inputs, Level 2 [Member] | Prepaid Expenses and Other Current Assets [Member]

Derivatives, Fair Value [Line Items]

Interest Rate Derivative Assets, at Fair Value $ 5.6 $ 20.1

X

- Definition
Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativesFairValueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.
+ References
No definition available.
+ Details

Name: us-gaap_InterestRateDerivativeAssetsAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_InterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 95 R57.htm IDEA: XBRL DOCUMENT v3.19.2

Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) - Foreign Exchange Forward [Member] - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]

Gross Amounts of Recognized Assets $ 35.2 $ 60.9

Gross Amounts Offset in the Condensed Consolidated Balance Sheet 0.0 0.0

Amounts of Assets Presented in the Condensed Consolidated Balance Sheet 35.2 60.9

Derivative Financial Instruments (24.4) (30.2)

Cash Collateral Received 0.0 0.0

Net Amount 10.8 30.7

Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]

Gross Amounts of Recognized Liabilities (87.8) (40.0)

Gross Amounts Offset in the Condensed Consolidated Balance Sheet 0.0 0.0

Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet (87.8) (40.0)

Derivative Financial Instruments 24.4 30.2

Cash Collateral Pledged 0.0 0.0

Net Amount $ (63.4) $ (9.8)

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeAssetFairValueGrossLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeCollateralObligationToReturnCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313
+ Details

Name: us-gaap_DerivativeCollateralObligationToReturnSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeCollateralRightToReclaimCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeCollateralRightToReclaimSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after effects of master netting arrangements, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against an obligation to return collateral. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 20
-Section 50
-Paragraph 4D
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after effects of master netting arrangements, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against the right to receive collateral. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (a),(c)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_DerivativeLiabilityFairValueGrossAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 96 R58.htm IDEA: XBRL DOCUMENT v3.19.2

Other Investments (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Mar. 31, 2019

Jan. 31, 2019

Oct. 31, 2018

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Dec. 31, 2014

Dec. 31, 2018

Investment [Line Items]

Payments to Acquire Other Investments $ 43.8 $ 0.0

Unrealized Gain (Loss) on Investments 8.6 $ 100.5

Zealand [Member]

Investment [Line Items]

Unrealized Gain (Loss) on Investments $ 2.9 3.6

Equity Securities, FV-NI 17.4 17.4

Payments to Acquire Equity Method Investments $ 13.8

Moderna LLC [Member]

Investment [Line Items]

Payments to Acquire Other Investments $ 37.5

Unrealized Gain (Loss) on Investments (29.0) $ 100.8 0.8

Equity Method Investments 82.7 82.7 $ 81.9

Dicerna [Member]

Investment [Line Items]

Unrealized Gain (Loss) on Investments 0.9 4.2

Equity Securities, FV-NI $ 13.1 $ 13.1 $ 8.9

Payments to Acquire Equity Method Investments $ 10.3

Caelum Biosciences [Member]

Investment [Line Items]

Payments to Acquire Other Investments $ 41.0

Option To Acquire Remaining Equity, Amount $ 16.1

X

- Definition
Option To Acquire Remaining Equity, Amount
+ References
No definition available.
+ Details

Name: alxn_OptionToAcquireRemainingEquityAmount

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 12
-Section 12
-Sentence Column A
+ Details

Name: invest_InvestmentLineItems

Namespace Prefix: invest_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740
+ Details

Name: us-gaap_EquitySecuritiesFvNi

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to acquire investments classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireOtherInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=alxn_ZealandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=alxn_ModernaLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=alxn_DicernaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=alxn_CaelumBiosciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 97 R59.htm IDEA: XBRL DOCUMENT v3.19.2

Stockholders' Equity (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Feb. 28, 2017

Class of Stock [Line Items]

Treasury Stock, Shares, Acquired 0.3 0.4 0.7

Treasury Stock, Value, Acquired, Cost Method $ 37.6 $ 0.0 $ 48.9 $ 85.0

Common Stock [Member]

Class of Stock [Line Items]

Stock Repurchase Program, Authorized Amount $ 1,000.0

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 98 R60.htm IDEA: XBRL DOCUMENT v3.19.2

Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

Beginning Balance $ (9.7) $ (34.4)

Other comprehensive income (loss) before reclassifications (28.8) 24.8

Amounts reclassified from other comprehensive income (19.4) 6.7

Other comprehensive income (loss), net of tax $ (37.4) $ 42.8 (48.2) 31.5

Ending Balance (57.9) (2.9) (57.9) (2.9)

Accumulated Defined Benefit Plans Adjustment [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

Beginning Balance (2.6) (4.8)

Other comprehensive income (loss) before reclassifications 0.0 1.3

Amounts reclassified from other comprehensive income 0.0 (0.6)

Other comprehensive income (loss), net of tax 0.0 0.7

Ending Balance (2.6) (4.1) (2.6) (4.1)

Accumulated Net Unrealized Investment Gain (Loss) [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

Beginning Balance (0.3) 0.2

Other comprehensive income (loss) before reclassifications 0.2 0.1

Amounts reclassified from other comprehensive income 0.0 (0.5)

Other comprehensive income (loss), net of tax 0.2 (0.4)

Ending Balance (0.1) (0.2) (0.1) (0.2)

Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

Beginning Balance 9.6 (13.9)

Other comprehensive income (loss) before reclassifications (28.5) 27.7

Amounts reclassified from other comprehensive income (19.4) 7.8

Other comprehensive income (loss), net of tax (47.9) 35.5

Ending Balance (38.3) 21.6 (38.3) 21.6

Accumulated Translation Adjustment [Member]

Accumulated Other Comprehensive Income (Loss) [Roll Forward]

Beginning Balance (16.4) (15.9)

Other comprehensive income (loss) before reclassifications (0.5) (4.3)

Amounts reclassified from other comprehensive income 0.0 0.0

Other comprehensive income (loss), net of tax (0.5) (4.3)

Ending Balance $ (16.9) $ (20.2) $ (16.9) $ (20.2)

X

- Definition
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
+ References
No definition available.
+ Details

Name: alxn_AccumulatedOtherComprehensiveIncomeLossRollForward

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax, before reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17B
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 99 R61.htm IDEA: XBRL DOCUMENT v3.19.2

Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Reclassification out of Accumulated Other Comprehensive Income [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax $ 1,203.3 $ 1,045.0 $ 2,343.7 $ 1,975.9

Other income (expense) 4.1 (12.7)

Income (loss) before income taxes 499.5 (418.6) 1,041.3 (67.0)

Income tax provision (39.7) (38.8) 6.4 (141.3)

Net income (loss) 459.8 (457.4) 1,047.7 (208.3)

Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]

Reclassification out of Accumulated Other Comprehensive Income [Line Items]

Revenue from Contract with Customer, Excluding Assessed Tax 9.1 (1.7) 16.1 (14.8)

Other income (expense) 4.5 3.1 9.1 4.5

Income (loss) before income taxes 13.6 1.4 25.2 (10.3)

Income tax provision (3.2) (0.2) (5.8) 2.5

Net income (loss) $ 10.4 $ 1.2 $ 19.4 $ (7.8)

X

- Definition
[Line Items] for Reclassification out of Accumulated Other Comprehensive Income [Table]
+ References
No definition available.
+ Details

Name: alxn_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLineItems

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 100 R62.htm IDEA: XBRL DOCUMENT v3.19.2

Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Other Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities

Foreign Exchange Forward [Member] | Other Current Liabilities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 23.0 $ 18.8

Foreign Exchange Forward [Member] | Other Current Liabilities | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 0.0 0.0

Foreign Exchange Forward [Member] | Other Current Liabilities | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 23.0 18.8

Foreign Exchange Forward [Member] | Other Current Liabilities | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 0.0 0.0

Foreign Exchange Forward [Member] | Other Liabilities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 1.8 3.1

Foreign Exchange Forward [Member] | Other Liabilities | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 0.0 0.0

Foreign Exchange Forward [Member] | Other Liabilities | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 1.8 3.1

Foreign Exchange Forward [Member] | Other Liabilities | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, liability 0.0 0.0

Acquisition Related Contingent Consideration [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 258.2

Acquisition Related Contingent Consideration [Member] | ContingentConsiderationCurrent [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 100.0 97.6

Acquisition Related Contingent Consideration [Member] | ContingentConsiderationCurrent [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 0.0 0.0

Acquisition Related Contingent Consideration [Member] | ContingentConsiderationCurrent [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 0.0 0.0

Acquisition Related Contingent Consideration [Member] | ContingentConsiderationCurrent [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 100.0 97.6

Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 158.2 183.2

Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 0.0 0.0

Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 0.0 0.0

Acquisition Related Contingent Consideration [Member] | Contingent Consideration [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 158.2 183.2

Other Contingent Payments [Member] | Other Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 13.5

Other Contingent Payments [Member] | Other Liabilities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 13.5

Other Contingent Payments [Member] | Other Current Liabilities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 13.9

Other Contingent Payments [Member] | Other Current Liabilities | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 0.0

Other Contingent Payments [Member] | Other Current Liabilities | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 0.0

Other Contingent Payments [Member] | Other Current Liabilities | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Liability 13.9

Interest Rate Contract [Member] | Other Assets

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.8

Interest Rate Contract [Member] | Other Assets | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0

Interest Rate Contract [Member] | Other Assets | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0 0.8

Interest Rate Contract [Member] | Other Assets | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0

Interest Rate Contract [Member] | Current Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Liabilities, at Fair Value 10.8

Interest Rate Contract [Member] | Current Liabilities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Liabilities, at Fair Value 0.0

Interest Rate Contract [Member] | Current Liabilities [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Liabilities, at Fair Value 10.8

Interest Rate Contract [Member] | Current Liabilities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Liabilities, at Fair Value 0.0

Interest Rate Contract [Member] | Other Liabilities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 52.2 17.3

Interest Rate Contract [Member] | Other Liabilities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0 0.0

Interest Rate Contract [Member] | Other Liabilities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0 0.0

Interest Rate Contract [Member] | Other Current Liabilities | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 52.2 17.3

Interest Rate Contract [Member] | Prepaid Expenses and Other Current Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 5.6 20.1

Interest Rate Contract [Member] | Prepaid Expenses and Other Current Assets [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0 0.0

Interest Rate Contract [Member] | Prepaid Expenses and Other Current Assets [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 5.6 20.1

Interest Rate Contract [Member] | Prepaid Expenses and Other Current Assets [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Interest Rate Derivative Assets, at Fair Value 0.0 0.0

Money Market Funds [Member] | Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 498.5 569.4

Money Market Funds [Member] | Cash Equivalents [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Money Market Funds [Member] | Cash Equivalents [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 498.5 569.4

Money Market Funds [Member] | Cash Equivalents [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Mutual Funds [Member] | Marketable Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 20.7 16.5

Mutual Funds [Member] | Marketable Securities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 20.7 16.5

Mutual Funds [Member] | Marketable Securities [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Mutual Funds [Member] | Marketable Securities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Commercial Paper [Member] | Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 240.2 35.4

Commercial Paper [Member] | Cash Equivalents [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0 0.0

Commercial Paper [Member] | Cash Equivalents [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 240.2 35.4

Commercial Paper [Member] | Cash Equivalents [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0 0.0

Commercial Paper [Member] | Marketable Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 33.8 16.7

Commercial Paper [Member] | Marketable Securities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Commercial Paper [Member] | Marketable Securities [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 33.8 16.7

Commercial Paper [Member] | Marketable Securities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Corporate Bond Securities [Member] | Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.2

Corporate Bond Securities [Member] | Cash Equivalents [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Corporate Bond Securities [Member] | Cash Equivalents [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.2

Corporate Bond Securities [Member] | Cash Equivalents [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Corporate Bond Securities [Member] | Marketable Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 28.0 122.6

Corporate Bond Securities [Member] | Marketable Securities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Corporate Bond Securities [Member] | Marketable Securities [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 28.0 122.6

Corporate Bond Securities [Member] | Marketable Securities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Municipal Bonds [Member] | Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 8.2

Municipal Bonds [Member] | Cash Equivalents [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Municipal Bonds [Member] | Cash Equivalents [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 8.2

Municipal Bonds [Member] | Cash Equivalents [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Other Government Obligations [Member] | Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 107.0

Other Government Obligations [Member] | Cash Equivalents [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0

Other Government Obligations [Member] | Cash Equivalents [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 107.0

Other Government Obligations [Member] | Cash Equivalents [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0

Other Government Obligations [Member] | Marketable Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 10.8 9.3

Other Government Obligations [Member] | Marketable Securities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Other Government Obligations [Member] | Marketable Securities [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 10.8 9.3

Other Government Obligations [Member] | Marketable Securities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 0.0

Certificates of Deposit [Member] | Cash Equivalents [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 12.2

Certificates of Deposit [Member] | Cash Equivalents [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0

Certificates of Deposit [Member] | Cash Equivalents [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 12.2

Certificates of Deposit [Member] | Cash Equivalents [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0

Certificates of Deposit [Member] | Marketable Securities [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 12.1

Marketable securities 33.2

Certificates of Deposit [Member] | Marketable Securities [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Marketable securities 0.0

Certificates of Deposit [Member] | Marketable Securities [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 12.1

Marketable securities 33.2

Certificates of Deposit [Member] | Marketable Securities [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents 0.0

Marketable securities 0.0

Foreign Exchange Forward [Member] | Other Assets

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 1.1 0.3

Foreign Exchange Forward [Member] | Other Assets | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 0.0 0.0

Foreign Exchange Forward [Member] | Other Assets | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 1.1 0.3

Foreign Exchange Forward [Member] | Other Assets | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 0.0 0.0

Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 28.5 40.5

Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 0.0 0.0

Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 28.5 40.5

Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Foreign exchange forward contracts, asset 0.0 0.0

Equity Securities [Member] | Other Assets [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 113.3 90.8

Equity Securities [Member] | Other Assets [Member] | Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 30.6 8.9

Equity Securities [Member] | Other Assets [Member] | Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 82.7 81.9

Equity Securities [Member] | Other Assets [Member] | Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Marketable securities 0.0 $ 0.0

Caelum Biosciences [Member] | Collaborative Arrangement [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivative Liability $ 27.4 $ 27.1

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.
+ References
No definition available.
+ Details

Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.
+ References
No definition available.
+ Details

Name: us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.
+ References
No definition available.
+ Details

Name: us-gaap_InterestRateDerivativeAssetsAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_InterestRateDerivativeLiabilitiesAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_InvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=alxn_AcquisitionRelatedContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_ContingentConsiderationCurrentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_ContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=alxn_OtherContingentPaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_InterestRateContractMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_CurrentLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=alxn_MutualFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_MarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MunicipalBondsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=alxn_OtherGovernmentObligationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_CaelumBiosciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 101 R63.htm IDEA: XBRL DOCUMENT v3.19.2

Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0 $ 0.0

Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High 702.0 702.0

Acquisition-Related Contingent Consideration [Roll Forward]

Amounts derecognized upon sale of asset (6.1) $ (4.7) 22.6 $ (57.4)

Acquisition Related Contingent Consideration [Member]

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Business Combination, Contingent Consideration, Liability 258.2 258.2

Acquisition Related Contingent Consideration [Member] | Level 3 [Member]

Acquisition-Related Contingent Consideration [Roll Forward]

Balance at beginning of period 280.8

Change in fair value (22.6)

Balance at end of period $ 258.2 $ 258.2

Acquisition Related Contingent Consideration [Member] | Minimum [Member] | Level 3 [Member]

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Fair Value Inputs, Cost of Debt 5.10%

Fair Value Inputs, Weighted Average Cost of Capital 10.00%

X

- Definition
Fair Value Inputs, Cost of Debt
+ References
No definition available.
+ Details

Name: alxn_FairValueInputsCostOfDebt

Namespace Prefix: alxn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair Value Inputs, Weighted Average Cost of Capital
+ References
No definition available.
+ Details

Name: alxn_FairValueInputsWeightedAverageCostOfCapital

Namespace Prefix: alxn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=alxn_AcquisitionRelatedContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 102 R64.htm IDEA: XBRL DOCUMENT v3.19.2

Fair Value Measurement (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended

Jan. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Mar. 31, 2019

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Increase in contingent consideration liability $ 6.1 $ 4.7 $ (22.6) $ 57.4

Research and development 187.6 $ 173.4 383.5 $ 350.0

Caelum Biosciences [Member] | Collaborative Arrangement [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Collaboration Agreement, Upfront Payment $ 30.0

Collaboration Agreement, Potential Future Payments, Milestone Achievement $ 30.0

Derivative Liability 27.4 27.4 $ 27.1

Research and development $ 0.3 $ 0.3

Minimum [Member] | Caelum Biosciences [Member] | Collaborative Arrangement [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Derivative Fair Value, Discounted Cost Of Debt 3.30%

Maximum [Member] | Caelum Biosciences [Member] | Collaborative Arrangement [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Derivative Fair Value, Discounted Cost Of Debt 3.50%

Subsequent Event

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Asset Acquisition, Contingent Consideration, Milestone Payments $ 100.0

X

- Definition
Asset Acquisition, Contingent Consideration, Milestone Payments
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionContingentConsiderationMilestonePayments

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaboration Agreement, Potential Future Payments, Milestone Achievement
+ References
No definition available.
+ Details

Name: alxn_CollaborationAgreementPotentialFuturePaymentsMilestoneAchievement

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaboration Agreement, Upfront Payment
+ References
No definition available.
+ Details

Name: alxn_CollaborationAgreementUpfrontPayment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Derivative Fair Value, Discounted Cost Of Debt
+ References
No definition available.
+ Details

Name: alxn_DerivativeFairValueDiscountedCostOfDebt

Namespace Prefix: alxn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_CounterpartyNameAxis=alxn_CaelumBiosciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 103 R65.htm IDEA: XBRL DOCUMENT v3.19.2

Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales $ 1,203.3 $ 1,045.0 $ 2,343.7 $ 1,975.9

Soliris

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 980.8 898.2 1,942.8 1,698.3

Ultomiris [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 54.2 0.0 78.8 0.0

Strensiq Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 141.3 125.1 271.4 235.8

Kanuma Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 26.2 21.4 49.7 41.0

United States | Soliris

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 496.3 395.8 960.0 731.8

United States | Ultomiris [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 54.2 0.0 78.8 0.0

United States | Strensiq Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 106.2 99.9 205.7 189.1

United States | Kanuma Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 15.3 13.0 29.1 24.9

Europe | Soliris

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 280.2 253.4 544.7 504.2

Europe | Ultomiris [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 0.0 0.0 0.0 0.0

Europe | Strensiq Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 19.5 16.4 37.0 30.4

Europe | Kanuma Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 6.8 5.8 13.1 11.7

Asia Pacific | Soliris

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 110.3 93.6 211.2 179.1

Asia Pacific | Ultomiris [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 0.0 0.0 0.0 0.0

Asia Pacific | Strensiq Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 12.1 6.3 22.0 12.0

Asia Pacific | Kanuma Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 1.3 1.1 2.1 2.1

Rest of World | Soliris

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 94.0 155.4 226.9 283.2

Rest of World | Ultomiris [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 0.0 0.0 0.0 0.0

Rest of World | Strensiq Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 3.5 2.5 6.7 4.3

Rest of World | Kanuma Product Line

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales 2.8 1.5 5.4 2.3

Product [Member]

Revenue, Initial Application Period Cumulative Effect Transition [Line Items]

Total Net Product Sales $ 1,202.5 $ 1,044.7 $ 2,342.7 $ 1,975.1

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=alxn_SolirisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=alxn_UltomirisMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=alxn_StrensiqProductLineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=alxn_KanumaProductLineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=srt_EuropeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=srt_AsiaPacificMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=alxn_OtherNonUsExcludingEuropeAndAsiaPacificMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 104 R66.htm IDEA: XBRL DOCUMENT v3.19.2

Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Revenue from Contract with Customer [Abstract]

Receivables, which are included in Trade accounts receivable, net $ 1,123.6 $ 922.3

Contract liabilities, which are included in Other current liabilities $ 3.1 $ 3.4

X

- Definition
Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044
+ Details

Name: us-gaap_ContractWithCustomerAssetNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 105 R67.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Income Tax Disclosure [Abstract]

Provision for income taxes $ 39.7 $ 38.8 $ (6.4) $ 141.3

Effective tax rate 7.90% (9.30%) (0.60%) (210.90%)

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 106 R68.htm IDEA: XBRL DOCUMENT v3.19.2

Income Taxes (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

May 25, 2018

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Fair Value of Assets Acquired $ 803.7 $ 0.0 $ 86.6

Effective Income Tax Rate Reconciliation, Change In Deferred Tax Expense (Benefit) 5.20%

Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit) $ 38.4

In Process Research and Development

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles $ 803.7

Intellectual Property Election [Member]

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Deferred Income Tax Expense (Benefit) $ (95.7)

Effective Income Tax Rate Reconciliation, Deduction, Percent 12.10%

Valuation Allowance Release [Member]

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Deferred Income Tax Expense (Benefit) $ (30.3)

Wilson Therapeutics [Member]

Schedule Of Asset Acquisition, By Acquisition [Line Items]

Effective Income Tax Rate Reconciliation, Deduction, Percent 19.40% 230.10%

X

- Definition
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangibles

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Effective Income Tax Rate Reconciliation, Change In Deferred Tax Expense (Benefit)
+ References
No definition available.
+ Details

Name: alxn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxExpenseBenefit

Namespace Prefix: alxn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
[Line Items] for Schedule Of Asset Acquisition, By Acquisition [Table]
+ References
No definition available.
+ Details

Name: alxn_ScheduleOfAssetAcquisitionByAcquisitionLineItems

Namespace Prefix: alxn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)
+ References
No definition available.
+ Details

Name: alxn_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationDeductions

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: alxn_DeferredTaxExpenseBenefitByTypeAxis=alxn_IntellectualPropertyElectionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: alxn_DeferredTaxExpenseBenefitByTypeAxis=alxn_ValuationAllowanceReleaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: alxn_DeferredTaxExpenseBenefitByTypeAxis=alxn_WilsonTherapeuticsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 107 R69.htm IDEA: XBRL DOCUMENT v3.19.2

Leases - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2019

Dec. 31, 2018

Lessee, Lease, Description [Line Items]

Finance Lease, Liability $ 80.5 $ 80.5

Lease, Cost 14.4 29.4

Lessee, Operating Lease, Liability, Payments, Due 231.3 231.3

Inventory [Member]

Lessee, Lease, Description [Line Items]

Lease, Cost 3.0 6.3

Lonza Group AG

Lessee, Lease, Description [Line Items]

Other Commitment $ 1,084.6

Lessee, Operating Lease, Liability, Payments, Due $ 88.7 $ 88.7

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCommitment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_InventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_LonzaGroupAGMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 108 R70.htm IDEA: XBRL DOCUMENT v3.19.2

Leases - Lease Assets and Liabilities (Details) - USD ($)
$ in Millions

Jun. 30, 2019

Dec. 31, 2018

Lessee, Lease, Description [Line Items]

Right of use operating assets $ 209.5 $ 0.0

Noncurrent operating lease liabilities 165.5 $ 0.0

Right Of Use Operating Assets [Member]

Lessee, Lease, Description [Line Items]

Finance Lease, Right-of-Use Asset 0.0

Right of use operating assets 209.5

Property, Plant and Equipment [Member]

Lessee, Lease, Description [Line Items]

Finance Lease, Right-of-Use Asset 121.8

Right of use operating assets 0.0

Other Current Assets [Member]

Lessee, Lease, Description [Line Items]

Finance Lease, Liability, Current 5.0

Operating Lease, Liability, Current 20.3

Right Of Use Operating Liabilities [Member]

Lessee, Lease, Description [Line Items]

Finance Lease, Liability, Noncurrent 0.0

Noncurrent operating lease liabilities 165.5

Other Liabilities [Member]

Lessee, Lease, Description [Line Items]

Finance Lease, Liability, Noncurrent 75.5

Noncurrent operating lease liabilities $ 0.0

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_RightOfUseOperatingAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=alxn_RightOfUseOperatingLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 109 R71.htm IDEA: XBRL DOCUMENT v3.19.2

Leases - Lease Related Costs (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2019

Leases [Abstract]

Finance Lease, Cost $ 3.5 $ 7.5

Finance Lease, Right-of-Use Asset, Amortization 2.5 5.5

Finance Lease, Interest Expense 1.0 2.0

Operating Lease, Cost 8.6 17.6

Variable Lease, Cost 2.3 4.3

Lease, Cost $ 14.4 $ 29.4

X

- Definition
Finance Lease, Cost
+ References
No definition available.
+ Details

Name: alxn_FinanceLeaseCost

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_VariableLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 110 R72.htm IDEA: XBRL DOCUMENT v3.19.2

Leases - Lease Cash Flow Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2019

Leases [Abstract]

Lessee, Payments For Operating And Finance Leases $ 8.8 $ 16.4

Finance Lease, Interest Payment on Liability 1.0 2.0

Operating ROU lease assets obtained in exchange for operating lease liabilities 6.5 11.9

Finance Lease, Principal Payments 1.3 2.5

Right of use financing assets obtained in exchange for financing lease liabilities 0.0 0.0

Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 20.7 20.7

Right-of-Use Asset Obtained in Exchange for Finance Lease Rent Prepayment 44.2

Right-of-Use Asset Obtained in Exchange for Operating Lease, Rent Prepayments $ 26.6

X

- Definition
Lessee, Payments For Operating And Finance Leases
+ References
No definition available.
+ Details

Name: alxn_LesseePaymentsForOperatingAndFinanceLeases

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Right-of-Use Asset Obtained in Exchange for Finance Lease Rent Prepayment
+ References
No definition available.
+ Details

Name: alxn_RightofUseAssetObtainedinExchangeforFinanceLeaseRentPrepayment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Right-of-Use Asset Obtained in Exchange for Operating Lease, Rent Prepayments
+ References
No definition available.
+ Details

Name: alxn_RightofUseAssetObtainedinExchangeforOperatingLeaseRentPrepayments

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of interest paid on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977
+ Details

Name: us-gaap_FinanceLeaseInterestPaymentOnLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for principal payment on finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_FinanceLeasePrincipalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 111 R73.htm IDEA: XBRL DOCUMENT v3.19.2

Leases - Lease Additional Information (Details)
$ in Millions
6 Months Ended

Jun. 30, 2019

USD ($)

Leases [Abstract]

Finance Lease, Weighted Average Remaining Lease Term 11 years 2 months 1 day

Operating Lease, Weighted Average Remaining Lease Term 10 years 5 months 15 days

Lease, Weighted Average Remaining Lease Term 10 years 8 months 1 day

Finance Lease, Weighted Average Discount Rate, Percent 4.85%

Operating Lease, Weighted Average Discount Rate, Percent 4.35%

Lease, Weighted Average Discount Rate 4.51%

Lessee, Lease Liability, Payments, Due $ 335.9

Lessee, Lease Liability, Undiscounted Excess Amount 69.4

Lessee, Lease Liability 266.3

Finance Lease, Liability, Undiscounted Excess Amount 24.0

Lessee, Operating Lease, Liability, Undiscounted Excess Amount 45.4

Finance Lease, Liability, Payments, Due 104.6

Lessee, Operating Lease, Liability, Payments, Due 231.3

Finance Lease, Liability 80.5

Lease liability $ 185.8

X

- Definition
Lease, Weighted Average Discount Rate
+ References
No definition available.
+ Details

Name: alxn_LeaseWeightedAverageDiscountRate

Namespace Prefix: alxn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Lease, Weighted Average Remaining Lease Term
+ References
No definition available.
+ Details

Name: alxn_LeaseWeightedAverageRemainingLeaseTerm

Namespace Prefix: alxn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Lessee, Lease Liability
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiability

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease Liability, Payments, Due
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDue

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease Liability, Undiscounted Excess Amount
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted average discount rate for finance lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

XML 112 R74.htm IDEA: XBRL DOCUMENT v3.19.2

Leases - Finance and Operating Lease Liability Maturity (Details)
$ in Millions

Jun. 30, 2019

USD ($)

Leases [Abstract]

Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $ 27.8

Finance Lease, Liability, Payments, Remainder of Fiscal Year 4.4

Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 13.6

Lessee, Lease, Liability, Payments, Due Year Five 29.7

Lessee, Lease, Liability, Payments, Due Year Four 30.0

Lessee, Lease, Liability, Payments, Due Year Three 31.1

Lessee, Lease, Liability, Payments, Due Year Two 33.6

Lessee, Lease, Liability, Payments, Remainder of Fiscal Year 18.0

Finance Lease, Liability, Payments, Due Year Six 9.4

Lessee, Operating Lease, Liability, Payments, Due Year Six 20.2

Lessee, Lease, Liability, Payments, Due Year Six 29.6

Finance Lease, Liability, Payments, Due After Year Six 54.6

Lessee, Operating Lease, Liability, Payments, Due After Year Six 109.3

Lessee, Lease, Liability, Payments, Due After Year Six 163.9

Finance Lease, Liability, Payments, Due Year Two 8.8

Lessee, Operating Lease, Liability, Payments, Due Year Two 24.8

Finance Lease, Liability, Payments, Due Year Three 9.0

Lessee, Operating Lease, Liability, Payments, Due Year Three 22.1

Finance Lease, Liability, Payments, Due Year Four 9.2

Lessee, Operating Lease, Liability, Payments, Due Year Four 20.8

Finance Lease, Liability, Payments, Due Year Five 9.2

Lessee, Operating Lease, Liability, Payments, Due Year Five 20.5

Operating Leases, Future Minimum Payments, Due in Two Years 24.7

Operating Leases, Future Minimum Payments, Due in Three Years 21.3

Operating Leases, Future Minimum Payments, Due in Four Years 19.9

Operating Leases, Future Minimum Payments, Due in Five Years 19.7

Operating Leases, Future Minimum Payments, Due Thereafter $ 132.2

X

- Definition
Finance Lease, Liability, Payments, Due After Year Six
+ References
No definition available.
+ Details

Name: alxn_FinanceLeaseLiabilityPaymentsDueAfterYearSix

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Finance Lease, Liability, Payments, Due Year Six
+ References
No definition available.
+ Details

Name: alxn_FinanceLeaseLiabilityPaymentsDueYearSix

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Due After Year Six
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDueAfterYearSix

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Due Year Five
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Due Year Four
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Due Year Six
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDueYearSix

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Due Year Three
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Due Year Two
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Lease, Liability, Payments, Remainder of Fiscal Year
+ References
No definition available.
+ Details

Name: alxn_LesseeLeaseLiabilityPaymentsRemainderofFiscalYear

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Operating Lease, Liability, Payments, Due After Year Six
+ References
No definition available.
+ Details

Name: alxn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Lessee, Operating Lease, Liability, Payments, Due Year Six
+ References
No definition available.
+ Details

Name: alxn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 113 R75.htm IDEA: XBRL DOCUMENT v3.19.2

Commitments and Contingencies (Narrative) (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended

Mar. 31, 2019

Jan. 31, 2019

Nov. 30, 2018

Sep. 30, 2019

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Jun. 21, 2019

Other Commitments [Line Items]

Research and development $ 187.6 $ 173.4 $ 383.5 $ 350.0

Distribution fees related to importation expenses 571.5 $ 1,349.8 1,109.3 $ 1,921.7

Subsequent Event

Other Commitments [Line Items]

Asset Acquisition, Contingent Consideration, Milestone Payments $ 100.0

Lonza Group AG

Other Commitments [Line Items]

Remaining total commitments 1,044.1 1,044.1

Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount 102.3 102.3

Other Third Party Manufacturers

Other Commitments [Line Items]

Remaining total commitments 65.1 65.1

Collaborative Arrangement [Member] | Caelum Biosciences [Member]

Other Commitments [Line Items]

Collaboration Agreement, Upfront Payment $ 30.0

Research and development 0.3 0.3

Collaboration Agreement, Potential Future Payments, Milestone Achievement 30.0

Derivative Liability $ 27.1 27.4 27.4

Collaboration Agreement, Acquisition Option, Maximum Potential Future Payment 500.0

Zealand Pharma [Member] | Zealand [Member]

Other Commitments [Line Items]

Payments To Acquire Licenses And Equity Investment 40.0

Prepaid Research And Development Expense 5.0 5.0

Research and development 21.2

Collaboration Agreement, Potential Future Payments, Milestone Achievement 610.0

Collaboration Agreement, Potential Future Payments, Option Fee 15.0

Affibody AB [Domain] | Affibody [Member]

Other Commitments [Line Items]

Payments To Acquire Licenses And Equity Investment 25.0

Collaboration Agreement, Potential Future Payments, Milestone Achievement 625.0

Collaboration and License Agreement [Member]

Other Commitments [Line Items]

Collaboration Agreement, Potential Future Payments, Milestone Achievement 838.2

Caelum Biosciences [Member] | Collaborative Arrangement [Member]

Other Commitments [Line Items]

Equity Method Investment, Aggregate Cost $ 57.1

Zealand [Member]

Other Commitments [Line Items]

Payments to Acquire Equity Method Investments $ 13.8

DOJ And OIG [Member]

Other Commitments [Line Items]

Loss Contingency Accrual $ 13.1 $ 13.1

Canadian Patented Medicine Prices Review Board [Member]

Other Commitments [Line Items]

Escrow Deposit $ 31.6

Syntimmune, Inc [Member]

Other Commitments [Line Items]

Asset Acquisition, Contingent Consideration, Milestone Payments $ 800.0

X

- Definition
Asset Acquisition, Contingent Consideration, Milestone Payments
+ References
No definition available.
+ Details

Name: alxn_AssetAcquisitionContingentConsiderationMilestonePayments

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise
+ References
No definition available.
+ Details

Name: alxn_CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaboration Agreement, Potential Future Payments, Milestone Achievement
+ References
No definition available.
+ Details

Name: alxn_CollaborationAgreementPotentialFuturePaymentsMilestoneAchievement

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaboration Agreement, Potential Future Payments, Option Fee
+ References
No definition available.
+ Details

Name: alxn_CollaborationAgreementPotentialFuturePaymentsOptionFee

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Collaboration Agreement, Upfront Payment
+ References
No definition available.
+ Details

Name: alxn_CollaborationAgreementUpfrontPayment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Payments To Acquire Licenses And Equity Investment
+ References
No definition available.
+ Details

Name: alxn_PaymentsToAcquireLicensesAndEquityInvestment

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Prepaid Research And Development Expense
+ References
No definition available.
+ Details

Name: alxn_PrepaidResearchAndDevelopmentExpense

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount
+ References
No definition available.
+ Details

Name: alxn_UnrecordedUnconditionalPurchaseObligationUndiscountedFixedPaymentAmount

Namespace Prefix: alxn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents the aggregate cost of investments accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestmentAggregateCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_EscrowDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of loss contingency liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_LossContingencyAccrualAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCommitmentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308
+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_LonzaGroupAGMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_OtherThirdPartyManufacturersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_CaelumBiosciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=alxn_ZealandPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_ZealandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=alxn_AffibodyABDomain

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CounterpartyNameAxis=alxn_AffibodyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=alxn_CollaborationandLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=alxn_CaelumBiosciencesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=alxn_ZealandMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=alxn_DOJAndOIGMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_LitigationCaseAxis=alxn_CanadianPatentedMedicinePricesReviewBoardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=alxn_SyntimmuneIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 114 R76.htm IDEA: XBRL DOCUMENT v3.19.2

Restructuring and Related Expenses (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Mar. 31, 2019

Dec. 31, 2018

Restructuring Cost and Reserve [Line Items]

Restructuring expenses $ 2.5 $ 17.6 $ 11.6 $ 32.0

Restructuring Reserve 9.5 9.5 $ 10.8 $ 4.2

Restructuring and Related Cost, Expected Cost 10.0 10.0

Employee Separation Costs

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 2.4 $ 3.1 11.5 $ 4.1

Restructuring Reserve $ 9.5 $ 9.5 $ 10.8 $ 4.2

X

- Definition
Amount expected to be recognized in earnings for the specified restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(d))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringAndRelatedCostExpectedCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 115 R77.htm IDEA: XBRL DOCUMENT v3.19.2

Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Restructuring Cost and Reserve [Line Items]

Restructuring expenses $ 2.5 $ 17.6 $ 11.6 $ 32.0

Cost of Sales [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.5 0.0 5.8

Research and Development Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.1

Selling, General and Administrative Expenses [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 6.5 0.0 10.1

Restructuring Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 2.5 10.6 11.6 16.1

Other Income [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 (0.1)

Employee Separation Costs

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 2.4 3.1 11.5 4.1

Employee Separation Costs | Cost of Sales [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Employee Separation Costs | Research and Development Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Employee Separation Costs | Selling, General and Administrative Expenses [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Employee Separation Costs | Restructuring Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 2.4 3.1 11.5 4.1

Employee Separation Costs | Other Income [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Asset-Related Charges

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 7.0 0.0 16.0

Asset-Related Charges | Cost of Sales [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.5 0.0 5.8

Asset-Related Charges | Research and Development Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.1

Asset-Related Charges | Selling, General and Administrative Expenses [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 6.5 0.0 10.1

Asset-Related Charges | Restructuring Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Asset-Related Charges | Other Income [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Other

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.1 7.5 0.1 11.9

Other | Cost of Sales [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Other | Research and Development Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Other | Selling, General and Administrative Expenses [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.0 0.0 0.0 0.0

Other | Restructuring Expense [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses 0.1 7.5 0.1 12.0

Other | Other Income [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring expenses $ 0.0 $ 0.0 $ 0.0 $ (0.1)

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=alxn_RestructuringExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 116 R78.htm IDEA: XBRL DOCUMENT v3.19.2

(Restructuring Reserve Roll Forward) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended

Jun. 30, 2019

Jun. 30, 2019

Restructuring Reserve [Roll Forward]

Beginning Balance $ 10.8 $ 4.2

Restructuring expenses 5.3 14.2

Cash settlements (3.8) (6.3)

Adjustments to previous estimates (2.8) (2.6)

Asset impairments 0.0 0.0

Ending Balance 9.5 9.5

Employee Separation Costs

Restructuring Reserve [Roll Forward]

Beginning Balance 10.8 4.2

Restructuring expenses 5.3 14.2

Cash settlements (3.8) (6.3)

Adjustments to previous estimates (2.8) (2.6)

Asset impairments 0.0 0.0

Ending Balance 9.5 9.5

Asset-Related Charges

Restructuring Reserve [Roll Forward]

Beginning Balance 0.0 0.0

Restructuring expenses 0.0 0.0

Cash settlements 0.0 0.0

Adjustments to previous estimates 0.0 0.0

Asset impairments 0.0 0.0

Ending Balance 0.0 0.0

Other

Restructuring Reserve [Roll Forward]

Beginning Balance 0.0 0.0

Restructuring expenses 0.0 0.0

Cash settlements 0.0 0.0

Adjustments to previous estimates 0.0 0.0

Asset impairments 0.0 0.0

Ending Balance $ 0.0 $ 0.0

X

- Definition
Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585
+ Details

Name: us-gaap_PaymentsForRestructuring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(1))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(d))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringAndRelatedCostIncurredCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserveAccrualAdjustment1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringReserveRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of decrease in the reserve for full or partial settlement through consideration other than cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869
+ Details

Name: us-gaap_RestructuringReserveSettledWithoutCash2

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 117 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 118 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 119 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 120 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 599 439 1 false 114 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Document Sheet http://www.alxn.com/role/DocumentAndEntityInformationDocument Document and Entity Information Document Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.alxn.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001001 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004000 - Statement - Condensed Consolidated Statements of Comprehensive Income Statement Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement Condensed Consolidated Statements of Comprehensive Income Statement Statements 5 false false R6.htm 1004501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 6 false false R7.htm 1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Statement Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement Condensed Consolidated Statements of Changes in Stockholder's Equity Statement Statements 7 false false R8.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Business Sheet http://www.alxn.com/role/Business Business Notes 9 false false R10.htm 2102100 - Disclosure - Basis of Presentation and Principles Of Consolidation Sheet http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidation Basis of Presentation and Principles Of Consolidation Notes 10 false false R11.htm 2103100 - Disclosure - Acquisitions Sheet http://www.alxn.com/role/Acquisitions Acquisitions Notes 11 false false R12.htm 2106100 - Disclosure - Inventories Sheet http://www.alxn.com/role/Inventories Inventories Notes 12 false false R13.htm 2107100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.alxn.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 13 false false R14.htm 2108100 - Disclosure - Debt Sheet http://www.alxn.com/role/Debt Debt Notes 14 false false R15.htm 2109100 - Disclosure - Earnings Per Common Share Sheet http://www.alxn.com/role/EarningsPerCommonShare Earnings Per Common Share Notes 15 false false R16.htm 2110100 - Disclosure - Marketable Securities Sheet http://www.alxn.com/role/MarketableSecurities Marketable Securities Notes 16 false false R17.htm 2111100 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivities Derivative Instruments and Hedging Activities Notes 17 false false R18.htm 2112100 - Disclosure - Other Investments Sheet http://www.alxn.com/role/OtherInvestments Other Investments Notes 18 false false R19.htm 2113100 - Disclosure - Stockholders' Equity Sheet http://www.alxn.com/role/StockholdersEquity Stockholders' Equity Notes 19 false false R20.htm 2114100 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income Sheet http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncome Other Comprehensive Income and Accumulated Other Comprehensive Income Notes 20 false false R21.htm 2115100 - Disclosure - Fair Value Measurement Sheet http://www.alxn.com/role/FairValueMeasurement Fair Value Measurement Notes 21 false false R22.htm 2116100 - Disclosure - Revenue Recognition Sheet http://www.alxn.com/role/RevenueRecognition Revenue Recognition Notes 22 false false R23.htm 2117100 - Disclosure - Income Taxes Sheet http://www.alxn.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2118100 - Disclosure - Defined Benefit Plans Sheet http://www.alxn.com/role/DefinedBenefitPlans Defined Benefit Plans Notes 24 false false R25.htm 2119100 - Disclosure - Leases Sheet http://www.alxn.com/role/Leases Leases Notes 25 false false R26.htm 2125100 - Disclosure - Commitments and Contingencies Sheet http://www.alxn.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 26 false false R27.htm 2126100 - Disclosure - Restructuring and Related Expenses Sheet http://www.alxn.com/role/RestructuringAndRelatedExpenses Restructuring and Related Expenses Notes 27 false false R28.htm 2303301 - Disclosure - Acquisitions (Tables) Sheet http://www.alxn.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.alxn.com/role/Acquisitions 28 false false R29.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://www.alxn.com/role/InventoriesTables Inventories (Tables) Tables http://www.alxn.com/role/Inventories 29 false false R30.htm 2307301 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.alxn.com/role/IntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.alxn.com/role/IntangibleAssetsAndGoodwill 30 false false R31.htm 2309301 - Disclosure - Earnings Per Common Share (Tables) Sheet http://www.alxn.com/role/EarningsPerCommonShareTables Earnings Per Common Share (Tables) Tables http://www.alxn.com/role/EarningsPerCommonShare 31 false false R32.htm 2310301 - Disclosure - Marketable Securities (Tables) Sheet http://www.alxn.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.alxn.com/role/MarketableSecurities 32 false false R33.htm 2311301 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivities 33 false false R34.htm 2314301 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables) Sheet http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeTables Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables) Tables http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncome 34 false false R35.htm 2315301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.alxn.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.alxn.com/role/FairValueMeasurement 35 false false R36.htm 2316301 - Disclosure - Revenue Recognition (Tables) Sheet http://www.alxn.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.alxn.com/role/RevenueRecognition 36 false false R37.htm 2317301 - Disclosure - Income Taxes (Tables) Sheet http://www.alxn.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.alxn.com/role/IncomeTaxes 37 false false R38.htm 2319301 - Disclosure - Leases (Tables) Sheet http://www.alxn.com/role/LeasesTables Leases (Tables) Tables http://www.alxn.com/role/Leases 38 false false R39.htm 2326301 - Disclosure - Restructuring and Related Expenses (Tables) Sheet http://www.alxn.com/role/RestructuringAndRelatedExpensesTables Restructuring and Related Expenses (Tables) Tables http://www.alxn.com/role/RestructuringAndRelatedExpenses 39 false false R40.htm 2402401 - Disclosure - Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details) Sheet http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details) Details 40 false false R41.htm 2403402 - Disclosure - Acquisitions (Narrative) (Details) Sheet http://www.alxn.com/role/AcquisitionsNarrativeDetails Acquisitions (Narrative) (Details) Details http://www.alxn.com/role/AcquisitionsTables 41 false false R42.htm 2403403 - Disclosure - Acquisitions (Summary of Total Consideration) (Details) Sheet http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails Acquisitions (Summary of Total Consideration) (Details) Details http://www.alxn.com/role/AcquisitionsTables 42 false false R43.htm 2406402 - Disclosure - Inventories (Details) Sheet http://www.alxn.com/role/InventoriesDetails Inventories (Details) Details http://www.alxn.com/role/InventoriesTables 43 false false R44.htm 2407402 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) Sheet http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) Details http://www.alxn.com/role/IntangibleAssetsAndGoodwillTables 44 false false R45.htm 2407403 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details) Sheet http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails Intangible Assets and Goodwill (Narrative) (Details) Details http://www.alxn.com/role/IntangibleAssetsAndGoodwillTables 45 false false R46.htm 2408401 - Disclosure - Debt (Details) Sheet http://www.alxn.com/role/DebtDetails Debt (Details) Details http://www.alxn.com/role/Debt 46 false false R47.htm 2409402 - Disclosure - Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) Sheet http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details) Details http://www.alxn.com/role/EarningsPerCommonShareTables 47 false false R48.htm 2409403 - Disclosure - Earnings Per Common Share (Narrative) (Details) Sheet http://www.alxn.com/role/EarningsPerCommonShareNarrativeDetails Earnings Per Common Share (Narrative) (Details) Details http://www.alxn.com/role/EarningsPerCommonShareTables 48 false false R49.htm 2410402 - Disclosure - Marketable Securities (Summary of Securities Held) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails Marketable Securities (Summary of Securities Held) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 49 false false R50.htm 2410403 - Disclosure - Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 50 false false R51.htm 2410404 - Disclosure - Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 51 false false R52.htm 2410405 - Disclosure - Marketable Securities (Narrative) (Details) Sheet http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails Marketable Securities (Narrative) (Details) Details http://www.alxn.com/role/MarketableSecuritiesTables 52 false false R53.htm 2411402 - Disclosure - Derivative Instruments and Hedging Activities (Narrative) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails Derivative Instruments and Hedging Activities (Narrative) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables 53 false false R54.htm 2411403 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables 54 false false R55.htm 2411404 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables 55 false false R56.htm 2411405 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables 56 false false R57.htm 2411406 - Disclosure - Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) Sheet http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) Details http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables 57 false false R58.htm 2412401 - Disclosure - Other Investments (Details) Sheet http://www.alxn.com/role/OtherInvestmentsDetails Other Investments (Details) Details http://www.alxn.com/role/OtherInvestments 58 false false R59.htm 2413401 - Disclosure - Stockholders' Equity (Details) Sheet http://www.alxn.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.alxn.com/role/StockholdersEquity 59 false false R60.htm 2414402 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) Sheet http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details) Details http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeTables 60 false false R61.htm 2414403 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) Sheet http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details) Details http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeTables 61 false false R62.htm 2415402 - Disclosure - Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) Sheet http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details) Details http://www.alxn.com/role/FairValueMeasurementTables 62 false false R63.htm 2415403 - Disclosure - Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) Sheet http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details) Details http://www.alxn.com/role/FairValueMeasurementTables 63 false false R64.htm 2415404 - Disclosure - Fair Value Measurement (Narrative) (Details) Sheet http://www.alxn.com/role/FairValueMeasurementNarrativeDetails Fair Value Measurement (Narrative) (Details) Details http://www.alxn.com/role/FairValueMeasurementTables 64 false false R65.htm 2416402 - Disclosure - Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) Sheet http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details) Details http://www.alxn.com/role/RevenueRecognitionTables 65 false false R66.htm 2416403 - Disclosure - Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) Sheet http://www.alxn.com/role/RevenueRecognitionSummaryOfReceivablesAndContractLiabilitiesFromContractsDetails Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) Details http://www.alxn.com/role/RevenueRecognitionTables 66 false false R67.htm 2417402 - Disclosure - Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) Sheet http://www.alxn.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionAndEffectiveTaxRateDetails Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details) Details http://www.alxn.com/role/IncomeTaxesTables 67 false false R68.htm 2417403 - Disclosure - Income Taxes (Narrative) (Details) Sheet http://www.alxn.com/role/IncomeTaxesNarrativeDetails Income Taxes (Narrative) (Details) Details http://www.alxn.com/role/IncomeTaxesTables 68 false false R69.htm 2419402 - Disclosure - Leases - Narrative (Details) Sheet http://www.alxn.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 69 false false R70.htm 2419403 - Disclosure - Leases - Lease Assets and Liabilities (Details) Sheet http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails Leases - Lease Assets and Liabilities (Details) Details 70 false false R71.htm 2419404 - Disclosure - Leases - Lease Related Costs (Details) Sheet http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails Leases - Lease Related Costs (Details) Details 71 false false R72.htm 2419405 - Disclosure - Leases - Lease Cash Flow Information (Details) Sheet http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails Leases - Lease Cash Flow Information (Details) Details 72 false false R73.htm 2419406 - Disclosure - Leases - Lease Additional Information (Details) Sheet http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails Leases - Lease Additional Information (Details) Details 73 false false R74.htm 2419407 - Disclosure - Leases - Finance and Operating Lease Liability Maturity (Details) Sheet http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails Leases - Finance and Operating Lease Liability Maturity (Details) Details 74 false false R75.htm 2425401 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.alxn.com/role/CommitmentsAndContingencies 75 false false R76.htm 2426402 - Disclosure - Restructuring and Related Expenses (Narrative) (Details) Sheet http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails Restructuring and Related Expenses (Narrative) (Details) Details http://www.alxn.com/role/RestructuringAndRelatedExpensesTables 76 false false R77.htm 2426403 - Schedule - Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) Sheet http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details) Details http://www.alxn.com/role/RestructuringAndRelatedExpensesTables 77 false false R78.htm 2426404 - Disclosure - (Restructuring Reserve Roll Forward) (Details) Sheet http://www.alxn.com/role/RestructuringReserveRollForwardDetails (Restructuring Reserve Roll Forward) (Details) Details 78 false false All Reports Book All Reports alxn630201910q.htm alxn-20190630.xsd alxn-20190630_cal.xml alxn-20190630_def.xml alxn-20190630_lab.xml alxn-20190630_pre.xml alxnex101incplana.htm alxnex102incplanb.htm alxnex311q219.htm alxnex312q219.htm alxnex321q219.htm alxnex322q219.htm alexionlogoa54.jpg chart-065336660b54572793d.jpg chart-1a4d05ee019a5c28a75.jpg chart-2233dba6a706559f890.jpg chart-2558ff03f0675fad9fd.jpg chart-270bd56111f51ba4323.jpg chart-2a9e8b01181c5afc92f.jpg chart-2be5ae4d6bc35201b7a.jpg chart-470b1c81f0072df98af.jpg chart-54231418cc365d0a16b.jpg chart-7726c3b84e715ea7a5c.jpg chart-7eb2fe509c415bcabe8.jpg chart-87af8901609352cd863.jpg chart-95052c11230d5ce8b52.jpg chart-996c588aaa81582da31.jpg chart-9cc04c86c1fe5bbfb22.jpg chart-a7367b5baf6e53a3ad3.jpg chart-c52813e437f858f69d3.jpg chart-d70f8b3d9fa957a6bcb.jpg chart-ec1239fbf0ab58a8a54.jpg chart-ffce7e2bcdc6598da5f.jpg kanumaimagea08.jpg solirisimagea08.jpg strensiqimagea08.jpg ultomirisr2.jpg http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true JSON 123 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "alxn630201910q.htm": { "axisCustom": 1, "axisStandard": 29, "contextCount": 599, "dts": { "calculationLink": { "local": [ "alxn-20190630_cal.xml" ] }, "definitionLink": { "local": [ "alxn-20190630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "alxn630201910q.htm" ] }, "labelLink": { "local": [ "alxn-20190630_lab.xml" ], "remote": [ "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "alxn-20190630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml" ] }, "schema": { "local": [ "alxn-20190630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 660, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 27, "http://www.alxn.com/20190630": 2, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 34 }, "keyCustom": 70, "keyStandard": 369, "memberCustom": 44, "memberStandard": 60, "nsprefix": "alxn", "nsuri": "http://www.alxn.com/20190630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information Document", "role": "http://www.alxn.com/role/DocumentAndEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Basis of Presentation and Principles Of Consolidation", "role": "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidation", "shortName": "Basis of Presentation and Principles Of Consolidation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:AssetAcquisitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Acquisitions", "role": "http://www.alxn.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:AssetAcquisitionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Inventories", "role": "http://www.alxn.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Intangible Assets and Goodwill", "role": "http://www.alxn.com/role/IntangibleAssetsAndGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Debt", "role": "http://www.alxn.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Earnings Per Common Share", "role": "http://www.alxn.com/role/EarningsPerCommonShare", "shortName": "Earnings Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Marketable Securities", "role": "http://www.alxn.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Derivative Instruments and Hedging Activities", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivities", "shortName": "Derivative Instruments and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "invest:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Other Investments", "role": "http://www.alxn.com/role/OtherInvestments", "shortName": "Other Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "invest:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Stockholders' Equity", "role": "http://www.alxn.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncome", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Fair Value Measurement", "role": "http://www.alxn.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Revenue Recognition", "role": "http://www.alxn.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Income Taxes", "role": "http://www.alxn.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Defined Benefit Plans", "role": "http://www.alxn.com/role/DefinedBenefitPlans", "shortName": "Defined Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Leases", "role": "http://www.alxn.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - Commitments and Contingencies", "role": "http://www.alxn.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126100 - Disclosure - Restructuring and Related Expenses", "role": "http://www.alxn.com/role/RestructuringAndRelatedExpenses", "shortName": "Restructuring and Related Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Acquisitions (Tables)", "role": "http://www.alxn.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Inventories (Tables)", "role": "http://www.alxn.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001001 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Intangible Assets and Goodwill (Tables)", "role": "http://www.alxn.com/role/IntangibleAssetsAndGoodwillTables", "shortName": "Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Earnings Per Common Share (Tables)", "role": "http://www.alxn.com/role/EarningsPerCommonShareTables", "shortName": "Earnings Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Marketable Securities (Tables)", "role": "http://www.alxn.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeTables", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Fair Value Measurement (Tables)", "role": "http://www.alxn.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.alxn.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Income Taxes (Tables)", "role": "http://www.alxn.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Leases (Tables)", "role": "http://www.alxn.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "alxn:LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326301 - Disclosure - Restructuring and Related Expenses (Tables)", "role": "http://www.alxn.com/role/RestructuringAndRelatedExpensesTables", "shortName": "Restructuring and Related Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "alxn:FacilityLeaseObligationNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details)", "role": "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "shortName": "Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-5", "lang": null, "name": "alxn:FixedAndOtherAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "D2018Q4_us-gaap_BusinessAcquisitionAxis_alxn_SyntimmuneIncMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Acquisitions (Narrative) (Details)", "role": "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "shortName": "Acquisitions (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_alxn_SyntimmuneIncMember", "decimals": "-5", "lang": null, "name": "alxn:AdditionalPaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "D2018Q2May25_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Acquisitions (Summary of Total Consideration) (Details)", "role": "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "shortName": "Acquisitions (Summary of Total Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "I2018Q2May25_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember", "decimals": "-5", "lang": null, "name": "alxn:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLaborAndRelatedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Inventories (Details)", "role": "http://www.alxn.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "alxn:IntangibleAssetsCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details)", "role": "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "shortName": "Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "alxn:IntangibleAssetsCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details)", "role": "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "shortName": "Intangible Assets and Goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - Debt (Details)", "role": "http://www.alxn.com/role/DebtDetails", "shortName": "Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details)", "role": "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Earnings Per Common Share (Summary Of Calculation Of Basic And Diluted Earnings Per Share) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Earnings Per Common Share (Narrative) (Details)", "role": "http://www.alxn.com/role/EarningsPerCommonShareNarrativeDetails", "shortName": "Earnings Per Common Share (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Marketable Securities (Summary of Securities Held) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails", "shortName": "Marketable Securities (Summary of Securities Held) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Comprehensive Income Statement", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement", "shortName": "Condensed Consolidated Statements of Comprehensive Income Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails", "shortName": "Marketable Securities (Available-for-sale Investments by Classification in Balance Sheet) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_CashAndCashEquivalentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails", "shortName": "Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Marketable Securities (Narrative) (Details)", "role": "http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails", "shortName": "Marketable Securities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Derivative Instruments and Hedging Activities (Narrative) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "shortName": "Derivative Instruments and Hedging Activities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": null, "lang": "en-US", "name": "alxn:ForeignExchangeForwardContractsTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_alxn_InterestRateSwapOneMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "shortName": "Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_alxn_InterestRateSwapThreeMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "shortName": "Derivative Instruments and Hedging Activities (Schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "shortName": "Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details)", "role": "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails", "shortName": "Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember", "decimals": "-5", "lang": null, "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireOtherInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - Other Investments (Details)", "role": "http://www.alxn.com/role/OtherInvestmentsDetails", "shortName": "Other Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_alxn_ZealandMember", "decimals": "-5", "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - Stockholders' Equity (Details)", "role": "http://www.alxn.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "I2017Q1February28_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember", "decimals": "-5", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details)", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income (Changes in AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details)", "role": "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails", "shortName": "Other Comprehensive Income and Accumulated Other Comprehensive Income (Significant Reclassifications from AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "decimals": "-5", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember", "decimals": null, "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "true" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)", "role": "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "shortName": "Fair Value Measurement (Schedule Of Assets And Liabilites Measured At Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember", "decimals": null, "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "true" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)", "role": "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "shortName": "Fair Value Measurement (Schedule Of Acquisition-Related Contingent Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByLiabilityClassAxis_alxn_AcquisitionRelatedContingentConsiderationMember", "decimals": "-5", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - Fair Value Measurement (Narrative) (Details)", "role": "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "shortName": "Fair Value Measurement (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "D2019Q1Jan1to31_srt_CounterpartyNameAxis_alxn_CaelumBiosciencesMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember", "decimals": "INF", "lang": null, "name": "alxn:DerivativeFairValueDiscountedCostOfDebt", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details)", "role": "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails", "shortName": "Revenue Recognition (Disaggregation of Revenue by Product and Geographical Region) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD_us-gaap_StatementBusinessSegmentsAxis_alxn_SolirisMember", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details)", "role": "http://www.alxn.com/role/RevenueRecognitionSummaryOfReceivablesAndContractLiabilitiesFromContractsDetails", "shortName": "Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details)", "role": "http://www.alxn.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionAndEffectiveTaxRateDetails", "shortName": "Income Taxes (Schedule of Income Tax Provision and Effective Tax Rate) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2018Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - Income Taxes (Narrative) (Details)", "role": "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2018Q2YTD", "decimals": "3", "lang": null, "name": "alxn:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:LesseeOperatingAndFinanceLeaseAdditionalInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Leases - Narrative (Details)", "role": "http://www.alxn.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD_us-gaap_BalanceSheetLocationAxis_alxn_InventoryMember", "decimals": "-5", "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Statement", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "shortName": "Condensed Consolidated Statements of Changes in Stockholder's Equity Statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Leases - Lease Assets and Liabilities (Details)", "role": "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "shortName": "Leases - Lease Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2_us-gaap_BalanceSheetLocationAxis_alxn_RightOfUseOperatingAssetsMember", "decimals": "-5", "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "alxn:FinanceLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Leases - Lease Related Costs (Details)", "role": "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails", "shortName": "Leases - Lease Related Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "alxn:FinanceLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:LesseeLeaseCashFlowTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "alxn:LesseePaymentsForOperatingAndFinanceLeases", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419405 - Disclosure - Leases - Lease Cash Flow Information (Details)", "role": "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails", "shortName": "Leases - Lease Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:LesseeLeaseCashFlowTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "alxn:LesseePaymentsForOperatingAndFinanceLeases", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:LesseeOperatingAndFinanceLeaseAdditionalInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419406 - Disclosure - Leases - Lease Additional Information (Details)", "role": "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails", "shortName": "Leases - Lease Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "alxn:LesseeOperatingAndFinanceLeaseAdditionalInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Leases - Finance and Operating Lease Liability Maturity (Details)", "role": "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails", "shortName": "Leases - Finance and Operating Lease Liability Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425401 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "role": "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "D2019Q1Jan1to31_srt_CounterpartyNameAxis_alxn_CaelumBiosciencesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember", "decimals": "-5", "lang": null, "name": "alxn:CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426402 - Disclosure - Restructuring and Related Expenses (Narrative) (Details)", "role": "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "shortName": "Restructuring and Related Expenses (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2426403 - Schedule - Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details)", "role": "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "shortName": "Restructuring and Related Expenses (Schedule of Restructuring and related Costs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426404 - Disclosure - (Restructuring Reserve Roll Forward) (Details)", "role": "http://www.alxn.com/role/RestructuringReserveRollForwardDetails", "shortName": "(Restructuring Reserve Roll Forward) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Business", "role": "http://www.alxn.com/role/Business", "shortName": "Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "alxn630201910q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 114, "tag": { "alxn_AccumulatedOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income [Abstract]", "label": "Accumulated Other Comprehensive Income [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_AccumulatedOtherComprehensiveIncomeLossRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "label": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossRollForward", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "stringItemType" }, "alxn_AcquisitionRelatedContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisition-Related Contingent Consideration [Member]", "label": "Acquisition Related Contingent Consideration [Member]", "terseLabel": "Acquisition Related Contingent Consideration [Member]" } } }, "localname": "AcquisitionRelatedContingentConsiderationMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_AdditionalPaymentsToAcquireBusinessesGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Additional Payments To Acquire Businesses, Gross", "label": "Additional Payments To Acquire Businesses, Gross", "terseLabel": "Additional payments to acquire businesses" } } }, "localname": "AdditionalPaymentsToAcquireBusinessesGross", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AffibodyABDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Affibody AB [Domain]", "label": "Affibody AB [Domain]", "terseLabel": "Affibody AB [Domain]" } } }, "localname": "AffibodyABDomain", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AffibodyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Affibody [Member]", "label": "Affibody [Member]", "terseLabel": "Affibody [Member]" } } }, "localname": "AffibodyMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_AmortizationofIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of Intangible Assets Acquired", "label": "Amortization of Intangible Assets Acquired", "terseLabel": "Amortization of purchased intangible assets" } } }, "localname": "AmortizationofIntangibleAssetsAcquired", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionCashAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Cash Acquired", "label": "Asset Acquisition, Cash Acquired", "terseLabel": "Cash acquired" } } }, "localname": "AssetAcquisitionCashAcquired", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionConsiderationTransferred": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Consideration Transferred", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Asset Acquisition, Consideration Transferred", "verboseLabel": "Total consideration" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionContingentConsiderationMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Contingent Consideration, Milestone Payments", "label": "Asset Acquisition, Contingent Consideration, Milestone Payments", "terseLabel": "Asset Acquisition, Contingent Consideration, Milestone Payments" } } }, "localname": "AssetAcquisitionContingentConsiderationMilestonePayments", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition Disclosure [Text Block]", "label": "Asset Acquisition Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "AssetAcquisitionDisclosureTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "alxn_AssetAcquisitionPotentialPaymentsForDevelopmentRegulatoryCommercialMilestonesAndRoyaltiesOnSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Potential Payments For Development, Regulatory, Commercial Milestones And Royalties On Sales", "label": "Asset Acquisition, Potential Payments For Development, Regulatory, Commercial Milestones And Royalties On Sales", "terseLabel": "Potential development, regulatory and commercial milestones and royalties payment" } } }, "localname": "AssetAcquisitionPotentialPaymentsForDevelopmentRegulatoryCommercialMilestonesAndRoyaltiesOnSales", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedBenefitFromPreviouslyAcquiredResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Benefit From Previously Acquired Research And Development", "label": "Asset Acquisition, Recognized Benefit From Previously Acquired Research And Development", "terseLabel": "Business Combination, Recognized Benefit From Previously Acquired Research And Development" } } }, "localname": "AssetAcquisitionRecognizedBenefitFromPreviouslyAcquiredResearchAndDevelopment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Cash And Equivalents", "terseLabel": "Cash", "verboseLabel": "Cash" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangibles": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "In-process research & development" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangibles", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, In-Process Research And Development", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, In-Process Research And Development", "terseLabel": "In-process research & development" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLaborAndRelatedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Labor And Related Liabilities", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Labor And Related Liabilities", "negatedTerseLabel": "Employee related liabilities" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLaborAndRelatedLiabilities", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Net", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Net", "terseLabel": "Total net assets acquired" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLiabilitiesOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Other", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Other", "negatedTerseLabel": "Other assets and liabilities" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLiabilitiesOther", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedNetAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Assets", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Assets", "terseLabel": "Total net assets acquired" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedNetAssets", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets", "label": "Asset Acquisition, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Assets", "terseLabel": "Other assets and liabilities" } } }, "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherAssets", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Share Price", "label": "Asset Acquisition, Share Price", "terseLabel": "Cash offer price per share (in sec per share)" } } }, "localname": "AssetAcquisitionSharePrice", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "alxn_AssetAcquisitionTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Transaction Costs", "label": "Asset Acquisition, Transaction Costs", "terseLabel": "Transaction costs", "verboseLabel": "Transaction costs" } } }, "localname": "AssetAcquisitionTransactionCosts", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionWorkingCapitalAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Working Capital Adjustment", "label": "Asset Acquisition, Working Capital Adjustment", "terseLabel": "Working capital adjustment" } } }, "localname": "AssetAcquisitionWorkingCapitalAdjustment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_AssetAcquisitionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisitions [Abstract]", "label": "Asset Acquisitions [Abstract]" } } }, "localname": "AssetAcquisitionsAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]", "label": "Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]", "terseLabel": "Available-for-sale Securities by Balance Sheet Location Classification [Table Text Block]" } } }, "localname": "AvailableForSaleSecuritiesByBalanceSheetLocationClassificationTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "alxn_AvailableForSaleSecuritiesDebtMaturitiesYearTwoThroughThreeFairValue": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Available-for-sale Securities, Debt Maturities, Year Two Through Three, Fair Value", "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Three, Fair Value", "terseLabel": "Due after one year through three years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesYearTwoThroughThreeFairValue", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_BusinessAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business [Abstract]", "label": "Business [Abstract]" } } }, "localname": "BusinessAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_CaelumBiosciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Caelum Biosciences [Member]", "label": "Caelum Biosciences [Member]", "terseLabel": "Caelum Biosciences [Member]" } } }, "localname": "CaelumBiosciencesMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_CanadianPatentedMedicinePricesReviewBoardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Canadian Patented Medicine Prices Review Board [Member]", "label": "Canadian Patented Medicine Prices Review Board [Member]", "terseLabel": "Canadian Patented Medicine Prices Review Board [Member]" } } }, "localname": "CanadianPatentedMedicinePricesReviewBoardMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise", "label": "Collaboration Agreement, Potential Future Payments, Acquisition Option Exercise", "terseLabel": "Collaboration Agreement, Acquisition Option, Maximum Potential Future Payment" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsAcquisitionOptionExercise", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsMilestoneAchievement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Milestone Achievement", "label": "Collaboration Agreement, Potential Future Payments, Milestone Achievement", "terseLabel": "Collaboration Agreement, Potential Future Payments, Milestone Achievement" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsMilestoneAchievement", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementPotentialFuturePaymentsOptionFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Potential Future Payments, Option Fee", "label": "Collaboration Agreement, Potential Future Payments, Option Fee", "terseLabel": "Collaboration Agreement, Potential Future Payments, Option Fee" } } }, "localname": "CollaborationAgreementPotentialFuturePaymentsOptionFee", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationAgreementUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Agreement, Upfront Payment", "label": "Collaboration Agreement, Upfront Payment", "terseLabel": "Collaboration Agreement, Upfront Payment" } } }, "localname": "CollaborationAgreementUpfrontPayment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_CollaborationandLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and License Agreement [Member]", "label": "Collaboration and License Agreement [Member]", "terseLabel": "Collaboration and License Agreement [Member]" } } }, "localname": "CollaborationandLicenseAgreementMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_ContingentConsiderationCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ContingentConsiderationCurrent [Member]", "label": "ContingentConsiderationCurrent [Member]", "terseLabel": "ContingentConsiderationCurrent [Member]" } } }, "localname": "ContingentConsiderationCurrentMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration [Member]", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration [Member]" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement [Member]" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "alxn_CurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Liabilities [Member]", "label": "Current Liabilities [Member]", "terseLabel": "Current Liabilities [Member]" } } }, "localname": "CurrentLiabilitiesMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_DOJAndOIGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DOJ And OIG [Member]", "label": "DOJ And OIG [Member]", "terseLabel": "DOJ And OIG [Member]" } } }, "localname": "DOJAndOIGMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_DebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt [Abstract]", "label": "Debt [Abstract]" } } }, "localname": "DebtAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_DebtInstrumentQuarterlyPaymentPercentageofTotalBorrowings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Quarterly Payment, Percentage of Total Borrowings", "label": "Debt Instrument, Quarterly Payment, Percentage of Total Borrowings", "terseLabel": "Debt Instrument, quarterly payment as a percent of total borrowings" } } }, "localname": "DebtInstrumentQuarterlyPaymentPercentageofTotalBorrowings", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "percentItemType" }, "alxn_DeferredTaxExpenseBenefitByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Deferred Tax Expense (Benefit) By Type [Axis]", "label": "Deferred Tax Expense (Benefit) By Type [Axis]", "terseLabel": "Deferred Tax Expense (Benefit) By Type [Axis]" } } }, "localname": "DeferredTaxExpenseBenefitByTypeAxis", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "alxn_DeferredTaxExpenseBenefitByTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Deferred Tax Expense (Benefit) By Type [Axis]", "label": "Deferred Tax Expense (Benefit) By Type [Domain]", "terseLabel": "Deferred Tax Expense (Benefit) By Type [Domain]" } } }, "localname": "DeferredTaxExpenseBenefitByTypeDomain", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_DerivativeFairValueDiscountedCostOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Fair Value, Discounted Cost Of Debt", "label": "Derivative Fair Value, Discounted Cost Of Debt", "terseLabel": "Derivative Fair Value, Discounted Cost Of Debt" } } }, "localname": "DerivativeFairValueDiscountedCostOfDebt", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_DerivativeInstrumentsAndHedgingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Instruments and Hedging Activities [Abstract]", "label": "Derivative Instruments and Hedging Activities [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_DicernaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dicerna [Member]", "label": "Dicerna [Member]", "terseLabel": "Dicerna [Member]" } } }, "localname": "DicernaMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_EarningsPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings Per Common Share [Abstract]", "label": "Earnings Per Common Share [Abstract]" } } }, "localname": "EarningsPerCommonShareAbstract", "nsuri": "http://www.alxn.com/20190630", "xbrltype": "stringItemType" }, "alxn_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxExpenseBenefit": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Change In Deferred Tax Expense (Benefit)", "label": "Effective Income Tax Rate Reconciliation, Change In Deferred Tax Expense (Benefit)", "terseLabel": "Effective Income Tax Rate Reconciliation, Change In Deferred Tax Expense (Benefit)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxExpenseBenefit", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "alxn_FacilityLeaseObligationNoncurrent": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Facility Lease Obligation, Noncurrent", "label": "Facility Lease Obligation, Noncurrent", "terseLabel": "Facility lease obligation", "verboseLabel": "Derecognition of Facility Lease Obligation" } } }, "localname": "FacilityLeaseObligationNoncurrent", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "alxn_FairValueInputsCostOfDebt": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Cost of Debt", "label": "Fair Value Inputs, Cost of Debt", "terseLabel": "Fair Value Inputs, Cost of Debt" } } }, "localname": "FairValueInputsCostOfDebt", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "alxn_FairValueInputsWeightedAverageCostOfCapital": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Weighted Average Cost of Capital", "label": "Fair Value Inputs, Weighted Average Cost of Capital", "terseLabel": "Fair Value Inputs, Weighted Average Cost of Capital" } } }, "localname": "FairValueInputsWeightedAverageCostOfCapital", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "alxn_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "totalLabel": "Finance Lease, Cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "alxn_FinanceLeaseLiabilityPaymentsDueAfterYearSix": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueAfterYearSix", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Liability, Payments, Due After Year Six", "label": "Finance Lease, Liability, Payments, Due After Year Six", "terseLabel": "Finance Lease, Liability, Payments, Due After Year Six" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearSix", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_FinanceLeaseLiabilityPaymentsDueYearSix": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearSix", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Finance Lease, Liability, Payments, Due Year Six", "label": "Finance Lease, Liability, Payments, Due Year Six", "terseLabel": "Finance Lease, Liability, Payments, Due Year Six" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearSix", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_FixedAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fixed And Other Assets", "label": "Fixed And Other Assets", "terseLabel": "Derecognition of Fixed and Other Assets" } } }, "localname": "FixedAndOtherAssets", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ForeignExchangeForwardContractsTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Exchange Forward Contracts Term", "label": "Foreign Exchange Forward Contracts Term", "terseLabel": "Foreign Exchange Forward Contracts Term" } } }, "localname": "ForeignExchangeForwardContractsTerm", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "alxn_ForeignExchangeForwardOpenExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Exchange Forward, Open Expense [Member]", "label": "Foreign Exchange Forward, Open Expense [Member]", "terseLabel": "Foreign Exchange Forward, Open Expense [Member]" } } }, "localname": "ForeignExchangeForwardOpenExpenseMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_GoodwillAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Goodwill, Accumulated Amortization", "label": "Goodwill, Accumulated Amortization", "negatedTerseLabel": "Goodwill, Accumulated Amortization" } } }, "localname": "GoodwillAccumulatedAmortization", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_IntangibleAssetsAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Accumulated Amortization", "label": "Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Intangible Assets, Accumulated Amortization" } } }, "localname": "IntangibleAssetsAccumulatedAmortization", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_IntangibleAssetsCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets, Cost", "label": "Intangible Assets, Cost", "terseLabel": "Intangible Assets, Cost" } } }, "localname": "IntangibleAssetsCost", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "alxn_IntellectualPropertyElectionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intellectual Property Election [Member]", "label": "Intellectual Property Election [Member]", "terseLabel": "Intellectual Property Election [Member]" } } }, "localname": "IntellectualPropertyElectionMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_InterestRateSwapFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Four [Member]", "label": "Interest Rate Swap Four [Member]", "terseLabel": "Interest Rate Swap Four [Member]" } } }, "localname": "InterestRateSwapFourMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "alxn_InterestRateSwapOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap One [Member]", "label": "Interest Rate Swap One [Member]", "terseLabel": "Interest Rate Swap One [Member]" } } }, "localname": "InterestRateSwapOneMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "alxn_InterestRateSwapThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Three [Member]", "label": "Interest Rate Swap Three [Member]", "terseLabel": "Interest Rate Swap Three [Member]" } } }, "localname": "InterestRateSwapThreeMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "alxn_InterestRateSwapTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Swap Two [Member]", "label": "Interest Rate Swap Two [Member]", "terseLabel": "Interest Rate Swap Two [Member]" } } }, "localname": "InterestRateSwapTwoMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_InventoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Inventory [Member]", "terseLabel": "Inventory [Member]" } } }, "localname": "InventoryMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_KanumaProductLineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Kanuma Product Line[Member]", "label": "Kanuma Product Line [Member]", "terseLabel": "Kanuma Product Line" } } }, "localname": "KanumaProductLineMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_LeaseWeightedAverageDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease, Weighted Average Discount Rate", "label": "Lease, Weighted Average Discount Rate", "terseLabel": "Lease, Weighted Average Discount Rate" } } }, "localname": "LeaseWeightedAverageDiscountRate", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "alxn_LeaseWeightedAverageRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease, Weighted Average Remaining Lease Term", "label": "Lease, Weighted Average Remaining Lease Term", "terseLabel": "Lease, Weighted Average Remaining Lease Term" } } }, "localname": "LeaseWeightedAverageRemainingLeaseTerm", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "alxn_LesseeLeaseAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Lease Assets And Liabilities [Table Text Block]", "label": "Lessee, Lease Assets And Liabilities [Table Text Block]", "terseLabel": "Schedule of Lease Assets and Liabilities" } } }, "localname": "LesseeLeaseAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "alxn_LesseeLeaseCashFlowTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Lease Cash Flow [Table Text Block]", "label": "Lessee, Lease Cash Flow [Table Text Block]", "terseLabel": "Schedule of Lease Cash Flow Information" } } }, "localname": "LesseeLeaseCashFlowTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "alxn_LesseeLeaseLiability": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease Liability", "label": "Lessee, Lease Liability", "totalLabel": "Lessee, Lease Liability" } } }, "localname": "LesseeLeaseLiability", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease Liability, Payments, Due", "label": "Lessee, Lease Liability, Payments, Due", "totalLabel": "Lessee, Lease Liability, Payments, Due" } } }, "localname": "LesseeLeaseLiabilityPaymentsDue", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDueAfterYearSix": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Due After Year Six", "label": "Lessee, Lease, Liability, Payments, Due After Year Six", "totalLabel": "Lessee, Lease, Liability, Payments, Due After Year Six" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueAfterYearSix", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Due Year Five", "label": "Lessee, Lease, Liability, Payments, Due Year Five", "totalLabel": "Lessee, Lease, Liability, Payments, Due Year Five" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Due Year Four", "label": "Lessee, Lease, Liability, Payments, Due Year Four", "totalLabel": "Lessee, Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDueYearSix": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Due Year Six", "label": "Lessee, Lease, Liability, Payments, Due Year Six", "totalLabel": "Lessee, Lease, Liability, Payments, Due Year Six" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearSix", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Due Year Three", "label": "Lessee, Lease, Liability, Payments, Due Year Three", "totalLabel": "Lessee, Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Due Year Two", "label": "Lessee, Lease, Liability, Payments, Due Year Two", "totalLabel": "Lessee, Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityPaymentsRemainderofFiscalYear": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Liability, Payments, Remainder of Fiscal Year", "label": "Lessee, Lease, Liability, Payments, Remainder of Fiscal Year", "totalLabel": "Lessee, Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "LesseeLeaseLiabilityPaymentsRemainderofFiscalYear", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Lease Liability, Undiscounted Excess Amount", "label": "Lessee, Lease Liability, Undiscounted Excess Amount", "totalLabel": "Lessee, Lease Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeOperatingAndFinanceLeaseAdditionalInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating And Finance Lease Additional Information [Table Text Block]", "label": "Lessee, Operating And Finance Lease Additional Information [Table Text Block]", "terseLabel": "Schedule of Operating and Finance Lease Additional Information" } } }, "localname": "LesseeOperatingAndFinanceLeaseAdditionalInformationTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "alxn_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueAfterYearSix", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Six", "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Six", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due After Year Six" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearSix", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearSix", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Due Year Six", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Six", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Six" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LesseePaymentsForOperatingAndFinanceLeases": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Payments For Operating And Finance Leases", "label": "Lessee, Payments For Operating And Finance Leases", "totalLabel": "Lessee, Payments For Operating And Finance Leases" } } }, "localname": "LesseePaymentsForOperatingAndFinanceLeases", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_LonzaGroupAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lonza Group AG [Member]", "label": "Lonza Group AG [Member]", "terseLabel": "Lonza Group AG" } } }, "localname": "LonzaGroupAGMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/LeasesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "terseLabel": "Marketable Securities [Member]" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "alxn_ModernaLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Moderna LLC [Member]", "label": "Moderna LLC [Member]", "terseLabel": "Moderna LLC [Member]" } } }, "localname": "ModernaLLCMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_MutualFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mutual Funds [Member]", "label": "Mutual Funds [Member]", "terseLabel": "Mutual Funds [Member]" } } }, "localname": "MutualFundsMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_NetProductSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net Product Sales [Member]", "label": "Net Product Sales [Member]", "terseLabel": "Net Product Sales [Member]" } } }, "localname": "NetProductSalesMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_OffsettingAssetsandLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Offsetting Assets and Liabilities [Table]", "label": "Offsetting Assets and Liabilities [Line Items]", "terseLabel": "Offsetting Assets and Liabilities [Line Items]" } } }, "localname": "OffsettingAssetsandLiabilitiesLineItems", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "alxn_OffsettingAssetsandLiabilitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Offsetting Assets and Liabilities [Table]", "label": "Offsetting Assets and Liabilities [Table]", "terseLabel": "Offsetting Assets and Liabilities [Table]" } } }, "localname": "OffsettingAssetsandLiabilitiesTable", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "alxn_OffsettingAssetsandLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Offsetting Assets and Liabilities [Table Text Block]", "label": "Offsetting Assets and Liabilities [Table Text Block]", "terseLabel": "Offsetting Assets and Liabilities" } } }, "localname": "OffsettingAssetsandLiabilitiesTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "alxn_OperatingRightOfUseAssetsExchangedForOperatingLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Right-Of-Use Assets Exchanged For Operating Lease Liability", "label": "Operating Right-Of-Use Assets Exchanged For Operating Lease Liability", "terseLabel": "Operating ROU lease assets obtained in exchange for operating lease liabilities" } } }, "localname": "OperatingRightOfUseAssetsExchangedForOperatingLeaseLiability", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alxn_OptionToAcquireRemainingEquityAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Option To Acquire Remaining Equity, Amount", "label": "Option To Acquire Remaining Equity, Amount", "terseLabel": "Option To Acquire Remaining Equity, Amount" } } }, "localname": "OptionToAcquireRemainingEquityAmount", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "alxn_OtherContingentPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Contingent Payments [Member]", "label": "Other Contingent Payments [Member]", "terseLabel": "Other Contingent Payments [Member]" } } }, "localname": "OtherContingentPaymentsMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_OtherGovernmentObligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Government Obligations [Member]", "label": "Other Government Obligations [Member]", "terseLabel": "Other Government Obligations [Member]" } } }, "localname": "OtherGovernmentObligationsMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "alxn_OtherNonUsExcludingEuropeAndAsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Non-Us, Excluding Europe And Asia Pacific [Member]", "label": "Other Non-Us, Excluding Europe And Asia Pacific [Member]", "terseLabel": "Rest of World" } } }, "localname": "OtherNonUsExcludingEuropeAndAsiaPacificMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_OtherRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]", "terseLabel": "Other Revenue [Member]" } } }, "localname": "OtherRevenueMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "alxn_OtherThirdPartyManufacturersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Third Party Manufacturers [Member]", "label": "Other Third Party Manufacturers [Member]", "terseLabel": "Other Third Party Manufacturers" } } }, "localname": "OtherThirdPartyManufacturersMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_PaymentsToAcquireLicensesAndEquityInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments To Acquire Licenses And Equity Investment", "label": "Payments To Acquire Licenses And Equity Investment", "terseLabel": "Payments To Acquire Licenses And Equity Investment" } } }, "localname": "PaymentsToAcquireLicensesAndEquityInvestment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_PrepaidResearchAndDevelopmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Research And Development Expense", "label": "Prepaid Research And Development Expense", "terseLabel": "Prepaid Research And Development Expense" } } }, "localname": "PrepaidResearchAndDevelopmentExpense", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_PurchasedTechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased Technology [Member]", "label": "Purchased Technology [Member]", "terseLabel": "Purchased Technology [Member]" } } }, "localname": "PurchasedTechnologyMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "alxn_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Reclassification out of Accumulated Other Comprehensive Income [Table]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "stringItemType" }, "alxn_RestructuringChargesAndAccrualAdjustment": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring Charges And Accrual Adjustment", "label": "Restructuring Charges And Accrual Adjustment", "terseLabel": "Restructuring expenses" } } }, "localname": "RestructuringChargesAndAccrualAdjustment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "alxn_RestructuringExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring Expense [Member]", "label": "Restructuring Expense [Member]", "terseLabel": "Restructuring Expense [Member]" } } }, "localname": "RestructuringExpenseMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "alxn_RightOfUseOperatingAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right Of Use Operating Assets [Member]", "label": "Right Of Use Operating Assets [Member]", "terseLabel": "Right Of Use Operating Assets [Member]" } } }, "localname": "RightOfUseOperatingAssetsMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "alxn_RightOfUseOperatingLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right Of Use Operating Liabilities [Member]", "label": "Right Of Use Operating Liabilities [Member]", "terseLabel": "Right Of Use Operating Liabilities [Member]" } } }, "localname": "RightOfUseOperatingLiabilitiesMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "alxn_RightofUseAssetObtainedinExchangeforFinanceLeaseRentPrepayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Finance Lease Rent Prepayment", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Rent Prepayment", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Rent Prepayment" } } }, "localname": "RightofUseAssetObtainedinExchangeforFinanceLeaseRentPrepayment", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_RightofUseAssetObtainedinExchangeforOperatingLeaseRentPrepayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease, Rent Prepayments", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease, Rent Prepayments", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease, Rent Prepayments" } } }, "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseRentPrepayments", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ScheduleOfAssetAcquisitionByAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule Of Asset Acquisition, By Acquisition [Table]", "label": "Schedule Of Asset Acquisition, By Acquisition [Line Items]", "terseLabel": "Schedule Of Asset Acquisition, By Acquisition [Line Items]" } } }, "localname": "ScheduleOfAssetAcquisitionByAcquisitionLineItems", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "alxn_ScheduleOfAssetAcquisitionByAcquisitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Asset Acquisition, By Acquisition [Table]", "label": "Schedule Of Asset Acquisition, By Acquisition [Table]", "terseLabel": "Schedule Of Asset Acquisition, By Acquisition [Table]" } } }, "localname": "ScheduleOfAssetAcquisitionByAcquisitionTable", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "alxn_ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Asset Acquisition, By Acquisition [Table Text Block]", "label": "Schedule Of Asset Acquisition, By Acquisition [Table Text Block]", "terseLabel": "Summary of Total Consideration" } } }, "localname": "ScheduleOfAssetAcquisitionByAcquisitionTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "alxn_ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Income Tax Provision and Effective Tax Rate", "label": "Schedule of Income Tax Provision and Effective Tax Rate [Table Text Block]", "terseLabel": "Schedule of Income Tax Provision and Effective Tax Rate" } } }, "localname": "ScheduleOfIncomeTaxProvisionAndEffectiveTaxRateTableTextBlock", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "alxn_SeniorSecuredTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Secured Term Loan [Member]", "label": "Senior Secured Term Loan [Member]", "terseLabel": "Senior Secured Term Loan [Member]" } } }, "localname": "SeniorSecuredTermLoanMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "alxn_SharesUsedInComputingNetIncomePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shares used in computing net income per share.", "label": "Shares Used In Computing Net Income Per Share", "terseLabel": "Shares used in computing earnings (loss) per common share" } } }, "localname": "SharesUsedInComputingNetIncomePerShare", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "alxn_SolirisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Soliris [Member]", "label": "Soliris [Member]", "terseLabel": "Soliris" } } }, "localname": "SolirisMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_StrensiqProductLineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Strensiq Product Line [Member]", "label": "Strensiq Product Line [Member]", "terseLabel": "Strensiq Product Line" } } }, "localname": "StrensiqProductLineMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_SynagevaBioPharmaCorp.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Synageva BioPharma Corp. [Member]", "label": "Synageva BioPharma Corp. [Member]", "terseLabel": "Synageva BioPharma Corp. [Member]" } } }, "localname": "SynagevaBioPharmaCorp.Member", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "alxn_SyntimmuneIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Syntimmune, Inc [Member]", "label": "Syntimmune, Inc [Member]", "terseLabel": "Syntimmune, Inc [Member]" } } }, "localname": "SyntimmuneIncMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActof2017ChangeinTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_UltomirisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Ultomiris [Member]", "label": "Ultomiris [Member]", "terseLabel": "Ultomiris [Member]" } } }, "localname": "UltomirisMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "alxn_UnrecordedUnconditionalPurchaseObligationUndiscountedFixedPaymentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount", "label": "Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Undiscounted Fixed Payment Amount" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationUndiscountedFixedPaymentAmount", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "alxn_ValuationAllowanceReleaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation Allowance Release [Member]", "label": "Valuation Allowance Release [Member]", "terseLabel": "Valuation Allowance Release [Member]" } } }, "localname": "ValuationAllowanceReleaseMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_WilsonTherapeuticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Wilson Therapeutics [Member]", "label": "Wilson Therapeutics [Member]", "terseLabel": "Wilson Therapeutics [Member]" } } }, "localname": "WilsonTherapeuticsMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "alxn_ZealandMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zealand [Member]", "label": "Zealand [Member]", "terseLabel": "Zealand [Member]" } } }, "localname": "ZealandMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "alxn_ZealandPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zealand Pharma [Member]", "label": "Zealand Pharma [Member]", "terseLabel": "Zealand Pharma [Member]" } } }, "localname": "ZealandPharmaMember", "nsuri": "http://www.alxn.com/20190630", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "Security12bTitle@anonymousType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.alxn.com/role/DocumentAndEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of derivative instruments", "verboseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "monetaryItemType" }, "invest_InvestmentLineItems": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment [Line Items]", "terseLabel": "Investment [Line Items]" } } }, "localname": "InvestmentLineItems", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "invest_InvestmentTable": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "This table lists the investments. The line items identify information about the investment.", "label": "Investment [Table]", "terseLabel": "Investment [Table]" } } }, "localname": "InvestmentTable", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "invest_InvestmentTableTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "A table of investments, shown as a text block.", "label": "Investment [Table Text Block]", "terseLabel": "Other Investments" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestments" ], "xbrltype": "textBlockItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r163", "r169" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r72", "r134" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/LeasesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails", "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r170", "r255", "r257", "r412" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/InventoriesDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/InventoriesDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/LeasesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails", "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r171", "r255", "r258", "r419", "r420" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r357" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts Payable and Accrued Liabilities, Current" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r35", "r256" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r81", "r87", "r89", "r262", "r300" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Defined Benefit Plans Adjustment [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r87", "r299" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r78", "r79", "r80", "r87", "r89" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r84", "r86", "r87" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r83", "r87", "r89", "r300" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r76", "r87", "r89", "r300" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Translation Adjustment [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r36" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Information by type of change in accounting principle. Does not include error corrections.", "label": "Adjustments for Change in Accounting Principle [Axis]", "terseLabel": "Adjustments for Change in Accounting Principle [Axis]" } } }, "localname": "AdjustmentsForChangeInAccountingPrincipleAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the types error corrections made to the financial statements.", "label": "Adjustments for Error Correction [Domain]", "terseLabel": "Adjustments for Error Correction [Domain]" } } }, "localname": "AdjustmentsForErrorCorrectionDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r265", "r266", "r269", "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r100", "r126", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r126", "r196", "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r167", "r385", "r404" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r18", "r20", "r64" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Holding Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r178" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Holding Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Debt Securities, Available-for-sale, Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r179", "r180", "r397" ], "calculation": { "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Due in one year or less" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r173", "r176" ], "calculation": { "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleDebtSecuritiesByContractualMaturityDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails", "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/LeasesNarrativeDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r308", "r312" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/LeasesNarrativeDetails", "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r282", "r283" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r287", "r288", "r291" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total acquisition value" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]", "terseLabel": "Consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r125", "r295" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Amounts derecognized upon sale of asset", "terseLabel": "Change in fair value of contingent consideration", "verboseLabel": "Increase in contingent consideration liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration, Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r286", "r289", "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r286", "r290" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current portion of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r286", "r290" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]", "terseLabel": "Assets Acquired and Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r129", "r130", "r131" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r129", "r130" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase during the period in capital lease obligations due to entering into new capital leases.", "label": "Capital Lease Obligations Incurred", "terseLabel": "Capitalization of construction costs related to facility lease obligations" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r14", "r44", "r128" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r123", "r128", "r132" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r123", "r348" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r305" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental cash flow disclosures from investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r399" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. A change in the method of applying an accounting principle that is not treated as a change in accounting estimate also is considered a change in accounting principle.", "label": "Adjustments for Change in Accounting Principle [Domain]", "terseLabel": "Adjustments for Change in Accounting Principle [Domain]" } } }, "localname": "ChangeInAccountingPrincipleMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement [Member]" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r55", "r229", "r392", "r409" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 18)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r228", "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r34", "r238" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 290 shares authorized; 237.3 and 236.2 shares issued at June 30, 2019 and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r92", "r94", "r95" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income and Accumulated Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of receivables and contract liabilities from contracts" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r249", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Net, Current", "terseLabel": "Receivables, which are included in Trade accounts receivable, net" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionSummaryOfReceivablesAndContractLiabilitiesFromContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r249", "r250", "r256" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities, which are included in Other current liabilities" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionSummaryOfReceivablesAndContractLiabilitiesFromContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bond Securities [Member]" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r101" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreationDateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about two or more restatements of a single financial reporting concept where restated amounts have been reported in a prior filing.", "label": "Report Date [Axis]", "terseLabel": "Report Date [Axis]" } } }, "localname": "CreationDateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "negatedTerseLabel": "Decrease to retained earnings", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r28", "r30", "r31", "r386", "r387", "r402" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r351", "r353" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r53", "r400" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Debt Instrument, Periodic Payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r136", "r239", "r242", "r243", "r244", "r350", "r351", "r353", "r401" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails", "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefaultFinancialStatementsDateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Date the financial statement was made available and submitted, in CCYY-MM-DD format.", "label": "Financial Statement Filing Date [Domain]", "terseLabel": "Financial Statement Filing Date [Domain]" } } }, "localname": "DefaultFinancialStatementsDateMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r46", "r352" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Remaining unamortized deferred financing costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r126", "r133", "r277", "r279" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r127" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r272", "r276" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r126", "r165" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]", "terseLabel": "Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]" } } }, "localname": "DerivativeAssetFairValueAmountOffsetAgainstCollateralAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r66", "r74", "r310" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "terseLabel": "Gross Amounts Offset in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r68", "r71", "r324" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Cash", "negatedTerseLabel": "Cash Collateral Received" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Securities", "negatedTerseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeCollateralObligationToReturnSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r68", "r71", "r324" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative, Collateral, Right to Reclaim Cash", "terseLabel": "Cash Collateral Pledged" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative, Collateral, Right to Reclaim Securities", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeCollateralRightToReclaimSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r65", "r73", "r310", "r381" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Gross Amounts of Recognized Assets", "verboseLabel": "Asset Derivatives, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r67", "r70", "r75", "r325" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral", "totalLabel": "Amounts of Assets Presented in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "auth_ref": [ "r69", "r71", "r323" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against an obligation to return collateral. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Fair Value, Amount Offset Against Collateral", "totalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r65", "r73", "r310", "r381" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts of Recognized Liabilities", "terseLabel": "Liability Derivatives, Fair Value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r67", "r70", "r75", "r325" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral", "negatedTotalLabel": "Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "auth_ref": [ "r69", "r71", "r323" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against the right to receive collateral. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Fair Value, Amount Offset Against Collateral", "negatedTotalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed interest borrowing spreads", "verboseLabel": "Derivative, fixed interest rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r309", "r311", "r316", "r319" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r306", "r309", "r316" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r306", "r309", "r316", "r319", "r320", "r327", "r328" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Estimated gains (losses) to be reclassified from other comprehenisve income in next 12 months" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r315", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r67", "r70", "r344" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]", "terseLabel": "Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]" } } }, "localname": "DerivativeLiabilityFairValueAmountOffsetAgainstCollateralAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r66", "r74", "r310" ], "calculation": { "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Offset in the Condensed Consolidated Balance Sheet" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r140", "r302", "r303", "r304", "r306", "r307", "r313", "r316", "r322", "r326", "r328" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of revenue from contracts with customer" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per common share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r99", "r144", "r152", "r154", "r155", "r156", "r159", "r395", "r411" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Earnings (loss) Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r99", "r144", "r152", "r154", "r155", "r156", "r159", "r395", "r411" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "verboseLabel": "Earnings (loss) Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r160" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r348" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r139", "r273", "r274" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionAndEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": { "auth_ref": [ "r273", "r274", "r278" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deductions. Including, but not limited to, extraterritorial income exclusion deduction, qualified production activity deduction, dividend deduction, deduction for dividend paid to employee stock ownership plan, Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Deduction, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Separation Costs" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Equity Method Investment, Aggregate Cost" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r45", "r168", "r183" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r25", "r29", "r182", "r390", "r403", "r417" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "auth_ref": [ "r147", "r148", "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error correction.", "label": "Adjustments for Error Corrections [Axis]", "terseLabel": "Adjustments for Error Corrections [Axis]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r391" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow Deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Asset-Related Charges" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r332", "r333", "r334", "r335", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r337", "r341" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Fair Value by Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Acquisition-Related Contingent Consideration [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r333", "r341" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r260", "r261", "r263", "r334", "r377" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r339", "r341" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r260", "r261", "r263", "r334", "r378" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r260", "r261", "r263", "r334", "r379" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]", "verboseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r260", "r261", "r263", "r334", "r380" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r337", "r341" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r337", "r341" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule Of Acquisition-Related Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "negatedPeriodEndLabel": "Balance at end of period", "negatedPeriodStartLabel": "Balance at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAcquisitionRelatedContingentConsiderationDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r308", "r313", "r327" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r360", "r365", "r374" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails": { "order": 2.0, "parentTag": "alxn_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance Lease, Interest Expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r362", "r368" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails": { "order": 1.0, "parentTag": "alxn_LesseePaymentsForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Finance Lease, Interest Payment on Liability" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r359", "r373" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance Lease, Liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails", "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance Lease, Liability, Current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease Liability Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance Lease, Liability, Noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "terseLabel": "Finance Lease, Liability, Payments, Due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearFive", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "Finance Lease, Liability, Payments, Due Year Five" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearFour", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "Finance Lease, Liability, Payments, Due Year Four" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearThree", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "Finance Lease, Liability, Payments, Due Year Three" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearTwo", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "Finance Lease, Liability, Payments, Due Year Two" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsRemainderofFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Finance Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": 1.0, "parentTag": "alxn_LesseeLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Finance Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r361", "r368" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails": { "order": 3.0, "parentTag": "alxn_LesseePaymentsForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance Lease, Principal Payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r358" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance Lease, Right-of-Use Asset" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r360", "r365", "r374" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails": { "order": 1.0, "parentTag": "alxn_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r371", "r374" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r370", "r374" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2019 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r197", "r199", "r202", "r205", "r383" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r202", "r383" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r197", "r201" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Licenses, patents and purchased technology" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign exchange forward contracts, asset" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign exchange forward contracts, liability" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r345", "r346", "r347" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Unrealized foreign currency loss (gain)", "terseLabel": "Other income (expense)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward [Member]" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesOffsettingAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r309" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedTerseLabel": "Unrealized loss (gain) on forward contracts" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r314" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Gain (loss) reclassified from AOCI to net product sales, net of tax" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r190", "r191" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r192", "r193" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, Gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r306", "r320" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfInterestRateContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r138" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r0", "r2", "r3", "r4", "r5", "r6", "r7", "r8", "r10", "r11", "r12", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r133", "r166", "r280" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax provision", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionAndEffectiveTaxRateDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r125" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses, lease liabilities and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r125" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r125" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r125" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r153", "r158" ], "calculation": { "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "verboseLabel": "Stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r195", "r200" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r97", "r164", "r349", "r352", "r396" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense", "verboseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r260", "r317" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract [Member]" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.", "label": "Interest Rate Derivative Assets, at Fair Value", "terseLabel": "Interest Rate Derivative Assets, at Fair Value" } } }, "localname": "InterestRateDerivativeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest Rate Derivative Liabilities, at Fair Value" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r59" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r15", "r62", "r186" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.alxn.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventory, Net", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r61" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r60" ], "calculation": { "http://www.alxn.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r103", "r104", "r105" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Investment (expense) income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r413", "r414", "r415", "r416" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r413", "r414", "r415", "r416" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Investments Classified by Contractual Maturity Date [Table Text Block]" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r182", "r384", "r398", "r418" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r372", "r374" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease, Cost", "totalLabel": "Lease, Cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails", "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Related Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails", "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Liability Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails", "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearFive", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearFour", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearThree", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsDueYearTwo", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityPaymentsRemainderofFiscalYear", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r373" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit, amount outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r40", "r388", "r407" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r28", "r386" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Revolving credit facility" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r31", "r233", "r387", "r405" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Outstanding debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, less current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r232" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss Contingency Accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r16", "r50" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r260" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Bonds [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r161", "r162" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/Business" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r123", "r124", "r127" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r90", "r93", "r98", "r127", "r158", "r394", "r410" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss) used for basic and diluted calculation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r143", "r145", "r146" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income and expense:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses", "verboseLabel": "Distribution fees related to importation expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r366", "r374" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r359" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails": { "order": 2.0, "parentTag": "alxn_LesseeLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r359" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r359" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r363", "r368" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails": { "order": 2.0, "parentTag": "alxn_LesseePaymentsForOperatingAndFinanceLeases", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating ROU lease assets obtained in exchange for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r358" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use operating assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r371", "r374" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r370", "r374" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Three Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r354", "r355" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "terseLabel": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesFinanceAndOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r13", "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r308", "r327" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets [Member]" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Other Commitment" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r297", "r298", "r299" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gains (losses) on debt securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r82", "r84", "r297", "r299" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Unrealized gains on pension obligation" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r297", "r298", "r299" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss), attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r297", "r298", "r299" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r87", "r96" ], "calculation": { "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Unrealized losses on hedging activities - tax effect" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r84", "r88" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r91", "r94", "r297", "r298", "r299" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r77", "r84", "r329" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Gain (loss) recognized in AOCI, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r308", "r327" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]", "terseLabel": "Other Income [Member]" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r21", "r22", "r51" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r308", "r327" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other Liabilities [Member]" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails", "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r54" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r127" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r105" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income and (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": { "auth_ref": [ "r129", "r130", "r131" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Value of Consideration Given", "terseLabel": "Fair value of contingent liability related to strategic investment and purchase option" } } }, "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r110", "r114", "r141" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Payments for (Proceeds from) Other Investing Activities" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r118" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r122", "r214" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash settlements" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r120" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r121" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "terseLabel": "Payments of financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r108", "r111", "r174" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Payments to Acquire Debt Securities, Available-for-sale" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r112", "r292" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Upfront payment for acquisition of Syntimmune outstanding shares" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "terseLabel": "Payments for exclusive licenses and equity investments", "verboseLabel": "Payments to Acquire Equity Method Investments" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/OtherInvestmentsDetails", "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r114" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Purchases of strategic investments", "terseLabel": "Payments to Acquire Other Investments" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Cash paid for acquisition of Wilson Therapeutics outstanding shares", "verboseLabel": "Cash paid for acquisition of Wilson Therapeutics outstanding shares" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/AcquisitionsNarrativeDetails", "http://www.alxn.com/role/AcquisitionsSummaryOfTotalConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r113" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment": { "auth_ref": [ "r114" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "label": "Payments to Acquire Trading Securities Held-for-investment", "negatedTerseLabel": "Purchases of mutual funds related to nonqualified deferred compensation plan" } } }, "localname": "PaymentsToAcquireTradingSecuritiesHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DefinedBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfFairValueOfOutstandingDerivativesDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidRent": { "auth_ref": [ "r17", "r19", "r188", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Rent", "terseLabel": "Prepaid rent" } } }, "localname": "PrepaidRent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r116", "r137" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from Lines of Credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r117", "r121", "r141" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r108", "r109", "r174" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturity or sale of available-for-sale debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sale of mutual funds related to nonqualified deferred compensation plan" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r115", "r268" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Net proceeds from issuance of common stock under share-based compensation arrangements" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r26", "r27", "r207", "r408" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r87", "r89", "r96" ], "calculation": { "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r119" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r119", "r137" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Repayments of Lines of Credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r119" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on term loan facility" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r198" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r271", "r421" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Fair Value of Assets Acquired", "verboseLabel": "Research and Development in Process" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Expenses" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r213", "r215", "r222", "r224" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and Related Cost, Expected Cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r213", "r215", "r222", "r224" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring expenses" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r126", "r212", "r218", "r223" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring expenses", "verboseLabel": "Restructuring expenses" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r214", "r220" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r212", "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments to previous estimates" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r212", "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "negatedTerseLabel": "Asset impairments" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r245", "r406" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r252", "r254", "r255" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Total Net Product Sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r142", "r259" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.", "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]", "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]" } } }, "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r369", "r374" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right of use financing assets obtained in exchange for financing lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r369", "r374" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesAvailableForSaleInvestmentsByClassificationInBalanceSheetDetails", "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Other Comprehensive Income and Earnings from Foreign Exchange Contracts" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule Of Basic And Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/EarningsPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule Of Assets And Liabilites Measured At Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r197", "r201" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsAndGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Fair Value of Outstanding Derivatives" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Non-cancellable Operating Lease Commitments" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Schedule of Interest Rate Contracts" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r23", "r41", "r42", "r43" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r216", "r217", "r221" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r216", "r217", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r56", "r135", "r235", "r236", "r237", "r239", "r240", "r241", "r242", "r243", "r244", "r245" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r102", "r185" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r125" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r167", "r194", "r209", "r215", "r224", "r412" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RevenueRecognitionDisaggregationOfRevenueByProductAndGeographicalRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r32", "r33", "r34", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r58", "r238" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesNarrativeDetails", "http://www.alxn.com/role/DerivativeInstrumentsAndHedgingActivitiesScheduleOfOtherComprehensiveIncomeAndEarningsFromForeignExchangeContractsDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeChangesInAociDetails", "http://www.alxn.com/role/OtherComprehensiveIncomeAndAccumulatedOtherComprehensiveIncomeSignificantReclassificationsFromAociDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeStatement", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r238", "r245" ], "lang": { "en-US": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Gross" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r33", "r34", "r238", "r245", "r267" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r33", "r34", "r238", "r245" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Gross" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r58", "r238", "r245" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock Issued During Period, Value, Stock Options Exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r38", "r39", "r172" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Stockholders' Equity Attributable to Parent", "periodStartLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r248" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/StockholdersEquityDetails", "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/StockholdersEquityDetails", "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/StockholdersEquityDetails", "http://www.alxn.com/role/SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r393" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "terseLabel": "Trading securities. fair value" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r57", "r246" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r57", "r246" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "periodEndLabel": "Treasury Stock, Shares", "periodStartLabel": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r34", "r238", "r245" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r57", "r246", "r247" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 13.1 and 12.7 shares at June 30, 2019 and December 31, 2018, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r238", "r245", "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement", "http://www.alxn.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/BasisOfPresentationAndPrinciplesOfConsolidationBasisOfPresentationAndPrinciplesOfConsolidationDetails", "http://www.alxn.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityStatement" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementNarrativeDetails", "http://www.alxn.com/role/FairValueMeasurementScheduleOfAssetsAndLiabilitesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/RestructuringAndRelatedExpensesNarrativeDetails", "http://www.alxn.com/role/RestructuringAndRelatedExpensesScheduleOfRestructuringAndRelatedCostsDetails", "http://www.alxn.com/role/RestructuringReserveRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r260", "r389" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "US Government Agencies Debt Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/MarketableSecuritiesSummaryOfSecuritiesHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r126" ], "calculation": { "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized gain on strategic equity investments", "terseLabel": "Unrealized Gain (Loss) on Investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.alxn.com/role/OtherInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r227" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Remaining total commitments" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r367", "r374" ], "calculation": { "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable Lease, Cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/LeasesLeaseRelatedCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/DebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r151", "r156" ], "calculation": { "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Shares used in computing earnings per common share-diluted", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r150", "r156" ], "calculation": { "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Shares used in computing earnings per common share\u2014basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.alxn.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.alxn.com/role/EarningsPerCommonShareSummaryOfCalculationOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r13": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77904769&loc=SL2265659-115463" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130533-203044" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624186-113959" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r418": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r422": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r423": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r424": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r425": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r426": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r427": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r428": { "Article": "12", "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12" }, "r429": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Sentence": "Column A" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r431": { "Article": "6", "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(c)", "Publisher": "SEC", "Section": "10", "Subparagraph": "(1)" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 124 0000899866-19-000087-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899866-19-000087-xbrl.zip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
1C%#_ BWN,W9=(;O=8 9BNEV-E^O3M88/M(CH5PZ:CB*KTEX79"W M>Y7(N68CNN_1&^/K05/[U&I;,/;W91;+(.9W7]=Q_=JO..6DCIU95>N=" HA MA9@I;PW%&!@-2LN$AU_J6V^=K>8M:/3N .KK/?][-KNY#;*H[H-=7_8 M#2Q'.TWW@I3+)>G82(D02'#L$182 6&U\[J,V>8:V/KQ8JVO+P/*4DOH/4I3 M!QE2;/;E6/6-W3,;#6VS53J;#Y=<)<[AW2)&-53-L'*D1T(]UXY8S9#$4E(M M( DV! [: &E-226)[X/&<[E6#K1.*'982\-)6("-YTAI:G>T,8 ;.(%:3KC2 MF#=YVUBD8Z[^\3UY9TI_O&R0ZV!\6('18S2[]-@N.BF<2.V MGA21&K#T90M\/]'?TKOL;)F'8UT2K"$QF KHC0X6N0J_F!V%@E*MQGE%N0V6 MG>1^8X3>HBP,(P-G*GZ,001:\B.8(IO.5NJFR#8KR.G,'P<;)SC,,&RE"208 M20D$L!Z5,XWI:L:S\6L/]+QE5'J[=+R9JT\GFQCK,VOVR\:)<=A7@)(JX7F?EXP'6[,;PS(,L\_JZ$/--P5)@XU+@W830EBE,2KUFE1>R7&O MU4U8=9+KC=!Y2_P?Y?H\--N'8??'[#Z?W\>K%=_-^>B27JE?8JUT*! ,J,#< M&"&<8B6MUJ@15NIJQK*7^49: Z?^84^VF.7%IEI'-OV<%7?O\W1QVE0[T271 M-EH@BF@D85CV) 1F/VNA>/V#^LY.[UIA:.**8E<9"[AG7!@BD94F9AZ3^M<7+(U(',]M: &8HEI]=N@]W2+"+RQV5 M7.- %1#,(KVC3G'*X;B-MV8,.\/]1@B]-3D8I1$W!O8/Q/;9(KNZWJYY9ZVW MEXV36!V!,&6%,B"8N@9!6RZ,*A!HQV>R-67/#P]'M7CVR[K^6/9K@.]N?7>2:=^U M29!'B +M+ ;$6TUT)']W:&]8OZ7DSZ;T_;)(0A:S>Y MC 2%\58P0W(_=ZU&Y)QHA6\-:._+'/V/M)C%-?QCNCKG?'C>-+%$82PM@(1Z M2B2R@KI]Z(RP]<^++K\3,ICCH2$H0[#Y[$;S9>.X-0O*QCL@.85(&BU9::QK M+]%(;9WF3#K![4;(O!6^C\H^&@.[AW<:1?PS>KAXKN MAG/#))XH *T4A$G' R+4.K5#PFC7("UU3Y$A[QN'@'8(US#17H&(;)O"KW*T MUV.7Q$,<[!L+%=1>A_54L?U;9IP@]4.%.CMYZC8FN#8TM8\2OW_^_UFGQ2HK MY@\?TH?X^X=@(85_TILLO_Z/JS%JZS(I@[V\EFFZF>SIUWI$Z,,DY@ MSPDMG5C6 E"I\'2_EX_;MQ7:0&88.S&L7[-\.IOL]%AE8_%9OT1#)X$4&$/I M%12660U+6J%Q]=V!G:7-[=9B;(9/GX$+GW?GN6?"%F-LM@I6ZK+RS$%8Q88RBVQ M>_WE+6_@/02OA>L-,4F[O;\?^F337:JZ#_-T<>RR??/K_,7L?E.&Z1';6!W@ M;]GT)KX D_!5&#(;_/F_I<6V7-3PR0?*&;^OE'C@1>N$<0UMD"\C%:71400M M!IHS;BBS0;U4>?FZINU\PH'O6B8<*FZ(-PPKQ!'"BAF[I8EX!WO-278FV4 # M?KPP$9M@D/:89*!2T,"N/OM5L:OC>2)8[E#3A KOF:" .2D@XSC\O")#=])X6:3UZYGBR?5AMD92.J+@@*JF!Y5KNWI5 I['C M/&YNSJ*7O&X-G+?!^%&=-X^$WRT='OV6K79S^)3.L^7I&V@'&\):0CQO&9+^-G63>;I;VZNE:3R?IN/4]7 MNUJ5,=E9D=W&E^!^EP_]3(18DV$3&A9$2B! E,-XF]=IY?:@,UK_&EOGV0>: M+>P#@#=V,3L;J=1LX$023;@BFD;;6UOD(=N_W]PI/4[SHE]!:4DZ&R'^+SD] MC=JHK*&W+)ZO2RPK)(5H,G 25K%@R&"C?6!3@$= HW9H04^"_>V[$VBXC;&6^/:\ M_D"+2+TM:1BER3,F(1@H1/!Q4?LES#(613+I\M;/\S_C&5M-;]6[Z( M)PX!X/FF)M.VI-I9BZ65\1./F/ :2^9!L"6!<%* $CMD&Q0QZJZD33,9>!YR M. "*_46H'3CB+:G4#[N3WH_9?%OE[W;V]6Q2ZSH#)L!@' #Q5 >("%+61/?? M!AVD":P?V-IY7H=V#)E>8.M+J [,]NRZ=K1/HIF$DD-F/ [&O)3>X')SBR"P M8-R63M>,S;N%\6V*S"C-H5RVPPBX@AB0B M)6T6P%[3?E6S95K@T_/\K2T@,Z1]\G&V_*.&%5)V2R ,YA9%Q C*!:*2\?WA M(N*,U#\M[SP!0W>V1DUP^A>#6'LZ%BFLE/OO5+=$06^@=QCJF))>:$HL+2DE MEOG79U=M9L M.-4M, Y77[/%KE;YZ4BL MBMT3$NPH:)5"@'AJ"*.!HI(:[,=4=;$3CG>(56W.EWZUF%[FTY_IUZO%&5X? M[9!0#XG51EL'A ^ <.GV,P9$UK<$.TRWT#9WVT*G-7Y^_C._C)_[#@DAAL=, M &'62*NP'_)F/V,J>/W(CPYS)'3-S[KH]+5./YUOB<'95?IXIT0K%!8>1U@0 M6BRI!ECH'94$*]7G[F[(-;HUA'KV -IL&=::C:OCS![_<(?$8N8!19XP[@3" MC&M6VA\D*)X^"[0/LKMO!9;AF%[5Z_NB2R*U%TXI8[R'CGCBC$8EA<8*,N[] M?%.VG96"1BB]17D8Y>Y]+&(PE!-G.\]LJI:[J3\Z,3/RL.!UHGP''%";$&6Z6- MD0()7])EI:VO$SK;SK?._N:P='DGLGHE$$B#]0IPT(>*<0^\E&@OHDC;^F_R MY5F0>K_17!>%SCE7N8*$TD(:$^L# @(!Y\:R-U(,V/7Q/Y(*8EZ&+P> M'H[*P.J7=?VQ[/(J( 0*9+S32$/K 7!2LO(,B"+H>BU?>UDUB!:06WQK0WI_K,EX[VH>QO\\G M5?Q6)WHEL3815<0APY5Q2@<5!4LZ@>3U[=/+$_X-XKQJ#YN!9>"LV^)DO\0! MPG38Y&MO.0C;?4NH*6EE&IEQFD>MKD* MR!3NV^ZBF%HNL_!G^CG]=D(N:HR60&"AY1HH22AF4H8]S1X7JT6OB\*EI]_O M&R=][!ZQ4=S+>TR0D$TCK4]S(YAWX87)MZ^BN[[.8H[6[$.LF9 OSA4=Z.:1 M"?5ANP<.CN"Y3#LML\E?;O+[@,-]6%^C M;L*[GZ,8X"=::?OI$\I_RR/:Z?QHAOLS/1*%&?+"L;" *XXT8<26,4@\?C7F M2+WZ;&\7E9&M15MK[Z46^USJL.5J=A<_"\IK2^_G7&>?BW2QW-9T:;XV-9Y" M8B5E0'I*E-;0!9M X3)&DC-HZJNC'J('>UNK^H:Y+T$O*;U:^'16_$; M! ^1]/QF,?M'-GVW<&FQ.%+\K]8X"5%,.J4)"*SAD@5VH3T6RN+Z?OT.BSJU M)W)=8M6_@O2S;W&^CZ&WE73:BUX)#%L0KX$E##CH+ !*/;X?#-170QV6>.I" M#35%9B"73W5G3T*#_>XA]YYHHS"F!NG=20D5W(KZF9LZ+/'4'J>;H?'(W4[* MO%0L?G)U?;W,5JN=6V'3YOTL_1+K&H=OZU=$.;(?>_ZX]+O'O3]1]N22[@G" MWKG 4P AXTI3YZR/TLI^I6G.".^ED HIA@36BFBROSN%"'>@SQS] ME0[FV^?[)4DD+D/K-:<(<(Y:%O[GF@(DA2$4T/)]Q-RC<1_4M\/$2W(%U,/K M+4O(*(_IQR<8PPA$%TDDG%.>8"\-M#"LY?%0%#TNX7C41W1-&'=)$HG+,.I? M/6S6T[W#8NOCVJZVZB: LER9?!Z]8D4Z5U^6&\@JZ8\:XR;6>B8 T@!Q&JMM MPK"0EUC!\.-XY*E32W<(, =P,)7DQ+JHWQ%:S=-TM'O"%"$N5F4%6"@DL7-V M=]*$F#2\4N'+H=12IYP^[IQJ"\RA]=DD[;P_98?0["ASCHW? +#>RBU4 !JCCRQ MG'-<(A>+R(\YN&!L.JUEL(?8TI53O?HRG]ULSC _YQ^SU;I8?,HFZ^*[4MIG MMGE5ADJ<-T'Y4T$1$$R&98 26R*BI!YU.J)AQ*\38,URG3VF]Z7"4&KI*5)AQTYY MV*:5&S4F'*@?WME#_,(X%]EVD.Y?.O>D9IC)XI[P@QR"EBGF<7&D9); MG!%2_WR]];U(S]Z1?@ =B8J\;'-[>HC$F!AO+1A64BD=E %#Y2+!-26]UA>] M/&2C8ZY?IO3J@CH&W;;9I5=WO9T:(+$":.9%L&,YL 0)%JM3E? J.NHTP\.) M5(N0CDU/=>Z& 1EPBZL,J,V7LR5CW7,NA#;FT_ MSFYN5W'W-)FGL[O:'I1CPR2!=JL@4M)0ZB#@WIG]BB 9JB]^O5P1&4K\6@=V M/")6PW/RIT]IN_#CAXC MHX+*MU08Z 0N(YZ1L([6%\=>;G^,>9%M!_%QQ)A_FMQFT_4\D/N$\JOU:KE* M%]-->M!RH 8!YVV_=LO]7-^?B$JOU"^A7CEOA:!0:&6PAU3O8LXPT5!5"WKM_:$*UH<9SAAW@ M1",+47GC&#D.>\T@<3!1Z5-A9@1QUAOT=)/VPVVR9>##T37G^T3^*) M1P32>'Q,N B_+7+#(-\T,=]!K!=E/1N#+)R3'P;@MQ;?.W><-AXNW_-TN6Z MR*97BX]QNU($:'2ZG"U_7^1?EEEQ'[%YM_BZ7L7+H8M)6.QW^#X2>S98NZM' M)@(@*A0BB#JBN0<&X-+AY!$6(TUIW*+D')/%<0#]+Y%N'^E1WEUX0Y(\C 2W M79$+.HTH)PS%>R->6:-HN=WS$.H1UMP8GN'5JWE=AF[O6E _.@?^-@O[[V)R M^_ ^N\_FU*^$(F@=8M 1(+PWU@!9NKN UV"$E[X28O9O_80%!AXW:NR1"_ Y^I;'IW9GUV)0BL #20(%ZN&$UT3#HBT3(KP!GB/#.9(E,HU_.?J M+Q6=W;GO7B2:HM277'PHLJ_I;+JK91/O\3U5MIO4SRW=V0;X#6>D,K[ZDYN4>[,Q&]G"'L/MGDF!%H10,HT EQ:ZD M3A!>W\MY^47BU[Z-;07AX>3G[%;E6)EVBJ+(=J_(T!" M8%A*(2OIAI34KTW9V0:V.0M?G*.U#5-?XA&LZNE^\F?%X4#KA'(-#**42LD] M8,["/6;$"3FBA)J=L;\Y+/T?IW=7.,0X8:C#S!B-#0;(.5XJ5B* K>_%Z.%$ MMQ27NH -$9?Q3,B7 MZC&E=L4@C1,C)"Z\)%8:%:]Z.&XM@Z3T!E.%8?U;4#VDH6Q38+K!ZU%>QI'? MZE!@RHAR6KV_*)/5(],QE"2>9 # $.%,&F35EBE$:&$KY8SNFK9S2:>>M4R< MP0(S 8SA(*QI5C"[$S1"-41]'FM6S!15@Q]'M78=#-(>DSHMB]43(0B_/1> M\%'R,0;\'/$W?O=]8HC"SA-K*0;*,X:Z=\ M2[^=Y]O3-H%ZRHCFTG#C*E1FN"M.5: M6D81H(!16E)G+1AMSJ"FIDRKL+S&XRS!N>?<$6DUTEK3H(U*HY\9*$9^C[TI MVZJ>:]5#Z2W*PZ@LJK&)P5L]WE2:$RL5]T!$UQP!&NR!A+Q!!%[_QYN565CC M>/,RF%[SE75O#72&*R.PX4@ H3C8430:E+&CQ"NK!MYKK]VF'C)=>)Z>+UE"1FE.3$^P;A4(.*14V2S! R# M#9,WE52?'B1]^C/]>K4X[FH[W2%A4E*JM?.4A%DC1I2&>QA4OXQMX9YP90;D M':#3&C\_A]87=E-8@;A"R&!,-RI*?1 ",1WAYIGN>UH;GLI5XF4W^6_Y1'M=+ZMVG6 [6=Z)))9QI$""'L5UBI-N-[3 MY1D=X8ZMC1/I=E$9(-)L]BV;/I76:L%ESWLE_W][[]HDMZUD 7[?'W,'[T?$ MQD;@Z?&N;"DD>V_$?F&4JZGNFJDNMNLAN^^O7["J6/U0/5@D :);GI@K2]T$ MB3QY "02B4QM"0/4(BPTQ!A1[>D!-\E8]W#D)*63AXM'Z(M,;H% NVM2?Q3H,>':K7Z<%44T;D7%,(P MHSUPT'@#+" 8BB:@U"OE6_DP1T#@<&GK;E/:QRS%[D3AM"(&6PO"GLD)+B!R39RF=LQU/S",%@XU#+%:N(NR0#QE M\-75@V5;3G>UFGV=[43_N%E__*JFT\W]IJY;>G-R-CSOV.SSV@)PHQR2F$E% M@$#.6*P:>(ERK6(6QPWYRH>!U6AZ2679=17IHL^MWXL+K*#RWE.OK+=04*/T M 2V+6.9^VS1$&8B=O1#_AZ?G4_P>Z?FV:'GQS+O?B^O;1X@A2)T0 2_- M$#KD8C(,F)1&0,OM=2IZ#,3*3CBG8N7!(')_;F;KQ[K[U6*[=S]O=YYM5U!N M("308.B%L)9*#D$CJ_2R.Z>2!>!E:U@."7PJDKWJZL6%]NCSA<$ <(=Y&+?8 M^["8&-=0WJIX2+TO-F1I3>5$@G&4_VR];.95,UG=^7GU5SV[ MUDOF?',3)MDZ.USMZJWF\VUTVL[M?=$8&N3]!:$.2Z,H"DLU =AX[I[6:J(R M+&CV= W-]RZ!GV M" "B**;.&. PD-HWDCJ5>X6^891X30Q:-[S>,T.R-(CR(\8XA(A1_ 0K!@16 M1 $DB5,*4-XDK+(2N0S3N VCN&N*GUR'42HV#%T220A)!<#(4H29(E(RUI1X MLB3K0I#H:!"U9FUM/94P2RP @MI//9&4:> ;U97I[3),('H0'IY?7;3 M&9/4EN>^VD)KH_/%\X6P.)A1DBIA@(2(:@B:C9OS1F1X]2:.OH= 9TRWZ'D+ MJX/#]/(+"PJ]XY0@" BU! DZ6W;/"'? MMRD@YI1*+.JP$*=X&)A>'&14 N5MM,96[/&,(H/!^#XIDZ4-^V:8,@Y#GA]R MAGY?-'^./E\PXY4/?P!D'&, V[ I:"Y6:*TRC*@;0$_5\,BDB\S\5BXV97W9 MK'$+_GNVOC.;U3HLSTOW]_ZPN\[$'?[_YK?)WV?#,:]^6\&"\2\5@$A1BU0] MPI XX,+2[H>O==!&N6,4'\21=E3M]U)%G=J="NJ$UY@RRI Q!WGJ89/?+BHR M*?H!E$KAI\* ?U\LR\E\]I^GD)J/BV=U!-1RMJIS?&V6X<]/X>?5C2Z_5LOR M_&P3X6N%58"'A5YH;)3$5A/@FFO%X1>P^_8]09:%*,0;'^2QR?M=!%@C\.N@ M>/4UC-%NE+WZ&X7EA%%GO(">0BD9 .R H7&R.U&CU4<=B:BQH]U[44VW7ZZS$RS6L_7CSXLPE._W;L+=[R)]NLF&\&FKV_MJ\>5NLBR3 M?NS7R7*Y5<'YK MQ/OYE>%A ,;U,W-;)*A6D_E/RVKSL#J$+]?/A.W%+&PU;CX^E,O=[O=#B^0="7M1:"Z9 M]9(Z+IQ&!$JW+S2IC>9(M KD>JNZN)3^(U$/"LFP% )3X 71W#LD]^E[M&'U MHIAPAWXV]T>6O#Q_Z)V)SK+.'O)E\\>J_'-3WQSZ%OZH@^$N7= \WJ( #%(M M!*"&&BZ0D);S!A2KDMY"O^I\+3O2O#[;'P3O9#$%](1J;PGU1FIBM7?$'/H, ML.AN,$3.Y9"KP= 'W>B,:%VKT&N!E/:2.>7J(F)(F\.XE4=GV]29WL M4?5V=;U)[3S3F"AG(>%8$:'VM3)#WZE6&=W"&T1O/62/J3=3YTXOEP^3Y?KQ MU\G)_*JG'BT4JBTUYST3'BG L":DD<0)TUV+D5,]Y&P.#0!TU%6U?-@LIW>3 M5:ENE^46OM<]/KE1OJI](2F#AD( K 30S:C6=E6%*/7TU[MSCA7$V=$HBZ17TCDJ-G-GW M5E)',\K6$$D+U> @I?*:U>ZBCU_5?+PR"N#9KJ2< 6\P M8 ?9+&?97LW/U; 8$NU43'K6RSK"Z=> V]-/?@M_6TVF6T@NY\&[[DV%%\!@ M2)7D6A!GL#1"-G@ J4R>EL= .GZ=_2X)=O]P*BLCY6U0:1P*F6H>Z%#MXK^> MB73Y?M39AD5];Y4@RY1U3(;E'%/I#](*D&'9S6CZ?'U]:DC@1LH5$L$2N"[S M4:0.%(02R[C"7""*#5+*D,;YK+B"MC-M(U]1S]U2RU)]R?(O7"/'64]"SS<6 M5E@HO"$42ZR@(AU#H:D2OF'O*]QRM+F_$$YFP%7S^NU.6_=AVP;"X9\"SZV:_8VT++#@6 M7E-HL:USEW+LFHV%%M!E7@QE,(VV9THOW'X,SF2Y-N9+E8'.C^H4%FLU_7,S M6VUQ-=OI\W9[HA(@NMG/H;_,YN5J72W*3Y/'K?OAU %3U_<5F!%D$822*B\- M!E##YC1.2]!C^4J5I3&KRTXI=='][/+)S10TUISD_?X0H%ZL]YTY>9#9HFT1 M[$P2;$N'&&3>A.$8AE C!^:V>RAXJDR0^7$J NZ=^?-T-?]P97@K<^MPEB9:0)'L6Q8$^E9VD-ZL@ M_FIEJOL_9HO)F:GUN; M _+Q0][68'[^>:/)A-OEC-I^M'^$9:RM1#XJP MA3:64H6A@)IY#[1K]DQ&*MO]WG&T%"UB2FA$T*]LEF'[V? &=TA8YB9 ! A&.@6Z[T3[AT0;DBL4_'H M<[DJP[?NZMQ @?'SZJ&&]7+^Q;/MPIB!3!&O.-&.0T(($HU%;1 VW6,5^(_, MJR$QCYJ$[%A*I"_3N_)F,Z_#A9ZV^-LB#F%Y-I[W MHMU\#$),-\LZ:^$NQF79_+/.N;6JVV^%^:VB))*0^B$*MPC+>%.J7W9=D6P3Z3V3F)MJ/: "B=8 M Q"6*&6.BJO.:O-@S2DJ#P!U*BOQT.?S^&T!^WU1_;$JE]]JD'Y>/&S6X=?5 M8AI:[>NUO)3ZXE%=]&\7&#,''7'>(6:1I]@CN\><245LWL?# _'I%$LS0_T? MQJ? /LO#[?=*]*&.QMMNJ\Y?N;SR-85DQA*(*238*P$@0,XWT@&>8_ZJC#1> M)0,^D_18P &F$2+04Z(\<42AIL]>/BO&EEEZK*P,R3Z0YI-/B9@ZVM4X: PR M'(:_&GX8(]*Y/(VNCMB?2*S4#8.WH\.LS(BTJDNGLNMS8EDGPYQ#% #20"N1[I M+B+GT7+&/3M:6WTO1GL?0YOW%,@PP3725GB"+;36,7@8?3KW"Q1# M*_P4GR)"^6/3*RL[\DVR:F0V;5TGJRTH^&(>C#.M"N:(QE9+JX+A[CE6XC#G MOL?WS5ASV[MU>:.^!=;?EKO^F,G#;#V9MV3)N5<46#@K*5.* M:ZD5XX(YT4CEB-F70<#KG:'!-5?@]]L./&= M@@4;@1A(.'..>F2P?L)2>-A]WHMV=2<[_N:@F+='\O\. SP)R^L/%'T]A!R'QX6^&$%=@R(&TPCS"2&I@# M+LRJ[G0>,[0I_\MWM#N*.(03/RC1_KN9S7RW_FBQOV@?<3O6@7@K(E>D9Z&M-[^._9^NX[&5A%." +9;==Y&IO \C4:V% S.U,45K+53BA?/%/< MAMU%Z1A/C8%AM4& <2AEV$;M+[L[)(5Y5U=?.[ GPCW7+KBGO-2:I/*DUD@( M[! UG").J4'6->([BE*&)B>/F+N2 )=J2UX'9=3H]&0E V% #4%A!&9 .*^] M4ON4D@X#:7R> 6_]5=BI=F WL'X,HF05NI8I/P8*-AFHMJ33!BJ%$5166J() M(UPVO<7()RWT/F1MR=9::%-;\CJ04OD5AJDM&6PVKRD-6U/B/<&. 4P;V3C5 M*=/POA'384@\4W%EO$I_UFG,D=$&6V&)$<0JW. A,7R3U2-;Z[AGR;]NV/W# MJ:S,D+=!I7$H%*MZ)+><"NNM@!X"0%Q]_ZZ1%@J<](I%G.J1K?5Y7?7(ZX ; MX>+A=K6_,L?7RS8%MDAIB+'2S G- 0"BD9% ;[NGZWP#UPO[63Q#8?JV8I:> M"]O^*MC GRR, (CIQR"@&F-B9>V09AZ2?*VHP9@3I2 H\& _H?2PR.=I1GW MCI@\#H-_KMTUY6K]>;(NZY".93!L+MI[IQL5#$ DJ9/*.@B=Y8""QIM'/.5) M690RX*"/PK^KKCP0NJDX]$NU*!]_F2S_MUS[S>+F\@[S>(, &(00U86T%%1, M8TRE::0S#G8_-\L\OFM [@R";&;YPEAGH#"!U MM6(-/-*T.4^@ /5(VI#J%M?X,\40P*8CS?*A=I*4NEKP58X\ M7B@G'*@+IG.'M)5**=2$6-$P;+J[O%-=51J?.@/@VME.^;B^*Y<_5=_*Y:+V MMG[\8SZ[G9P_'&G5KH "<488=4Y#RXEW JJF_]+K[KN?:+6'LN%%#("3K4_E MS8&\>Z)-#R\ MR;R)U;*LNY&COQA MB#0@OJF8Y/[X!1H)S"#51M#D>#TLY3[E=?[MGO+UQ3&HAA,X#3@^8<_QVTM'VX5/R.C;=4/^'\2FPS_U@^%T1_?WL3)S0P>SQ5EC% MG,5.&XX:22'JX4-[P\6;6FO_FBW*=4!W=JJ-5 -,:+?ZA<38T2@!\/U_M4T\^31ZW4;DM'+6G&A548V.Q,8PYA8%5F*C&&.=" MB.ZWK.*?->=%F2%A3I8N:3*?+*;EE[NR7'^H55NK\/SF]E23@F$/@-* *$$- M]M(+W9@1G$G6/2/\]2>(;VQ?.Q"D8Y+FHF5^NE%A';& (H\T I(32Y1JO(;< M,Y/Y-:S^RFO!AEY(O5=>9+G5RHD.(YW_359WM9OWVV1^UC8Y^WR!POH+5)!- M884YX( W?*Y1^O%4!%.> &4&D $)9Z/4A MWE98J;MO!J+%I,92_R =4_%LOOTBQW-V5PL)YXO&. .062L%(P:0 &1S:(3 M=C:NNS$6+3YTZ E\(&B2CNDV>C_?H% V;&.YQ!QZI0,ZV--F4ROJFO?Y17?& M&LE]L4FJ^2L&?JMV!<=*6D$%0QX(S!ETKKE"**"1W0^^HD5SQN+!0!"-M+A? MS8@S30M+);'>&@($ Y"IL(0U T :R[MG5(X6F1E_F>^+4O>U_O@)Q9ZN%];] M%FT+IV5]2$:9Q1@I8A$G#;\E,K+[44&T\,G!;8#A84HU#7Q:E@^3V8W[^Z%< MK,K:S?U\,FMI\K=_28$41)X#0<(?3CCH(&WNNTB%1(_2H=&B)2/,#=$ &WJ6 MZ#0]-!=J QQU D(:MK:($D2T;0Q@"8-)U%W5;\%9-SA (X2WGJF;W2[.]5SA M[3KIME% H\DA(!*Y9I88>DM[&XD7+^#>&,'@U$ 3DZOI!7LB:IM;\\QTE() MX075!RP %9GFBXZE\%ZE[+M!^6/3*\LSR3?%JI'9M"M8DMOS,;D!NK$C7VKPF,I-) .2FHP MY\8)T\0"*!K^E]]IZ'C,QDW.C&V:IN&'+Y>S;-IGMLWW#&58?&M7*WOKZ?6^88%M4QK1KD32G$)L0*X MP5,+)VG&*]:H?!H4UL27WW8.[.ECDY)S"^1UK+KR3040-&Q/.>*@/C8+^U.E MFDHWVK(>66!2I;D;JY)A5)Q'YMU3&=E!R'?V=8555B!M!#&..1C^YZ5ND'%8 M91@#E34#AP0[W1KZE([XR<+4# ("1.>,D%46 J -O!@0V#) MNT]WJ;+JC;:JQL!W7'X]P[$/R8Z_IJ!(: <()91I:@6#_I#_RU@$N]MOJ?+T M9<6T04!.=F5KLPHPK%:FNO]CMMC%LAP_R3[,U6=8U^%M15U_ J,/(? A[V1 M$[")@S:(^N[NKE2Y_48B7WRLGSCX?_[7*YA#]_]W^XLC/]^_XP7D?_WUU[_J M,(E_3:O[_]IB?E?>;.9UM;::?<_2%.C'9_\X\.M40,^U[RD\5M @ M1QPW2&&N'-?[Z"1%O82MS)%A9=S2I:=\N_ ,3,,.!V-'P@Z; >RXM?N('X6@ M4SJABW4RGW\_\T366)4&MTFI,WG MY;0N"/-I686IVB""T=@S231H>H^, M25F+?F15#XM49SW_.^RK@JUR%W:Y#^5F/9M>N-E\ZOD"*BJM$$*).H>UX5@W M&0$5#E->RIJ[(VMV((C2^4KW&VZU6=]5R]GZ\<)]A>,-"D*%@5@Y(JQU'@%S M2,VF",$X9=+$3&SY00$;CPX78[]/-2D("7,-XRY,8Q10J MI$0.T7SM.R' M4MM%%O1"Z3WR(2OK/C<:C!0P4(-=?IA]*V^"<3I9W,["3+ASV>O'7R;_4RU; ME7)H_Y;"L7IBI4II9;T SC/:S+*$<=H]4\;UAD1FZT@\%#-@TU/_?YWYMRW <"M7_B5M1"*!@T)>4976M*R*"J,J4AU?+X\3*=G6'2A9:$!M5Y[9\.T M+007S"#=R-OK;ET+F;_";/B3>C/[.ML:^O#FZQ)^,_XC\V4(R: -^2%C)/(!6.^H.6L$]*JX,?I$E8>!1 M7J!WIFR;"==LRU+]O#AYDG.*F(.\O% >44QA?>]5$,C"$+;[^SV*&4ZZ6UR# MWV))2+\QH.U,LO!ALUFO)HN;_[OZ(XR&=?4U/,1W_9LM]IUO;ZOW?VG8M@!* M ))$&6T($PH=AA=3E'3/#COX;96$I$H):=1H[6>AS4_('7X8K()OL]I9$^;C MPSC:"W<^ 'K D.O(P>,O_0)!T)^JZN:OV5.T;KHOM@PNC]B#YQPX^5#WT/?H M?M0/9Z+CKVE>"&,8]%XHB)%ASGF(;.B.-M)137&K*. XTC^IZ(P@IR+HKW]) M88P@P#/+* BB Z=XG5]CBP12*&D\]-$0^CAJK1+A%2ET?M@[9,_6S4LE!(^W M* 1 S " K<$NV.0*($T:4 10W0]0(P75Q]3[B>M>_2!+?:WP>6]W>[;+IU87 MVQ9 ,FD8TE@J[HEC@$#?R(RTE'F?B/;69 MF#('7C\&5+,\T\Z/(0!O7+X^+ MR6WY;:)GU:>[R?)^8JKEP[_.Q^V>:U-@A*R5ACKNC3L Y>_+Y@%C"JB;&<8B]P0$.8 MIL^&R.ZV0*2@W 2V0!^ HBOUY"!^]43A+-4,"D\AEH'<4 >^-_V&X>5YKMX= ML7^MN5X8O!T=9K6JIE5=.I7]$N"[W]R?5=J+9PII#>&&<^NI=MI0A%5C/V"- M3$8IJ3NC7@TC>U2]3?Z^K+?GSQ3>(TJ(1 QK!S **[EV^[X3HE#WZ//!HQL& MT5L/V3,(THP47"Z10,A!(KU40&N@ 6SF+1*FL.X%E",%ER?TC<2#,0,Z18[Y M1<2'#0:FU&A-';)(Z09SP@5#>5IC437?,_BW&Z+_,"TKF_$M$VP<8GV836M, M%[?J=EGN2@!M^%25>BOI$^N^#4V>_[:?-)@=,=<60@YML."51 U+*92R^\B.ERP^LF8' M!2S5L-Y6,?T.CE;UI(^W*J16TH?U$T%!+:KS2]##H;OBICLQXJ5W3S3DAT-M M?"OS]U7Y=3/_,/MZ-CE[B^:%M1Q89CQ5 #LM.75,-9(SV:/JQ!@FPH?>L2<1 M,!N?+:N?EM79"QZ7FA:>8F:Q=Q)S6!?>1?4UEKW$EO2H/3N&(1&3)9WPZFQ0 MO/ZXJ58G Y.//5LPS"WF'DJ$M<8$&VR:0U+F@>JNUS',B.YZ'0J@5$.]"0Z] M-*Y?/%=P1R@F,(!#!)?:HMJXW;>=C' MW*C[:KF>_6=[NZ+;+'_B946PAJ"&W!O )1<\;(J!/J"">^1BB5>J9:1Y?Q@$ M!UL)VK/CFN8%X\Q#XT78/S'%*"& T48:'D#LS(=XU522K1?#8-:9 9"3JWH40P$O$FU=P0F\GW4D]<.(]\#_58N@KIG*;XP]@7*IBN/'UI< ME_S^X0+7E^ =XL1B:Y5FDJ%=47:C)%:ZU4"*+-FN(N7ZTCW(H\\7 BJ+B99* M*P2(I@88NI=/(-!C2S'PE<<^JCE2L;@O$"GO,K:*Q_RTK.H$2!^77\KEM]GT MW/6$8X\6U#B#/178!)D-\,2S!DSA'$F9\>ZJR+R>RJP&A25FP.V^>_4JL>_@ MZF1TT]GG"^%TV ][BK%W2" F*$:-3"8,I#RCY?JKZ'M=#P;.^U!\5L%KF>A[ MI'BCS1_SV?3W]3XIU&&2NQ"*?:Y9P9P7B(39T%OKM28.*MTLE]ZC[C-\Y+MH MP\SP$2 :FPQGBWZU;UQ H9F""EC@K4>8>+>OLA*D=HJ;/->#817:DB6]4?M1 M.)/54I([5<9R/NY[^GGRUR^3=;F<3>:M-L?/GR]0V&J%"1@SZB$V"F%$X6$3 MAGH<4$0+8(JQD^P!27)U_[M:_F^;M+/'&Q1&-5L1(S)5G%ABYETY9:#)* M4AQ3X7TP2:[QVK.ZNBNWWL56&G_1H+#6(<>==8 $@3!E3].7LIQT/T&(%J44 M0^-],$FN\?,GB\\?*PSD7BA /1.0*L(U$*"1!'O1/08M6EA2#.U>CT3DHX&# M SWJ4<"'NN)EW)>'<5-7UPP[[X]ATS=9SQ:WVU\T.8\?P\*YV=;ABIH(9 M[9_JYF;;>#+_>?&U6M[O\\>G^GISUO,LZ?/8AR0?PB)6EMONV7(U77N2- M/3.57&A9"$<8K6_V0*.Q95AHN;.%M'",HU9IFE/*?.D0Y4RKPC(E!0'66V4! M-(+HIB2=,,ZWDS7%4KEQ-'#V9UQ/:E[NR7'^HE=@B5>2) M)@608==)'9*<&Q!VGA IWL "G,WVU&405;_.[S8,2*ELK6/=O9SJ[V2CPABE MO5%"8$F4DPA!=)"24Y)YA;S^RFO!AEY(O5=>9.EIRXD.U]+@1(#OY]GMW?KC MU]]7Y<&.O7!?M$VS,%LR+25B=5H@Y16C?.\ZT,*B %1^_K,A5%%%0RB9@WU9 MA=ZN'S\%,-9UR8 _-[-V%0@OM"PTHM(I!I6 QBOO&&"FD1=SFU&>K B,B -2 MTOOD^V/*:RZ3'VE2<.!Y[J*!\'SO3 [2:4B[NV"C7?.+-=3[8I/P4D\M_W8#_$3@[0QU1OUG6A4"(S[8KZMJKAPEA-O5(( M8"]!(VL87BGCM49FQ) XC3%#'(XZ]I9,RRGB=;,"0\,$9)!A(@"33E#9&+T. M"-5]9Q#-)$PQ1_2$:9Q)X@I*G&]8F+#"$HFMT(H2@91RY "AR_+\-LTTT1.H M4>>)7ZO%M-M4\=2R4$X8J"4V&H;)$0!*96,YU>)F5"%UE-FB,U(C3QBMN'&Q M;<&#D5Y7OX8.4@&L\F&IW,OL@[G=W>\8+95$XFFC,U91 T.>!1*8R>K.SZN_ MQ@AB^%QNTR_4.9HN!"\,\]&6U4+?H? _:5Q @"#=R.P$QWG&1?17894.K!^# M*%D%2F3*CX&.S3Y4B_],?EI6FP?UT_E#LN^?+)#4WGHFF0P=LT92K_;^/$F8 MTDFOEK6H$S4\]M60^(P9]M0U*C( K#T1%',0/B_L,=RC82\TXMT3&X\1]=@:ZFHP1$8]G;CV3**P M'AN(",?0((II'<9C&C<)%"!#;<=R_ R!3RK=[YS,QTL:?/=,P8S0BBE(O&($ M0B>#-(T,6+*4EI5\U\FR_\MU_47OI33^L)WO/2SQSZE MODUF\_I'OEI^FLKPA(JP2A!E /A%5HG["! MA=55C7AD^I)=KV6Y='3:HG6A'17$(HX0:2:-5 M;,1^F"OHBF"'E96&.<^]=A9[U,!BF4U9I/@J9^N@*F_K=+T.K+?J7(->;K-K M"F"--0 9ST@S"H4%)XJ_9^]T;:V\]EZV;DB]5UZ\+:?K"'08AP9UH*!:W-3_ MJ:_1?@O38YM:YN>:%4(H[R&'@AB C8(P_*>1U$":86G[(=1614.HLP/^V#;B MO"_^=(N">0SKQ&D,.(W"/M01<>BSIJ[[JJPX*0:W*>MZI<&TIF! MWO85A=(2!$([Y;3%AB@:C/4&@8!OAG[\-+N/2 !&]?@<(WK+*.L8GH\OF_O[ MR?+QX]>G'_UW.;_Y,?T:&'$L)/9<>@&(<8 3L:>)#RM)JRM=;]6O81QWAC"A M,226<4^!;(:(-=BG3''16)^9: M+;/%[<>O1X18U:GV5\=_=7&[.^1GPOKNA.),$NV)"+M*HP\VO_.*9I[#KS<_ MJNR@_8>LW1'-TIOSICDZDONGNK\/"U#H\:=)6(DN^WV./5][RV00#0BMD'32 M6<4;5[J#R":M'=9N[S>.:E^[B 8 ,QU1E@]5V "6NJH1N^A-:M6N,!K5R;NP M,%@3Q9@)-DLCJY(]#/IH/J5,B#,\\L?<5X'V_]DE/M&3U5G7 MU+6O*J !VA!@C%3<<*84LJ9!A''1/;U;)L9^L\VJ\].R M6JU^7RS+R;R6ZZ>@"5U^K9;E;Y._N_.MW?L++#3'SEMJG6%8,,HQL X%P+;(0S5F.E#;#[LJT< :[9QZ*MA,8AU\# 9@\NB'J[9;F0MC# MLKRK7=G?RI\7X9=UV<-G(_#44UEVRMQ-%K=U06M536=C!V*TZ&\]GWUH$8MQ M[:L*60>.6TNY]XIAKC40^ZD18 MD*[M\5%0NQ65<\YJ">NHM8AA3Q9#0B#N^ MGT8 H@AUKP8\<(!&/#6_GA_CH9=UL,:7=1"Y_EH=^[I^K,6N%K6WX$+(QMEV M!0Z&L"-.28B9U2K8(0XT ',LZV(&(<%53SH4IEPK[IZ\8S[Z/,%U!12KXGB MPCGD .7R,#@=H33OR(J!]%;%0^I]L2'+T(6<2##2;NYICK0U^N6-+A?A+^NZ MRMM*W?S/9G?9^:)S_KH7%5PS0+P02@F.G!<$7XMUT]NC*<[\K6KK5YCKZ%/JU>%P0F0I$H01*UW%!(H#X@H!3-,;A.- M0#$ &X%"37^;)/K_7=[0\QI>=7]_ M(:6B&C-H*2(,*(X)9H=]"#&P,]FB^3FCD2T9BB,P<'LR.]]=1^VT\IUY0<&4 MH9HBQ2G2 @)J.2 '[!WM[BN/YLN,QJ'A8.I\1[/EWO!S(+*OEG]-EC='&-#Q M304$VBHJZE1#FE MK6ZN+0*B84[IE)-Y;M) .<*<P.)15@CX#2@"#3G[" L^*S[2C4XM:)KO)M/L".2J3,%'NOZ[N3P]U?'[!MT+]6_5I0H6]%^ &*>,M<$AI MP.4>+XPD29D0ZFA80&I:7%C^8H+[ T8-.. E)Y9"1!2FJKX2IQJ G.V1F3QR MU$ B6EP51G =EF_KX)@QYBD@@ M!I4(0."_VLA%&D7C+802M]=;J!+D;4N^+ M#6\PC" M"49W>&9\C,>TI1P9[#G'WDI-*>0-=MR0I!6J^AS!M.9 E&.\ZU#\ M$6(1$'(:.>XY=0 H8R2 OD%$:=']FD+B6(0!>!4#L/<>"R6\0(J%(>6XIEAK M(S79HT$!]]U+KR>.+AB /L/#-99KO.VVX<(>J\]K"RN41E8QHB2GC$(#%6V0 M\@9W-Z8B%VT=9PN6$.K<27G1>._WXL)"R:'50$@:Y@4%%>&'(:R%S'S/EX8H M [&S%^+_\/0\:EGN1M\C/=\6+2\:B/U>7!@2[.8 E_+:0B"\@LX=E"2 S6\? MFXH> [&R$\[I6/FM7&S*^@2PJ9#W[]GZS@0K.71]Z?[>;^+5:E67/;RY%&MQ M]=L*+)#UUCHFA4..*!1V;\I;#*:.\LL0A:)#6T$!XP#X.^>X!$G+BR\4@6#]14Y'J* M[VA&RFRQJ9.B[0JV5HN]!,TN[^]R] M F($$/N+D3#\V+?:ST>2Z%2$XO$'"\"\HKPN^>"$8@QKI?91X)"J(-W8(8=# M**$:$(&4<8&KY?K9HA+^]7I!"3\J3+6IS::'R7+]^.ODY/'4J4<+[42839&V M5AO%ZNK.N!&?82E2NJ9:'3GUU6(U*!X=3896FOUUO#AQ M[>-#M?C/Y*=EM7E0/YVO5?S]DW5R;^8)0!A#PAFPU /0]-$@D]%Y1"3LJR'Q MB3FVG]+3'G>"?/_3LKQ@!O1Y9:&DT@Q[R2T1@&!N@=QG>X!<$-O=7HP4H3*@ MN9 0MYB,.M7-LTO$^49%D(8C*0#BVD/O-'6V&2_<0DKR-2#2*+6*C.1[XTMV M=L1;H\E 1L;_5T[FD\7->?OBQ4,%I( 2*"3F)DRD1E CX$%8ZY-&X%PV+8:" MN1H(C\Z:^J4*("TF'SZ8\\IZ_5Q!B8!:*"^0!H)Q)((-W/3/RYQJE<325T]( M.JO,SJ;U=\_KZ\5#A=%0 >N@J?-V24(9IPE:MIK-R,3U3^>SIFV!PN[2X& !6BH=P%!QV2 D M-0<9I;T=4,VQX$DU\E^6'JO/D3\NVHW["RT+YP"R@=<,*J6%)4Z)9MJ4P/6H M3SCX"AYAU \+3MI[\D\UD/RW7V=G&'#L\8)(2XPGT$O%%&"00> ;R0AFW6\, M#K[T1U#[ (BDU?4U08BG8M.@%U8BR[A0A#M.PI[?-O(9!3(J@PNP//=*I+I[)? GSWF_NS2GOQ3*$9L5Z%_0KF MGA!JO"3-"L6D\=VO-,:)D^J">C6,[%'U-OG[LMZ>/U-0A!14%(1^UESEK@[_ MVO<=29;15=1!]-9#]G1WX$\:A!<3*IUM60!-E3"<:HF! M.6=23,,G#G:IN/);^-HK5"[FC3G9I@C"\# $H%3(=$BR),J-0JPA7V6C+G M+?.B<434)3#R,?,&U-5KE_T@V(QC3MQ-EK=E>QMB]WC!I ;2>RJ)%!@Y*B4] M2&:U2YGOOG52IHA>M0$P&D7[>P#::G__>"'JB"-/7'U=I X5LP"! Z\=ZS[U M1TL!G$[[W3 :1?LOS>7Z?&2Z_SMLRX@SKR@XDO562D%+@')4.P&;M903B+N? MXD;+])N.)YVS7 9;=.9NI%JMJ/KO9IJK9HG8V MC\*QAPL-@1+600*P9\KP8#N1!@)B1&P-M)HY8G:0@5G=5V+W3>@]ZS\B+EHNYQ]@Z'PD]Z MLPKKXVKU9;>PM*Z<=ZQ=89U!D /KL9*. (*5TGM9#="@>U!?1D<0U\[\,9!+ MQI)=%R\ZEE\\5Q@G&/9U9CHB(+/88W2012)A\YS^!];3:^T/@-#;UGI6DW]. MRAY'R8W VP#DU0[S\U/_B19AM83UY7V\O9F"M9"XV55A S'N'F-PO6LHNTE_ M&,S&Y,0N/OURO9*+;0LBM>'("ZN$ !0)S1@]R&PTSWM9Z*W)%LP8 J\?@RM9 M+B;Y422#*MASAQ;["WGD&@ M W+2(Z0;=YQE,J=(]@%UU3+$Z3IL4NG>3Z:S>5VT=UX%>^CVHN://E] ZI@ MAB)G$45* &X;4\DBA[K7K8D6YC*\WH= )I76MWEP7@A_4?&GFA3,&6XE)%L' MC"2$(H@:"8UWW0\DHP6O#*_[@< 990]15].^9N?0/%\8KZ@7W )&A264(P@: MV0+G\(1J/ .*K?U7\ZG-E\J'85M2XL#6=:%9Y[":Q%V"NMB)26 M4=;(&<#L3H'KL]!DMT ,A]O(_+@X09QM5UC!%(;8".$(-A;C.D/37M: J2_*@Q#B7JN?+CUR^3^9E\QB>?+0QR%$C"&%78 D^= MXH>E$GK=W;$0S:$TD(ZJ89%):#^6X5MW8:VTY;=R7CULZQ;L;D%M-=#>:2Z0M@@TX8/>2]E],HCF:HK#B.&Q2AH,;+ ""W2L01'-3Q>%-3-0N M,^A$?NP7=O:EV>)"B\(AKFF@GD9",&A#GY%H^DPLZ7[/>O LN'$T/2P^25W2 M.R#:^:*?/QNV8AS;- M"\*QU%X3IKFRQ!OC_4%R"DWW&9]?S8GLW \1 ,R%.A4 C--3!AO F' MH05AQD2'^XS6VLPS^@RKX"O9TPO!'XU'67HOW@)],C@AZ9@3!@%!C#$2<5"G MI ?"$MQ(5NR8 J(%O9=M'\F0DSQ@AI>0 .RBEX 13X"'?>W0 "&BD M#-WOGS&BM6)[9(RX#K"4&2.&'&L](_\Q) AB@HPUUD'MM!:B 4F2'M4Y,\HI MT9H(5T;^7X?=VXSN!I "Y+3QG% DD)#6\T9&;@7(>RLTF 9;AWEWP^M]5N0_ M!H1JZ^J*68PZ!H.DJI$-H9QRX,?3^Q#(O,7(_[ IEZS>ICM+'0HVE:4'7ELM MNY>)&B'ROZON!P)G%._5]^Z$MGN([UL&^QI:%)!2CCGCD0S$WU^= (B9'KI!?XPSCMY+08S#$4C&F MJ;(:4'@AR!F*G&I28 .P=QP*B2"$AEFD#@@Z03.\0AB+$P-!-.9ZH:;3Y68R M5S?_L]D5VFV=(OWD"\(0T('Z"C B-1 6UK(WTGNCNX?W1 OI2KFF] 9L3+I\ M*=?K>7GS[]GZKMJLS61UAZ[DRY$W%)HA2CE PC%C*=5$BGU<#*AO\G9/EAHM M'BPE8?HC%OF\]5NYV)2?RVEUNVL;[7#U]8?L;#6YO5V6M]M A'JKN'U"/WY: M5C7&@+/!0*&$RE95HR*/87A+3P0*4L&G3AF#<=.;Z;UQ(BG/)< MN%52\?UT]''Y)FJM.?%-I MO1H4OX[VU35,6(65:=_!\_GE3SY?^""$"&8<Q90SSF=&\S:FDI=WF>\O97 MT?>Z'@R<]Z'XK(YP,]'W2$Z777\O'MF\>*YPQ#O+ 65 84:,9$+91I;PGXQ< M\P/IY+53I0<:,4?PX?+/\RW%F97\Y/,%Y1 A7Q=8LZBNINX!]XU,SLJ4909S M7\Z' C$J,7;6X_,>GIW:3SY?*.RIP)88P:$GS'M-5",3EI[ENZ8/H*RY*+V/LE?E]%^WU;?_FE:;Q7KY6.N;-_^HUSK;'I6C]\]5W B M!%=A/T&XAC90,0#1R("MZ3ZE#GY4.;PR^Z+1.3W$-LCJUVKQ^\K]/9UO;NJ4 M!EMBU>DK6JCR^I<4F$B"$7!>0.TADM W=87JC$VP^YYI\!/'8?4<':ID66:B MU. CG'FEH9>1R3(DW6C' 3$:<3@7:/,-,<@,ESE=JZ(?2VM9[5!BLG90]D&'RIYK/E['2JL.\?*K!' M3&)A#2!.$ PI+SKV#(RI".RU4 0=%;.[_-U=7]9/:\>*P2W0F-M MH8/20TLPQ*#I7?A7AC=*!E!0/Q"ZCY_ULIXT_MQ[R#^$Z>#"6#K5H(#(*R$H MAMQ01XU4F#;SAF9:=S>8H\5P#C&N!H*CLP+_G\EB8 ^XM0HQ0 M"@'4RKI&>(VIS6BW,Z#RA@$C7>SDUH+W 0E3+=;+R71=Q^^9S2K,'.7RL%%3 MJU58TLN;WR9_7XY/NN9M 1>CPMX1$,LY,-0X;QM*&REDTF/BMC&58X6+MR?VYFZ\=D'QH[QM3,)ZO5QZ_;CGUH$39Z]/G" N6118PJ M)R31V!&!H>:0"0%8RXH0D?9_AU0BVR[KQZT [5/W?-RL35FR_6P,9T]-G1E#&7U]-E\\>J_'-39]P.,]"ZOE=\R:]X MO$519_Y'" ,L>=AI8P(<07M0O' JVTC,013]FCR#8)3,9?1];R^[CTZU*2QA MUFQ+!$IM5# $6-C][64$WF0:?3F8YBXSH1=.[Y,3>;H7LZ%"%A2X7,;@V/,% M\99@I167WD+&#:\O?.UEH^'O^6VV!M#3>-S/K-@7 CGH MPA;3.>BQ8P:RQOK2R'7/K!(YGC.*43 02JF8\+R;%^?^[Q\NL*'$:4\4,PYP M123PL)$*:Y5Y$@]Y'T7=W?5XMM/UM4.'OU;,$E M]40XSY2FWK-M+=!&)@%!]ZD^VD+?1S'?E37K!T>ZU3WT\'/YL%E.[R:K\M.R MCK.Z5YOU7;6<_:>\4?=UH.JY1!A>O"@) M'0;P'T7!*15/?EN6D]5F^;B5XLO=9%FNU/3/S6Q9GDNM=J95(8B3#E/KI*( M.H]E& 9[.97*L=S=L'P8#IM1./#_3N:;LNEPG-@PUQ$Z MA&!@F2#8BP/[19A\\SMLC\B*84"*>ISV:B<;Z]3HY5?&/C)ZU9TVIT:GFA3> M8>2Y51X"AE&P(*799;]1GG$G6KE#TGC\+IT8'7F\<#;P% &*A>#2:KY1X;% MB&K%.&$.6<>1E8UT4B*=IZ\IG5*KR$B^-[YDY9IZBS3)XLBJ1S2#E@)@18 5 MW., F<;$-X: MZ![&8C8!Q=#+#;#@O,VCZRU-0 QJS %87=.)&;[Q*-!1DBU MS'-%&4QSK<^NN^'T/CF1U:J1'Q6RH$#', 8%B;,.6^$$M5Q8!ME!-BM01HDK M!M13JS"&ZY!)I?4F__AOU=ZA=MQL.F<:M'U%$>!4@FJ*)5:*8(DPQWL$.*(P M:7::3MSH[_^(A-5%7^;^Q_4??TQ6Y?_U?_S_4$L#!!0 ( 'P_^$[XTJ V M!P&ULY+WKDMPXDB;Z?Y^" MI_?'Z39+=1$ 08)C,[.&"]DC,Y6D(ZFF]UC;6E@H@JF,KO_]>;-_V2?W@6B7-W?%KM#P/?%\E"L M@^^;PTWP]W51_1Y<[\O;X._E_O?-P_+-F^X_"MH?MIO=[__2_./KLBJ"']7F M7ZK537&[?%>NEH=6]LWA MU"[]I?F-7W;%MP;OC\5^4ZX_'Y;[P[OEUV);J]%^[69?7+_\B>U^_^@+#4)I M@Q"(&X3^^RL?/OR\*_[M3]7F]FY;P_.+@?X:"A^>*^M*NQ:$]SI*CJ'Z](.6 M]?U23]W"KL;//VE9YVZ@9;NUB_'[]+.6=;>KLM.141Z66\LCX]DG+^J\;7[K M7?U3_XO-UT?HMQ7>D^K9AXL?AV*W+M8M:3[Z=+!9_]N?ZI\6]]6;;\OEW>+M M[J&H#DU@JD3Q]4!WZ^R?]YO#S\_%ZGZ_.6R*BGZM#OOEZK!@48PA%52$.(Y( M%M(L R%+XH3'D$:<+EH)BV+WYK?/@S[M7SF3^"<5E)[COR^J\GZ_ZH)7K6H3 MNSOM__U,R:N@43-8[M9!IVAPTC3XQZ#K__K77TX&/X*]7+TTCEH-KY?5UU;- M'IM:74!^*;:':OB;-\W?O E!'Y7_NSJ(3SU1KEQZH@-VVV0GY;X?V8\&(-VO M@G*_+O9UUC3\1\O]ZA4/]K_QRZJL4X&[PYM'SFRR)_>&EI+N#V; MN(W4,V$/RTW];[=%7NX_+[<%+W>'S>Z^O*]^V]7YYG;S7S5KEE7UL:PV3=[X MKJBJ+S?+'8"_UK]Y4RT2@C(>I;C^?VD8PYA@F ]*0I+'B\,QO+TZPR=6384% M#A>"] @5'/5_EZ-VCQVO1O\MXY][^?D@4/8\@+W7IXT4=GTR M$DUFBQ!$,(UPG@$0YI30$',QR$E93%6" MC_K7'<>/7J&@.FKTU^"ZH?T'==K7@$Z.N=VB9DB^O7)7+^?@=1#]SS?OWT[+ MJL_P&B%&?6S]X#8#_4M;HTR-83X5#\7NOLAK4QK.:[+POV\.-_R^.I2WQ?Z8 MF0L$2$IR#F@2HE3P%%#<2F<<) F437MLB7,WI7H-NT+SH&-7@1ZTG&TI*XG> MR 2SC;\?T\ZZ5:7;46MUBGXI?AQ8C<;OBSQGL>!)E F"4U)K040VB!=Y!%5R M VM"':<,PW3]5*S*;[LV-U/+$^RA:X4!W0#K@ (;18-64[](\ B@/@NJ^^ / M08,:9JGQH"YNLD385(#: I#85*MM6=WOSTJ'89)E/$8DBW/!>$[#B)).9 ;C M!&22T]-(AKLI>2I^!6>*S9:(C*$T,N^L@.O'7+-C2NE@\&G.*5I5Q:&BN_6[ MS?+K9MNN.7XMEHT.ZP^[3\TZ9%\O2.I?>%_N]L,?V;+:5%^:PLF"YYC7LSL- M85BKDZ9QEL2#?C4'A"K9QW1:.4Y/3O/V*NAL:5?F9]8$@SE!N0N.!K6_=6Y2 MT-I4A]W&JLNS?6X?*Y*L5^[59N1>XWX+=,2'KWG/+5>;@BU#[),YU+,H,)W= MET+&Q,B_%E^J_6'!R_M=S9EWR_WAY_OE;4%_;*H%8Y 0E$',$PP3C#D<4L,, M9AAF,F%"^^..V?YS(L\6GXJX>+3?+JJ#?]D4;39]*%N7M-@I3GLM2B#V)T_-*IY@"LUB$]W6ZF0=98PYZ#51K+"2- MSP5JLH_O_'SEP*;2Y8B48[;E]L=NP9?%]OZ6;6HRX!1I:5[, MUOW=F_;*S/S8/5+'*89/N+VQL&'N-(Q1V/+VF,TOT+05B.9E93LFE!:'C.+I MJ?JW/US3_;X>&RWCMYFKR-.<89S$(,KS"&5QB/ @*\%,Z?BNG@37IZCJ7PC* MZ^!,K:$4]69Y]G=?ZA^KY:J969720M407[D:H7MHU7C9!:INSEN]!-S8F2LC MH/VHPQG:\/3LE05$9#GJ3$K5U>;.!M/Y6.J94F0,)9 SC@01$2>1H&C0(D6 MJ["7;=F.>>U<78FII[1"=N8..;*;TQ-J-&C9"4X84!'-$6YTY1<_6-.9=>4T MHUN-:7FYK?]8[NNEQ$-QIE(O-!$))B(7!.0@#*.,)R ?A *"@ JQ&HIR7DT\ MT^Y1/J.VT+0%K!Q%3HBI:AU1&TXG[#<.U C964+8#VZS94SI9!1JGM%A/]M= M7KY=5E6;DR(!*0,(419GA"5A&))!7@1RH70;2%^*Z[ROT29HU=%:IAK )T=- MTR"GF*?)@^;VU,E33&1.D6CCZ ?W6+#CTBD/0V0T3P6^<(ZD/3CRVZ[\6A7[ MA^;\R-O=W?VA.86_6VVVF[9>>ZYLO[G"24@0S&@&01@SAJ(\%8.Z.$\C@T." MTRDYV9G!X.O/X-%$UEK3SN=,1?KTV8\&[#O+&M@5J/*' *?WHV?L/QL,XT<$ MY_*+;.QYVVS*%]7AT_)0#+=,^O0Z#@%,<992D0&0B23$X7#H*,IQHA0]#,0X MYO]!LZ!1[73_2F]Q;H*F''U/!*0: >MBZ*@#U26$1MC4 JQ^\*$-0YYUE+*$ MC2PG_5KNBI^_+O>_%X?\?K<>"I6< @IGE* 8T90CCE@S"> :FSS(8B''-1 MJU70J16T>FGRD"Z"1F9$=XQA-(/SC$UHK0ZO!1."OYZ M?[A?;L^%B"B/19[ B'"!$4HS' V$AE$H=UQ%\].NN:552(M5=+$:9Y,)8%)D MD>D14CC_YQ8IO9-_:HC)G?E[9N>ETW[Z@'APSL] ^=+*H%#=S;V]+?:KS7+[ M<7E7[(=SA"+F(.-A1 &/6)A#AH>SVSB$F>(FKHX$YWNW@U)!JY7VEJT6>K([ MM:Z!4]V@5<7,T;[L"[",;L>:P.A''F9HP[/-5W-$Y/EE?]=L\Q:LW*U/7=B& M568<(\PQ 3Q)(BQ2 L,A\ZO_.B=J/&,BR3G?],H%C7:/VGEK$H\1K+($-!6B MJD2D#:8C1AK!:929;.#K"T-9L>494]E#2+I&=;_;K#9WRVTC4=G%*"SK)TI1KU%27E(J N:E*O0#* M6$W*!$,_>,;,A*?U*',\I*I1'PXWQ?YOY4.QWS5+\0]?MYMOR_.3NH# )(YB MG&4,B"3*,P+H(#/-F=2&G!U)CGFFU2\X*1B<::A3F3%'5J*4-2FH:C3D'YX* MA:])<=6K@YGA*U<7>PV&2V4R:_!Y4#6S9TOI8H IKGF+_6%SO:GA+*H/UZ*X M:QX[&$XV$TQ0G#+ ( JS$/%(#&<],!0P55KQ&LAQO=X]4ZVY[=DKI[O:-0%4 MKG"MH2-])KG<%YMON^S'ZJ:Y M=5'_\?MRO^Y%1@R "(E:G$@ I5QD^4"(<0YBI8*>/FXX;%/P*,=I MPBB#:4KJ13HEX2 L$D")H31%..:F%Y[\U"(E70#EZ&@"[-2(2 ,V)PST,C C MW&.(I!^L8VI$:75T:=\+'9K^_CR[&9:3+$KR$$&2) "PB.+A%GV]<$R4SD*8 M27+,.T>-[-P1U8%2,A.:#$4U!E($T/5]T>?8C"5 5C#U@XLLV7+Y[J@Q0LK, M--Z,7.[>T6.M^[M'&0Q)%$8HS+$ &1YF."CWHE:NX[YM76]:GQTH_39=#>[ M53J?BQ59]P_A7<5%K)ECW3*Y*[QEHL'LOO8LHLR/QZ6H-+]F\OOA=%6G]]T# MT)^*[?)0K+MWHK^UW:1WU:9V9ZO2L"7/TIA$!#!,01J'>1Y%@PH)1U2J4;T3 MP8[CS9FZ0:]O<%(X>*2QSFZO=3](;*;/Z0*UH/"'0U]AZWU.+^CMQ)]I_,;< M&W([\XHH7=JH=P6V!_OVSDPK)QBLJB>X3E(_+G^V71A[@9@A+A#G<9Q1% J* M(CH\^9000N3?'S 3,\G9K;,Y-ZBG?=!('U")0#,=EFIAQ2<850]K30*GR4DM M+5@5CFE= F#TC)8Q:AX0O25#GIW.LH2-;$&-+>M!LRH^WQ3%X5V#9SW$VOI= MC/(PI*QY#!9SE*I6"5J=@4&J6XO0E=$8J$<: M^E% ,#>CM#S0S.=-7Q\0621"#'/(8)@FD8@H'7;_DSSF2E=C#,0X3GXNS2*M MFJ\)FOH\Y !(.TPT2WGU,D**;*0(J[]\I&J(!"-I82-]S'I9W33G!!Z6V[.\ M 49A%-):%D44)6$21LU=??[??,>Y;G$D"9)&',2I20D5("<'?OK$9$RHN86O(2_UA!1VIQR3LQCX[L=1VMPB2# M '*1DACS$(=1.BQD"0\SJ5JZF037Q:M^!ITIIK,RT@=08E$Y"7:*]:NY85-8 M3DX"G]YB4@M&N:7D):LO+22-4?)@&6EN0VESW&BD@L^%41%G29*B!.24)7F, M>BQ4XC40N>!22. 0QK=?! M S^F7"2)08E,7=C4:9)1L4P#2ZV*F5L8#]?!VHI\^A=PQ+LQA ' N$((T$3**!,U/(4_E+.E:DN:ZSC>JH53NR M@K%,^6UJ>!5+<9XBJU*AFQIAS6J=(=*2A3L),"X6\6P"Z4-!SZH]I:LAIY;5 M?MP7=\O-.OMQ5^RJHJ*[]7EN_6BK!U( \R0D4?V/C&0@ WAX4"2ED"@=(K$H MUG&LZ#4-!E6#Y6X=/%YI&AT]L>D N:1X)NS5 HE%V)WDRO(@CF3-#CSA1_[L MPK#2^2@VSZE[@5Q$% (J,($"X@A&3 Q[,BG(L?QKNF9B)LNBS;M]&.*IGS@[ M@%(W8YX=1?,DV0&:IMFQF]XG6IU.[(#F;R:L:HA$"JR%C49GV^./_[&I)>]7 M-S_?%0\UE&WS2L8HIV$:YC %(,0IS8:'!M)< *6ZKB61CIG]K.'?4;DV 7M/ M_].T\:T1TG()[@P@JW&^";ZN^^*.(#:2R5J&W(\LUK91EUOFVL-,F?OZ=HAM M&[4J>C FO@G-]KX(7Y[!ADUL[ MOE DR2@3 !7)SC%VNM1V%72*7072 M4+IEMNL9:))9+D22@G(R1D!8CJ:+K+R,I6R+!2'KH*#-2MUM,=^OQ9T+J7WA?[O:/7@UY MM]D5;P_%;;6HZ9*',8A$GB88-54[ 08=$4VE&E_-H]F$-;3^S$93OSD_[SR8 M%+2/2?16=%6>,[."UJ[@'XUE06N:+H-.XW!%SO7.U_HL/9F;W;*[#8_(Q(-) M/>]9!)G6]DLQ9P8/R$8I4>PW#\O#YN'\$:L%3&/,\R3.681@2%$4AL-I4!K' ML=)A3#T)CJ/&2:G3BW-J;*\)G!QKN\=,C7V5X'+"FB\B,L)^9@CZP6*&-I0V MQY1Z>^B:S9YTC#WRH=A4JVW9T-]"I A%!),D9C'EJ*:W6H5./J,(2]T,LB_5 M]=G&IB5R<5)1O7NT)7#EV&@>7-48JH6TR?6>MIM^M)=^4G7ZYM-2"(XPFGTO M^,%R#NQZH7&U"^1DV?#M[J&H#K>7A&(1,Q;C)".4)BE -$1#8L=(EF(5"C04 MY9CWSAH*5\=FM6KD9XJE'.--"*,:S9TIY@6QC0,UPF:6$/:#PFP94SH9A8IE MRW)?;+[UMP-7/YN3T_OEJKOR\I(6(<&4TP0F87.''(28TG300L10::EH6[;K MTF.G;E#\6-W4?U\$U^7^^W*_#E:]XO4<73:Z*]81;7M LE(X(_B*M< >]T'5 M8-"U+PUZP8R*<(X5\APYQ@_N=&;=TV*<4Q0-V;4Z5E5>S$JI()!Q$O$LSD#] M__.4#:IDB"J]\N9$ 0]X=JM7Q7/C#R/"GD>!5>=?.W[R MFH0MF2C'Q#;QE%^9UW14Y]B?EH?B5!_MMVM.86$1 Q#%),,@V-= M *6)4I)K2Z9CTAW4#!H]@[,-@$[3.K,]G,UUU46\)=AE5_/3(ZZZK+<"MJ,E MOA1ZHVM]N_C[P9G6K7JV^G>!FADSGNTXG'B&3F:G=LI:FQKWQ]N'I97!W6$>EVZR \& M=FKATS?JG:,I?3JIKSC\?7.XX??5H;SM'T!\7QSZ#F\+ &@:Q4F*>)SQE%&1 M#_TP690"3)3.)5F0YYAO/Q6KH@Z-7[=-TO3]9K.Z"9;[(MCL5MO[=;&N?PB^ M[)?K(EBN5N5]\XK[_OA?7 4[U2TN*QZ0/+PT,?B*QY9Z[8+OM7K!H-]Q'^M] M\X]>RXE/++T.V]A9)8N@^\&45BUZ>C[).EHF3'ADWT%TQ$B.(!.4Y00BEH$0 MP$%TAD-F2H7* EV?SASFY/9\)?DR*78]8X='%L[^ W,^5/>#/B$Z=8$=1CS; M8O*&$)_"ILB(VJC[2XGZ)DEPHB%>LJ3X^; \M+U^/ER_W:UJP#;8MU-T6/F@;E M=?!(Q:#3,?C'H.7$=^L4,1R9KZZ\X, $![%Z2 D9KE4_VS-3SO.7$X3\Q^M/HH7F%5Q4N0U^Q#ITM9KZ+CEIE:X M#/6H >89LR@J?XDX=#!0YH7/JV*WW&_*MB-J" 7,4I1"1.(L%(1F<73DH"16 MJOSH27#-$KTN6KV6-3%3I IG<"DRAB12;OGB' P9VM "SS/VT+/A$HD8("+- M);V(WW;57;':7&^*==\7M+FN3XG@F&1I!$+*(I(=Y>5 J;NQOI2)..4J.%-- MLV&Q 922-#,)BGI4HPB@&^:YA,\8^QACZ@D#F=OQE(4L(:.9C! MC-=KJEI(#/(PCU OJ/Z;3.E\EL;GIUOUO-/MW:0#FF).XP8O[260#%1N\YIW M$DV,#-#SA$\,#+B4SNAB(\42O3[.4T]W]0QE\7$Z_!_,(G1'6T$/1#\+0U+VT,8[4:*)[$?%Y-;<16-CN6].])P/GB]E-W1.15^*VM-^\/GD5I?SSB\[,>3)'=$O^^6NJK5HE-RMVS]M MVZ.B=/V_[[L6*1*V+ 3(<@8PHH2E%!.8HG#81H@Q2I2:*/NEN>-X--S]7@UW MOP\G0^Q$GYD<;A:C_/>U]4CVK O F=%M_[TSLX.3W2HAT(^XY\2W&M%QWC'F M=PR=&1O)2.N#!TWC,7U8;K:-_.MR7RVWQ>=C^SXUK4G,8@$H;6XL YQSEJ/A M@$_"\ECIR;JY=74<BG,# M9QAU??2O]3A[-/)-;>6;QLS@9.U4JO_GOF;BZY_-(T;5?Q3K;X5,;7F!0 AP&-;:9B#) MLQ")<#B^D,0$*9U+FDW)2;8"1]<*9R8&)QN#915T5EI9(W@V,DS#I4>#POK: M<9+Q,'&,-/.75HR<:(CX'B.G@D$Z1D[JEXD.PRP88#!"-&0"D9S"#/.-;%C]@B";J[@RW2 M[O0[4EBWUNY!%D64Y3OH/%-H4&:10QJC+(\;N8S'@,0,#Q(3F.8JG&XBQS%? M\\M,K=H%QP!+.>:="D8U5I7F4Q]X= 3"$8ZT ;P?_&?%DF?=;FRA(\M;GXKJ ML+]?'>[[AZ<_%=NF#$]7=6;=;;8,!_^R%),Z9<[RD&0< !9% M\[4GT-T\?*1C7U5NM0Q.:LYV0%<:P)%9:-\)?LQ)!W:5KH>OZOWRFV)]ORT^ M7%_0A)?5H>JZ9:1IFH3UZC9-21(A'-;)331H$ *6J-TXMR?7<:5T4+6)EI=G M;*Q[/T2_WK6MV C!'5 MR!T=@VF2,911Z/84,H)2CJ&E05",G30"=,-1% M?$:XR1Q3/UC)@AVE[=&FQD39[=VV_%D4GXN'8K^LC?ZUN/U:[!)^E6,FH$I(V@'/U, 9X:^9SA MUJL4_*-3:F+FN0#-".^8@ND'ZQA;4=H=8HH/I2]77:OW;5G5[-;+0F&$F<@X MH##&60QJR720!:':]3$]"8[9IGWVX\VQ8G*SW']3O=VEB9PK)PFH5:+H'SVGDD$SS](!AS M,UXZ062.BX5R\[MC!T?,$2."Y?7_ 81KFLLQ&D2S4.V=5RL")RT\-TKV>T2M MF@8=7.V@;5R/=@.T25%:#^.IR]3O))K!6H7=#XZS:Y)\U5H7+RWNZV5^*K?; MO-Q_7^[7BS0% B9M\_V,YS"M4[S^8=<0QAPI]7PTE34IXQTG8:-AT*MH0G4Z MX&JPG&-<30A.$5+WS/8<*UE2,T#90SXSL6:,RHQ1,F&Q18R88 B0I"9'D.&< M9"$?1*4B0XN[8K\IUY\/R_U!G\!>%:,RNYYJ)#W16/%ML]LUDXPMMTW-SYRH M7L=/GYVL@F:!DN;G($7BD0;07[:1-T&"8A3Q,#Q\W:1H;W=MC\WVYT4"HI F M2?-248JRB"81PT?I#*7:69*!S$FSI>)'T]!%M0)N#5X-)IH(61-R>GHF\RH8 MU&S_Z,6I]J?@R?*8!?@]I#8;5LF=9S=$398 /RY_-BU-JCI]>Z3( O$0Y5D" M2 H! #P6D![SN(S@5*,+EK8LJ?EHW,6*+ZN;H"H.AVW[MHLBU>D#*<=M;L'3 M(K-!I>"Z?%*AGY:Y+D$S0E7&:/K!3>9FE)9'F?FRCJY6^_OE]M1N"=34QVK* MHV$7V1KD\?'%6IFMNE=_OB85/>5T&M_.:VYC>3/,P M9_T%H6.(+2P1KX)>Q[-^=?,O&Y_CIKB0- #>#XZS;93$8M,8,Q/^^]QF(.N_ M;PXWY?VA24K@@L40XR2$)(NYP)A%*0E[Z4A01C62,5NBI\G-VM-8P>;V;KG9 M:R1GUG#6)T!GV-IDP%[)X'NG9="H.3\'O@"=(@F:@.\O"QI9)4&#YJ@9E?V4BT+ MH;\32=X$F4JU&AZO39'E]L=N42M!3#$&)*.)@$B0>MF6 MTFZ&\I#04+RVJV-=GKL@=J9E,-(.3:)-B&/$UV7]L3IK:>^L^(G\(Q5G\, 3 M=FNP:#@K#6,4MHREBLX++.8,X'F9S9U9I>.!J=MX14*7IF57V\'@2_'CP&J8 M?E_$+$TS%,$\822K%W&,(SAHQ7&D5$5RK8OC\M)YFQ#).=PU0=-MT^+(8W++ M,9^)CY\6 M^7!_D%+PB7)9E&:0T)R@,$P9BB'+^3$^$:%T67HBE9P?]GCR9DM3_9$F'=5B MW#1.E*W5>><_U5*>B>MF#Q1V\!^M64SJ8#_"QM1&/ZN+S("Y;!#I1'VNE[KM M.8^^[O;YIBB::QETO=XT*B^W8E.MMF5U7\\]]K/^PUU9+;=_VY?W=U7]B>U] M4[5K?J?<'3:[^]JHNZ+K2C&T3HM12DC3,XU$+,DSF(K^RBR/:Q,BE2CCB\Z. MP]"@<="IW)Z'ZY0.SK4.3FKK]8_T!4[)&.6+NNZ"F /'.XE6$WEB))SY-A;\ MB'?>H5+Z/8,5*V_W7ZOBG_>UXME#_8^FYU7;;"^, 6[ZZV&.>=*VN$J209J@ M,56JJ&G*<%TI.ZH5M'KI=^C4!E&RR#4!?HK%*QWHW!2C7L9FK,ADB*8?K&AL MQ=.BD!54#%BG;ZV71XC@E,]5$'.4BQW$:IDG&0 A2 MS(ZR.(X-6$A2PL0,9,0YLJ!I\8T#O RY9IX652_"(D\QBC!Z22^J-HQ3BQ8B MK]%*M3\L/M6CITN>\@BS7$0XYRF+!,NSB!^_'2(BM8A2^Z+KO:1&$:4EDB(@ MXQ3A#@O%?1D9&&18H#;HC 'J/SV=_8\L?F&VZR$R[^S6U+DT&0.*L[?GAIP1 M2%F>QAG->,)SR/@QY<@PE'JK1/6;T\Q@I:6&,BR2L]@!(EKSV,:R07XF7XS< MNKAX,IM5M7XZG[6LEIG1OVYVF]O[V_[[2<)$)$)("2)-RQ&6@;X5&R< 0ZEV M'^I?=3RK>V5>3TU-P7E]9KO#16UN2T-B;78_LOS"_-9#9_X9KJEW:3HN%&;Y M\L?9]UGSEBN*:"9 E" :$8K \'W,*):>Y4I?=3W+.V5T9KD:.!*SW!DNBK-< M%A)[L_S<\DNS7 L=#V:YGMZEZ;CP[9!/N[2(<"3BA**$0(PXI)1'P]*")A0H MW2GP1.5)C_@$[Y>W>MNIGJ#ES0D>Z[Y5XU@-M_Y!#^B\LG/LF:?]J-'Z!LKD MIW,T?"8;Z93T:.9EOU4FB DYQ%&*:* 1S$?.CIQ2FFJU-+2E0YSQ"*M#79G M3I ++S[@;R%>S+(UKXG=2 AP[0T_.-VYE>6T8]R =?FCRP[=D:@DRF)!\@PD MA-$H(TDD!JDYR96NF)G*FI9%'RNHE=L;@ZO!FHYQ-6)'-4C=L^1SK&39T !E M#UG/Q)HQ=C-&R0*+]>R)2()(SC 02) 4UW_*^F8VG!&0*3T/8RYM7B8SSPSU M(#9F,P?H6N6S^?.^E_#2XS1%K+UG-55[Y'E-"RE_ZK_OC@]WL22-19[B+"$9 M@Q%(,Q /%B20)'X5@>7U=LRV_07THZU70PN\H#6W?1WA9'!P9G'P]6>@Z3ACYYQ9N*LYN!I!98_!Q#?]#*]CN)EQ]]'%9^Q% OD9F\T*WK/;DVF$T7 M:+KZY_VF:A7EK?QOM27U3]5FW2OQZV9;5(=R5PRO&2Q0'$$! 4@QS5..0L! M-.B2AG+5&+<:.(ZU7?_L,\6O@I/JP2/=KX*C]L&@ODKC3&<^&H][_KA'+8+] MG^ 9E?ZF/GA(L]FI(T])MC[5!.Z%6#Z-(WQHBNK($1CVA",QB#..;_7\NM_=%NYB[W_7O3GZX%L77PR*'"4?MWLEB-K'[K?-[Q.FR]:J\S\QB24+V^FV$;M>DK+!OXHNY?VARFN.;6EE(8H#"-,X(CBD+,\[)41!@2@UD-#[O>"*=--)_4$\' M-+D4RC%>:JF/(E2.[IX^!62$7 S0\X-33 QX=N'2$ L]!N'+0_&MW&_^J[MQ MTK?3YBA*<,9KF31G-7-A>!2,HHCH,XJ6N,D8IM+LW&(#4AV^<8ZF+O]( #D! M^[P$CS0;&6'K(SN9&33*5A:PDNY#]4)UY].F^KTES!2 5*0\BW$48YC 6+"H M%]GPJ'1_)!,9$U>Q6ZNAF(LAQ O!2^4^SA9L1G*KLY!A);7:2!]$Q.ST' M2(J=#'#UC9U,3+G(3L;XR++3\ZIE2X6"Q6F$* 8IB1'DG&+4%RT1(E$B.Y$T MO^YN"@U;E&<:S1+>7P9F9.H8(NG'I#$UHK0ZNDPG2C\OHX2G$4M%RWDU.L:=6+/F7> M0QF?1"%$F."0@B@",6%]<[):,L"1;)-%&Z)<)F^#=L&R.AZ5.5]ESK)E)0': M:$)G#W(_YIM5BYZE=[;1DIV%[\O=^BA\D)2PD$.,<9HF>1AG ASG>Y215.K! M19/O.UYQOB\/@?FF'(>Y!E*-L^Q@Z(2W7@!JA*=,8/6#EXPL*.T-,MW: M5W7FPA<[>ISJ\K5H\Y%?]N75=7] MB[DX[3)J4M1F 73?&,Z&21>)SAI>EOCNV/5AD66"\9R%(Y^&P+1X) M KG>IIJA4,?+G:,BD_"> M96N,\-S-K\=U3G)0ZRCB2_'CP&H0?E]$&$8Y!I 1$%)$HS!B_3O'.H;:D>2 M8P8\6V']6BP;W=1ONAM"*<=UTZ&H1G!G )X_S?./1K>@56ZNZQ0O 37"8W8 M]H.\+-ERZ5*%!81D:>I=T_;P=".T3@OC'!(8A8B3G"59"OHW-&,1(R [F12_ MZF[V=(IH7'BV,U<>XS R.30!\V,VZ"I?6ADT:N.]?X9I]ZV3UK7"^76SV]S> MWPX=<3X5S=9K#=J'Z[R>B97P9,LSBE/NW2:;,G "W^IEA>'$H#\OM M.)=;%:C$VD?=E*E@C !J==L)'S0**_3#M(;Y.!7/!K<>Z7J-M$*_T3D0U^LR M:@]YN?:BDLB\$)>< .M!*U'K)I4.!Z+EJ%*/R@6""82)2.K8!4&*0@#C9!"= MPRRR&E5D!'H55>JO6.8Z* HHYBGB$5^'E>VF9[V0 MQ1: M+&/M,K#, K/EH&(9[BE"R@CL]@+*]](DG"B@^@<))BH6J8829;2, \EQ92+W$I,T1/M07@QVQ=WY1+#J./>&_8#D)^. ML!27W#O$78@R/8Z@$:Y>A$LG3>NCZN?-CT66 MI"'C&64H0Q21*$W2;! -LUBJ[;)5@1X;7TRIFX,Q5BW#Q"AJ/F MTDGS;@#/C@?A!X4](X8T!]S.OI%MK!WN&\T#L]U](]MP3[!O9"O8F,48:ZAZ M$UKL6:2X;Z2.EI7B&KVNEPV#?)X1"A!@!!- FQ/<,(H&^3Q66 99E>I)F:W5 MV44-2,T%%BINSM!W4W;S!'B+%3AG#G!;AI-TA)UBW#E&NA4Y+9P]"$5N[%*I MS1D@9[5 ]TB/. HAY6$<(T";\W@E>JT>=.-F[MTZGO&2!IH\CW2+R@/ ]I M(F*,6!HS'J(0#^)!CNRG82 M8*T[IH),3XJ$:E=IK ,_'H/FQ-Q-:5#U"LT$32Y'K]RX\H ?S<^L6Z72PU(; M-:N-*\^T$ )#!"%) 8Q2""'"*#YJD<5*;[C8ENU=K4J/-ZV[1(X_Y_2&ZPK5 M/(RJB.@(L[KRC1\,Z\PZG9Z2VBA:S4?;F_MY5&>^%'.D8J)=6KG%2^;X@#^"WFI=:1=YF9JO0+F3 WO=!?Q)T?_&!/!W;I9*@:R#G) M45L]*& B)IR)!.$4H)2P$ QZ9# 5SK)4*>F>YJGJ7.K ,0YR5>L^F29;G9YE ME5&UE;$J><@/UG5HGTG6JH&DS;RU[6D8HRA!B$:"1P01 AE(CN)%E%E/6Z6$ M^I2URC=2M8^]O9S5.NP.4U:5!JK39:P7&JXZKTW*J*J:4T M55$>I5 MCBK]A(Q]["WFJ+9A=YFC*CP=,V&.^O)3,\Z( MQE'S0$']CQC6^3&DO1H 0.PN1Y41[FF.JLR@]KWB($>U[9!I-*M6")RG(,I[PF*09ST%.DN'D M%Z!IAE7(U[YTQ^S[9*;7L[K3.>B5?C+=-[OFG$\[ZRLU]G7@%SGZG=?'>L7*CNE-25G"-94YV MXQ77E"SAD'D9^0BK#4)6]]$?C(\U#-2E8UTL[;/QYJ$/"QF(:D5RUO15B@B, M2,I.82$*$S=L+"W>/S:N57?+QO*NL7^Y_OB0+]6A_UR=5B$+"(90PCA7("$YRC%">00)C@A$<9'%!I2XGFTF8@SLZU=390P= :0IQC)T%'GD- M-MM,\AR1<3HQ0- ;3C&QX3FQ&",BN^+Y>/]UNUG]=F@.#V^*ZI@*M8069SF! M49W\Y$+DC$49H*P7F>8Y5#J38"1HJO6/4G9B!T*YQ<]DZ&FN@6SD*LHKGS%0 M1A9 5K#T8QUDQY32P5BSPT)?ZJ_T] <(BRF@H0ASD4,4Y5DX%'S2C"96N$A! MW'2,I)3SV 34C)D<8:G-3S9R(&L,=0)'@Z'PQC8L"EHK N%LH,\FGY_==E/2,WRVVU@/47 M81BA&.< <0H1Q. H"X)0BT24)#CFD5J7X'901I,^U!!39!!G8&EO,S60'56Z M"OZV+ZN)3_>]"(X,H6B!Z1FGZ-EPB58,$%%FEK^7^]_?[C[NRU5150N>)AGF MC$8\10G-8Q'RM!=&!>!*/3 T13CFED:9-YO=F[M.'4UV441-D5[< :;-+XU* MS=GA7JEY&>81/C(4HP>H9QRC:<0EDC'!1)EE\LUN4]T4Z[^5Y;I:")'!+,E$ M%D;U]Q&.3\LM*I)(Z8$=31&.6690)OC6:*-),HJ@*9*,.[RT2>:(6JO3O!SS M"!X9CM'#TS..T33B$L>88*)S9G7!09(3&N(\)@#3*&$A"0<1*">)S&.[6A]6 MXA/U!W4?GU;5Y!,I@!19Q#8VVMPQ!HOSD[LR_*""E&>LH*3ZR E=1?ME&>#S MJJ:8^VWQX?K%TWI?BA\'5MOU^R*'@ '!O&C&*8K]Y6!XV#\7;7778MT^9-Z>'_J-8?]OL MOM%5_:_:/3&QJ5;;LKK?GZF4I2',PC"'4-3IFN )COK=_#A$J=K[4DX5<;R4 M.^D>G"G?'J+KU0].^JMQJ5O_R/&K-ZY1XUPEKP0GW6LVGHN'39 >X>9)'.@' M7T]C:CG#!)'C]>7VQVZ1+?>[6F[UL=CS\O:VW'V^6>Z+X^4WFM(X3FD8IH * MS$@<<=Y))#"F.'Z%%FR(<#?K!\6"6K.@4RUH=9.YOVD?RG6Y:H=#/3K*G3>0 M/M)J&FB?\&5C<<.":1BCL.5 "0Q>H#B;R,W+8%8M*>V/*]T%]YGX5C!;5IM5 M38YBL[T_%.LG66X,D""$1$F8QD)PDH>$#=H(E"CM+KK2P7$V>5PK?K@.6D6# M6M.@5S5X- E;8W07YY8=H[I6G\\G^DOWY^!?]2Y:GKG(G]6\$L92BWLW7O,C M=W1NY<6EOTM4I1G[_FM5_/.^S@JRAS9_'0($AU$<(1%F,1I3E, M.$AE9[[N]QU.[:-*0:?3;#T^+H$S-B=-\?1DTAF;\716V<%%<]ITE_\SD:<" MAA@1DJ098W&]M.M%13&*B%(6HR/ =8KR9.+H]?O0@TZ+;>RC9L8T\_3Z> D4 M>891P]!+=E$T89Q9=/"0N;5_EA;\\WYS^/EK<;@IU\WN0'5H%NW/_[8HWB]O MNR8"6009#E&M4QP3 >.4@ZA7!Q-&I9H=.E?",3N=M+P*&IV4FX:X]< X@7D% MOOI1"Q7630W%3,Z7RHU23'%\G1,GA-"4]2;KES*.R05FLP3D_-QERY#2 M^B S6D&^.UX8S#,$\T30'(0Q@AS4?)?UXN(D(TH]"[2%3+Z2?*=[+5@?1ZTE MI1L(39>5,NA-L;9\)W%?V!A0+]>8&F:,KS-U<9'NGM)WC_Y2TE7-?_OBY4H(91BFB-$(I1 GJQ2<0@UBIAXHMH8[Y:= SN"[W0?%CM;VOF@-%V\VJ MV%5%=YJH:%4/-B>M%;NM6'. ')'-@KT:L1UA/Y1!KV30:1ET:@9O)=!VTY1% M$KT1XK/N #^(T+Y93]NTN,%-_:QL7_KCB*"8A)PG(NK:0 M.:;-+*T&+R&D-'440?5U\JB:\>KTT<)%/BOMY!1K6O6B3[<0?BUNOQ;[!65) M)%*:Y"') 691R,+CU 5)IIBIFLMSGKT.*@;+ZGC9YZ1E\(].S\ESME>1&\WC M[.'NQ\RS:M&S?,\V6B8W*C]MJM_;&)H+#C*>4$X03R )"4WZV^U10A*H5$(S M$C3=^O%\VLV0$8ZA)+5J,@#7EVEFPQ2)*V^:^$A=:7N[JT=A41T^U5/Z\_?E MW8==T<_B.$TQ9BS+<03S$,819> HC&949DH9BG"^/]\I%C2:!8UJ0:W;ZT', M*HKC!9H) 53=G?< .X5+@--@J'?_3Q=+N:M_%RU_@:4M0>7!A3\+1I16AX\! M)W^I_3N(2[(4,41B$H2Y]9+\O3.H!YR-1:9HQQM3XN6FR=UT.HEY:!+$T% MAPF'4" 4L9#VK84B$B(D51XRE3$]5S?*V2 :%2 UF-H1AL9$/0=\!C3M"$9K M+"T'IQY)GVR7Y6@-M#RD:!TKQAA:&Q7UVN&[T[,A((WRB$5A&,,HB5,.Q;!K M0!@12N\!Z7Q_PI,F[W2/_FKA-L[%4T&FQL.J:#DNJ;Z3..5K J!O!50-"R[6 M3771>(U+NF.H9X+>ETUL6F[I;7F_.RS26,0)I"%$.4TH9U'"CLR5QSB3ZW!K M*D5EBF@UM#UI=A7L>MV"9:N<'+<8XSC.+U,"J,LQ5\&@5$#'D1OAF:I8_?5; M^?!+9W##,JC_N>$7=,8OKT#R L?8 G%>GK%F16EW:.GF+OGF1[$^SYT63$1Q MB 5$A &$(&8Y/C)<&L>)6E=M$TF3\LYUHUZP&9+]?:V@;EZC@:EJ?N,63'T. M:O4*'BV9YLIWGD$DE??H ^M;_F-@R<4\R!0=J>(7K:KBT%X:J#8-%YZZ J$$ MBH1AF/&(X88)&<@[89Q$,)4JKNM_W=T,:G4*SI72:X!J@)Q"M68:!/6*-7I( MRE5J+MI]J5!C#I0'=1H+1I16!X\!D[S4TAD+1"$4$$2D7L!%H0!QGV#Q-$Z1 MU.-EUH0YKM^JW M#J2')&]DSAC=F^.D\XK4*5\]I;+5DT:MD),,D2Q/"4ZS&!$:T>Z^/L>"\4CJ M:*(KV8[#PN,'C\YWNWBY:X.SXB5YZ]C++8_GA%TMEEQ&_$Q;CWI32^$YLKYV MY1D_UMS.K!MY?LH^BNK$RI?53;XMOS=W-HKJ[6ZUO5\WY0&ZJJ/^_;:YT/'A M<-.^9'"W+VZ*7=4>05^5M\6[LGJJ;:TJ(33+:9HCGL$4P^$8#18ID.O?-K>. M$Q)UJW7P2.V@T[OM?&NK]X%%FL.DHJ LTS-'R+5#.A<#&BS>D5 M]9.R*:)5-?.]VRR_;K;MZY1/ UXL,@SB*"8)B[,T!3P^R@]3B*5W,:Q* M=1PJ3KH&G;+MRN=,785*O%VT)38[9@-:C=1?Q5B%KEW#KK 3,AO\>ELB5MT@ MMSNB@M"E;1(G*'NP7^+&KM+U^-1>[M1Y>)N&=[K01[K\6BR;_9SUA]VG8G6_ MW]GY]6LZD6/!^NA[E-S^9V M/;4'.P)Z.%L2::][IG"F\L+',S\:K'R.#KJZ1-5'?]:+G:-%[=ND/NWY6'") MW.IG0M=[M_R9TO;+ZY_)/2 ;@HZ:22CTVZ[\6A7[AT:OM[N[^T/]KVM_U/]5 MFVJ=5(T2F,209X@F$4VS+ U3WJL:93Q4:E8YBX)3!J33T8TWGXIN>Z%9']50M/YR%),@Y=!>=V!:UAP6/+9@]5+KPT M$K%F'11^!*YY(2@]FJ2**ZE3(?'SH19S4VYK3U7=BPC' ] P9(0#@& :800P M1U'_.BG/$8IBZ=T$*\(<)LOGY?]S#?_OX=60V1[VED%N+*>UBKP?4]ZR34]S M4 >(R3PE^:FH!LE=$TS*8)JS4 C*0X!C"'(R2!"YW"4 G>\ZSN3.U%%^5U<9 MHG%V<4$ MJKJ_S 5:",@FYWQ?= \_U,(ZTDF8".O/9P#3)*D3# #@("9D JK4AY0_[IP3 M[LK](6C440K%R()#&S4_UA;ZZI>61H]JUY3K MY?WV<#P+=%R]5(W@OMD<1"F,,QS2),PQ"+,,9=D@FM;+%;4626:5DL(&[>NDXBD*<\1G%Z9-HTCM6NS1I) ;0QM*FP-+L3I4WMZ6NW9SJL^RD, 1"4D:-0269REAK'^-.L=YO?!4 M*@\I?]TQKW0*==NRB@\&&" F62-R"I8:EZCAY*9.]!2.L4*1-G1^\(>!_D]+ M189(R/(&7:\W72/?C\O-^NV.+^\VA^6VETF:;IDB0R(G<9*1%$1PV-'&&827+,)R?E@D:[-YM=T.NGR2Z&N,HQS720JK&."9I..&@4J!$^L@.P']QD MR9;2Q1!4XZPO^_;XW,]S=J0 I"!)2&DF/^\WK>EEX\CD.0X MY!A"P4,@$,;Y(!^F']IC](>RCNG[MBRAEQC9 M UPR29H%:\6$R01F-QF3+&ICV9-UY/U@.@=V/^ M7EB>TCA$/$DH#!.<$12RH705YQE52K(T13@_=]1I=>I+J,=RN@#*4=H$V*GQ MEP9L3ECK96!&*,H023_XR-2(TNKHTMRUY]ME5?77*]I]N"06!)&8"D(30F," MW&:(;T=>V4IKNO8C3['"T9F6_7J""INTSL%3[&NK82;V_WYI[#([,UK M0^D'XUBPX]*>O"$RTOME9V+ZC3D(($\XB^M_ACP+$\1Q.@AB*58Z$:GQ^8F9 M1FL?7@V?_^[XZM*<; M\W+_OOA>+]N:QS#KI.GCOMS5/ZZZLX\MCZ$PPD1P&E% 2<8H(=E1AQ!'2HVE M[$IVOK=V5#:X+O=!K6YPTC=XK+!6"F39$;*;;W/Y0'4SSB+\CG;G%) YQ><:-L4]/F7$W.SRO8#*V#:?"8A^ M,)&9"4\W^LSQT,O6>-M"NWVWX4APF]UJ<[?M;N9%@M3BXTCP6@/"8IH)T>N0 MI E6.IEM5_+$V5JG;O]TRREIZ#6VD*X9>T(G79O2"6;IFAG^$^1KKT IG:_9 M',\=*MYK (X5]:R![P!R_[&H_[D^&Z!G36+8S[,_]+^X6]/;1O%NPP-D&2&1"),LHE$: MU^0<#JK21"AM?,ZBX,0,V]H8G!FIE93.XTHY%O;>BV;$K>Q -_<='8 \0NZS M^M2/># O!$\O:\[O#[U*QA/%^QVO"#$8Q7G6W!1+.< 0YL=)'$G.Z0TUPG3@""<,JHCH")NZ\HT? MS.K,NG*:$:[=3>3SS;(>YF=O6B\BFF @<(P @ABFJ8#YG;_TK=U[1 -?R=+M5*"J$:,^DJZ[ MDSQ#::PT:P-8XB-_D^0I3RX0#QGF:1J+%,8 A8BG>!#$4LC5 MF4I#R"3\]&)>\?*%4M7;)>JHRO&38RC56,D&?HYNF3Q%:825#"#U@XM,#'AV MH<00"ZUN)!W9+5*!4B$ @Z2Y&I?2FN*&DY$D2;!0)QX=*9,PS^->&T-$-VA, M(@NA',NXQDV-9A3!P)JZ M0D(3AA#" $4XX7R0F,94Z3R-B1S79Z)?G"Q7P:"?,2E.IR/-TL2N^-1U.OFBRE:Y0^8Q-&J- .W@IU9W>5M5]L1;WS4O. MW4&0CH?;?_FAO=Q293^*_6I3U:2^;8YSMRT%??P;GO_=Q^;/]:]IL>EP%O4E7 MP6!4U6RN=99KU+T^A_C6?XQ3K8S/YS%U-30GYUVIN;MSH!V^[-/"EFIU+ M+ TYO0TL+^N!TS1M6O"!+*4Q(ACC" QZ(!@KG3FQ+]TUH[=M4CJ-@T[E?F(? M4[+N5WK%CQ1@AZQ-W&+$U1-Y1&,KPZXSIF3ARYBJD[ %_WC-P3;LDZ-@:TA: MR:J;4]?[S:I>F'=MPIH$XV_[LJH6<<0Q3:(X9!%B"<01S**C,GEB+[/65V%& M+AY*?R?E>RKH4[36 (OYLX&?+.30T[C('CF;>6?Z3/DBOKK9LKG#O&9K:T:J M9,VV,+61.8_HPI,(IB1$F(,($IIA<-0%0J#4WL>-!O-GT.Y)V]1)YKGT-/ZQ MGD_[S]CCZ&IFUN;>\IJO;=FHD&';0E3C)N&7\L)33FT<:2MZYX6_3\4_[S?5 MYE!\+O8/FU71&?&I6)7?=NU76GL6$1 ) "06849S'.(H/1Z.2#F+U!Y-F5M9 MQS'@_([=H0R>/*(6G!Y1NPHNE6,;*NI-#7I;>ZX*SJS5O@,YTQB1BRNSZ^DN M!,T_,ES?WG3BL9&PYLU@\2,"^@/'Y4NG/OA)-JY>>K3G71W*WQ>'#]=?EC\^ MEOM&C?-#YE_*[HCY(@I#SN(0HHR3*,GJE5D\W)"@/!9$)6RZUL5Q5&S5#Q[I M'W0&!']N3/C+55!;T70"K>VX"GI+O#B[;XC\"'U-Y5,_V&DR:\MY9H[BW1B* 020H'A004N5(C M/G=J.&:4D^9!IWI#'L^ZH@]MXXYG%,Z;#2O>]G3H,;GZ2491&(,,IH2)G">-Q&+)C% F3K+]+ENW6 M4,[) XFJ4&AH&%[V;,V!Y2NN96/^3 MX1PTS2]Z01F&3'6.:(B88(K\'WM)619;/V:-B0&O7U)6P\)*0Y=:5)CPB#&0 MP>:1O3SA0V]/D; )YM'_#UJ0R*+LQXRR8XI*"Q(U?%Z;9PTD=]D3,!4AATP6T$X1#05DFL^0V^+SCI713 M>>NU"EJU%)_+-@%N?.4[$69J*]HYX5J7J_NFCMX6Q^>&[9$R+N%[0MB->0T- MIV&,PI:$+QO\ O5:0&=>PK5A0&EMI*BE,)^*5?.PY^9ZLVJ'34WG]7I\M>K6 M\,7Z4K6V;<2, 4V:<\D0)W5"A?.,T6Q0*8YQHE+Y=*J(8\)^JGM0WK=EM3/U M@Y$=%YW&^F[])E?_],9E:O'"K;><)+,F2(\DNY,XT(]D>!I3RQDFR#1\W[>B M3B,6)31BN-8B9@+F($X'I9*,*C7 =ZR*YYROU3G?M??<\KX#QTW+_+-TXS=# MVP'[*[KQC\W_JL9:B@!:&+N. ?U") -YO?I G.5U:*JU((#W!S P0$D<31$# M)%7Q/ 8HE2FF\I[;&.# <=/& ,7:R+PQX-7'$"=RXQ\[!J@::RD&:&$L?4?E M)/]O=:1I#M_Q9763;\OO_U&LFU[NK#OMV-ZH:M&0_&_UJ53X5VS805C>;N[;4%7*$:ODY M9K5&$:2"-QL=K3*012!4"2..5' <-WJU@G.]M/8%7'E CN\] %^-X'5P=\+3 M>LB-$+-C5_C!Q*Z-+"<=WFI<^X*TOFK$XA2D"8AYCNKE0IKF' T[!Q"$0HE. M]:7,PIA:574#).5H<1H0;3#?+!7NB_",T)LYI'XPF 4[2MN#3?$0[%GR6S"%T2!+A$"I99R>!,?\\W@%V,PDO?6Z)GQRQ.,>.372 MT0#-S>'@EW 9.Q5LA*,?3&-HP]-SP!80D3H G)?[8O-ME_U8W30ML?L76C_< M%?5?-6T)AC)I5!,8$)3",,HQCV(LR+!5AE NN/218%L"'?-/KV8PZ#F\=-RT M!"^:OVYUU3D*:PWQ<8Z:#6PUROH#X*QP"'D.O/6.)=O"7>ZLLB0NETXOVX;5 M@_/,UDTJ'0Y#A7@RU$$_+0_%Y^_+NR_?RT%8Q!.2A5@P#AFMD^.<'X5ADDB= M;3,4X3AF'/\P$Z!Z:?!4(_;=;&4X_*+ MEE]B;W.H/.!K"T:45H>/6A6A._+PN1Y([:LW[\KNK$1;/Z4" TRC#/*$\HRR M$"5]+WR,PS11.G!F(LFPE*5J#5A=%)I&,%H MI-Y@ UD_J@Y6+"GMCSLK[-375;,PBEG"8I:+)$1Q(B+,!YDQ@U*E!SN2YF,H MK8T70UB-6,H!HM9X:I9=F%&BT3O^)CCY00U:FC]M3*1MO7RBTBW;'I?14,Y8AD.0-$93-15Q#IUG4TBVGVTH]7H!E-.4P M@=$//C&TX5F*88Z(_/7!-N;FM4F\.5^\7!W^OCG<\/OJ4*Y: 9!L&@=/"]UCH8 MU&Y>=6OCL M9I]K-*U[@C/#KLYOC 7GYG6D\^C",7\;;&H3^UO& M5\'1RN'IC?8]#HM709R.";F \8<8#FI19?Z1,/WE% -/C02JV0>'']%L?AA4 MKL!,YQ>#HZ-#I*Z^%/O;!8=)(G(2PH1%"4I$(J+A3'S"F%P+0VO"9CHR>LQ_ MJZ!1T_@(HR+"X]%B%G#56-]37(V/A;K#U^Z14%F<38Z"/L)"[1BH'HP>'"FR M:L[KQS]-<'HM'FQV#T5U.(M>[\ONS4-ZVSQ+LZ HACG)8IQ0FD 6Q9%@@[3F M7\F$ 5,9CME_T"98MNHT/8_6IW1UW14_#@& P6W-RS>7 M6<'S<6*U%N'7$'%9F^B/(KU8GSBO3AR'7/.,0&=R/]S.K/:R6F'L2_/JQ73# MZ0]5S9@0%KWJQM1^DXW.@Z8?=OERLV^?XFY;0E7] ]W_5:S?[K+E?K?9?:L6 M$8W3C+(HC 5-TKA>!L&C#E2@5"7$VI7L.$YVC+=M&>]Y4*0]Q>UJ0KOKWT6I MFH,[5^U?U6GS0757UK)?Y$+:?"Y1BTOG\:>..(VR0:MMUUJO"D[Z-EG)H/&T M,44)S)' X,8I?K"[(]O**8:U[BHHW_QHY)WN2BU %+*L?[<0D$00O=L6W)LOZHG*]1DV$U"Q* MNUGT3!OU8YA%IY;1B=7789/+'YQ 9>64ZJR'4^6/I4HCY@>':&L_?A15$05Y MKGBHUV;E_J?85*LZE;_?%U^*'P=66_3[ J4Q85$:@IQ FN193BCJ1-(,$*QT M:,E(D.,@/.BV&7G2W0%ZLOPQ$7"J9-*K%9ST"O[1:!:TJDU^]/TR2J-48P%< M7WC'ABG/2,@:/K*,]&'_;5DO/]K2$"]W5;G=K+M[R;OUQWI #MO='Z[SS6ZY M6VV6V^.5P(I^K=J]SP7$%)$DS"(B0BIB GB(.]TX1QR]]D#OM,JXFZ7G^E\% MCRP(EKMU<&Y#4Y(Y6G&Z3UL%_Q@,F7A.6P%_9/)/ZUP_6&)BF\LYIY,:[[PO MOM/5JBDRU\OOC_MR5_^XZB1_V//V@,7;W?EO;&K][K;%E^77;;&(4(9(RF", M2,PB@%+(Q:!3EB=8)55RJXGKXQ'%]^"D6_!8_7I\!YT!30GRT:_U-M0I1&.% MXF5#Q[Z3BQ7^N$TM1KCVF)/88 3V2$R8QHE^Q(*);"WGF";*KWCUXNIPLULO M]^OJM[LZ,A7UZ(M#V%\#C06(84)#EL>(DH1'@/9'@7C&6:AT^=*.1,=;$.J_KF4#<#EBGAYK-0*V K.K5Z]>1VZ$3>TB[P=K6K;I^:M4 MUA%SG0&_V^R*MW627BTRA$1*2$08 @CD(>4@'/1**5=Z,<6]-KYGPHTE06O* M1.FP@B/=IL1N?#AQ6BSC/J]RXR/J#O)C=8_ZP?83VFLI3]9%6NXJ8+.%37?= M6[O-=?Q#M2!APA(2 X&3,(U1$G*&!C$ ,H6K?QH?=\SAHMAWQV%.!=+FO$93 M.NT>M^[45+F2IH/@.-M. IX:>78PT8EA4KFIYQ@NS9MY:K!)7L1[;NH+!&^, MB@\7[4S4+RV-#A4V7:XVV\WAY[MB614?OFXWW]KATCPX>[_?UZ-G$=(TS""( M8Q:2-.8Q%[B_S#3/&PPUVQ M7S;I>ROXT^;;S>'#]6]5T<:<1PJ:%5[4UZ_J97KLLF)CW", M 35V-,,*P'Z4$"S9\O0HA46$9-GJX[ZX6V[6GQH^)"$2,X0@+TBZE MWPX*F60C"MCIY"%N0#/,0-Z]"MP$B<=1">F40QU+/RC%V(K1-$,7%5FJX5T3 M@,U#W]KPP_6379!^C^/M[F.QWY3K#]=T7=ZU-01$.8P$:AZMPAAR2$.1# J! M"#.-2VX.M9&:@,;WX42QVK?L=2CKA.:PW.R*=5#,G YD[MFL9VKBPXKK<%T];:S4/9>"80PAXRG"4TB2/>$AHJZ ( 2;7_O[7[#DU3]=K9]=^^:;I4!46; BDN_2=TH62U MP$_O*188VH,QCZSHNRCVS:^N@L:6H#&FZWSUJ#7C5?"U->I9B\:KZ9\DLN>/ ML;+&]$[W8\TTA^%/BR=S82_]NNUPN?;LPNW'LHMSQ^NV691F$: $8Y)11AE* M>;><$S!)()2]2F]%EL/4_?A^]*-K\(.&LUV"EX%M9/I;1=V/B6W7I*=/R]K' MZ[7)N"XVBW?%M^4VVQTVAY_TQZ9:Y R'$*,,)7E((L:(Z+N."T@XS*2N&NI\ MUW'6U:H3=/K4,ZK62'+)JX71."^YAD>-?E20>8%GJJ8G"2//2?'3(3_ONX_T#]@!%#*(\2;D(TS!)"6;A\'F,!9.= M\TH?=3SAAP'=::,PV=60>7VF.P-%;9K+XF%CBI^;?&%^:Z$R_^364[LT' V* M+07:LXO'E"%.&(I#R#C)XY2'F'.$CD(8!$J] ]0^[7B*JUSMT05';H7A$!>U M6=XI,MN2X3$.(XL#3<#\6 ;H*O_TPKT)!M+G&NK%/MVMF__)_GF_>5ANVX96 M![[<[W]N=M_:]MN+*(I & *19QR2N%[IPRSK9:<4Q4H<84>B8^IH"W7-7QE@XB,@,LB-G?:PBKP? M)&;9IJ=G.!P@)DMYOR[WOQ>'9J_L<[&ZW[>[*;R_2Y/53)H))FB.3#&1XYC>3JH%U5$W-6HS0E&.T*8"4(W&SK [J745<+6K=':(:P2A M$;JR@:L?)&7%DM+^J-/J\=:\;U+45%A+?E\Q!B%),M)'%/"P" 2 M4J)TT\Y(D&-*^K)?KHM@V6O8O-K4J]@^RJ35PTT34,DEW518*B[P!@ _G0%8 M:S8308VA-+;\LP&N'Q1EQY27>['9P$?Y.89:T@*&+$0L27$>QVF2Q74NQ@<1 M.*&9V@4;I4^K3!VM6S4R3RZX?2C@_>@%5"VT_)@+>JI?:ORO;K_2&;>N_#), M*AIBD$*1@/J'>D42\3".CY$_P^IGU=0^[SCX#A)JG:9WK\=W&FH=^-= M T>YZ.L80K68>]X1::8X^QR/UPY>Z8'G!X^8&/#202@3+-1V7089B$0X2G+( M"&64,"(YW] ME[F2<4E^T /+#VKX_\A[T^;(<2Q;\*_PP]A,EIFRABL(OO<)&[.C+3(5':&L MLI[\X$:Y4Q*[7*3*E\B(^O4/X.+N6MP%@ #(J#&K[M06CG//)0\N+BXN-+&_ MN?6BQX!\RPK13F;W_1-_0':H7HD\Z).H[Q)Q#>:!3!($24A 3E% 6!"3PY T MR-5Z6(P8R'K@T6&[\IX$NC;N* =\&BO_<:3*:8DS/M6DY4CEIP.5[$CE;ZX; M[%RBZ8+X&&%W'EIDQI17736,\:-P:RM_T*K;==?"9\M'8M^6Z_VJJN]_:9K5 MG]5ZO:!^"O(X\WF\A* ?B-1H/@Q-"56\D=' @):5ZXBQCW(TU,H,L7*JY9Q3 M-?4ZH7.(D3A"[Z<#1F\ ^1?GE\.^R]O%;(U!VNGVWK&F^9&7N\/$\ MJ LR F.?,IRGC \ A[([A .FM DL_:&6Y6K H290\I3(B9 5-M2$YETBK*B( MA%(HWNQ:;(9%N>A&R-M.)_&U69$+9.["(,8 M)3@#..:Q2!Y&"<2'M5:$(ZB>PGWW(YWD;O5SMN]3HI*L-,F3>KL?RPZE6@?BJ^BV(R#H'_9+,O5R>XAMTP MB!(2(D"CG"1^"AG%AY(;'",Q8SQ;K7 58+$2[&=!5?,0SFM6':F&M8\>_*A9%UNK^_(IEQ5QSK< M&"1\Q4E@!.*$\/@UR(6C0.!->16JC^9!6E::^ORDW MC[2\/8R4Y#1B<4[\*(8T!A0.':SY2#E#:FM1C<^WK"D]#.^IV0PW+:XYRI_Y M1SUZ*XY345MT&)24%LOD*2K+@22!YZ LWJ_%[KW3G79$YC4[ES1F!)D(LO5;O:N_",G+[-Q"EJ,CB ]DY07WE'W,\O M&CBY FBB6$R?Y MJZL!S\Q!=%X8VSM\*C?*&-]:Y/F LS8,H)"S*_3C$-!U* MI @%4:)08=!A8H'R^3IU#Q,GSH[P\Q[=0\CN)R' M;(VVXJW:A]&L:.R:#@-1%$ _9Z+8/,]#E+,$PF&@,,! I1)"X^.=5$6,EAD= MWI0W.FU0IKVE.5E^2T%11G W#S$98\#Y/4@]+G3R6B?56A!&*(1AGF9Q&(4Q M'S<:0]@NJGB6RKKRUF*ILGR^AM1/<*E0J9[CLL3BN#37\73( MG!)>4C6<([F=B?J,-.)"YDN;$XO)KQ-, 4-1& 51$F8 $!] X _=6 G*<6PY M_Z6 Q'8*;*I\EXHSK*6\+/G!6=9KJHKW452;S7UIN' >XNO(UO$9,&V&I2[@ MS?NJ@_8:\.O;=77?CGXRJ)^$;;/&*(JSB/#_,< ."V&F<-GN^*$LB_$ D$>6 MXG+MY@!QY,V@[QK^QBMIF+$9W/AIT)C&RE.E%@#1\J[DG[^Z*;Z=+/T6*(D M17$8) D#0/G7<6>9N;"U'!2#+G,=V/-:(Q^H I[E(]M3%!?=]JW%N!04P9#3'&+$T3 M2!(:P/2PQF-)IK2>&C^:90$Z(O&: 6L_9>MO8XVG6')#RRF[BEM;!S9;<+-8 MZKS+UZ4-+V-),?A9UX#5)GHD@&#'EG/UZ;&XTM M^06,!PD<4RXN TCP)SZFGOQ[WZNDTUX$YOO[S.DO.MNE!SM[?;) M=MGEMM>E29J'+F@A/[^AKFB]].U]S>-CM1/='\6QX4,>=BE&C.(4PSA@.2(X M\QD+DV@H_Z&)'RBU.!HSCO7]IP.T[L*^4W#>3[\UN](+X/FF@>9YE=,/5Y2J MZRHVWE9[VP?^3O'I M?[][:#;5O\H5_W&4_C5J P(>P_XU'/ZDVFY%%XYBY_WGOBZ]R+_RQ-YQ^X>T M7):/M^7&BX+VI_#*X__DJ5SNJJ_E6K%'@+J3Y(,P:_Y1C[RX:[YTKFG17'D? M6H+=QUVGG+P3;&G1-P_YTH?_1E@U@@?I+DVK524J XKUIZ):?:A)\53MBO7) MZ(LD36-*_$ ,&\8I!2D:DMPLH %6:LXT?CC+9S.'I^H)CS*D^,.2^]2=D&A#/(]#\TR:=#+-DJFN9+5 MM9M-66SWF^\G BK.G40!2S'-2!RCC 9T6(RR-$-P49?WQ:Y,$./^[5XJ=O-/"Z!3YORH:RW_,7Z M4"^;Q_)CLQ5WDUS?W13?%C ,<@(9 &G,$(PC .APM)_YB=K=1Z;'MAV"'>$. M%\:> O;6'*MR)TRSY$M&9A/RKABFG5#>U1$\P^IU8+V?!-R_=-B;--Y M9TP50B\%<99<,P^!M&;=ZRZ9%EF4E=;/Y:ZHZG+%BDU=U??;$U2TO*N6U8YK M>A)1F,$ 1RD(>-"?M!T&.1*=U\:&,ZR@ X(O;*'J*:6)OB4$TC'5*IIXH'% M 9WWTZE,]@ =7QWW/F,71,\@W?/0.9,&-=8>S;&[FPM$THSF( C]').,PH#& M0Z$'8YF?JA1@:7R\DSJL[;.=N?+R91".]MV4]MND:9S'JS/&@'?WUQ2Y,'6[ MR@+[29R0D&$,^?]+(?;3X#!L$">:E8IZ@[DN7VSS-TJOD262Y>9^I_RJS?QO MWZ$RKXM3Y"HDQS$[#Z4R9X[B!2F*/"E4!SSQ%5)[()>/RP.-:E.*^BE:;9?K M9KO?E(?Z! Q@&B":!8"&OKBF*B:T18 SYM- ]KR"R2&M!MP]+ ^7-0^R=MO) MBG 4&+N\F6V<]WF\E%8L>[T%;HD]V5?UD\ADM(.WZ8U/#1_M@&)X1H]H;LIO M.[P6FUJ ^CSZB0%)$")^DN1!"@)_UHQ M%6'/ 7+".0ONU52TA]P&+ETJ]SGJH[8><7M_".1>"]VQT.HR?$%UK3MM'A)L MW\S&\ M5)MNFR^-XI3 '">,81I1AO+^?A4"$I0#M;(FNU L"S7=EZ(NIZE+[SO'Q9_< MMHNDXA:;96]([KC-QQ%JJBW@>4>T5][!DI_OFLW/6V[+U="(\CO_[;I5'U$H M*RY2K>K[=7GXM4?Y;ZZ\/UL;/6ZD)ZR\\H2=4Q0GC'/*I4T\-]Z>A]R[,O;E M%I]+CJ6:L\DB$D!N_FQN'C;-_OZ!_ZY%_-BN\G\P9S[#/D>GRG5B-,'K&[.T>Y_- MH)^C6WN;J=X.DRNUXW<+D%,_2S."*6$@9 ',HVP8/H5!KK)_9VQ0R_MX;+NK M'MM07E6ES=-K8I%EB5GCRZDYK8&.WVFO=C1H_Q'6-3IF*:U@M'F3K^?A+[>( M$J[O2+%]R-?-G]O#M@5 4< "PC_>]WT0,X()"/*< K#*(AETQZCQK#W%AY@ MM1=4BVS"D_7G:;I8ZV. W7F\;&9,>57_8XP?V9?JMW(GAOJT:;Y6JW*% MO_^^+5C_DE&6)PFD<@XAU&84M'^N@42Q[Y:-U@+PUM> MXK=OWUW[]HFGXJ1';'' JMA"Q(8/Y.1N8OK51%"D$V+7IJ'F-HTL''VQ*OV"_B?_;;K]G33?"X%4]6ZY/". MISUN&E6H 8EHDD0D"D :T#B*<)0/4,-,7/:HTF%@ H"6Q?O$)M&?:#-8Y=5< M6ZKN:!;_N?AN:5[GIW&YY%)T[MY6S/<^=_3!H/; W;,S>.+7/\JL8L-)E];) M4SX3\YB9IJ7@50^(R?TA?WW-$Q?7JLWG\Z_795]ZB![%19K_ZO8H0IKE(B7@ MQUD"XACR638:A@8(*Q+3G3 VP)1C($6[H&YWW2+DBO4<[G(:5F37IU88YQOLQ?58HV&_[@M@F>+7D0 M7WZH.B3)(?0SJ6F=C';SM6T@$5) MWIW8$6K;*(H,ZE+U6M2)K]D0C4[5K0O^73I->E='-$S"Q<\ M+CT]E;)@29)"BGT*^<=#$.<9C8?!2$:5+C;4',*R&+6H?KX5L-HV/ ,NK_PF MOE;8KY"67T$4:8,*%+08IPC&%U$]0.HR:QC%=?"TW MMXU\0YMQHZF\/Z? I%^C 6#?H? 481(/4C5#CS'H>[7A%M.[%T/I$RB;-''*HFC#KZ>OW05IPK7Z) MVZ-[?--<&GV.K8N9,D-$ST.VS)ESYDII0SS)"E?>;,KJOB;M'8O+[S=\0;H5 M&ZA-_4M1U6++ I=W_&]$4T/1;LEB+FSV\NPZ\M^S1M_U:O9_N.7+%*].,>D%. )TSKZ6% M/4IO@.F=X/0$T$.GUML6K?M.K0H\7E!)&]Z8AV!:L:RQ_RRKR>@PSG5-RTWU MM=BU;6&WNTU[;$KTA?VT*7DXM AC!!.^BHY\2H ?Y)3FP_ 9!G4T%!C8SL7 MT!.]]/C[S%WT9['I;J$4>]^*H:,Y'\@IJ%O>M>3S1"$%P4>! M=2N>LA1>4$[C7IB';)HWJ['\]*H)YE$%CD ^U%_+OGYF@6D:,ARF.,C2-,KS M,(B&O6! &8TU='+LD,[E40BCU]XXM^$?=E\M^S:77G5$K2:1HUF74T8G3&L) MX@F[+[3Q@P2G5C3P';(N2)\IFN>A>,:L:>P\C&KZUC:.^HU;7FP?NB4]Z[81 M%XR"*(_YH#C(4<[7\( EPW@XP3K*IC^8&TUK\:DIU0C^Y#3*,F=:ZM1UL>M! M'UR.^^^?Y>>"((WG=!Y29,".QO33IB8_? QQWU-)R^Z_)S7&_K9MV\$=3XYLM^6N2[6?M!M7$RZ3 MS,LIV42DJTG; -+[:8#Y%\']\?A&#W6RLQOR+%X00 NNF(*/[\/L6.A/ U;4H2.(+UN8K?&)/>E;W1?.D+ MGE@7UYQJT20&TC1(,5?6$-,XH7$.OS.5;:T;'E7K_09TA>J3YORJ:A60]%,OY@>&K:C M=AVW"' &8H8S/X8P!#$.04(&,'YN*%8S@L2-M/50AP,-W4*WNW>X6_F.%3PS M7M%50G>>,"F1@U-ZN">W6:#+/G&DFS*L*@FJ43?-56G-&OFN!%O@=/RJ^5/Q M702OXI3O'GU82?9!C.49CPV=E7NS%EFU^D][*Z?0>_!CQ*^ M<;QXO\2NUG+>B+OFJM]FC91>\AODU'R#R46>AD$01BE-(YP10AG!0P5ZFK?= MR^2;5AL<5DFGU=M6_S8T&WLZ:4#U5K?G"@P7*4)XR%F1)2BD@8481.R2C,U_GK(UI"(X2 MOSUJT4NUQ^V-N3C$C7?D]'@2C^C=5VS8"W9N*5:C\X($VW+,//37FG4OKR*V MRJ*T\HKF&>5JFW,>Q*"H7@UWL%[?G4>T"$,&0A P"((\2_V8YLEP)P:,,9&Z M?-(V!LO![P"["WT?AYMKFXW77HC7W'G%ZVOR5D(6M@<;%(78EK,D!7D&?E(4 MYF&W"=9HA MMBMW&0NS>\ G"NX)R*UV'T%/'&F_SZI*M&W01S-1;IL6OA=U&V?32.3]:['Y M1[D3$\C)S!'C**$$8P)@B+"?89@/N1?(TDSI/)?YT9U&VT.$[5:HS7O,0.!M MW5G&0^XCXA/9GE&0_1:CNN'U*._,1)[MV:<24AM@4CN8YL">RLWN^R?^J.\X M*L9_VG8?73!$@S3RLYSF.<-!@H)\R,K $&/;']Y3N9%,J:I&499&,$G2((]B%$=9 MC 84D.9LT#PUN3,UNH;X:>K>7;/Q?GJ6"?O+LW!$LLS=C4_4=-&I,\:II"$O M6-5-23HE5-2T8^:EJ<:M.Z.P=E@T?P!A@0)&TCS !*0I0RS@ YE!!F)0VS@ MR);.L$J[0(:.;/VT'\K>WSI_8.OXP?L>D!/6B'M^X&J,8/;XWRP2@5=46_434]@)[QX:T+Q*H+K DOS5IHC1@H)[CF MN%1-$ES?B5KJ#]OMG@,H2;/=;1=9GE$&TIR@@$9)ED4P&$JGLICE8Y*@.L.Y M27^V)>55#\Q;"F1Z2WPM1M66\]98'+=T'PKS!V >NQY7/+;G.@&._3#R@1^F%"4H!8@,S?L0X$MDC1!)>RS' MV\--[7%)>_3635%[=\52],/ZKB9*^K3*:9)=*K4DZ0A)*)$ ]7/+HH#E5I'. MD7-!D$;S.0\]&F]&8_@Y&Z%&S]2/I#XD040PQ4F:HL!'03",%T9$IS)/?S W M>O3BA1H3(XW@54./S'-I0I"FC)'.TB,K25J4SE"3].RX)$HCF-$H-^%#]W6R M?,SF\;&IO^R:Y3\6699N6K$*K?C"T6.\%KMZKC]O?=!7 M:S3+&2JQ&?;T+,MR2)V_$#EO7_/'S=L^%)ORY]MB^_)$;['9B*L?=) M>HK+OC?&I+I:=%X/SSO@F_"8[EMT2::^QE$]$RDT9\^E8[<&F-(1PA,U;FON MWMC&7- T!4$$XB/(D\"F)DR1!$/"X=]C]Q3D*,Y4@T^C EB/,#JM80 M"H>0P2'M%R=PW2JL"I$7--:*/^:ALG9,:QP\SVI**T9Y,=+G@RST2)[_X.0O M/Y6;JEF]OD)MN=Z+#HVG9G6F+G":!VE(_)ADE-M XS09*@8Q"Z- );:=&707 M\7$G)I5589\9K9)3P\Q0VYMV]<:7FE7
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ª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
YGK[! 9KCL.;O410NF$BXZ$3K+'(T0[$W@#WC.T2:QQ;+:W5SGZD+J=?[7#Z>M3P SP>I%?>5& M1X.?K,ES68EA%MZ%CH6MQ+*?8 OH#8?;Y%<:E!;='W1P!@ M5UQ-5H4;]0Q +=KB(9D0GR;6(",W-O:Y&3*-.@$.9^-ND%;B-7FT-624(Z47 M-QZV#H"GS6MK!&^6'Y; &P**@<9*T+4T'(!7O;$"<%X&VHN M5X4&L%$.'^NH3K)4I. [>'-)GDX6-HC[)XH@EF)I96"X*=HA-%3(\9SS-5%I M%\^CK>HKPA#6"F6\F+1E334,9U4G!R3[2B.1ZUC'+Q^L*,=+'SS\C/M7XL'' MG\%&<_?Y(7C$%=7>)N\[KS#?R,&G6CWW!82EQ?W#GQ'_+GA74R(H,\C113$' M'AC9&61Q^&*@XFI7AQK#Z&6*7$URNL6Z'4_0S\/'UVT^JCDBJ641I@AO!730 M5Y=%N40IP^!:Q\>BB2:,(2.)-ZYT$9)3=CM@)-74CCP63 LT,KQMUR[= MKRL.;RM%%W(22,M+6]X^ZICF,G)'5."=.%.02Z(2F0XHE=6E#]$6^VURP#96 M";OD@N"55M5&'&TZFR8.:?-+"#QH^M:D#9 M[IL901,9R2R$U?'+ KQ3/X) M>T,"#40]WG]8.3O!B8)8F$3H]GF58GQ6\CM^PV["_!,*8V&RU]U% QYNN.NR M9^M&MFQX-S0-C-4A;P'1-:7'0O!R]:6LGJ^J;5HTQ >6R&O7CD8H*<%5[5R" M0\T;\O,)2+(9ICR2DQR51Z&CA911E-R/,(+J(N3S>HTBL&PA,[3#R,IG)GNO M.6?9:*';KQ(IQ<^E /P&LNTO^H8F*(OFJ0S;VKWY?!/5CK?;!NU134]ZB)@D MN(17;C:"OYLIQ(_'(9D%\K7A*=IF"]R&E$$;WOHV+28P#?J&5W!%.H(L&+D1 M=5-,AD+KTV$N+T[EF3R>SLG@FA^^$$CS*O;-F(0?WN>SO,KG>8;-7/R6DUWG MH.2%G.QG;L\C[\*?#+>$,R>+DM)PC!P42DZ=ZK=YQ^5PQ9$A:5Q0&OFR=&/X MJ2:V_8.WK]Z^^\D?16@?4G-QVS*T$:LWCQMLFCFR&FJH9(6GA4VRD/LXN7"; M'PV[N3HP5]2)JT5IOF[VL[5P?O @O(YU!\+75Y+.*I,MLP23&0W[7"$?'SVSURAL>%/EK_Z24_N=?MA+_PW=> MB?^:*:WGH5QJ4[E<-Y84\<:47'T;HX85PQ8K#K65:=A;\X/(F-FC19>]V%A] M/(?:8\TF<15?6AM0?F24C?ASH!76!H 8+^#.(]T=@\^T)IVSB?($<0: &Q?P M'/0N.(\J]%2-9]"=;^,6-E.TM;EZKND7',2JAH5@(^$N5Q( !72;U5.JYY-S MM+0UA@U"[X"PEI9HE=M"&5)5^?R[*0W@909CVMU?1B9XX]J#N.SQCU^8*_#K9E&]$RZI:>*" MQUYC'G2.\<#\T2(+1?@77P/0(I2T&K+Z$GC1(C>OM&40R3,94KV/;]&HA-CO2[S9H]+\6%_"X2 MUV_,AXJ8!A1<("UHJ#%'[BLC28KF:$ZY7%I#]O$2.57]F@5CT$('P=$N M05SQE=:V96L:0RE5B V!WJ.HN9N:3%".!"=$**-Z5"Z7<<2N:(!^/'E/:Q3_ M=/JK5\"3V.VFT0SJL"UMBXMRRG0!U^U%<_OZX-$4O,<&([TF%CBC8D<\3.W- M"W/4QD1&BFE!%$4JH= ,D8C5U_9F>05FKICL AM8'X!BW]274AD1K/ M15]2 M&P#@!"CM1O4<_E)TC"@+4?<=59](R=:^AD%AF:DWK8+A;P_#BM!.4)>(*SJ- M0'SI)TIV8=9]@W7C%HJDW7U-8JF<6#&K%*M]R_;5[+8NR,)+SX:2_Y+(L!ZEW,^01\Z"W!MPX:HIY%EKTSE?T%/Y[T1G64@^4;R*0:3KTA "R,T MX#VNM5%#(Y,0H;(8F@#(%DQ1M6.%<[P[967 ](:T;\B#BC":?JY]!A)3CZ)H4@QEO:$M_>-X^<=7 M7;(R6A!-"GJ[ZY(03'&$$\V0G 5'@29'BUAZ2!3LEA1=E0A][ASB&=6:NE+K MZ]=#;,90[L-,XN1EQT^G7@ZJU_-%\0_)$1L#5ES6RTOFWX@P@ 5! A=)'5G MH411/4@+(,;^BEZ/T#,A*;T%M2 F)V!%+)H275<*7LHFZYIX\&<*':EGSH+@ M4=HW0%'"Y'Q93[6MZ[K&@:C8&%T6M^D&N&6U$]5("RKP][[_R.&P]E_=4. W M+3O*%\*0!UFP=G7@'COR*J&!(?MV&Q3^N'X?.N9O+8Y-_D#EPCGJH)^A'OLM M=?Z\"5UHUYNSV["= ])08__D9_9K0$$PH M%"P:_TL6@8$,V3BSL"J:="L/JY(JTTF4,F ZL^2NRR8=?/T86YN0C4= -NJ* M6W+?\Z:^ZH0[2=B*M) GO CH#^O7,4GPHG>>,)!V^O$LXDXR3!Q+9ZJJMO!4 M=0:<>9A%A$U;6)D6-Y'58I9,2[$!$5OR,K6,P\TIJK+\!\[[FW$=>X-@!VO> M,#QG)J*KN%NJJIC)1-(,A]EQ5KH4*B0?!V;H+VGC#A_%!&XGBF-0!-WCM/XH MBKE1GC<%8W:=J7.;@(H7^:1=$;0[U)EOYLT*>+\N8HH6)6K^S02 STF;&4Z: MV8R2DZEGOAPU/H[-J^$WK9GS:9"0LZAUYD^4% M^+-S!%3+;>4&!F)L1"1G! "LNG VW M)*EOKG<)MC91!:R[$.CGI21LV/WAM1 MKV'=%-X9MW&.-$KYU0V+E_M%'H'E0O2D%F08.A41G$B-DU&X-*JBA'-?U=84 MB&P"N$U33[Z"POGE0N&?B-&? TPN!#/\BA^%-_%2;J"P$-G?<.J"NY8B98:((+)/ETY]2@VO2#1^5EG1B,J:V M69CH/?5K9)^,51Q2J< D=<&+0?_#,(F7KED !N2!NEMBT+ M2IN2P0VH&ZMBH!<,DC3GP%Z!QECQ+T(Z0KS(G6>0B^X-GY)8;DQ#U^>+1WUC M/M28?4AK;@.QMP&BRG=9.Z,XQZU-.9Z^0@HOD/.FRWF(M>>T"ZWAF#B;?DGQ)"@)%P3'$-K4D M -!Y2#'>R#2B%U:Z?\H0]T2A.1L_7Z>2^#'<'+&S DB08*$4">2,#M-#F??C MNJY]-W4 LHA!3\3>;2N0Q^N)ZR\^EX$"3'7 M7&7Z256@#%\FI\-M.BKFI))F3)'RFH;"%]!@#ORZ&HYY?R@3/@BQIYKW0Q5= MJOU,X]G%')ZFSRS3/C'W)9:X"=7TN _4\LY&7@3]N@#@K4,TWIEV&(U.VY8B MAOA 36<\7UR3@5C^(,+"!-I,6]\9H=",9#*=G_/6SZW"_RP80^@308( MQAFXP%1?(R[ET)'=-TGM=^%MWP'E7H)EG:O;+JY)JJSI^9(OM6$J$HUAR['A"EX+X5>;\%/\'7"QQ5$NE(*F5 #^FKS5'+B84'131_ MA0AI[7?C=[(;[U;"X4__R6F#JO2!!VJ@"#HL3F*_G_;[Z78L(-%U*AG%@ A2 MC;/]?OI.]M/7N"U!_437HRD$#SB3(83!VBD0^X-1MS:;-QJZ!2H:>LM^5 MW\>NO&LKESIMXUGM[XE9 S"0\F.Q+"_J>LZ4P+Y:8=/G-RG<'4189>YN'ZDQ MX+,>0>$)S0VNB^CJ_ZTC5I6[7)4O02'[!VXPY^3CE MM$=B:U4X(S&/9.S;GG(/I?3XMFY$[6+#S)N$Z4OJZX+9!KY%^OVIG#%6U5(D ME@*$6!O%]'-Z<=>(E '/&\ZKRBU[1#@A3N)OL@)@&ZBVF.WWOK%-*XE\Y[)<%-1M\VDS,;YY,%ZA@KX@:HN&&WD$*N 6<$!OS]0!6Q]& M/26KHF&A<@!_>Q+!*SN-]8F>['CR7$AJ PD>ECO=E=A"H^\#[9 BOJ-$TH'' MSE2/;0*H:(J5%-AU&GUSC4#/F)P7)&H\]EG9S/J58CEH^S,C(_VTOKX"BK(Q M2JI_68#_R1[@_[ES%U&;#_PN0@[5DP6)G(,A@:NI;1?84^LQ3,0TM(==8M\+ MBH"_! >8AW0XA#]W5\4<8I0?X!:8:_UA20VT3FNV'U 0C\)XV4 VX MZ:\_BKZBQSM6Q7DN2.4@G2KL15ZI-!!*4,)\R169>;[*SVW[]++419\M\W*U MPP<4N/D"B%KR**J>8!Q](W_TO4UT5)QM(E.E?;>M]V"I:-"O"=@;VQRQMCP.$* MY@G&F@T/F2SXH8KJ)6[_%.56CS=V!Q#\:*\\7E# "HP M#]3N$IOQHA,R."QIA.D0D!/@3(A?,@&\LW+4QXI:D?B[D*=(OJISH\><( M5E+6?>M>D 056!H9;J<%4/G#;L(1H9,)GZ+V??^POK*C$7H%0Z?5AI M>J.Q MCOZ^\A%@WPY=!'O%\"P7J291ZE0P]0"[R,'C]P0LAD<0F#CR:.N+PBU<;G$57[>EW,T@+0^6K+=9Z)PV!2@,",XF9_A2PD_/(A> MJ+RC.0@=;[(^E>FEMP5.3%Y'L+L@Q$F549.U+3JV>:LU74U3,-1U7G"]PQ=YA_@A M&;@A4AJ!MYZ?0X&8N^7IYWB7'NC\*:LJ.*:P+D).%P\+E%[X9VPS^5NX9+*J M;LM4A4K$*0>!M^GNE0"!#YITI\2\X/ZOU0%H61B0WI.AVC3"8%W0]1$?27,, M\S9N44"4SF0,'*KJB33M(IGTFPRQLYVS?$+CU'"Z8&H:/!8>9QH];$O.@4G2 M2(L1TTA>B["3>J]F6\,F'7"Z/$RWRQ@\3H E/&ID#3X6HM8E!! D<4?7/91] MB,B\2Z)Y..GF6X'#!],:D_C (_9-BM0&X59%@:61@T&(4;KTR\)S;YG&U7Q, M_S;7!GZ1^O1.M=N!/=.3\OT8@@&W_[CI0GL"&TBI5M>T@]DLAFE22AIAMS*8 MA@O&-,F:2\/]:4=Z!^[0'U(/W)"AT(HSJ8D0FA(.3W#E4>:G[1MG^2KA"XGM MD9X4X[TCMT3Z1#V@?@?:HU4B*T4=.+1.4?]B0+['#Q=-5,Y?P9+%A+OFV!QZ M/MWHE4:3K:P=$D5YCU9^?N5KC(*/%;#BB"R=_T?; K MMMEF/;?$J]2D0BW\H1%5W,B66 GQC4'/W8^Q]ICLKF>/W!4(HN#:BM6/\J)D M4-1)?@+.FN\?S=!7*1_!K:Q/D,1T'LHE M?GZ0_Z=-6H.EEG,XP?&[=+X2*_+X-+NZ9WP2H(PS<'*+==G6\R+,A62"I'>9 M6;I+< ]+Z2#N^XJYJF+_,IHO^0B0A M_2R -G%+=4<&Z:] -[F9$32BH XKZR9LRV"H022$=J/UY9' E LX)2=5^!@5 M<6OB8#)""*)M[7*LR+.B//.D8"/.'D^H)6;:FX3D @=!0V)G#.8*A2"^[HGB MU'=3QKY0HG^UP!OK$_$@/?'40.27^RUID$Y>OGR9/DZK+-2_*AUH5;#$)/2* M3F,1@$8[FC<.@)W'_;:V>2<(P+=]XEO2J^>-,FG:(9/P$1N)X8IFOOL*H88O M&6GWU\:;NW36PC]4YAI#7:;LV*Z07[G)HD2;,WC5)M9L#OF=97[5]J44=_[1 M-Y)!BX^EKKG[)W*TU.E+$JG6Y^,&PI'FLFS8-2B>&P=!O2HC1%S:GGG='2*W MK,RE0<,M;,^P;?A.6*\6J#B&(=^&C%L]RVR41K7>U@0]#QIR3(.';: QLN$A&*B%8&>79)G(('Z(:;0'^LC0KQM]1@V<_Q Q[Y'<= M3UXYQZ4&H?FVA+VRE/56MJ&NM%B SSG?3:(V)I#?[;PZ4X!_@05S\YAF@;J (-"OD_J&,&?UK43MT3=9*^',;R4Y]XB[D(/";N ]*; M&H?F@5_$G8&GO0E>1+,JW(LRZSMKJ?\ZT!B/42K1759-G6E=)&> MEY$-2:')I2%M@\&/'4^>Z?1E6_NH&0%12)K9T\[P3>.!%4;Y$63QN \35IMQ MOK^#J,LW4H+<]MNA\]8-]NWKO_I,$E==!TJSXS_,4@,T&9+.VX,+&%QP?P\N M^-RYJXJKC+EE35]A*C\?;!91PEF&X>BXH(F62^1B_IFB$Y_7(EY1G;OEX,)$ MDBR4HZD$,\H3Y3$Y]YI$,@N B8NK^,!AV-8!N)>O; ML3?L13I&Q@I&?TEU!K96PCT0"ZZ\))!96Y#/-S;LS3Z M2/+%;8671C>!Z&LKIYO6QRQ%Q(J)F%2RE&&)C\MC+]>.*04%N3:M: ] MAJ\77DVR1[$OL].>XIM/L=7$9M/C>,,B>T9SKX%+4ZY$F!:K$%C4-/T:F-V" M+B'-=^1742H#="WQ9RQGHVPKIG2+];+T)217[*G%\$XQ(:FJ=/MP.^.N5R\; M$XK"0:(; %:E58\OIN%X9Q=%OJ:XEL53U4!GJ,J1^C4-"@ %I>AS43D2.*W[ MZKR'V@I=;,X;9Y%!Q0(HR5N<:8;V$+L+3/SG]3M@,>I&*XZ\6,,!8YS3IL[G M0-U2<,TV@HNWP'#1013&_T[2FTR%5G,.DN1\R%6S55E_P..HS3)$UI;'C9=U MK' _0Y UB ME<25_?^R7O8,:8XGV3V%;F(+\QC@TF)F1,G'!@ZRX\E?0D$SY@:22U&#,N<# M/?6W,+R>CN'_FECQXH:Q(%&8=?9-;278SG>4W;+CB#4?R68TQ3:6OKCLFUQN MY!5'NX15PRH6'>E4[83/OM>FH)I7V?4*L!CXU,;419:'DX$T233ZP:_DLWQ> MK,K9^ ]11F(P7$I,5TD/\\)3;X?<-V-)BH[$*4+G/5S"FO7$_ &.,HTFK\,E MD*:A&OW*]$OHH.-)"9@"$-WV<_43U\[Z]CPPZB#;5ZK=-G"6V=2M=#N,)"K= M3>*H)C8/=D6BC1G+5TA(C=M]R_UMSP M_5^-ZN4.:U*9&N1V,D+#7^M0DQL$%^IYP9+(AO1G2O 738SST=GR]1$Z=*G( M"&"D[=SU)W<'W[,'?B/39I]%R"M)GB]!!R(^--&%1\$S%.+=7XD!J6FQJ MN2BCL,FS]1$+-,B(-Q'COGR/X0^*%7T. 'Q%J#8@9FR%\]/L\FKO_[\ M*TW3V:O30Y$X55R@N$$6F!*1)-*RV! KD4K]I*\;L5["D167A27$]E(%@9!Y M11:1?14-[#1+G^RGRDK-6(E=-&VDM(\M@: IW%A?L*3&R"D-SJB''^WL-GH? M.A6L]>6JFO*6#=2D"I-5PTU?W'RP1V@U,Y/<&$N4+.H(_FBE3^B7):F66?B M)A"]8(;7IQ1>=NQZ_/RK4\56X1 HE,-KW@OY\OA0@@G11OG"NX^C)^^ZQR<7]ON\]U2=%7EO< M@C?&P.;QMDP$2[,E$W.XNY;C963/&=$XZ$I/[;S[\TU7N"G%9://O=XB,)-\ M^IUKY(RN,TQ@XQ5O6W1U/0XBX)6-AAE?&)(ON07&-_+[$FAZO1A%+V<"5G(G MZ HVQ=(UXTXSJ7'Z9CSAJB 2ET];M57_]+LT:DTPEBRJV0J4S+=VF[-?_,9( M5#9_!KBDPW,GE XR*1:6FH>ZU;.H9$"'V;@E1;E2&_DFMQQMO+G8> MBA2:)H;]$J&-([1TIIALI$ML[T?9MDANLDME'B$6SO[-0L1/5(:.P3OE+);- M@45%[ZEF"D"DX38Q8:7=W'&98IFD[4=[ZC(J833]N@O?V5)J&NM#SI)N#Z-C M\CN:OK\1[^$#,B;_J)6O^S;88;IG?=NPAWJR2@+:9'1G$*!T4[GU5ST";!SW MEM+W1CM+\I1>_E<*,XGN4!<$1V5]_1>,YH%B^8NB8V"C[IRU\S*]I'5RIXE3 MR#E6Y^=$O48B''P\.:,4?;ND=:2,<*FWM3;YE0'A;L:Y%BED*_AK_EE:\F3G MT12E4F",?'B ,;O_>$AW+JHAG5M8JJ#7R[Y"FIF_;ROR!DG*T'G& 5PZ?WOJ M0=9+Z6T<,027(_+!TX+/Y);W]"K4)MF@,%E3EG+C!WE M/(4=O#:^^7&,P4Y M[PO*4W37=#E5IZI0<030F.L4[%R8YZ[*65,?U;LS0L"*:4UE0R U&/\0*I7NA]SRK%HI MP^I.2SL<(@V)0FIQ3=A2R2Z7;E#3021%N=B.JS:RG/)K)-(4+S+4?TX?&0C] M7:0K'*](9XQ##FW,;-S*,3C%05MKY2,:BS:.VT%1R7=YJ65&N:]&&KI']@.' MBM&.$!PUA-?&U-JE"[=#M!**,T96FA5YM R-$=&_N +IS!& _+QV!,);Q'<>YP0-V MOC:'P^T7[17I[-TDZ /HH5HE4CL!Y@$9>P0@_9Z@ M=L:O8O@*-*G6^L9OB8*JQQN&MYO77F47TT/CI(6@O<8UX?F\X83 )K&8I73@ M$]'<)8+15:[64 X@XS*TG=X[N/)'X]T>;9LJ\:D-/5]L&6_CA*7WP;)NN]#: M/"^16O'PK0 WR,0!!A^>Q6LLMEQS^H41USA+.NXXJSITP.VX?>,+LS%AWWG/ MWINJE&?&.E#2<^3^+0'=L6863G2A?[IHF<\GIS__G]>3DZP=ALSFLC-E]R6E:M@=:B%9:$U,'G8\T:8\*ZPM>24W0N,IT1&62,6[]:+W MZ78#VZ95OESTE?8-@IQJ4C0-33BI;V]!E4Q9+\G0" MAHU]Z5!'$2,E*01_[R"HF )F>%DVS,^JH$7S'I*6CDB$AG0W2)]$% M@P,[XK'$MY"5=9\M:VFZYU\KMP](JOCNX'3,P2J5BI1E]&[2$W'6L1JS4=XVU0;H%J:;;Z%ZCDR,,.IZI M%A^H4&K?LDZH5LJ?F>4YV@R::(O0EX:XB.Y43XY%F"!$:GCRW+<;PSZZH_WW M/B>"6W=$WC%QD#M5+\@5/+EW]/=M/:#:\#@$1T9\U+Z!A1X!Z5%%^0[H)7=W M/_TJ\'1T@M+1PMIZ <88^(SD&Q?KO'];$]0YI$&BM*D0K\0;:IBDE0;#ZPV- MS\_:?>.6JB?SYTQ<3D!F\LO<=8$6@W4/!S*?<<&M@]&F0CE%Q7FSNTM&:5,^ M(4(/XFN,4BV,3R;EJUMNDK, _Q=N"N2'+-7!A$\;8DY#XI M4[ UJ3^\NQ-GL,C=%AQH[;9QSI=NCDAR?L)7T3/G1.)EWUPD@$HG=T$=/'I)UZ!(!+,9 _1 M&VG=$X'L9O)S7?TSAW(\.'#]U+JGO7?+G:\)>4B_\7[M?N%X\BK:#);:VR3' M0,AIZ$2&XP)'327M8!QN%UY1MCI?%L'B1]SBSH)WY9*KY8S+:(<"R[P%Q0'? MIK:<5Q:2H;^&IBUJ5T3.P+9^716)!C BZQL(N[9>:K%#CO%PQOO&].'N&II? M"Y_\&;7$ UY#3ZZ '$L9Z IG?WGUUGJU'4TOHYJEKCE2UQMD9$"9%[!J9866 M*X:0;!3.J#E%-U;<]Y9%<0Q?QK[_HG0^ S;IOJ+/%?V'WVE%_ROD/\+N/W;? M,2IS%@L(VQ2X=J'R3I1QG:5XCR\VXU4K&(V^Y@PFNK@BU [!"FG[IPKPFX"# M"91X3$G.N75+%A^X(MT8*KD<#9>G3:7BBX&-U,; OI'75\"Y@S= HM2\:E*- M KF*K@ F ,*7LLB!"1&O9$RDP%DGA\9A^9A;L&PKYQ M4S/,)\0Q29ZF6:\'&C06X84ZCBE,,$^0Y(!3J.3&&#;.*H9)KJLC9N63A\-* M>@)8<<'C-C1*&95-RBX_DG3?ZH2]-S6FJJZ,;>??0_P0KR,86$M-^A'O$>K$ M@:@UY"O*RY+E91KPCI$O4AF8&N? $Y*FW;U2*7M?+-PQXL3GM/'$UU[R+:K( MA#W$?8@F[%).NHBUU9=0X0[!RU)V)':SIGVYG!_5O>[I<"PB!^XE8?6X7D); MA2+K\V4]S9EA9&_V%(,C(M!V&/A36:0/0YI MY3P:_'-J-W862%]"?;>:Z$&IW %-'/S$:!$K(+2QJK&WJ4 M'DP2WW&+T6<\@/'DX__>CF4Q55*-K\80*AU/7MMN,($PX=AB@QHZ]ZA'RS90 MC$9[(SSLGB$O['^:X?'O;SL6?JLS2-_7I?62X?[WUG?QJ;M:APS%QG _&^@9 MTH.>TUC9#"1[R_L\E,K-@1J(EU [B&V']@THANB1G1LH3?.'Q!F?N7U?KXHF M=9X5RI8@EG(2Q)1K0&ZFSB,)" #P 7#[C1;.\]%!)/R68RR0VG=,=00@.Q(7 MT?U@U?JNBBUI_T$!R9/@Q4B<&,D':B3B6-0BK7*[(C8A6JDDV[.MF!2="[H# M+NM&MU??*K'?OB+OB3SL)M8-X+4>F?@M[]RGG9]%TRR"';?@\L"^DAAT MX6[J"GPY&2<*J ';T0& O-CG>UE5Y^C@N&I+48^Q.5ORAD0/K;T3 %N M:]%UB=*ZX&2Y=:J;]&OW('ZY>%5LX R,<3KJW=W^IT8EQP"S6D$^*SAP:W J M'G><\DBQ:&F'14@9!#8'Q5!$+<>QMVM]G0QID;D[8GF:C$]P7[C"M1LPY.O; M"X%Y(,4$6%)?NA="M:8\4)DJ,''F=GS?$1.1"D??,;332K^/YN4,MGD9- M0SJO:X+%<'61F72 $_$00[FK!@!#F(V[SQC]D2U2X11Y31ESP;3;(\EM<@58 M4.@FA< G:B>UL7G,4G;;9H4#(U9]J#A8>MMV0WF6OYTUI<_BQMAX<7RQ M;)BB#FZ%*">-Z;/=HH%%CERR*7 /FHN.DB#ZHUXBP.A5&A!9L(+'DU-L!:Q> MV&;4\+X-31P/0TH"BE8/,/4$F:XIL+$NG]8G.1&;8=XYG!BH*_!9DA!Z%GR%R&N',MO(D4W?2NHA"37, MA/%(Z $=9OV,L->M=(!W.!NG>?S0V;$5AS&>05J$=I$D2YIRL$:7RGAA(7$D M]W5_KOL_VM?]/UN(SH-_=(M1+0S7%-?#\)]Q*4DU$W?W5',KISVPD>TT:*$M MGJGYB$I(0'Z+S01=)(5>(U)AF]=(^A6_T8EN"U\19549)6<9LR$>QCP(7LMF M@%IBB9@1/&3:2"<@RCZ &D)-W@JH!C*DE/$;C%1"($KNA@&*B.=P]HL+'F > MWW?<&J7 ;DY5!,A'].MT<-V0\F;>,I8B:DI#&,EL*KZ150AO701GN3^E#U5J M1)IV73-O+\5HG'RZ$+ENK^HUW200U;C'BFHF2"!J_*N$4'[_4*2<%@I"IST: M$Y.^O.?!^9)^2'P"(8S3+=QY!#0IR<$O=RJ%'4EXF >V.[K3&.I\U*[VSGU7EL> MHY 7MBGU))^.++[(KX7$ 0OU1>*FHSQ'6,C%2_=&WB'("]Q M(:!ROZ?D8M]IDZIAMVZOB'\P\:)X([MX;HQ'@XFBRBCERN9W41N*/""2HK[' M(65 V4Z"3=:Z<9K<2TDD1B)86M90ZM$-%%4G4K%\,](!!"GGBT M2:)9GQHJB=R;BL377K9;MQH14=>$LB""O4,OU,YR$EU0#(T>T(GHO7NR1/*! M6U2*BCD]G7*!*F 8@2I<)%BN2Z& MU^G3\N+2%U"M O76N!40G;.6JMQH1D) M50/$@0B8/3M;@YZUF]9%QR,V=*?M;)T5&# M_#'\>DM\9]--M#H9E+2K8FD@==Y;\IPGH,*+N-U4%UWIXF)T4;1M2*/ 'D7S M\]8/6*,+B\"4W-5_4:Z3G4J#*Z8;/F.E$5G$2GD*5^QCM@!MFC>12Y0-D_MD M-5^.'S4F+/".S\MQ&CT^\QVMV=K9-2. D^;#D$VGRMRYG'Z;]1GB&S-^"PE$ M8T7Q2:SB/-W.TPM IE%%-2,:L*M8AU+S(3IIH48"G$E+.2H/6!L./N6C_ X+ MYK=(PW^0RC>W(4H."3U"S<+Y0!/P^9M*5Y($&B?+T5T1KEKM"O9%]D%.?7PG M[:YSH]#%JUP[VV\UK3"KTX*8L,0.;K%S"Q=T&Z%JM72,UM0C$8+PMC\_I^.( M0$PZ$?W!R1,0?K" # MQRWTTHSSE"@32PIJ@O'4+(0?(\U4U'>3WM%B#>@L>;4 $_9R MZ;0IF'^5*XP7!:D> ]L)U9I9'!M#0UTEGR(KZAUB ;WSXW%8$N2^'1%+XV$' M!4#UM*$'5KDD]D?93?A\,J4M3UGAU<_O)#%[I\;MI4M8A!GU/YR-1=QQ^OU MK:6JW3ALX=0P(G>+UI ?X?9)@Y\:RFF M\H*#+9F4MJ@(&;W"CWJ+&[J13)6@*XBM)0Z@C*<>\0$44O+R?89]DT+AY?HZ M[QE-24/FIBS(Y3&!/DC<%%:G]2K18?*#E82D-GP8%'C(: )I&^,W:!M: MU2[TI['RKX4I",=;@26DG520%Y-SZP6A;WT'&U17*MHM$C6'2?FMDP IY E" M#_BJMO?A,*3E,-1LTWALGE02@_ -9G37$;IK64J8?QA:%:A-CO*#.VLB3%XS M4"&NQA(@\(72LVISDJF"G87(QP(MLD*2I[;N2.3&\C4^@_QCE/!?YQOZSX-% M'=,ZF2'J3N]$V#FGM0RXQ*KH&Y!M3PXBU=C#L%&,(0-1TT4^CPN+"#E[5OTC MASOW+Q<4)_DA-FF \8?@OJS,6-:40Z?,,80##2JAX$ZBK=R5=L'&=C;9'3L[ MZK^*=8/3[$]VR2J;@YOTF@O$MOG[LPQO=N 11)?NV"-IB#&B(?G2Z.V%%XO7 M&J0 U(N0:)(%.\DWB[5H0_EN2K]>%^5_MRY Q3".N:2\\OLD39G M9^AL4A0:DR:P&,9U#!N#^YNM,U,1=])70*Q=:$ZSQ)WFE",+..:NBOMR@!2D M!"JX+VQR,GII>^+#\#D7O'0;9RYA!>@%$V:4]G ;D]3UQDZT/-SK AB_[2'^ M#0"@%4\FIJ6:7:"$2 \_KQGJS ;"T[9Z0%TIG1;&1A5*UN-.VLM&WL+=J 3XW7)#>")44":*5Q(5 M.#R!Z+*X)%\HX0?!K])/(J[L[[H6:A 4X2% M"00S,-HA1CUV-_=$=[TTE1#371Y?JUFRW:[).5R?51C=5N887G 7G[,!,(+/E M9>'[OH\H&=BO"!255*( 5%GF?>66Q/J>(5BX.1WA\P2K&N+U;BJ"0PHE!W9* M)P># .10J/2A #6G6Z2*U"$P/"&2':-WQS^UI2&W,!S(U^]C#!9DF4U:_O%\ MR!;$D[MIG>:1G*/..>H."K^!V3;D>^MO\ M(U]H%J'!'<;2F&"N>U%80D(?V=A/S0> M]#/*^,(%K+C8%)RB=P'CF&Y9#R%QEV%="7MG)G55F-NP53&(-:%^E+#].8F- M;/N&5UN0AH>I#"K2><)G0_6G1R9$!6\ MF QG7>)3SR\^-JZR,JLA'6C2^Z1;/TBAP3]MMW5$7:<781$\IK4F55"CA-Z+ MT%&5#PC\:Q]T$\^JFY8C*:NC?;A'5:C K%!>U+5T\%]K MHCS7GK8(,G<-.55S.J,'+0HW+78+:A1(L(A.@I$LW=W+ M4& PH>A+=<#*"%?,A=%+:Y<#QI4QCC@NHFCJSIM) M$WX*(F=$U]?*"J<*\2BM;8\\)/_K+^^S252W MBIB2TD4%NML8'E-XU;/A5YLY"*8LW\UY X_5,-K+ 0,;^CCL"8IC;(O3-9LP M':5"V*;3%I< 2(H-/3>3,$BPG3Q_>FQS\^N'_G-P[H;C;5XSH MV[^6;GA!DD")2OP#<&GRAR"WYR4:PVESO_L6CMO+ER_3MQ/],TR7E_JE\]E1 MBTCZGH$1XK->]OW&G8G5BM .V!5BCEN6&@&R;%57M8O]*[0R=N6TGBL!;'51 M3LNN]2#H)O?L>"]F[R3M\)*>7A-]8P\#-3EX>?X7?D?W'Q/Y<=$.1$$SH8:( M9R?S"+ ZW-I\[W+^'(T"Q@WI/%\]VG'((H=V6G)M"NZ9<^[]N5NJ"Y]^".R# M@3,\IA_TRV.;DGRH3<_P.D',8:L-1R-AA@*9F;1'C%/(_OJN]0@>9[N[XJ9N M-M"VE,RH^+%*^>[>8JGM"-R7@>K2N ,1C86O,/%=4D3]NB3(O3EJP04S8(<( M$^V?9V7,0T>0OQ\YWS4JR\%G9U+?# M+7CID=J!:PO.+;.(0M^E))&]K2\K>77YFIYUU$^L[1YF\+*(4Q[S#[&AX!8@ MX GBO]+%6E[K).Q0TOF-S8AHW"]QF'06@0G O7UWLS\G[WDC1<'=[HNGA;[._8/:8 M#X']AVF^6$3A,N<&A'G=2A;-$"YQ-(IG^14+YREE,25T.U"%%("))*X/P2AL MYK"5_PK^(+93@QP3[ M#3]S@P+JJ[BT0QJ4])*S'K5Q_V66<%A!N%[Z.M;UVL_**O]H&O;<:S?U3 1/0N#45Z$%WC>U)^4OVZ["P86<7!A."CGR*?'MZXSP9O&C M5B[!%E<2E;XI)-!?E#N)4\1C@3CW)6N8;OO^Y=R$?OT@R.%]+VX^,60A@_@]YYKIMS2@%H6%.[16B(^+KO1DZ2] MEU(13(NS4Y;%-G)&C$:8<9?!0F$,D%M..)1<9P(.G**:UFX9R@!=&TQ"EX MPQDS\JS@<'J"8E-)=B.EY<&\J'C,RET^+*[XW=H!#'-C6OTKB4KD;%H,7/(0EPHH0?TR;:A(9 M)IS=M1E(R7E[)E:DB2=#[47R!^H*&3'+D!K')?'MGA@X@6I3B M/^(Y9$S=K%@N9<;^OS_=^Q/^W!*'O?S9![CQI-HI^5 2O?]KMP/?U>X _3@9 MSF;G@N!NK@_3P-4]AR+D;D[_*/_Q9WPT^CC12= ;RR*Z(=R03DA^/THEW+_/ MO_H%U_?I_?N/?TSR _Q.V]_@IHS(UR[$B_>F+)7DZTT5T%56;@!=+]M7C,VT MIECVX.6[GPXC@]6IN&^C,P.%OK/V(1_-/J!-\8/24IIB^WXDO/.E?%>=V55C!T Y1+HGF7KRB(IM"T@.P% MW!JD5<)OCZU19%+V)V)_(N1)L[^I;BP(-,S:!F@K,;\Z[X A/E&4D MR 1Q68;K0<,_\3@"!':$DVM+',E:+TV]7C.N2%)U>,Q^.^^W\^]Q6R[07!$R MD%Y/,@]5;P:&<%6M;KLC6\1?+NNKHWZ]WX;[;7C;=T#])NPA5!,\II=8"HH5 M=$SI#H^*1?M-MM]DM]YD^>QCHKLBO-&>+WQ0M]GOK_W^NO5=&IK9(PYOI6X8 M"X'V^VN_OV[[#EY?KIAC&XEP)#6)4 E?$1/HXBU0U%07;K_+]KOLMN]@)+," MU30C67!#DN;"M$[U[O9)EOT>_)*:0,9'2Z[-.75Z&@Z4;3"RK2[=?B?N=^(G MQPS)UFITVVW;9"(.R@C*_8;;;[C;FSX#Y+*RB=LZ50%UWR*0(EWA]C%;E2;' MMS'+W43L&P-N#8.=B]0ON26W[8Y2WJZG;%+00Y&R7I5=5Q2HD_2MR)QRL^7<:XCD[$V(+0\(/\;99,*HP(I1ID5@ M6*XT(.A%N!Q$LUO@NJ%SA3'0^UMA?P@^-2@+FL>Q.M(H%4LB4ASC]RUB+'S4 MW1*&^U-8SOO1)I$R5OGXDB""0%AH\1@A&TJUF@8;]5ONC#/TF*9QP--CRKRD$C2VX29E(<_4(+@9$V$= ME:'8=R)S)_+3?2?RY^]8*UGG&W\STUK%6'PC (]-B&3J">+94_2N]T.]S!1 M!X^+MYH.@G]*>9D9KD\24RHZL)\Y+_)@6;?M(??]ZMN+A&V$VLRTZ4X9^M$< M' LEU^AS(-W&J>\.=G^%6^3>C^](5/(%=T?@KTY^M,H"H8=(@'C-N3:JZ="U MAY(&2Y)6PKYM:%L]*RP];8QBAKYA.%WLEP]]/S9+ 41,Q)ZUQ(2UGD]4U$>I M$RJ,M8YXP1?.GZ] 64Y43M&\:78;K$&+LI.P?!L]L3*O63KRZ(O8:F3W3&MJ(0 MCNS I==EX&FU#SZ>O"\!0"L\+ZZ0] 1&Y7!0+\H6CB?@:KH-4U[4@R'7\!;V M*"6?>A]33QUJUS%N+MOZ"/ZMLA6%F_3WWK_Y>=NOI<(HXT3SGW#'NGG[\.[L M]?N7?\=S_W;Z^I=7IQES'26"4.'J16^!4"I&E%S:SL&$*X\8$.YNR(OPEJQ\ MVA .UCM^ABE2@@5D:L9(G'7U;3_)K5?M^/WQB$25;B2HQY&) MJ'R7%)EW#CJ4?&CHA-A>6/\K0%?JZMJ+A25 A?^3N)4 '!86/"//%-2_6 _, M&9JWOIUKQ1PS\TQ_5XW3_JKG'3R^:$4M"5PD_ZTS#>/\AK2 M:PB5!VIJ;,^8DD<5FJ2A^O=OW]UAA[B1O/F61CYIG/7B#)]BN1.EFIUV41C* MK*Q<@4K,_3%?;EKABL59=MXG;2JE2V7*,,LE)6VLAD^4F,R8]7]97ZDP->4/ MN,$M2'?P],L@%O9R2_X=AD\;5J3_G@Z%'4TF?=C.L2;*S%E@LQ&Z.:+_LUU/PNC;EMTW>$B@M?B-S0KN'.)]+GX;IB5>9 B(UXY]])5WDFI/1:_ M\QI=3>#+-?_J^4N&!*UC' RC0W.7U>G2^8;$DGX%D6YG%IKRDET#:CYL^I4Z M[2(6H@]B0L#9!LXF3Z\QY\R=&C[D?W8):7-KI *YZ>X>F[1''H=#*7C(V@H! MF'#L\\XEIX,>JX\I]XL#,^2$)$T]=JMYMS-N!1^HBAE5[2QO^:^.67A MBZXK5NLND4-3RKY,L[UCW,+J"P=7\O:.U';G:2OW:S9IB^+CUI$,7?"21>MB M82"X5<:Q3)WY\4?=QIMGFM@#]ZOQ+QHB-'HICB.N]6>)?O8P5@9QAIY:ST 8 M8>0YF,!3CG'$X)<*E8A]S*)3KPG*,1X(^SEYD-H/[N&,=*D_44\&FA]7,#@M M91M"&VG"C)6Q0L[\: H<1&-$0BW1B,UBD [?N/<5E(I23BA_9U=Z0?@8&K:$ M5C^0A//U#6LF;HGQ5IC5SE_^.^33LL*AFFV=PHB.-&15@T@*#CN[+W\ZS#FW#(M%K\ _X5'S0S?[*A%O#]( M=/!I/P(I&"5&T)MROLF\^T,D49D0MHCFMGIP9$2,:@U22M1!N&+++3RL*]*6 ME@1.-%[-G K!2(M/&Q&W,NAUQJ9P3!F0-0%!XJK2[+TJ:>S#R'+DWV8ZY]QW)$Z#01AC62C^%VXD5VCL\2X+!J5'WQ,//A0J]. M]6:8KB4GF4;F#ZE4,V)Z_/ M5_Q&>!YA&X; Y+P@Q@+)=\#$,]%>M4FF3#W(>>XL2(SIF6G(9 =_&YL2CC$TNJS,8S+ZIS%XGA\I6$;2#-8OKZ MR>#8>^%.*(JH.#!.# (SII,VAV95N,#0A1E67[V[8**S<$AQ@,/=1+O1ZW*9 MZVE@[GR45&6$$?7Y-21GHB2-GHAF<"^RB2Q6W)U+Y43_MHW8;D7 M=T5A6[+(T94E\&.?#&4-,RII F&V$1$FHS>T+L%U8BKG_Z M&I^I]<2./(QU"0:?UGD(2RB\^$_86'0\U[!%8MUH3.LYP&VU*"B#RVS#@7)5 MX[\.O)GD#&M1=%5WE%PL)A^+39"-3:R/RC\.=:=V-HSCF9 X ),!/8^-$?[U M(K^W$LR6E/T6BFIL[IE0=!4VS\K? MRUS8-^[HR#HATUE4)1.Z.C.U@APYS@U@O-L74MV.(,65^21/%N=N)-GCI=,C M]EHC2P&-D-;( >=IFE9K^D^SFD^>Y63/.WP\2 <$K9*M< M//:$C^)/(!C,UQ!-HBE"ANZ9O4L#?K6QGQKSF"\IJE M_*W2IV=0BQ%9=YZXOZ%&P]LB& M,RW%M-/X?U)/EY)/8'KBT"LW;MW? _)U9/L'OZ;,PNL*'8! M_(6[*=SGN?-C<<-3%0]%S4[N7)'F8W@5G@1W*=^_=__!\>0TL#2&>]I>]-OV M9W3=*R;"[E^]37&3%E+@6;L+CTXVB2-L&)L0YBF,DJ7?B1+/OX>\-;T.$J8; MF_GROP%8A!<$T)P7WH'K8C%?JE]!7*T,"/+/LBS[]'L7Q?Q<,+1XJO^@,>1! MB'*DM+;39V<(D+ %538AYV35EZ4O4MJ36IUZYA[# #8>Q\_JJ8B%2<4(Y!&;04DMJ4FW:4[Y? MC4];C=*H4FDE26]A?]UJ!B7R&;0<(AP$\D4JL,[R]H),YY40/8= >,R/-5; M]@9)/1UN$OM'9:19$W[#:TRM^V9-0F768(QF0GV,L16W@Q1LT9QK\&UOF/V6 M^WQ:%>HG27,2;K'H+X)F"V^+!HSY;1N%,EQU;=%UO%^&W[\,BV7QF[*G$_Y] MZ1Q:P#OJ1K@3\IF7+?*^9D+ M2F5KF!F?J=BA.J?>"?>KA3K%[.19)$QH LBL]5.T@S.T$L5%#K9!Q@>!=]*] MD/!O ;G82]$8G!>+'%3_U*PB=!Y16#;$!&)"YJNR*N'CT[3FYTPQ@_P%I%V6 M$L?1):82EGZ(MD6R@(U9ROT$@ A"<@;MARCS5GM$*_[)*Y0KNI0D38T5O-V. M Z3! +12<818:H:P-O1"&NGKZM5]!\D(>N8G MKJ*?]ZG9'%12W7 N@1[1Q&U7$MD&YCKR36HB5.<"P3K?1*-S>VM;R:\IV(H4 M#'OBF[ 2U1>K($.>UN0 -5>:@$.[TM.81!M@*3W6>=L6[-'Q,SV"Q7:.X.F[ MFWEX$_L7UN,_]I/ X7'1=N6J M4XR/#_0!^<;)XG/"9U"E[[B8KB?/IGUOU7.X.PGS\?K(B!>):)*75QS*D0.1 M'(>)/VN[>S!^C6^")B?PI[D&='Z$9E,P4GR[2&\&&WI,(%DY;<2?Q;,W,[U'X)F[G:HDR,LBQ9$XPB<%*!M#IP4BR M !=W,;NHZF5-A?Z8E^)%SYX%G2/VM]J+;D?0;AQ3\P@9APDP$[@TN MRG5,WD$WGKN7VHLL@&25Q#$N'D[[DF@JW$_'8!:3$J)&G.J"$=-]DWS.7C[J M#27NZ1KNZT"Z5["L];+WGCJ5QPE\7HE@NJHQR209G/6*VNT:N]+TY;:8]4PY M-9DM\U9#!/VTS+/6,S5IO*$/EZO#>)&"?B>#][B?7(.,6Q"V#>":G5FA(VIZKS6X%#F%"/$@5!EIU(+^D(NBHFV$+50B=:3_!,5UZDV=%J;, MZEXJ:VSML1E@&C;1L5X[T$#7<5V%" M)4T#+0KWKW16$>7A&90.88/F&1/B1A[PV_@E):Y$G$;+(N\.NK7DL]I M-:V\0(IGR3V\;D;"^PL88+9E^%QX$4*)CM',W! UJ:\JOJ'9H:@;$;QW?T)K M%NP]#8]I,/Q5W3+NDR::.VBI4\9_#P0E,U^**CN@2;B>31/B[AE)LA8C(_A( M;A'=P@WSVLVU&;_+557><&\@D\MTP>[WW6U)Q4R,=60K"8)D["2A+Z"@0K>V M9H?$-/)58XOH'3[.:^$H9'HTHI-@OI7%76SV-TB M\)0Q:$K #YJO](R^IY.C1C++W94R N#W%.\?-0?62 MNBG"MK'9=XN\&MEA66H\<'6,#K%&>M\=P;8P:2+4F-+]; OZFI:S7OA $_V. MDFQWB],E0X=4LK+N5#X<(V1]J'5X(@S$K_/+G$GJ>((16VN6UK/*>4:8*V@P M54D75]P*)E^JB1D+30("BHP!GQ.N(EYW6ER #!3R9E,_-$:>E,MTD7=T%LC5P0X+U2_.VPJ_#C!3"5'7! M/=.--S@!>V>;D=P.478>ON1M.3KJ$F#"2=Q5SKL59L8 RH3WV5&10\R>,R&; MB8L/EO!0SH- HW(RTW@7!S&Y]1>**AN!Q01DH" M?(R),&%%NY:;*2&X!"O&>:#L&"5J8FD7OMR.Z:ZZCX M252%R5S0CC?+6"<6QH]2 B;0W&Y=1W:UD+@@0M:BH<@J)6;YC_B>^*.5+'"Y M?'4EBZ.]DL7P25$K ]5"347JV]<:W&^D;V8C>4M,7?[EDENM24.*3>-B0H%> M%]6KV-@)U6K!4+IIM]]T^TUW:XX1STE$N\>G04Q&:5L5MJ/46V>S +96GC)+ M2NP0>@PH5T?IX[84:(V/+RU'$T5VX>[?;^S]QKZUP)2EZ^(R)2)-%4&P[2B* M&IU))HV+6^7^^MYON,\23O=0G<9P,"5Q"FHB&DS-H[^/0I6$"_:F#?FOB[4[ M^1ZP=K^G,>GW13&&JDCJSUG,2^3Y?)@(\,IF&7[<1\=[J[CE&L8()<\7F)_H MW4Z>_-B" 9\97_*K7%@M$I!FG&EB;\3;_T.,4>6\BQK<2[07M6# MO]CJ'=)>W._ _0Z\Y3LPAI 2.>1QEUY5%#3UC8OAE&J!+,64+25DI0_ M/(5V0-+>M:SM5ZUN7E?%#$4AK;"A44=X^>AST8T!D(X0IZ)F1)5'X0=*.04 M=TA*&ZU._#;JM2VE\=M4P GHT!3#ECZ!@D-JYZ)>TJ"/)^^+2R"SO 42Y9Y^ MZN((".]4=0_(->@B/=>"QWG18[7&%5')*DV?+;V+*K//^ C[)/^PHNE %Q^] MMA6G"YC-&V7JF#R"H65N4W+@$PJ,0VHY3!U*ME'X%/5O715C$TFXE[F9\LS M38B9"GL S=TLA>5/@26Y) 4(+ M&Y*,0B0#W,J -^H:P,C6+4Q'[AR=WK3]J>6755-7^42C5II+$>W%-(-CXWEM/6J(%,E!8A: M@17T&]2&"9),J2L"GL+(:R3' YIX#ERV2LAX$N!1G&+@G1!U M@]$6@1%)FFOZ!N!E#=06N:')]C^QB!3)@ 2?0T] -I[=TS:Q&TY&&TU4#-72 MJ3*RF]/-I(_NY&7YL6#N06$ &:B24:H[( IU-$$R.";TS ?]59Y/.#2K!5(' M\0*VK:D?!'_4[0HZAT/$I[@X0]QG;+,@..?[DWD44WEY7MIQ7A,&U[H("WC7 MB[PI@C*6#!WN0!:IGJ'D6OAC:!T&258(7ORB7 =JC%))Q;4=IHGZ"0'SZDJ6 M(A$UQ;L8@YM.4 <$7-FN:"Y^#28 /BX$[2X;I1V7;AG+=T@[/!$PY^:VB+VD MKN=7@DY,RZ+6CV!@$S?>2(=KHHB[NY>8\-MX1!U+@8*+QG16!P^'>QU:ZW*( M2\"]@P=)$\.A-UR9]1P:OON&+(UM!FV_],\.] M04V\U3D.L>X'O[;Z]61MI<,+8$4E8T]Z"X;:.K(;6>4U?KRH Y%=V&W5';?P M7YS&C%B)V6X]N)=!7.Z+_T0F5R(Y- TK7ON-?/M=0]\' KN8?_E9^+>GV2,2 MV/OB#P::UY\C=P'_Y?3T+327T[)!_(3VR!U5;"W,2=QM!7%QQP&-*)# MQGDN:;@*YQ%G%P>'3FM#;#QZ!KCED$4/X215@&U?42KEB"A"^1!3'=9]"R3W MA)8B8OZ%SZFA7XL&3$;=_ZHPV5+'H@^K@_N9$C^2UL%O%).'SF<$84L@RG6Q MZ[YS7@&['H:#(&R097'.A;6$QPQ.=S%G=*S!IS,?@6#H\]_TSVR,/$?G#=?2 M& E&U/IOE,%\/ZIO1==?89?96%&RYWZW(XV9;'XUD"Y^.S\O9".9'W:>G1L5 MQEO*)/5=2_(=D9;:<]I-92VZIYXLUBI.A.HY^I291BPS= *MREH'E]Z9XL 3 M9>.I$-2/U/-)D-'KWT5!CW"74;V?F!1Y$U?&XPBD:<;%((47AL>;3 Z-'(P6 M<+-5XU>=2.5FF". +NSR*NT3'""LU*TMU;&T?C-1.@X?LX8P-1OK\9K#P\YK M*MMTC8)]=-.91+>S6&9307%0KNPYK!#K^&@2V+T!=>2*.LK2=M#"/%&7<'$E M#;A_.WW]RZM3?L$)AX%@L]V[X9?08O/ M#:N5G,::WLJ:A\7QR2U:"3<+W+Z&GF)A \WGY%7IJ?9:CQHC)NOB5DJ, GW5 M?-ZN%[L<^D4WA'\4L] A&G*"40/K,,JA5(%;+OI;.71LPNGQ4^< Q&ZY+'9J M%^38[*+_AE:W+^]R/_Q0PH_N^^ &95LIFR23 M5$&2U[LD0RGW?UV@V_WO >CVC42DORH.N& C6FT2\61R1E4W2WSQ(A#0:FK6 M[_N(]_CFS;YMK[.(.''5%%R65M_?MK=2K"/T'-&8(P8Y92_!/2NC(4]SN73# M[#G%#]83&VID0[:S#"$'JF;NS>O5GPF\[YRQ><^Q0L1N@!N_[9:%VT)7U%+X M][Z/2QG'TD!BOYXY0:6&DL(9]J$8F9 M%#,\0XP4-_%HCLD07YEHRK0BN)FEE#(522EVZ ,O:F S?U\4D]>UVQG4M/F% M33S_D1[S'W#C9PIQN??C,_>*I8D\G]4B6$+BV?C,R9=G@E<1ID5==U1P;O4O MW.RT]1(5=UL8 E7,_VWO39O;.+)TX<_O^RLJ?&=BQ F035*+)?M.1U 49:M; M"RU*XYF/!:! E%6H0M="BO[U-\^:)[,*)$63LD!C)J(MDD MF2?/?IY' DYT MZYP^?L,I<6)]4O@+-_;W?X%@W7KT+(3ZF=0XOWK#]2^ M<5OI_(7'[.[S3#>659955J:#T7 9G4%&=#XRQ_"%BX&E^ -_.SDZ1'\VXOT4QY1FDN]V2""P)5?'AZ#HZ6X5!@2U'F/$M-]Y)V+Y]R) M&'QA?CC/K?[BW3^T1^.L*MQ%H9+#QYK?;%I-.B]G$@OZ5UM2+IRCO@.@"*A* M;=R,WP;>A)Q*6"VX(CR#+^2L6+3XLIR=P6B"4S"R$G%H2=@!/IFEM#MX)1&Z(I@(BKH*[(A;&_/; 3RO$Y_SYV6 M.JR*:C'.TQ&A!XR2]UW3Y"F^PX?.Q?(7E,#AY_V/_L*JF)A*YM)]8H)!'T"S M0$O!A0:OM,0*0F#G7.I )#D$R\L^5HWTHR#P"^;,#/X3'QC89O5 F$17**0-WI@LV.# , MB2M ^$OAZCM1.*UJX>P%\*F2L .:7TZS<5K3A<5,:DJQSI9=*[5TPG^BZG0UM4G(B+1X"62=N2'0YGZ0M&1W M %FXW/'N.-L70$[1O DF9:"Q"2V=!3?R!8B,\S(1N)$MA8=:9QAEB.J^0;#O M*< QY3L3]L%5V*HSS-&ZW7_A=-B"M=H31G; %AY,NLPJ8*D4G(NSO&*U$5X9 MA#1$Y[)/"T"R 2DAHW*Q@7,>;PXI@IE[^=>QQ;DD3(D))*S2BS^YRLM3]C7Q M(QFM(@9+'6=<6F?T"YJ-!-/< ?HK'7].&9E4,]I7:^FTLLYM!%===WVB4-#= M0JP\\>105;VLT+D7RN3,PBZCRB)-VAIC#X[N(. 5*RM5]\DYIP*+13T3L*0LEMMQ-7T?-> ULE_I 3IO6^FN'I\@A;)?0,+-1J%(K:2 M@*H.A:,ND#+:%WH/?7*?M71>JO,B8=AY51=3I&^/#@O7)CR"YCFHT (')/$0 M2=H9-YO:CM%-L&/EBQ3RT&CTF%Z6%P7,0WD!8.+4KF<1'?1$0/ MM#N +I,AM&G4(;"E-$&OWI^,?!.H>Q0,'3KW>C4&WLZ728%\Q%#7R\'%9X9> M4V/^2"T,*YL+@1#/F]M7(@(8-ZS#5B8%H\K8(O^,(Q(I@NIR/5,5+BR +&J+ M:]YA;51N!FYC>#U?6=Q\,4 !_N$X M:\_!M<.JFW--G(RUW)^9G",35-HFS+*%K$.((NYQL%9WY1I'AP%@/!$U FX6 M^*0SB(_PU%-L^R6NCOM[+[H-ELIZ/)+ZH!YC&R,WH;6UY\3#36-3EUPO@A-' MU83[!%ZI"TJ1F4MX?8?\.ZR\$EXDS7'(8F%.Y0._M*C7W,_W7?Z>Z)+/WDB"Y7%-2UFPHA#O$YR Q"U>_-P-89&Q3(C-V-?R28VUTU_%IHZ[X6!>(;"9 M&O23^ W8FB@+)MV9/BHC,X_",?4P=1CH3*ME2T^=0>;);5B*N2&>RUI-YK[: M]T#Y>5>?IJ4T7L">'DD;RF&UK8].P6!$JD$[;6+*<375,2Z39P+4IYB+'I]& M3^\"D$W4S96#T$O_2V+&O1Q\BU/,V/V?U976P4E;$'T-?(_3S!S@:&]16I/K M1%HW5&IAV02/*)1-O&7&&.BJKV"]P'_';3_J2(\3Q+*/$)GAKD9BN4)X[U1: M4?MRI^!G8"&B<;T+9Y+7C0_##U98QR\,GX(*%0VWVC8A+A\PWJ.WEBJU6FI9 M>Y_$0^+VWQ+ 6#/D[[/#+4D&<)LY4M,@;0ZYSV&"6>(I;YID];G?I+KW\KPD1L+>[@0BX'+6,RW=!!P,/6P(FV@6D;E,:!9Z ZZRD=OK8Y>"ASRA?G9MRPXJDD*IJDD@ M3C690"B46KCF9 /"=W_D$$W?'0JARIU3;TXBB$;$2R944%F3;D1J(U+7 W4L M(*WD/7*&6KZ _@%,Q5*R)/?X*+-^3><=*!(D4.$#6&:U\'6 "ZU M4WG;5[=I%ND<>KQ:)766.DF3<.=Y$,<:2F\/=8+A!K3\5"6U+P.^P]P= A+: M95<#?2DJ84R\X]]#H*$MV](ST%AFZNS4"8]U'IW$'()_L*@M#X+.2*S?P:+1 M<:4.4FJ$@W9DKI?#"M&?CI:>S;K5@H0G_\J(]I>H.7&=/+L5OQ/>?']W[Q'\7:5[_4LJ*XN=0B!T]DZBH/N-EGJ/4W>&%I5:=.U:VMC<+;*+R;4@PHS**4 M(:GGDZ#YRA::?#LNY@]V%3#RX48$-R)X;9L;->X3I.%GL9$,R@7_9 @%;/?8 M2-A&PJ[=]XFQ N",U>*UF'M!DB#QZ\TTH7FE@D<&/(:IQ97FAN]>%R0Q MT0_WT%_95SXRF!0\S"NEGAK FY23B1-?0PU+FL M4^068./264>P67TRDL%F?5@6MVUFFG26UMMU!NWFT(HLB53H]@53ADU9 M/;7I(2>EXT1ZHA5,CI\=,XJ$S4S]*P5624CURO"&XN9O8PNY\61YFIRDT"PXY9\52\+YI^HIZ1UO$A6Q&FRG$O_LT/_9WJP_2/X(SA&;!5*OV4E03_/HI>E8>%(^'XRA 0X>R[ZA6<"OVG>Q3W M;L_YW0X ,N_; 'VX&;K":F2%$.[Y"U 6@J$60-7K=8V;+4,J@JG.+_/L/L(" MX(2RL46 3(B"!60?A';ZM[Z@576TNV!(J'A"TVI>0+#5]+R/B16;@OXKX1C> MF8R*2'Z(Q@H0"8%LI]/:VZ2U>RJ=+*^H;Y[\\6J<+9;.=BNX 5-EK3B US-_ M IVC>%PS5@3>SN2$,N.GD">$7EHU69#NCS-EYUZK!!=9'IE62B\CG[,I'6X'1,>4IO?=2GMLA&E5%&E-DZXUHX'0 MR8[["G729[B_T#<3A!OM-\&7N7DRC3Q^ 2!IQ/:B.N8W4F^:]SW$P+# Q=1& M (97T&R$Z<4W6630>ULR/.+U5B;V(XZZNF*<+%!6_YLY4_(<"O7-/#D&**!1 M+AGN74_=88>]*'T;JC0Z$O#JZ#XN*2 MY<+I1]8HW ^1GPU=!A"Y\0BYW8<.EOB1SC/P\.+'N<9C@!#0L\@A9;H+RC_& MTMH3+$LM!B-C KG.8&MN]TX[%[<0FG@[K]&Z&8AGF+(]8Y^38<)!V7)8IG_$ M;NNZ\W.CG;,Q:->0C1%N;!B@I!5'(RUG^< OA7N:&^)WX4$[7A8H3F'/#W\? MEP+'UA*DV]'ZDYPF]XMSP P7 ]U0W 5\:/%1@>L.GA:XZ"1MZ%S(P;&S?081 M0#[PQ\X)+_2'N38MB2T4DD%\!1RXQ_EWI\4R@?Y+6R6W#)1*J$J<-&SF!6E> M\-&W/B_X[8;G@Y9(,"+4J4#!S)O=C4G.@ M :<83IZOG@RZW +V$IMYB8R,F@\ 9RKO3D+8JH -2R?M(^(6F%YNPWMOGBKS M%/)^XMXP9J+T32)0$!NFP)N;I,5$(:[MBW!#*<15[IF13]1$53O.]?J4G>> M4 =/OF*1Z*E:G#<5*TMWNOH--(R,'L";4N+,F5T"9:4LZ^VW.#+#)#_\.D,4Y+!:D@X MJ*UYJTNO2&)75!R*^T%N;#E )J"@#YXOUF?+]HA5JG"D'SU#G"?.A*PSO=RO MGM)V@$S7+C"7"4;J%!C4-:34.GS_CCBCPI1DTP&&EC2 /23>\N)V:^H-N@< MV*JN.M&R4ASS(@ I?M^V#HEDV\-?$_RM.VH(2=1+N[\X&"5';PY&G!9#NG9X MZ3ZXU=%'=R 09_>DU80"_.'-SZ]_Q51!DX62B5P([MM,S%1GTELZXJP 9O.* M1=4@6(!3Q1 ,]["-[3/_='@\2GYZ[?YG\M.;8RJE@,RE$[=\ISF9Z+J#V!8' M(P)ZUP GGD(?GQFTL#/AW9LL$]2CYR+XVTZB=%+@O5Y&0(^4I(CW324SMHE9ZBU0'8U="YFJ2+QD@W?T=_6S LR1T+R*J M#2]."=P)^>14(T5/A%4)SDCH&9DF#X0=3G6-.TJIU)ZV1C3:2)*94L!*M$*C M^*5*YW:'2*U#J\0T9E43-:-*G1U M1MCE @'J3EL@9SW\^Q<''AL?Y-O.T8'; P1ZDD*@Q\@].1;P$TG="7P5DIAY M.A4^0T(0KIEB,;Q;Y1ZBIN(>6:D'8 ?\[:SJ&]9X6S1F1"2I&17P*1\1+4?@ M]X7K >_LRYM^.P*U(BNI'[0[;?06&3XH@P:?F @;@DA_4#8TE4)%9&^R_'<. M>U0NFJY!U.L528^_5DD=V67L&;$G,0C7]-#YXBK^8)83!K_""3J*MJ=U>IYB MFA V_\%ENW^QI6Z.%&Q]*;BN /=]O3&K7_4W([;,";MTYR)RFY[[J'#DM M\K&9"].V9T I.K?7=('@)]^]6J3CK,#?1U[KK"O$=[WD$)OF/W"Q-=S(2C7<;POU(O5P]"R=KUF'U%%P1N!9,'9XD8%T",OJ MP6F-K9]8RSR@"\)'CPN(:']&E@JWIOI*)]P+]>#CB;OHP?'/KTZV["L#Z"Q! M)&==XU8W=YH&%"^YZ73'SAEAIX=0KIF(#NK>13EBUI!%?Y+- ?9@C6 MEB!N,0O5I#/ K4.GFI@<%+4?8W]G]('7U1TH*I-@U1X?R<_\9CNG.Z,D.P6> MAG-(#[H?VLG.%O,A^(VZ\3U!^<2WC5M9^F+"0[ILYL20FL^-J^F%/>-^;]97 MJ[T-77:@&?VF_/6B.LF+7TBP%/-S,%P3JQ M(ZF0;B]/*X3$"^N$&^&Z)\+U-8 7LR*](/(2=,IRH8^8=4V*M4SZ?1:3G<1< MG,]?'Z R=/^EWB[NUHA=/&K=T>81;#@Q9<=FXP_>1TF^"0_B!\IJ]+W:_Z8;&KYZZA*[SX_HTV-/W+WS\8*;T3G6N", M5W>HWBE(WJ.G=VNX G0?!B*R3,!0YZL!V1&M60 M;H/F=MPE"<.?QA1UNI,@_/GIK@&.!+>=0+_DQ--IP'R-SF)-#5&XF7TC=3B\"\A7D*S049C"N=80\D&1R3[<.+NH M>"0+QF-I]<]IZ6F2AZ$1%XL.TF8@5=#E:I<&ZNW*^Q3G2' \5:'+X#Z"4S9+ M?LLJ=\2F)AIUW\4<7;#,JU>'UM;%K3*:9@>0QEF9S?)6%]A^[T%5HQ8H*RRQ MC2N8@8;5TU*]?Y0ILJC'PWT65&FX8G(N>QHA&UQ M;MS1;V87R0H>+TY9P?0[[V)=+6MLU#==T1DT:J%=.&-P.'RR"\ MQ--+/?0D!,-SJ(0H $@$J/0]P=UI79WW05;=UKE8U>V"A2-:WU[H7S.W1$6> M<0*2AZ68MQ2 @U,((YH;HQG MVM JH@VI%9A4P//:;#(O*QAB)50"@#!%5%+,&2#H8'#39;Y$6" "?QMZE!K- MK60,FC8]I3[LP&X!LA^8$I%8U*3Y:3X=E,1 B%D'R'@$F=\! FQIXG:[ '\E M8BFV<9P9)APB %*R%%4[R8?*/IA3X #-G7*D4$&XINP#OPQ T]"Z($R7=>VV%-_24WR_>O]8 M']X]5NW< %SDFCO=B=@;AR>"1ZDSIH>YB,=':3B"-C#Z$QM+JSMBQC$>M.BQ MTOQT>&R&8..YI[ 29*:IJ_!S,)0MR%!\F&A8:9+60'O>*8R67- C6=($3E1S M$H;UX9D?T;3<$!*)NPP_H:V$'05 0V> _8.MD7FBK=%!9#Z(E?Z+Y 71K9Q_ MF#7>@^7Y&3U58@%&?AAU"!4!AHGRLL/A%W&HC6LQB)4 ][GWXYK7V"S!_"([ M0IA*,(;5VP2+'I$C :% F7O9KAE,CCZ*8VA0NX5!]AY@A'XF0L]<9\R(ETYE M5L@S.+0Z>/()HB#KB$4\&"[GXX$(F(7'Y[,C\3G!O^&('_BRH'Z9HR$8:;K" MHGE%NV,@"QJ]!1<]$9FFS;QY]G:#/(HS0,P:-%SD;X["_H\1D9_(W'CEKD.# MI?@W%?V"G.?X+;8:SG_B#N_6BHGB)$/_<"YRF'-A:XV(43#@U[_G+W-J. M<_16)@#^97DS$8OFZ,V) JR#:6<^2O<^%:8EV!?JEM.T#1?>2#6(>H4(XF6636D&MLDR]Z[N(*,):M&V*":0 MO&=H7 '.#)W$*#(55DU\/1B;;IQ3#]&;< )C[6]7>_J)W_-&$71G"_1.Y#L(H@ MR.$]\O.( L6"TX7^/,]I*E>\4A>X\[U9?;!_E9=G57$6S7Q3N,!PXX*_:Z#Q M N#BY 5;\ M"+,6K6XL=7#@>9-6Q$87.GA1IOA!.!O@PYS0\+HM14>[$.!59 M7O0F/9,(RT64A?$O/&E-#!>@3ZLX'!QN"H#- (I\$D &2!TH2E!=@KH#]_@$ M#WCJ;"LH4X.;)HMJM )!F\,1.W.>CD3%Z%=VSM^?*(HJ"%KEM()'@Q?/0#A!>,\D!!U1 %,V*HH8\G[6TR#)7BJ,!HYPA,AV%K1NY"$0 M@-4XVP840/@ /'L)TF@^ 6:!/[MXP/BX3#7A^;]:Y7J2]YEQ;>3UHJ.-EJ@8BF.+PRV%UT26V M 79-Z?PJ-2=@@8XIY(N0B">UO0 M'),&P'2!>T_W4-6DFH!=H87(;JH+A@]_^O/'D]6GO\2_Z_F72@+4\0+7?>Y6 MK/06D+46+L04G#!JH@(\NAH@+C5#SKC;BZHFN.(K7^O#^Z.W)Z]^"77"TC_BT"M"D2-ZQ5&2Y>1EXG@/5B0*P/?C M;_ ?X#7<;TE(\&@)R]/K@]R85@GI;A/Y/7H M[?/MW=VGVWN[^"'Z\1G\"'4=KI5H.G0MEA@4@Q<*/.]7X2!!%4M52\][ T4:@ M&&N]43Y)(=D^\%6AD E9@?(4&5.JQCVE;%$O:5HY8W!J0.;&G"CII9P]']Y0 M(#;4P<75; _#)H.''U]_>/<&+9A/OZXP8#;,D2UK,+])-#$Y0?1-.J?J,DC> M 2$-YK6HG0Z/1F_S-9.WJGD,%2K.(E+Z=(/?B "U=B,I- M^,0*DV^^.ZO3CHIJZ;B#BMW@KOH4A*=R0[R+P9SF)36ZF*I@G8W7K[V&4[.N MC.X=+:^ >1/+JZ@H5 Y.E+/DD%+;!U+)0TK(3_GDTSB=?"*_H1%R&.P?S:;N M.!?)284(.">"'XD70+&0CC5*P\[(T_'-,U(*"U*Z)"=R;519 %(X3.&\MMOW MP:P?4L/^4];YA( ?=>V:X=HD8*&[?W$5"U*UU/=1 6$V51JQ7]%M-/+T2C;. MQXC$Q;7H2L[!CGS6OOH+=!5<8_1!UH-B@M1%D@3@_BD7]B9@41G1LB*A$E4X MZHESY:D(G/$_JGJ:U;P%:5U#NAV0NJN:]P2]:2VC\B4RN@"E>N$"E!"XL$<] M!UA^J!HQJ*T,HZ&:)I[7-UAVA="4_I5/1SY;*D)H+LDEXP8H;*3LQ5K9]FN! M38#^HI21;Y%#%SJ:L3:'$D9LKR"J!1((18IC6/#M]!)TOQ-&[EE>(<-"WNXD M!Q!:G>4>@)C^:%IR#P+5)5?68O8"HD5T ;+/SD[A5#[QVDE7/5X,6'@N6YX/ M6'K[K1+4W(9Y))1Q5T%KV5[LO# Z]: M\3"Q].+^>ZW*3.)\>+'*FQ.H_SB3/T($G_)6(9.$,[== 0*+&X>BZ99,7'R? M0G^>2+-)/KVY+:-,5[RU>'$MT.%PZ\K'VX&,@VWC M\:VP*+QC(._ROA=W/W$;;3H!%6 I83WE4Y.UK: &:/KD)8N\603+0GW (34T MRDK>L"BR4^K<(C>!W0%3L#&MC KU0M\J!#H>U6R=>=(.<&J=[%4+Y&*6QZ,> M"#,K@I,)_G/D0B(E-+^('"(-YV1*W=P8!HN%-C,+:J,Z 9&:D[-]ZHP!47 ME*ZAOAL?7?Y(U-'4B&.<*.@,"#:TD1BP\:\$8>"9V/0.\>T9.NK0'[-J)%I -![ MM2H'X2:7VS 8:"#,5+/8=JR]$IC0<7LYQIHK4)(3ESKN6M,0=5/:,A6U!O L MDL[U0Y?/AZV3;(J0'%31QYH,MEI#Y" ##"FU'"Q@CRDEDKD+5Q=9UFLZ#CB@ MC.^A73WG@^A!_0H0RQ>F M*?,&NC>[.NLGV[R2MND1:/,:Y*]*Q]RIGC03MUSL;S0#%_9]Z3[BSQL1/79] MKN(3S\,V UT25*I]42O:'6GK%1[WA0+ZP'(EFN M\K:"6J4_.'W%WF![<>:;YKA-CJ9[/YD_<)>=/Z'8\(-M[:;C982F&__18RCB M!DV)>%"OBS-K'9E-9P1U1GR_Z8RX,>R_NO%1$SLPZ:6UEFZ/CP\.(\-FH@EG M#934-[1W#\"KJ4KGK1&!("<]3[H2>O8SR%=NF?3F3O1UWP(?'N" 8REHL ;U M26'Z(73@RX4TYX(#N[.,:JO0-,'1W9AAU#B+$H8&-)[HXB[0#?.J68)!(;H^ M3#BX5^.D@[;#:Q.>J7QQXZV8VZ./;LU7T]2LF$&@GB^I %E@:DK,:X_=/>B7 M^V_)+>%N40=*SRV,,NWD)CZ0-A/FT<%?&F;G "1A*UI4*6P(CQ]>.\2?'X*< MEZY&:FE6%L#^AB0/J)[/B3W?&EQR:_<6E_*"_-@EZ;#D@7\(R3CB)20*9 XJ M+LP)*9I[*R2GID!D()?'JSG"!FHN%0:3CM-L!@T0DG++L:]I#V@>OYZ7E:^QE 3$7YKCZR]L/#9*EX MXB0=)9SD"W?'":0_I7G=(W_ EVE0OXDFTJ"-)ZNE(&_Z";&-D;*.V#L(K,AO M77"9[#T=?<4P\! S+MZK/L3A1=[>:P9_7RV<_>[OW/ "K6W0XC%%$:Z*G"8( M30[8IS TT,R*)B,2990V=P9^Z9Q[E]5.S)=*4R'WA[4T+#1WQ&:H5RU-PY;NNL)' VA1Y(^1=R'YGNLYO#ZMZ=(G!;^@-^ M8RFSLCZE8&AH/2A &FR>,UERV#)W/ 54+ C';CD(@^KEB/2;G9+NN,(YZ>I M63A5!7!XU#:*4X8P"! ,TWI,+#'_I;."L(Y,;]T86 $=C-8!4[%'.A>^/@V9 M[WI18TB6'8*/]'L<(70P4A=V4ZZO;N@W0%(GP;'Z;/_<29Y#Y;S&ED0[F P5 MKTFEO$.KBWJ4#2@*"[X7 H9AT(0@G1 YI;7".?*\O+>_D@8$Q#>C!) (G)U7 MWWE.32FFN8""*Q3C<>N]I%I!\@,1\4";-,[2E30[3TU$-?6-N//W.\YU:[^6 M3O?[*AL\0.A/!BALB5_&G>37.50G>$)$T%44BV5$CHL+=Y?F0;##BT%"LG). MCEA8UA[TZD??4DD/@M14->GB6IE] MM24E9[B_*Y+:X VHSQ!6":X$]T:[BHTHERP6A2@$T"'ME$75V@0,ZSSZ6D/M MVX@UX,N&N%):XG6K\V2E..CR8+1\T#KOOLPNU#J_ T67Z;J]R"G3!X_S!L8+ M)_,.&L<:*PM^$?$I$7]$-3*_)W#4,!B2)+P>[^X]F&P]>+CE3NFIT]6_RS!- M"FX6M5--$]CVKYGPN333\]=,\6QA^8KZ!:?T^5!]Z$% L>>$,4N2V_!7! CA M1.HG$@O1*0,)FY\9<&EWDU&>X61/SQ!L/8G M:94U&B]IP:FR5\"[Z%4 M)NQ#ZP"X<4130O]^D]9N\6 =S>4XHXX[["STIF. .@:>;CH&;CR:T<:*(F]T MH)]*X@BY&K992D18QC&0,U8+;-2?15S64!2AO)KS&GE:ACO5 +NU1= : MUCV#=P@=#HRB?6Z;RO:J!;/HW6[%]E%2(6U,X95]LS]HKO/(/_!JVBB78:\0 MM8/V52$2Y-3^;45*0QH @4HSV!]8 HC5! M3N>-&ICN]-&GQ]U#- =.-4L]<4:P&_5,/M1U4DPOQNG]ML>K&":C.LJG0*.J2C># E MJD2,,"N3-U5)G_81&B4BX;;_ZO*6>_$'NFRBMIBA"3M_T>!0# Z282+6G;3% MLN4"EG.XP294I+V<;O&'3Q3<4*I#B=U8I&13*:\9*I'(SONH9F>6,X M ] B3!Z#0C)P2.'WA<+64IL3Z[AT,JDA^\W@D--.<1^=0'>F%< \PA9-.'AU MH[ 69!')DX0QF@5!0[JU03*AJ&-*>YQ,$LT/]*N*)CN6X>"EJ&ON\%#6$P]O M*;EX1@-!)]'M:JA.8%81" IN5LIA$P-S0_M+7W?X\(F MEK<=4PKR;4[>:Q)"\O? U#-.:ZI*P6,;FXM(A31G(+"6R#R;0P'6V8HIC2-Y$N)I\8&@8T K/-M-/A*P845.$MC( 1:@YU M.1ACLMH!0 /EG&QWI%U$<@[*EA9GA"Z@!MP&6=?@>)LBLU'MOF+DO\4UHJOK M0SR(YU$BW$+7@B]ASHMWU:XX-P25*ND1#[&('F9=G;=SQ?**G91[6-R^1F7K MD(&]W9>& $44C)OZCXUW8@1T,G@-S/9?C.Q0%H) @RVDDV,H6WO N\!7!O4 MT>9<9O"<:A(0(QR$IS!AM"KY&1]_5:2RAA.J\Y,X)$: $&=JCF3S5 U MRL&I^TMCF_U $TBR?$[P[7 AO^&4(\!LHZAR[ MM^V7ND1;YTCC4FN82:^)'>"^D%U<*-CQ)5T)]F'YS9I@@0S4BM;)%*2=4.K3 M(:&RAALT)7B/D[3)O$1?(LS.Q@C._L XH]Y'8)&H'Y:6"SUBS[1S.6Q"Q)/=I_[:F#P M9S)B.JQLAJVBKOZ@+0L$%Y_8KT$;X1^.\TIR%1X:#"\G!!O^$U! 1"HL]I<9 MTAT2"1-($T=UH1<':M:>FVL*I^PH*Z@QM\>!;S&VYLN1R0/)X]$X-6;!N"6 M6D'>-H@E! APU4N1]K%-C[;K@9P?MI3^E#CU*$744$-*%DUSE-=95O#W1+2L MDR?+PO4G>752^;"%GQEHQ>Z=%\9HOZNF6H9 MM54[Y'&/JD:)8#^6"/%[(N@O5,LQY@/SU8BVF)ZBF(/IYJN-T#Q1[8ERBD&_ MD2"",Q1]QOO: ZO ]"$W2I5US;Y-/-9:G(Q&L]T&W]BQ#W_.-4Z[.D-E _S=IP?7W/7RGQ-',[ZM0UYQ5I MZ<.,L1W:BP;IS+EPUB7#8>[ B906=4PUIU0*'TC.#6#DL=WX0#7Q9IA.6"9; M(9Q1MTSF61G)>$%=4I'9P60^MD!]0<3!VLTG=\@CW-1EJ2[[;%.7O7F_.L7% M\^I<\D2]D1@;_2$)4G 4Q3NS_H3Q3.L,64Q6!"?KJ\4^S)6R'>,>ZM5&_\0O M#X-08*+0]U1@BT9FU7F)H(MP8VP A;:Z MV+K[MPZ\2Y-S8 8X&T%C&XVXGS((K,$]E=[;"L,-9ZGO3NP>WK&N.XF&U'CS M&]I[Z'SHB :M /.*S@J'".FR6;'<',R1HPVBRGEI;'BB\ 8"0:D 1I!EV(F@ M=3 %C^8+7^*^@50463JU<<14QCXI&3PE-).P+\(YJ[W(/QAODHM><@V 0X,\ M?3]KD4W8'8!7IO3%A)O$T0_!]FF?8O>] +BX?C5#+Q9A0TW"[MC, SI]"+FGFLSF M%7^-YWTR[T5KC4Y4MZ:NI=N<@93!>9/X@R*OWB=CS\ZDN/$2\.9\-TBX#-SI M2P)<'9#R+46H_GK [W7\Q3N[6!?>! =&3=D2CD%#IAWF )757",6 KW,I.@9BS M(!K(F%DPHA<.W)[1RJK35\AC_$E8]%Q<%N)8.[MJP&Y\_NZR?-3(]&\,=S*) M&Q$.GWAZZ"&RNE *0O("TXEB6F0H2,M"\_-E-;;H9.__[POUBSB[!OW1^PZU@WC"H M&;6LS58"AXG+'NEH%M@A54W:;CC6ND<02<=!&(ZKX<*8B=9?SI!M#?%A8UPC M SIOO]+G6EE!8':EAL,2:9 LD-,<#DY)%6OLO*_S+6ZUQ_(,!348Q+=9&7*X M."%:PK2J-(!W,:EHM;H_VX_)HT,>CGU>5)WOD_6 %HU/CHZAC]VI#;@ME ,] MB(AGM%F1OR?L=;?"PA9(?C!$;5 R_VFP&*;M7 C*:3I49#W#U<"2N$'7JVJO M.2GFM:P$(TX\SQ(/X(:&"<(21:Z:F1Y&<%^A= =)Y8:Z*#&$ D4>(2[29#^3 M\!)XDRZM/\H,;"@D:#D9&% 3/&' ZS.B0*W1)HPH)8\CBB+(/H?N];/:/M84 M0F1/4.0L%GBK3$:HZ)D0!Q7W'AGR)LC(Y^(I+(?@DQKV='EV:)+ )<4B-W&P MY:>$:48-M=..QYKA]87X%@)-E%U"FX/ 4P?CX'&RM(9.1GZH1B*[G>2DHT$S M_W%.SEF%,% 3Q?0)ZMM@LF5PBCUH3FAL%T8(@G-YQ1B4/2^T^#TD$7T%%C>. MP] 9^T4(%S:E?^>EO8)O\RBLDW0-VIBOK"5V @ SMX=L\T)GHA/HF:, M\4M97I""@R] EY>0&\:>%O+I1!Y3I8XEELIA[E&\*^_O<<-)H$C7UV[Q2!5L M5$%305E= _Q[W(\0*F'*"_L#'8RLT%ENZRJ55OYQ P8@A#8!AZH Q"#QDIX M2^!Q'#/Q&]3-E&*.+$'+#"V>?H/I#1ANA=!VY-$'N V\O1BMO#CYM8E;"Z<[ MB3)$.W+; %V5G?*!"&+$!)$F#C;:3R4U\&K1C84>"/':6-$%ICL:G&NI1(9I3>GU,L:54@-!S%(5D@8ZQ33KP!\JNH*'!!Y"[ M-U9'F!LJ!8= :IA1"!]&1'%"5<=A@H86Y.,SC8Z4B5(Q[ YK%K;5]; MZ77:$1J#HFL=-4K[9-'LDGI$J0=QE6BB5!\CX](W=U;UXTR_,S0$KL6(O-1D MY_HJ=.'C<5Y#H@C7E M 8P\@-PQ';8YRTSO+@\$$Z)=-.P%>Z>GNIIW@QNT$ M?1MR0UV"_B8RZ,$Q#W-0%.)YNR$CSQ8R6.] 76K72T$-^X#^M(6MFSTX>31X MZ&R2@A+(1+>4V],,,L73OO]95M2GIQ-M^ B,-1MXO4+P=.GKKK:,*U\OMZD" MM^P1R9A-@+P/4N2>A^2Y;S:_%4(2_["AWP^@ 1PI8*V8,+ \-"4X?>Z/ G?I M/BY9Q)"3DPJUHR );)=3P@R?\^%Q07GZ%YW M^+/[U$1^5CT::BJK>#XX5[A)WF;GR?O*[0O(?*RS6J=KVZE,.PX*Z7;457A.G3M)5#CM-OO1GFR9\? MP(?8/Q Z)@N A5@6&74N";4D(K' J&(X4+TRIA M:0,XAA_8]EE=:OSEEF4LY.AS(WIE_\$OUC>G$X@$NO"2,Y697KNC"_>$V#9) M#26]4'LPNI-"7(.GSX0X6BH)OLJ] 9%<\/8%WX=2*;4Z4N1CNT$PG4J15@=[ MUT#IEA)5/K(RO3@]E,9>R8?EN>6 ?GVW_'EV47&YY,9IUMGJ5* F E%8!H0D MQ-C\;P"O HZ5@]DLS9V,29;QI$-&^1. LP=-].#ERY.MGG!1)B9SBYGSSE-A MFSAK*2NKW4=8;0HR.8)]Y$]X+ <#G1%@)5Z>G"@&#=0)3N@#U-+S_>[#Y,#7 M'L[G&4HB#^)A=0=YDPUV;E'EB@0]AP.#<#H]D0U8^;"-P /; M6%9/1LF"#@N"][\P;Z+K0.4PD\P&:CO[;#$S>1^)OU$\BZ%)!),F'SP3*R(:KRQP0&0 8[+/&\9](#ZZ(2H0 MN (O;8:#H6?YE!B(A?('GVY@JXGE(HI_J-H]P%;)K0^_<_>@\D*ZE?[YU?'! MP?JJM[=RWJ3;0,;0B,@$>@IKQ;U!1!'J"&EIPV!@Q2I M]$@!5W X#!=KH&$-P24LHED-&)N]S)M^[*@O%-X/""CXEOCCQ^0%W/G8W_D% M F60>]($H#LT+R76$)]0F$&B=PZ?M$D$=MJTBK-+V2.*-6-KO!>@9M+BXG?1 M[LR[[;>!FDQ[5L>C\4^<&&'=LO4,D^I@G=%D#S=Q[=!ZF)VPC<1X-?'XV_Y6 M4Z0C.BP3B^E5L?]RH4S$[A2ITQTBY" >98-F*WA9B=N ?Q+U8I<3M!28KG"N MD3Q,PZ0CG&N^P;M;3J696*,>R+FY_TRO&A%@]*S4R75NH$POE2O>>BJ'AN+D MWKFWIN$ ;\ 5WV.%C*'T@)R74],+G0OT/W6=AN?8 !-/#.L7QSO!K)B=X=]T95%7UMZF*^O&A2L_ MX[K(H,LC;Q:-4ZD-85L/T5C!&7/G9_A44(*F_[_KDV'Y..A0T6S&U*V7&-'0'8&=6(#GYS,+ZVAA.* 30:#3H@:ED02DP;?=. MU,JJJ$XO&/=1.(=F=>I'CZE\S[PPV+4+8>;\@!X'4R6!C%9X3!D)4" MU\@T6>:2#<2*U%['DSE1#D_O@$!"V>G%3G*BC#71U318!:#X%C/)L#PMY)&) M:4;B4I)N@3<>1;S)#[E69(E"^:MAE)]Z)4M>6C0 -1N^@-F'0LC8%[O-LF? H(_@J:OE@!CSMD4<@FGSH[G/"ZAN9>%^RHDZ4>7"?. $+,-/^L* M<*^X$D+#!EZ?\(>$(]BN))^4\S<,Z6(*/]KYL<&?9CFG['W&O"2 M3EVP4\%4F;S^#=>95@2XGA4X<>[^)R)@1J1<=XJP'[*$]D:38'"JB,#X)9+V MN:.=Y.?J/$,05EEV!H74]0Z1$G$OJ1\Q'N8A-=W.(1'D\X(?0?*FGY[Z$ M_$V!IJ>@!_>*,V\"90_8MHN-!2DHKTIQ$156"C"8BK MT#H0_*ZH: C1?;?(2DQ774.!\IRG?[BIOCD1];@_M'PCQ)BD1W6"VF!N[G7^ M*;,#&B6[^!9A9J3 "9X]8JJ"S.H*5Q:]:WHR*\T+<+U8;<-=.NAT.,O=,V2- MOJB\$82;%(_B/(XR:%=J>OD=.32L:"32(]DPI'>'I>R!%#ZYZ$Q2,7%O6"WP M[-D"0T3^Q3>)?D+HF$@@G@,=UM""C".(+* M>LS0,%J54Z;^(S[6-OD0U$16YFE![JLR\ZE:S(Z(ET/TWX$G0\7>"->&L^0K M,7CE5,8A^%K-1+V51B6&U(.4HO@,'KK,%#:4HIYFIJO%&$IXK?=DG%2XZTB- M?(2H3N@/"'9ICNUA9K!I\!/N "] Z#PH%"PW"SX_K-N*2:9@2C@]QV86*P6$ MTJ2W0NRE 632(%5'0XE]-'M*;EM, ,96;T1+ 0?N^OK _SQX^_'- ;AOZ< V M\G\]YFMV>@K9E):R#(,;.''W_018AN?S*F&.7K? R]QG)N;(?5I<-%53+9 H M+@==L83!-K@F&W<$1+.R=LGWV%DES"^X#[\8"@_Z])A_2&EV@^5H4\QW-C!O MNZG?&@8KY)T%ZB[WP%A/W9'F'O\=5H0"/4AE'''SP.6T4N62&8(B=P2\G)YQ MNPZC<[/6X[$C'&4I$"6N*Z']+HGUHW]IR.+V5\>^BWLPUEZ]\CS.16G=X"P+ MX/E#_CO37>'LB[.7UU%:(P:,6[IC(U4#0&J0?S?N'7*&NO/9?[4_&[KKOG@ID(>(%"M<%_MH5OKMN0[P@998J>404/.FLIXZ%LCJQ+R %;7WOZKE/D2;8[C34\T1'FG:.F#-XP MVJ.XK\1G+ ?0R,AI,TULI,N6%>%3$'NP>^"S[-+]LSN.9HR^*^BGH#TKS.// M0.-)R;G_+4[IF&P,]\:*G@G_2"HGKR?=XHS[PM'WQFOM)"]\# UP$IJ\*59F )& .4H,+;PG-&**DE.0':#%0JACLIE/K9#JM\%%%F9-8:WSA\J<81U M96V2&2D835T/GE5C8=3',= 6!MIK7+^3S([T&P7(LB+WHH[8#...DYQ0F5<_ M(-M9G3NS"D2+1/^)W(H["9PYV82EP9\25R%BD(6F&D*T:FUM32AIH_:+F.!8 M[B2^#UP-?4L(/.E;%T0FFM*/68V'WWR-44+\5]/2WO0BZGN0W(7 R!"\E,)* MTG5]@9"*??ZU?M7)[KF^[O[WS--PSPOH,M3 M^:3HU@"W=>KDH_5A@J=!.>K #J3EP 8!R2C2CE%N -Y7*(>E+T.^?$Q?9CYP M0JUFK'AL&FA=>$I=W;0\+[-QC1,>,-[A6^G0-\(AYC:'DCT#;LGL]DZRML?M M",AQ\ID73TBHHWR-@O8I()@$TF 0IX8P\4#G5GBHF$Y^E""]"&9:M!?:UH10 M.39 CP^-'T%L(KEDW'ID9H;V>6B(Q/O=4D_1 MBYQH5R226B&\PJT-.T-,JYA@A*DI)I2M_#6#A!HV[I]5GVA!XH/UMMI)]A\^ M?O;TX2-I>* F%6W.820!.?)RSAESVQ^9I_*"!PL7QCCU-]E)R%^K2FYZ0%UY M[.W>![![8$#E+5&R&@B96NXHPKU%4HVSW%D_7"28)10H6-7T:T)VA>4Z'S)HAQ MD!@6IB8GI%NCF'%>?;YI);22Y Q?XO>;3E^F7V&$1KWX:0:#3,NY3HLCT2-/ M+_JK11I.M$'>R(?(FI.:@6-5U4O <\'Q+::>/\,PAOT$/++.67A(S_GSQQ.N MJ(&M!2<"?W_ZYJ?U=6H1BHU2X%9G@3B4:5U7YU0#%7:NZ8@5-M9^N-#5E6I1 M8=TE%@880\I58L#"?C/2;ZJ8B-]%!2O>72<[;-AG!32ITD!9+5%:8#TUJOMR M&.>,W#A1 TI[4'+23[8DIA 07+*)E74 IV M5QVY;08*\$:3F^3@ \>'!.B8[>/KBZVD@RF8K/0WL)ME5FNVM2L!4YCGV-#O MAKR=G,A,8G!$4-1JJTVOLHBA*:>C2\Z/OKLV?U (C*N44M&<1,[I^ZX5C.$: M,HBI>AE?<'ML0S$W9=FE7 1Y@AS<1<%Q1-RAW,1E(_VY(?DF/0TYA'+_G41\ MYO/LDCQ,#)4H%?F ;YFKACQ2'*@%"/7J*H6Y!EQJT[80F #.NRXO)JD_\>NK M*4],LH.JQ(A1C+8*LY$)4]U+%@EZ+=B9Q"#$!^AQW##.JU7\2T'N)(CK,6E4 M-!D2GNR$X_ZMX47TG& VM FR"I"#F)K\@^#V(](W)1?2QD@/SZ]@/P)%_"(@ M^ T.EQ;.E7?/ ]&(;=[GIA5C)=R)T-$@:,0PPC;HDL@91V;QB.@.5N6W;IJC M7C>Q1F_I>CF1$_8FS#>(DKO.MDT@CTT4/>OCCT"VJ+A6,I>[I(< [UU697;>$\6A@H_ "U;BK]L)W7"1@9,O[CUKMQ6 MU(CD\UM#BO7O;0]#7TI$3'SDLBJ1%]%JD6$HA[ M&H](+7(%.>#F%/+(,JKK@5O4PBY>OT/(/E7)WN@O2@*6?@,U"M+!NMK MLX(\;V#T%9""X!E]OZYW<4;T[QS,7*]\IK48T@N;MH-SS=Z@YVCK4::S\MQX MZ34([SQ+SW(8.1UR'$HY-')-X-=A/D35 8Z[L< MVFIHNP0'VJIM_4D8G@6RFXA2\&.'E9)B$U0IWOQ%#AY2ZBQ-\.S2B=KYB4Y] MT_ M&>\=\43!!&GC*S;\2Z$M6OY70T5>[&2D,0'?GXF=B]%0?9 !Z4"=I0R[R3[3YQ9*1TGW(C*4 S&^XYT#P%NI1M<&'U"W-N&8T M0C)+\QM M*8AK$,,KC;"Y%0^I.111*DR&W,/.!KV^?5@N)D/%1\8VO_1N)BX->" ]J3 7%TY?(6.M]Q&T)GT9>^EAF-76E]6$, MN3 'J95&2(+Q[,3EM69I082V9W"6T*6-NIH:?\^!(\)%+UN@NN1^,RB2$K = MA )=;ISKSMQ>[N@Y6;/\*F?R58EIUFT811TEA_/.73<&MSZL=D;)ZW:Z@T\" M"C5O^Q'=/U*0)<1@HIUR?LG'UQ_>O:$L,#\;=(7J5]KSBKZ&'#ZB/6!ZE*9= M(99V2IH8KNC1'IQD6?+624L"SRO'Y9;$F'Z$R_P 2;=\X@3[4+UDVK5#5$;< ML'[+]__N[[ZR5K50'S!S\'".&P1'+YM*HB&?1#5\2QPYF_P$;5;>)+\H[UT? M=OP71D/TPQ5U=IK60J;49)QWL6$O^1JX-5L[+C3Q0Y1MO_R*D9_R#0>J%9M$ M:]:PUU&I1J#",QT>:+3]P:-X(/%SGHGJZ83PT0EC$!M)G$K!EZ"/]:\=FD>Y M6-;K&;+=D%H]C=]Y9?L5'EH^)/B..O,6'"//[ D6+YN*Q:,,DK _:\>8_-5Z MR["Y) .J'/O7]^5G&9+YK9N>*CSC!OU\@Q,\\ +7[S:4>I2QIRKE&PCTC;A= M&VP_KJ)@FBK(4179CQR';.1J(U?73#O1N#%#DO&D'S*,9M0A?Y;6.0(S%CC[ M2_/BZ%0TD"HRZPAYLNL)NS)4QQVM..,LC( ME(^/$)JOR:A%P^>?XHS#3CB"I*&^-%>,HCQQ7KI8+>46%(KA1D(P"I2\C#./ M(Q)!XP,5L9"7ED":B[0K"<\RM4,3W*AKAH7X]]1O#I_T'6=;1-$DVA+&A;': MFX9I0LN)*3CJC5O=EO"T@V)G4T$?-_2?54U#V-O"!&CRV]JA*V/[P6#@6/A. MD8H@U5?0#G"KT M\'''*SH_="< \U.X;NI7#, '1YHF='B>\VZFHOFC29 /7!*2K"VFDU@= _I<_FR MC#)DC"Y)*(?>EDG/*JT ^P4[R8'?;5EG%G46X"I42=I5 14AFA]&O>/>B4X7 M=<_"A<,30(3(Y< DGX'(U\_>!"(]&CO*XEXU) [1.^0R\<.U,J#LK<%;G;*%%KH, JQG%0MM83-(_G2BD M>(T& 3I(.9N'.PC&LJNQ.U43L73PJ'4,R9B40<+/<]7Z\0OZY#0#*!A**M,X MCO:NF.>9,+$P(+H0S6CJQ_>W(Y:A7#4/Z=\;!6/"P\FX;'3#6=9:?AMT0SEI\W/ M5K?>1#5)>\OZE<<'W,L0AHE= #O>0-ZO+%V6UM P0IUY0CUBW0*HQ05="G;( M?:T57@BHM>@XA TP;(ZT\XV6"9#W2O"SZ8BQUB!C $YVNQH]5?>^5#SK!S: M$K?N.?/.0&N.9 &@E@2P&^Y]L/4>'K ),4L1A)X<6VWB-,WE%&0 K/24H6H$(9 F MS^&Q#%YZ,*A_S9[7$=E-YR%*QWPIT$+T)T:NP_R&?$5]135";/X"AY@&>:6/ M5[K?+P?'$(>?Q@Z #A LYZ37O.U,(GX.<#6KFE&M/)V<@A/PDH#U@]Y>%<2SZ#2(IZT]NSC7 MT&O:U40IY1BH60HN EH7W$4=.*;B%I1CG5R45S+T DT*NXC[Z'5LE4L0]:0-J4 MMAL!#Z6%.7[[,\5*/W\\X0DAC=1I3,6]F.;JAU=AQ)1U%.5(1CI,!-!KH3\J M,"38HS &.A/L#J(6ARC+A""5ZZM?/\P'7:S8794>,495M%&C,3HRW0J-J3DK M)35,-"6 M_7>".#]/+^);V\-B7M!] J!C[/@3L.$)=QY?C%[KY0O"P>,C,;" 9K+T@8Q6 MA"OF;K\U='_5[A0^06X 0@0UY&O.@,=A7 /, ,H51$A*.T#L6%3%/3XF-.J[_JHJ'\S04& MS??=$!EWCIKFLNVA2%RZ$??VZ2DC-3)P.A[D.QF#J9@'-#I3LEFB\'BX2>] M2;_(<^L_X!9SFSGYQ(Y[GEY"DE6!V.>>,UZ,Q@S+4F#HW9X+?/9/9PY*^+)G=,M6<(+.3@X:@9' MJ8F?V;\/K!9Y%ZC9-;G"1MYVQ-*TV4C:+]U*D&W:2=Y%$,8AV9,TK$/[H/MI MP.8MB;\T9.^BL67\9UBMV,&1 P;UL%]!5]-?M@E2"]YLC6QGON'TA%@!L6,1 M] Q9;D<&3]9="C#8W>;), 1!&9_3:IWF PY<#,"TZL@*S U&+C!,K<4-A@3N MV1AYKC"U/9DX5ZC&2IL,X /<8VV0B=R-_(V=9T*YI=V>\8,;I"B,19*5DO@*G'L3.X;%G MK;+"J98XJBJIP*#$NT*1;!.(4%<5!%4AJ"*/2ZZ,U3T9EI.S_X!G!28TR"E^ M0DB)58-DIZ=ZIOE*'!,\W<)RB Z.Q8_FG\:?.KF"?10)M4Q8Y;\ R O>C3?8 ML^OKFP/.@LYT>AQ> G]H23W&QD&L%KIWLK=;IFY]P12WHE%_.E-"GY?-P M!1>(C2@U$6MN8!HAM.^"K#0*I)HIQ*>19W!''!3\@V8K"#3Q5E2)3X=""T2] ML'8/\EK62J8KH@OY?@5CX\YV8TXM73((*DM+,Q_!R-5.\@9;99Q>AZ#$UK3*R/J8!0Z\W@)H;SR6%M(7U?&TJ?#+]&@6 M1W&:1GDCZI"HLX&*;C6A/BY?N(WJ=.:6_Z%_5(C8H(V4H$?ZWQL1U0QE>(D4 M.288!;_4A97I9^IE&,KGRA<'^]3\4X1WJ[-\,>[<*S-"$FED6'*,&RB+YH(E MQ/C )T>H FHKT. .E*K'60IP$.U\89:<'!W^[<6[?X1MLFJ]>0[-#^+)P-M M/=[Y/9-_=3F5ZDS;*?-50:H7"!)284F6>UB4^THX;^!A*L'HXJ%4#D:.)4] M'EPIGZ>)>?J"ENC=GPHOH".N:@+@)B3.I_$Q@I/IMKA:QLB;MGV-7D"FL/CN M_F'QG,A]L28>KBLW8,-WZ4ITQ*N)QWDF10*;%]]4N+J+CN M%:XY_ ^(;"/49)9CB"X/J^%45^>DW&J:4<#0WF(C BO"KJR]34,G1W4.2Y!G M8LM,UN 0T3>^#.P7:;?LJ02 IC[<:J?*?%:DHW0@I( M.:P)G_B%VQ <0H0,&0G@PETJ@JLQ*@1VIR/*9'#D6C5JL[HCG8)'!)"7%\N6 M>N\6%3EL3#$;<-NX+4])4UTUR)J73F_E Z,4=^=(/+SC-, [U'SUDK#YPHW: MAATQNXDXBD 7UM40)FK7DA3JK!H'55T59Y1B@XZLCJ#Y@I9CI@\$9Z2NBFC& ME) [)URR]-88#R'--#",'8N4P$*14H,R(K*8HB50+6^_K4V,8+VF'(!?L'U+ M<] %H@F>5S#^Z7YXX>T _/[8>20X]4(_GB#H1EH340I$Q[]50JVUZC+N@UCR MAK^?NP\#]S;D\P%7#ZJY]H&!^J>M3C.TGU#&8M(H=]']QSN[_R[W =25-B74 M(M6Z0-LR*5+$<$/+59 :/(,Y(AA(@IP-'N5O"SS-8E07@ M6H+]I6?%AHELEM50,"+I8!0P>7#0%8QU%E!/9(D((IY:8]2Q!A,P*HYL1WS< MU(VE@)&O_P]=']MJ:9EK?J*A1R>E$9,&F"#FRU4SYVSW'D89V4A=W_54W7-N MJ6 O-_664A2V.K+I*@,,HK7"OD(RCZ14["@E!2U0!^+^$&J:*&DTOKYQ&MTD MTN34/(\?$@+30(6'BOO7'MPS9Y+,HY]0IP0Y2_N[#T5*])6$I/XU!E1TSMTE MYOD8@Q*F,T2UZ;0EM>5\%B:S/=&8Z.D;CEPJ0RP]?GYC*.&1Z+G9-6^P9Y[+N5_^O("0BRDIG+QPCTW1"'.] M":6P;>)($[NL[WOGSQ^LOOLZ<'CQT=[^T\/C_9>/G^^>PC?25_;,;]RB!1$\S[LR<3^N,Y/NWC^UTMOV%_PJX60_2!51MPYL!KVU MMWY1Q98RF]+3Y793X&>[:R6D/8O N.^Q_O\BZW>9L8N>FDW;XYW'N]\_W=M_ M_.\_CG$J=QN!5I=-]H/\HQ=Q>3/I/@(O_E_?[3WZ;K59I%L]_/[?C1$-_[;W MZ)*_W?J?'M[Z%;_!Q[_:/2''\\=Q.OET6L/ \G:HU ,)WH]\3_LS>[#[/8>5 M87J&O>0H>']Z>\[!4V^?9OA_??N$SS&%O!U&9#]@(AQ.)$"(8APY[ :IP.]_ M]VVN*L<>?]:Z.GM0.D/4]QH+C<9HC_A3)U4:8-MKI5K43-.P=(Z/U MS/UR[$*(XB(Y*$NW5%#T/N96](W<;938%\G=F_1SON@6R0OPJ>ODOW%DW,L? MEE#>I!?)_V9M\CPS\N@'GUCV5N4EKN/J?5V/[O:A])9U7B1[VP]WB)K+9&)V-T=D8G34T.GL/=W?BEK'-<;U7QW5C9#92NWY2NS$R]\?( M/-I[=$^.ZU\ELOE'5V:;HLW&ZFRLSL;JK*O5V=O?V]G='-?[?%PW1F8CM>LG MM1LC=;O_78!G\,W*V:"@BHY4[?RG'8W8D)7>]V(6^V*!O+]V?Y:U=M]*V: MQJ\B''^&W?S#>F?=U_M.;]>-M%,U&T6Q,\^;$_"5/S!^8^+DGBQ" @0Q# MCUZ.=K3W#8 UO2J3MV[1)TY!\#0$WP@0A MVH49M_W'!!^S]P2,V"E:X87>;$CSKU&(W M5^,"\*5IL05O+C5(_09@DC ,5]Z:@><0I900SJ?( PP/ED_\!= MP"-8W1IFQP:@J@=0]?@^ 52]^_#ST?ODU=N7[]Z_.?CPZMW;/P0[9:V+8NF) M)=F_6TORMBIO2N;PY&Z?[(J#_?+HZ/#)HX.]W>_W=Q\_>79TO_KP MQ[#E@DUY%/G-$8+F'49 UW[$.*D_](@Q-%;TC-=ZP]N(;,/XXM%3?)0'Z=8M M>X%78N<=?2;\W!_^B&=D/MW;D&\2BPR9Z?X("-G#[U;K0KK%TQLA;CU; :MU M;;B5KQ'K\NX]_B)C^FT4I+_15[V61?TZ[2%I\-E!W#)5*KN[+U_^&/@>&:F3 M'[]+YG4V^Z_OTN)SF7W>V]US4?BR2,MT9]XN;M/EVK-])^D7R<\WF\V["\&^ M0Z_WI=/B$*U#%B9Y50( #A 1'+OM3MYG35OGR & 3'+)QS)ODX/3.LN4I5!2 M-0!^!,0A/[D':/_S/U<:I*_KP&]4\485WRM5O,^J>'P'JGA_HXKOARI^F67- M1@5_2WIIHX+OBPI^N+?WK_V]9[>M?A_N;3SA;ZIG\[N_'\)+ >4ZL0$=SO-L MEAQ]SB8=JN5W3""Z[.JF UKVMG)_98*E@TF;O.^ IW/O8;J]]PCK:'N/I^Z? M(^3ZGE9+T.7VRTRAE#S#@W#[B#MQD:[_F5>]=YK MU_T[TJX;YW8-M.O+O$Q+)*&[4^T*>+H;!;M1L']%!;M_-^[K_L9]70<%>[G[ M*CIR[VGR<>=DYW#'_^;AX]TK5>NSW2="F]E7KQNU^FU(X$:MWHU:O1N_=7_C MMZZ#6KW<;]VHU8U:O?]J]18K43?!HMCHN[O9C9"V<^'47NWT7$-DZZ"3#HKL M,ZBIXWE:+]))UN$:-".H8.TDOQ _9W&1O,^6%? EE0G6N?9VMW_!JA5<0U@\ MLQ)&&1 (3&# X#/NKBU3K/]/FY5-#MUES[O&F>JFX0O#T[U.R],.*, >_,_S M]Z^W?D@>Y%MX_<,*6MA@BL3]"Z?"<(;A>5HXM>W4ZCS+@(0>N=O#NT-FX44V MHTF2 M+(S.J\)Y<J.9OZ_??WV'9N,__S-Q.F>*?K+3K,YPE$XQ8ZL"C'M!*)54R/B\=(E M3_]VQ6A )(BV<;W7R4Z2&?>VW_&TYM,8'0C_=U[+Q9=N*[;'=99^VDYG[H5_ M2(OS]**!UN5Y'4Z]O#A\^/C)\T_GXT>.GSYY___+QDZ/G+W/XLF'JY9)&'J<>#5;_Y@OS1B8O+2'Y/7OWT]N##Q_=')S<;6MH#K?3U!JQZ M[_;=WX_-::%Q4CQ2:D$YSJ1#M/<03N#>XP?3+0TZLTGGM$WNSG%0@7%_WGOV M\-&(+WJ:-RWT?B9SYT=-.^?Q3=*.!G?S!@9 P?NC4]RX7<]P2C=WCS#.YFDQ M2\9DJW'MZ0-XY3KK2OC&.:6 MVXOJ=])&/WYC QJ+M#[-2WI1M\.5_()5YX\W&N!X^&SUF,8E).R/O__6B='7 MEBGX)KF&.+C=NT6[L+>\#J?TZZ/_>?7N;7+\\\'[-P>'1Q\_O#H\>'TRHB5[ M]?;P*E?_6W%Y-SFWS:O>17KQ*[[SG[*G-TV??D,9O.<7/WSI&X<(3'THI3M> MD3\<$%RY)G]K_D:RT/_?U]WT/#]-WNXD/SMOMJG*47(\WWEQ,T5_#\3GA8O@ M?TC^ ?[W_J,;4S/<6P5QJ^]W,_RRNS\NUSL3?];3K6IM^3;^[\&RSLM)ODR+ M)--'K.@1M[YUF[MQJ3:ONO$>-][CQGN\IO=XG'9%\H^=Y! JRQ>K/M7_WXUW MN?$N_[0>DKL_,>&QP!J1]]?^V[E"R7&=-3DDM['TOJ*M#K]H'*J9?N JA^H^ M%6._^3O:(N#_]W__-JZF%W_____OW^;MHOC[_P-02P,$% @ ?#_X3A-X M\JB/# /S\ !4 !A;'AN97@Q,#%I;F-P;&%N82YH=&WM6VUOVS@2_KS] M%5PO;N$ 3APGZ9N;"^ Z;FMGY-WXPWMRM+??(F-)4\4U%RE-FLW>H$9JL=99N]F]JYA/N#YNVJ^P M6-.M=CP1X8(HO4C8WVN12/5N1&<\6;3'?,84&; Y&8H935^9>XK_Q=JM_4R_ M0L%#?GER3$E*9S!6LUX[.6Y2 M^-^,\C_\R@E/V6[,<*#KQ;!CFC=:OWOKH"? MR7"YBO M<[O&1"0A3-%YW_MG_VQ SM]UAA\ZW=['<;_;>3]JD/Z@NW=S83,:AH!3NQ.A MM9BU6\^RJV^T 0"_YRAL;S#N_]$CY^\[@XZX=TI&X[/N/\C'07],.A>=X2GIO!WV>A]@J^3-V9 ,S@:[O5F6B 5C MY+0_['7'9\/1XW3Q50%NBW&=.95AFY!_$_CW'S)D2DL>8"(=:1%\(A]3KM6/ MH:)O(\ 70N3/7&D>+>PE#FZ3WWPX/7M5U MS$BM,Y6,(=^J[9#)@M T)!.FYXREI).P*XA-NV<2IB"PPU<33&M2"2DC@D. M 9R9*?-P(-+0$$I%1 17""X2XF>Y=&9EG#E'9R93H*!X30M26H* ,!_H@K2> M-BQ!M)*]Q8?)*5!+D,' CEG^FLV:O1(+L2FB(;]DY#P!H>H4I 7%A; P2LU3 MPJ*(!9I$4LR(!A:) N'OAEFAAL-0(?.8!S'A"H9XQ<$<8"H&F3,1F0'AG!?SWX_*[].(/KXEUOV.N,;AU5#9+E4N7H7FCXV#J*-;Z+ M!Q+3Z]S5!DK9?Z'BX>#Q^!P- I:91UPPN.#%S^#&UX=&O3846L#4-N(*E?V30% M_+RMO5N:YG,4U2216YL<@FAPSO M4O32B;B$?*/RR9^8BAP.79=;?:BY$"]'/9'K\E2Q()?P M+8-2!#2W%R?,7V?ASAKBW5U,I"$ , MKXWP!L*CU:$39$%"5"-("?$EX(:@ \D M[@ZV$7=_0):#E>X:>39H3&::P$+ U*(\ 3M>PO1@+.*KD! M)&[#$AD&E!V*$B@ODV.43AV.S;Y:^K".J;9A4W)7R6:4IR;'0GS!P%SDB!WR MD@?,>N(I$(X W-1QV"KPY"8>\&)Y75#I1PL:Z-U5GLR#+N-@B/*HX049Z81 .NC[*8'9=( M6'53(-9 :'Q&:;B#:YH($))-!7RSOHA+-SR00P3CWD6NBR$V;5@Y&TXK?#8# M5(3M@0R;XC"37$@_9]GG/$V$\,!E;%A2THUI.C4WNZ!O*9(5,&V8:-SHITPI M6[YB'&Z,B-!:#ZT+W] #0D8U)!KX5@]N/2UZL?7)>0PU=VP2DX)?=;YC:T0R M%0))O55D \>'S'H&TFZ;?5X+=!IX&$F_$A".(0>&S7!Q!T0<)L2,A7)@'B
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
)%%E145$;H>@@AY M4<*6+F=C5Y1"U.(=!W2>R*]I>F+VEV6@%MU +7FX;A'X/_:A,29G,[8\7+HM M1^G A@E+5$3P@]O\+&HY"E6#6O1^T0W\HB-6*-/3OE<;6H,SL_=-M^YFA)] MV:(6AS^X'%335KS,\%^'I\&TMF_G']]0]1M(6JE]N*86EQ/Z$/43"K7JQLI% MX K/+8M>J9I7%'\?-+>^;+9.M"^WYLW>M1:J-^_L7SYZQ.HO>_;_\J+)/OTO M4$L#!!0 ( 'P_^$Y;'&*;]BD *(N = 8VAA7E4$^GZ9B$HFQ"1?9&H*(@(M NBB(DT+2@T1-Q0 M$*(BLHF(@@:-*=DW(:VHM*!$641$C,K6; D0EE::CBR"0$,V%Q:1*ME*4JE, M>7_WWKEGIL^9.3/SYR3G2RI5WZFOGN]]WN=]WA/Y.[D06.;FLM<%4% 7\ M#OXM76DSJ;8&P]5S'Y\T:2[OPM:L_GD^3A5-3U] T.CM>86ZRS7;[';:K]M MNX/S3[M=7/?L=3MP\-!A[R-'?0).!9X."@X)O1 5??$2+>9R?$)B4G)*:MK- MK%NW[V3_>C:UM+:U__[J=7=/[]N^_G<# M@R*QY/V'CY]&Q\;AK],SLW/SR+>%[[@4 ,5_0_];7%HXKD5*2HI*RM]Q*2RZ M]'V"EM+B51N7+'?R4CX1J;UZ4ZR*SH\W'KYH4C7;O!_2/7F^2TUOS1;16O@[ MM'\@^]\#%O=_A.S?P/X[KD%@J:("'CQ%+8 ,8-BZ_#3@_X]_CF>>_':&6J]C M8!E]QPLX*-G6\8JH0=L%MDAQ- PK"^E!"GZ"Y$#*,SLK#V6?MU'KGAD?>-X] MFUY&/!COP:FM2AOYZJM^*\EEG7W8X$2.W9>")\%SEY_E1I<&QS559FP:Q+JO MNKKY[3<\NZ6M]\R)NU\^>WO%&08]MS_7;'LB;6_XSR\*?@#>YM>PER(=S:0M M5=QZ"$QSW"$N]; ZS'D3O8.M,9%SN"Z\."PG8'VH@QVZX#'\_O#ELOA:ZR_W MS\/^@^5/^$JG8GW(0Y?MY_BH&7>P-F+N6X_GRRT'P&"["X76@^^V/M["LQ_* MO%?]9U4XP[KS0=V),Z>U63;7[/[7NY/3>NV;B^?!JPK'#3"UO8I#7#<@6A>= M8;2SH'W$03G0*@>JIEK(L=Q*FZ*'Z";X;'4Q\J2CB?B2G$D^S4\EJO79+D>< M/9'[8@]U#UD>-^RAFKT5F:@5QCJN"Q'P#?X0I5?2";6))I1)*,F8 _7D# MFF]EK/AM3("I'9#N1S?(6*"P!-0E;:41A9W\5N; YKE,9#=$%NGSJ$KCG-4- M2-B#"="4LXSQ^A*7$&5K@O[X]@Q]AYAB$D+20>Y*78;(+2R3HS2P::)T=-"E MVB)AQD/9$WOU]1J9OH[=21A0EE FUP9)/1@]Y!?9DSLES&2J(9T*!8C8GZ=A M01/1B&-,W]2 [ P74Q6P-P[%;62U8<09AZX9!+>W6%D;M^0MAEE-9*V]A>,+ MU-1'R2T,#7A)@IVQNM\%U]ZI2FH<>)R+K&>U,@>S)6 C=SGMT[$Z2+F)-6 >!/%?LT75R=?\^_IG;=0]OM M3>JRUZDF&0:!-B]>!QZYG[4C;L^)7UU:%O_2NN['MNU;:["I8^?KY4!CLFD3 M9VQG+#\4^TD.G.1>O\@B<(6/'627DA83%?KH6L_0G>$4YNMA50-U*A_"S^^ M-C/CD4T&/.1?40-@=4[*VSZ?HVWCTTV3E>/C\*,MBPQ.G=]YSN5JV^7X=]?C MW_5/7Y"J,+I!U61\CQ&K"%X,*'R;9(ZYB7+^Z_7] !%)'&N]HSQ8* M MZF\"LR?]OB_*G[?/286U?NO]@#PM#S:B\@YW5TQH:+?.UW*RBQ$"1;KV2W; M+F)];.R:I>\O#0Z!2]JZ7<^IFMW+U+ &S<#GQ>WDC'"I+X-/7D;:;I^ NL,= MDJ#)>*D?QB<:UBN*B(-UD@S^I#OTZ0"45"#U#+U\N 1FSAVKX]0@AH%24W0G M1.') 95@TT70V^($1_M2VH^OY8"0U59'($Z,K$+BGP4O3,VV%=[>[Z1T;<]. M)[.'\RLT &N[)%=&0?&+%2XNKO/)^S93A36F,',QM+?MDRM1R+A'2(Y MD":6 W%B^A)9'-T+_H2O( ="N7$DA0;9+?IN"461\59/H,79@7#QN9_C2X^@ MIWLI;8+K#)4W$66DM1-&G=R4^NV%89@53$UZ%E[O?J706?C.^LSGF2M[N.6[ M*\K=:Z9NC@S;G@V?++.QZ5MWY^,57TN;C^55.>?RCZZLR,$6?(/]!G?$1-B\ M3_3Z$A1BKG;MTP73 @VKYY]Z-_\":NUZ5L>>P%9<_30=* >4^N&/\9"ZQ+6U MX1*FQ50;)Y87IS%T&*_]5@N#FL,=IL2$-FH:".WCIQ&-S;O?PZX\]H"@%3."]:\QKSUXV5U9:L@@A(5! M[>(/GS)6Q>]#8B4-%HW8HAZ[M94+%$PM0.K$>"M8,B,'!KXO\O)9HMB[#S-' M7>$VEH2O3PN;VP=73\9>%;'5D,TB8CH:\"AXCJ5)MX(W"]M2'TWX;X5O9R?7 M[RRFY;8)=.EFH@8'A1+N??!<0#5 +(GR_IWZ/+E]CQP(%@P$B,#6$(;%F!S0 MCRX[::LSRK&!KV8WL;2P/_LW(H*F$3M8/\$Q0.0!"B/2T:,2MC9J"U.OH4[Y M(XA5*T.GS_'HL[]\:?$_C]SF:/\R,<1SRWWXU^L.K"TEG3ZYN8?G;WI0/_S&RM@6%!\B6@^;!YF\ MS"-%AXC6;K"QUYX,^G'+A\.6QY^_2W6^:7=\RFOWCD'KBFZIJZ@=75X\=QHY M!+NW@-HH\0D:7KYIS*>(U$:T. MCS(@:=]H.S$>E7B]?H#^2/W M22& M1Y?NB\3#5UK!"K UP@"E(F61D(_5!#F9JLFQ0'^$]>K ,H0KY"06A7HON-/7 MU-'HAB4^XT9E?<7%P^,+(Y4EXT9D EEXGU7NS2.D^RBW1JB-^>_(M%V$M(L) M+:Q$HEJT;>J(W5ML"=T(R89#R7J[87NQ;%"\&$*_4E71%VP8^F!HK?0E!S8% 6V./GKRH&" MHW 0MH*J*0>F+5Q1)U";/)I=*@>2';/D0)Y_V!0!R335P_?QD+L2K>3 ;C\'+VH&\:4]JJ?X/?)[DTG;JSX^ED.*&[@&GNK+PUT6,Y.;-E^XLFA,A?=&.@VK'/S]K&= MP5]K2IZY__;XM;6L70,^[-R*J-6P-"5] ;$%:25Q)?[;Z/Z&KKIN&6JSEN<# MUIT8Y_@_[K1Q\,UU0V-T'MHN'J]'IOR:BCMBBX/D3")8QR=.#B M-&WGGJ0:,5<#B1H7O,NQ2(E6/!OT=F9X8W3G_AV^OA]SUB9-/CP'[S[[BQQ0 M%E2ZHOKIF%H0Q)O+DQ5PC&CV$ONXJ"D5NB,R#8.-(SH]7QBJZ-;>9QOH]B+; M%-*J-UMV;)\U[K3\,O6QLGM&>F1M0^VEFMJHD$\7[[A8-''%JW#+R97IDQ7D M@"@)\94#K]-DU:HS)V%UPT1>@.5ID_4E)Y_/1&[IG3;I]#C ]M0]_JC@YNOU M;IN/O7+;NV/0P^I>CQA]J7UOQ89PD:53I5L&6S\H8BYA\LJ,;_@+F2R$];+] M^K%Q*G(M!#(O X!"'I'A0E@LEBX:3AZ(\?,A6![N^8*]$CQD]1>,;&5_D M@"?KC_)ZRLV/JMYIO="GSQ^D9!HIZ#>(U3@5/V*8YUZV?&XO;G)XC;5K^#&B M,D^-,%YUA$WV Y\=QT8=&BJK2O+_VFQ84>8V8CRA7%V7MCT;1<&_@TG^NY.C M)6-ZGB^/COEDX*\=O[!@B0RT+Q^-] MNRK>V5EI+RG/'YO7#"]R=O3:65'(VY)&_TLR.M1>8^Z5$W3D#W I1?56X+N_ M^+I&!NCKZ _)C2>>G)QPN6Z1U9/PY/5]R_61]]TB;PU>+UX<8QT^;PG9) ML S0F7A;[*)Y\/'CDD/W3NB;EU;EWZL,V7KS(@7O!JI\,$LP+&+(>0Z/TZ27 M= _-ET>L*&X#"4@$CV5"6CN:LR2Q$!%XE7?/A!,]8,^'8<5C.=&% 8&5MV]7 M1#:%+Z*_^"DMO9$]>>J\\AMOR%"**]TK">,M=>XAGL8KE_,/]^?>._#6Q:-PUNTC&[5/GL0UR-4; M%N"RO*08TP%Y-,8@=R8:7"$'(&$H**):>%'[6.-\#3SH.V_@;"FV_2H''H-K M0"+X%,6U:K?>59PNU]OE0 [E*2BJ)X=3%QRXF7A?!4LYB0 M Z@V;XXK>\)8Q1ADE4_%H=%29]0?!A/H3N*&T/YC4'\*/1 L"1ZLK#!= @?. M_$ =<%.ZI.4:$Q(>E=*^Z JM\/T#]N>=GH?VCA\D=G.3*(BY,LKJ_XR3*R"/ M*P>>3+7=EG46_T6=]_ZFAI$7G(4_; =UW_<^-]A@ON06H UP5ED#>*EHY7G[[4Q#]@Y.5HWCAG$1^6%SVKH'B_XQUE?T MWZF:?!F6LOJ\SN0=6L"9C8T[3D5OFXC/C(S-:@6.LA/!4#GP;G,CKOV4--RY MU'"LL3=<)<<+HNV.=H^H"$M(;+,UH&]CM?DO@::NF\%/_=5@S^RBGN)L=^F_G9_-6ZOK0W=7JQ^Q&9JPUE0:9:%.)0W+KB4/QW3D&K3OESL MFKU/=0U+1$0BE3Y1Q7W/"4][E>3&/[UL-$KN+JN[Y:WBEW;S BBVXBN"7;\@ M>,$FL.+EP+<$=K_W-6S#7DN;Y8][;X;(@3/GL)+2XF?A5^ORB NO;LJ!-Z&3 MZ%+O;-FV:=>)H#3<+V<0%2L)Z0PMI 'JF$N3O>0&7<5-4#-% 55%O$7$.-# MT;*89BRR;:8F<_2[ZBV*$ O1Q6R\W0);_*B-.:>K3^3[#"/=?HK4BE['D">= MT5?$.X9WO7[1/L-LI;S;W,S2[=G'[>4&4P:GFTU#[7KC[5D MY-K(!K!K+];/OHFAETWM9?2(;;7"_#?"0:F.% E1:WQD$]R>00^2$+2&!1-XAY>= M41_ #F-8PJXI=F&OGE5:!QRJO:5BW=I083I&_9V+[HX11BQL(IJ"HFD(E ,_ MW)ZW0+6YF#I?1!F2SF4]E]VOP%U^:0M7S<:V7E5"-F;J3X ZJ+TX3"6KZ=-N MPJ.MMP-$&::B1[WD*N_7-?H/K5OKLM-V"8LU0X3\U)BM?AF=Y3:&>?JV'<_? M1M+^<.[R5NDYK\%%-D?NO0!Y>-WN&A@S[C_%'56L(\;H*MGA([\N8ZQ"LI66O5_FNC+.R6#E+[L9]V>";QYEZ@X78:UWK.D3>)_]BM7) M=5LSXMNLA]O1L[@8S+0I?;ULF7<2C"%/O0=1/]-_'X''+O"^%S)P'_AQ=:!0F8YCXCJZ N?WG1?&EQKWWJ]O%,MEI4X8JEX M4U*RDM!1!H9:_SUZ,6[T]TONU11'8Z5"\FS0/=9?;-,?N%<\ MM-T0\^)6NZ)Y_9/I$R9\N5F4ZK.4>_#KT!!>Z8'1;[?A-SSM1]RO:;SH=A M<%PS^5M!?XO%;-H"67)H3#:/A4T9[B9W1.!+7+5%NCY4/Y #G&PTK.\3<]J6 MVX-V);*"9""/71_(J,-+NS+W@Y7@)566@&T Q].1;.H-AN]E@G0,;./B#;HP M(? $[@'*&*]>NL'M1N.@GKKC39>4&L00WK"T_ >OF[L,R9N7%6S815XA-A$C MBIG+;]:)--=48X8OF%^#OW1H8]T=.,5__6R!%>)):#?/&CO9H/P&7(\IDL/! M;XX1@Z78G]IB/O;(Z#Y(YWD]Q]75HV*4_&$<+X29_9"5-,S=F/&.5>F\X0:^ M/)1*CF .W!\Y?;Z9B'AQ0Q74&&\MI"Q9N[3 NO;5_-KI' PU8LH.G6M/P0I9'&%N9G[8.^#[8?,%@ *:*IXG2O.P% MQVPW?&$N5W8+TT4#D1O*23-LE58\\PR/A.D[U#.,NVSLC!NL7(^>B2Y58;0' M1I:&;FKF.)V;/W_GHO&/6*S7+B*3!0EQNRW$43:5#-9O5Y#0DRE+K.;L%5']$7SB;B &"'\EMH; MMZ/P_LJ[>?#02(U8XRS",^E1][!U>U'7\-O7$W=.9^H=.7GG\)ZA#RL(DEE#'S/.SOZI^FV,994- MY34-;\SQTDNYP@ZJDY4PC)JDK@@XYU]5 6>6P.H^D""#OCNF]!WM]"A-F7>> M9O$SM+7F@NAJ1)O^RZ-'/"0> 4Y(_ ,DW@T2)&?YU56\21_W-X\@[ 8?V+P\ M>I':CVZ27D/L_S8^A1'(2@M4JS6)@&I/S.%V\=HH9]6!;^Q4)UG8A+7QG B) M?DICN_3PXQCF8RP-QP-PNC>B()QB7LZ[*UI'TD%*Q5BJF*B%;/W4G$,_A_PI M$>],S"R2<-4F_!=!W R[J>1!USCZ48G5MHJKRM0Z/RHO^[)@<&6<@O+*:TZS MRK\$O_S,92.!\PK?/8LFWO/$;0.[21@ "HM;N&A/#U?4"$*NQ 77_L]XJL5% M:('3[M3GE7_2VELQ0P04V>K0IMIRWB8GH40A5W."L0&FIE0>Y?"+1DV-H)&[ MT4\G:ON*SCFK7R6[=3]]-C45M#*EK.P]W>3X<[(%^#?W=D6W$3 5B1S8LR!C M<2$/L2T6$C9.68VQ+I#D@/Y-/11E9S#(2K14D%L&U3K>]>V%74 MSQM6=X/)U[_0-XL$ )+;[K^QNS[D(1)VM*?>#7$B@3K]8.\6X[LV,RP5 MZG P9O[\360T?TC*,]5\4Q\)XFS2GUPEI&@C!X0=*/B&8SR11X "<>'CF-%_ M*(?U$D7A5[R@Z.Q$QBI:UIY*V#;!CJF#^! ,Z60XKUQ$,48B'=WS.V+R'?Q> MI/XS]LF7AN4 %>KX0L+M53*^Q4TFX!B16CZ/J=;OQOELC9,SZZ*G!4E%>LO0GFL5C0UQ7133SWU,>5)B+]!759CWK+<9G^] M'O1TK7Y:?4#,VCMW\6]7$5Y")N\K\ART^BLCBWPZGDST#6K>OU3PUWA>I/)D M#_3Q4[L]Q[0*LF\90!<7,]Z$2*W\T5!WLA(A&:)?R?(NAYH18ZD6&L75.Y5( M#[BJ'%\$'Z-J^#9W39PYF_F8;E,F/K2ASG8",[S:]&]@A\C0+AQ"K $.$&>W M((DI_@'<*#X>PH6$1,0L668V)53&U.AX4]2YD\%;9+#(89G*@NENZXU$9CRF MHOX],12)T!1[8#IS>Y?C+HJ8DKJ)49Q#%C4*(%?;[PSYAC/DNZCGN,FTD1IX MJIFJA+I"02XP)U=L?)4HH;;4D1.,;#.>EE6,U9N)(E)(J[JCK:: 4M:! MJMXM>TAK)AQ\$4)33A$G]W'(O$#+CJI.&1;-K<6(&J8XRP@2K4RWI &VK?Z$_[..11TV/-68F&0*<; MB'$H)0*::#7B)SI&7BC<+9H$=S'W]FUX-MAQK,[ZU"+&9:LEAMK*7XYT .0ZS'M4C M+HYB:?)+QDEV]H-!&9_1K8%Y I#M_ S9^7)?REY*_GO-'L5 MCFW1=^KO68E_DKA!?Q$]]%O6@XLX:Y482SA_<&3/'=?:)^!6K"&LB4I@F*-[ MX(A).^$>;"VZ"0D0^9*7#"#5V+*P"!6$VD8R@VW3*IGZM!X>41.U*D0\^]LP MS:[*W ;WMB&;>B_Q?>5=T->)2SFWUERQ;V*GCRQ'/@@U-HN)\2YEX<5^X_X6 MT)?2?"39TX&<6F\AL5V$%!R%R$RZEOC^FL[SM1%ICMH2JN;$B!Z\^)[]I:K( M\9Q#O+'YA:3[:XMF7_TKGM-6F(DBSMQSWR4=!7!8E%3P6W$QR+N&V[1,\@R3 M/2#%KV.KR?R6MU)U_[5PNJ0] 5,.):NNAMMRQ>M0,APA9B>3-'QH/1XO*^J@ M]GC'<,ECVTF&2;ND(YD;)P=V=V$KD3\%>Y$3HK*3W;S]51$I(S] _K$EZBIT M)\V'ZHK3+,Q$&5\E\K\*BP QA_7EP):*__$I1E;+@8]W&DK%5%3'=S>T,SF. M[BJB#O1+6*W\1?2]R"BKO/@:/488[BUTR7Z L,5^_/1*RJ*0^+U52#*3S MF4/HHQ]X,#%GY)HQY$8EA.KE_)SSMK)GM'K!0X8Q4\C"!X/V"=&4S.4TUMPE M1%I,4YP[E=54Q:VP;U77@BZUY*U #L6((Q*X&IA=&/LQ$L1CZ[[K3' M_3TX)G*.B&JU8S=FI610F-M"1;O[AWR*)T&(_U.V)+9WAIIB=0*B'$7"'FA0 M]D(9_6G'D2MD+S/+XF1<0&@@?SBL26$?51?1V1@=:9B>8-%]:H6OZ32NJ< MJ7\ C(1A/$W^42$(_U!#*=2%NI"]Q&?Z<;?P,AG5GI^SDR4)VOFINUM M^.&(-9S.HYK4+Z.'B^Z3_;L"RF'O3%25C5QIU;NCE[<*:L_@&"+\8P@H82T- ME>SIG>U4^SC/PS9 7\J*7CVF@7[]6S1^\BW[PBP=U]O<>FZD_&>GW3K[%/YC M*"=B/2RE26X(84 @N=2XH^%BA'HKG"X*RB29L%/+/O=XY?*R21N@V;D;@6SS MNVOZH/%X5TY-52_+/8\6/KMM,J\Y)B!-- PZOI4#(90T5J5YO!A,$:B@^B+F M=3GP@MW(OU[+;HY8',+8B"2PEN*SP%2N 5T7W^HIB;6M9*V@>=L,,8FK$G4E M=Z=OD\:#T'VT:LEB5FITN*_/6\=5RLF.^@]#JA;90\JV*9T-Z14>@"U?3-)VHHZ0?/)4;(+XJ1L.,P%;HL/>3AJE"'[ MD@Y11:[79J:6C"ZG;T/<1>JR"+_^J#&[%;XMIM9P7EW),(TI7E)7-M$]L,*4 MF.&C/WG@"?9.#BPFK:69"0GQ]1Y0M7 D$?9M+A-?=9^+[7&T9D_,"0RW3"5N M' G3\]?(%3U[.:>%N$F::O^P-[K*3TE8>+75^^*!9ILU<82N\76*7\T.RA(= M@\3\3(YQ&%.)1FTD*J.&TL-CD!3IH8CVDS!]?],>QF;4 DF% MGN!FX$55YM=YYPHD7K2"VIPUL?7BA5>Z#1_Z;N6\X,9U?]Q=57=S./R92I*W MV;MU#PCMX:3^N2R$*75'+:J0:HC;[&^,W)7JH"L1%JPH*BI.KG>59$&2N5*D M#"]E"5O):N&SGN52*Y$@+?YE:QFEN8 /02N3M@R:205>R;"Z6YP?P*Z M422S]\5ZGR.KH$N-6_-4H%DEUS34 M>[\OC?H3!([I+;F 78E>L;GQT[-M10\(G7)@D,@35+I42[WI2D@L)!'JQSL& M0 )A='O+9ON42B9S(2+>CKVV,$XD1HJXAD/!_JMZZ,Y%S0O5R;,[;?@^ MW57C>EO_K"=.&DNW3F [T^>LNDGZ(=CR-XYVTFV,7I8J:=V$PX;JY<&7&7>A M'M$4CY**J86;-1_>ZA#^7MO_W2MQV:+^/5U'0JJ(D^E5R(#!-%1O.OT9> M51\@W<'H&RR;0G6,AR(!TG#4JR]Z@LAT$+2J=Y2YBJ:ND59B?P@6 M<8/DP(K?&1H#R!+<<2ZC29TKD:N2%>Y-M:>PS2^@1Z4E?DAH.'CD18]G23 W M!CW3C:VD71%>+!!.Q7$U9Z92%CZT)V5:_\](#.1#F M1\N7 SR&Y=X//:O:H-9]&^YJK@/ M/I:SEIWFZ/$!R6[3*.X03VDYA9=-9,^]D7GM!G2GDR?CH9/40;.Y0[)\3/GH M6*U>R5/Z0<0*MFHB&57#:Z8'@ONP'_KI:Y\,TC8?JNV=7%G#[3KU!O49M*D. M9(_]0F*+I#*'?M]NM=#+5PO39Z[J*$#V[:R!2RW8)B1<:D13%A4Q$[98[YB[ M)"LD![)2%O[,LIY9\,PJ1DG(NI[6LK$\???P3?.3WGU]+B,:RC_G[#"PZ=Y9 M3O71JJFW;Q< W+ PMA'8M,M1 <)+)%G=&E65AM)R?VIXP]F&Y(IO]]^'^+MZ MP5-X$,N+T]EVA/@[5()M)5D'*>;-^R_".U-'JP)7R19^1&E'I M]FC?4K"O=IUBD^/1 H0KHC2M,&L2+"81G> =7E!U,MU.Z$=H7IAO,28F3T:* MAJWV5$/C@A&D=I[GOZ92O\HA\'Y]=UO47@]4VJR2M SS=Y<2&5U4'3 0?#W#?+7;X[1C1LYMQ+CGC\@, $3W"O M<>QDN0REHW1+^&Q1D?GM J2]W5ZP%%7,#W,H3J]@Q0E4HYG+CE'Q[;4] 2NV M&/FGBZDI%[F$F1 23S_=T;5H*/1F&7_NAZQ]/3.^&ONEG]?_ZZ^7_W>#(!_X M;U!+ P04 " !\/_A.XZWZ$8$N "/,P '0 &-H87)T+3DU,#4R8S$Q M,C,P9#5C93AB-3(N:G!GU7MY5!/INV8A*EMC1 0$-'%!4 %I!00Q)BJM"(AI M5$1 2"O*JL8%)&!(B<@BB/DI*BTJ41$1 :.RR98("= VK8CL(&13V:4*(92D M4IGJF;GWGON;>^Z9N?/'G GGXT#J(]_WOM_[/._SU"G4W6H)L-!CE_LN0$,# M #3P+T#=![CBO_W?O?[^D/_;S]!0OP$,M($_-)9I:JP$YAAH:!IHJ$4 "=_G MO/\Q ?B?+XTYFG/GS=?2UM'5PR>4+03F:&AJSIFK.6_>W+GXU7C\.C#78-ZB M%1NVSS?T/J*U\LSBC0G7'VJOVO&RSFA?*V1A?_3L)1U=8Y,EIF:K+:W6K%WG MX+C)R7FSB^LO.W>Y[7;WV'_ YZ#O(3__X&/'0T+#PB/.146?CV'&QB5>3DI. M2;V2=B/SYJW;6;_?R7Z4^SCO2?[3@F>O2DK+RBM>5U;5"T4-C4U_O/WS8UM[ M1V=7=T^O5";__.7KX-#P"#SY?6I:,8/\F/T[+@U \U]#_P_C,L#CFC-WKN9< MK;_CTI@3\_<$@[GS5FR8OVB[M]:1,X8K-R9H+]YQ_>'+.IU5]OL@HZ-G6W6- M+1RDJ^&_0_OOD?WO!7;IOQ39OP;V;W'U C]I:N"'IVD 4 $,6_,H#?C_>E@M MS5Z[Y%BPZ>>8IAT+W(+O*#A3N(*V"0Y&M_$YF^W5G%&E( $R368G$9@BUJ9-H"(4D2FJ=I,8O MY>"U\VS'C^AVR?T+;T(;[W>AACQ%J*J83\!:21H.X^92VO@%I2/[/:@-AH!+ M6!:J7'2UDH;U4HBJ9]A2U!F*,?N0QDW2;R$8C;B3TF4W7?S^TC>6NC(:Z"E8-H7^I;1]T.* MZN.AE&R[19X9J[Q=2WN]2KK+N+UVDJP4; MBKSC6@:UBLMOD72(2@.3+.)?Y M)A,UK^%-!9"R+B[CVG49R=C=J/BQ(CN$$_DLPN"0/ZVPOWM3232C0/C([2D_ MHS"=E 0&>]DI$A$_*%B6,CX/KI;01 P#K(U:.C$>(V77^#UI,CHPG'Z?E5I-#=-;%*S0=J2 MENV;AE(A-2!S$&M$49.YNM'-](7(-T_G,JHNZ@*MSY*H@83; PL_Y$&;TJU2 M,%MFAF]VS[A7JBF\W .TN(\E?=@3MJ:_]HH+/OR:(-O M5<7!?3ZW\J_X'8J>:SS7X)/!]8/6B*&J[-3S+$6=ZFG'J><^OHJ+R*MGA6=^ M]O&6!](U#E 6+W@# !( ,)H=O,PV!D7[__K.JE:>4Q*4=AINYN."$K"T5E F M6D=LR1SM)AUO9K/9<5E([,'![RT?S9NXR,4>$F&0.B*8;5-59\LVB@O5P$GP MJ,KGUWK5\4Z%H&SK&8:%'WK!2?*!K&U ]_\%C MD_)5SM6EII]ES%A*_N!7P7N]\1CP^TPTGCQ[$(Z*?SZ!L;\)($L&ME[ 5 -7 MMJF!P@0UD"U0 U>M)F/0 T? UD?QU*_5]'X!VBJ6845@[D2?S09.F7_PYB;N M OM[@^8O[WV?_IHU7KY9:_S\'=,ZY2^;34<3!?SY[%O8:6IDM1K@5O-0G;MJ M(#WWWRT.BAZ '6_4P#NZ&FA@LQ T?J6LVBF,E3)&.W9 M26X;I?:H@9Z!YM[@#;_3CHRQJZ\-5G1LS2]5_$-0^N7SX9J/6.TLA=FO!@SZ M+G\/LE(#!P4=G#'^$\E71G:5[7Y? "'R2L"0XX'M=SY2FSN5NKT]9Q3 M^K8T:WGO-/KAI_S@O7,Q\'\Z?"%39:0:>"MEMPL4IZG&@FG'CE'E=Y[$7M&E M!C+K507@F(1M"XY$%G9-"UI)F,KVM"K1J09 DF05()794Q.X,](/[,^Q;X+YF"6M7 7'Q* M)J+*5@-CC"[!- G@6>'9TQ4'=@.03I\&XG?<'.A'G!( M,F>;Q2P0Q\U;NWR..Z!Q@P9HM&=VZV)>E UJH,X-#*=>";)&NN 4*2=5#43H MB7M2%#M5_P"/\GH?R65N;\+QD&B70T:E3DT3EXAKD%$YM3>@B:M%H8035_$1 M.+8PO,KXH51EKPAO+)6(;UA5KDK&2_4Y:[?J40V> MKKF0ZC'?$6LF&9?2+V=7"#D]3?+01GU:8PES$6C"5$4)YK-(L%4&>7,>NJ6\ MO7[#"T>)UO"I=-F=&GOIDXYCK:R?!]:6QL?QDKI"P*#6LYJO\Z9E.]\D3T27K$NTZ:"8/VG!V? _K3+ M@JK_<2369Z$L73DNZ>\I==7)J[G9*B!)11# MIM:^5FPU:^F'*'H2?TTK?]YPA3\O\13;"J$W\K?"B]"=<'+>8R;HCC.WD&80 MQC8+])59"J21%]@DQ4<\!<5(H21E3 H%-*J!.0Z"!($)VY8Y6B\HX32(K_CS MDLF,9ZB;BHN16/I(-5PHS:^[P#-GGFO,/L&>WUD3Q;9@MC7Y!AFIN#>^"NN[ M*%;E^$+7^,LCXP+YUZ$F4>^\;JUOCD:3G/%8'HL%==6-NS51 ?YZ[#UWWB"T M:@1S1.[\'9$TBT-9Q]KZD;\8H0M=,)XLLN$C1D0#D.T%0[W)V;8VT96H:[Q, MW\VSO-5!=7# R\QOPI9QHG("P>$O$O1:R:EC/*A%-CCNI"7LHZ>2#&WMT',/ M^U!GR"V-OS0K4F!EX5"'$S',4 [1&3T\!?4@V?RK=* MFCYYE*9_V(-1FO[6 E!2_KGU""ZV]-$QFIXB3PV4)"!X:14\Y]'%]T$-;KD MS3$9]_P;:S#.$?L#@P3%&%Z\D_O/,%2I+[BS+ZY@L=B'B1\K4!RCKW+Q0N_P M^VZTV)L^8/5CTV+OG4#\Q'^.\&0.LGH"Y3:-X5P3S,8G/M6Z:JW,HKT6?.-- M&F%@O"WU<[54#2@M7JB!V=?O"=/?%2SP[5.90.F\9$(5^OI$-+Y:L];,@W_C MM!464::?"6_^H8-J.0!EDUGC=DH"]B>IW)"YCM'K)O$5"M)]!83HZF61]7'< M=/+F)^*17O_>D8/9>=\25 6K*P554$SJ2R?UUK;%CIT#S_NDS_PNY+?J%(Z>K;^M:':ML>W@[, ML3[P_5A:CT76T6>Q5_L6KP?^4 .I^=03XEDG0D\6I@;00#7P]94@AM,J:-C< MN/&:WVU'"SQ'246U83_PEF,'U@@,OZJ!SIJ[C),!%\#JCDEL@BM1DKII(G$W M5^&!-/.8>B+!8FHH>)GOV,DW'7:AI=28QQ0C]NZWM]H)S>;)(H)(T%7%SZZ, M)Z-$?0A[FEX81B1TG9BFZ0W%E4=OM=Y=P@]Y33D'QV Z#Y6Z:.Q'LNL#-$!U MET)"Q+O@T :.,7H&WG3G&6=APW$>+DK%*35;I303I,LWT:NK:!'> ;K0+5(: M(=SLTF&M%[=;/,IWOG);1.:^'41W;E:&J('6U^R_!#.X3L#+P/$F+DZXY0R5 M>=H]@ZA2IQ$ZE!A!<.;P[ MSLX$Z]8())7T4G <5@:%@R5=(D$B=Q[+1!HYD1;*SL)7>#\/-N+F7"?C-D(F*EK/W+OJC9KKE LK%F M->O\^CRR>-[!TT+IL-+_5=*: ^?NW32,V.!57E3VLIQTY6R15\2A.)^(JK)\ MLZBVA_O6_NEE<3>BV;,XV] ]3U(4;@7K %:C)*HE) AJ* M-]%Y$50MOF,@'=G2$+02RAOON,>>LRG&-\>\DQ$54'B71FVX3E/X#;Z\$0!2 MUCR9O$/N;IU9@Q!-)?PU\G6OJ\CVF3+[N-=F4<]DTI0-(CK.,;++@PSMKWX=9'8U"0V=9Y)&'>Z.E MA,)?G[?EZY9^L7(T"K?>-$7I4_'4P-%BJJ*(,6?4A=%$YX E$]=8\YX-<8[( M"9>"7,PV1@R8E2 I$FJJ/R^EQDW28A#.MT3 YP.40OQ8=_&AE/1H.[W#3.X; M_S&=IV%5Z4-=_-60.!4[@N!,,71N98?EP7L/[REQ$ MW'A:Z)C46::H!LW50 K"?B^>VHEM5@-B08H [<+U"0%2W1<,I:/GU( )( _ M>+SG.)!)L@J506P6M@"OY!\OT G,DO.&-+NYT@33?4<6C- '$4J3F+I8#?R& M=R"6GRH'#.?TG M G@-G)F0_HW.*5!$@ .PU!H\(JWC.#UUDV '-H!C^-T? M NA@^!(2]U"#@ =:5$4PWZ;7L^LMR>TK^]+F];75$Q>7(U*?RVG4.3\0^3Z3B^ MU17G@%1GMV4T&]F>5WR?:\5)^1GYR2*/JX-D6_^RI_N+[NN6'6E>]SKN@_M; MCZE^6:87QJUCQ=935GSQ*>'KM?Q?OB[:<8L[MH"F?% M0QPUL-K)&->4Z3JXQ='F#G+']=7 #1(N,Y7K[ DJ'^[/WGN[U4 _0_D97\2< MI"Q6 RPNQ)LP?SXZBQ<@/1;SZE& 7:B+LK'U/YKY:+0*$TB[!HSCN=-J8 '_ M^P3]/^N@J"-89^>M!J1\:HBP[ 69SCLV3@8;-.2:+<2+73/K:M8-*G-_^/Y0 M397B^YS 9?S8#7RS(W)G:E=+#^YD+'/3\/L)?G9:D!(J]UQ'K(UQCV/WC82[36=I%? MY_%CU6#-/8%W'?B!:*(&=(;!2:U! NIB@NG@?[#+5;D%SX8&7N!-3_%\[\"E M.4XF0W^ H2"ZW$: 3+,YWFZS_0W@U'Z8@!%+[+!PPE.)8(B@AR\Y)?BA^3T% M6X;_/!>'2>X*U7TU %U\I0;D'4-J0!3!@WR,6)W!*[>E[2P*9$ MKW:',):?Q'8!J,=,MK4ZJ*0J;EB_X'B6[@IM.5WG5AM<#@^QW#ERXP- MBEJC6VPKV1X?L]MF;O M^HW^#JW>==(5JYV/G(9N^I^Y&;;OZJ/.=^X[';IVW7^_$'6"7HX2J_$R^D,N MIS2MPD((_C\$>#E]KJZNS [ SR/D1OCC6(N0\Q:JK)UG)/8GVM;=YNZ_M;Q M)9VW-4U3ZSV*?OOTT(Q#V'(;;7_-W3S<]?K@R]R:5O>OBJ2+8G= MRV2&5)XW_#E)I]W;9_4NYRK'7(_]WFGW'CSZ_.CF78^F!A+TC=;-P#(2I5:8 M(5?5X89NR53@U)S[&^*.G\"@&HCV[9WRS<,JX%#58M05/\.BYF;L$>LZSI2B MK1+2[$IG_$V#FKMJX/<: 64,R<66O57B*&Q]P;)0 _4XCU?]??)GV4)PZ@1) MAPK=4P/?GBF#TJB=F(T:>,1-!:'I.[%@.^T& 4FIT50#O[AI@S*G3/"[2=9@ M/W<-8J4'R^C>:7T8%L>#7,S#WO":63&A[ M.+1]J6^LUZE$%8[X#YTU1>>#?P^)SDW]ZR7R5WW-VL:KUO*7/G!T[JZ--^4> MCM;O'W^6L:_>M^Y1&LGUK>DBB(Y/3> MK:3'H2!AF3:D[!9RIVP'(NU MD?G#V='%9;=N52UZT;=]L&Z3V6+2U 52&8CA-O2*&/UXD#2.MU*K M,N51O-S;L _@;'E-(-W&=[;R^NE!0HO%VT%RNM7-+[>.3][,N_W;O3RKRX\^ M/>Z?W\J\.K+6X6W7C5]@>N[8FF M2A;8.L;NP.4H@WJR,");-\NGC2K1N$H)8^.<8)5N Z!J=#&.>,; \5 M_OV2(];%+>,V@LA:I[%6J$W6-.ZFW,7Z!0%E\:ZR ^P54$PZ>Q-K=R=Y:]&3 MNU!,T^S[>U77[I^1T2P_'QKIC;^6>\+BSZ;8\+FO5_\, I'38DQ[JQI8&Z3" M]S-F!0>K@0-T4=4/(E6*)G/FG"F.V&SI[5&\WE"V[N:SMN;3IPOV/MYX]?!# MY[T.!QXZ>ZSSONE_\]CS[+C[E2%6!C9-=NDBWS/,3RO#.Y^V[:UU:-M[,/QQ M)FU713]W:(2RE!F@.1,WL5T-V'-P^OWQ@)?CV/*WTQP+E9V,/ B34@6AM.2X MKP)>A&]58T5Q1!5Y9O9)\;,1IT6!XA'_C.EW8UDF65T5&]^>B8XFLN^]Q)R3X6O,SG[0D/\D9YE6+D1T;OUY=YXFS MPKT#M5],-V5V6'/SOU8:N^>TY;EM>3M9([NE4W5S;<@=MN'/^;L>YS:ON_DP M/=??87"-\M7-19FV72[8H:6#AS$1Q*E1+079,,[.@DJBR1<9 8JS$GO!7409EX?VC!1OX# MAB@>9V5* M:=VNBAV076J4P!@7I02A6)>9^TNVYWV2B$)L>SZ5$>GY^O9 I'O(B_8BAK2Z M]+9GP)7Q?LDMTP?9AWZ_>3UA-O@7J/.6= )OPB&VDRK>6\/X"K_.Z%/+OY-? MFBCX#^,5K%A>]1CF>V?RQUV%9?^(]9]-(7[7P@\:?2>SG384[\W.U>T>\V$% M'MIW-<_1PVB#T;J]#NV#F]=8/LK;[-&5R>C_<_(P=]5#\B;/FU\J=YD5^P8] M(5F_D9Y>'''P=)*3?]2+TH(=T8?7MB46K*E\76]PJM4==^]GB+__[]Q!W!_P M +=LU"G'?.]MI,_?E5&? CA]#$7#_*\]NU7/J&';7 _O*-)&*F22[?/JYA*U MER]DKN3[*KTJ4)4_WC'WD-"S@BYL\ UE7F5.9"%O/K+WPMT[CW-D,G!!6";M MS!G[TAO--J^Z2S.];*Z^G]SB<&.+<4B(Q>]N0FY*TQ+(+?%:7'#]K,[P5-NH M?C'6@K1'<_?5'7CS/GVW0OD K;,UW;\E4+CA<\^E5EIU#9=3A MEA@HFKDQ>MT!KN+ROGM?ML3[5)_S4 @Z?<9CBF_WQ:B!Y8S2/K"E@X?-KI!0Y].+TT;P^FP0@BV:M'ST?9_3 K0/VK9$WQJ>S9W:@,'6T3%RW8: MJ_CGM:VGY9CV%C)>H?/HJANWUMOV7\N'@W4S16-G(#N9G[//V29@T>D%@ 6D M#SXFH-:\E%JJ%%_^["ZJ=,F'N&N[U< _0 N-&RYIU?F(55VOSR>7Y"PI33^\ MJ_/+N]KQY,3'?OWUQS)DY_3?E=W;WQBTENBT=N6WC![S=7\1TD6@QU)*O+#G MVZ[7Z\N-!C=O"KUEXRG3/G@HYO??GDF-8MR49EEE!P)#O=L4I:I'*5:E*4X; MQ7KUAL*C+[I3.%=527&.]RC/Y._&GNTX118?RK)SLO8M*5><+QGN>C!+^.*Y MTPA-BW_S7[ESC0\-I!)/BA V$17;*0Y_< "3!::XZ/DZB,M0Y(I)&MM\A$1D M@"'4)>Q6BN%':J@X?;:AI5X-)'/-'2;TD&?*'?"IQ.*^,+KQ-Y04.C^)VD#2 M15U@+>$,')HR%MT\FC7)Z!Y5W(?!IGA/!8B$'X>=Y-R+K"U0KB1EO%E.(#%+ MY%DB0C)HQ'*+A3,EM$:!#OM]U:DLN5VZ0/\]!QJ53]3S$F!DL(&]ZA7L&;%O M.PP$L!R[L-41KYBC0O:*UXS>B:OT^93%V ?J M03NBOWO4BVAIVD+>E%EFTU MVZ6$)4.=+E\YX-Q6]T5[RF<^O%-LW?77'Z<<:H-$?1%5.T=V@GD#_D'"Q<.# MO3-C#R$G/Z[T4 FT/D&:82@U2:X!_[Y+FJ,'E2=*QTEOS%+JP;2@98E"P4+V M B3Q#32L+\6E4C)E3:"]T*Q_)MEV:G2)KXBH#[V;LKM%.^0R)4SF-%*TN0<_ M3 _7D&1)+Z";FD&0J$J17DS4 M1\;O[9+&C,4H[5@NY9VH'Z1LJOJ+J(7H0\+Z#R,#SHC7\WXF5\JX6K9FBOY3 M3_%,&GLI\\;L#!U:+SB[NH-E51SX:23;J"-C;/*O-Z26O]NRTAMKI9"1+N56 MU$OU6*O1VI/1RU/4JUY1C_6#>R!PG%L<>)@9VHAIOE8]MIGB)1'7JI)P73,' MU$9M$4NN"LDVI@?X" M\T2\GL1Z_RS15C;=A"FHXSLCP]!^7[BXSJT*;F.W@$3V:E3W)3SPT&&[[6 G M.32/17X!$P6V1;_V\@5/1Y)[UTB[T\>HT'L#0<@GT6CW1]>^494Q"9 MK7@RO+1*<(7L5M@?05P!KR\[?6G4KVO:R_- I4KUZ:;&\$W<9>B5ZU;GB !/&22@MKSXG,^N'DS4^, MLX-N!<=<./-9:/-NJ>L! MRS> L7"XY;C4?/BW3FFKBJNXAUB=5.YFXYDUYVOTCY8P@^RNTO7(9Z O+"]& M2/;5@:65.%?Q2M-M8QW>6E:D'##;.OVN_/'LX>]"1D'3"85A\U+?!:,_OO*4 M'JP#J@('DB&Z"W&3"'YBA:HRV/-9QSO8ADQK3Y@CLD!"E9ZH%R*4\%+X)- T M'#1=CQDT/4 =$=?<3STC ]HG-?A1&]G052;?)F2:W>/N2RQM2N M,B4;V5]OQLAP$Q$2J*74!/))*4&#Z22[GU6O"J['YG>2S\AI*92-2$H>ZD W M9.YAVLFLTM -MDV766[%X>&P9GV<^(H#W139T:EX_W5F6[:U:NNWVIP)11X2 MJ35.DN+>(:ZWK=$E7V0;*60[PD9?>4>D=Q]*2/IO)??MW_1^:4F:%BP)>GO\ MB%.&8X:6;$&B3-]:R"9ZG?_6ML.N@'FG9JL1=K&JI87T,D7(Z-7S@ =%O#1! M&;5>M:!-SA"1",P86A=E33AH7,I8&K8IFYCP5#PP))B'+682]D*G$JR$G,O\ MA8+.Z?Z8O9G>'37;96+3T:K[7:G8\LBJ@5K;ZZU2I.,AN\.%-\Z!]LM\+U$ M9(M(K,?6'Z(;U:P;L&H7A"VSK^_%!"?AS+W(_F5?7QZ7]/#-1NV.D"X_)YL7 M"<_D?T)2:469QV..DU?*=B\'IMZ9*Z1(=!&3MZNMY1+;D:RF*D4(9=D9$,D$V#]=FLT\A[N6QKTK4\N4!W-&@.),APG$CI=;O$ M\I-;.Y?&:]&K ^G"K#AQ[_)+&EK++VZ?UOI'Y*35 542.536!G43OB(PY['=!*R 5YR)_$>H! M-V64Z:__+AM,&YM6!0N/#LB;JK@)I;^C[O"J7VL_" )OGO0Y/!B1<"_8>FM2K*7%JY"6X/'D9 M+1UWDE/KP52N+F]::1XV81>UA99*,>A UU)*0D/)UP,& L/="\T1V_7' B(K M;3M[):G'SP(4-M0T_@42>U=_/ K/"'D9U'E%-<%0;B/=G+TD@KH(-<\KY2YF M+V-M_5#*,T3>#PHIRR#"E9IH^3+KQFQ2=+=Q8!E4T>#ENKWRQH0[ ME*3JY,@B];5,#JL$-1LDXWI-)K@AH6BP/Q+GPM0DRD^")I6>E%^)]Z?Y=&14 MYB34HQJ$!1EWE9&T_)B^,I,K#NGT18CK(9B6] #.PGVHZ2AE,2Q(,115V51D MK\KK6\(_TS8.AE-3\3P(ZB\PTD$]=+54<(7[DE9/^-O]4,S\F1=$[,W4!=0( M0=H %7$-AIZ(#W]@K_:""G 1$R.]G>8H, ZKFDA"W>S2^>N&V:MAXUL%;M)J M@3:RM\4?5@,E[$8Q+CW#FNE7^%L1@=(/70N-9S5RS9FN>UMY?(LA^I)2WC(F M34@DM44+QCT)ETA:+,UP"7>!F&DEO7WW:809)W6BQHT7T3MXC;V2F=S;%P!_ MS8M>79$T1=.Z&$_BL3OH/TU1>U?544OL>LC!S]!M\.W[,M6.^/T>4,.GG+G0 MY8%%4#E7[OBAQD=N_M:F](\:'QE57ZP&3@P133].![*O44-\6)LKD6FJY(X%NV2&RW*!)I/?XS\GU^R'(6-5'^*;N6FVSR1MS- MD>ZS/V!$U3-'06^UQ$I$2"$! M-:9R4K(:T'Q.67&G9F<1"VQCF18S;Y/2!(0H@9[X+D'['=1%CRH($L0XY5E)+EQAG/F#V-6T(8G[M\ZILL^4O1\.AD%K2)93&@$8;S%J2 MR&?./=XI'0>W<=P[;9[W-A]N(X*@JIPR_S#[HQIXY39N"JVBM479[@]"'D)@ M$]$8NAJTNJ:ZS>&"W;+ H0I#A'"8Z]LF?=U>:LW11][W[8 7W)4M6V_244,M M&#X?UWFKXM>7Y=$XKL+$/15T>(S^,N@Z5$V#;B=(>3U"Q6/$'7;S:SW^.M.U M;:HEF4M@F[%HT/YPXJ*7+]L8R[,5C32C,..J76E"KU=F)TR6U%8H;7[=J_%V ME 3]RB$P0]2 _-I#&>S".%T8M PI+F =:$=70'WU=&,':S$):1$& 5T.MF9B#WC3R\A-N=)WQG(_ M2J5,T*M@S+9J17^INMH91/IX'-9DAT"7]4E:>%"T=K=52^H\VF&#FL =M_1W=0S]N MA[K'3J!O+=P-WV[8K=$H9G<3%]VM!TL&RG#E(3!D6S K%-F0!;@(,\7E7S$W M\00:@#MIQXK++#LYWN>R&OR;TFO"I9P4MM%'EE6D'-0*ZWTWD"<_F16T!MZ; M^( 9&UW]SF/1UKN2KH8)'=99:/X=F%"7>["\[?FTG2$2X]/*&]]X(J0QT:B#JP+R4Z D]YJ7WYM5]SM->ZZ132I7KWAL?9P>_ M![BI[E/#O((5H:I;9*ILXB)&:*-L9/^5;9P.R3J_UX%E^1G8,F:G6-A+K^?I M("8^,$W(O0H2^"1_BSC?#,=EI#'V!H0NY^@W/XY@D]JF)@Q63R+5P@'3"LXX MM;M+P:I6W<'FAXL7E(67FK+>OY.#=Q!A;AYR3=.1G./19>PI^8MHW#KA19*,*+JH!T1++D;=R0I_1\%51[%.1'G.3QVGRK;L7L^8\G.@ M&I>G%_=$SAXC%")L-;"WK'/J4G8.-WSE1=8@;(?IVCY"B,(ZRBJ(-S8*M\@& M$R@6:!2MI^T-A0QM*H16>7Y@^<+K!QMZ\Q,;K6*&7MAVBE M_JK&\3R[E#(]+TNOB-[AJ0"5):8&W$0X>$^:U[OD-^F0:SLJYVECUNP>,X(L'B,+$^J@-OV=W.NB C M:3!7-;@$9@\3+2H_'(,7W,\S?SO%)F/-?"N\1S.ZV]Y0]6U8*QZ&BTL$XRN4 M-JA;9]0=1O['J/M4Z4S=KAQ;QAZH*B \2Q#!+W^U"0IS.=;:77?^^GCV[(>, M=U(^!9FG# ADMF&Z&A)""J:#^#$DM+[]HM[5WY+@)I%X\?.:B>2X^;E**Y:1 MZCXY,/8I:^DK)#:^ ,EOH)"J(),T=+LTT(QJ.CQ A'_I(IJ_ZIQNT?=K?M8? M<#$^X1F[2PW\-.7.=EY&VXE<*B?-G>8F5P'M4USM?N830KJ_H %7?Q<:^7KX M!OR8^TY&'H*G.Q^1/?.1R+>)>U^NE?U2=?G%Q^4GC[[$#;GKFW2H6?$;KA&2 M43W8NM%_9CPA=\BEXLU$DK]C_J4I-4 <#0U 7)^Q3E>^ZIQ@[9E,"&9?!)J M:8P;Q(&V% GV-=N5_SS,UXE/PKU:],GU7J["V6^5#R)6]C.BXNF_OLRQ3I[. M1F84YHB>G-Y3(=F95<\U'O'?%^Y/OL.Z3&@C6<=2G[GS18<>O_U\? M.,Y<.CA[CQUH/W%5,>SY[QVQY?QSV(7H9?9O!I\[Y_T_^M\"=<]_ U!+ P04 M " !\/_A.;$QRKT:& "[E0 '0 &-H87)T+3DY-F,U.#AA86$X,34X M,F1A,S$N:G!G[+H)4%/;^RT8+BHJ0@0$9(R*BHJ RJ0(R56N("!$1 DRY2(J M0T1$0"*$1&2>KQ,H"!$0(R!$95(,1$B JXB168*02666 M[U_]WNO7KZNZJY/:J>2<7?OL]>W]?6NMG"/[+./"-KHX.CO"%!1@, 7Y&R8; MA3G(?_V/O?X9Y']T# 796YC:6@4?!7M%A6VPW]04%-449$P80C[/U?]K!]C_ M]E+X37'5ZC5*:]>M5Y9W:-@(^TU!4?&W58JK5Z]:)3^;(#\/6Z6V6GWK_B-K M-#P"E;9%;CJ0>*MTK='1%VV:IWJ![1;GKMY[..[HZ=QKMV[[&TLK8Y M>,C6X8]CCD['G5T\3Y_QPGB?]0DZ?^%B<$AH6%1TS+58_/6XI.24U+3TC,S; M=^[>RR^X_Z"PK/QQQ1/*T\JJEW7U#8U-KUXWMS.8'9U=?[][W]<_,#@T_'F$ MS>,+OG[[/C$Y-0W^_+6P*%R"EE?^P:4 4_S/T/]#7&IR7+^M6J6X2ND?7 J_ MQ?[306W5ZJW[UZ@?\5 *C-38=B!Q[::CMTI?M*TSLC@%:)Z[VKM>:[LE;P?X M#[3_A.R_#=C-_TO(_C.P_P,7&[9!44&^>(IJ,!1,*MU5E@G[G]%,$$R;PD;R MHYG8%=4[6O1:[RG=XN\YI7YAD9//<;8-#7=_3;%/L)E#PR]"]X?99*@\+'S8 M&!OY>7M/M+#_F:/QY\>!?SD]-?JE>?)NT$&7DSG'.SWNEMI8K>NP_+)]ZKWF MIO/U=Y)YAVVZ=[WO.<'_MJ[3XMXAEP/984>.?%1Y41_OZGUG-A)2/#K&(ZM,RF ;RT"[PJ\%D09_A%J$@"-L=*S!5Y3'%*/P?K M.9M"FX=>//G,>A0F]"%6^7QU,WB6WXNV##@G@[VH^3*N U%XW7GZH75=H)%P M%(B=NV08L<%MK^ZU(EZ$/L$8))2L>M5P!W.!_H:&3GTY8IRNV!8>85:MTMNW M7\4C];UZQIL-SH.R7:<5T&.]7EQ- /MUT,K5IV"X,; MG,K5VTTM=$D]4&R&8 RV!6*%/1OX#7N@AS(8^Q.>DIFSYR#I4E5@A9\\MJ_EU!.09?4?5"C]IR][+IJ1SP^\FATI3_K8OCDGV MQGBU&H\XB[]OL:7ZA*2:%%SCC?_HB\T,,,ADO?71HO+)&Z<+,Z<+D>E2 M;4!*-4];9&W"QP8,+LP8:'>6Z/;9'5'[9&6^$6\F@S%MC^6_V=&:8\\/B[W6 M6!<'9Y RQQ6ANL?3MJQ$JZ;!\(7PL?)5JS%V_C$^C6&X MNV\!K3ZIFS7%SBVN'&7C=-VRAWT"RBG3URJM4N9JF/0'2%WY_CF)=W6!8@41 M*%BM:;P7D!/J!FA>! M@8?!5G9^]Y AKO ]FR9[O&+N'9N^(@WE[S1!W* P[0[?^?8ZX82!SX,4PL[# MHT.EV:>83WE3#C-6URO;'-8APLJMTH6+>SIZ#S$B[:Z0?," 35U M>Y(S,"S>,;Q.JXC_^O*/Z+4-0678L2E=0H!!O(28 #_EJ9VQT+-F]-0@P62= M*T?=>\KKP(YW\P0'40"Q)T +U&;(8,HX\F::0>@S\L2D?L7I[;"R&3:Q\ MA/\^M=<.7NL_$Q=3/)[&DR ZFY-JB[AS:&9S?MX%?C':]EJ*O62Z7G$B(E4& M>Y["NE'/N6%M+I@S\B#=)*^BA])3U-VTDR_6VXY31 YXR#==/A M4--2&>S/@-%IZY3:'S'#@X:!I/.5>Z.6ITEMUN(C2DF6Z-1\A)[EC'F:U!0R M%NTE&$A*+:>0^JY/\5F='L1NK6OY<:JO@2;F5:AO")Y:!W6V?YF4;JT;KC=' MC(8*4ZS<%/;&##6WO%H,\.3] 6IDX[,.EZ:EA %G]KSVNA>W_\.+@RYG!+.O M(FT]<\^F4AYV)D^YG9L6 ".6U=]^E:=_&+Y=1](R2DN>8+PVN'3,Y>#UYNC3 MH8XIUR_/J)8H:Q8ZI@>NA2S62\$A1B+1G M(Y364;(QBY]:E,#GK)Y";&I(B&!HZ3IEU#;4D%=3K93A&847'^ ,TS&^(#SE MLF5WI3G!JOQ= K6'LC:FVMYZXEASX\!%,!X![79ZJUD/G>7G:8YAQ?90!.C+ M51?']!$N"%S#,2?>],WEY5B:KV'QQC#MSR<+?*JZ**[/NJNG6P\TWHY0&IEL M5,=U5[)X66]0&YVK@T2;ZFV'4V+TJ/H^>N%Z LI<(AA_)K>+X8:+KQPA#C3' M,G,.F*HJO[8Z)&BB PGTW)H_FEL^:%^9Z+UB(F47P\:WZWI"1 M/U3.ZW'UZ$/]F9>.?3Y43 V5_C9@^;>O"[AAY4Q:"BTFZLD8GHYY M1 NE&6+-+O29:9Z-M6&'?\RB%+D=&&#\23-Y4JZ[G(H+.%"Y]LQ#T&IJD.(V MP IQK]7^_-4E.[@[[=V+7GSZ.E1Y.6ZGN^;N'6/ZACM##>84=:?D&@_GKSMV[9'GAJ*;T[WXB4KQ] MB+C#7VS41\.N*154Z]0^^Q$M04Z%O/& MT.CA&,3Z4>@F5FUJQ7ZNMN)Z!2/X@,M9P3Q;F2N#,> :H^T7''AFAGJZ::PW_3[,8& M?78 .2$J8=4GIU^H9%*0N1K>5YC=2[0.I:O7@&G\ULM@=@;-&6!# 8G' %0Z791>J$(> Q+/6PE M?#Y)T-^Z#3K,$!:LM) S8TR-,"] :AHAXE%&S4)"7->)5&'["LO[9\@W(H(V MO-J1KG8Q\GWP7Y^8@DC+YU=+MN43IW>=N[(O^[E']KX7%:ST\E.6H#OA>>F> MWDHO]SPJQA)<=^'@],#!6)/\<-4M-:EM@55\P09[=\3I 0!:?G]PY!!_PFO MQ#/F>95^/U77K'A7%>;T 93DL57_;.1=UKPCO#[-CLP4#LS7B70U%8& ]QDL,UXX8G.R7Q51;&C1).A9NX]4NW3+$OON9E^9\QA* 3 M^,,?;OZQ>.5!<$J.V[FH+WU[HG^R3Q4?RZBTLYO^_JKJ;(F%LA/\]JG4G:TK3VU!H=KO14T5VNN.2NIY;)" 0UJM>O]WL0?G#/9]:+1=*HAC#B$\&T M#'KC Y56A.I&I-L%/R4<[G\6XV_"7 G.U.A<.584YC.;VYY#^MH2=\PQT;B-=30:[R%DG[3V)OQI^H+L# MNVZN=<\QWK7!FOGOC8VO@2\E1FY;<"?9#KCH3DNMJ:<=%_]R;KFLKJBSGN@, MS,^J\;&KQ\2'0,H-XA:Q!:#-G%\+"?C7WM2.AY"5&GK0;YMEL%2D.631UKH* M#"B0I/#_R:NL6D+HXRGD;T#'1"J!Q$<8X-P,QA]&%_LRAL]TQQE']BGK_K<)[I S]B/[P[&/>A8 MRYOI:PM\>C1[CU>'P#_.'$[G(D85N4M92$U\%#\X/68F8E5W/)#'A7>PM/&7 M%\(*6[H2%\ALV[4\*.I"0F7HBNWH=$\5[AWI$2/JR5LT.7#'V.*3HE#+$W$& MVL(7DA*[(Z 9-HF-Z4#!6:"N@4-7W!\ENH6F 9V!SP@'\D/$L>4Y#B?[3:-C M!VF'5%HZ*ZX_,2L;[IN\@N;K'8XO7J]CI;D,[T :+B&=5X0EP,C1#8!2SKX\C W](#\N*:UV;;6Y"G1&KK).?&IHM_* MS>FHY#%RL_@D%(I*F;-"SQWJR7_!>P-/O^)'R=C1U)RY)%+?;-0WIW7YN M; +T=.FDEY._[\;@E[E7[H;R#SUW.>1NV+J^9.?!9Z62H**#*]]53E%R: #I M=+%?^)X2=OUK8(22\=[;SIZ(Z,8^/TO8#S4/7A&_&K8;;]D0?L*$<;%[6OS: MHDU@X'+?/$IOL3GZ^9G0^/4>*TD\4AIA46PHRP%*X)*4(5*[Q]03T(J. MP)?I+*2+,52WJF-*233CU;0FVT\OAZP,')>.?EK(&O- !D$Z(DUH6'BQ]WL+ M%%,KWD8'O]IBVJ@IS:B,4LB7[V\K%/#0R82H\B_0=Y+6V(P,IB7VC(KBHS;B MD8>G]LX1]DCU@-@T,5IA:(&S%OONZ;O B"ER@PPVNPQRA$GH=5#$6]1FF@:7 MFG+E2+5Y!SPUP!Q 9%M)S/D<=LF8Y9AVA]P.W)#N(-B ?@%KF^JU;^%:5?L6 M>Y",3D282#LC>"!Z*S(GZIU^T\U),,!PL]^$2@[OK#O-T-B.4G24]*I[ZLQ= M;XP&ZL^<:*_P\9XZR? Z\_S^":\]IX'( M7\5HZ7J3\NEQY4^M6\5;(5,!/;-D4YVD1+Q5=(K@>]L@JGU\TU"KMG@K6&^X MY< MSS5K0,'E;/&*1@/FWDPB#6]_JQ]#^R"W-=$^A=,\.^2FUZG#C:A"Q*X3!T,D MH'E&8#XKDE]A9%B8WD?;"GA-H]=-(W4 /^3>_FBL&F%#KYET^Q_$35">&T#/ M$3MSYP[ -[J"<$9CG'WGK6C+X-9/?]KDV\6+]A)[E[";B?@&_!OWA*U +,WP0*X>BA'CW8HHI9SEHV_,H:_ M^LNU=V'S[-=7.5;QX:&!))N1$@V&W1^2$H1./VLPO S[G:6UF:5R986/:!/MS M+A+L=>6*X[)>CNW]M=]_2H>O1QL_\*2F4GS3!.Y/["^> ;VK#O4X\UY>=U7> MD<&8A2R$/_O%'G+-]-OG,-+Z1?(&@C[4 B9UR6 *Q(V$P%:0DFQN#$8PY],P M2(OG PN28%[%8T;'N-JGQ3%7WGQ6_;SR]-+5,)LZ?^\I 9-MGG)NV/)U$HG MGSRG!P1S&[Y5I#&INJ/0U>D)IU>@_J0E21WG7 8%]*T86,]WC)N0&1%TF=)6B$E)NDAMJ8/ M _2E[;37@SL'$'>:!7PP0]7E]Q [-YW>RY?756.\&OT=#K!V?\\L M<7/2WEOCH)9T>M]TS76&0E9W" ^PBMSSINU336;'1>_CZ)%SX*'L4 <]W]$( M5!AK9!X-44*!4TO\U,10T%K4L1&_9[1]:>,T>$)J0@/R'PB*;8XD."^TE3D\ MG0G0')QMP,(92(JV>+N)L-M-C;JH8N%97R>PTQ1=%!M I6"W$V0,- 7T$Q(B MHWAY63X_Z/P$K16>Y=@:$0^=05#@Q?<<&#)I,=M,\ BJ#@NP:FU(8TH-!B*B ME=W0[Z9R_XU?49L,N3JV=>-\[UT!]_HXR_B["OF?(9O:;2!O/ MX&)RD)O";"D=/7J=1"5(6ZY.)MI8*5+#!NCJ^.9A+F##Q&J+[<& 6^;9A.-V M9VL<^!&:(VR!^02=Z+D&1 MT4PL+$$-6DK,/J+3#+6'&J?)6AC&J3!V$/[#9$'AR?[@-[K6F00'OAZN9^=X MS?S<&QP.M%H(:=V$SY_GWJ-T%:.$ 8-(.P>^BD*T")$;EU^*XWVNQT*_?QWE M.XNU<8(B$3S--BTW?]JR$:QAL+M*_4*N->FN1&$-Z!=D,+83OZLKW(:O2>W$ M)A52V_.4.'A?7R@<0/,+VN;U\51&@!IX.4/E\7 )R\00;"VI#D0J!%Z)X+>O[_6\*_%XW&,\Z\YW N<5"\9^-B+I:BLAME#B, MH:_GO+TD/121.31N5 ?^PE]#9-"! K,"!$.9GGEM'^'XZUY?WD*)L6U:\2,G M_MU>XQBL@[(#(_W"]>#AF6\_/U#NN3\)VFOEOBM,HQK]V]@NQ].G$1J!WQ8K M>1?OF6D_G!YH/QO\[D6A&S]#HB4(]/?DA,)]AG6+7>K"0L+?BH&>) M1?ZS;[H?'^//T8C5&_STJ\ _MKIO_F#E091.&:P>G=+% MP&8T6Q>([,76 )W978SQ ;Z-%_,1Z3XVZ<%0A6+3S59$@$,XO['I+%$K["\\ M,>$JQYD&$H;SEVR1^\IK15Z^QB"+X.E MB1WDW)1AJ -1>3,DU1G;]I#G$+:+34Z]-!L(P)F3M1<.-"69N;^(B%U3Q+>H MF%GZB<=A MV)1'7CLE@VWB >@,HAZ>[@GU\P^C5,5'^JQ0&4NV-=_?5(84#A5'FMTY;]EB MY'A7^=XTZ2+IK;MJ94 M^1".00U!,0*.GI, D1X7%E+G'6);5O.0;45))WCHK^0^;VYH#OV5UP9%.9A^ ME*3:*&/W5][[VG 6S7 W^ T""[\I-E%A5GMR&B_L&",42MTT#CD5>-2JWGJ M(;+&0=D=]]E+48=O3V 9K70J:SJ94@HGHG]1GS'2GLM@WMW3%QLJ[F*2]WVF MM=-V!_ZLY)4][:U!:^QY4<@<8I[.BJ'_'E*6*7XJ\?N?=3/B_[11'] O87-\ MG&8G1-;BT] ,7X?F $\C;IID1^3:.1*,-\0BC0H8;.V,:).::\-.#85+[JG3 MPB5G[?Q(MEM"J,JGXD>%_%U?@Q$YQE+5>#DWQ>R^@%215&5X!=X"JML^ M0(]540K8,W]=06E'RM6Z>1J>=.#COL]A' S5=_6108K+F^0]\;O?3_=_K5SG MNWS^04?&ARL'#W66F&BZ)$\8XCL?/_MF>#G@PI,O[[L6L,=(AV0P4&->K$&1 M)G/8U7(FQ"31EZ=Z93 UI%R>V9(FW215=& 0?U@&*RF.YX!*8G<9K,P()8.U MVWR3S%M&D2Y_E<$6]C%(7&))0(@T>Q=U B7=EB"?>[0,]JE(=(;$JP)B93![ M6Q3?F ,9HR7KZ T8J2Y5B?2KOURZ19X&G(4_@F4PR%%,;_F>)(HUEL%*4^7T MK[CP\Y?30N!_YQP1_S9%Q.AKE&3#/@Z$H!04HLK7F_PR%JZ3S^\Y\0,=\,C3 M(#@!E+?^<+[P3J78[!/!BF^N]@XT;]) XF=Q!LQQI]4OP(F_%\/"ZQYL^V-9XJY M^P]=#$K+V3W4QN?-SO3GQ)VD.GJFC-USL=IZREZP?:4D%:'FH.EB!2P&^MS] M47Y*%;QLVNF,VKV37*B5Z<8X^/?'2$AP<$7P,*;K8,?JNU>.&UBP3@ 64W?> MLCS?4O=^]ME5=F/]?T-3+0Y]TZ_05-MW1>]*&_+&A(Z06DBZA*/F"DEUQIV^ MY)$2JSN"Z #5U\A5)J%:I?&K1['>.ZG7RT/[]]X*0VY_ ?3C8ENU^TN4;Y'X MAQ/V?/+QK^\.-_]6F_>4.#C%0\$I>00/D;\KX#C10=?? Z74"SPH%4I1'>!K$?8K]2%W2A&TL$/'-U%G%L4/RW5$J% WMS%0ZTC> S, M$^$^H4MQ]Y5^# Y^J\AIZ)B;&VPI+GYLX3AP M"V9<0@-0]^KAR!%F3H$ M@!%MHZSU8N*P[VG)HU8D3C>_K%5ER%R\2@:K*\BD_XG*R@-&C[P&.Q^<&U\U M>$H@6.Q*B]X)8%,:PCU/?B)N_^S;$1L86!X !9T<$OMV 03/WH6\5!EL \T9 M)\(13)J&I+L)>^](M6)G)5PZVW16K ADO:6_1,S>Y&RE>I_745OB4W.6[X5RE/ MHB&D@,'I=GKF'9J2RH:\1!2\%276@JJ#^?,JD*(P^274P,M1[J"_3)O+ T2" M9*(A*:,P@36G5NU00?A]H%5W2ODUA$BD=M)Z1&!-9):K.[(5!PI]P=A7^M>\#?"H3=0$F7RA>]4/D+- M'*EGGFQ&(UW A8?EE^PO\DV<,[WH'"Z +2=)E7?(8+M:)8TRV&P25"Z#N=2_ ME\'VO4,-.4M%I$E'^J"Y=+V-W.' \%3A=DD9[1#H-<&\AMVP2(>U%@EFZ&NO M8X&[HWC'&?]>(W"5U/#7'#70]H-/X*N$@\ZA5U,G'3>H!X=*'Z#4+<%!"3TR5.T>>7IZ7'^\Y\GR#IV #V)J7I1?@<)];N7WZS]<[YTI M42XIUF?M*T^J/D5NJD2$NFL:?$,7@M]]HH[5YE"_YV9*\TD\^112$ L>I BZ M:/$1Z5=+N51'2;K60P8[IBT4R6!T'R49[#!;FB'/R-("&:S7I(L.99VCT:?F M"Y$:DO,\\Y6]K] 4\4>@)7QB0H*+^%[XWS$LBK]+KGT77,!YZ;;/5/.5^.]) M_\\,*2>YI%,RV-<&Z0A"Z"+=0)K&"58D&G(JFB3\#M(9G"QLG79Z/35'S1N/ M8T3Z0P_%J\ERM]Y!_RR#,0.V@M:W*G&Q0K):JRHA!$A+M3L&"/BQ'28F!G;0 MSF'N/-/-@OFN EV##_9H B;[[4C5Z!@N]CFJ$P'M0(@U"I@<=3L,H->!;;C< M4"D^):M"[1I!_&Y'\<9[,\I 2G7C7!V8Q10VT_.NU?=Y> MJW)W/=#A+"1YR>?:2V04BJ8B:J=:K8>P#H/A,7.:#=@DG]1';.2;( .FE^U0 M_N7%=>[DZI%CL3$&3RBA7\='G:*N_/4QRS*1GB,.X$EW"P+L>UYE;><9[LKW MSRF]YUD&GK4VAF.+UN7_"=Q[7>E#J/2J0&(^+)?=K6_)H_TM/L;57^/KH)PN M0.J>"=Q3ZZ+3J!79X/+R8;A9#.E:9&OAX=JT#N)>B"=R:I/!5J^&(@-YV/1Q MXT'B'K&KY 5)OC0;Y6IX@QDJM/@35-(,J@@]D **EZ[[]^0L? MP3#<#ETO=15@,TL.0#)8?"FK= 3Z:[*I$-UY 0SS)1B@W>3P$Z4#6+@Q1 :P M_+39&5$ E,9LM:2#U-F(9U.&B@!\SD#0HGQV4+H>^B7 I-2H-HDV2[M+=(#& M>P!:*&F&!&5AAE8 J[/8@:^40PNDB$T!2MH$#9@;S^*;JU!2@R6K)"4D[A-R M'67.'L2=@/R!*H2&FT"".3)LI7PX3P.O= :8*Q#:I&W)\QBHJ1@VG%[DGSFK MCHM'["Y_]:H;=EME<65MX;6*"*%6GA-P%S5RZYUJ89#O*SEYE15K'2I[/D*! MO^BR"WG18]"4_[*LRO;E#27>SIP ME[>^2E/]3G*%^^/3-<&[G*.#Q[\N_T S#SH'O;3K5BKD"GR\KY^[8C7%WU4% MI-C>>3SM>36S55\O+Y9!CLZ870KTXZC,6'HF/@P&!$V4)?[H.MS7?82=>]B;FKF M!&U>X_+H5X@4J:,LK'&Z9A\IW,LO^ ZB8%/),#XGZS: YO<54OZUT-VK$TD MEHH\17^+,9<>?:1Z,W-"_"^'RO^K0WQZ$>Y!X\SMFM70LR._<(W:213*8!9S M&QVR"476ES_Z7MMW0*'TV*:3"O]%@_V^Y>8!^"K#Y#A=MZJXIX?>V:DZ;S8& M]1$>72X^NQ3V63S5XE_7E9[:PS>W&9:,[0YYM.KM@D'4IYC%%5'?#=A;F,(G59A8+O"0FO*- M^8#T+E4Z@!*ZQJ E!T-CQ*9T3L12T7*A5"*#74+ O,5>DH>M.PG[!Q:5QTS< MH:3 4NB R+/_%-O- 5T/&F?1#C_V"QC9\37*QWZP'A-NJ1RUX;GETS+OL0.4 MG\ERG:V 5++8+X.E+(-%JXL0X![H&OY+)$ML5&X7^W9%]9YD*[NCLK'VAVJ]!IY1<9:L[VA]@@7_ MAS7K938)_N<5Z)FUQFZ\RZ_JW/; "[KS.@'4/:G;:@XY7SV=]3TS1+\4 B7%#JD3J)4 ]\BA0TTAB%F:6 QK:VA.*^;D5" M+5SR2#QC/V$+]*Y4;#D0P]*9_H3/:U/:0..;&M/\PV3A2:^#0,+(_@#U^H $3\MB6 EYTA%*'7SG\-VQOPY7086 MD%:KM# Q5W9("RH=(D.O;&F^J9?NVAFPN\S9Z$+,&OI]NW-\6E'VP6IXX=;(O?CXSZ?:+UW*-Y%XZ%&%&/0W;329.=@(9V; MEHD*)^D%3,I@P'%ZIBYFSK=2C(+\0;0PY1-13QP@_YK0JAQ*TD5N#VTTA$N> M+I#4\3-\2@=< 3?$@=LY YVL#O*Z^L,1&V;(2@0C'B=-!M.PTC%MW=+&+\8R MV..)O&[$8X*1R 5/=9*O_"N" X06<-A=;^5$AJHB=IZ"_KG#LB[Z#5T)[\# MJH@]GA"BDGZ_S?'.QV["Q2UE$W>.XX_V+6% ZS?5V-!KUFSC J54L0ZOQ[K_ M-&T(Y23=0NPFUV$ZXN<.>T+E(B0!#MVJ##4T3&KW\2H5S">3X80+"4\@GZ'K M/\)I5I0QZ ZCL+BC(&WNA]EEXZ;>\/-9)VZ>_7[;Y/1UOP8CT0YIMRE_&;F% M/%+'70=^96>SF:U6J#5$/836NVJ_4%;YE[#;^+^@/V?03UF/NW<^L)K!ZCV( M7C9\]PV'"ERB M\0IH+ 8$QX""W 5X9BL"BGT$%;4USR_D4[;H3]3"];.!+W]>W8??/)'YJ\6< MI]2> \?^\U!#/3:5!*\G:4#H=J]Q!: IO9Z^&A^$'B;8<'$'RV[VMQ6N>1%< MX5 9,J[1F+HVL GX7A2#*W?8M/^8P>W.S/+>$%A9YJ[_2EO6ZT TYK5CUXJ/ M2QX1M:>;8W,^TD6'Q.L+!$M9U/!Z>_MZE#H^R*WOQR)]$Q3UMC![94"E!N*T MZ?XA51ZPPY9C1T.$MF>:.LQ3?Q2V] Z;8UQ@*]\SETG\M+E(@,P=R@"H'3*8 M.@(+="4B]TZMT%:<'1:CTP&"-]:$! NXS;4? ><,(=)-V4FN$MF(@Z M3AM:F7 -)*6*G7DYZUE>PW:[J7@'1_!:RV/(_&_PS&!J'9^5BN-CE2$2_V)6 M?,)C2BKA")^\@5E0F'JG=JJYX:W26#VF9T5I#@V\8=)UD+L)&GV8CGXH2>Y3 M$_?2X@4(-6>>P3E.FULP*IW@QJMQ=0 ^OK';WR,PWPB%R6#MPTG,H7'-_H8$ M&^?"']U.X5X1:CD.Q_HA['KB*%G5*K[8G=5EN!:B ^>$B)053"=998JC0=-8 M/Q-@"P4^PV,'!L2N. %"'Q_4%J">UO;\RU2^S_3,N$W]':FZ2M01 MH/%N(3F]H^;-"2UXX12#VP.#WT/)!>8F&@9P M$FZ4/"'NPVLN_"T.!KIX3*DM4%\X5!+CO\-J?@.N<&=-16/%DZPLAX3S3?F] M>D5'8BX'IUN>"WFGBLIZC>)^G8=V/[K]NQ5Z9$:/(PVI&9EF+B)1VR7.Q@-W M>DA8.G#6\;2\,@401VM_/,V26X\-'V>?9I9-G-CQX'/*&<7;'WY7O/T[]=#KMS_8&5GO:=AK:L*:U=? MY:[=SH,/KQ>Z^8\)W60;[OI('9:"DZT-EL"/RX,G-2<6P#&8S""G\RU7^;0YR)U/$B%C9^BI" M!E,Y&"'%2/R7O:7L'M)D4);\$K]D,)35$IDN@_W?@Q(!KJ-9RV!E>JER%NN7 M?WPC#7+NY?W_"/\_AU!*XGZ5P:#=M:K_)/-6[SSH98'_[]M)'R0SV#'$['70 MH0.E*U=M,M@(50#/Q;J1= @>D"9 Y2ME?NV==2]X3$^G8;DM>GY#>B?Z?;Z# MS_;ZGFPES^9?G/Y6P]N]KN34&]:R69$$I2(7,:8V/^ABYB5Z,VFJA50U(=9( M3)(#1]+/>67T)DG?8V'L0QLSC/XDZN OE=_,7I6.1YGV'J;IM?^ M9?]?P)!1&D0R>5=]KHYP1O^8WQK5?-V82H=5$[HQ.]SW7\TDMY8MG!I8^:C1 M)=B/?W@Z\F#5Y_3VY N:7H^?E!M[F%0WW@F5=$4!..%'23XI!&TH]H0" 5\! MA4'.,#P,6<3EDS;2#O$BU#Y/8YIM-^\-"#_56WYG=F4I;=;<:FV]J2>SOVMJZ'&,S"O"2Q M'K@7SW)I!LC98H_',X9;/RV:*K>Q[V4W.704%I>4\LPWK9LC'#9\,G6!UQ-U M9L*Y;SZB5.PFR97!@E#L6"Z*&<&NM \[3(IB*4E#H$. M@:*W'+4&'&NME"4DPH&(V0<">M80254<62K><9/#P*I%HS>%D! $$B\OK1_O MR.$UR76VU""^K;#VM9PE$TDO67/A//B(@S"BMY9^?CZ/O(J(DOYS*S2VBZ4C M-J=!'F"14*MY($*J1^PG6DM*K3CJH24JP%*NV D\S*VM*0LAK@:7DFG*?#>E MKG4 *P 8JMB#+^)=J^$?AF\(@"(Z$%UI8XAFDAHJC#0RSPMNF],6W@"I'62E M*1EL-X?!KIEBW8=[MPSD6GOTI M'\E1X=O\3/].3$[#<3%S2D"$\#ZP37P"TA9(X'RGQ"+_8=H!PK%'":_.=O'A MRAP#"Z:/)3CMY9/PK;6\;'J/T#;GF?#%.URL_E_'5]UJIDZ8SXX"4<(621Z= M6]P\/]L/S/-8XIT(!%%7KGXUQ#' G\ MW;%87LTIG'E*H;")6V3JQ#?.H%EPYQ7P%*>!N8N]>Q=8SZ?9.^^L:(CV$[9E M<6UF10")M_'V]VD9[*U<-OZXP[?'G&P)1V- XYSMS[-.@A-9BY(S$Z_O>(/& MV;3P>#Y<$W_'IY#/3PCR'[)2<0G]?GOJ\9_P:_^!8%38?%YMINUK+EQIU555 MBZ293'$&N"36P'8B]PX2G$'#;D%P^CF(#&Z5P7 U&GSK6]50'E,WKWTK-X*= MQRO((, E6=SYM45K:+T-\'5A ;J2XL4= V9FE#R/.BBTQG>O5I/N@L8H\4WO M[X@"]M)LN>@/8B]GG9TY@! 6#;9N@I1XK&3+FO4K>N0;AF90&A6B^D-I@,BA M%][&TFHM%Z!605KF*EWR@G'MP060[/RBWC_2BJ4#'7[K)XR XZ.D"PIGS"I.(^H*\;\"3&AP(/_K)B@X=X=,'B H$*T@-G MYF=L2?*/@!'\>NUV\TW2ZWUQKW<"WQ;&%8=/%#YIXIJL"Y9<*+N!0G6URV#L MH5%A!^C4.>-F(8PAI=I2VC]+-X9Z-1E:0T]:[=TTCH"8'+MX'D=]6I> 5?%E M9%5R<*W;7_;&%*\?QMYF=SDW-@]&S\7]G./UF=R!U( LX1#@-M&!SJ!K+9!& M8KOH]>8Y=@C>C#+6,!2[4;I_!(J;GC\";FI.?0 ,.P$_RH$2!^ .EYIV*2;\ MVM+Q?L)A\US"F5KH"1^MCO]U"G1_716 N\:IN'M2Z2NG#3N"%C9!OES$R/?E M!O3(=_-L5!TJC;B=L!?XUE)2!Z*\H'#0F(?J8 +$&GXB/SZ+NB:D9!<0G+6 MU864VN)^I.S,N\ ?V[/D^FG1?CU8OVQWLKDI#?E34M2JS! AQ=H IKUB&,%< M6ME@.T[AH]0;,J<\H*S.$DL0^5I -\ -%1[U"\C1&J= M1_'SF:(^Q;94^_?\.'U2J8O<-)^1=Y,>Q,DS-/>'_PY:X+%M+Z!$PF%^M4(5 M'N>;8(3MC>AW&:Z? XOFMBT_TEI)>7K;NI#MK.:_.171_8P,>$K\WAF1&%K2 M=D'4Z[>057QBOK&BU+@K\:%J'&9![E%66VPE_<_+V<9C"T] ' MVQ_"E*[B-<4F]CV-0AG,N4G4(X.9\A=1<\.+F!M^IG]-?$$5G[.XU+R971]U MS_'N!$;#K9T\\/S.5Y>5WD+KI"DOMZRN_+-N."_<) MCBZ@9N7)TX?"O+QG_[!_W%*Q^[WXK^SH4)\][^S1 VCHNK!&!G/T%RG+8+Q" MFIQ0%Q' KSE?:?8;H;9<"UI=E\'^>1!6Y-8D%H_*8!R(#C4C^\/EO"[GX26I MN=2,+N^2'M5&7MA6+H.E')3!S%([1RJ# MR2/6T2LLBEA>;I+!Z" )C"8Q#W%9*VH>HM(,K3!;I(12TG.(GM1%XR6+F9)$6N'WH"2#]7 MZ&;$?T&35S]*8O70)3*87+]DE4NWLM:0/F7F23<)Q/1ID_[Y7P-RM'5\8XGF MZ[RQY/_T9Y3Y]'O.4\Z_1PW%FV W271B9\UEL-0PN10J&%R.^A?%6+$_ E3%6TB33Y, "N*;#.810":54,3'R&JHR9H/Q%GC HG#,LG+2^+X M;_&2AP*.'*1/=M,#26(+#%G<2NTF_RN..6O.KU]RC4;BRV#\R?]XP5#\O5"& M#';LS24A=Q&ZO6]+_F,-E])^RE] M5K.2\[_'C?2?XS8&AW9@YF(%V%$X Z%50\-QYU=!2FZ0TW5 OJY2]5ZI%DM@ MJN28YC*TD$/$U(4?D.]/W>+BXMJ'S:85K06ACQF4$?:H=O+OI_\PDMK^Z]ZB M/T%!-NW'OP*#+#IO'8GFRNPOQ+91]\'IMT\Z+N' MNV'BP-OS _N@+Z8G7O# /;5['D\V+S)=2\ZF'W?)&@ MVN@;(98]"-_VON[RMD[!2_$9NT'^OGO$VLJAZ .7$N+\I!^S=XB:!RH'!,&U85:42X,(AP@BYP.9L)'@G*6#!E MI2UA.X[BS<%=>6?0\*VS&)GW9%J;<[Y_$:WN2H$P;F^:P9W53T(Q<3Z8+O)( MG1_4]8S(TK7IHJ>M4+MR?FOW1_M"ARB$H)W34A^./)G&+2.KO^'H1 M+[S#="^7DC;E_Q:O@CK=1YT_UU0W,!O\2DR06VVR]#VJ?HF)9C-XVO(Z,(+A M49C'D5L"\%A7X#1=O1ZK*]8"TV9_\8,!>C(IY#!5&>\KI$%*8%?[THLI$IQ@ M5(M?F=H"90$O$R*Z#+< 9&:$/A1Q-.MWJ*A<;%9TL@TJ%ME*>TGUY#E[0<1O M/:)M>)'0&7( !+Z2!G-4,%R>.RIEDF(S@C&H),R0/$8J$KR@0WS$J*> DR5G MR$HPB;&"2*^7)U2KW%(E(WB(Q%;U::GU ,&);V#1Q=E,NUC@$W"/AU F:9)' M)^8BVM$YJ#I.5QN? 3@(2#>)9GF_X;! +OZ3V!IJBA!X\/RO2,J[^ZWD)CWL9L)/Y1' YIRI 8S 28@)Y%@*LC19B(MH*A( MWB@ZO42S'CR'DVX!3#F9EA'0<=K^4'[QU@;E48Z*_\S*JLJ:J6O-V=:QNKEW M=K26;[K*=HZP(-I+N[!KZ:$1:5@MJ;Y<$!;,EO)9*@Q< MS>?]2EY.#!:.K1K9"!]]_U\^)F32V6I,_$1>+=TP7:+7V[J+X @,WUPTUWR M=6H6I)X2WR>5FK?Y\,%HX:B? #YM,)'F6$,""@H0)_;J)MJ+! :-4CK:GT0X.J M'Z=%;UU+0WRND:.H^"J4GN\4^S60TY42W7)YE'DG)&!+8^]W6C,@;5!)94B' MZ'5Q6+%MOU.G^:IWL:!7__%6X*CO=$2,(264KW(-NQY/C!\MPET/IQU"I-MA M(V*X/6NALO"-,TB+>AJ0>M^,YAH<4W%48>&,YE?D.F@)B.?;9!/.<.&KQ$?D MLQ3[<[L&/+&]]3.5AB&H%S$1D-/B\EZS'3=-#*YQ&$0C)4; SF9 ,E0=SJ.J MPR&GAJGZ.9R64C:8-H<%7-M]6+GB;78XN7VU!Q"I!"Q?3F9*WMU7"F*'2]8# M":S<&/KZT)6>CC+HZD2G=8!N8DRU#+:^K1K-MS$[W^L"?F>>OKRVJVW MDIRV/4Z??&08(3H26AC0 -3Y]EGU(!E>O0UNOFU:NK4%56Q?[%1A+CE6\ ^6 MZQ>>G@UP,JT8*_Z@"GP9]>O8KG%T7O_IWQ]4STH>T"_"O/\Q>9OW7=P ;\]+ M.[MJ_RK]R4-_V^G_FL'N)+4%CD^/>6X>6<=\_"I.?)H,V@5$3ZX.LA!64P2I4T$4AKUX]-?XT, M?A"([])@7'G[G>21KYN*]=71_;E2BU";^V9[O3&@;!FWAU#[D/.J@A7\OM4I M/4I_#5SCZ&8:6?G^Q].'!!@U7;/3O+F=+0_]3UC%XCJZG7?$-BRBAL)0(VG" M,TVAL0.T<75G=WUY0@)"5"Y>HW18^*&K!9HD;EC/-K?14CW2J>VP0K M(IHX313Q)B'ZLT"8+BDA!4M0/!GL1D."JT#O\XRV[I*:)T/534V1R/-^_$;GYF9:_DUCH@/L3G;,(;'^U_1G/CAEM/8&R(R!<# MT?!D4-FX!X)GU;EK$ISO?Z>:YOZ&#?!DNXZEDF\+YS._;K#]AC6N(GSG#1N%U^ MZ/)SP'>/V_.<)=C=9U0/L#4>0C6Q- MHI/;=1X.!^=?H3\EG[X]X.-%T82I>\"*R,=5AVRN_3&V.9NNU([:\#A$[=/OK$5QIVFW2U=O-+MW\)MS\YGRN)UO'-NO6+7Y M6A;D/CT1=&;$7URV*&*\S5)?%+XDYK/#2 % X]4M^'5U'&[N^@)DU/_13TF; M_H>&9ZMQ 1C'VC=Q*P@)CAODM)^0$YT_'$>(KH:(<129?2>3I,##GBSB,T@? MO5=4520EFC&=X%*0=Z+\17E=AV6PE>,*R "?""QF'BKJ_UR3GEA/'+/,;0UZ M@K1@BJ?!'-GU)(!F6O*%M6X0:-P,71(JL^X(PT]\-J-T\Z.E-#U6#\%W4RW, M+FVB))"MQR1:EWP:ED]?=DA2F\=B+<7MYUQ+#*#BBX9@KWE?G!>08N?$9L.CP_OA$KF\I3/ MI"1#9"<82(EA;@@DW AFVA?" F?(H. F('W@NQX.>\PT?H^:,4,[$&.6T9FQ M6V-F=J!8*#!@T.0^/7%1\P<8WY0WDH4.&-180 6_M(>1EDQ!?'19YBO Q-$6 MJGUUK0JB,>ZX@JJR8CE^Y< X4#I]3&M$:Z) C5LX\YYR48U+#,\B=2+4/,8= MX9QN*D02TK2#K&RF$CD*HC8#D'/2)AQ#RDZ/._0FU5O#G:]NV^P8K?(ZTP:. M8_ALZ'C@Q?"=@4/-O=+8*U!KM7# GEP*C0&>L)B+*PF.QJ9 M/9.J<7ICPSO +_<@0,F B\&5"EE[+XF\Y9 T,!C'V$Q>WR2G+NUCN,K8-\.B MQ!,VY=#19R5C,D'*+HI9P+UF^5;0"GXNNM!T\GLC8PUT-5U8\# MR:N@RUG:4%4:9K0HG5 M7L,,CG=O$/0X/_M)Z>V!_<5Y22);[4>M 1N^42*>D9-RKI,78(B2SW2"V$U< MV!Q3W6"+#$UC[E5PB(B% &3?K'#F/^U,*Y6; A[M%9/F5,)<7EM6YJ4K//,D M8H7$9]!+6/LVRU_A?@[9X(IMSB:LNX+OMS7FK=INK8M5XPA^4MXQ$?%[(3E' M4$>$-SM]_,2=UT8["7/10\/<:#^P QU[-]5 M+V\X>ZYY47U_5_8M]X./78X)X;^ %)JA]DL*H7[KO^5Z6->4EOH"-'\+^F+. M\?R+&K:NWRW9AW!=V>_BW2=XRT;,WY9O^A2W?U;@FR?*O9?AW?[PUH&QL^71JNZ=?SSF/)0]DX+8"?*E[WL3' MHU7>J2&W?_]CY.2-@,..Z6?$L^:HSA=5'! 0W,<642I/S4XZ@:^0[14P)Y=I M4@G^]ARN;2!O0OM?@&79T,;HR&U9NI N7TD[F^S;<:;J457Q5>53RR-MR^2D M;MH@1VD&>DR^#)%%VS?1*FBB8!QLT.>:PSP$>^<*P9$FUD*, V^6\3=#E,;T M4;I,DLC2AJ*KKY/74?.18ST5>7"F[+?*G@,WSE;6/JWKJ2#^Q& W2%J6,L_# MKTRO0E%R\3#M>Q'J-#.EQND3;%7U0(-3F).+ARI!C;MDZ>'9%69*^U4 [Y59 M)$]23W61PIP.SWWR7^W4]"4[VJGIXX>OVQ>Y)C_X>&^NMLI"P;\F6S:NS4E? M[?>@RC.E>>3%6[.?RO0LWD">+./DAH_'LH_F44H_/7CHT>:J@:<;G0HOVG78 M:GL%(?PFNN4L8U _Z9]MGF866],\KQ?]%<5TO^AJNN5)_HY[NTY>S;O>4%CI MZ!H0.?_T^,>@;\2=#*IR*;N16/F5U:WD5A'39GHZ)P2RY2 @##9F:$G#4Z8% M\40M.3CAL)"XB+62(1&1M>NA*2%MT5#KA=S 85(7WZ*$CEK##WC^-:QLB"0: MMF2L/=T6CB[I!CN;?;>3MT#B25N()NHA+C=793*I\[\R++/AO;DP5 XH9)[U>^2Z'\>UAD6.9O_=G. MV"V_.+CT+"H&0/=@/*O=;+VJC!,C\.,FDS>#6A--N7"2&G>TFV4R#NBP-B)' MH=X$1U/RL\=C$AU;4@S9 *IL$8G9M%6.'CS_C)L4'?YF>=W:#5T5XZ[Y<$PA M8M>3X[82R!7X"08#)/+)DE,> M0FS2*'&(Z0::EPBPO/)=\^M'YF[-#Z^0P:? AQ4N/V/MR-T5.. M&B70G@@?=^1]6X5X4"^ E%9@[.JA:%3B%+D]6XI-*W> #NE1# M,S4.XREC'/;0-[E"R;11IP#<0D*WT!)^ YNO;,/KZ'SK, M_0_C?7@UBXCA]IBI[USHT3+*?^RM\#\,5[T-NVR-VIS]/S/[XAZO_(=%$=RS M=56U7Z]%"/SN_?85:1NT#S(WJ;*S[J5/%_?]7T.=N= +K5?C'/ZWSC?" G0I M4=86_J/<@M^DCHRF/>H1.97H>$BZ.=1)R_GIZ>'Y4]TS;GXNY9T5X\[W#YX/ MS&PMRKFA?_OT^W_&C+K_$'Y?#L#F'I.===#\5N9IBO4?6VU^PIMGFZWYUT/I M.G\>H8+!#=3^%KD?-D)"^*R#1PS9L,^?[ C%Y_GE2P()[F;&8'6*XZZ2G-:-*1EE;7P_#:R@KS1)M?#M MF%8%'GEQ>TG0OUQJ=XFLZW(^PVI=&L/7V_NOA]D9-O!%PW_ M#,Z;-YUH_7I9UWK!7Y_"S&<^1&\--N_=)/O]66E"=]9!>C8-%[YM';1^)=]FJ'DS;O7"I\SGN5N=O=Z4.B<( M/3+N_%VPL#/%*^YVS674X"06>>9#OYQ!6XD&>S[L<(N/B?D'(_JFO;2^X E+ MJ4 ?<51QU#B_8 UX9&\7TQ)##VUD*]C,D1/Q 47+(N_?>N+Y:CSD7.2?;E>7 MBK67/]]Z\@T?*8ODE-@5S)[\NBK7T.1J6E_S]LDT"RM'Z,).!5*K=?_3KBN> M-_)BFZ.OZ6^S,'ARM.!IT?[;P&E1#\?6T 45MKSKI:%U#HI79!U()RU6IET:Z-;)]%,,63=E[>BP4CDGF:B/:(+6)^!H:$H>)$AF&3&$KS B)2:C MV\;5N-6H.5RFQBFR>'(=[P:S;>!(,]?)^Y6[0'>:\Q/CPBLEBH^V$^Y1G5JX MXL^]9KFWG%GNK J6!ZM1 AY)-5%:PP_E^&0M.87-/"1W\I"*;Z*+3"DRSBN! M!NO=L"%$8_/7E.97%R#.<'LV@WBJ1P8+HP"MN=<:N._U<:;2UK (,:6S4NEKOH42]_%R^ C.^RG4HP6P!ZPU^U M@[4'/Y,7/H,VOG@J87";A[=!]3$*HA;3%HRNJZS(8.5!VB*6!C03'Q-1.'K+ M6=H6?-EG+3)_]1^+T6B7%W(!MTM5+0BPM'Y%^XE)5W!,^D>KEX\) M#*>I*V"MAJSE[3P,3:]VU1NBW5D;X%./Q#(=HIS2R&4/4)H3^.? W#T=,Q$L M4\2D&_"CI>P(R/B*' Q6>L''N ]@J_]TSDC2 #*2Z=$DUZSBI%$U+0%*E< MDR,*RDJTW6PKO!W;%995+[J&J0O'%,!$Y6^JO_,R7>&K!:,#]3%RRB*JO-1/ M:*S_Z6&(0FQ('UZJQL7109K(;'E-?:JAQAPFWRDCO6". !<*#! 5L]>O /YM M^^5 ,RZP<'YM0)4:I^MX@=A82FB@/9LL+1*1\^R_ X#N# M69W/Z=SGLTGD]8RJ7N<7T,)K<\0DECYC7:/#>>0@S)7K$)3/H98&GY#3G4QK MR%[F<3,/?I:+Z5@=Q#Z;D38BI&E@Z3A$SA%F)C_TDU^I!25>H'NEC*CY:L'\ MJ#/K%U1$K"B8/ E%*7C)CDY0 F.'\&AE.XLT!,_*4@L2*WRH(L%"YG%9<+)= MEB$<*!MTPF,Y8S%B7PI?:SD#TKNM;!_#+R%BLW&+R$C1P5K+W/R"_:IC+#*: M=YM)5Q75[QHG5IB+:'%DLU[2%]0T8$ \20)I31+=L#KK?1U\'VDTJ5'PW+R) MFNB[#'[P&*;L@6F%#+$KV)+J>%5:[&;? *Q"PJ!/EGKRH]S2#P,,%YG.W^V> MXP8_$VN,Q#S#L<7C,ZOG%0617BB#N2M"08LEU%/@"L$J1Y]LN%4N2 5^XUWW M70WUIE1P8N<,8L! 65OZQ$4I)]F>I1^Y &?<9L0E(X)H(+@*Q1#V6)=UNSES$70F[ MGU0XD0>/=H7^Y>';7CGD)ZQ.M\@?&[C$+O2T>Q0:VO5;]-J^QE]^HF[[^4?[?\>$-.T1XE'',NA..D&49W7*KJ_//2 M]I0YAJ-++TJYVLQ#*DP#T24XAJ*IVO6_!NS_M9:NI=M^*EE MK&\:]R_UCRR2;=ME1_W[4B7(=,N4/Z/T][N?2\T]<)]D\8__^Q'1.;![V]CC MD9NED>3>P0-+;,G/B6[?M531JGJ*8%4'60+_!J0S%CY,$5-A/R""*S(]]F;]; MZV:0%=^]:E@3M&\AQL]IW41L(TIA0K/O\D[DI.PQ-'R/,&[?0$W%9(TMM?^; M<@8D) *!4UJPJ^^/UVO^Q%3N0I8AVD\T0BC@EYEI"9NE"4>#RH@\!%ZC*6 M4&) 7L7T$JC2Z[68> 'L @4WUZ_I9%F/7B/B@Y#=,DE"UM;[;]Y\HSV'N'&( MJU2'3%K1;YOV\K+[NWFWE^_/I:&?=,C#I!V0R4 8K=]"&=S+Q&B_VS"-Q7G)Q1EA$4_TS& MT0D8WM2^M22[LU)%W=,>IN,U_&7*K3R#F-QT;OOIUQU:%K)PK9.7GS3 M\:+]*_;E##\,L+VP].ZG,IY1TZ$PE[J;S>>VPP$[/^A:X%,;Y&>?R*#3A[L@ MPX#ICV!7KF]*P>$2TX=Y2PY;#5B/4.&-!9QZ>Z;S>[)3X/!VJ*4)G\0M+T8\ M.PE*!_@9--N(K@"#6VB)P&)OF?@FMXFU_4?!8K$F8H\%X;BH8J8GQK9O@!L8 M-[*(L&LS>2/,Z/'J_L(-E]5REP8:IX_F,6?!0&4TO'?>@3Z W@*UE PL35!= M(?=B@SIY]&Z9!YMI*[4@K0C\W;.E8&])X/UA0_#^ X.BHJ9SRZX=EPP_GG4- M--ZS8<6FXQ.20(B@6E"AQB%F C5N<^#?G^T+2XB5C&3T^@" XHEJW-V*Z&(1 M;7I1IQH',K#[\A[IC%EH3?JN5>,>V7&Q7-&BQGVT) ;\W_U0L'[\-2*3&N8] M$@2?=0K4."FFRK^[N@SPG=6X/4'8=2T,W=YXX89SGK*ZY:0Y#;H:!SL"Z(EV M)6\%\-Z$JL8U*-2XK_>O_Y^<3/>\49@14U+=[ST0U/\Q@M 6]W$&*)&\4 T)MFG._<<_%.];8+@+67+R^PW\N*LSSOZLXKZBX!WZZ-NWD,YZ MQC^?#SXJ= H/,X\_&S&[<'54J++@^!Z=+;J1*8K<;:.OFA>WU&_/LOY[J5W: MKBL.S*GQ+-:5B!GQZE#Y0V?6K'.<*U\!_W20>-UPM",U=SW23YFTT\;*3FRZ)/',IH[M2K/(8G>!774%9&VMA +B\,F_(_PVB5V_ M?JT0?Q2;\AT49CODR[BFPHA];W]_<29;%MC-0,J7O/916'3_^V_+A6W=&^9? M-I]YGY);^O+E'9=.&KB/^-V:9JC&]313<-XQO#'^3.L#LE2@?0) MNA*<3:Y?#RN.J&[E02YQ+$/_[8A))VL!\S3LEC_&71XLN!B\B+L([3;3R?3N M /PQ5N/JAY&2)(2MDTQ;2&/OG5,8O\4Q-T!$Z7!I 7QBOK%&T&R2J,9AXO4< MJ7\!Y3PG-E+0^ N$<%7(8?YS[7./ MEJ#]RJX=F;G$?L5R]AT,7?M=E(&02PM1!^T87@N;@$(OC&=TK!0'P9&F:->& MF@V25)O:0Y*#_A^33V>T%Z3_VKFN?>ND(Z7TP_>YWOB*T4H?>^'LW,7XZA)O M7Y34\C)?:[?":FW;:WP+F>1'*9P-.WJS- MG27B=Y2P7!H<;>]>NDLN_>OB=Y]E=B3\I'^O\M2CCVWX0':1>ZJK3U37V%%2 M+OF BL.R9G62+53/*-)' BTL@P!&#+QW.ZHSQ'KKP&V4Z""[P9(,K7B^EDR2 MA&I"RI<1.:Z\<0_[^LV0.(%$_*5]RG&O/#5 X=I9T#WL3=%A4(5>SC7"*+"W M 4LBRL<]@N#@1?Z^%(C+Z51>@>OF?T/[*.4M0IX^<0%B*%#=0M
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

Document and Entity Information Document - shares	6 Months Ended
Document and Entity Information Document - shares	Jun. 30, 2019	Jul. 22, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2019
Document Transition Report	false
Entity File Number	0-27756
Entity Registrant Name	ALEXION PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3648318
Entity Address, Address Line One	121 Seaport Boulevard
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	475
Local Phone Number	230-2596
Title of 12(b) Security	Common Stock $0.0001 par value
Trading Symbol	ALXN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0000899866
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		224,226,878
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 1,984.2	$ 1,365.5
Marketable securities	105.4	198.3
Trade accounts receivable, net	1,123.6	922.3
Inventories	494.6	472.5
Prepaid expenses and other current assets	460.7	426.4
Total current assets	4,168.5	3,385.0
Property, plant and equipment, net	1,123.5	1,471.5
Intangible assets, net	3,487.6	3,641.3
Goodwill	5,037.4	5,037.4
Right of use operating assets	209.5	0.0
Other assets	541.2	396.7
Total assets	14,567.7	13,931.9
Liabilities and Stockholders' Equity
Accounts Payable and Accrued Liabilities, Current	728.7	698.2
Revolving credit facility	0.0	250.0
Current portion of long-term debt	126.6	93.8
Current portion of contingent consideration	100.0	97.6
Other current liabilities	76.2	34.4
Total current liabilities	1,031.5	1,174.0
Long-term debt, less current portion	2,438.3	2,501.7
Contingent consideration	158.2	183.2
Facility lease obligation	0.0	361.0
Deferred tax liabilities	341.2	391.1
Noncurrent operating lease liabilities	165.5	0.0
Other liabilities	269.5	155.6
Total liabilities	4,404.2	4,766.6
Commitments and contingencies (Note 18)
Stockholders' Equity:
Common stock, $0.0001 par value; 290 shares authorized; 237.3 and 236.2 shares issued at June 30, 2019 and December 31, 2018, respectively	0.0	0.0
Additional paid-in capital	8,677.0	8,539.1
Treasury stock, at cost, 13.1 and 12.7 shares at June 30, 2019 and December 31, 2018, respectively	(1,738.8)	(1,689.9)
Accumulated other comprehensive loss	(57.9)	(9.7)
Retained earnings	3,283.2	2,325.8
Total stockholders' equity	10,163.5	9,165.3
Total liabilities and stockholders' equity	$ 14,567.7	$ 13,931.9

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Millions	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	290.0	290.0
Common stock, shares issued	237.3	236.2
Treasury Stock, Shares	13.1	12.7

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,203.3	$ 1,045.0	$ 2,343.7	$ 1,975.9
Cost of Goods and Services Sold	99.2	95.3	185.0	186.9
Operating expenses:
Research and development	187.6	173.4	383.5	350.0
Selling, general and administrative	299.3	277.3	580.8	534.4
Acquired in-process research and development	(4.1)	803.7	(4.1)	803.7
Amortization of purchased intangible assets	80.1	80.1	160.1	160.1
Change in fair value of contingent consideration	6.1	4.7	(22.6)	57.4
Restructuring expenses	2.5	10.6	11.6	16.1
Total operating expenses	571.5	1,349.8	1,109.3	1,921.7
Operating income (loss)	532.6	(400.1)	1,049.4	(132.7)
Other income and expense:
Investment (expense) income	(14.9)	7.7	27.6	113.5
Interest expense	(18.3)	(25.0)	(38.2)	(49.1)
Other income and (expense)	0.1	(1.2)	2.5	1.3
Income (loss) before income taxes	499.5	(418.6)	1,041.3	(67.0)
Income tax (benefit) expense	39.7	38.8	(6.4)	141.3
Net income (loss)	$ 459.8	$ (457.4)	$ 1,047.7	$ (208.3)
Earnings (loss) per common share
Basic	$ 2.05	$ (2.05)	$ 4.68	$ (0.94)
Diluted	$ 2.04	$ (2.05)	$ 4.64	$ (0.94)
Shares used in computing earnings (loss) per common share
Basic	224.2	222.6	224.0	222.3
Diluted	225.6	222.6	225.7	222.3
Net Product Sales [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,202.5	$ 1,044.7	$ 2,342.7	$ 1,975.1
Other Revenue [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0.8	$ 0.3	$ 1.0	$ 0.8

Condensed Consolidated Statements of Changes in Stockholder's Equity Statement - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]
Common Stock, Shares, Outstanding at Dec. 31, 2017		234.3
Stockholders' Equity Attributable to Parent at Dec. 31, 2017	$ 8,893.1	$ 0.0	$ 8,290.3	$ (1,604.9)	$ (34.4)	$ 2,242.1
Treasury Stock, Shares at Dec. 31, 2017				12.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Acquired	0.7			0.7
Treasury Stock, Value, Acquired, Cost Method	$ (85.0)			$ (85.0)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0.3
Stock Issued During Period, Value, Stock Options Exercised	24.6		24.6
Stock Issued During Period, Shares, Restricted Stock Award, Gross		0.9
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	105.3		105.3
Net income (loss)	(208.3)					(208.3)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	31.5				31.5
Treasury Stock, Shares at Jun. 30, 2018				12.7
Stockholders' Equity Attributable to Parent at Jun. 30, 2018	8,767.4	$ 0.0	8,420.2	$ (1,689.9)	(2.9)	2,040.0
Common Stock, Shares, Outstanding at Jun. 30, 2018		235.5
Common Stock, Shares, Outstanding at Mar. 31, 2018		235.2
Stockholders' Equity Attributable to Parent at Mar. 31, 2018	9,112.7	$ 0.0	8,350.9	$ (1,689.9)	(45.7)	2,497.4
Treasury Stock, Shares at Mar. 31, 2018				12.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Acquired				0.0
Treasury Stock, Value, Acquired, Cost Method	0.0			$ 0.0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0.2
Stock Issued During Period, Value, Stock Options Exercised	15.1		15.1
Stock Issued During Period, Shares, Restricted Stock Award, Gross		0.1
Stock Issued During Period, Value, Restricted Stock Award, Gross	0.3		0.3
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	53.9		53.9
Net income (loss)	(457.4)					(457.4)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	42.8				(48.2)
Treasury Stock, Shares at Jun. 30, 2018				12.7
Stockholders' Equity Attributable to Parent at Jun. 30, 2018	8,767.4	$ 0.0	8,420.2	$ (1,689.9)	(2.9)	2,040.0
Common Stock, Shares, Outstanding at Jun. 30, 2018		235.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative Effect of New Accounting Principle in Period of Adoption	6.2					6.2
Common Stock, Shares, Outstanding at Dec. 31, 2018		236.2
Stockholders' Equity Attributable to Parent at Dec. 31, 2018	$ 9,165.3	$ 0.0	8,539.1	$ (1,689.9)	(9.7)	2,325.8
Treasury Stock, Shares at Dec. 31, 2018	12.7			12.7
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Acquired	0.4			0.4
Treasury Stock, Value, Acquired, Cost Method	$ (48.9)			$ (48.9)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0.2
Stock Issued During Period, Value, Stock Options Exercised	21.3		21.3
Stock Issued During Period, Shares, Restricted Stock Award, Gross		0.9
Stock Issued During Period, Value, Restricted Stock Award, Gross	0.0		0.0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	116.6		116.6
Net income (loss)	1,047.7					1,047.7
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ (48.2)
Treasury Stock, Shares at Jun. 30, 2019	13.1			13.1
Stockholders' Equity Attributable to Parent at Jun. 30, 2019	$ 10,163.5	$ 0.0	8,677.0	$ (1,738.8)	(57.9)	3,283.2
Common Stock, Shares, Outstanding at Jun. 30, 2019		237.3
Common Stock, Shares, Outstanding at Mar. 31, 2019		237.0
Stockholders' Equity Attributable to Parent at Mar. 31, 2019	$ 9,706.6	$ 0.0	8,604.9	$ (1,701.2)	(20.5)	2,823.4
Treasury Stock, Shares at Mar. 31, 2019				12.8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Acquired	0.3			0.3
Treasury Stock, Value, Acquired, Cost Method	$ (37.6)			$ (37.6)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0.1
Stock Issued During Period, Value, Stock Options Exercised	11.2		11.2
Stock Issued During Period, Shares, Restricted Stock Award, Gross		0.2
Stock Issued During Period, Value, Restricted Stock Award, Gross	0.0		0.0
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	60.9		60.9
Net income (loss)	459.8					459.8
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ (37.4)				(37.4)
Treasury Stock, Shares at Jun. 30, 2019	13.1			13.1
Stockholders' Equity Attributable to Parent at Jun. 30, 2019	$ 10,163.5	$ 0.0	$ 8,677.0	$ (1,738.8)	$ (57.9)	3,283.2
Common Stock, Shares, Outstanding at Jun. 30, 2019		237.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative Effect of New Accounting Principle in Period of Adoption	$ (90.3)					$ (90.3)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net income (loss)	$ 1,047.7	$ (208.3)
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	193.7	202.0
Change in fair value of contingent consideration	(22.6)	57.4
Share-based compensation expense	117.6	105.2
Research and Development in Process	0.0	86.6
Deferred taxes	(40.8)	111.5
Unrealized foreign currency loss (gain)	(4.1)	12.7
Unrealized loss (gain) on forward contracts	11.3	3.1
Unrealized gain on strategic equity investments	(8.6)	(100.5)
Other	(2.3)	13.2
Changes in operating assets and liabilities
Accounts receivable	(196.4)	(137.0)
Inventories	(24.0)	(4.1)
Prepaid expenses and other assets	(126.8)	(55.7)
Accounts payable, accrued expenses, lease liabilities and other liabilities	23.6	(130.6)
Net cash provided by operating activities	968.3	(44.5)
Cash flows from investing activities:
Payments to Acquire Debt Securities, Available-for-sale	(41.1)	(612.8)
Proceeds from maturity or sale of available-for-sale debt securities	139.3	1,054.8
Purchases of mutual funds related to nonqualified deferred compensation plan	(10.9)	(7.5)
Proceeds from sale of mutual funds related to nonqualified deferred compensation plan	9.0	5.9
Purchases of property, plant and equipment	(82.8)	(129.4)
Purchases of strategic investments	(43.8)	0.0
Payments to Acquire Intangible Assets	(8.0)	0.0
Payments for (Proceeds from) Other Investing Activities	0.2	2.6
Net cash provided by (used in) investing activities	(38.1)	313.6
Cash flows from financing activities:
Debt issuance costs	0.0	(7.6)
Proceeds from Lines of Credit	0.0	250.0
Payments on term loan facility	(32.7)	(293.8)
Repayments of Lines of Credit	(250.0)	0.0
Repurchases of common stock	(48.9)	(85.0)
Net proceeds from issuance of common stock under share-based compensation arrangements	20.5	24.6
Other	(2.4)	(4.7)
Net cash used in financing activities	(313.5)	(116.5)
Effect of exchange rate changes on cash and cash equivalents and restricted cash	0.7	(6.1)
Net change in cash and cash equivalents and restricted cash	617.4	146.5
Cash and cash equivalents and restricted cash at beginning of period	1,367.3	586.3
Cash and cash equivalents and restricted cash at end of period	1,984.7	732.8
Supplemental cash flow disclosures from investing and financing activities:
Fair value of contingent liability related to strategic investment and purchase option	27.4	0.0
Operating ROU lease assets obtained in exchange for operating lease liabilities	20.7	0.0
Capitalization of construction costs related to facility lease obligations	0.0	33.2
Accounts payable and accrued expenses for purchases of property, plant and equipment and intangible assets	$ 14.3	$ 15.8

Business	6 Months Ended
Business	Jun. 30, 2019
Business [Abstract]
Business	Business Alexion Pharmaceuticals, Inc. (Alexion, the Company, we, our or us) is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. We are the global leader in complement inhibition and have developed and commercialize two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as the first approved complement inhibitor to treat atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In addition, Alexion has two highly innovative enzyme replacement therapies and the first and only approved therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). In addition to our marketed therapies, we have a diverse pipeline resulting from internal innovation and business development with strategic focus in hematology and nephrology, neurology, metabolics and neonatal Fc receptor (FcRn). We were incorporated in 1992 under the laws of the State of Delaware.

Basis of Presentation and Principles Of Consolidation	6 Months Ended
Basis of Presentation and Principles Of Consolidation	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. These accounting principles were applied on a basis consistent with those of the consolidated financial statements contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2018. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of our financial statements for interim periods presented in accordance with accounting principles generally accepted in the United States. The condensed consolidated balance sheet as of December 31, 2018 was derived from audited annual financial statements but does not include all disclosures required by accounting principles generally accepted in the United States. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2018 included in our Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the full year or any other future periods. The financial statements of our subsidiaries with functional currencies other than the U.S. dollar are translated into U.S. dollars using period-end exchange rates for assets and liabilities, historical exchange rates for stockholders' equity and weighted average exchange rates for operating results. Translation gains and losses are included in accumulated other comprehensive income (loss), net of tax, in stockholders' equity. Foreign currency transaction gains and losses are included in the results of operations in other income and expense. The accompanying unaudited condensed consolidated financial statements include the accounts of Alexion Pharmaceuticals, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Our significant accounting policies are described in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. Updates to our accounting policies, including impacts from the adoption of new accounting standards, are discussed below in this Note 2 and within Note 17, Leases. Reclassifications Certain items in the prior period’s condensed consolidated financial statements have been reclassified to conform to the current presentation. New Accounting Pronouncements Accounting Standards Update (ASU) 2016-13, "Measurement of Credit Losses on Financial Instruments": In June 2016, the Financial Accounting Standards Board (FASB) issued a new standard intended to improve reporting requirements specific to loans, receivables and other financial instruments. The new standard requires that credit losses be reported based on expected losses compared to the current incurred loss model. The new standard also requires enhanced disclosure of credit risk associated with respective assets. The standard is effective for interim and annual periods beginning after December 15, 2019 with early adoption permitted. We are currently assessing the impact of this standard on our consolidated financial statements. ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract": In August 2018, the FASB issued a new standard on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement (CCA). Under the new guidance, customers will assess if a CCA includes a software license and if a CCA does include a software license, implementation and set-up costs will be accounted for consistent with existing internal-use software implementation guidance. Implementation costs associated with a CCA that do not include a software license would be expensed to operating expenses. The standard also provides classification guidance on these implementation costs as well as additional quantitative and qualitative disclosures. The standard is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. Entities can choose to adopt the new guidance prospectively or retrospectively. We are currently assessing the impact this standard will have on our consolidated financial statements. Recently Adopted Accounting Pronouncements ASU 2016-02, "Leases": In February 2016, the FASB issued a new standard that requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right of use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as financing or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. We adopted the new standard on January 1, 2019 using the modified retrospective approach. We have elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the consolidated financial statements and recognize a cumulative-effect adjustment to the opening balance of retained earnings on the date of adoption. We also elected the “package of practical expedients”, which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. Results for reporting periods beginning after January 1, 2019 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2019, we derecognized $472.8 of property, plant and equipment and other assets and $372.2 of facility lease obligations associated with previously existing build-to-suit arrangements. We capitalized ROU assets of $326.1, inclusive of opening adjustments of $70.8 primarily related to prepaid rent existing at transition, and $255.3 of lease liabilities, within our condensed consolidated balance sheets upon adoption. At transition we recorded a decrease of $90.3 to retained earnings, net of tax, primarily related to our derecognition of previously recorded build-to-suit arrangements. ASU 2018-02, "Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income": In February 2018, the FASB issued a new standard that permits entities to make a one-time reclassification from accumulated other comprehensive income (AOCI) to retained earnings for the stranded tax effects resulting from the newly enacted corporate tax rates under the Tax Cuts and Jobs Act (the Tax Act), that was effective for the year ended December 31, 2017. We adopted the new standard on January 1, 2019 and elected not to reclassify the income tax effects of the Tax Act from AOCI to retained earnings. We continue to release disproportionate income tax effects from AOCI based on the aggregate portfolio approach. The adoption of this standard did not have an impact on our condensed consolidated financial statements.

Debt	6 Months Ended
Debt	Jun. 30, 2019
Debt [Abstract]
Debt	Debt On June 7, 2018, we entered into an Amended and Restated Credit Agreement (the Credit Agreement), with Bank of America, N.A. as Administrative Agent. The Credit Agreement amended and restated our credit agreement dated as of June 22, 2015 (the Prior Credit Agreement). The Credit Agreement provides for a $1,000.0 revolving credit facility and a $2,612.5 term loan facility. The revolving credit facility and the term loan facility mature on June 7, 2023. Beginning with the quarter ending June 30, 2019, we are required to make payments of 5.00% of the original principal amount of the term loan facility annually, payable in equal quarterly installments. In connection with entering into the Credit Agreement and the Prior Credit Agreement, we paid an aggregate of $53.1 in financing costs. Financing costs are amortized as interest expense over the life of the debt. Amortization expense associated with deferred financing costs for the three months ended June 30, 2019 and 2018 was $1.3 and $3.2, respectively, and amortization expense associated with deferred financing costs for the six months ended June 30, 2019 and 2018 was $2.5 and $5.5, respectively. Remaining unamortized deferred financing costs as of June 30, 2019 and December 31, 2018 were $18.3 and $20.8, respectively. We made principal payments of $32.7 on the term loan during the three and six months ended June 30, 2019 and as of June 30, 2019, we had $2,579.8 outstanding on the term loan. In January 2019, we paid the outstanding balance on the revolving credit facility of $250.0 in full and we had no outstanding borrowings under the revolving credit facility as of June 30, 2019. As of June 30, 2019, we had open letters of credit of $1.0 that offset our availability in the revolving facility. The fair value of our long term debt, which is measured using Level 2 inputs of the fair value hierarchy, approximates book value.

Other Investments	6 Months Ended
Other Investments	Jun. 30, 2019
Investments, All Other Investments [Abstract]
Other Investments	Other Investments Other investments include strategic investments in equity securities of certain biotechnology companies which we acquired in connection with license agreements. These investments are included in other assets in our condensed consolidated balance sheets. Moderna During 2014, we purchased $37.5 of preferred stock of Moderna Therapeutics, Inc. (Moderna), a privately held biotechnology company, which was recorded at cost. During the first quarter 2018, Moderna announced the completion of a new round of financing. As a result, we recognized an unrealized gain of $100.8 in investment income during the first quarter 2018 to adjust our investment in Moderna to fair value as of the date of the observable price change, based on the per share price in Moderna's new round of financing. There were no observable price changes during the second quarter 2018. On December 6, 2018, Moderna completed its initial public offering (IPO) and shares of Moderna began trading on the Nasdaq Global Select Market under the symbol “MRNA.” As part of the IPO, our preferred stock was converted into Moderna common stock and subject to a one year lock-up period. As our equity investment in Moderna common stock now has a readily determinable fair value, we are recording the investment at fair value, with the effects of the holding period restriction estimated using an option pricing valuation model. During the three and six months ended June 30, 2019, we recognized an unrealized (loss) gain of $(29.0) and $0.8, respectively, in investment income to adjust our investment in Moderna to fair value as of June 30, 2019. The fair value of this investment was $82.7 and $81.9 as of June 30, 2019 and December 31, 2018, respectively. Dicerna In October 2018, we purchased $10.3 of Dicerna Pharmaceuticals Inc. (Dicerna) common stock in connection with an agreement that we entered into with Dicerna, a publicly-traded biopharmaceutical company. As our equity investment in Dicerna common stock has a readily determinable fair value, we are recording the investment at fair value. During the three and six months ended June 30, 2019, we recognized an unrealized gain of $0.9 and $4.2, respectively, in investment income to adjust our equity investment in Dicerna to fair value as of June 30, 2019. The fair value of this investment was $13.1 and $8.9 as of June 30, 2019 and December 31, 2018, respectively. Caelum In January 2019, we purchased $41.0 of preferred stock of Caelum Biosciences (Caelum), a privately-held biotechnology company, and a $16.1 option to acquire the remaining equity in Caelum in connection with an agreement that we entered into with Caelum, see Note 18, “Commitments and Contingencies” for additional information on the agreement. As our equity investment in Caelum and the option to acquire the remaining equity in Caelum do not have a readily determinable fair value, we are recording the assets at cost, less impairment, and adjusted for any subsequent changes resulting from an observable price change in an orderly transaction for identical or similar equity securities of the same issuer. There were no observable price changes associated with these assets during the six months ended June 30, 2019. The carrying value of the investment and option of $41.0 and $16.1, respectively, were not impaired as of June 30, 2019. Zealand In March 2019, we purchased $13.8 of Zealand Pharma A/S (Zealand) common stock in connection with an agreement that we entered into with Zealand, a publicly-traded biopharmaceutical company based in Copenhagen, Denmark, see Note 18, “Commitments and Contingencies” for additional information on the agreement. As our equity investment in Zealand common stock has a readily determinable fair value, we are recording the investment at fair value. We have considered the effects of a six month holding period restriction and determined that the impact on the fair value of the investment is immaterial. During the three and six months ended June 30, 2019, we recognized an unrealized gain of $2.9 and $3.6, respectively, in investment income to adjust our equity investment in Zealand to fair value as of June 30, 2019. The fair value of this investment was $17.4 as of June 30, 2019.

Stockholders' Equity	6 Months Ended
Stockholders' Equity	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity In November 2012, our Board of Directors authorized a share repurchase program. In February 2017, our Board of Directors increased the amount that we are authorized to expend on future repurchases to $1,000.0 under the repurchase program, which superseded all prior repurchase programs. The repurchase program does not have an expiration date and we are not obligated to acquire a particular number of shares. The repurchase program may be discontinued at any time at our discretion. Under the program, we repurchased 0.3 shares of our common stock at a cost of $37.6 during the three months ended June 30, 2019. During the six months ended June 30, 2019 and 2018, we repurchased 0.4 and 0.7 shares of our common stock at a cost of $48.9 and $85.0, respectively. The Company did not repurchase any shares during the three months ended June 30, 2018. Subsequent to June 30, 2019, we repurchased 0.1 shares of common stock under our repurchase program at a cost of $9.0. As of July 22, 2019, there is a total of $393.6 remaining for repurchases under the repurchase program.

Defined Benefit Plans	6 Months Ended
Defined Benefit Plans	Jun. 30, 2019
Retirement Benefits [Abstract]
Employee Benefit Plans	Defined Benefit Plans We maintain defined benefit plans for employees in certain countries outside the U.S., including retirement benefit plans required by applicable local law. The plans are valued by independent actuaries using the projected unit credit method. The liabilities correspond to the projected benefit obligations of which the discounted net present value is calculated based on years of employment, expected salary increases, and pension adjustments. The total net periodic benefit cost for the three and six months ended June 30, 2019 and 2018 was not material.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Asset Acquisition and In-License Agreements We have entered into asset purchase agreements and license arrangements in order to advance and obtain technologies and services related to our business. These agreements generally require us to pay an initial fee and certain agreements call for future payments upon the attainment of agreed upon development, regulatory and/or commercial milestones. These agreements may also require minimum royalty payments based on sales of products developed from the applicable technologies, if any. In January 2019, we entered into an agreement with Caelum, a biotechnology company that is developing CAEL101 for light chain (AL) amyloidosis. Under the terms of the agreement, we acquired a minority equity interest in preferred stock of Caelum and an exclusive option to acquire the remaining equity in Caelum based on Phase II data, for pre-negotiated economics. We paid $30.0 in the first quarter 2019 and could be required to pay up to an additional $30.0 in contingent milestone-dependent fees. These contingent payments meet the definition of a derivative liability and were initially recorded at fair value of $27.1. We allocated the total consideration of $57.1, inclusive of the fair value of contingent milestone-dependent fees, to the equity investment in Caelum and the option to acquire the remaining equity in Caelum based on the relative fair values of the assets. The agreement with Caelum also provides for additional payments, in the event Alexion exercises the purchase option, for up to $500.0, which includes an upfront option exercise payment and potential regulatory and commercial milestone payments. In March 2019, we entered into an agreement with Zealand which provides us with exclusive worldwide licenses, as well as development and commercial rights, for subcutaneously delivered preclinical peptide therapies directed at up to four complement pathway targets. Pursuant to the agreement, Zealand will lead joint discovery and research efforts through the preclinical stage, and Alexion will lead development efforts beginning with the investigational new drug filing and Phase 1 studies. In addition to the agreement, we made an equity investment in Zealand (see Note 10). Under the terms of the agreement, we made an upfront payment of $40.0 for an exclusive license to the lead target and the equity investment, as well as for preclinical research services to be performed by Zealand in relation to the lead target. The market value of the equity investment was $13.8 as of the date of acquisition, which we recorded in other assets in our condensed consolidated balance sheets. We also recognized prepaid research and development expense of $5.0 within the condensed consolidated balance sheets associated with the research activities to be performed by Zealand. Due to the early stage of the asset we are licensing, we recorded the upfront license payment of $21.2 as research and development expense during the first quarter 2019. As of June 30, 2019, we could be required to pay up to $610.0, for the lead target, upon the achievement of specified development, regulatory and commercial milestones, as well as royalties on commercial sales. Each of the three subsequent targets can be selected for an option fee of $15.0 and has the potential for additional development, regulatory and commercial milestones, as well as royalty payments, at a reduced price to the lead target. In March 2019, we entered into an agreement with Affibody AB (Affibody), through which Alexion obtained an exclusive worldwide license, as well as development and commercial rights, to ABY-039, a bivalent antibody-mimetic that targets the FcRn and is currently in Phase 1 development. The agreement with Affibody was subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and, following receipt of such approval, the transaction closed in April 2019. Pursuant to the agreement, Alexion will lead the clinical development and commercial activities for ABY-039 in rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Affibody has the option to co-promote ABY-039 in the U.S. and will lead clinical development of ABY-039 in an undisclosed indication. Under the terms of the agreement, we made an upfront payment of $25.0 for the exclusive license to ABY-039. Due to the early stage of the asset we are licensing, we recorded the upfront license payment as research and development expense during the second quarter 2019. As of June 30, 2019, we could also be required to pay up to $625.0 for amounts due upon achievement of specific development, regulatory, and commercial milestones, as well as royalties on commercial sales. In connection with our prior acquisition of Syntimmune (see Note 3), we could be required to pay up to $800.0 upon the achievement of specified development, regulatory and commercial milestones. In addition, as of June 30, 2019, we have other license agreements under which we may be required to pay up to an additional $838.2 for currently licensed targets, if certain development, regulatory and commercial milestones are met. Additional amounts may be payable if we elect to acquire licenses to additional targets, as applicable, under the terms of these agreements. Asset Sale and Out-License Arrangements In connection with prior asset sale and out-license arrangements, Alexion is entitled to receive contingent payments upon the achievement of various regulatory and commercial milestones and other events, as well as royalties on commercial sales. The amount of contingent consideration related to these agreements is fully constrained and therefore has not been recognized as of June 30, 2019. Manufacturing Agreements We have various manufacturing development and license agreements to support our clinical and commercial product needs. We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial products and product candidates. We have various manufacturing and license agreements with Lonza, with remaining total non-cancellable future commitments of approximately $1,044.1. This amount includes $102.3 of undiscounted, fixed payments applicable to our CMO embedded lease arrangement with Lonza. If we terminate certain supply agreements with Lonza without cause, we will be required to pay for product scheduled for manufacture under our arrangement. Under an existing arrangement with Lonza, we also pay Lonza a royalty on sales of SOLIRIS that was manufactured at the Alexion Rhode Island Manufacturing Facility (ARIMF facility) prior to its sale and a payment with respect to sales of SOLIRIS manufactured at Lonza facilities. We also pay Lonza a royalty on the sales of ULTOMIRIS. In addition to our commitments with Lonza, as of June 30, 2019 we have non-cancellable commitments of approximately $65.1 through 2020 with other third party manufacturers. Contingent Liabilities We are currently involved in various claims, disputes, lawsuits and legal proceedings. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Because of uncertainties related to claims and litigation, accruals are based on our best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), we may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse adjustment to our operating results. Costs associated with our involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If we were unable to prevail in any such proceedings, our consolidated financial position, results of operations, and future cash flows may be materially impacted. We have received, and may in the future receive, notices from third parties claiming that their patents may be infringed by the use, development, manufacture, importation or sale of our products. Under the guidance of ASC 450, Contingencies, we record a royalty accrual based on our best estimate of the fair value percent of net sales of our products that we could be required to pay the owners of patents for technology used in the manufacture and sale of our products. A costly license, or inability to obtain a necessary license, could have a material adverse effect on our financial results. In May 2015, we received a subpoena in connection with an investigation by the Enforcement Division of the Securities and Exchange Commission (SEC) requesting information related to our grant-making activities and compliance with the Foreign Corrupt Practices Act (FCPA) in various countries. In addition, in October 2015, we received a request from the Department of Justice (DOJ) for the voluntary production of documents and other information pertaining to Alexion’s compliance with FCPA. The SEC and DOJ also seek information related to Alexion’s recalls of specific lots of SOLIRIS and related securities disclosures. Alexion is cooperating with these investigations. The investigations have focused on operations in various countries, including Brazil, Colombia, Japan, Russia and Turkey, and Alexion's compliance with the FCPA and other applicable laws. At this time, Alexion is unable to predict the duration, scope or outcome of these investigations. While it is possible that a loss related to these matters may be incurred, given the ongoing nature of these investigations, management cannot reasonably estimate the potential magnitude of any such loss or range of loss, or the cost of the ongoing investigation. Any determination that our operations or activities are not or were not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations. Alexion is committed to strengthening its compliance program and is currently implementing a comprehensive company-wide transformation plan that is designed to enhance and remediate its business processes, structures, controls, training, talent and systems across Alexion’s global operations. As previously reported, on December 29, 2016, a shareholder filed a putative class action against the Company and certain former employees in the U.S. District Court for the District of Connecticut, alleging that defendants made misrepresentations and omissions about SOLIRIS. On April 12, 2017, the court appointed a lead plaintiff. On July 14, 2017, the lead plaintiff filed an amended putative class action complaint against the Company and seven current or former employees. Defendants moved to dismiss the amended complaint on September 12, 2017. Plaintiffs filed an opposition to defendants’ motion to dismiss on November 13, 2017, and defendants’ filed a reply brief in further support of their motion on December 28, 2017. On March 26, 2019, the court held a telephonic status conference. During that conference, the court informed counsel that it was preparing a ruling granting the Defendants’ pending motion to dismiss. The court inquired of plaintiffs’ counsel whether they intended to seek leave to amend their complaint, and indicated that if they wished to file a second amended complaint, they would be allowed to do so. On April 2, 2019, the court granted plaintiffs until May 31, 2019 to file a second amended complaint, thereby rendering moot defendants’ pending motion to dismiss. On May 31, 2019, Plaintiffs filed a second amended complaint against the same defendants. The complaint alleges that defendants engaged in securities fraud, including by making misrepresentations and omissions in its public disclosures concerning the Company’s SOLIRIS sales practices, management changes, and related investigations, between January 30, 2014 and May 26, 2017, and that the Company's stock price dropped upon the purported disclosure of the alleged fraud. The plaintiffs seek to recover unspecified monetary relief, unspecified equitable and injunctive relief, interest, and attorneys’ fees and costs. Defendants’ motion to dismiss the amended complaint is due August 2, 2019; plaintiffs’ opposition to that motion is due October 2, 2019; and defendants’ reply in further support of their motion is due November 16, 2019. Given the early stage of these proceedings, we cannot presently predict the likelihood of obtaining dismissal of the case, nor can we estimate the possible loss or range of loss at this time. In December 2016, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts requesting documents relating generally to our support of Patient Services, Inc. (PSI) and National Organization for Rare Disorders (NORD), 501(c)(3) organizations that provide financial assistance to Medicare patients taking drugs sold by Alexion; Alexion’s provision of free drug to Medicare patients; and Alexion compliance policies and training materials concerning the anti-kickback statute and information on donations to PSI and NORD from 2010 through 2016. In April 2019, we entered in to a civil settlement agreement with the DOJ and the Office of Inspector General (OIG) of the U.S. Department of Health and Human Services to resolve this matter. As part of the settlement agreement, Alexion paid $13.1 to the DOJ and OIG. OIG did not require a Corporate Integrity Agreement with Alexion because it made fundamental organizational changes, including hiring a new executive leadership team, replacing half of the members of its Board of Directors, and effecting a significant change in the workforce. In May 2017, Brazilian authorities seized records and data from our Sao Paulo, Brazil offices as part of an investigation being conducted into Alexion’s Brazilian operations. We are cooperating with this inquiry. In June 2017, we received a demand to inspect certain of our books and records pursuant to Section 220 of the General Corporation Law of the State of Delaware on behalf of a purported stockholder. Among other things, the demand sought to determine whether to institute a derivative lawsuit against certain of the Company’s directors and officers in relation to the investigation by our Audit and Finance Committee announced in November 2016 and the investigations instituted by the SEC, DOJ, U.S. Attorney’s Office for the District of Massachusetts, and Brazilian law enforcement officials that are described above. We have responded to the demand. Given the early stages of this matter, an estimate of the possible loss or range of loss cannot be made at this time. On September 27, 2017, a hearing panel of the Canadian Patented Medicine Prices Review Board (PMPRB) issued a decision in a previously pending administrative pricing matter that we had excessively priced SOLIRIS in a manner inconsistent with the Canadian pricing rules and guidelines. In its decision, the PMPRB ordered Alexion to decrease the price of SOLIRIS to an upper limit based upon pricing in certain other countries, and to forfeit excess revenues for the period between 2009 and 2017. The amount of excess revenues for the period between 2009 and 2017 was not determined to be a material amount and was paid in 2018. In October 2017, Alexion filed an application for judicial review of the PMPRB’s decision in the Federal Court of Canada. On May 23, 2019, the Federal Court of Canada dismissed Alexion's application for judicial review and, as a consequence, affirmed the decision of the PMPRB that we had excessively priced SOLIRIS. On June 21, 2019, Alexion filed a notice of appeal of the Federal Court of Canada's ruling. Pursuant to an order made by the Federal Court of Canada, we will place approximately $31.6 in escrow to secure our obligations pending the final resolution of all appeals in this matter. This amount reflects the difference between the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive for the period from September 2017 to June 2019. Pursuant to US GAAP, our revenues for the quarter ended June 30, 2019 were reduced by this amount. In addition, on a quarterly basis until the appeals process has concluded, Alexion will be required to place amounts into escrow for each vial of SOLIRIS sold in the applicable quarter equal to the list price for SOLIRIS and the price determined by the PMPRB to be non-excessive. In October 2018, the Japanese Ministry of Health, Labour and Welfare (MHLW) conducted an administrative inspection of Alexion’s Japanese operations. The MHLW inquiry primarily focused on our communication efforts regarding the proper use of SOLIRIS in Japan for aHUS, among other matters. We have cooperated with the inquiries and the investigation, and in March 2019, the MHLW indicated that it has completed its investigation. Chugai Pharmaceutical Co., Ltd. has filed two lawsuits against Alexion. The first was filed in November 2018 in the United States District Court for the District of Delaware against Alexion Pharmaceuticals, Inc. alleging that ULTOMIRIS infringes one U.S. patent held by Chugai Pharmaceutical Co., Ltd. The second lawsuit was filed in December 2018 in the Tokyo District Court against Alexion Pharma GK (a wholly-owned subsidiary of Alexion) in Japan and alleges that ULTOMIRIS infringes two Japanese patents held by Chugai Pharmaceutical Co., Ltd. Chugai’s complaints seek unspecified damages and certain injunctive relief. In both cases, Alexion has denied the charges and countered that the patents are neither valid nor infringed. A trial date for the U.S. case has been set for May 2021. The case is still at the briefing stage in Japan. Given the early stages of these litigations, an estimate of the possible loss or range of loss cannot be made at this time. On February 28, 2019, Amgen Inc. (Amgen) petitioned the U.S. Patent and Trademark Office (PTO) to institute Inter Partes Review (IPR) of three patents owned by Alexion that relate to SOLIRIS: U.S. Patent Nos. 9,725,504; 9,718,880; and 9,732,149. In each case, Amgen alleges the patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid. We expect the PTO to review Amgen’s petitions and Alexion's submissions, and to issue a decision in September 2019 as to whether the PTO will institute IPR. At this time we cannot determine what decision the PTO will make.

Basis of Presentation and Principles Of Consolidation Basis of Presentation and Principles Of Consolidation (Details) - USD ($) $ in Millions	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	Jun. 30, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Derecognition of Facility Lease Obligation	$ 0.0		$ 361.0
Right of use operating assets	209.5		$ 0.0
Lease liability	185.8
Decrease to retained earnings	90.3			$ (6.2)
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Derecognition of Fixed and Other Assets		$ 472.8
Derecognition of Facility Lease Obligation		372.2
Right of use operating assets		326.1
Prepaid rent		70.8
Lease liability		255.3
Retained Earnings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease to retained earnings	$ 90.3			$ (6.2)
Retained Earnings [Member] \| Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease to retained earnings		$ 90.3

Acquisitions (Narrative) (Details) $ in Millions		1 Months Ended	3 Months Ended	12 Months Ended
Acquisitions (Narrative) (Details) $ in Millions	May 25, 2018 USD ($)	Nov. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)	Apr. 30, 2018 kr / shares
Syntimmune, Inc [Member]
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Upfront payment for acquisition of Syntimmune outstanding shares		$ 400.0
Additional payments to acquire businesses				$ 800.0
Total acquisition value				$ 1,200.0
Cash acquired		4.2
Transaction costs		0.9
Asset Acquisition, Consideration Transferred		407.4
Cash		4.2
Deferred tax assets		25.1
Other assets and liabilities		2.9
Total net assets acquired		$ 407.4
In Process Research and Development
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Cash paid for acquisition of Wilson Therapeutics outstanding shares	$ 749.3
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles	803.7
Cash offer price per share (in sec per share) \| kr / shares					kr 232
Potential development, regulatory and commercial milestones and royalties payment	19.0
Transaction costs	15.1
Asset Acquisition, Consideration Transferred	764.4
Cash	$ 45.1
In Process Research and Development \| Syntimmune, Inc [Member]
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Business Combination, Recognized Benefit From Previously Acquired Research And Development			$ 4.1

Acquisitions (Summary of Total Consideration) (Details) - USD ($) $ in Millions		1 Months Ended
	May 25, 2018	Nov. 30, 2018
In Process Research and Development
Consideration
Cash paid for acquisition of Wilson Therapeutics outstanding shares	$ 749.3
Transaction costs	15.1
Total consideration	764.4
Assets Acquired and Liabilities Assumed
Cash	45.1
In-process research & development	803.7
Employee related liabilities	(71.4)
Other assets and liabilities	(13.0)
Total net assets acquired	$ 764.4
Syntimmune, Inc [Member]
Consideration
Transaction costs		$ 0.9
Total consideration		407.4
Upfront payment for acquisition of Syntimmune outstanding shares		400.0
Cash acquired		4.2
Working capital adjustment		2.3
Assets Acquired and Liabilities Assumed
Cash		4.2
In-process research & development		375.2
Deferred tax assets		25.1
Other assets and liabilities		2.9
Total net assets acquired		$ 407.4

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Inventory [Line Items]
Raw materials	$ 38.2	$ 31.4
Work-in-process	116.6	90.4
Finished goods	339.8	350.7
Inventory, Net	$ 494.6	$ 472.5

Intangible Assets and Goodwill (Schedule of Intangible Assets and Goodwill) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Cost	$ 4,768.4	$ 4,760.4
Goodwill, Gross	5,040.3	5,040.3
Intangible Assets, Accumulated Amortization	(1,280.8)	(1,119.1)
Goodwill, Accumulated Amortization	(2.9)	(2.9)
Intangible assets	3,487.6	3,641.3
Goodwill	5,037.4	5,037.4
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	47.0	39.0
Finite-Lived Intangible Assets, Accumulated Amortization	(30.9)	(29.3)
Licenses, patents and purchased technology	$ 16.1	9.7
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Finite-Lived Intangible Assets, Gross	$ 10.5	10.5
Finite-Lived Intangible Assets, Accumulated Amortization	(10.5)	(10.5)
Licenses, patents and purchased technology	0.0	0.0
Purchased Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,710.5	4,710.5
Finite-Lived Intangible Assets, Accumulated Amortization	(1,239.2)	(1,079.1)
Licenses, patents and purchased technology	$ 3,471.3	3,631.4
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Finite-Lived Intangible Assets, Gross	$ 0.4	0.4
Finite-Lived Intangible Assets, Accumulated Amortization	(0.2)	(0.2)
Licenses, patents and purchased technology	$ 0.2	$ 0.2
Minimum [Member] \| Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years
Minimum [Member] \| Purchased Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	6 years
Maximum [Member] \| Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years
Maximum [Member] \| Purchased Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years
Synageva BioPharma Corp. [Member] \| Purchased Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Licenses, patents and purchased technology	$ 3,122.5

Debt (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
Debt (Details) - USD ($) $ in Millions	Jan. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Jun. 07, 2018
Debt Instrument [Line Items]
Payments of financing costs				$ 53.1
Amortization of deferred financing costs		$ 1.3	$ 3.2	2.5	$ 5.5
Remaining unamortized deferred financing costs		18.3		18.3		$ 20.8
Credit Agreement [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Letters of credit, amount outstanding		1.0		1.0
Credit Agreement [Member] \| Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity							$ 1,000.0
Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Repayments of Debt	$ 250.0
Credit Agreement [Member] \| Senior Secured Term Loan [Member] \| Line of Credit [Member]
Debt Instrument [Line Items]
Debt instrument, principal amount							$ 2,612.5
Debt Instrument, quarterly payment as a percent of total borrowings							5.00%
Debt Instrument, Periodic Payment		32.7
Outstanding debt		$ 2,579.8		$ 2,579.8

Earnings Per Common Share (Narrative) (Details) - shares shares in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.9	2.9

Marketable Securities (Summary of Securities Held) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Fair Value	$ 444.1	$ 225.6
Commercial Paper [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	274.0	52.1
Gross Unrealized Holding Gains	0.0	0.0
Gross Unrealized Holding Losses	0.0	0.0
Fair Value	274.0	52.1
Corporate Bond Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	28.0	122.9
Gross Unrealized Holding Gains	0.0	0.0
Gross Unrealized Holding Losses	0.0	(0.1)
Fair Value	28.0	122.8
US Government Agencies Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	117.8	17.5
Gross Unrealized Holding Gains	0.0	0.0
Gross Unrealized Holding Losses	0.0	0.0
Fair Value	117.8	17.5
Certificates of Deposit [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	24.3	33.2
Gross Unrealized Holding Gains	0.0	0.0
Gross Unrealized Holding Losses	0.0	0.0
Fair Value	24.3	33.2
Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	444.1	225.7
Gross Unrealized Holding Gains	0.0	0.0
Gross Unrealized Holding Losses	0.0	(0.1)
Fair Value	$ 444.1	$ 225.6

Marketable Securities (Available-for-sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Due in one year or less	$ 438.3
Due after one year through three years	5.8
Estimated Fair Value	$ 444.1	$ 225.6

Marketable Securities (Narrative) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value	$ 25.5	$ 128.7
Trading securities. fair value	$ 20.7	$ 16.5

Derivative Instruments and Hedging Activities (Schedule of Interest Rate Contracts) (Details) - Designated as Hedging Instrument [Member] $ in Millions	Jun. 30, 2019 USD ($)
Interest Rate Swap One [Member]
Derivative [Line Items]
Derivative, notional amount	$ 1,531.3
Interest Rate Swap Three [Member]
Derivative [Line Items]
Derivative, notional amount	$ 300.0
Derivative, fixed interest rate	2.08%
Interest Rate Swap Four [Member]
Derivative [Line Items]
Derivative, notional amount	$ 1,300.0
Minimum [Member] \| Interest Rate Swap One [Member]
Derivative [Line Items]
Derivative, fixed interest rate	0.98%
Minimum [Member] \| Interest Rate Swap Four [Member]
Derivative [Line Items]
Derivative, fixed interest rate	2.79%
Maximum [Member] \| Interest Rate Swap One [Member]
Derivative [Line Items]
Derivative, fixed interest rate	1.62%
Maximum [Member] \| Interest Rate Swap Four [Member]
Derivative [Line Items]
Derivative, fixed interest rate	2.83%

Derivative Instruments and Hedging Activities (Schedule Of Fair Value Of Outstanding Derivatives) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Interest Rate Contract [Member] \| Other Current Liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 10.8	$ 0.8
Interest Rate Contract [Member] \| Other Assets \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value		0.0
Interest Rate Contract [Member] \| Other Liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	52.2	17.3
Interest Rate Contract [Member] \| Prepaid Expenses and Other Current Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value		20.1
Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	35.2	60.9
Liability Derivatives, Fair Value	87.8	40.0
Foreign Exchange Forward [Member] \| Other Current Liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	7.6	7.3
Foreign Exchange Forward [Member] \| Other Assets \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	1.1	0.3
Foreign Exchange Forward [Member] \| Other Liabilities \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	1.8	3.1
Foreign Exchange Forward [Member] \| Prepaid Expenses and Other Current Assets [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	12.4	16.9
Foreign Exchange Forward [Member] \| Other Current Liabilities \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	15.4	11.5
Foreign Exchange Forward [Member] \| Prepaid Expenses and Other Current Assets [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	16.1	23.6
Interest Rate Contract [Member] \| Other Assets
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value		0.8
Interest Rate Contract [Member] \| Prepaid Expenses and Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value	5.6	20.1
Interest Rate Contract [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Current Liabilities
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value	52.2	17.3
Interest Rate Contract [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Assets
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value	0.0	0.8
Interest Rate Contract [Member] \| Fair Value, Inputs, Level 2 [Member] \| Prepaid Expenses and Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Interest Rate Derivative Assets, at Fair Value	$ 5.6	$ 20.1

Derivative Instruments and Hedging Activities (Offsetting Assets and Liabilities) (Details) - Foreign Exchange Forward [Member] - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Derivative Asset, Fair Value, Amount Offset Against Collateral [Abstract]
Gross Amounts of Recognized Assets	$ 35.2	$ 60.9
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0.0	0.0
Amounts of Assets Presented in the Condensed Consolidated Balance Sheet	35.2	60.9
Derivative Financial Instruments	(24.4)	(30.2)
Cash Collateral Received	0.0	0.0
Net Amount	10.8	30.7
Derivative Liability, Fair Value, Amount Offset Against Collateral [Abstract]
Gross Amounts of Recognized Liabilities	(87.8)	(40.0)
Gross Amounts Offset in the Condensed Consolidated Balance Sheet	0.0	0.0
Amounts of Liabilities Presented in the Condensed Consolidated Balance Sheet	(87.8)	(40.0)
Derivative Financial Instruments	24.4	30.2
Cash Collateral Pledged	0.0	0.0
Net Amount	$ (63.4)	$ (9.8)

Other Investments (Details) - USD ($) $ in Millions	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
Other Investments (Details) - USD ($) $ in Millions	Mar. 31, 2019	Jan. 31, 2019	Oct. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2014	Dec. 31, 2018
Investment [Line Items]
Payments to Acquire Other Investments						$ 43.8	$ 0.0
Unrealized Gain (Loss) on Investments						8.6	$ 100.5
Zealand [Member]
Investment [Line Items]
Unrealized Gain (Loss) on Investments				$ 2.9		3.6
Equity Securities, FV-NI				17.4		17.4
Payments to Acquire Equity Method Investments	$ 13.8
Moderna LLC [Member]
Investment [Line Items]
Payments to Acquire Other Investments								$ 37.5
Unrealized Gain (Loss) on Investments				(29.0)	$ 100.8	0.8
Equity Method Investments				82.7		82.7			$ 81.9
Dicerna [Member]
Investment [Line Items]
Unrealized Gain (Loss) on Investments				0.9		4.2
Equity Securities, FV-NI				$ 13.1		$ 13.1			$ 8.9
Payments to Acquire Equity Method Investments			$ 10.3
Caelum Biosciences [Member]
Investment [Line Items]
Payments to Acquire Other Investments		$ 41.0
Option To Acquire Remaining Equity, Amount		$ 16.1

Fair Value Measurement (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended			6 Months Ended
	Jan. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Increase in contingent consideration liability			$ 6.1	$ 4.7	$ (22.6)	$ 57.4
Research and development			187.6	$ 173.4	383.5	$ 350.0
Caelum Biosciences [Member] \| Collaborative Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Collaboration Agreement, Upfront Payment	$ 30.0
Collaboration Agreement, Potential Future Payments, Milestone Achievement	$ 30.0
Derivative Liability			27.4		27.4		$ 27.1
Research and development			$ 0.3		$ 0.3
Minimum [Member] \| Caelum Biosciences [Member] \| Collaborative Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Derivative Fair Value, Discounted Cost Of Debt	3.30%
Maximum [Member] \| Caelum Biosciences [Member] \| Collaborative Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Derivative Fair Value, Discounted Cost Of Debt	3.50%
Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset Acquisition, Contingent Consideration, Milestone Payments		$ 100.0

Revenue Recognition (Summary of Receivables and Contract Liabilities from Contracts) (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Receivables, which are included in Trade accounts receivable, net	$ 1,123.6	$ 922.3
Contract liabilities, which are included in Other current liabilities	$ 3.1	$ 3.4

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	May 25, 2018
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Fair Value of Assets Acquired	$ 803.7	$ 0.0	$ 86.6
Effective Income Tax Rate Reconciliation, Change In Deferred Tax Expense (Benefit)			5.20%
Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Income Tax Expense (Benefit)			$ 38.4
In Process Research and Development
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Asset Acquisition, Recognized Identifiable Assets Acquired And Liabilities Assumed, Finite-Lived Intangibles				$ 803.7
Intellectual Property Election [Member]
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Deferred Income Tax Expense (Benefit)		$ (95.7)
Effective Income Tax Rate Reconciliation, Deduction, Percent		12.10%
Valuation Allowance Release [Member]
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Deferred Income Tax Expense (Benefit)		$ (30.3)
Wilson Therapeutics [Member]
Schedule Of Asset Acquisition, By Acquisition [Line Items]
Effective Income Tax Rate Reconciliation, Deduction, Percent	19.40%		230.10%